<SEC-DOCUMENT>0001213900-25-035115.txt : 20250424
<SEC-HEADER>0001213900-25-035115.hdr.sgml : 20250424
<ACCEPTANCE-DATETIME>20250424165656
ACCESSION NUMBER:		0001213900-25-035115
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250424
DATE AS OF CHANGE:		20250424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		25868697

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0237489-20f_scisparc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:55 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sprcy="http://www.trpx.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-28343">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-28344">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-28345">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-28346"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-28347">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-28348">2024</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-28349">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport" id="ixv-28350">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-28351">001-38041</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-71"><b>SCISPARC LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Translation of registrant&#8217;s name into
English:</i> Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-28352">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Jurisdiction of incorporation or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-93"><b>20 Raul Wallenberg St.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-97"><b>Tower A, 2<sup>nd</sup> Floor</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-28353">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-28354">6971916</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-28355">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-110"><b>Oz Adler</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-28356">+972</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-28357">3-7175777</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Email: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress" id="ixv-28358">oz@scisparc.com</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-123"><b>20 Raul Wallenberg St.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-127"><b>Tower A, 2<sup>nd</sup> Floor</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-28359">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-28360">6971916</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-28361">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities to be registered or to be registered
pursuant to Section 12(b) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:Security12gTitle" id="ixv-28362">Ordinary Shares, no par value</ix:nonNumeric>&#160;</span></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-165"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPRC</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-28363">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-28364">10,828,251</ix:nonFraction> Ordinary Shares, no par value, as of
December 31, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Yes &#9744; &#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-28365">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-28366">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-28367">Yes</ix:nonNumeric> &#9746;&#160;&#160;No
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-28368">Yes</ix:nonNumeric> &#9746;&#160;&#160;No
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-28369">Non-accelerated filer</ix:nonNumeric>&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-251"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224; The term &#8220;new or revised financial
accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-28370">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-28371">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. GAAP &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-28372">International Financial Reporting Standards</ix:nonNumeric> as issued by the International
Accounting Standards Board &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9744; Item 17&#160;&#9744; Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-28373">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 8%; text-align: right">&#160;</td>
    <td style="width: 86%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 6%; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="text-align: center">iii</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="text-align: center">iv</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY RISK FACTORS</span></a></td>
    <td style="text-align: center">v</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="text-align: center">72</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="text-align: center">72</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="text-align: center">72</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="text-align: center">113</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="text-align: center">113</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="text-align: center">114</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="text-align: center">114</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="text-align: center">114</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, patents and licenses, etc.</span></a></td>
    <td style="text-align: center">123</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend information</span></a></td>
    <td style="text-align: center">123</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="text-align: center">123</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="text-align: center">125</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="text-align: center">125</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Compensation</a></span></td>
    <td style="text-align: center">131</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="text-align: center">133</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">Employees</a></span></td>
    <td style="text-align: center">150</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="text-align: center">150</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Action to Recover Erroneously Awarded Compensation</span></a></td>
    <td style="text-align: center">150</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="text-align: center">150</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="text-align: center">150</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="text-align: center">155</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="text-align: center">156</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements and Other Financial Information</span></a></td>
    <td style="text-align: center">156</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="text-align: center">157</td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="width: 86%"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="width: 6%; text-align: center">157</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_041">Markets</a></span></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_043">Dilution</a></span></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="text-align: center">157</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="width: 86%"><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="text-align: center; width: 6%">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="text-align: center">157</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_050">Taxation</a></span></td>
    <td style="text-align: center">158</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="text-align: center">168</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="text-align: center">168</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td><a href="#a_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="text-align: center">168</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="text-align: center">169</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="text-align: center">169</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center">169</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="text-align: center">169</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and rights</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American Depositary Shares</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: bottom; text-align: center">170</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="text-align: center">170</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top"><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">170</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td><a href="#a_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center">170</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_061">[Reserved].</a></span></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td><a href="#a_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="text-align: center">171</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center">172</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="text-align: center">173</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I.</span></td>
    <td><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="text-align: center">173</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J.</span></td>
    <td><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSIDER TRADING POLICIES</span></a></td>
    <td style="text-align: center">173</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K.</span></td>
    <td><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="text-align: center">173</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_078"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: bottom; text-align: center">175</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">175</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">175</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="text-align: center">175</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="vertical-align: bottom; text-align: center">178</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INTRODUCTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are a specialty clinical-stage pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based
on cannabinoid therapies. With this focus, we are currently engaged in <span>the following development
programs based on &#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors,
or CBR, agonists: SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for
the treatment of Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status
Epilepticus, or SE. We also have a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products and others
on Amazon Marketplace.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated under
the laws of the State of Israel on August 23, 2004. Our Ordinary Shares are listed on the Nasdaq Capital Market, or Nasdaq, under the
symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us, &#8220;our&#8221; and &#8220;SciSparc&#8221; refer to SciSparc
Ltd. (formerly known as Therapix Biosciences Ltd.) and its subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to &#8220;U.S.
dollars&#8221; and &#8220;$&#8221; are to currency of the United States of America, and references to &#8220;NIS&#8221; are to New Israeli
Shekels. References to &#8220;Ordinary Shares&#8221; are to our Ordinary Shares, no par value. We report financial information under International
Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board and none of the financial statements
were prepared in accordance with generally accepted accounting principles in the United States. Unless derived from our financial statements
or otherwise indicated, U.S. dollar translations of NIS amounts presented in this Annual Report on Form 20-F, or the Annual Report, are
translated using a rate of NIS 3.699 to USD 1.00, the last exchange rate published by the Bank of Israel on December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this Annual Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of
the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by
the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;project&#8221;
or other similar words, but are not the only way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
include, but are not limited to, statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td>our ability to raise capital through the issuance
    of additional securities and ability to continue as a going concern;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td>likelihood of the satisfaction of certain conditions
    to the completion of the Merger, as defined herein, and whether and when the Merger will be consummated;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the expected benefits of and potential value created
    by the proposed Merger for the shareholders of SciSparc and AutoMax;</p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance the development of our pharmaceutical product candidates, including the anticipated starting and ending dates of our anticipated clinical trials;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assessment of the potential of our pharmaceutical product candidates to treat certain indications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully receive approvals from the U.S. Food and Drug Administration, or FDA, or other regulatory bodies, including approval to conduct clinical trials, the scope of those trials and the prospects for regulatory approval of, or other regulatory action with respect to our product candidates, including the regulatory pathway to be designated to our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment and changes in the health policies and regimes in the countries in which we operate, including the impact of any changes in regulation and legislation that could affect the pharmaceutical industry;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize our existing product candidates and future sales of our existing product candidates or any other future potential product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our expectations regarding the commercial supply of our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to integrate our new eCommerce operations business, which focuses on the sale of hemp-based products on Amazon Marketplace;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to pursue our intended restructuring plan which involves transferring our pharmaceutical activities to Jeffs&#8217; Brand Holding Inc., a wholly owned subsidiary of Jeff&#8217;s Brands, or NewCo, or the Restructuring Plan, and list NewCo on a leading stock exchange;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall global economic environment;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political and economic conditions in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the multi-front conflict Israel faces;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected capital expenditures and liquidity;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors referred to in &#8220;Item 3. Key Information - D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects,&#8221; as well as in this Annual Report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements are only
current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. You should not rely upon forward-looking statements as predictions of future events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this Annual Report which are designed to advise interested parties of the
risks and factors that may affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue reliance
on any forward-looking statements. Any forward-looking statements in this Annual Report are made as of the date hereof, and we undertake
no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Risk Factors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk factors described
below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should
carefully consider these risk factors, together with the risk factors set forth in Item 3.D of this Annual Report and the other reports
and documents filed by us with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Financial Condition and Capital
Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a specialty clinical-stage pharmaceutical company and have a limited operating history on which to assess the prospects for our business, have incurred significant losses since the date of our inception, and anticipate that we will continue to incur significant losses until we are able to successfully commercialize our product candidates.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated any revenue from the sale of our current product candidates and may never be profitable.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will need to raise substantial additional funding before we can expect to become profitable from sales of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate development efforts or other operations.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The report of our independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Merger between SciSparc and AutoMax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the exchange ratio is fixed and will not be adjusted in the event of a change in either our share price or the share price of AutoMax Motors Ltd., or AutoMax, AutoMax shareholders cannot be certain of the precise value of the consideration that they may receive in the merger between SciSparc and AutoMax, or the Merger.</span></td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the proposed merger with AutoMax is not consummated, our share price could decline.</span></td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the conditions to the Merger are not met, the Merger will not occur.</span></td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">The Merger may be completed even though material
    adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.</td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;The market price of the combined company&#8217;s
shares may decline as a result of the Merger.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Discovery and Development of
Our Pharmaceutical Product Candidates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are heavily dependent on the success of our pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. We may also find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our pharmaceutical product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Reliance on Third Parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our pharmaceutical product candidates and our business could be substantially harmed.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will rely on third parties to manufacture our active pharmaceutical ingredient, or API, and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed supplies or fail to do so at acceptable quality levels or prices.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Commercialization of Our Pharmaceutical
Product Candidates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the market opportunities for our pharmaceutical product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively in our markets. Further, if we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Pharmaceutical Business Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements. There can be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically invest in transactions from time to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to our Intended Corporate Restructuring
Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Restructuring Plan may not be completed in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Subsidiary&#8217;s eCommerce
Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to successfully integrate or execute our new subsidiary&#8217;s eCommerce operations business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Ownership of Our Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need additional capital in the future. Raising additional capital by issuing securities may cause dilution to existing shareholders. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Israeli Law and Our Operations in
Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law may make it easy for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders to convene a shareholder meeting without the consent of our management, which may disrupt our management&#8217;s ability to run our company.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including the multi-front war that Israel is facing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to AutoMax&#8217;s Business and Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s business is sensitive to changes in consumer preferences and global trends in the automotive industry. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Combined Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combined company&#8217;s success depends on the experience and expertise of its management team and board of directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. KEY INFORMATION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.</b> [Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Capitalization and Indebtedness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Reasons for the Offer and Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Risk Factors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully consider
the risks described below, together with all of the other information in this Annual Report. The risks described below are not the only
risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially
and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could suffer
and the price of our Ordinary Shares could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a specialty clinical</i></b>-<b><i>stage
pharmaceutical company and have incurred significant losses since the date of our inception, and anticipate that we will continue to incur
significant losses until we are able to successfully commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have historically incurred
substantial net losses: including net losses of approximately $7.5 million for the year ended December 31, 2024, $5.9 million for the
year ended December 31, 2023, and $2.6 million for the year ended December 31, 2022. As of December 31, 2024, we had an accumulated deficit
of approximately $75 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted substantially
all of our financial resources to develop our product candidates, and more recently, to a lesser degree, we have been searching for strategic
transactions. We have financed our operations primarily through the issuance of equity securities. The amount of our future net losses
will depend, in part, on completing the development of our product candidates, the demand for our product candidates, the rate of our
future expenditures and our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. Pharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We are in the late stages of preclinical
and at the early stages of clinical development for our product candidates, we have not yet commenced pivotal clinical studies for any
product candidate. Although we have begun early commercialization efforts for our proprietary Palmitoylethanolamide, or PEA, oral tablets
formulation, CannAmide&#8482;, which we expect will be marketed to pharmacies and other retail outlets across Canada following our entering
into a distribution agreement(s), it may be several years, if ever, before we complete pivotal clinical studies and have our lead product
candidate approved for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenue will
depend upon the size of the markets for which our product candidates may receive approval and our ability to achieve sufficient market
acceptance, pricing, reimbursement from third-party payors and adequate market share for our product candidates in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until we are able to commercialize our main pharmaceutical product candidates, which we may not be successful in achieving.
We anticipate that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and development of our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand the scope of our current clinical studies for our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing and distribution infrastructure to commercialize our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from the
sale of our current pharmaceutical product candidates and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any of our pharmaceutical product candidates and have not generated any revenue from sales of our pharmaceutical product candidates since
the date of our inception. Although we have begun early commercialization efforts for our proprietary PEA oral tablets formulation. CannAmide&#8482;,
we do not currently expect the sale of CannAmide to result in material revenues, nor is CannAmide&#8482; our lead pharmaceutical product
candidate. We do not know whether or when we will become profitable. Our ability to generate revenue and achieve profitability depends
on our ability to successfully complete the development of, and to commercialize, our pharmaceutical product candidates and on the demand
for our pharmaceutical product candidates. Our ability to generate revenue and achieve profitability depends on our ability, alone or
with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize, one or more of our pharmaceutical product candidates. Our ability to generate future revenue from pharmaceutical
product candidate sales depends heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing research and preclinical and clinical development of our pharmaceutical product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory and marketing approvals for pharmaceutical product candidates for which we complete clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) pharmaceutical products to support market demand for our pharmaceutical product candidates, if approved;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing pharmaceutical product candidates if and when we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of our pharmaceutical product candidates as viable treatment options;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing any competing pharmaceutical or biotechnological and market developments;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and/or developing new pharmaceutical product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and retaining qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if one or more of the
pharmaceutical product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated
with commercializing any approved pharmaceutical product candidate. Our expenses could increase beyond expectations if we are required
by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to perform clinical, nonclinical
or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory
approvals to market one or more of our pharmaceutical product candidates, our revenue will be dependent, in part, upon the size of the
markets in the territories for which we gain regulatory approval, the accepted price for the pharmaceutical product candidate, the ability
to get reimbursement at an acceptable price and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably
expected population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant
revenue from sales of such pharmaceutical product candidates, even if approved. Additionally, if we are not able to generate revenue from
the sale of any approved pharmaceutical product candidates, we may be forced to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect that we will need to raise substantial
additional funding before we can expect to become profitable from sales of our pharmaceutical product candidates. This additional financing
may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit
or terminate our pharmaceutical product candidate development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, our
cash was approximately $2.1 million, other accounts receivable was approximately $0.5 million, we had working capital of approximately
$4.9 million and we also had an accumulated deficit of approximately $69 million. Based upon our currently expected level of operating
expenditures, we do not expect that our existing cash will be sufficient to fund operations for at least the next 12 months. We expect
that we will require substantial additional capital to commercialize our pharmaceutical product candidates. In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than
planned. Our future funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, rate of progress, results and cost of pharmaceutical product development, clinical studies, preclinical testing, and other related activities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of regulatory approvals;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of establishing sales, marketing, and distribution capabilities; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of any collaborative, licensing, and other arrangements that we may establish.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our pharmaceutical product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts
or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders
of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause
the market price of our Ordinary Shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or pharmaceutical
product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating
results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the commercialization of any pharmaceutical product candidates or be unable to expand our operations or otherwise capitalize
on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The report of our independent registered
public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern,
which could prevent us from obtaining new financing on reasonable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our independent
registered public accounting firm on our audited consolidated financial statements for the period ended&#160;December 31,&#160;2024 contains
an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.&#160;Our consolidated financial
statements do not include any adjustments that might result from the outcome of the uncertainty regarding our ability to continue as a
going concern. This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity
or debt securities or otherwise. Further reports on our consolidated financial statements may include an explanatory paragraph with respect
to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash
needs through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at
all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or
commercialization efforts with respect to our products. This may raise substantial doubts about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Discovery and Development
of Our Pharmaceutical Product Candidates </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are heavily dependent on the success
of our pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development.
We cannot give any assurance that any of our pharmaceutical product candidates will receive regulatory approval, which is necessary before
they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have invested
substantially all of our efforts and financial resources to design and develop our pharmaceutical product candidates, including conducting
preclinical studies and providing general and administrative support for these operations. Our future success is dependent on our ability
to successfully develop, obtain regulatory approval for, and then successfully commercialize one or more pharmaceutical product candidates.
We currently generate no revenue from sales of any pharmaceutical product candidate, and we may never be able to develop or commercialize
a marketable pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our pharmaceutical
product candidates is in the late stages of pre-clinical development or early stages of development and will require additional clinical
development (and in some cases additional preclinical development), management of nonclinical, clinical and manufacturing activities,
regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts
before we generate any revenue from pharmaceutical product candidate sales. It may be years before a pivotal study is initiated, if at
all. Any clinical trials in the United States will require the approval of an Investigational New Drug, or IND, application by the FDA,
and we cannot assure that we will obtain such approval in a timely manner, or at all. We are not permitted to market or promote any of
our pharmaceutical product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,
and we may never receive such regulatory approval for any of our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We as a company have never
submitted marketing applications to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our pharmaceutical
product candidates will be successful in clinical studies or receive regulatory approval or what regulatory pathway the regulatory authorities
shall designate for our pharmaceutical product candidates. Further, our pharmaceutical product candidates may not receive regulatory approval
even if they are successful in clinical studies. If we do not receive regulatory approvals for our pharmaceutical product candidates,
we may not be able to continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally plan to seek
regulatory approval to commercialize our pharmaceutical product candidates in the United States, the European Union and in additional
foreign countries. To obtain regulatory approvals we must comply with the numerous and varying regulatory requirements of such countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing and distribution of our
product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval
in any other jurisdictions. If we are unable to obtain approval for our pharmaceutical product candidates in multiple jurisdictions, our
revenue and results of operations would be negatively affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes of the
FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain
regulatory approval for our pharmaceutical product candidates, our business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to obtain
approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical
studies and depends upon numerous factors. In addition, approval policies, regulations or the type and amount of clinical data necessary
to gain approval may change during the course of a pharmaceutical product candidate&#8217;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any
pharmaceutical product candidate, and it is possible that none of our existing pharmaceutical product candidates or any pharmaceutical
product candidates we may seek to develop in the future will ever obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applications for our pharmaceutical
product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a pharmaceutical product candidate&#8217;s safety-benefit ratio for its proposed indication is acceptable;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from clinical studies of our pharmaceutical product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, in the United States or elsewhere;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This lengthy approval process,
as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market
any of our pharmaceutical product candidates, which would significantly harm our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inadequate funding for the FDA and other
government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services
from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions
on which the operation of our business may rely, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire
and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the
agency have fluctuated in recent years as a result. In addition, government funding of the FDA and other government agencies on which
our operations may rely, including those that fund research and development activities, is subject to the political process, which is
inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future legislative and regulatory
proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have historically operated. We
cannot be sure whether additional legislative changes or executive orders will be enacted, or whether any of the FDA&#8217;s regulations,
guidance or interpretations will be changed, or what the impact of such changes on the agency and its scientific review staff, if any,
may be. In addition, disruptions at the FDA and other agencies may slow the time necessary for new products to be reviewed and/or approved
by necessary government agencies, which would adversely affect our business. For example, political disputes in the U.S. Congress may
result in a shutdown of the U.S. federal government, and in such cases certain regulatory agencies, such as the FDA, would have to furlough
critical employees and stop critical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a prolonged government
shutdown occurs, or if legislative or regulatory developments or global health concerns hinder or prevent the FDA or other regulatory
authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also increase the time necessary for new drugs or medical devices to be reviewed and/or approved by necessary government
agencies or to otherwise respond to regulatory submissions, which would adversely affect our business. For example, the&#160;Trump&#160;Administration
has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the medical device and pharmaceutical
industry, transparency in decision making and ultimately the cost and availability of prescription drugs or treatments. Additionally,
over the last several years, the US government has shut down multiple times and certain regulatory agencies, such as the FDA, have had
to furlough critical FDA and other government employees and stop critical activities. If funding for the FDA is reduced, FDA priorities
change, or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our
regulatory submissions, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development involves a lengthy
and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study
process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results
of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer
significant setbacks in subsequent advanced clinical studies. There is a high failure rate for drugs proceeding through clinical studies,
and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed
satisfactorily through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results
in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know
whether any Phase I, Phase II, Phase III or other clinical studies we may conduct will demonstrate consistent or adequate efficacy and
safety sufficient to obtain regulatory approval to market our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may find it difficult to enroll patients
in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in clinical studies of our pharmaceutical product candidates is critical to our success. The timing of our clinical
studies depends in part on the speed at which we can recruit patients to participate in testing our pharmaceutical product candidates,
and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the conditions for
which we plan to evaluate our current pharmaceutical product candidates are for rare diseases. Accordingly, there is a limited patient
pool from which to draw for clinical studies. Further, the eligibility criteria of our clinical studies will further limit the pool of
available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease
is either severe enough or not too advanced to include them in a study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the process
of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete
our clinical studies because of the perceived risks and benefits of the pharmaceutical product candidate under study, the availability
and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients
and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline
for recruiting patients, conducting studies and obtaining regulatory approval of potential pharmaceutical product candidates will be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
the completion or termination of any clinical study of our pharmaceutical product candidates, the commercial prospects of our pharmaceutical
product candidates will be harmed, and our ability to generate pharmaceutical product candidate revenue from any of these pharmaceutical
product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs,
slow down our product candidate development and approval process and jeopardize our ability to commence pharmaceutical product candidate
sales and generate revenue. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition,
many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to
the denial of regulatory approval of our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the FDA does not conclude that our pharmaceutical
product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our pharmaceutical
product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly
more and entail significantly greater complications and risks than anticipated and in either case may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek FDA approval
through the Section 505(b)(2) regulatory pathway for our pharmaceutical product candidate- SCI-110 and potentially for our drug candidate
SCI-210. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section
505(b)(2) to the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or the FDC Act, or Section 505(b)(2). Section 505(b)(2) permits
the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant
and for which the applicant has not obtained a right of reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not allow
us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval, and complications and risks associated with FDA approval, would substantially increase. We may need to obtain
additional funding, which could result in significant dilution to the ownership interests of our then existing shareholders to the extent
we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms
acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in new competitive pharmaceutical
product candidates reaching the market faster than our pharmaceutical product candidates, which could materially adversely impact our
competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that
our pharmaceutical product candidates will receive the requisite approvals for commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the approval of a number of pharmaceutical product candidates by the FDA under Section 505(b)(2) over the last few years, some pharmaceutical
companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). For example, several companies have previously
petitioned the FDA regarding the constitutionality of allowing others to rely upon FDA findings that are based on their proprietary data.
If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies
and practices, which could require that we generate full data regarding safety and effectiveness for previously approved active ingredients
and delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry
is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors
of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and
mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon
for a manufacturer of an approved pharmaceutical product to file a citizen petition with the FDA seeking to delay approval of, or impose
additional approval requirements for, pending competing pharmaceutical products. If successful, such petitions can significantly delay,
or even prevent, the approval of the new pharmaceutical product. However, even if the FDA ultimately denies such a petition, the FDA may
substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section
505(b)(2) regulatory pathway for our pharmaceutical product candidates, there is no guarantee this would ultimately lead to faster pharmaceutical
product development or earlier approval. Moreover, even if these pharmaceutical product candidates are approved under the Section 505(b)(2)
pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the pharmaceutical products may
be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor
the safety or efficacy of the pharmaceutical products. Our pharmaceutical product candidates are at early stages of development and are
subject to uncertainty over what we must do on our development program in order to secure approval under Section 505(b)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining marketing
approval from regulatory authorities for the sale of our pharmaceutical product candidates, we must conduct extensive clinical studies
to demonstrate the safety and efficacy of the pharmaceutical product candidates in humans. Clinical testing is expensive, time consuming
and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at
all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful.
Events that may prevent successful or timely completion of clinical development include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a pandemic or the spread of a virus that diverts the attention of regulatory agencies from reviewing our study design or results or which, as a result of such pandemic or widespread, requires us to materially modify our planned clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching a consensus with regulatory agencies on study design;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical hold by regulatory agencies, after review of an IND, application, or equivalent application, or an inspection of our clinical study operations or study sites;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in recruiting suitable patients to participate in our clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty collaborating with patient groups and investigators;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to perform in accordance with the FDA&#8217;s Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines in other countries;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients dropping out of a study;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of serious adverse events associated with the pharmaceutical product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical studies of our pharmaceutical product candidates being greater than we anticipate;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical studies of our pharmaceutical product candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon pharmaceutical product candidate development programs; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our pharmaceutical product candidates for use in clinical studies or the inability to do any of the foregoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any inability to successfully
complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. We may
also be required to conduct additional safety, efficacy and comparability studies before we will be allowed to start clinical studies
with our repurposed drugs. Clinical study delays could also shorten any periods during which our pharmaceutical product candidates have
patent protection and may allow our competitors to bring pharmaceutical product candidates to market before we do, which could impair
our ability to obtain orphan exclusivity and successfully commercialize our pharmaceutical product candidates and may harm our business
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In respect of our pharmaceutical product
candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another party obtains orphan drug
exclusivity for the drugs and indications we are targeting, we may be precluded from commercializing our pharmaceutical product candidates
in those indications during that period of exclusivity</i>.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are seeking to obtain an
orphan designation for some of our pharmaceutical product candidates in the United States. Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population of
fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. Additionally, designation is granted
for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic
condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the
necessary investment in developing the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
first NDA applicant with an orphan drug designation for a particular active moiety to treat a specific disease or condition that receives
FDA approval is entitled to a seven-year exclusive marketing period in the United States for that product candidate, for that indication.
In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers
and 10 years of market exclusivity is granted following drug approval. This period may be reduced to six years if the orphan drug designation
criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market
exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In a letter dated September 29, 2016, the FDA informed
us that our request could not be granted at such time, and is being held in abeyance until and subject to us providing additional information
pertaining to the overall prevalence of TS in both children and adults, and further clinical data to support our scientific rationale
for our request for orphan drug designation within 12 months. In September 2017, we responded to such FDA letter within the designated
time frame, and provided the FDA with our articulated and reasoned responses including documentation and clinical data that supports it.
On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA accepted that there is adequate scientific rationale
for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide
benefit in treating TS. However, the FDA stated that it was unable to grant our request and indicated that we did not provide adequate
prevalence estimates, and any evidence to support our statement that only moderate to severe TS patients would require pharmacological
treatment. We further responded in January 2018 by providing additional information. On January 23, 2020, following additional correspondence
with the FDA, the FDA still did not grant us our request due to the fact that we have not yet provided adequate prevalence estimates.
However, the FDA did agree with our position that we could potentially qualify for orphan drug designation with respect to the moderate-to-severe
TS sub-group population only rather than the entire population. After we had provided additional prevalence estimates, the FDA raised
a concern in its letter, dated December 7, 2020, about our ability to limit the use of the pharmaceutical product to the subset of patients
we are pursuing. Due to the fact that we disagree with this concern, we requested a clarification call. In the clarification call conducted
on February 2, 2021, we agreed with the FDA concern about our ability to limit the use of the pharmaceutical product to the subset of
patients in addition to a safety concern associated with THC treatment in pediatrics population so we suggested to amend our preliminary
request and asked to include only adults in the treated population. An amendment letter was discussed and the FDA described what it would
want to see in such an amendment. In March 2021, we sent our response to the FDA. In June 2021, we received a response from the FDA explaining
that they are unable to grant our request until new information becomes available to support our request for orphan drug designation.
We will re-visit the application after we obtain clinical results from our upcoming phase IIb clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully obtain orphan drug designation for TS, any future rare indications or orphan exclusivity upon approval of any of
our pharmaceutical product candidates that have already obtained designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we do obtain orphan
exclusivity for any pharmaceutical product candidate, the exclusive marketing rights may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. Moreover,
a drug product candidate with an active moiety that is a different cannabinoid from that in our drug candidate or, under limited circumstances,
the same drug product candidate, may be approved by the FDA for the same indication during the period of marketing exclusivity. The limited
circumstances include a showing that the second drug is clinically superior to the drug with marketing exclusivity through a demonstration
of superior safety or efficacy or that it makes a major contribution to patient care. In addition, if a competitor obtains approval and
marketing exclusivity for a drug product candidate with an active moiety that is the same as that in a pharmaceutical product candidate
we are pursuing for the same indication, approval of our pharmaceutical product candidate would be blocked during the period of marketing
exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved pharmaceutical product candidate.
In addition, if a competitor obtains approval and marketing exclusivity for a drug product candidate with an active moiety that is the
same as that in a pharmaceutical product candidate we are pursuing for a different orphan indication, this may negatively impact the market
opportunity for our pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been legal challenges
to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges
could lead to changes that affect the protections afforded our pharmaceutical product candidates in ways that are difficult to predict.
In a recent successful legal challenge, a court invalidated the FDA&#8217;s denial of orphan exclusivity to a drug on the grounds that
the drug was not proven to be clinically superior to a previously approved pharmaceutical product candidate containing the same ingredient
for the same orphan use. In response to the decision, the FDA released a policy statement stating that the court&#8217;s decision is limited
just to the facts of that particular case and that the FDA will continue to require the sponsor of a designated drug that is the &#8220;same&#8221;
as a previously approved drug to demonstrate that its drug is clinically superior to that drug upon approval in order to be eligible for
orphan drug exclusivity, or in some cases, to even be eligible for marketing approval. In the future, there is the potential for additional
legal challenges to the FDA&#8217;s orphan drug regulations and policies, and it is uncertain how such challenges might affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>While orphan drug product candidates are
typically sold at a high price relative to other medications, the market may not be receptive to high pricing of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We develop our product candidates
to treat rare diseases, a space where medications are usually sold at high prices compared with other medications. However, our product
candidates are repurposed drugs, which means, among other things, that they contain drug substances available in pharmacies for the purpose
of treating indications that are different from the indications for which we plan to use. Accordingly, even if regulatory authorities
approve our product candidates, the market may not be receptive to, and it may be difficult for us to achieve, a per-patient per-year
price high enough to allow us to realize a return on our investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label or result in significant negative consequences following marketing approval, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of dronabinol has
been associated with seizures, paranoia, rapid heart rate and unusual thoughts and behaviors. Undesirable side effects caused by our product
candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive
marketing label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Potential side effects
of our cannabinoid-based treatments may include: asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal pain, nausea,
vomiting, amnesia, anxiety/nervousness, ataxia, confusion, depersonalization, dizziness, euphoria, hallucinations, paranoid reaction,
somnolence and abnormal thinking. Results of our studies may identify unacceptable severity and prevalence of these or other side effects.
In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us
to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug-related side effects
could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product candidate liability
claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product
candidates, a number of potentially significant negative consequences could result, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw approvals of such product candidate;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require additional warnings on the label;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a risk evaluation and mitigation strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use, or ETASU;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm
our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval for
a product candidate, our product candidates will remain subject to regulatory scrutiny.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,
sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including
both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217; facilities are required
to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good
Manufacturing Practices, or cGMP, regulations and Quality System Regulation, or QSR. As such, we and our contract manufacturers will be
subject to continual review and inspections to assess compliance with cGMP, QSR and adherence to commitments made in any NDA. Accordingly,
we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product candidate
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain
adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for
our product candidates. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product candidate&#8217;s approved label. As such, we may not promote
our product candidates for indications or uses for which they do not have FDA approval. The holder of an approved NDA must also submit
new or supplemental applications and obtain FDA approval for certain changes to the approved product candidate, product candidate labeling
or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our product
candidates in general or in specific patient subsets. If original marketing approval were obtained via the accelerated approval pathway,
we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our product candidates. An
unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Furthermore,
any new legislation addressing drug safety issues could result in delays in product candidate development or commercialization or increased
costs to assure compliance. Foreign regulatory authorities impose similar requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a regulatory agency discovers
previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, or problems with
the facility where the product candidate is manufactured, or disagrees with the promotion, marketing or labeling of a product candidate,
such regulatory agency may impose restrictions on that product candidate or us, including requiring withdrawal of the product candidate
from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among
other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue warning letters;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose civil or criminal penalties;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any of our ongoing clinical studies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize or detain product candidates, or require a product candidate recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
and our operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to numerous complex regulations
and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, testing, development,
manufacturing, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, marketing, distribution,
possession and use of our product candidates, among other things, are subject to regulation by numerous governmental authorities in the
United States and elsewhere. The FDA regulates drugs under the FDC Act, and implementing regulations. Noncompliance with any applicable
regulatory requirements can result in refusal to approve product candidates for marketing, warning letters, product candidate recalls
or seizure of product candidates, total or partial suspension of production, prohibitions or limitations on the commercial sale of product
candidates or refusal to allow the entering into of federal and state supply contracts, fines, civil penalties and/or criminal prosecution.
Additionally, the FDA and comparable governmental authorities have the authority to withdraw product candidate approvals that have been
previously granted. Moreover, the regulatory requirements relating to our product candidates may change from time to time and it is impossible
to predict what the impact of any such changes may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing product
candidates that are controlled substances as defined in the Controlled Substances Act of 1970, or CSA, which establishes, among other
things, certain registration, production quotas, security, recordkeeping, reporting, import, export and other requirements administered
by the Drug Enforcement Administration, or the DEA. As a result, any product candidate that is a controlled substance (or includes a controlled
substance) cannot be marketed before such substance is rescheduled by the DEA as a Schedule II, III, IV or V substance. The active ingredient
in our product candidates is dronabinol, which is a Schedule III controlled substance. See Item 4.B. &#8220;Business-Government Regulation-Controlled
Substances&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture, shipment,
storage, sale and use, among other things, of controlled substances that are pharmaceutical product candidates are subject to a high degree
of regulation. The DEA also conducts periodic inspections of registered establishments that handle controlled substances. Facilities that
conduct research, manufacture, distribute, import or export controlled substances must be registered to perform these activities and have
the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure to maintain compliance,
particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect
on our business, results of operations, financial condition and prospects. The DEA may seek civil penalties, refuse to renew necessary
registrations, or initiate proceedings to suspend or revoke those registrations. In certain circumstances, violations could lead to criminal
proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states also have
controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions,
they may separately schedule our product candidates as well. While some states automatically schedule a drug when the DEA does so, other
states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale of any product candidate
for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness
of such product candidate. We or our partners must also obtain separate state registrations, permits or licenses in order to be able to
obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory
requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal
law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Reliance on Third Parties
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon and plan
to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs, including Target
Health, Inc., FGK Clinical Research GmbH, or FGK, and others. We rely on these parties for execution of our preclinical and clinical studies,
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us
of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current cGMP, GCP, QSR and Good Laboratory
Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European
Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may
be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must be conducted
with product candidates which are produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat
clinical studies, which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable
terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot
control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If CROs
do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the
quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory
requirements or for other reasons, our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory
approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result,
our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability
to generate revenue could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Switching or adding additional
CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines.
Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or
delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will rely on third parties to manufacture
our API and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed
supplies, or fail to do so at acceptable quality levels or prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the infrastructure
or capability internally to manufacture the API formulations, and we lack the resources and the capability to manufacture any of our product
candidates on a clinical or commercial scale. We plan to rely on third parties for such supplies. There are a limited number of manufacturers
who have the ability to produce our API and there may be a need to identify alternate manufacturers to prevent a possible disruption of
our clinical studies. Any significant delay or discontinuity in the supply of these components could considerably delay completion of
our clinical studies, product candidate testing and potential regulatory approval of our product candidates, which could harm our business
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We and our collaborators and contract manufacturers
are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely
may not continue to meet regulatory requirements and have limited capacity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All entities involved in the
preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates,
are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or a product candidate
used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and
procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational
product candidates and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or
to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We,
our collaborators or our contract manufacturers must supply all necessary documentation in support of an NDA, or Marketing Authorization
Application, or MAA, on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and other regulatory agencies
through their facilities inspection program. Some of our contract manufacturers have never produced a commercially approved pharmaceutical
product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some
or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations
as a condition of regulatory approval of our product candidates or any of our other potential product candidates. In addition, the regulatory
authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our
other potential product candidates or the associated quality systems for compliance with the regulations applicable to the activities
being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners
for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval
of the product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of
the regulatory authority, if ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulatory authorities
also may, at any time following approval of a product candidate for sale, if ever, audit the manufacturing facilities of our collaborators
and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation
of our product candidate specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant
regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and
that may include the temporary or permanent suspension of a clinical study or commercial sales, or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our collaborators,
or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose
regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an
approval or suspension of production. As a result, our business, financial condition and results of operations may be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if supply from
one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or MAA amendment, or equivalent
foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer
is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in
our desired clinical and commercial timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors could cause
us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization
of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more
replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential
revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our reliance on third parties requires us
to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we rely on third parties
to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need
to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Commercialization of Our Pharmaceutical
Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the market opportunities for our pharmaceutical
product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our projections of both the
number of people who have our target diseases, as well as the subset of people with these diseases who have the potential to benefit from
treatment with our pharmaceutical product candidates, are based on our beliefs and estimates. These estimates have been derived from a
variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research and may prove to be
incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out
to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately
predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for
each of our pharmaceutical product candidates may be limited or may not be amenable to treatment with our pharmaceutical product candidates,
and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations
and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition and rapid technological
change and the possibility that our competitors may discover, develop or commercialize therapies that are similar, more advanced or more
effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are highly competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities and
research organizations actively engaged in the research and development of products that may be similar to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based pharmaceutical,
a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called Unimed Pharmaceuticals,
with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment for chemotherapy-related
nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market, other pharmaceuticals
containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed by SVC Pharma LP and
Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole cannabis extract administered
as an oral spray. Furthermore, to the best of our knowledge, multiple companies that are working in the cannabis therapeutic area and
are pursuing regulatory approval for their product candidates. For example, GW Pharmaceuticals PLC, or GW, which markets Sativex, a botanical
cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval in the United States in June
2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut
Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among others, cannabidivarin, or CBDV, based therapy
for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba Pharmaceuticals, Inc., or Zynerba, is developing
a transdermal formulation of cannabidiol for Fragile X and certain refractory epilepsies and ASD. Skye Bioscience, Inc., or Skye, is focused
on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Corbus
Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for systemic sclerosis, cystic fibrosis, dermatomyositis
and systemic lupus erythematosus and metabolism and solid tumors. RespireRx Pharmaceutical Inc., or RespireRx, developing dronabinol for
OSA treatment. Synendos Therapeutics AG, or Synendos, is a developer of endocannabinoid modulators for the treatment of central nervous
system, or CNS, disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric
disorders. Synendos is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous
cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing
peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance,
and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More established companies
may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of our
competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors may
have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before we are able
to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer,
more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and marketing
their products. These advantages could materially impact our ability to develop and commercialize our product candidates successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates may
also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of marijuana is legal. There
is support in the United States for further legalization of marijuana. In markets where recreational and/or medical marijuana is not legal,
our product candidates may compete with marijuana purchased in the illegal drug market. We cannot assess the extent to which patients
may utilize marijuana obtained illegally for the treatment of the indications for which we are developing our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we successfully develop
our product candidates, and obtain marketing approval for them, other treatments or therapeutics may be preferred and we may not be successful
in commercializing our product candidates or in bringing them to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing
and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in
even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than
we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase
further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in
these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective
or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization
and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have no marketing and sales
organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and
sell our product candidates, we may be unable to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our employees may
have sold other similar products in the past while employed at other companies, we as a company have no experience selling and marketing
our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result
from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates
receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize our product candidates in major markets, which will be expensive, difficult and time consuming. Any failure
or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, given our lack of
prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required sales force may be
materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such,
we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates
or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets,
we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable
to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize
our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate
sufficient product revenue to sustain our business. We may be competing with companies that currently have extensive and well-funded marketing
and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable
to compete successfully against these more established companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The commercial success of any current or
future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the
medical community.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even with the requisite approvals
from the FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the
medical community, patients and third-party payors accepting our product candidates as medically useful, cost-effective and safe. Any
product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical
community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number
of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which approval is granted;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative convenience and ease of administration;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment, particularly in relation to competing treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity concerning our products or competing products and treatments; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient third-party insurance coverage and reimbursement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a potential product
displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully
known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates
may require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate
level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient
revenue to become or remain profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The insurance coverage and reimbursement
status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products
could limit our ability to market those products and decrease our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pricing, coverage and
reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure. Our per-patient prices
must be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability
and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive
treatments such as ours, assuming approval. Sales of our product candidates will depend substantially, both domestically and abroad, on
the extent to which the costs of our product candidates will be paid for by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. If
coverage and reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize
our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish
or maintain pricing sufficient to realize a return on our investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S.
Department of Health and Human Services, or DHHS, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to reimbursement for products such as ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the
increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the
pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United
States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and
may be insufficient to generate commercially reasonable revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, increasing efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates
due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has
become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures may
have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of legislative initiatives to contain healthcare costs. The following are among the provisions established
by the Patient Protection and&#160;Affordable Care Act of 2010, or ACA, of greatest importance to the pharmaceutical and biotechnology
industry:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the Average Manufacturer Price, or AMP, for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the AMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, or MCOs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (now 70%) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of the entities eligible for discounts under federal 340B;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. This center is currently focused on the following priorities:</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">testing new payment and service delivery models;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt">evaluating results and advancing best practices; and</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt">engaging a broad range of stakeholders to develop additional models for testing.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt">implementation of the federal physician payment transparency requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or the SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ACA may be modified, amended
or repealed at any time and may or may not be replaced with a different law or health care payment system. The ACA is expected to continue
to have a significant impact on the health care industry. With regard to pharmaceutical product candidates, among other things, the ACA
may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements under
the Medicare D program. Since the enactment of the ACA, numerous regulations have been issued providing further guidance on its requirements.
The ACA continues to be implemented through regulation and government activity but is subject to possible amendment, additional implementing
regulations and interpretive guidelines. Several states have decided not to expand their Medicaid programs and are seeking alternative
reimbursement models to provide care to the uninsured. The manner in which these issues are resolved could materially affect the extent
to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and Tricare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2016, CMS issued a final
rule regarding the Medicaid Drug Rebate Program that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. In addition, on
December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including
some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical
manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two bills affecting the implementation
of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the TCJA, included a provision that repealed,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year, that is commonly referred to as the &#8220;individual mandate.&#8217;&#8217; Additionally,
on January 22, 2018, then President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation
of certain ACA-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019,
to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In July 2018, CMS published
a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under
the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine
this risk adjustment. On April 27, 2020, the U.S. Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217;
denial of $12 billion in &#8220;risk corridor&#8221; funding. Congress may consider additional legislation to repeal, or repeal and replace,
other elements of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued that the ACA
is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the ACA will remain in effect in its
current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a
special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to
judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden
administration will impact the ACA and our business. We continue to evaluate the ACA and its possible repeal and replacement, as the extent
to which any such changes may impact our business or financial condition remains uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the Budget Control Act of 2011 among other
things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of
2% per fiscal year. These reductions, known as Medicare sequestration adjustments, went into effect in 2013. However, under the Coronavirus
Aid, Relief, Economic Securities Act of 2020, and related legislation, Medicare sequestration adjustments from May 1, 2020 through March
31, 2021 have been suspended, though sequestration has been extended through 2030. Additionally, there has been heightened governmental
scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several
recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the federal level, including the former Administration&#8217;s budget for fiscal year 2020, there
were further drug price control measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part D,
to continue to allow some states to negotiate drug prices under Medicaid through supplemental rebate negotiations and other mechanisms,
and legislation was introduced to eliminate cost sharing for generic drugs for Part D low-income patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
the U.S. DHHS, finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by
excluding rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or pharmacy benefit managers,
or PBMs, acting under contract with Medicare Part D plan sponsors from the existing discount safe harbor under the federal Anti-Kickback
Statute, or the AKS. The regulation reflects the first change to the AKS Statute discount safe harbor since the Medicare Part D program
was established. In addition to the rebate exclusions, two new safe harbors were added. One of these new safe harbors protects point-of-sale
reductions in price from a manufacturer to a plan sponsor under Medicare Part D or a MCO, for a prescription drug payable, in whole or
in part, by a plan sponsor under Medicare Part D or a MCO, provided certain conditions are met. The other protects certain fixed-fee services
arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Congress and the executive
branch have each indicated that it will continue to seek new legislative or administrative measures to control drug costs. At the state
level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, similar
political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state
level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare
in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers
have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement
of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those
wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between low-priced and high-priced
member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.
In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these and other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and
in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or
other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs,
once marketing approval is obtained. We cannot predict what healthcare reform initiatives may be adopted in the future. However, it is
possible that there will be further legislation or regulation that could harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our product candidates, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have relied
on trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Since 2015, we have also sought patent protection for certain of our product candidates. Our success depends in large part
on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with
respect to our proprietary technology and new product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to protect our proprietary
position by filing patent applications in the United States and in other countries, with respect to our novel technologies and product
candidates, which are important to our business. Patent prosecution is expensive and time consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not including patents and
applications which we are in the process of being assigned, we have a portfolio of seven granted patents with the U.S. Patent and Trademark
Office, or USPTO, nine patent families and two trademarks, of which four families include Patent Cooperation Treaty, or PCT, applications,
that have entered the national phase in various national entities. We cannot offer any assurances about which, if any, patent applications
will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened
by third parties. Any successful opposition to our patents after issuance could deprive us of rights necessary for the successful commercialization
of any new product candidates that we may develop and would allow other third parties to compete with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have exclusively licensed
one U.S. patent family from Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., or Yissum. We cannot assure
you that we will ever enter into definitive license agreements with any third party licensor. See Item 4.B. &#8220;Business Overview-Intellectual
Property-In-Licensed Patents and Patent Applications.&#8221; To the extent the licensed or future licensed patents are found to be invalid
or unenforceable, we may be limited in our ability to compete and market our product candidates. Moreover, the terms of our licenses affect
our ability to control the value of any of our product candidates. If we or any of the parties that control the enforcement of licensed
patents elect not to enforce any or all of the licensed patents it could significantly undercut the value of any of our product candidates,
which would materially adversely affect our future revenue, financial condition and results of operations. Moreover, fluctuating currency
rates may create inconsistencies in the royalty payments we are obligated to make under our licenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, there is no guarantee
that the patent registration applications that were submitted by us with regard to our technologies will result in patent registration.
In the event of failure to complete patent registration, our developments will not be proprietary, which might allow other entities to
manufacture our product candidates and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found. Such prior art, to the extent it exists, may
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even
if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in
such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and
any future patents may not adequately protect our intellectual property, provide exclusivity for our new product candidates, or prevent
others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Engagement in any type of
intellectual property collaboration agreement requires diligent management of intellectual property rights. Joint intellectual property
engagements may create additional administrative and financial burdens and may place us at heightened risk of disputes or litigation regarding
ownership, maintenance or enforcement of such joint intellectual property. For example, our collaboration with Clearmind Medicine Inc.,
or Clearmind, has resulted in filings of provisional patent applications related to certain combinations of our respective proprietary
compounds. As a joint-owner of intellectual property, we are generally or would be unable to use or exploit the intellectual property
without the consent of the other joint owner. If we cannot obtain sole commercial use rights for such jointly-owned intellectual property
as a result of our collaboration, our future product development and commercialization plans may be adversely affected. Moreover, if we
cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively, and our business
and results of operations may be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to identify infringements
of our patents and accordingly the enforcement of our intellectual property rights may be difficult.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug substance in some
of our product candidates is repurposed, which means that it is available in other pharmaceutical products for the purpose of treating
indications that are different from the indications for our product candidates. It is possible that if we receive regulatory approval
to market and sell our drug candidates, some patients that receive a prescription could be sold the same drug substance but not our product
candidate. It would be difficult, if not impossible, for us to identify such instances that may constitute an infringement of our patents.
In addition, because the drug substance of some of our product candidates is repurposed, such substance may not be eligible for patent
protection or data exclusivity. Even if we identify infringing parties, there is no guarantee that a court will agree with our arguments
and find that a third party is infringing our patents or that the court will issue an order for an adequate remedy for that infringement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to maintain effective proprietary
rights for our product candidates, we may not be able to compete effectively in our markets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the protection
afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part,
by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve
the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining physical security of our premises
and physical and electronic security of our information technology systems. Agreements or security measures may be breached, and we may
not have adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently
discovered by competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from
third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially
reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third party intellectual property rights
are held to cover our product candidates or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize product candidates or our product candidates unless we successfully pursue
litigation to nullify or invalidate the third party intellectual property right concerned, or enter into a license agreement with the
intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that
if they result in issued patents, could be alleged to be infringed by our new product candidates. If such an infringement claim should
be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new product candidates or seek a
license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, certain U.S. patent applications that will not be filed
outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published
approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred
to as the priority date. Therefore, patent applications covering our new product candidates or platform technology could have been filed
by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations,
be later amended in a manner that could cover our platform technologies, our new product candidates or the use of our new product candidates.
Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will
be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on
terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in pursuing the development of and/or marketing our new product candidates. If we fail in any such
dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new product
candidates that are held to be infringing. We might, if possible, also be forced to redesign our new product candidates so that we no
longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require
us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new product candidates.
As our industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our product candidates. There may be currently pending
patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain
patents in the future and claim that use of our technologies infringes upon these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for designs, or methods of use, the holders
of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a
license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be
available on commercially reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and
would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us
in the U.S. or any other relevant jurisdiction, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, pay royalties, redesign our infringing product candidates or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue
from our patent applications, or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing,
or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed
patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all
other requirements for patentability are met, in the United States prior to 2013, the first to make the claimed invention without undue
delay in filing, is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the
patent. After 2013, the United States moved to a first to file system. Changes in patent litigation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could
have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our new product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. The validity of U.S. patents may also be challenged in
post-grant proceedings before the USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new product candidates
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on product candidates, as well as monitoring their infringement in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries can be less extensive than those in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our product candidates. Future patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products in violation of our proprietary rights generally. Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts
to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Pharmaceutical Business
Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>From time to time, we may sign letters of
intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements. There can
be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically invest in transactions from time
to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements.
We may never enter into definitive agreements after signing a letter of intent and/or entering into a term sheet or other similar arrangement
for a multitude of reasons, including, but not limited to, regulatory, operational, financial and other considerations. There may also
be forces outside of our control that have an effect on our ability or decision as to whether we enter into such definitive agreements.
As a result, there can be no assurance that upon signing a letter of intent and/or entering into a term sheet or similar arrangement,
that we will enter into definitive documents. This could have a material adverse effect on our reputation and could cause us to incur
expenses if any legal claims arise as a result thereof. For example, in November 2019, we entered into a memorandum of understanding with
Heavenly Rx, Ltd., or Heavenly Rx, pursuant to which we and Heavenly Rx agreed to pursue a business combination. In accordance with the
memorandum of understanding between the parties, any transaction between the parties remained subject to entry into definitive agreements,
and to shareholder and regulatory approvals. We never entered into definitive agreements and do not expect to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, we may strategically
invest into various pharmaceutical companies. However, we can offer no assurance that the value of our investment will increase or that
it will not fluctuate because the value of our investments may be adversely affected by a number of factors, such as negative changes
in a company&#8217;s results of operations, cash flows, financial position and accounting impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, on March 31,
2022, we entered into an agreement with and invested in MitoCare X Bio Ltd., or MitoCareX, a company focused on the discovery and development
of potential drugs for cancers and other life-threatening conditions. Subsequent to this, we signed a non-binding letter of intent relating
to the sale of our entire ownership interest in MitoCareX to a publicly traded company in the United States. In addition, on November
17, 2022, we invested in Clearmind, a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived
therapeutics to solve widespread and underserved health problems. In addition, on August 13, 2024, we entered into an exclusive patent
license agreement with Polyrizon Ltd., or Polyrizon, for the out-licensing of our SCI-160 program, or the Polyrizon License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The potential benefits of
the agreement with MitoCareX, the investment in Clearmind, the exclusive patent license agreement with Polyrizon, or other potential investments
may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results of operations,
cash flows and financial position. The potential benefits of agreements with potential ventures may not materialize or may not be realized
to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results of operations, cash flows
and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to expand our organization
and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are so leanly staffed, we will need additional managerial, operational, sales, marketing,
financial, legal and other resources. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing
these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our
infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the
development of additional pharmaceutical product candidates. If our management is unable to effectively manage our growth, our expenses
may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize pharmaceutical product candidates and compete effectively
will depend, in part, on our ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify, license or discover additional pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a substantial amount
of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing pharmaceutical product
candidates, the success of our business also depends in part upon our ability to identify, license or discover additional pharmaceutical
product candidates. Our research programs or licensing efforts may fail to yield additional pharmaceutical product candidates for clinical
development for a number of reasons, including but not limited to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential pharmaceutical product candidates;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">we may not be able or willing to assemble sufficient resources to acquire or discover additional pharmaceutical product candidates;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">our pharmaceutical product candidates may not succeed in preclinical or clinical testing;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">our potential pharmaceutical product candidates may be shown to have harmful side effects or may have other characteristics that may make the pharmaceutical products unmarketable or unlikely to receive marketing approval;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">competitors may develop alternatives that render our pharmaceutical product candidates obsolete or less attractive;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">pharmaceutical product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the market for a pharmaceutical product candidate may change during our program so that such a pharmaceutical product may become unreasonable to continue to develop;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">a pharmaceutical product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">a pharmaceutical product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these events occur,
we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license or discover
additional pharmaceutical product candidates, which would have a material adverse effect on our business and could potentially cause us
to cease operations. Research programs to identify new pharmaceutical product candidates require substantial technical, financial and
human resources. We may focus our efforts and resources on potential programs or pharmaceutical product candidates that ultimately prove
to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for any of our pharmaceutical product candidates and begin commercializing those pharmaceutical products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal AKS, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things,
our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal
government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the federal AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine requirements under the ACA requires manufacturers of drugs, devices and medical supplies to report annually to the U.S. DHHS information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these
laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud
statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the
ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal AKS constitutes
a false or fraudulent claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties,
including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare
and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to
operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>The COVID-19 pandemic
has resulted in delays to our product development and may adversely affect any potential future revenues, results of operations and financial
condition.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">COVID-19
and the various precautionary measures taken by many governmental authorities around the world to limit its spread had a severe effect
on global markets and the global economy. The extent to which the coronavirus impacts our business and operations will depend on future
developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of
COVID-19 and the nature and extent of governmental actions taken to contain or treat its impact and the availability, costs, effectiveness
and public acceptance of any FDA-approved vaccines, among others. COVID-19 and official actions taken in response to it caused a major
slowdown in overall economic activity in the U.S. and elsewhere, curtailed consumer spending and made it more challenging to adequately
staff and manage our business and operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
COVID-19 pandemic impacted our various vendors, including CROs, and caused delays in the development of our product candidates. We also
experienced delays in the preparation toward various clinical trials, including being unable to receive prioritization to conduct clinical
trials, availability of physicians and other staff members involved in our clinical trials. At this time, we do not anticipate that the
COVID-19 pandemic and official responses would cause a material adverse effect on our results of operations and financial condition but
there can be no assurance that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of any of our pharmaceutical product
candidates and marketed products could result in product liability or similar claims that could be expensive, damage our reputation and
harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential pharmaceutical product liability or similar claims. The pharmaceutical and nutraceuticals industries have
historically been litigious, and we face financial exposure to pharmaceutical product liability or similar claims if the use of any of
our pharmaceutical products were to cause or contribute to injury or death. There is also the possibility that defects in the design or
manufacture of any of our pharmaceutical products might necessitate a pharmaceutical product recall. Although we plan to maintain pharmaceutical
product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be
unable to maintain pharmaceutical product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide
us with adequate coverage against potential liabilities. A pharmaceutical product liability claim, regardless of merit or ultimate outcome,
or any pharmaceutical product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration
and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of, our insurance
coverage could have a material adverse effect on our business, financial condition and results of operations.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of
hazardous materials, including the components of our pharmaceutical product candidates and other hazardous compounds. We and our manufacturers
and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities
pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts, business operations and environmental damage resulting in costly clean-up and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste pharmaceutical
products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these
materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate
the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages
and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials
and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended
to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently
carry biological or hazardous waste insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the eCommerce&#160;Operations
of SciSparc Nutraceuticals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to successfully pursue,
integrate, or execute upon the eCommerce operations business of SciSparc Nutraceuticals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we&#160;purchased
Wellution&#8482;, a business and brand which sells hemp-based products on Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management has limited
prior experience in eCommerce business operations. There can be no assurance that we will be able to successfully implement our new business
ventures or successfully operate within this industry.&#160;The successful integration of a new business also depends on our ability to
manage the new business, realize forecasted synergies and full value from the combined business. Our business, results of operations,
financial condition and cash flows could be materially adversely affected if we are unable to successfully integrate&#160;Wellution into
our existing operations and any inability to do so may also hinder our ability to grow, divert the attention of management and our key
personnel, disrupt our business and impair our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on Amazon Marketplace and fulfillment by Amazon.com and changes to Amazon Marketplace, Amazon&#8217;s services and their terms of
use may harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s products
are sold predominantly on Amazon Marketplace and orders are fulfilled entirely by Amazon Marketplace utilizing the fulfilled by Amazon,
or FBA, model. In order to continue to utilize Amazon Marketplace and FBA, we must comply with the applicable policies and terms of use
relating to these services. Such policies and terms of use may be altered or amended at Amazon Marketplace&#8217;s sole discretion, including
changes regarding the cost of securing these services, and changes that increase the burden of compliance with its requirements, may cause
us to significantly alter our business model or incur additional costs in order to comply, which could negatively impact our results of
operations. Non-compliance with applicable terms of use and policies can result in the removal of one or more products from the marketplace
and suspension of fulfillment services either of which could have a material adverse effect on our business and results of our operations.
In February 2024, Wellution was in non-compliance with changes in Amazon&#8217;s policies concerning claims associated with vitamin and
cosmetic products. The new Amazon policy mandated that no claims, in any form, could be displayed on the product label, in the Amazon
listing, or within the product descriptions. For instance, phrases such as &#8220;Our Keto Weight Loss Gummy Bear Reduces Appetite&#8221;
were no longer permissible. Instead, it was required to describe the product using terminology such as &#8220;Keto Gummy Bears For A Healthy
Lifestyle&#8221;. Due to the extensive descriptions present on both the Amazon listing and the product label itself, it took several weeks
to achieve a comprehensive understanding of Amazon&#8217;s new requirements. Moreover, each word within the description required prior
approval from the Amazon team, with revision responses typically taking several days or longer. Often, these responses originated from
automated systems, lacking the clarity and specificity needed for effective resolution. To navigate this process efficiently, Amazon experts
were engaged to assist with the necessary adjustments. As a result, all products sold by Wellution were removed for sale from the marketplace
and product labels were updated, a process that spanned several weeks to complete and caused the sales on the Wellution platform to dramatically
decrease for such period. Since implementing these changes and resolving the issue, we have experienced no further instances of non-compliance
and remains committed to maintaining compliance. However, there is no guarantee that similar issues will not arise in the future, which
could lead to product removal from the marketplace or suspension of fulfillment services, adversely impacting its business and operational
outcomes.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on other information technologies and systems to operate its business and to maintain its competitiveness, and any failure to invest
in and adapt to technological developments and industry trends could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on sophisticated
information technologies and systems, technology and systems used for Wellution&#8217;s websites and apps, customer service, logistics
and fulfillment, supplier connectivity, communications and administration. As our operations grow in size, scope and complexity, we will
need to continuously improve and upgrade our systems and infrastructure to offer an increasing number of consumer-enhanced services, features
and functionalities, while maintaining and improving the reliability and integrity of our systems and infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to use A.I. tools and infrastructure, including logistics and fulfillment platform which leverages, to meet rapidly evolving
eCommerce trends and demands. The emergence of alternative platforms may require us to continue to invest in new and costly technology.
We may not be successful, or we may be less successful than our competitors, in adopting technologies that operate effectively across
multiple eCommerce platforms, which would negatively impact our business and financial performance. New developments in other areas, such
as cloud computing providers, could also make it easier for competitors to enter our markets due to lower up-front technology costs. In
addition, we may not be able to maintain our existing systems or replace our current systems or introduce new technologies and systems
as quickly or cost effectively as we would like. Failure to invest in and adapt to technological developments and industry trends may
have a material adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on data provided by third parties, the loss of which could limit the functionality of our platforms, cause us to invest in the wrong
product or disrupt our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use third party software
to determine market trends and what markets to enter into. Our ability to successfully use this software depends on our ability to analyze
and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon. Some of this
data is provided to us pursuant to third-party data sharing policies and terms of use, under data sharing agreements by third-party providers
or by customer consent. The majority of this data is sourced for free or for de minimis amounts. These sources of data allow us, along
with A.I. tools, to determine trends, performance and consumer sentiment on products and searches within eCommerce platforms. This functionality
allows us to help determine which products to market, in some cases manufacture through contract manufacturers, import and sell on eCommerce
marketplaces. The connection to multiple eCommerce platforms through application programming interfaces allow us to develop the automation
of the purchase of marketing and automate the change of pricing of product listings on those eCommerce platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, any of these
third parties could change its data sharing policies, including making them more restrictive, charging fees or altering its algorithms
that determine the placement, display and accessibility of search results and social media updates, any of which could result in the loss
of, or significant impairment to, our ability to collect useful data. These third parties could also interpret our, or our service providers&#8217;,
data collection policies or practices as being inconsistent with their policies, which could result in the loss of our ability to collect
this data. Privacy concerns may cause end users to resist providing the personal data necessary to allow us to determine market trends
as well as our ability to effectively retain existing customers. Privacy advocacy groups and the technology and other industries are considering
various new, additional or different self-regulatory standards that may place additional burdens on us. Any such changes could impair
our ability to use data and could adversely impact select functionality of our proprietary software, impairing our ability to use this
data to anticipate customer demand and market trends, as well as adversely affecting our business and our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
depend on our ability to build and maintain strong product listings on eCommerce platforms. We may not be able to maintain and enhance
our product listings if we receive a substantial number of customer complaints, negative publicity or otherwise fail to live up to customers&#8217;
expectations, any of which could materially adversely affect our business, results of operations and growth prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maintaining and enhancing
our product listings is critical in expanding and growing our business. However, a significant portion of our perceived performance to
the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services
and other third-party delivery agents and online retailers, mainly Amazon. Because our agreements with our online retail partners are
generally terminable at will, we may be unable to maintain these relationships, and our results of operations could fluctuate significantly
from period to period. Because we rely on third party logistics companies to deliver our products, we are subject to shipping delays or
disruptions caused by inclement weather, natural disasters, labor activism, health epidemics or bioterrorism. In addition, because we
rely on national, regional and local transportation companies for the delivery of some of our other products, we are also subject to risks
of breakage or other damage during delivery by any of these third parties. If these third parties do not meet our or our customers&#8217;
expectations, our brands may suffer irreparable damage. In addition, maintaining and enhancing our current and future brands may require
us to make substantial investments, and these investments may not yield sufficient returns. If we fail to promote and maintain our brands,
or if we incur excessive expenses in this effort, our business, operating results and financial condition may be materially adversely
affected. We anticipate that, as our market becomes increasingly competitive, maintaining and enhancing our brands may become increasingly
difficult and expensive. Maintaining and enhancing our brands will depend largely on our ability to anticipate market trends and customer
demand and to provide high quality products to our customers and a reliable, trustworthy and profitable sales channel to our suppliers,
which we may not be able to do successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial number of customer
complaints or negative publicity about its sites, products, delivery times, customer data handling and security practices or customer
support, especially on blogs, social media websites or its sites, could rapidly and severely diminish consumer views of its products and
result in harm to its brands. Customers may also make safety-related claims regarding products sold through its online retail partners,
such as Amazon, which may result in an online retail partner removing the product from its marketplace. Such removal may materially impact
its financial results depending on the product that is removed and length of time that it is removed. SciSparc also uses and relies on
other services from third parties, such as its telecommunications services, and those services may be subject to outages and interruptions
that are not within its control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial number of customer
complaints or negative publicity about our sites, products, delivery times, customer data handling and security practices or customer
support, especially on blogs, social media websites or our sites, could rapidly and severely diminish consumer views of our products and
result in harm to our brands. Customers may also make safety-related claims regarding products sold through our online retail partners,
such as Amazon, which may result in an online retail partner removing the product from its marketplace. Such removal may materially impact
our financial results depending on the product that is removed and length of time that it is removed. We also use and rely on other services
from third parties, such as our telecommunications services, and those services may be subject to outages and interruptions that are not
within our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; efforts
of SciSparc Nutraceuticals to acquire or retain customers, and our efforts to sell new products or increase sales of our existing products,
may not be successful, which could prevent us from maintaining or increasing our sales and achieving profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not successfully
promote and sustain our new and/or existing product listings and brands through marketing and other tools, we may fail to maintain or
increase our sales and achieve profitability. Promoting and positioning our brands and product listings will depend largely on the success
of our marketing efforts, our ability to attract customers cost effectively and our ability to consistently provide a high-quality product
and maintain consumer satisfaction. We also use promotions to drive sales, which may not be effective and may adversely affect our gross
margins. Our investments in marketing may not effectively reach potential customers, potential customers may decide not to buy our products
or the spending of customers that purchase from us may not yield the intended return on investment, any of which could negatively affect
our financial results. The failure of our marketing activities could also adversely affect our ability to promote our product listings
and sell our products, and to develop and maintain relationships with our customers, retailers and brands, which may have a material adverse
effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the eCommerce operations of SciSparc
Nutraceuticals fail to offer high-quality customer support, our business and reputation may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-quality education and
training of customer support personnel to deliver high-quality customer support are important for the successful retention of existing
customers. Providing this education, training and support requires that our support personnel have specific knowledge and expertise of
our products and markets, making it more difficult for us to hire experienced personnel and to scale up our support operations. The importance
of high-quality customer support will increase as we expand our business and pursue new customers. If we do not provide effective and
timely ongoing support, our ability to retain existing customers may suffer, and our reputation with existing or potential customers may
be harmed, which would have a material adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; efforts
of SciSparc Nutraceuticals to expand our business into new brands, products, services, technologies and geographic regions will subject
us to additional business, legal, financial and competitive risks and may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s business
success depends to some extent on our ability to expand our consumer offerings by launching new brands, products and services and by expanding
our existing offerings into new geographic regions. Our strategy is to use our skills to determine which markets to enter and optimize
the mix of products and services that we offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Launching new brands, products
and services requires significant upfront investments, including investments in marketing (namely digital marketing and Pay Per Click
(PPC), information technology and additional personnel. We operate in highly competitive industries with relatively low barriers to entry
and must compete successfully in order to grow our business. We may not be able to generate satisfactory revenue from these efforts to
offset these costs. Any lack of market acceptance of our efforts to launch new brands, products or services or to expand our existing
offerings could have a material adverse effect on our business, prospects, financial condition and results of operations. Further, as
we continue to expand our fulfillment capability or add new businesses with different requirements, our logistics networks will become
increasingly complex and operating them will become more challenging. There can be no assurance that we will be able to operate our networks
effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also entered and may
continue to enter new markets and provide product offerings in which we have limited or no experience, which may not be successful or
appealing to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce consumer products
goods industry is subject to evolving standards and practices, as well as changing consumer needs, requirements and preferences. Our ability
to attract new customers and increase revenue from existing customers depends, in part, on our ability to enhance and improve our existing
tools that enable us to pinpoint new markets and introduce new products. The success of any enhancements or new instruments depends on,
in part, market-accepted pricing levels and overall market acceptance. We may not be successful in these efforts, which could result in
significant expenditures that could impact our revenue or distract management&#8217;s attention from current offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increased emphasis on the
sale of new products could distract us from sales of our existing products in existing markets, negatively affecting our overall sales.
We have invested and expect to continue to invest in new businesses, products, features, services and technologies. Such endeavors may
involve significant risks and uncertainties, including insufficient revenue from such investments to offset any new liabilities assumed
and expenses associated with these new investments, inadequate return of capital on our investments, distraction of management from current
operations and unidentified issues not discovered in our due diligence of such investments that could cause us to fail to realize the
anticipated benefits of such investments and incur unanticipated liabilities. Because these new strategies and offerings are inherently
risky, no assurance can be given that they will be successful. Our new features or enhancements could fail to attain sufficient market
acceptance for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">delays in introducing products in new markets;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">failure to accurately predict market demand or end consumer preferences;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">introduction of competing products;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">poor financial conditions for our customers or poor general macroeconomic conditions;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">changes in legal or regulatory requirements, or increased legal or regulatory scrutiny, adversely affecting our products;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">failure of our brands, and products, digital promotion activities or negative publicity about the performance or effectiveness of our existing brands and products; and</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">disruptions or delays in the online retailers and, or in addition to, logistics providers distributing our products.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully identify new opportunities or develop and bring new products to market on a timely basis, which could materially
and adversely affect our business and operating results and compromise our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; use of social
media and email by SciSparc Nutraceuticals may adversely impact our reputation or subject us to fines or other penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use social media and email
as part of our digital marketing efforts. As laws and regulations rapidly evolve to govern the use of these channels, the failure by us,
our employees or third parties acting at on our behalf to abide by applicable laws and regulations in the use of these channels could
adversely affect our reputation or subject us to fines or other penalties. In addition, our employees or third parties acting on our behalf
may knowingly or inadvertently make use of social media in ways that could lead to the loss or infringement of intellectual property,
as well as the public disclosure of proprietary, confidential or sensitive personal information of our business, employees, customers
or others. Any such inappropriate use of social media or email could also cause reputational damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers value readily available
information concerning retailers and their goods and services and often act on such information without further investigation and with
no regard to its accuracy. Our customers may engage with us online through our social media platforms, including Facebook and Instagram,
by providing feedback and public commentary about all aspects of our business. Information concerning us or our retailers and brands,
whether accurate or not, may be posted on social media platforms at any time and may have a disproportionately adverse impact on our brand,
reputation or business. The harm may be immediate without affording us an opportunity for redress or correction and could have a material
adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if our emails are not delivered and accepted or are routed by email providers less favorably than other emails,
or our sites or mobile applications are not accessible or are treated disadvantageously by Internet service providers, our business may
be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If email providers or Internet
service providers, or ISPs, implement new restrictive email or content delivery or accessibility policies, including with respect to net
neutrality, or begin enforcement of existing policies, it may become more difficult to deliver emails to our customers or for customers
to access our sites, products and services. For example, certain email providers, including Google, categorize our emails as &#8220;promotional&#8221;,
and these emails are directed to an alternate, and less readily accessible, section of a customer&#8217;s inbox. If email providers materially
limit or halt the delivery of our emails, or if we fail to deliver emails to customers in a manner compatible with email providers&#8217;
email handling or authentication technologies, our ability to contact customers through email could be significantly restricted. In addition,
if we are placed on &#8220;spam&#8221; lists or lists of entities that have been involved in sending unwanted, unsolicited emails, our
operating results and financial condition could be substantially harmed. Further, if ISPs prioritize or provide superior access to our
competitors&#8217; content, our business and results of operations may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
are subject to risks related to online payment methods.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We accept payments using a
variety of methods, including credit card, debit card, PayPal, Payoneer, credit accounts (including promotional financing) and gift cards.
For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise
our operating costs and lower profitability. In addition, our credit card and other payment processors could impose receivable holdback
or reserve requirements in the future. We rely on third parties to provide payment processing services, including the processing of credit
cards and debit cards, and it could disrupt our business if these companies become unwilling or unable to provide these services to us.
We are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers,
which could change or be reinterpreted to make it difficult or impossible for us to comply. If we fail to comply with the rules or requirements
of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment
methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines
or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card or debit card payments from
customers or to facilitate other types of online payments. If any of these events were to occur, our business, financial condition and
operating results could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if we are unable to manage our inventory effectively, our operating results could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To ensure timely delivery
of products, we generally enter into purchase orders in advance with manufacturers. As a result, we are vulnerable to demand and pricing
shifts and to suboptimal selection and timing of product purchases. We rely on our procurement team to order products and we rely on our
data analytics to inform the levels of inventory we purchase, including when to reorder items that are selling well and when to write
off items that are not selling well. In these instances, we may be unable to always predict the appropriate demand for our products by
customers with accuracy, which may result in inventory shortages, inventory write offs and lower gross margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our sales and procurement
teams do not predict demand well or if our algorithms do not help us reorder the right products or write off the right products timely,
we may not effectively manage our inventory, which could result in inventory excess or shortages, and our operating results and financial
condition could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals,
including the costs and supply chain, are subject to risks associated with sourcing, importing and warehousing.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We source the products we
offer from third-party vendors and, as a result, we may be subject to price fluctuations or demand disruptions. Our operating results
could be negatively impacted by increases in the prices of our products, and we have no guarantees that prices will not rise. In addition,
as we expand into new categories and types of products, we expect that we may not have strong purchasing power in these new areas, which
could lead to higher costs than we have historically seen in our current product categories and types. We may not be able to pass increased
costs on to customers, which could adversely affect our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we cannot guarantee
that products we receive from vendors will be of sufficient quality or free from damage or defects, or that such merchandise will not
be damaged during shipping or storage. While we take measures to ensure product quality and avoid damage, including evaluating vendor
facilities, operations and product samples, conducting inventory inspections and inspecting returned products, we cannot control merchandise
while it is out of our possession or prevent all damage while in our distribution centers. We may incur additional expenses and our reputation
could be harmed if or current or potential customers believe that our merchandise is not of high quality or may be damaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks associated with the suppliers from
whom our products are sourced could materially adversely affect our financial performance, as well as our reputation and brand.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on our ability to
provide our customers with a wide range of products from high quality suppliers in a timely and efficient manner. Our agreements with
most of our suppliers do not provide for the long-term availability of merchandise or the continuation of particular pricing practices,
nor do they usually restrict such suppliers from selling products to other buyers or directly themselves. There can be no assurance that
our current suppliers will continue to seek to sell us products on current terms or that we will be able to establish new or otherwise
extend current supply relationships to ensure product acquisitions in a timely and efficient manner and on acceptable commercial terms.
Our ability to develop and maintain relationships with reputable suppliers and offer high quality products to our customers is critical
to our success. If we are unable to develop and maintain relationships with suppliers that would allow us to offer a sufficient amount
and variety of quality products on acceptable commercial terms, our ability to satisfy our customers&#8217; needs, and therefore our long-term
growth prospects, would be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also are unable to predict
whether any of the countries in which our suppliers&#8217; products are currently manufactured or may be manufactured in the future will
be subject to trade restrictions imposed by the U.S. or foreign governments or the likelihood, type or effect of any such restrictions.
Any event causing a disruption or delay of imports from suppliers with international manufacturing operations, including the imposition
of additional import restrictions, restrictions on the transfer of funds or increased tariffs or quotas, could increase the cost or reduce
the supply of merchandise available to our customers and materially adversely affect our financial performance as well as our reputation
and brand. Our competitors may have greater existing inventory positions and other advantages that may allow them to price more competitively
relative to our products. Furthermore, some or all of our suppliers&#8217; foreign operations may be adversely affected by political and
financial instability, resulting in the disruption of trade from exporting countries, restrictions on the transfer of funds or other trade
disruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not accurately forecast revenues,
profitability and appropriately plan our expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our current and future
expense levels on our operating forecasts and estimates of future income and operating results. Income and operating results are difficult
to forecast because they generally depend on the volume and timing of the orders we receive, which are uncertain. Additionally, our business
is affected by general economic and business conditions around the world. A softening in income, whether caused by changes in consumer
preferences, a weakening in global economies or inflation, may result in decreased net revenue levels, and we may be unable to adjust
our spending in a timely manner to compensate for any unexpected shortfall in income. This inability could cause our income (loss) from
operations after tax in a given quarter to be lower or higher than expected. We also make certain assumptions when forecasting the amount
of expenses we expect related to our share-based payments, which includes the expected volatility of our share price, and the expected
life of equity awards granted. These assumptions are partly based on historical results. If actual results differ from our estimates,
our operating results in a given quarter may be lower than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operation&#8217;s operating
results of SciSparc Nutraceuticals are subject to seasonal fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce business is
seasonal in nature and the fourth quarter is a significant period for our operating results due to the holiday season. As a result, revenue
generally declines and loss from operations generally increases in the first quarter sequentially from the fourth quarter of the previous
year. Any disruption in our ability to process and fulfill customer orders during the fourth quarter could have a negative effect on our
quarterly and annual operating results. For example, if a large number of customers purchase our products in a short period of time due
to increased holiday demand, inefficient management of our inventory may prevent us from efficiently fulfilling orders, which may reduce
sales and harm our brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The inability to acquire, use or maintain
our marks and domain names for our sites could substantially harm our business and operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have registered
trademarks for our brands in numerous jurisdictions and have registered the Internet domain names for our websites, as well as various
related domain names. However, we have not registered our trademarks or domain names in all major international jurisdictions. Domain
names generally are regulated by Internet regulatory bodies. If we do not have, or cannot obtain on reasonable terms, the ability to use
our marks in a particular country or to use or register any of our domain names, we could be forced either to incur significant additional
expenses to market our products within that country, including the development of a new brand and the creation of new promotional materials
and packaging, or to elect not to sell products in that country. Either result could materially adversely affect our business, financial
condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the regulations
governing domain names and laws protecting marks and similar proprietary rights could change in ways that block or interfere with our
ability to use relevant domains or our current brand names. Furthermore, we might not be able to prevent third parties from registering,
using or retaining domain names that interfere with our consumer communications or infringe or otherwise decrease the value of our marks,
domain names and other proprietary rights. Regulatory bodies also may establish additional generic or country-code top-level domains or
may allow modifications of the requirements for registering, holding or using domain names. As a result, we may not be able to register,
use or maintain the domain names that utilize the Wellution name in all of the countries in which we currently or intend to conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any significant disruption in service on
our websites or apps or in our computer systems, a number of which are currently hosted or provided by third-party providers, could materially
affect our ability to operate, damage our reputation and result in a loss of customers, which would harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to sell and market
our products relies on FBA platform whose functionality relies upon a number of third-party related services, including those relating
to cloud infrastructure, technology services, servers, open-source libraries and vendor application programming interfaces. Any disruption
or loss of any of these third-party services could have a negative effect on our business, results of operations, financial condition
and prospects. We may experience interruptions in our systems, including server failures that temporarily slow down or interfere with
the performance of our platforms and the ability to sell on eCommerce marketplaces.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interruptions in these systems,
whether due to system failures, human input errors, computer viruses or physical or electronic break-ins, and denial-of-service attacks
on us, third-party vendors or communications infrastructure, could affect the availability of our services on our platform and prevent
or inhibit the ability of selling our products. Volume of traffic and activity on eCommerce marketplaces spikes on certain days, such
as during a Black Friday promotion, and any such interruption would be particularly problematic if it were to occur at such a high-volume
time. Problems with the reliability of our systems or third-party marketplaces could prevent us from earning revenue and could harm our
reputation. Damage to our reputation, any resulting loss of customers, eCommerce confidence and the cost of remedying these problems could
negatively affect our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to maintain communications,
network and computer hardware in the countries in which they are used may in the future be subject to regulatory review and licensing,
and the failure to obtain any required licenses could negatively affect our business. Our systems and infrastructure are predominately
reliant on third parties. Problems faced by our third-party service providers with the telecommunications network providers with whom
they contract or with the systems by which they allocate capacity among their users, including us, could adversely affect the experience
of our customers. Our third-party service providers could decide to close their facilities without adequate notice. Any financial difficulties,
such as bankruptcy or reorganization, faced by our third-party service providers or any of the service providers with whom they contract
may have negative effects on our business, the nature and extent of which are difficult to predict. If our third-party service providers
are unable to keep up with our needs for capacity, this could have an adverse effect on our business. Any errors, defects, disruptions
or other performance problems with our services could harm our reputation and may have a material adverse effect on our business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<b>Risks Related to the Merger between SciSparc and AutoMax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the exchange ratio is fixed and
will not be adjusted in the event of a change in either our share price or AutoMax&#8217;s share price, AutoMax shareholders cannot be
certain of the precise value of the consideration that they may receive in the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of the
Merger, each outstanding share of AutoMax will be converted into the right to receive a number of our ordinary shares, to be determined
in accordance with the exchange ratio, or Exchange Ratio, agreed upon in the Merger agreement, or Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger agreement does
not provide for an adjustment to the total number of our ordinary shares that AutoMax shareholders will be entitled to receive to account
for changes in the market price of our ordinary shares. Accordingly, the market value of the shares of our ordinary shares issued pursuant
to the Merger will depend on the market value of our ordinary shares at the time the Merger closes and could vary significantly from the
market value of our ordinary shares as of April 23, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio formula
described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (other than us, which currently holds
shares in AutoMax) and its advisor are expected to own approximately 49.99% of our share capital and our shareholders are expected to
own approximately 50.01% of our share capital on a fully-diluted basis (subject to certain exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Ratio is the
result of the following calculation : the number of our outstanding shares on a fully-diluted basis (subject to certain exceptions) divided
by 0.5001, multiplied by 0.4749, then divided by the number of the AutoMax outstanding shares less the number of the AutoMax ordinary
shares held by us; so that, in any event, immediately following the effective time, holders of AutoMax outstanding shares (and its advisor,
but other than us), will hold together 49.99% of our share capital, on a fully-diluted basis (subject to certain exceptions), immediately
following the effective time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our ordinary
shares and, as a result, the value of the consideration that AutoMax shareholders may receive pursuant to the Merger Agreement, has been
fluctuating since the date that the Merger Agreement was executed and publicly announced and may continue to fluctuate through the date
of the completion of the Merger. Accordingly, upon the completion of the Merger and the issuance of our ordinary shares to the AutoMax
shareholders, the market price of our ordinary shares that will be issued to the AutoMax shareholders as the Merger consideration could
be greater than, less than or the same as the market price of our ordinary shares on the date the Merger Agreement was executed, on February
13, 2025, or on the date of our and AutoMax shareholder meetings. Share price changes may result from a variety of factors, including,
among others, changes in our or AutoMax&#8217;s respective businesses operations or prospects, risks described in the risk factors of
each of us and AutoMax; legislative, regulatory and legal developments; general market, industry and economic conditions; shareholder
litigation relating to the Merger or otherwise relating to us or to AutoMax; and market assessments of the likelihood that the Merger
will be completed. Because the value of the consideration will depend on the market price of our ordinary shares at the time the Merger
is completed, AutoMax shareholders will not know or be able to determine at the time of the AutoMax shareholders meeting the market value
of the Merger consideration they may receive upon completion of the Merger. Similarly, our shareholders will not know or be able to determine
at the time of the special meeting of our shareholders, the market value of the consideration to be paid to the AutoMax shareholders in
the form of issuance of our ordinary shares pursuant to the Merger Agreement compared to the market value of AutoMax ordinary shares that
are being exchanged. You are urged to obtain current market quotations for our ordinary shares and AutoMax ordinary shares in determining
<span>whether to vote for approval of the Merger-related proposals. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the proposed merger with AutoMax is not
consummated, our share price could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consummation of the proposed
Merger with AutoMax is subject to a number of closing conditions, including the approval by our shareholders, approval by Nasdaq of our
listing of additional securities application of its ordinary shares issued in connection with the Merger, and other customary closing
conditions. We are targeting a closing of the transaction before September 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the proposed Merger is
not consummated, we may be subject to a number of material risks, and its share price could be adversely affected, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred and expect to continue to incur significant expenses related to the proposed Merger with AutoMax, even if the Merger is not consummated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger Agreement contains covenants restricting our solicitation of competing acquisition proposals and the conduct of our business between the date of signing the Merger Agreement and the closing of the Merger. As a result, significant business decisions and transactions before the closing of the Merger require the consent of AutoMax. Accordingly, we may be unable to pursue business opportunities that would otherwise be in its best interest as a standalone company. We have invested significant time and resources in the transaction process and if the Merger Agreement is terminated we will have a limited ability to continue its current operations without obtaining additional financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our collaborators and other business partners and investors in general may view the failure to consummate the Merger as a poor reflection on its business or prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some of our collaborators and other business partners may seek to change or terminate their relationships with us as a result of the proposed Merger or the failure thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management team may be distracted from day to day operations as a result of the proposed Merger.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On July 16, 2024, we received a written notice, or the Notice, from Nasdaq indicating that it is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. On January 14, 2025, we received an additional written notice from Nasdaq indicating that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025, to regain compliance with the minimum bid price requirement. No assurance can be given that we will remain eligible to be listed on Nasdaq. Further, because of the previous delisting of our ADSs from Nasdaq, if we fall out of compliance with Nasdaq requirements in the future, our ordinary shares may be more likely to be subject to Nasdaq&#8217;s delisting process and no assurance can be given that we will be able to regain compliance. Any delisting could adversely affect our ability to obtain financing for the continuation of its operations and could result in the loss of confidence by investors, customers and employees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In addition, if the Merger Agreement is terminated and our board of directors determines to seek another business combination, it may not be able to find a third party willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the Merger. In such circumstances, our board of directors may elect to, among other things, divest all or a portion of our business, and, in such case, the consideration that we receive may be less attractive than the consideration to be received by us pursuant to the Merger Agreement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the conditions to the Merger are not
met, the Merger will not occur.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the Merger is approved
by our shareholders and AutoMax&#8217;s shareholders, specified conditions must be satisfied or waived to complete the Merger. We and
AutoMax cannot assure you that all of the conditions will be satisfied. If the conditions are not satisfied or waived, the Merger will
not occur or will be delayed, and we and AutoMax each may lose some or all of the intended benefits of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain of our officers and directors and
AutoMax&#8217;s officers and directors have interests in the Merger that are different from yours and that may influence them to support
or approve the Merger without regard to your interests.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our officers and
directors and AutoMax&#8217;s officers and directors participate in arrangements that provide them with interests in the Merger that are
different from yours, including, among others, the continued service as an officer or director of the combined company, the continued
receipt of compensation for such service, and continued indemnification. Each of Amitay Weiss, Amnon Ben Shay, Moshe Revach and Liat Sidi
will continue as directors of the combined company after the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss is also the
Chairman of our board of directors and serves as the chairman of AutoMax. In addition, contingent upon the approval and closing of the
Merger, shareholders are asked to approve a one-time cash bonus to our Chief Executive Officer, Chairman and President. Furthermore, certain
officers, directors and shareholders of AutoMax entered into an AutoMax shareholder support agreement, pursuant to which they agreed,
solely in their capacity as shareholders, to vote their shares in AutoMax covering approximately 55.65% of the outstanding shares of AutoMax
in favor of adoption of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Yaki Baranes, a business
analyst, presented a market overview on the motor vehicle market in Israel and a company overview of AutoMax as a vehicle importer in
Israel, to our board of directors on February 23, 2023. Mr. Baranes was appointed on May 30, 2023, as our VP Strategy and Business Development.
Mr. Baranes previously provided services to AutoMax. In addition, Mr. Baranes and Mr. Amitay Weiss both serve as members of the board
of Charging Robotics Inc. and Mr. Baranes provided market overview services to certain other companies of which Mr. Amitay Weiss serves
as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These interests may present
them with actual or potential conflicts of interest. These interests, among others, may influence our officers and directors AutoMax&#8217;s
officers and directors to support or approve the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our board of directors did not obtain a
fairness opinion&#160;in determining whether or not to proceed with the Merger.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors did
not obtain a fairness opinion&#160;in connection with its determination to approve the Merger. In analyzing the Merger, our board of directors
conducted due diligence on AutoMax and researched the industry in which AutoMax operates by obtaining, for example, an independent third-party
valuation report on AutoMax from E.D.B. Accordingly, investors will be relying solely on the judgment of our board of directors in determining
the value of the Merger and will not have assurance from an independent source that the terms of the Merger are fair to us from a financial
point of view. The lack of a&#160;fairness opinion&#160;may also lead an increased number of our shareholders to vote against the proposed
Merger, which could potentially impact our ability to consummate the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Merger may be completed even though
material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, either party can
refuse to complete the Merger if there is a material adverse change affecting the other party following April 10, 2024, the date of the
Merger Agreement. However, some types of changes do not permit either party to refuse to complete the Merger, even if such changes would
have a material adverse effect on us or AutoMax, to the extent they resulted from the following (unless, in some cases, they have a disproportionate
effect on us or AutoMax, as the case may be):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes or conditions generally affecting the industries or markets in which we and AutoMax operate, and changes in the industries in which we and AutoMax operate regardless of geographic region (including legal and regulatory changes);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acts of war, armed hostilities or terrorism;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial, banking or securities markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any change in, or any compliance with or action taken for the purpose of complying with, any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any governmental body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority), or changes in any interpretations thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any change in U.S. generally accepted accounting principles or interpretations thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the announcement of the Merger Agreement or the pendency of the Merger;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the taking of any action required to be taken by the Merger Agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pandemics, including any worsening thereof, man-made disasters, natural disasters, acts of God or other force majeure event; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in U.S. or non-U.S. general economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown of any governmental authority.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If adverse changes occur but
we and AutoMax must still complete the Merger, the combined company&#8217;s share price may suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of the combined company&#8217;s
shares may decline as a result of the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the combined
company&#8217;s shares may decline as a result of the Merger for a number of reasons, including if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of the Merger on the combined company&#8217;s business and prospects is not consistent with the expectations of financial or industry analysts; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors react negatively to the effect on the combined company&#8217;s business and prospects from the Merger.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;Our shareholders and AutoMax&#8217;s
shareholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with
the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company is
unable to realize the strategic and financial benefits currently anticipated from the Merger, our shareholders will have experienced substantial
dilution of their ownership interest without receiving any commensurate benefit. Significant management attention and resources will be
required to operate the two companies. Delays in this process could adversely affect the combined company&#8217;s business, financial
results, financial condition and share price following the Merger. Even if the combined company were able to operate the two businesses
operations successfully, there can be no assurance that this operation will result in the realization of the full benefits of synergies,
innovation and operational efficiencies that may be possible from this integration and that these benefits will be achieved within a reasonable
period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>During the pendency of the Merger, we and
AutoMax will be subject to contractual limitations set forth in the Merger Agreement that restrict the parties&#8217; ability to enter
into business combination transactions with another party.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Covenants in the Merger Agreement
impede the ability of us or AutoMax to make acquisitions or complete other transactions that are not in the ordinary course of business
pending completion of the Merger. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors.
In addition, while the Merger Agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting, initiating,
encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead to the entering
into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition of our securities, a tender offer
for our securities, a Merger or other business combination outside the ordinary course of business. Any such transactions could be favorable
to such party&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of the Merger Agreement
may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the arrangements
contemplated by the Merger Agreement.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Merger Agreement
prohibit each of us and AutoMax from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover
proposals. Because the lack of a public market for AutoMax shares makes it difficult to evaluate the fairness of the Merger, the shareholders
of AutoMax may receive consideration in the Merger that is less than the fair market value of the AutoMax shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain shareholders could attempt to influence
changes within our company that could adversely affect our operations, financial condition and the value of our ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shareholders may from
time to time seek to acquire a controlling stake in our company, engage in proxy solicitations, advance shareholder proposals or otherwise
attempt to effect changes. Campaigns by shareholders to effect changes at publicly-traded companies are sometimes led by investors seeking
to increase short-term shareholder value through actions such as financial restructuring, increased debt, special dividends, share repurchases
or sales of assets or the entire company. Responding to proxy contests and other actions by activist shareholders can be costly and time-consuming
and could disrupt our operations and divert the attention of our board of directors and senior management from the pursuit of the proposed
transaction. These actions could adversely affect our operations, financial condition, our ability to consummate the Merger and the value
of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We and AutoMax may become involved in securities
litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of our and AutoMax&#8217;s
management and harm the combined company&#8217;s business, and insurance coverage may not be sufficient to cover all related costs and
damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities litigation or shareholder
derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale of a business
division or announcement of a business combination transaction. We and AutoMax may become involved in this type of litigation in connection
with the Merger, and the combined company may become involved in this type of litigation in the future. Litigation often is expensive
and diverts management&#8217;s attention and resources, which could adversely affect the business of us, AutoMax and the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If any of the events described in &#8220;AutoMax&#8217;s
General Risk Factors&#8221; or &#8220;Risks Related to the Combined Company&#8221; occur, those events could cause the potential benefits
of the Merger not to be realized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s business is
expected to constitute a significant portion of the business of the combined company following the Merger. As a result, the risks described
below in the sections entitled &#8220;Risks Related to the Merger between SciSparc and AutoMax&#8221; beginning on page 41, and &#8220;Risks
Related to the Combined Company&#8221; beginning on page 69 are among the most significant risks to the combined company if the Merger
is completed. To the extent any of the events in the risks described in the sections referenced in the previous sentence occur, those
events could cause the potential benefits of the Merger not to be realized and the market price of the combined company&#8217;s shares
to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to our Intended Corporate Restructuring
Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intended Restructuring Plan, which may
involve transferring our pharmaceutical activities to a new wholly-owned subsidiary, may not be completed in accordance with the expected
plans or anticipated timeline, or at all, and may not achieve the expected results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
January 25, 2023, we announced that our board of directors resolved to pursue a restructuring plan, or the Restructuring Plan, which may
involve transferring our pharmaceutical activities to a subsidiary, which may be listed on a stock exchange. As part of the plan, we announced
that we would examine a spin-off of certain of our assets, followed by a listing of NewCo on a leading stock exchange, while maintaining
our controlling interest in NewCo such that we will continue to control its current business activities. We also intend to explore other
potential new opportunities, activities and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
November 22, 2023, we announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated terms as
announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Pursuant
to the Restructuring Plan, on June 25, 2023, we entered into a securities purchase agreement with AutoMax, pursuant to which, at the closing
and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, we invested NIS 2,500
thousand (approximately $691 thousand) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS 0.5. Following
the closing, we held approximately 5.6% of the issued and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
January 14, 2024, we entered into, as lender, a bridge loan agreement with AutoMax, pursuant to which AutoMax received a bridge loan in
the amount of $1.4 million, or the Bridge Loan, further to the previously-announced non-binding letter of intent for us to acquire AutoMax.
On April 10, 2024, we signed the Merger Agreement with AutoMax. On August 14, 2024, on November 26, 2024, and March 27, 2025, we and AutoMax
entered into an addendum to the Merger Agreement, or Merger Agreement Addendum, a second addendum to the Merger Agreement, or Merger Agreement
Second Addendum, and third addendum to the Merger Agreement, or Merger Agreement Third Addendum, respectively. On June 9, 2024, we entered,
as lender, into an amendment to the Bridge Loan, or the Amended Bridge Loan, pursuant to which AutoMax received an additional loan in
the amount of $1.0 million, for an aggregate amount of $2.4 million. On September 5, 2024, we entered into a second amendment to the Bridge
Loan, or the Second Amendment, pursuant to which we extended an additional loan in the amount of $1.85 million to AutoMax under terms
similar to the Amended Bridge Loan, bringing the total Bridge Loan amount to $4.25 million, or the Loan Amount. &#160;During the month
of September 2024, we provided AutoMax with the loan amounts due under the Second Amendment to the Bridge Loan, and offset any interest
due until November 30, 2024 from the principal amount, such that on the closing date of the Merger, we will be entitled to be paid the
due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the Loan Amount, accruing from the period
beginning on December 1, 2024 and ending on the effective date of the Merger. In consideration for the Loan Amount, AutoMax established
a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor
of us. On February 27, 2025, we announced that we had entered into a loan agreement with AutoMax where a $2 million loan was provided,
or the Additional Loan Agreement. The loan bears an 8% annual interest rate and will be repaid in equal monthly installments of $50,000
and interest, with AutoMax retaining the option to make early repayment without penalties. The interest on the loan will be cancelled
as of the consummation of the Merger Agreement and AutoMax will continue to make monthly payments towards the principal amount of the
loan. As collateral, AutoMax pledged a first-ranking fixed charge on its subsidiary&#8217;s shares, in accordance with a fixed charge
debenture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2024, we signed
a non-binding letter of intent, or the Spin-off LOI, for the spin-off of our advanced clinical stage pharmaceutical portfolio to a publicly
traded company on the Toronto Stock Exchange Venture in Canada, or TSXV. Pursuant to the letter of intent, we will sell, assign, convey
and transfer to Miza III Ventures Inc., or Miza, certain assets for consideration of common shares and contingent rights of Miza, based
on pre-determined milestones. Following the closing of such transaction, we would hold a controlling interest in Miza, the exact percentage
of which is contingent on agreeing on definitive terms between the parties. The resulting entity, in which we will hold an equity interest,
will be active in both the pharmaceutical and supplement sectors. On December 16, 2024, we announced that we entered into an amendment
to the Spin-off LOI, solely to extend the deadline to enter into definitive agreements by no later than March 31, 2025, which was extended
from July 31, 2024, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed
transaction by no later than April 30, 2025, which was extended from October 31, 2024. On March 31, 2025, we announced that we entered
into a second amendment to the Spin-off LOI solely to extend again the deadline to close the proposed transaction to no later than June
30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Completion
of the transactions contemplated by the Merger Agreement, the Spin-off LOI or any other potential restructuring plans or transactions
in addition to the possible listing of NewCo on a stock exchange, may be subject to, among other things, market conditions, tax or other
business analyses, regulatory approvals, receipt of any necessary consents, final approvals from its board of directors and shareholders
and satisfaction of any closing conditions to effectuate such corporate restructuring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Unanticipated
developments or changes, including but not limited to, changes in the general or financial market conditions, possible delays in obtaining
various regulatory and tax approvals, changes in the law, and challenges in executing the Acquisition or any other restructuring plan
could delay or prevent the completion of the Restructuring Plan and listing of NewCo, or cause the restructuring and listing of NewCo
to occur on terms or conditions that are different or less favorable than initially expected. These or other developments could cause
us not to realize some or all of the expected benefits of the Restructuring Plan and listing of NewCo or to realize them on a different
timeline than expected. If the Restructuring Plan and listing of NewCo do not occur, we could pursue other transactions involving our
pharmaceutical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Restructuring Plan and listing of NewCo
may not achieve the anticipated benefits and may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not realize the anticipated
strategic, financial, operational or other benefits of the Restructuring Plan and listing of NewCo. We cannot predict with certainty when
the benefits expected from these transactions will occur or the extent to which they will be achieved. There is no assurance that following
the Restructuring Plan and listing of NewCo that each separate company will be successful. Whether or not the Restructuring Plan and listing
of NewCo is completed, we may face material challenges in connection with the intended transactions, including but not limited to, the
diversion of management time on matters relating to the Restructuring Plan and listing of NewCo, the impact of having to operate under
the terms of any transition service agreements, the impact on our ability to retain talent and potential impacts on our relationships
with customers, suppliers, employees and other counterparties. In addition, we will incur one-time costs and ongoing costs in connection
with, or as a result of, the Restructuring Plan and listing of NewCo, including costs of operating as independent, publicly-traded companies
that the separate businesses will no longer be able to share. Those costs may exceed our estimates or could negate some of the benefits
we expect to realize. Further, we have not yet analyzed whether the Restructuring Plan and listing of NewCo will be tax-free to our shareholders
for U.S. federal income tax or Israeli tax purposes and there is no assurance that the Restructuring Plan and listing of NewCo will qualify
for this treatment. If the Restructuring Plan and listing of NewCo is ultimately determined to be taxable, any of NewCo, our shareholders
or us could incur income tax liabilities that could be significant. If we do not realize the anticipated benefits of the Restructuring
Plan and listing of NewCo it could adversely affect our business, results of operations, cash flows and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following any Restructuring Plan and listing
of NewCo, the trading price of our Ordinary Shares may fluctuate significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
the market value of our Ordinary Shares after any Restructuring Plan and listing of NewCo will be, in the aggregate, less than, equal
to or greater than the market value of our ordinary shares prior to such transactions. The trading price of our Ordinary Shares may be
more volatile around the time of the intended separation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Ownership of Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need additional capital in the future.
Raising additional capital by issuing securities may cause dilution to existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred losses every
year since our inception. If we continue to use cash at our historical rates of use we will need significant additional financing, which
we may seek through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, an existing shareholder&#8217;s
ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely
affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may
involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making
capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms
that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Options: NewSection; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not know whether a market for the
Ordinary Shares will be sustained or what the trading price of the Ordinary Shares will be and as a result it may be difficult for you
to sell your Ordinary Shares</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Ordinary Shares
are listed on Nasdaq, an active trading market for the Ordinary Shares may not be sustained. It may be difficult for you to sell your
Ordinary Shares without depressing the market price for the Ordinary Shares or at all. Further, an inactive market may also impair our
ability to raise capital by selling Ordinary Shares and may impair our ability to enter into strategic partnerships or acquire companies,
products, or services by using our equity securities as consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a substantial number of our Ordinary
Shares in the public market by our existing shareholders could cause our share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of our Ordinary Shares in the public market, or the perception that these sales might occur, could depress the market price of our Ordinary
Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The exercise of outstanding warrants or
conversion of outstanding convertible securities will cause significant dilution to holders of our equity securities and could adversely
affect the price of our Ordinary Shares. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 23, 2025, holders
of warrants (including pre-funded warrants) may exercise their warrants into up to 3,993,375 Ordinary Shares. In the event that such warrants
are exercised in full, the ownership interest of existing holders of our equity securities will be diluted and may have a negative effect
on the trading price of our Ordinary Shares. On February 25, 2025, we also sold and issued to certain investors convertible debentures
which are convertible into Ordinary Shares at a purchase price equal to 95% of the subscription amount. In the event such convertible
debentures are converted into Ordinary Shares, the ownership interest of existing holders of our equity securities will also be diluted
and may have a negative effect on the trading price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities may be
highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Ordinary
Shares is volatile. Our Ordinary Share price is and will continue to be subject to wide fluctuations in response to a variety of factors,
including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse results or delays in preclinical studies or clinical trials;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports of adverse events in our product candidates or clinical trial failures of our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain additional funding;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delay in filing a regulatory submission for any of our product or product candidates and any adverse development or perceived adverse development with respect to the review of that regulatory submission by the FDA or European or Asian authorities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">failure to successfully develop and commercialize
    our products or product candidates;</p>
    </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to enter into strategic collaborations or failure to successfully integrate acquisitions we have made;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us or strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws or regulations applicable to future products;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to scale up our manufacturing capabilities through third-party manufacturers, inability to obtain adequate product supply for our products or the inability to do so at acceptable prices;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products or technologies by our competitors;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed financial projections we may provide to the public;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures or delays in our intended Restructuring Plan;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed the financial expectations of the investment community;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by our competitors;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our platform technologies, technologies, products or product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key scientific or management personnel;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or shareholder litigation;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations of similar companies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in general conditions in the economy and the financial markets in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the multi-front conflict Israel faces;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our securities by us or our shareholders in the future; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volumes of our securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies trading
in the stock market have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies. Broad market and industry factors may negatively affect the market price of our Ordinary Shares, regardless
of our actual operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Outstanding warrants and pre-funded warrants
to acquire our Ordinary Shares are speculative in nature. Furthermore, holders of our warrants and pre-funded warrants will have no rights
as shareholders until such holders exercise their warrants and acquire our Ordinary Shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of the warrants
and pre-funded warrants acquire our Ordinary Shares upon exercise of the warrants and pre-funded warrants, holders of the warrants and
pre-funded warrants will have no rights with respect to our Ordinary Shares underlying such warrants and pre-funded warrants. Upon exercise
of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights of a holder of Ordinary Shares only
as to matters for which the record date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrants and pre-funded
warrants only represent the right to acquire Ordinary Shares at a fixed price, and in the case of the warrants, for a limited period of
time. Specifically, holders of the warrants and pre-funded warrants that we issued in private placements in March 2020, March 2021, June
2022 and October 2023 and in our November 2020 and August 2023 public offerings may exercise their right to acquire Ordinary Shares and
pay an exercise price per Ordinary Shares (in the case of the pre-funded warrants, $0.001 to $0.026 per Ordinary Share and in the case
of other warrants, ranging from $68.38 to $637.00 per Ordinary Share), subject to adjustment upon certain events, within five years from
their date of issuance, with the exception of the June 2022 warrants, which will expire seven years from the date of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot assure you that our Ordinary Shares
will remain listed on Nasdaq or any other securities exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs, which previously
represented our Ordinary Shares, were listed on Nasdaq from March 2017 through July 2020. On September 21, 2020, our ADSs were delisted
from Nasdaq as a result of not meeting the shareholders equity requirements of Nasdaq. Between December 2020 and August 2021, our ADSs
were quoted on the OTCQB. In August 2021, our ADR program was terminated and our ADSs were converted to Ordinary Shares on a one-for-one
basis. In September 2021, our Ordinary Shares began to be quoted for trading on the OTCQB under the ticker &#8220;SPRCF&#8221;. In December
2021, our Ordinary Shares were re-listed on Nasdaq and began trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on July 26, 2024,
we received the Notice from Nasdaq indicating that we are not in compliance with the minimum bid price requirement for continued listing
set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under
Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the minimum bid price requirement,
or until January 12, 2025. On January 14, 2025, we received an additional written notice from Nasdaq indicating that we had been granted,
per our request, an additional 180-day compliance period, or until July 14, 2025, to regain compliance with the minimum bid price requirement.
There is a risk that we could be subject to additional notices of delisting for failure to comply with Nasdaq Listing Rule 5550(a)(2)
or other Nasdaq Listing Rules and no assurance can be given that we will remain eligible to be listed on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, because of the previous
delisting of our ADSs from Nasdaq, if we fall out of compliance with Nasdaq requirements in the future, our Ordinary Shares may be more
likely to be subject to Nasdaq&#8217;s delisting process and no assurance can be given that we will be able to regain compliance. Any
delisting could adversely affect our ability to obtain financing for the continuation of our operations and could result in the loss
of confidence by investors, customers and employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to achieve and maintain effective
internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, results
of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting,
which could have a material adverse effect on the price of our Ordinary Shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal controls
are necessary for us to provide reliable financial reports and effectively prevent fraud. We are required to document and test our internal
control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments
of the effectiveness of our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal
control, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude
on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. Disclosing deficiencies
or weaknesses in our internal control, failing to remediate these deficiencies or weaknesses in a timely fashion or failing to achieve
and maintain an effective internal control environment may cause investors to lose confidence in our reported financial information, which
could have a material adverse effect on the price of our Ordinary Shares. If we cannot provide reliable financial reports or prevent fraud,
our operating results could be harmed.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not paid, and do not intend to pay,
dividends on our Ordinary Shares and, therefore, unless our traded securities appreciate in value, our investors may not benefit from
holding our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our Ordinary Shares since inception. We do not anticipate paying any cash dividends our Ordinary Shares in the foreseeable
future. Moreover, the Israeli Companies Law-1999, or the Companies Law, imposes certain restrictions on our ability to declare and pay
dividends. As a result, investors in our Ordinary Shares will not be able to benefit from owning these securities unless their market
price becomes greater than the price paid by such investors and they are able to sell such securities. We cannot assure you that you will
ever be able to resell our securities at a price in excess of the price paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable outcomes in legal proceedings
may harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of whether or not
there is merit to the claims underlying any legal proceedings to which we are subject, and regardless of whether we are found as a result
of such proceedings to have violated any applicable laws, such proceedings can be expensive to defend or respond to, and could result
in substantial costs and diversion of management&#8217;s attention and resources, which could harm our business, and potentially could
cause substantial and irreparable harm to our public reputation. For example, on May 2, 2023, Capital Point Ltd., or Capital Point, filed
a lawsuit in the Tel Aviv-Jaffa District Court against us as the sole defendant in connection with the warrant we issued to Capital Point
pursuant to a joint venture transaction entered into on May 15, 2020 by and between us, Capital Point and Evero Health Ltd. one of our
subsidiaries. The lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust enrichment
under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version), 1968. The lawsuit claims damages
in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the lawsuit, liquidated
damages according to the provisions set forth in the warrant, and seeks as well for the court to order a mandatory injunction order for
us to issue a warrant to Capital Point to purchase $340,000 of our ordinary shares, the return of any unlawful profits received by us
and punitive damages. As of April 23, 2025, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by
Capital Point are dormant and were forfeited by Evero Health Ltd. As of April 23, 2025, we cannot predict the likelihood of our success
in the lawsuit. If we do not prevail in such lawsuit, our results of operations and reputation could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of our Ordinary Shares if we are or were
to become a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, we will be treated
as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive
income&#8221; or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income.
Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. We do not believe that we would be deemed a PFIC for 2025. If we are a PFIC
in any taxable year during which a U.S. taxpayer holds the Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S.
federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing fund,&#8221;
or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of the Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#8217;s
holding period for the Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of
the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable
years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest
charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.
In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have
determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers
that have held the Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be
a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. U.S.
taxpayers that hold the Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing
requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to the Ordinary
Shares in the event that we are a PFIC. See Item 10.E. &#8220;Taxation-U.S. Federal Income Tax Considerations-Passive Foreign Investment
Companies&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Israeli Law and Our Operations
in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We conduct our operations in Israel. Conditions
in Israel, including the recent attack by Hamas and other terrorist organizations and Israel&#8217;s war against them, may affect our
operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are incorporated under Israeli law, and many of our employees, including our Chief Executive Officer and our Chief Financial Officer,
and other senior members of our management team, operate from our headquarters located in Israel. In addition, all of our officers and
directors are residents of Israel. Accordingly, our business and operations are directly affected by economic, political, geopolitical,
and military conditions in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Since
the establishment of the State of Israel in 1948 and in recent years, armed conflicts between Israel and its neighboring countries and
terrorist organizations active in the region have involved missile strikes, hostile infiltrations, terrorism against civilian targets
in various parts of Israel, and recently abduction of soldiers and citizens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Following
the October 7, 2023 attacks by Hamas terrorists in Israel&#8217;s southern border, Israel declared war against Hamas and since then, Israel
has been involved in military conflicts with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly and
through proxies like the Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following
the fall of the Assad regime in Syria, Israel has conducted limited military operations targeting the Syrian army, Iranian military assets
and infrastructure linked to Hezbollah and other Iran-supported groups. Although certain ceasefire agreements have been reached with Hamas
and Lebanon (with respect to Hezbollah), these agreements failed to be upheld and military activity and hostilities continue to exist
at varying levels of intensity, and the situation remains volatile, with the potential for escalation into a broader regional conflict
involving additional terrorist organizations and possibly other countries. Also, the fall of the Assad regime in Syria may create geopolitical
instability in the region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">While
our facilities have not been damaged during the current war, the hostilities with Hamas, Hezbollah, Iran and its proxies and others have
caused and may continue to cause damage to private and public facilities, infrastructure, utilities, and telecommunication networks, and
potentially disrupting our operations and supply chains. For example, our SCI-210 ASD clinical trial at Soroka Medical Center was delayed
by three months. In addition, Israeli organizations, government agencies and companies have been subject to extensive cyber attacks. This
could lead to increased costs, risks to employee safety, and challenges to business continuity, with potential financial losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
connection with the ongoing war, several hundred thousand Israeli military reservists were drafted to perform immediate military service,
and military reservists are expected to perform long reserve duty service in the coming years. None of our employees have been called
to active military duty as of April 23, 2025. The absence of our employees due to any future military service may materially and adversely
affect our ability to conduct our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli
government currently covers the reinstatement value of certain direct damages that are caused by terrorist attacks or acts of war, we
cannot assure you that such government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
global perception of Israel and Israeli companies, influenced by actions by international judicial bodies, may lead to increased sanctions
and other negative measures against Israel, as well as Israeli companies and academic institutions. There is also a growing movement among
countries, activists, and organizations to boycott Israeli goods, services and academic research or restrict business with Israel, which
could affect business operations. If these efforts become widespread, along with any future rulings from international tribunals against
Israel, they could significantly and negatively impact business operations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Prior
to the war, the Israeli government pursued changes to Israel&#8217;s judicial system and has recently renewed its efforts to effect such
changes. In response to the foregoing developments, certain individuals, organizations, and institutions, both within and outside of Israel,
voiced concerns that such proposed changes, if adopted, may negatively impact the business environment in Israel. Such proposed changes
may also lead to political instability or civil unrest. If such changes to Israel&#8217;s judicial system are pursued by the government
and approved by the parliament, the reaction to such changes may have an adverse effect on our business, our results of operations, and
our ability to raise additional funds, if deemed necessary by our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law may make it easy
for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders to convene a shareholder meeting without
the consent of our management, which may disrupt our management&#8217;s ability to run our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company listed on an
exchange in the U.S., Israeli law may allow any one or more of our shareholders holding, in the aggregate, at least 10% of our voting
rights to demand that we convene a special shareholders meeting. Also, in the event that we choose not to convene a special shareholders
meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others, that such shareholders may independently
convene a special shareholders meeting within three months (or under court&#8217;s ruling) and require us to cover the costs, within reason,
and as a result thereof, our directors might be required to repay us such costs. If our shareholders decide to exercise these rights in
a way inconsistent with our management&#8217;s strategic plans, our management&#8217;s ability to run our company may be disrupted, and
this process may entail significant costs to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations are subject to currency and
interest rate fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incur expenses in U.S.
dollars and NIS, but our financial statements are denominated in U.S. dollars. U.S. dollars is our functional currency and is the currency
that represents the principal economic environment in which we operate. As a result, we are affected by foreign currency exchange fluctuations
through both translation risk and transaction risk. As a result, we are exposed to the risk that the NIS may appreciate relative to the
dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation
of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations
in Israel would increase and our dollar-denominated results of operations would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could
prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of Israeli law
and our amended and restated articles of association could have the effect of delaying or preventing a change in control and may make
it more difficult for a third party to acquire us or our shareholders to elect different individuals to our board of directors, even if
doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay
in the future for our Ordinary Shares. Among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law does not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association require a vote of the holders of a majority of our outstanding Ordinary Shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision stating that each year the term of office of only one class of directors will and dividing our directors into three classes, requires a vote of the holders of 65% of the voting power represented at a general meeting of our shareholders and voting thereon has been obtained, provided the majority constitutes more than 33.33% of the total issued and outstanding share capital as of the record date of such meeting. The affirmative vote of at least three-quarters (3/4) of the directors, in addition to the approval of our shareholders, is also required in order to amend our amended and restated articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association provide that director vacancies may be filled by our board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict us from engaging in certain business combination transactions, with any shareholder who holds 15% or more of our voting power. The transactions subject to such restrictions include mergers, consolidations and dispositions of our assets with a market value of 10% or more of our assets or outstanding shares. Subject to certain exceptions, such restrictions will apply for a period of three years following each time a shareholder became the holder of 15% or more of our voting power; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict certain transactions which may have a significant effect on the Company&#8217;s structure, assets or business, including significant mergers and acquisitions, a disposition of all or substantially all of the assets of the Company, a voluntary dissolution and material changes to the principal business of the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Israeli tax considerations
may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty
with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral
in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two
years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted.
See &#8220;Item 10.E. Taxation-Israeli Tax Considerations and Government Programs&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a United States court against us and our officers and directors and the Israeli experts named in this Annual Report in Israel or the
United States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Israel
and our corporate headquarters are located in Israel. All of our executive officers and directors and the Israeli experts named in this
Annual Report are located in Israel. All of our assets and most of the assets of these persons are located in Israel. Service of process
upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S.
directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel
that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel, or obtain a judgment based
on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S.
securities laws against us or our non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a
claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing
the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect
on judgments rendered against us or our non-U.S. officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, an Israeli court
will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same
matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel
at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Competition for skilled technical and other personnel in
Israel is intense, and as a result we may fail to attract, recruit, retain and develop qualified employees, which could materially and
adversely impact our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We compete in a market marked
by rapidly changing technologies and an evolving competitive landscape. In order for us to successfully compete and grow, we must attract,
recruit, retain and develop personnel with requisite qualifications to provide expertise across the entire spectrum of our intellectual
capital and business needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal research and
development as well as significant elements of our general and administrative activities are conducted at our headquarters in Israel,
and we face significant competition for suitably skilled employees in Israel. While there has been intense competition for qualified human
resources in the Israeli high-tech industry historically, the industry experienced record growth and activity in 2021, both at the earlier
stages of venture capital and growth equity financings, and at the exit stage of initial public offerings and mergers and acquisitions.
This flurry of growth and activity has caused a sharp increase in job openings in both Israeli high-tech companies and Israeli research
and development centers of foreign companies, and intensification of competition between these employers to attract qualified employees
in Israel. As a result, the high-tech and bio-tech industry in Israel has experienced significant levels of employee attrition and is
currently facing a severe shortage of skilled human capital, including engineering, research and development, sales and customer support
personnel. Many of the companies with which we compete for qualified personnel have greater resources than we do, and we may not succeed
in recruiting additional experienced or professional personnel, retaining personnel or effectively replacing current personnel who may
depart with qualified or effective successors. Failure to retain or attract qualified personnel could have a material adverse effect on
our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a holder
of our securities will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of holders of our Ordinary Shares are governed by our amended and restated articles of association
and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in good
faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the Company and other shareholders
and to refrain from abusing his or her power in the Company, including, among other things, in voting at the general meeting of shareholders,
on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and certain
transactions requiring shareholders&#8217; approval under the Companies Law. In addition, a controlling shareholder of an Israeli company
or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint
or prevent the appointment of a director or officer in the Company, or has other powers toward the Company has a duty of fairness toward
the Company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available to assist
in understanding the implications of these provisions that govern shareholder behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We received Israeli government grants for
certain of our past research and development activities and programs, some of which we sold or are in the process of selling. The terms
of such grants may require us, in the future, to pay royalties and to satisfy specific conditions if and to the extent we generate revenues
from the know-how funded with these grants. We may be required to pay penalties in addition to payment of the royalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts with respect to some of our past activities, which was focused on developing an immunotherapeutic monoclonal antibody for the
treatment of Alzheimer&#8217;s disease, which we sold in March 2015, and our Anti-CD3 technology directed toward the treatment of inflammatory
and autoimmune diseases, which in part was returned and re-assigned to Hadasit Medical Research Services &amp; Development Ltd., or Hadasit,
and in part is still in the process of being sold, were financed in part through royalty-bearing grants from the Israeli Innovation Authority,
or the IIA. As of December 31, 2024, we had received the aggregate amount of approximately $1.1 million from the IIA for the development
of our abovementioned technologies. As of December 31, 2024, our contingent liabilities regarding IIA grants received by us were in an
aggregate amount of $1.1 million including interest. With respect to such grants, we are committed to pay royalties up to $1.1 million
relating only to technologies in our possession and excluding any royalties for technologies that we sold to third parties. We are required
to comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 5744-1984,
as amended, or the Innovation Law, and related regulations, as amended, with respect to those past grants. When a company develops know-how,
technology or products using IIA grants, the terms of these grants and the Innovation Law restrict the transfer or license of such know-how,
and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior
approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer or license to third
parties inside or outside of Israel of know how or for the transfer outside of Israel of manufacturing or manufacturing rights related
to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement
under which it permits us to transfer technology or development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Innovation Law and
the regulations thereunder, a recipient of IIA grants is required to return the grants by the payment of royalties of 3% to 5% on the
revenues generated from the sale of products (and related services) developed (in whole or in part) under an IIA program up to the total
amount of the grants received from IIA plus the relevant interest rate, if any. Under IIA regulations, grants received before June 30,
2017, bear the annual interest rate that applied at the time of the approval of the applicable IIA file which will apply to all of the
funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear an annual interest rate based on the
12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%. Grants approved
after January 1, 2024, shall bear the higher rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or
know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our technology
assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted to and follow certain home country corporate governance practices instead of otherwise applicable SEC requirements, which
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations, including the proxy rules and the short-swing profits recapture
rules. In addition, we will not be required under the Exchange Act to file current reports and financial statements with the SEC as frequently
or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we will generally be exempt from
filing quarterly reports with the SEC. Also, although the Companies Law requires us to disclose the annual compensation of our five most
highly compensated senior officers on an individual basis, this disclosure is not as extensive as that required of a U.S. domestic issuer.
Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under
the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you are
entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
United States or Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), we currently have limited international operations, but
our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product
candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical
trials, outside of the United States and Israel. Doing business internationally involves a number of risks, including but not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our products in various countries;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an outbreak of a contagious disease, such as coronavirus, which may cause us, third party vendors and manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
significantly harm our future international expansion and operations and, consequently, our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with the FCPA could subject
us to penalties and other adverse consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the FCPA,
which generally prohibits companies, such as us, whose securities are listed in the United States, from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign government official, political party or candidate for
public office for the purpose of influencing any act or decision of such foreign person in order to assist companies like us in obtaining
or retaining business. The FCPA also obligates companies like us, whose securities are listed in the United States, to comply with accounting
provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. The U.S. Department of Justice and the SEC, which have responsibility for enforcement of the FCPA, both consider employees
of government-operated health care systems to be &#8220;foreign officials&#8221; for FCPA purposes. In addition, the U.S. Department of
Justice and the SEC are both engaged in a long-running FCPA compliance review of pharmaceutical companies. If our employees or agents
are found to have engaged in conduct that violates the FCPA, we would be held responsible and could suffer severe penalties and other
consequences, including adverse publicity and damage to our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cybersecurity issues, security breaches
and other disruptions could compromise our information, expose us to liability and harm our reputation and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business relies upon information
technology systems operated by us and by our third-party service providers. These systems may fail or experience operational disruption,
experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of our business we
collect and store sensitive data, including intellectual property, personal information and our proprietary business information. The
secure maintenance and transmission of this information is critical to our operations and business strategy. We rely on commercially available
systems, software, tools and domestically available monitoring to provide security for processing, transmitting and storing this sensitive
data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hackers may attempt to penetrate
our computer systems, and, if successful, misappropriate personal or confidential business information. In addition, an associate, contractor
or other third-party with whom we do business may attempt to circumvent our security measures in order to obtain such information, and
may purposefully or inadvertently cause a breach involving such information. While we continue to implement additional protective measures
to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used
in such attacks change rapidly. If our third-party vendors fail to protect their information technology systems and our confidential and
proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information
and we could incur liability and reputational damage and the further development and commercialization of our product candidates could
be delayed. While we have not, to our knowledge, experienced any material IT system failures or cybersecurity attacks to date, we cannot
assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages,
breaches in our systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could
have a material adverse effect upon our reputation, business, operations or financial condition. If such an event were to occur and cause
interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of
sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to
our or our third-party vendors&#8217; information security programs or defenses could result in legal liability, reputational damage,
business interruption, and our competitive position could be harmed and the further development and commercialization of our products
or any future products could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack
or vulnerability may require significant investment of resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers or breaches, employee
error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures, natural disasters or other
catastrophic events. Furthermore, significant security breaches or disruptions of our internal information technology systems or those
of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access,
use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property,
proprietary business information and personal information), which could result in financial, legal, business and reputational harm to
us., Any such compromise could disrupt our operations, damage our reputation and subject us to additional costs and liabilities, any of
which could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our shares, the share price and trading volume of our securities could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our securities,
or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the price or trading volume of our securities to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to AutoMax&#8217;s Business and
Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A decline in available financing may adversely
affect AutoMax&#8217;s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of AutoMax&#8217;s customers
finance their vehicle purchase. As the credit markets have historically experienced volatility and disruption, such downturns could adversely
affect the credit market and affect AutoMax clients&#8217; ability to secure the required financing. A part of AutoMax&#8217;s success
is subject to the availability of affordable financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, AutoMax has
non-guaranteed credit lines from four banking corporations, which aggregated to approximately NIS 175.5 million (approximately $48.12
million) for the year ended December 31, 2024, of which it had utilized approximately NIS 170.5 million (approximately $46.75 million).
These credit lines bear interest rates that vary between prime +0.5% and prime +2.25%. If the financial market or the banking system deteriorates,
AutoMax&#8217;s ability to obtain additional financing may be affected. Such a decline in available financing could have an adverse effect
on its business, operations, and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax signed certain indemnification clauses
within asset and share purchase agreements, as part of the sale of its digital media operations between the years 2017 and 2019, and if
such indemnification is sought out, AutoMax&#8217;s results of operations and financial conditions could be adversely impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the years 2017 and
2019, AutoMax sold its digital media and advertising operations to various third parties. As part of such sales, AutoMax has agreed to
identify the buyers in case of a breach of representations provided by AutoMax. While AutoMax estimates that there is a low probability
it will be required to indemnify any such purchasers, any such indemnification could adversely impact its financial condition and results
of operations. <b><i>&#160; </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to renew AutoMax permits and licenses
or their revocation could materially adversely affect its business, results of operations, financial condition and cash flows. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s subsidiary,
Global AutoMax, operates in accordance with and subject to the permits and licenses granted to it for the purpose and within the framework
of its activity as a parallel importer. The main licenses used for the AutoMax operations are in accordance with the Vehicle Services
Licensing Law, Licensing Regulations for Services and Professions in the Automotive Industry (Vehicle Import and Marketing and Vehicle
Trade), 5775-2016, or the Vehicle Services Licensing Law. Since its inception, Global AutoMax was granted the required permits and licenses,
and these were extended, from time to time, new permits were obtained when required. However, failure to meet certain criteria as detailed
in the Vehicle Services Licensing Law may lead to such permits and licenses being suspended or not eligible for renewal and/or extensions.
Furthermore, such permits could be suspended or revoked until the required conditions are met. There are currently pending legal proceedings
against AutoMax that could, among other things, impede on its ability to renew or obtain new licenses. Cancellation, conditioning, limitation
or non-renewal of any of the AutoMax licenses, due to the aforementioned reasons or for any other reason, may have an effect on its activities
and business results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s ability to import and sell
vehicles depends in large part on agreements with suppliers and, therefore, any disruption or deterioration in its relationship with such
suppliers could impact its business. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax purchases its vehicles
and components from a limited number of suppliers. Disruption or termination of these sources could occur (due to several factors, including,
but not limited to, supplier capacity limitations, bankruptcy, acts of war, terrorism, fire, earthquake). Good relationships with such
suppliers are important for AutoMax&#8217;s business prospects. If AutoMax&#8217;s relationship with its suppliers were to deteriorate,
or if its suppliers fail to supply vehicles, its business, financial condition, commercialization and results of operations could be materially
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, as a result
of difficulties faced by major vehicle manufacturers, there has been an increase in consolidation of activities and mergers and acquisitions
in the automotive industry, as well as collaborations between vehicle manufacturers. The acquisition of a major supplier by a larger group
may lead to cancellation or non-renewal of franchise agreements, and concentration of the import of brands to Israel under one importer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s success depends
greatly on its ability to retain and/or recruit suppliers who will provide it with a vehicle inventory, in the scope that will enable
AutoMax to remain competitive in the marketing of vehicles to its customers in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exchange rate fluctuations between the U.S,
dollar, Euro and the New Israeli Shekel currencies may negatively affect AutoMax&#8217;s earnings. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the international
nature of AutoMax&#8217;s business, it is exposed to risks associated with changes in foreign currency exchange rates. Substantially all
its cost of purchases are either in U.S. dollars or Euros while the majority of its revenues and AutoMax&#8217;s management, marketing,
sales and research and development costs are in NIS. AutoMax is therefore exposed to foreign currency risk due to fluctuations in exchange
rates. This may result in gains or losses with respect to movements in exchange rates, which may be significant and may also cause fluctuations
in reported financial information that are not necessarily related to its operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Increases in interest rates could materially
adversely affect AutoMax&#8217;s business, financial condition, and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
recent inflation, geopolitical issues, increase in energy costs, increases in interest rates, unstable global conditions and changes in
currency exchange rates have led to global economic instability. Furthermore, as interest rates are reaching historically high records,
it could impede AutoMax&#8217;s ability to obtain financing or comply with its existing credit lines if the banks. Such changes, and their
impact on the global macro-economic environment, can impact AutoMax&#8217;s business, operating results, and financial condition. Furthermore,
as the majority of the customers require financing to purchase vehicles, such increase in interest rates could make it less appealing
and/or more difficult to purchase vehicles and thus decrease sales, which could adversely affect AutoMax&#8217;s business, financial condition
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Import product restrictions may impair AutoMax&#8217;s
ability to sell vehicles or parts profitably. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of the spare or replacement
parts AutoMax installs in its vehicles are manufactured outside of Israel. As a result, the AutoMax business is sensitive to customary
risks of importing merchandise, such as import duties, trade regulations and restrictions, transportation costs, unforeseeable disasters,
work stoppages, exchange rates, and general political conditions in other countries. Changes in trade policies could limit AutoMax&#8217;s
ability to import vehicles and/or its ability to purchase vehicles and/or parts at reasonable prices. Such restrictions could additionally
limit AutoMax&#8217;s ability to provide servicing for vehicles and decrease its sales and/or marketability for customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any inability
to receive the required approvals to import its vehicles or any disputes or disagreements with officials regarding the import duties,
tariffs, or similar matters, could adversely affect AutoMax&#8217;s ability to import vehicles into Israel as well as impact its profit
margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax is subject to various legal proceedings.
If the outcomes of these proceedings are adverse to AutoMax, it could have a material adverse effect on its business, results of operations
and financial condition. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, AutoMax
or its subsidiaries may be party to legal proceedings and claims in the ordinary course of business. While the outcomes of these matters
cannot be predicted with certainty, AutoMax does not believe they will have a material effect on its consolidated financial position,
results of operations, or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently two pending
legal proceedings against AutoMax, certain beneficial owners as well as officers of AutoMax and its subsidiaries, which AutoMax considers
material to its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2021, the Tel
Aviv District Attorney&#8217;s Office filed an indictment against Global AutoMax, Haim Levy Trade-In Ltd., and the following beneficial
owners and officers: Daniel Levy, CEO of AutoMax; Yinon Amit, Chief Business Officer of AutoMax; and Haim Levy, Trade and Procurement
Officer of AutoMax and the son of Daniel Levy, or together the Officers, together with Global AutoMax and Haim Levy Trade-In, the Defendants.
Pursuant to the indictment:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global AutoMax was accused of committing forgery offenses according to the Penal Law, fraud under the Penal Law, smuggling according to the Customs Ordinance [new version] and money laundering offenses, according to the Money Laundering Prohibition Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haim Levy Trade In was accused of committing forgery offences under the Penal Law, fraud under the Penal Law, smuggling under the Customs Ordinance, tax and customs violations under the Customs Ordinance [new version], Value Added Tax Law and the Purchase Tax Law (Goods and Services), and money laundering offenses according to the Prohibition of Money Laundering Law and the Penal Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Officers were accused of forgery offences under the Penal Law, fraud under the Penal Law, smuggling under the Customs Ordinance, and money laundering offenses according to the Prohibition of Money Laundering Law and the Penal Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preliminary hearings were
completed, and the evidence trials began in March 2023 for each of the Defendants. AutoMax denies the claims against Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were informed that AutoMax
believes, based on the position taken by its legal counsel on this matter, that Global AutoMax has strong claims in order to deal with
the allegations in the indictment. Furthermore, based on information received from its legal counsel, in the event of a conviction against
Global AutoMax, the penal sanctions would consist of a monetary fine, and if convicted of money laundering there could be repossessions.
In addition, AutoMax could be exposed to an administrative procedure on behalf of the Israeli Ministry of Transportation and Road Safety,
or the Ministry of Transportation. Subject to Section 8 of the Vehicle Services Licensing Law, the Deputy Director General has the authority
to refuse granting a license or the renewal of a license, if the applicant has been convicted of a criminal offense that, due to its nature,
severity, or circumstance the applicant is not deemed fit to provide vehicle services or to provide services in the automotive field for
which the application was submitted. The Deputy Director General has the same authority in the event an indictment was filed, even if
a final verdict has not yet been reached. Furthermore, under Section 10(a)(7) of the Vehicle Services Licensing Law, the Deputy Director
General can revoke or suspend a license until the licensee complies with the conditions put in place.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional lawsuit was
filed on September 29, 2022, with the District Court in Tel Aviv in the form of a request for approval as a class action, or the Request,
against Global AutoMax, Union Motors Ltd., or Union, Lex Motors Ltd., or Lex, Toyota Motor Corporation, or Toyota, and Denso Corporation,
or Denso.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicant claims that
the defendants, Toyota as a manufacturer of vehicles; Danso as a manufacturer of allegedly defective fuel pumps, installed in Toyota and
Lexus vehicles, and are the subject of the Request. Union and Lex served as direct importers of Toyota and Lexus vehicles in Israel. Global
AutoMax served as a parallel importer of Toyota vehicles in Israel, and Global AutoMax imported the applicant&#8217;s vehicle to Israel.
The applicant claims that each of Lex, Union and Global AutoMax breached their obligations towards the group represented in the class
action, inter alia, producing and/or importing and/or marketing and/or selling vehicles in which a defective fuel pump was installed,
refraining from performing a service recall on all vehicles in which defective pumps were installed, avoided bearing the costs of damages
caused by the defective fuel pumps and the service recall, etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This, according to the applicant,
is in breach of the defendants&#8217; obligations according to the Liability for Defective Products Law, 5740-1980, the Sales Law, 5728-1968,
the Contracts Law (General Part), 5733-1973, the Licensing of Services and Professions in the Automotive Industry Law, 5776-2016 and other
laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicant estimates the
total damages for all members of the claim exceed an aggregate of NIS 2.5 million (approximately $691,000), and as such that cannot be
estimated by him.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, Global AutoMax
submitted a reply to the Request, in which Global AutoMax rejected all of the applicant&#8217;s claims in the Request. In February 2024,
the applicant submitted a reply to the respondents&#8217; reply to the Request. A preliminary hearing is scheduled for July 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While AutoMax cannot accurately
predict the outcome of this proceeding, it does not believe the claims are substantial and estimate the exposure with respect to such
claim is likely immaterial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax is dependent on its management team
and professional personnel, and its business could be harmed if it is unable to attract and retain personnel necessary for its success.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s success depends
highly on its ability to attract and retain skilled, professional personnel, consultants, and contractors. The departure of highly skilled
professional personnel, in particular, any particular key management personnel, could have an adverse impact on AutoMax&#8217;s operations
and ability to execute its growth plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s efforts to
retain and attract professional personnel may also result in significant additional expenses, which could adversely affect its profitability.
There can be no assurance that professional personnel will continue to be employed or that AutoMax will be able to attract and retain
qualified personnel in the future. Failure to retain or attract qualified personnel could have a material adverse effect on AutoMax&#8217;s
business, financial conditions and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s business is sensitive to
changes in the prices of new and used vehicles. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s business is
sensitive to various changes, specifically to changes in the prices of new and used vehicles. A decrease in the prices of new or used
vehicles, due to a reduction in import taxes or a reduced tax for purchasing vehicles could reduce its profit margins. For example, following
an update of the Pollution Regulations and the Procedure for Testing Pollutants in Vehicles in the European Union (WLTP) the Israeli green
taxation formula was updated. Pursuant to such updated taxation formula, the tax benefits in relation to vehicles with a low polluting
level and set tax benefit limits, are gradually decreasing, which causes an increase in the prices of the vehicles that benefited from
the purchase tax. For example, on January 1, 2023, the purchase tax on hybrid vehicles increased from 40% in 2022 to 50%, while the limit
of the tax benefit was reduced from NIS 40,000 (approximately $11,055) in 2021 to NIS 30,000. The purchase tax on electric vehicles was
doubled from 10% in 2022 to 20% in 2023, while the limit of the tax benefit was reduced from NIS 75,000 (approximately $20,730) in 2021
to NIS 60,000 (approximately $16,583) in 2022. On January 1, 2024, the purchase tax on hybrid and plug-in cars increased to 83% and the
tax benefit limit was cancelled, and the purchase tax on electric cars increased to 35% and the tax benefit limit was reduced to NIS 50,000.
As of the date of this Annual Report, the purchase tax on electric vehicles is 45% and the tax benefit is NIS 35,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax operates in Israel,
and prices AutoMax sets are denominated in NIS. Any depreciation of the NIS against foreign currencies in which AutoMax purchases vehicles
from manufactures and the reduction of the price of the vehicles by the manufactures or the importers for other reasons may adversely
affect the value of the vehicles important and marketed by AutoMax. AutoMax has a policy in place to reduce exchange risk, which includes
both financial protections and options to import the same vehicle models from different suppliers in different currencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors could lead to
a decrease in the value of AutoMax&#8217;s inventory, and a decrease in AutoMax&#8217;s sales, which could adversely affect AutoMax&#8217;s
business, sales, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s business and operations
face many risks inherent to international trade, and its location in Israel including the ongoing interplay of the Israel &#8211; Hamas
war, may exacerbate the import process, which is material to the success of AutoMax&#8217;s business and operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax imports, distributes
and sells vehicles in Israel, and all the vehicles AutoMax sells are manufactured outside of Israel. While AutoMax manages its inventory
of vehicles and spare parts in a manner that allows AutoMax to provide a rapid response to its customers&#8217; needs, AutoMax&#8217;s
business remains sensitive to customary risks of importing merchandise, such as currency fluctuations, import duties, trade regulations
and restrictions, transportation costs, unforeseeable disasters, work stoppages, exchange rates, and general political conditions in other
countries. Changes in trade policies could limit AutoMax&#8217;s ability to import vehicles and/or its ability to purchase vehicles and/or
parts at reasonable prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions to the maritime route in the
Red Sea may adversely affect AutoMax&#8217;s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Red Sea is a vital maritime
route for international trade traveling to or from Israel. Following Hamas&#8217; attack on Israel and the Israeli security cabinet&#8217;s
declaration of war against Hamas, the Houthi movement, which controls parts of Yemen, launched a number of attacks on marine vessels traversing
the Red Sea, which marine vessels were thought to either be in route towards Israel or to be partly owned by Israeli businesses or persons.
As a result of such disruptions, and in order to mitigate continued economic harm, suppliers have changed routes from Europe to the Middle
East, and, as a result, AutoMax has experienced, and may continue to experience in the future, delays in vehicle deliveries, extended
lead times, and increased cost of freight, increased insurance costs, purchased materials and manufacturing labor costs. All of these
factors have had and may continue to have an effect on AutoMax, which is substantially reliant on its ability to import and sell vehicles,
and such delays and increased costs could have an impact on AutoMax&#8217;s inventory which may prevent AutoMax from supplying vehicles
in a timely fashion to purchasers and/or impede AutoMax&#8217;s ability to replenish its inventory based on consumer trends. Such delays
in supplying vehicles could result in purchasers cancelling orders, which could have a negative effect on AutoMax&#8217;s results of operation.
Furthermore, such increase in costs could impact AutoMax&#8217;s ability to sell vehicles at competitive prices, which could materially
affect its financial results and operations. Additionally, some of the main maritime companies have announced they will no longer plan
routes to Israel, until such time as it is safe, which could impede on AutoMax&#8217;s ability to import vehicles, and as a result could
have a material adverse effect on its business and financial results. The risk of ongoing supply disruptions may further result in delayed
deliveries of AutoMax&#8217;s products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Turkey&#8217;s trade embargo on Israel may
adversely affect AutoMax&#8217;s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, the Turkish Trade
Ministry announced an embargo on trade between Turkey and Israel, which restricts the export of goods from Turkey to Israel and the import
of products from Israel to Turkey, or the Embargo. The Embargo could have a short-term impact on the supply of vehicles and on the prices
of logistics and transportation of vehicles to Israel. As a result of the Embargo, AutoMax may experience delays in vehicle deliveries,
extended lead times, increased cost of freight, and increased insurance costs. All of these factors have had and may continue to have
an effect on AutoMax, which is substantially reliant on its ability to import and sell vehicles, and such delays and increased costs could
have an impact on AutoMax&#8217;s inventory, which may in turn prevent AutoMax from supplying vehicles in a timely fashion to purchasers
or impede AutoMax&#8217;s ability to replenish its inventory based on consumer trends. Such delays in supplying vehicles could result
in purchasers cancelling orders, which could have a negative effect on AutoMax&#8217;s results of operations. As of April 23, 2025, the
Embargo remains ongoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Macroeconomic factors such as fluctuation
in vehicle prices, fuel prices, supply chain disruptions, and vehicle-related technology advancements could have an adverse effect on
AutoMax&#8217;s revenues and operating results. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Macroeconomic
factors that affect oil prices and the automobile and commodity markets can have adverse effects on AutoMax&#8217;s revenues, revenue
growth rates (if any), and operating results. Significant increases in the cost of fuel could lead to a reduction in miles driven per
car and a reduction in accident rates. A material reduction in accident rates, whether due to, among other things, a reduction in miles
driven per car, vehicle-related technological advances such as accident avoidance systems and, to the extent widely adopted, the advent
of autonomous vehicles, could have a material impact on revenue growth. Similarly, a reduction in total loss frequency rates, due to among
other things, sharp increases in used car prices that make it less economical for insurance company sellers to declare a vehicle involved
in an accident a total loss, could also have a material impact on revenue growth. In addition, under the AutoMax Percentage Incentive
Program contracts, or PIP, the cost of transporting the vehicle to one of AutoMax&#8217;s facilities is included in the PIP fee. AutoMax
may incur increased fees, which it may not be able to pass on to its vehicle sellers. A material increase in transportation rates could
have a material impact on AutoMax&#8217;s operating results. Volatility in fuel, commodity, and used car prices could have a material
adverse effect on its revenues and revenue growth rates in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conditions in Israel, including the ongoing
war between Israel and Hamas, and other conflicts in the region, may adversely affect AutoMax&#8217;s operations and limit its ability
to market its products, which would lead to a decrease in revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>AutoMax
is incorporated under the laws of the State of Israel, and its employees, including management members, operate from their headquarters
that are located in Jerusalem, Israel. In addition, all its officers and directors are residents of Israel. Accordingly, AutoMax&#8217;s
business and operations are directly affected by economic, political, geopolitical and military conditions in Israel. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations
active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various
parts of Israel, which have negatively affected business conditions in Israel.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against
these terrorist organizations commenced in parallel to their continued rocket and terror attacks.&#160;Since the commencement of these
events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of
Yemen, and most recently with Iran. As a result of the war, operations at two of AutoMax&#8217;s branch locations were closed permanently.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on AutoMax&#8217;s business and operations and on Israel&#8217;s economy in general. These events may be intertwined with wider macroeconomic
indications of a deterioration of Israel&#8217;s economic standing, for instance, a downgrade in Israel&#8217;s credit rating by rating
agencies, which may have a material adverse effect on AutoMax and its ability to effectively conduct its operations.&#160;As many of AutoMax&#8217;s
customers purchase their vehicles through credit financing, an adverse material effect on Israel&#8217;s economy could impact the ability
to obtain such credit financing on favorable terms, which in turn could lead to a decrease in AutoMax sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service. As of April 23, 2025, none of
AutoMax&#8217;s current employees have been called to active military duty. AutoMax also relies on service providers located in Israel
and has entered into certain agreements with Israeli counterparties. AutoMax&#8217;s employees and consultants in Israel, in addition
to employees of AutoMax&#8217;s service providers located in Israel, may be called for service in the current or future wars or other
armed conflicts with Hamas and others, and such persons may be absent for an extended period of time. As a result, its operations may
be disrupted by such absences, which disruption may materially and adversely affect its business and results of operations. Additionally,
the absence of employees of AutoMax&#8217;s Israeli suppliers and contract manufacturers due to their military service in the current
or future wars or other armed conflicts may disrupt their operations, which in turn may materially and adversely affect its ability to
deliver or provide products and services to customers.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
the event that AutoMax&#8217;s facilities are damaged as a result of hostile actions, or hostilities otherwise disrupt its ongoing operations,
its ability to deliver or provide products and services in a timely manner to meet AutoMax&#8217;s contractual obligations towards customers
and vendors could be materially and adversely affected. AutoMax&#8217;s commercial insurance does not cover losses that may occur as a
result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of certain
direct damages that are caused by terrorist attacks or acts of war, AutoMax cannot assure you that such government coverage will be maintained
or that it will sufficiently cover its potential damages. Any losses or damages incurred by AutoMax could have a material adverse effect
on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax is a holding company and as a result
are dependent on its operating subsidiaries to generate sufficient cash to fund its ongoing operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The continuation of AutoMax&#8217;s
activities depends on its operating subsidiaries&#8217; ability to generate sufficient cash and raise additional financial sources in
order to develop its activities. The loss of operations or not sufficient operations of its subsidiaries could have a material adverse
effect on its business, sales and results of operations. There is no certainty that AutoMax will succeed in raising funds in the required
amount, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s business is sensitive to
changes in consumer preferences and global trends in the automotive industry. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax may be affected by
various global trends and/or events in the environment in which it operates, on which AutoMax has no ability to influence, which in turn
may affect its operating results. The vehicle manufacturing industry has been characterized in recent years by significant technological
progress, especially in the fields of vehicles driven by alternative energy sources and autonomous vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there is a noticeable
increase in the cooperative economy trend and a trend of decreasing the environmental damages caused by the use of vehicles, which are
expressed, <i>inter alia</i>, by increase in demand for the use of electric and hybrid vehicles, by the development of new models of vehicle&#8217;
sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels. Alongside this, major cities in Europe are promoting
processes intended to reduce and even limit completely the entrance of polluting vehicles into the cities. This trend has recently expanded
to Israel, as part of which, restrictions were imposed on the entry of polluting vehicles into Jerusalem and Haifa, and potentially in
other cities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The developments described
above may create uncertainty in the long term regarding the motorization level as well as the growth rate of the vehicle manufacturing
industry in which manufacturers whose vehicles AutoMax imports are operating, as well as reducing, in the long term, the demand for car
ownership, which in turn may influence AutoMax&#8217;s activity and affect AutoMax&#8217;s business results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax may experience credit default or
losses if AutoMax&#8217;s customers default from the financing it provides.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>As
for the date of the report, through certain subsidiaries, AutoMax provides its corporate customers with credit lines in low volumes (by
way of payment in installments). However, as is customary in the automotive industry, it is possible that according to AutoMax&#8217;s
management decision, sales made to its corporate customers will be partially made on credit. In such cases, AutoMax may be exposed to
the risk that these customers will not meet their obligations to repay the full amount of the loan made available to them for the purpose
of purchasing the vehicles. As of April 23, 2025, these credit lines are in volumes which are immaterial to AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s operations are subject to
a wide range of governmental regulations and laws. Its failure to comply with or any changes to these regulations and laws, could adversely
affect AutoMax&#8217;s business, sales, results of operations and financial condition. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax operates in a highly
regulated industry, and it is subject to various local laws and regulations. Additionally, the automotive industry in Israel is characterized
by vast regulation and strict regulatory requirements, including the standardization requirements, which may affect AutoMax&#8217;s expenditures
and its operational results. Changes in regulatory arrangements that apply to the automotive industry, such as changes in government taxation
policy, changes in the policy regarding the classification of vehicles as private or commercial for tax purposes or changes in the policy
regarding the value of use of a personal vehicle provided by the employer for the use of the employee, or changes in the standards of
vehicles permitted to be imported into Israel, may, in AutoMax&#8217;s estimation, lead to changes in demand for various types of vehicles,
and affect in the long term the results of its activity. In addition, regulatory changes introduced following the recommendations of the
Committee for the Increase of Competitiveness, as well as changes in the legal provisions that will completely remove or ease the barriers
to entry into the industry, will allow the entry of additional parallel importers, increase competition and, as a result, may cause a
decrease in AutoMax&#8217;s revenues and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax operates in a highly competitive
industry. Failure to develop and execute strategies to remain a preferred importer and seller of vehicles and to adapt to the increasing
use of digital and online tools to market, buy, sell, lease and finance vehicles could adversely affect its business, sales and results
of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The automotive imports industry
is highly competitive, including publicly and privately owned car importers, which import the same vehicle brands in a variety of models.
The value chain in the automotive industry includes international vehicle manufactures and importers. There are approximately 25 official
import groups in Israel, representing various manufactures, and responsible for approximately 97% of the automotive imports to Israel.
In addition, there are a few dozen parallel importers, who are collectively responsible for approximately 3% of the imports. AutoMax&#8217;s
competition is dynamic and changes annually based on the selection of vehicles its choses to import and hold in inventory for that year.
AutoMax&#8217;s selection of product lineup is done annually and determined by a comprehensive analysis of various factors, including
vehicle availability in the importing country, local market demand, tax advantages, currency exchange rates, and other relevant factors.
Certain of AutoMax&#8217;s competitors have access to more capital than it, which may provide them with an advantage in forging relationships
or providing customers with more competitive prices. Certain car dealers leverage relationships with vehicle manufacturers to sell used
cars as &#8220;certified pre-owned&#8221;, which could provide such competitors with an advantage over AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, competitors
are shifting more focus to online sales, as this is becoming a consumer trend. While AutoMax currently provides online sale services,
there is no guarantee it will be successful in transitioning to online tools, for buying, selling, leasing and financing vehicles which
could adversely affect its business, sales and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s agreement with Al Damani
is conditioned upon receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s
strategic agreements with Al Damani New Motor Vehicles Trading LLC, or Al Damani, is contingent on obtaining necessary regulatory approvals,
which have not yet been fully secured. These approvals are crucial for importing and distributing vehicles in Israel. Delays or failures
in securing these approvals could adversely impact AutoMax&#8217;s revenues, market expansion, and competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">On March 13, 2023,
Dalhom AutoMax Ltd., or Dalhom AutoMax, entered into a direct import agreement with Al Damani, a United Arab Emirates manufacturer, to
import, distribute, sale and market fully electric Al Damani vehicles in Israel. Dalhom AutoMax&#8217;s obligations under such direct
importer agreement are conditional on receiving the required regulatory approvals from the Ministry of Transportation for the import of
vehicles manufacturer by Al Damani to Israel, which have not yet been granted as of April 23, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to secure these
regulatory approvals could delay or prevent the importation and sale of Al Damani vehicles in Israel, which in turn may negatively impact
AutoMax&#8217;s revenue and plans. Additionally, any changes in regulatory requirements or delays in the approval process could increase
AutoMax&#8217;s operational costs and affect its competitive position in the market, which could adversely affect its business, sales
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New laws, regulations, or governmental policies
in response to climate change, including fuel economy and greenhouse gas emission standards, or changes to existing standards, could adversely
impact AutoMax&#8217;s business, results of operations, financial condition, cash flow, and prospects. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>AutoMax
is subject to a variety of local laws and regulations that pertain to the environment. Its business involves the use, handling and disposal
of hazardous materials and wastes, including motor oil, gasoline, solvents, lubricants, paints and substances. AutoMax is subject to compliance
with regulations concerning, among other things, the operation of underground and above-ground gasoline storage tanks, gasoline dispensing
equipment, above-ground oil tanks and automotive paint booths. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
Clean Air Law, 5768-2008, or the Clean Air Law, authorizes the Israeli Minister of Environmental Protection, or the Minister to set provisions
regarding the prevention and reduction of air pollution from mobile emission sources, in accordance with values commonly accepted in the
developed countries of the world. The Clean Air Law determines that a person shall not sell, import or market a mobile emission source,
except in accordance with the provisions set by the Minister. This law also states that it is mandatory to include the degree of air pollution
of the vehicle and data regarding the fuel consumption of the vehicle in any new vehicle&#8217; advertisement, as part of the advertisement
itself; and, in addition, said data must be displayed by any entity engaged in the business of selling and marketing new vehicles within
its premises. Similar provisions were established as part of the Clean Air Regulations (disclosure of air pollution data from a motor
vehicle in an advertisement), 5769-2009, as well. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>To
the best of AutoMax&#8217;s understanding, it complies with the provisions of the Clean Air Law and the regulations established by virtue
thereof and includes the required data in its publications. In addition, the Clean Air Regulations (air pollution from vehicles), 5772-2012
determines what constitutes unreasonable air pollution from a vehicle and regulates the obligation to carry out an air pollution test
for a vehicle before registering it, issuing a license, and renewing it. It should be noted that new vehicles imported to Israel undergo
inspections to verify their suitability for delivery and registration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
addition, there is a noticeable increase in the cooperative economy trend and a trend of decreasing the environmental damages caused by
the use of vehicles, which are expressed, inter alia, by increase in demand for the use of electric and hybrid vehicles, by the development
of new models of vehicle&#8217; sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels. Alongside this,
major cities in Europe are promoting processes intended to reduce and even limit completely the entrance of polluting vehicles into the
cities. This trend has recently expanded to Israel, as part of which, restrictions were imposed on the entry of polluting vehicles into
Jerusalem and Haifa, and potentially, in other cities. The developments described above may create uncertainty in the long term regarding
the motorization level as well as the growth rate of the vehicle manufacturing industry in which manufacturers whose vehicles AutoMax
imports are operating, as well as reducing, in the long term, the demand for car ownership, and thus influence AutoMax&#8217;s activity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to maintain the security and functionality
of AutoMax&#8217;s information systems, or to defend against or otherwise prevent a cybersecurity attack or data breach, could adversely
affect its business, financial position, results of operations and liquidity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>AutoMax&#8217;s
activities are linked by information systems, including telecommunications, the internet, network communications, emails and various computer
hardware and software applications. As such, it could suffer damage to the aforementioned communication systems. In the current environment,
there are numerous and evolving risks with regards to cybersecurity and privacy, including criminal hackers, hacktivists, state-sponsored
intrusions, industrial espionage, employee malfeasance and human or technological error.&#160;While AutoMax implements various measures
to minimize and even prevent these risks, including having a detailed action policy, it cannot guarantee no cyber-attack may be carried
out. Computer hackers and others routinely attempt to breach the security of technology products, services and systems, and to fraudulently
induce employees, customers, sub-contractors, agents, distributors or others to disclose information or unwittingly provide access to
systems or data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Although
AutoMax has invested in measures to reduce these risks, it can provide no assurance that its current IT systems are fully protected against
third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats. The cost and operational consequences
of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly
intense, complex, and sophisticated global cyber threats. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Despite
its best efforts, AutoMax is not fully insulated from data breaches and system disruptions and, accordingly, it has experienced and expects
to continue to experience actual or attempted cyberattacks of its IT networks. To the best of AutoMax&#8217;s knowledge, no cybersecurity
incidents were detected. Although no attempted cyberattacks has had a material adverse effect on its operations or financial condition
thus far, AutoMax cannot guarantee that any such incidents will not have a material adverse effect on AutoMax&#8217;s operations or financial
condition in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>As
such, its tools and servers are vulnerable to computer viruses, break-ins and similar disruptions from unauthorized tampering with the
AutoMax computer systems and tools located at its facility, at cloud services or at customer sites, or could be subject to system failures
or malfunctions for other reasons. Increased information technology security threats and more sophisticated computer crime pose a risk
to the security of AutoMax&#8217;s systems and networks and the confidentiality, availability and integrity of AutoMax&#8217;s data or
customer data. Cybersecurity attacks could also include attacks targeting the security, integrity and/or reliability of the hardware and
software installed in its products. System failures or malfunctioning could disrupt AutoMax&#8217;s operations and its ability to timely
and accurately process and report key components of its financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance,
or ESG issues, including those related to climate change and sustainability, may have an adverse effect on AutoMax&#8217;s business, financial
condition and results of operations and damage AutoMax&#8217;s reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Public
companies are facing increasing scrutiny related to ESG practices and disclosures from certain investors, capital providers, shareholder
advocacy groups, other market participants, and other stakeholder groups. For example, certain institutional and individual investors
have requested various ESG-related information and disclosures as they increasingly incorporate ESG criteria in making investment and
voting decisions. With this increased focus, public reporting regarding ESG practices is becoming more broadly expected. Such increased
scrutiny may result in increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on AutoMax&#8217;s business,
financial condition or results of operations. If AutoMax&#8217;s ESG practices and reporting do not meet investor or other stakeholder
expectations, which continue to evolve, AutoMax may be subject to investor or regulator engagement regarding such matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
March 2024, the SEC published climate disclosure rules, subject to which we, upon consummation of the Merger, would be required to disclose
certain climate-related information such as governance of climate-related risks and relevant risk management processes, among other things.
While the final rules have yet to be implemented and are subject to ongoing litigation, AutoMax cannot predict the ultimate scope and
impact these rules will have on AutoMax&#8217;s business. If the SEC&#8217;s climate disclosure rules are implemented, they would likely
result in additional legal, accounting and financial compliance and increased general and administrative expenses. Moreover, this could
result in increased management time and attention to ensure AutoMax are compliant with the regulations and expectations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in local or foreign tax laws, changing
interpretations of existing tax laws, or adverse determinations by tax authorities could increase AutoMax&#8217;s tax burden or otherwise
adversely affect its results of operations, and financial condition. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A certain degree of judgment
is required in evaluating its tax positions and determining its provision for income taxes. In the ordinary course of business, there
are many transactions and calculations for which the ultimate tax determination is uncertain. As AutoMax operates in numerous taxing jurisdictions,
the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions.
It is not uncommon for tax authorities in different countries to have conflicting views. In addition, tax laws are dynamic and subject
to change as new laws are passed and new interpretations of the law are issued or applied. For example, the work being carried out by
the OECD on base erosion and profit shifting as a response to increasing globalization of trade could result in changes in tax treaties
or the introduction of new legislation that could impose an additional tax on businesses. As a result of changes to laws or interpretations,
AutoMax&#8217;s tax positions could be challenged, and its income tax expenses could increase in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that its effective tax rate for the year ended December 31, 2024 will not change over time as a result <span>of
changes in corporate income tax rates or other changes in the tax laws of the jurisdictions in which AutoMax operates. Any changes in
tax laws could have an adverse impact on its financial results. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s business is subject to a
variety of local and international laws regarding privacy and data protection obligations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax collects, uses, maintains
and otherwise processes certain data about clients, suppliers, candidates and employees. AutoMax&#8217;s ability to collect, use, maintain
or otherwise process personal data has been, and could be further, restricted by existing and new laws and regulations relating to privacy
and data collection and protection, including the Israeli Privacy Protection Law, 5741-1981, or the Privacy Law. AutoMax implements measures
for the purpose of adapting the relevant aspects of its activity to the provisions applicable subject to the Privacy Protection Law and
the regulations enacted by virtue thereof, and for this purpose it contracted with a company that manages its information security and
privacy protection aspects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax may not be able to satisfy its debt
obligations upon the occurrence of a change in control under its debt instruments or to obtain additional financing based on existing
debt. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>AutoMax
intends to continue making investments to support its business growth and will likely require additional funds to respond to business
challenges and opportunities, including the need to purchase inventory of vehicles, improve AutoMax&#8217;s operating infrastructure to
support volume growth or acquire complementary businesses and technologies. Accordingly, AutoMax may need to engage in equity or debt
financing to secure additional funds if its existing sources of cash and any funds generated from operations do not provide it with sufficient
capital. If AutoMax raises additional funds through future issuances of equity or convertible debt securities, its existing stockholders
could suffer significant dilution, and any new equity securities AutoMax issues could have rights, preferences, and privileges superior
to those of holders of its other classes of shares. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Any
future debt financing that AutoMax may secure in the future could involve restrictive covenants relating to its capital raising activities
and other financial and operational matters, which may make it more difficult for AutoMax to obtain additional capital and to pursue business
opportunities, including potential acquisitions. AutoMax may not be able to obtain additional financing on terms favorable to it, if at
all. If AutoMax is unable to obtain adequate financing or financing on terms satisfactory to it when it requires it, AutoMax&#8217;s ability
to continue to support its business growth and to respond to business challenges and opportunities could be significantly impaired, and
its business may be adversely affected. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s collection, use, storage,
disclosure, transfer and other processing of personal information, could give rise to significant costs, liabilities and other risks,
including as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about its
privacy and data protection practices, which may harm AutoMax&#8217;s business, financial conditions, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>AutoMax&#8217;s
operations are dependent on secure processing, transmission, storing on its computers and networks proprietary and confidential information.
AutoMax uses various third-party storage platforms which could make it more vulnerable to such cyberattacks. Furthermore, AutoMax relies
on digital technologies to process payments, both on its networks and third-party systems. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Privacy
laws are ever changing and continue to create new individual privacy rights, including regulations regarding the manner in which such
personal information should be handled. As part of its ongoing operations, AutoMax gathers certain personal information from customers,
vendors, manufactures and others. AutoMax has invested in implementing security controls and adapting its systems, amongst others, by
engaging Integrity Consulting and Risk Management (I.C.M.) Ltd., which manages information security and privacy protection within the
company. However, any misuse of such information or storing it inappropriately and not adequately protecting it could lead to inquiries,
litigation, fines, legislative and regulatory action against AutoMax. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
light of the stated, there is a certain dependence on the information security, backup and retrieval capabilities of those providers.
In this aspect, AutoMax has a system of backups, designed to create a recovery mechanism from a situation where one backup environment
cannot, for whatever reason, support the provision of services. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law may make it easy
for AutoMax&#8217;s shareholders to demand that AutoMax convenes a shareholders meeting, and/or allow shareholders to convene a shareholder
meeting without the consent of AutoMax&#8217;s management, which may disrupt AutoMax&#8217;s management&#8217;s ability to run the company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law may allow any
one or more of AutoMax&#8217;s shareholders holding, in the aggregate, at least 5% of <span>AutoMax&#8217;s
</span>voting rights to demand that AutoMax convenes a special shareholders meeting. Also, in the event that AutoMax chooses not to convene
a special shareholders meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others, that such shareholders
may independently convene a special shareholders meeting within three months (or under court&#8217;s ruling) and require AutoMax to cover
the costs, within reason, and as a result thereof, AutoMax&#8217;s directors might be required to repay such costs. If AutoMax&#8217;s
shareholders decide to exercise these rights in a way inconsistent with AutoMax&#8217;s management&#8217;s strategic plans, AutoMax&#8217;s
management&#8217;s ability to run the company may be disrupted, and this process may entail significant costs to AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a United States court against us and AutoMax&#8217;s officers and directors in Israel or the United States, to assert United States
securities laws claims in Israel or to serve process on AutoMax&#8217;s officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax is incorporated in
Israel and the company&#8217;s corporate headquarters are located in Israel. All of AutoMax&#8217;s executive officers and directors are
located in Israel. All of AutoMax&#8217;s assets and most of the assets of these persons are located in Israel. Service of process upon
AutoMax or the non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against AutoMax or
the non-U.S. directors and executive officers may be difficult to obtain within the United States. AutoMax has been informed by <span>AutoMax&#8217;s</span>
legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel,
or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim
based on a violation of U.S. securities laws against AutoMax or AutoMax&#8217;s non-U.S. officers and directors because Israel may not
be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.
There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered
outside Israel, which may make it difficult to collect on judgments rendered against AutoMax or AutoMax&#8217;s non-U.S. officers and
directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, an Israeli court
will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same
matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel
at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Combined Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The combined company&#8217;s success depends
on the experience and expertise of its management team and board of directors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical company
with limited experience outside of the drug development and healthcare industries, while AutoMax is engaged in the business of importing
and distributing vehicles. These are distinct and unrelated businesses requiring different operational expertise, industry knowledge,
and strategic approaches. Following the Merger, we will become the parent company of AutoMax, and the two companies will operate as the
combined company. AutoMax is anticipated to continue to operate its current business with its own board of directors and management; however,
the management team of the combined company will be the same as our existing management team, and the combined company&#8217;s board of
directors will have a minority representation from AutoMax&#8217;s management. Mr. Amitay Weiss, who is our Chairman and AutoMax&#8217;s
Chairman, will be the Chairman of the combined company after the Merger and has experience in both industries, which may help facilitate
the oversight of AutoMax&#8217;s operations. While the combined company&#8217;s management team has experience in the pharmaceutical industry,
its experience in the automotive sector is limited and may present challenges in effectively overseeing AutoMax&#8217;s operations following
the Merger. Although AutoMax is expected to retain its current management team, which possesses automotive experience, the combined company&#8217;s
overall unfamiliarity with the automotive industry may impact its ability to effectively oversee and support AutoMax&#8217;s operations,
and achieve the full extent of the expected benefits of the Merger. This, in turn, could adversely affect the financial performance and
successful operations of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The combined company does not anticipate
paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor AutoMax have
ever declared or paid cash dividends on their respective ordinary shares. In accordance with the Trust Deed, until the Series B Bonds
are repaid in full, AutoMax will not distribute or pay any cash dividends. According to the terms of the Series B Bonds and the Trust
Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual installments, which will be paid annual as of
February 28, 2023 until 2026, inclusive, such that the first payment that was made on February 28, 2023 constituted 10% of the aggregate
principal amount of the Series B Bonds, the second payment, that was made on February 28, 2024, constituted 15% of the aggregate principal
amount of the Series B Bonds, the third payment, that was made on February 28, 2025, will constitute 30% of the aggregate principal amount
of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute 45% of the aggregate principal amount
of the Series B Bonds. Following the closing of the Merger, the Series B Bonds will remain outstanding and subject to repayment in accordance
with the terms of the Trust Deed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor AutoMax anticipate
paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future. It is anticipated that the combined
company will retain all available funds and any future earnings to fund the development and growth of its business. As a result, capital
appreciation, if any, of the combined company&#8217;s ordinary shares will be the combined company&#8217;s shareholders&#8217; sole source
of gain for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Maintaining and improving the combined company&#8217;s
financial controls and the requirements of being a public company may strain the combined company&#8217;s resources, divert management&#8217;s
attention and affect its ability to attract and retain qualified board members.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, the combined
company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and Nasdaq rules. The requirements of
these rules and regulations will increase the combined company&#8217;s legal and financial compliance costs, make some activities more
difficult, time-consuming or costly and place strain on its personnel, systems and resources. The Exchange Act requires, among other things,
that the combined company file annual, quarterly and current reports with respect to its business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sarbanes-Oxley Act requires,
among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial
reporting. Ensuring that the combined company will have adequate internal financial and accounting controls and procedures in place is
a costly and time-consuming effort that needs to be re-evaluated frequently.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and AutoMax do not expect
that the combined company will have an internal audit group, and the combined company may need to hire additional accounting and financial
staff with appropriate public company experience and technical accounting knowledge. Implementing any appropriate changes to the combined
company&#8217;s internal controls may require specific compliance training for the combined company&#8217;s directors, officers and employees,
entail substantial costs, and take a significant period of time to complete. Such changes may not, however, be effective in maintaining
the adequacy of the combined company&#8217;s internal controls, and any failure to maintain that adequacy, or consequent inability to
produce accurate financial statements on a timely basis, could increase the combined company&#8217;s operating costs and could materially
impair its ability to operate its business. Moreover, effective internal controls are necessary for the combined company to produce reliable
financial reports and are important to help prevent fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Nasdaq
rules, the combined company will be required to maintain a majority independent board of directors. The various rules and regulations
applicable to public companies make it more difficult and more expensive for the combined company to maintain directors&#8217; and officers&#8217;
liability insurance, and the combined company may be required to accept reduced coverage or incur substantially higher costs to maintain
coverage. If the combined company is unable to maintain adequate directors&#8217; and officers&#8217; insurance, its ability to recruit
and retain qualified officers and directors will be significantly curtailed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and AutoMax expect that
the rules and regulations applicable to public companies will result in the combined company incurring substantial legal and financial
compliance costs. These costs will decrease the combined company&#8217;s net income or increase its net loss and may require it to reduce
costs in other areas of its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish unfavorable research about the combined company&#8217;s business, its share price and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for the
combined company&#8217;s securities will depend in part on the research and reports that securities or industry analysts publish about
the combined company. The combined company may never obtain sufficient research coverage by securities and industry analysts. If no sufficient
securities or industry analysts commence coverage of the combined company, the trading price for the combined company&#8217;s shares could
be negatively impacted. If the combined company obtains sufficient securities or industry analyst coverage and if one or more of the analysts
who covers it downgrades the combined company&#8217;s shares or publishes inaccurate or unfavorable research about the combined company&#8217;s
business, its share price would likely decline. If one or more of these analysts ceases coverage of the combined company or fails to publish
reports regularly, demand for the combined company&#8217;s shares could decrease, which could cause its share price and trading volume
to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to maintain effective internal control
over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the
combined company&#8217;s share price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 404 of the Sarbanes-Oxley
Act of 2002 and the related rules and regulations of the SEC require an annual management assessment of the effectiveness of its internal
control over financial reporting. AutoMax maintains disclosure controls and procedures and internal control over financial reporting pursuant
to the Israeli Securities Law in its Annual and Interim Filings, and has complied with applicable Israeli reporting requirements. To date,
AutoMax has never conducted a review of internal controls over financial reporting for the purpose of providing the reports required by
the Sarbanes-Oxley Act. During review and testing, AutoMax may identify deficiencies and be unable to remediate them on a timely basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company fails
to maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented or amended from
time to time, it may not be able to ensure that it can conclude on an ongoing basis that it has effective internal control over financial
reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If the combined
company cannot in the future favorably assess the effectiveness of its internal control over financial reporting, investor confidence
in the reliability of its financial reports may be adversely affected, which could have a material adverse effect on the combined company&#8217;s
share price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a substantial number of shares
of the combined company in the public market by its existing shareholders could cause its share price to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of shares of the combined company in the public market or the perception that these sales might occur, could depress the market price
of its securities and could impair its ability to raise capital through the sale of additional equity securities. Neither we nor AutoMax
is able to predict the effect that sales may have on the prevailing market price of the combined company&#8217;s securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The combined company&#8217;s securities
could be delisted from Nasdaq if it does not comply with Nasdaq&#8217;s listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Nasdaq rules,
consummation of the Merger requires the combined company to submit listing of additional securities application and, at the time of the
Merger, meet all of the criteria applicable to a company initially requesting listing. While we and AutoMax intend to obtain listing status
for the combined company and maintain the same, no guarantees can be made about the combined company&#8217;s ability to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company&#8217;s
securities are delisted by Nasdaq, its securities may be eligible to trade on the OTC Bulletin Board or another over-the-counter market.
Any such alternative would likely result in it being more difficult for the combined company to raise additional capital through the public
or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the market value of, the combined
company&#8217;s securities. In addition, there can be no assurance that the combined company&#8217;s securities would be eligible for
trading on any such alternative exchange or markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales and issuances of the combined
company&#8217;s ordinary shares or rights to purchase ordinary shares by it, including pursuant to its equity incentive plans, could result
in additional dilution of the percentage ownership of its shareholders and could cause its share price to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The combined company will
not be generally restricted from issuing additional ordinary shares, including any securities that are convertible into or exchangeable
for, or that represent the right to receive, ordinary shares. The market price of the combined company&#8217;s ordinary shares could decline
as a result of sales of shares or securities that are convertible into or exchangeable for, or that represent the right to receive, shares
of the combined company or the perception that such sales could occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and AutoMax expect that
significant additional capital will be needed in the future to continue the combined company&#8217;s planned operations and costs associated
with operating as a public company. To the extent the combined company raises additional capital by issuing equity or convertible securities,
its existing shareholders may experience substantial dilution. The combined company may sell ordinary shares, convertible securities or
other equity securities in one or more transactions at prices and in a manner determined from time to time by its board of directors.
If the combined company sells ordinary shares, convertible securities or other equity securities in more than one transaction, investors
may be materially diluted by subsequent sales. Such sales may also result in material dilution to its existing shareholders, and new investors
could gain rights superior to its existing shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the combined
company may grant or provide for the grant of rights to purchase shares of its ordinary shares pursuant to the combined company&#8217;s
equity incentive plans. Increases in the number of shares available for future grant or purchase pursuant to the combined company&#8217;s
equity incentive plans may result in additional dilution, which could cause the combined company&#8217;s share price to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. History and Development of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial name
is SciSparc Ltd. We were incorporated in the State of Israel on August 23, 2004, and are subject to the Companies Law. Our registered
office and principal place of business is located at 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup> Floor, Tel Aviv 6971916, Israel.
Our telephone number in Israel is: +972-73-3447180.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our website address is http://www.scisparc.com.
The information contained on our website or available through our website is not incorporated by reference into and should not be considered
a part of this Annual Report, and the reference to our website in this Annual Report is an inactive textual reference only. The SEC also
maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file
electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC, including the proxy rules and the short-swing profits recapture rules. In addition, we will
not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S.
domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures for
2024, 2023 and 2022 amounted to $8,000, $0 and $9,200, respectively. These expenditures were primarily for purchases of fixed assets.
Our purchases of fixed assets primarily include, computers, and equipment used for the development of our products, and we financed these
expenditures primarily from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Business Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty clinical-stage
pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With
this focus, we are currently engaged in the following development programs based on THC, and/or CBD and/or other CBR agonists: SCI-110
for the treatment of TS and for the treatment of Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of ASD. We also
have a 50.86% controlling stake in our subsidiary, SciSparc Nutraceuticals Inc., or SciSparc Nutraceuticals, whose business focuses on
the sale of hemp seed oil-based products and others on Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 13, 2024, we entered into the license agreement to outlicense
our SCI-160 program, which was &#160;a novel pharmaceutical preparation containing a cannabinoid receptor type 2 agonist for the treatment
of pain, to Polyrizon. Therefore, we are no longer engaged in development of this pharmaceutical product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-110 is a proprietary drug
candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide&#8482;, a
proprietary PEA, formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules
that regulate the expression of genes. We believe that the combination of THC and PEA may induce a reaction known as the &#8220;sparing
effect,&#8221; which has strong potential to treat various diseases of the central nervous system such as TS and Alzheimer&#8217;s disease
and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-210 is a proprietary drug
candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. We believe that the combination of CBD and PEA may also induce a
sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the positive results
obtained in a phase IIa TS study conducted at Yale School of Medicine, we developed a regulatory dossier that was submitted to the German
Federal Institute for Drugs and Medical Devices, or BfArM, and the Israeli Ministry of Health, or MoH, and the FDA for our SCI-110 program
for TS. We plan to submit this regulatory dossier to the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial to evaluate the safety, tolerability
and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary cannabinoid-based technology. In
December 2021, The Israeli Medical Center for Alzheimer&#8217;s recruited the first patient to participate in the phase IIa clinical trial.
In June 2023, we announced positive topline results from our Phase IIa clinical trial of SCI-110 in patients with Alzheimer&#8217;s disease
and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting that SCI-110 is safe and tolerable while significantly improving
agitation symptoms over time in the elderly population with Alzheimer&#8217;s disease. This Phase IIa clinical trial was an open label
study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and agitation, to evaluate the safety, tolerability and efficacy
trends of twice daily oral administration of SCI-110.&#160;Results showed that the clinical trial met its primary endpoints of the number
of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110 related
safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not cause delirium,
oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial also met its secondary
end point of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory where out of the
fifteen patients treated with SCI-110 at least two consecutive times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day
showed amelioration in agitation with no need to use rescue medication to control agitation. Although not significant, in the exploratory
endpoints, eleven patients reduced food intake and showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia
scale. There was not an effect observed resulting from the treatment on cognition and sleep quality, as measured by the Mini Mental State
Examination and by the Sleep Order Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct our clinical trial for SCI-210 in
patients suffering ASD. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial with pediatric
patients suffering from ASD. Our regulatory request to carry out this clinical trial was granted by the Israeli Medical Cannabis Agency,
or IMCA, on July 10, 2023. This randomized, double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pharmaceutical Drug Development Programs</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-110 - TS, Alzheimer&#8217;s
disease and agitation </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-110, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its early
phases of clinical testing, the application of SCI-110 has extended into several treatments, including TS and Alzheimer&#8217;s disease
and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>TS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TS is a neuropsychiatric disorder,
characterized by physical (motor) tics and vocal (phonic) tics. Motor tics generally precede the development of phonic tics in TS, and
the onset of simple tics usually predates that of complex tics. TS ranges from mild symptoms to loud noises and forceful movements that
can result in self-injury (e.g. punching oneself in the face, repeating other people&#8217;s words or involuntary swearing). Many with
TS experience additional neurobehavioral problems and comorbidities including inattention, hyperactivity and impulsivity, anger control
problems, sleep difficulties, and obsessive-compulsive symptoms. Pharmacotherapy is used when symptoms are more severe and interfere with
the ability to function. Furthermore, according to the CDC, in most cases, the prevalence of tics decreases during adolescence and early
adulthood, and sometimes disappears entirely; therefore, there are a limited number of adults with TS and it is usually manifested mainly
through moderate to severe symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rising healthcare expenditure,
favorable government initiatives, the increase in use of telemedicine and increasing aging population will drive the TS treatment market.
North America was the largest region in the TS treatment market, accounting for 47.72% or $1.06 billion of the total in 2023. It was followed
by Western Europe, Asia Pacific and then other regions. Going forward, the fastest-growing regions in the TS treatment market will be
Asia-Pacific and Western Europe, where growth will be at compound annual growth rates, or CAGR, of 7.21% and 6.26%, respectively. These
will be followed by North America and South America, where the markets are expected to grow at CAGRs of 5.96% and 5.14%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global TS treatment market
size was approximately $2.23 billion in 2023 and is expected to reach $2.98 billion by 2028.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the CDC, the
prevalence of moderate to severe TS is reported to be 44%, indicating a significant portion of individuals experiencing notable symptoms
of the condition. Interestingly, adolescents between the ages of 12 and 17 show a more than twofold likelihood of being diagnosed with
TS compared to children aged 6 to 11. It highlights the impact of TS on various age groups. It emphasizes the substantial demand for effective
treatments within the TS treatment market to address the diverse needs of individuals with the condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the CDC, 83%
of children diagnosed with TS also have at least one additional mental, behavioral, or developmental disorder that serves as a driver
for the TS treatment market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmacological intervention
is considered the first line of therapy for TS, but is reserved for more severe symptoms that interfere with the individual&#8217;s ability
to function. Today, a full class of drugs that interact with dopamine and non-dopamine systems in the brain are used in the treatment
of TS symptoms. Although as of the date of this Annual Report, the FDA has approved only two pharmacological treatments (for adult TS-
haloperidol and pimozide &#8211; these treatments have a &#8220;black box warning&#8221;. Many drugs approved or off-label to treat TS
are limited to the treatment of a narrow range of TS symptoms (mainly tics), and are associated with severe side effects, both of which
limit their utility. Furthermore, several of these drugs have a black box warning on their label due to their potentially lethal effect.
A black box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable
evidence of an association of a serious hazard with the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medications commonly used
to treat symptoms of TS can be divided into the following groups:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antipsychotic medications: belong to a class of drugs primarily used to manage psychosis (including haloperidol, pimozide and fluphenazine), all of which are associated with severe side effects (including weight gain, sedation, akathisia (a state of agitation, distress, and restlessness), nausea and tardive dyskinesia (involuntary movements of the face and jaw), among others).</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha2 Adrenergic Agonists: belong to a class of drugs primarily used to manage hypertension and migraine headaches prevention (including clonidine and guanfacine), which have limited utility despite common application to children with Attention Deficit Hyperactivity Disorder, or ADHD. Similar to antipsychotic medications, these also are associated with several side effects, and some of them, such as clonidine, might even be lethal.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benzodiazepines, an anticonvulsant or antiepileptic drug: belong to a class of drugs primarily used to manage seizures, panic disorder and movement disorders. Of these, Clonazepam is used off-label for the reduction of tics in TS patients, which also has associated negative side effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the currently used medications
are managing only a small number of disease symptoms with limited efficacy and questionable safety, there is a clear unmet medical need
for the management of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
TS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our SCI-110 platform is a
drug candidate for the treatment of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, we announced
topline results of our Phase IIa investigator-initiated study at Yale University of SCI-110 for the treatment of TS. The study was a single-arm,
open-label trial, in which each subject both received one daily treatment of SCI-110 via oral administration and was followed-up for a
period of 12 weeks. 16 subjects participated in the study and received SCI-110 at the Yale University Child Study Center at Yale University.
The primary endpoint of the study was to assess the performance of SCI-110 in the treatment of adult patients suffering from symptoms
of TS, as measured by the Yale Global Tic Severity Scale Total Tic Score, or YGTSS-TTS, the customary index for assessing symptom severity.
Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting of 10mg dronabinol and 800mg CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The topline results of the
study showed that each of these 16 subjects with medication-refractory TS sustained a significant reduction of tic symptoms (paired t-test:
YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4 +/- 8.3) to endpoint YGTSS-TTS:
30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample of 16 TS subjects. Six of the 16 medication-refractory
TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater than 25%. Improvement over time with
treatment was also observed when generalized linear models were used to analyze repeated measures data on the YGTSS-TTS. In the study,
SCI-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression or obsessive-compulsive disorder, or OCD, symptoms.
The medication was generally well-tolerated by the subjects with only two subjects stopping treatment early (one due to sedation and another
due to lack of improvement in tic symptoms). 12 of the 16 subjects elected to proceed with a 24-week extension phase of the trial, which
was also completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Phase IIa study,
we announced in June 2023 BfArM approval for a Phase IIb clinical trial for SCI-110 in subjects suffering from TS, with a view to such
clinical trial being carried out in Germany at the Hannover Medical School. In August 2022, we received MoH approval to conduct the clinical
trial in Isarael at Sourasky Medical Center. We also received Ethics Committee approvals in 2022 from Hannover Medical School and Sourasky
Medical Center and Internal Review Board approval in 2023 at the Child Study Center at Yale School of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we initiated
the Phase IIb clinical trial at Sourasky Medical Center. The 86 patients in the clinical trial are randomized to either oral SCI-110 or
placebo at a 1:1 ratio. The overall estimated clinical trial duration is 18-24 months from the time all clinical sites are up and running.
We may also be required to conduct further preclinical studies in parallel to our clinical plans as part of registration process with
the FDA and EMA. Following these clinical trials, if successful, we intend to conduct a Phase III, multinational, multicenter, randomized,
double-blind, parallel-group, placebo controlled clinical trial to evaluate the safety, tolerability and efficacy of up to twice daily
oral SCI-110 in treating TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. The request is still pending and we are in communication
with FDA. Our last communication was in December 2020 when we received a letter from FDA raising a concern that it will be hard to limit
the use of the pharmaceutical product to the subset of patients we are pursuing. There is no assurance that we will successfully obtain
orphan drug designation for TS. However, in light of the fact that we disagree with this concern expressed by the FDA, we requested a
clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March we sent our response to the FDA. In June
2021, we received a response from the FDA, explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not allow
us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval, and complications and risks associated with FDA approval, would substantially increase. In a pre-IND meeting we
had with FDA in February 2018, the FDA did not oppose our plans to submit an NDA via the 505(b)(2) pathway relying, in part, on clinical
and nonclinical information from literature related to dronabinol and the FDA&#8217;s previous finding of safety and efficacy for the
reference listed drug (Marinol).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2024, we submitted
an Investigational New Drug application with the FDA for our phase IIb clinical trial for SCI-110.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Alzheimer&#8217;s disease and Agitation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzheimer&#8217;s disease
is the most common type of dementia, accounting for over two-thirds of cases of dementia. Alzheimer&#8217;s disease is a neurodegenerative
disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention,
reasoning and judgment. Symptoms of Alzheimer&#8217;s disease depend on the stage of the disease. Neuropsychiatric symptoms like apathy,
social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also common in the mid to late stages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Market Size </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is estimated that the global
Alzheimer&#8217;s therapeutics market is projected to reach $10.4 billion by 2035 from $4.28 billion in 2023 with a CAGR of 9.23%. The
demand for Alzheimer&#8217;s therapeutics is accelerating due to a wave of breakthrough drug approvals, increased investment in disease-modifying
therapies, and advancements in precision medicine. Researchers are focusing on transforming treatments from symptom management to targeted
interventions that slow disease progression. The integration of monoclonal antibodies, small-molecule inhibitors, and gene therapies is
expected to reshape treatment efficacy and accessibility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current pharmacological
treatment of agitation in Alzheimer&#8217;s disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
Antipsychotic drugs, which are the most frequently used drugs for this purpose, are only marginally better than placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
Alzheimer&#8217;s disease and Agitation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product, SCI-110,
is a unique proprietary combination of dronabinol (synthetic delta-9-tetrahydrocannabinol (&#916;&#8313;-THC), and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we signed
an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial to evaluate the safety, tolerability
and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary cannabinoid-based technology. The
study&#8217;s primary objective is the safety of SCI-110 and the secondary objective is the ability of the compound to ameliorate agitation
and other behavioral disturbances in patients with Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase IIa clinical trial
was an open label clinical trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and
efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its primary endpoints of the
number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110
related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not
cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial
also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory,
or CMAI, where out of 15 patients treated with SCI-110 at least two consecutive times during the clinical trial, thirteen of them at doses
ranging between 7.5mf-12.5mg/day showed amelioration in agitation with no need to use rescue medication to control agitation. CMAI is
a standard measure for measuring agitation in people with dementia. The clinical trial showed that these subjects had amelioration in
agitation (paired t-test: CMAI mean difference (mean +/- SD) =10.6+/-14.88, t= 2.76, df=14, p=0.015) from baseline (CMAI: 45.87 +/- 15.17)
to endpoint (CMAI: 35.27 +/- 11.09). This resulted in an average reduction of 23% across the entire sample.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the exploratory endpoints,
a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least two consecutive times during
the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not significant. No effect from
the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam and by the and the Sleep
Disorder Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-210 - ASD and SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-210, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its early
phases of pre-clinical and clinical testing, the application of SCI-210 has extended into several treatments, including ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ASD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASD is a neurodevelopmental
disorder. The specific etiologies and neural bases of autism remain largely unknown; it has been proposed that alterations in multiple
genes in combination with environmental factors constitute the cause for the development of the autism phenotype. ASD is characterized
by early dysfunction in communication and social interactions, presenting with repetitive, restrictive, stereotyped patterns of behavior
and loss of interest in diverse activities. Additionally, ASD is frequently accompanied by impairments in adaptive functioning, sensory
processing disorder, aggression, or self-injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2024, we announced
the enrollment of the first five patients in the clinical trial of SCI-210 in children with ASD at Soroka Medical Center in Israel. In
December 2024, we announced the renewal by the Israeli Medical Cannabis Agency of the clinical trial for SCI-210 in children with ASD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the World Health
Organization, or WHO, fact sheet on epilepsy in 2024, around 50 million people have epilepsy, making it one of the most common neurological
diseases globally. The risk of premature death in people with epilepsy is up to three times higher than for the general population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Globally, an estimated 5 million
people are diagnosed with epilepsy each year. In high-income countries, there are estimated to be 49 per 100 000 people diagnosed with
epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The epilepsy drugs market
is forecast to experience significant growth, with estimations projecting the market to reach $11.85 billion by 2033, up from $7.92 billion
in 2024. The growth is attributed to heightened global incidence of epilepsy, advancement in drug research and development, and a surge
in public and healthcare recognition of the condition. Improved healthcare spending and increased accessibility to medical treatments
further amplify market expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Strategic initiatives taken
by global health organizations and campaigns to raise awareness about epilepsy are significantly influencing the market dynamics. Governmental
health bodies are reportedly fostering an environment conducive to the approval of new epilepsy treatments, which is propelling the market
forward. These campaigns, coupled with the growing emphasis on National Epilepsy Awareness Month initiatives, improve the understanding
of epilepsy and encourage an increase in the quality and reach of treatments available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry has seen a host of
developments aimed at enhancing the treatment for epilepsy. Increased investment in research and development aspires to produce new and
improved drugs, addressing not only medical needs but also economic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No cure exists for ASD. The
goal of treatment is to maximize patients&#8217; ability to function by reducing ASD symptoms and supporting development and learning.
Treatment options may include: (i) behavior and communication therapies - successful programs typically include a team of specialists
and a variety of activities to improve social skills, communication and behavior; and (ii) medications - to date, no medication can improve
the core signs of ASD, specific medications can help control comorbidity symptoms. The main symptoms to be treated in patients with ASD
are: epilepsy, aggression, hyperactivity, irritability, attention deficit, sleep problems, obsessions and anxiety. Antipsychotic drugs
are sometimes used to treat severe behavioral problems and antidepressants may be prescribed for anxiety. Among the main drugs used in
the treatment of ASD are typical antipsychotics such as Haloperidol, Thioridazine, Chlorpromazine and the atypical risperidone, Olanzapine
and Clozapine, whose use is more common. These are used with the objective to treat the child&#8217;s behavioral problems by blocking
the D2 dopaminergic channels, causing a diminished reaction to stimuli known as &#8220;neuroleptic syndrome,&#8221; observed as calm and
quiet behavior in the child. In turn, some atypical antipsychotics also exhibit an antagonism of type 2A receptors for serotonin, aside
from their effect on the D2 channels. It is important to individualize the patient when these drugs are administered, since there are
no pre-established criteria for dosing and such drugs could present extrapyramidal adverse effects such as tremors, sialorrhea, sedation,
impaired liver function, etc. Serotonin reuptake inhibitors such as Fluoxetine, Paroxetine and Sertraline are given to children with autism
because they have been found to increase 25% of serotonin levels in platelets and serum. This treatment is based on suppressing symptoms
such as anxiety, depression, OCDs, and self-injurious behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, about 40% of
children with ASD and disruptive behavior do not respond well to standard behavioral and medical treatment. Consequently, an exceptionally
high percentage of parents are seeking help through unproven methods, including the use of compounds made of the cannabis plant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
ASD</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct our clinical trial for SCI-210 in
patients suffering ASD. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial on pediatric
patients suffering from ASD. Our regulatory request to carry out this clinical trial was granted by the IMCA on July 10, 2023. This randomized,
double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety and tolerability of SCI-210 in treating patients
with ASD was initiated in July 2023. We initiated patient enrollment for the clinical trial in January 2024. In February 2024, we announced
that we had successfully completed the manufacturing of the SCI-210 treatment for the clinical trial. In March 2024, the first patient
was enrolled in this clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SE</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SE is a common life-threatening
medical emergency characterized by an acute, prolonged epileptic seizure. SE can represent either the exacerbation of a pre-existing seizure
or the initial manifestation of epilepsy. In order to avoid neurological sequelae, a timely treatment should be started. When the continuous
seizure does not respond to conventional drug treatment, SE can pose serious life-threatening risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, GW&#8217;s Epidiolex,
a plant-based, pharmaceutical grade CBD extract was approved by the FDA for the treatment of seizures associated with two rare and severe
forms of epilepsy. Our study for SCI-210 previously met its endpoint (efficacy) when comparing its effect to the effect of CBD alone in
an in-vitro hepatocytes model of fat accumulation; the effect of CBD was enhanced by the addition of PEA, lowering the required effective
concentration of CBD. In this study, we hope to meet the study endpoint (efficacy) when comparing treatment using our pharmaceutical product
candidate compared to the effect of CBD alone on SE and its neurological cognitive sequelae.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first-line treatment for
early SE mainly comprises the administration of benzodiazepines, the most frequently used of which include Diazepam, Lorazepam, and Midazolam.
Seizures continue and progress to established SE in about 40% of patients with Convulsive Status Epilepticus (CSE) despite benzodiazepine
administration as the first-line treatment. The second-line treatment for established SE consists of a loading dose of antiepileptic drugs.
Frequently used antiepileptic drugs include Phenytoin or Fosphenytoin, Valproate, Levetiracetam, Phenobarbital, and Lacosamide. There
is no clear evidence for the relative superiority of any of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 2022, we announced
positive results from our pre-clinical study of SCI-210 on SE, conducted at The Sheba Fund for Health Services and Research at Chaim Sheba
Medical Center, which reaffirms the potential of its proprietary combination products to have a positive effect while minimizing adverse
side effects. Our SCI-210 platform combines PEA with CBD. The non-clinical trial objective was to study the potential therapeutic effects
of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae. A pilocarpine SE-induced mice (C57BL/6 male) model
to study SCI-210&#8217;s effects on seizure severity and mortality was used. After calibration, four groups of animals were studied: an
effective-high dose CBD group, a sub-effective dose CBD group, a SCI-210 group (a combination of sub-effective CBD dose and PEA) and a
non-treated control group. The results indicated differences in mortality rate as well as seizure rates over time. In the low-CBD group,
a higher mortality rate (although not significant) was found and therefore it is reasonable to believe that no significant impact on neuronal
protection was achieved. In the high-CBD group, higher, although not significant, levels of neuronal protection were found together with
a decreased mortality rate when compared to control. The level of neuronal protection in the SCI-210 treatment was significantly higher
compared to the control group and no mortality was found in this group. It was concluded that SCI-210 treatment may potentially be more
effective than a CBD monotherapy. Moreover, since the concentrations used in the combo treatment are significantly lower than those recommended
for CBD monotherapy, this treatment also has the potential to be safer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Our CannAmide&#8482; Anti-Inflammatory
and Chronic Pain Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CannAmide&#8482; is a cannabimimetic
compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their metabolism, and is particularly
attractive therapeutically as it appears to have a very high safety profile with low or no abuse liability. Although numerous clinical
trials have shown the favorable effect of PEA as an analgesic agent it has low solubility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we announced
the issuance of a product license for our proprietary PEA oral tablet CannAmide&#8482; by Health Canada&#8217;s Natural and NNHPD, for
the recommended use as an anti-inflammatory and to help relieve chronic pain. This license was issued by the NNHPD under the authority
of the NHPR. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of one tablet
three times a day. Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the World Health Organization,
half of the most prevalent conditions responsible for living with disability is characterized by the presence of different kinds of pain.
With the NNHPD license, we are able to offer safe and beneficial non-opiate pain management products. CannAmide&#8482;&#8217;s active
compound PEA is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their
metabolism, and is particularly attractive therapeutically as it appears to have a very high safety profile with low or to no possibility
for abuse. On February 10, 2021, we announced that we had entered into an agreement with Procaps, a leader in contract development and
manufacturing services in softgel advanced technologies for the global pharmaceutical and nutraceutical industries, to develop and commercially
manufacture both of our drug candidates, SCI-110 and our proprietary PEA oral tablets CannAmide&#8482;, in softgel capsule form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cannabinoids have great therapeutic
potential and have been used for years for medicinal purposes. For example, cannabis and cannabinoids are being used to improve the quality
of life of patients with numerous and diverse indications (oncological patients, chronic pain conditions, etc.). We believe that the novel
approaches and unique mechanism of action of our proprietary technology platforms, including our drug delivery systems and unique combination
and specific dosages, may be expanded to treat additional diseases and unmet medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may consider
expanding our pipeline to include these additional indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Collaboration with Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we entered
into a cooperation agreement, or the Cooperation Agreement, with Clearmind. The Cooperation Agreement includes, among others, examination
of the benefit of integrating the core technologies of each company to explore the development of psychedelic-centric drug candidates
and targeting mental health-related diseases. Pursuant to the terms of the Cooperation Agreement, we conducted a joint pre-clinical study
with Clearmind. Under the Cooperation Agreement, we aim to pursue, develop and commercialize psychedelic-centric drug candidates. Our
collaboration with Clearmind has resulted as of the date of this Annual Report, in the filing of thirteen patent applications. All patent
applications refer to the combination of SciSparc&#8217;s CannAmide&#8482; with Clearmind&#8217;s 5-Methoxy-2-aminoindane, or MEAI, an
innovative proprietary psychedelic treatment for addictions and others.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to a psychedelic combination
therapy treating numerous binge behaviors. The patent application referred to the combination of our CannAmide&#8482; with Clearmind&#8217;s
MEAI. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment
in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide&#8482; treatment at the lower
sub-effective MEAI dose. Additionally, in May 2022, we announced positive safety profile results from our joint pre-clinical trial with
Clearmind. The clinical trial tested the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s psychedelic molecule,
MEAI, for alcohol consumption. A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas,
spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine the safety of the proprietary combination of MEAI
and CannAmide&#8482; versus control (mice) that were not exposed to alcohol). The severity of changes was scored by a 5-point scale by
a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results indicated a high safety profile of the
combination treatment with no treatment-related changes observed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to treating cocaine addiction.
The patent application refers to the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s MEAI, for treating cocaine
addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, we announced
additional positive pre-clinical results of our psychedelic-based pharma collaboration for treatment for cocaine addiction using MEAI.
These pre-clinical study results added to our announcements regarding our collaboration with Clearmind for their combination treatment
based on our CannAmide&#8482; compound and Clearmind&#8217;s MEAI for various addictions, including pre-clinical studies results, the
filing of two provisional patent applications related to compositions comprised of MEAI and n-acylethanolamines and uses thereof and treating
cocaine addiction. The pre-clinical trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research
Center located at Bar Ilan University (Ramat Gan, Israel) and was designed to evaluate the possible reward-like effects of MEAI with connection
to cocaine and its ability to abolish cocaine-induced conditioned place preference. In the pre-clinical trial, the self-administration
paradigm was utilized, which is the gold-standard model for examining drug addiction and is based on operant conditioning. Rats were catheterized
and trained to self-administer cocaine. The results identified a statistically significant sub-group within the study, in a non-biased
manner and high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine as compared
to non-treated control group. This sub-group, representing 60% of animals, showed a very high response within the group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
that Clearmind filed a provisional patent application related to metabolic syndromes including obesity, regarding our collaboration with
Clearmind. The patent application is the third of the collaboration, each referring to the proprietary combination of our PEA and Clearmind&#8217;s
MEAI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2023, we announced
that announced that Clearmind filed three provisional patent applications were filed by Clearmind with the USPTO as a part of our ongoing
collaboration. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine
and our PEA. Additionally, in February 2023, we announced that as part of our ongoing collaboration with Clearmind, Clearmind filed three
provisional patent applications with the USPTO, for unique combinations of future psychedelic-based compounds. The patent applications
refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine each with our PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we announced
that we and Clearmind were to conduct a study evaluating our combination treatment for obesity and metabolic syndrome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2023, Clearmind
filed a patent application for the treatment of dyskinesia, a combination of the pyschadelic molecule 3-Methylmethcathinone and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, successful
results were announced from a pre-clinical trial on rodents, testing the efficacy of the combination treatment of PEA and MEAI on obesity,
performed by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an increase in the metabolic process
and fat burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, we and Clearmind
filed three patent applications under the PCT referring to novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine,
and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, we and Clearmind
filed three patent applications under the PCT referring to novel proprietary compositions of MDMA, ibogaine, and ketamine, all combined
with PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2024, we and Clearmind
filed a patent application under the PCT referring to the composition of Clearmind&#8217;s MEAI compound and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2024, we and Clearmind
filed a patent application under the USPTO for PEA combined with MEAI for treating metabolic syndrome and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
August 2024, we announced that an article was published by Saja Baraghithy et al. on the promising results from a recent study on MEAI
for combating obesity. The study was conducted by a team of experts lead by Prof. Joseph Tam from the Hebrew University of Jerusalem.
The study demonstrated that the treatment significantly induced weight loss and beneficial changes in body composition in diet-induced
obese mice, without altering food intake, by decreasing fat mass while preserving lean mass. There was a significant improvement in glucose
metabolism, increased energy expenditure and fat utilization, while maintaining a similar food consumption and increased activity-specific
energy expenditure (without overstimulation), providing support for its potential to impact energy balance. Furthermore, there was a decrease
in fatty liver, as evidenced by lower liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing
fat accumulation. These results further show that the treatment was well tolerated and led to increased oxygen consumption and carbon
dioxide emission, coupled with elevated energy expenditure and fat oxidation which in turn indicates increases in the metabolic process
and fat burn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
another study, evaluating the acute effect of numerous doses of MEAI on metabolic and behavioral parameters in mice, in combination with
PEA, the administered drugs exhibited a remarkable degree of tolerance, leaving the animals&#8217; viability unaffected across all experimental
groups. The most favorable outcomes of the combination treatment were notably pronounced at the MEAI 20 mg/kg dose and PEA 25 mg/kg, observed
as increased energy expenditure, enhanced fat oxidation, and decreased meal sizes. These findings underscore the potential of MEAI and
PEA in modulating various aspects of metabolism, locomotor activity, and feeding behavior, warranting further investigation of their roles
in the regulation of energy homeostasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2024, we and Clearmind
announced the publication of its patent application under the PCT for innovative combinations of ketamine and N-acylethanolamines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, we and
Clearmind announced the publication international patent application under the PCT for MDMA combined with N-acylethanolamines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, we and
Clearmind announced the publication of a PCT patent application for ibogaine combined with N-acylethanolamines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
January 2025, we announced the publication of a European patent application submitted by Clearmind under the European Patent Office for
innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption,
shopping and sexual conduct. Under this collaboration, we and Clearmind are researching innovative combination therapies that integrate
psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
February 2025, we announced the publication of a patent application in Mexico for MDMA with N-acylethanolamines. The patent refers to
our innovative combination therapy of N-Acylethanolamines and Clearmind&#8217;s MEAI, addressing binge behavior, including alcohol consumption,
eating, tobacco consumption, shopping and sexual conduct. Under our collaboration with Clearmind, the two companies are researching innovative
combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including (PEA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
April 2025, we announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia,
and other eating disorders. The patent application covers the use of 3-Methylmethcathinone in combination with PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into a collaboration agreement with Polyrizon, a biotech company focused on the development of innovative medical device hydrogels delivered
in the form of nasal sprays, or the Polyrizon Collaboration Agreement. As part of this collaboration, we worked together to develop a
unique technology for the treatment of pain, based on our SCI-160 platform and Polyrizon&#8217;s Trap and Target<sup>TM</sup>&#160;intranasal
drug delivery technology to target the central nervous system. We have agreed to pay development fees to Polyrizon up to a total of $2,550,000
upon the completion of certain milestones, as well as royalties in the low single digits upon sales of products under the agreement and
additional royalties for sales under any sublicense by us. On August 13, 2024, SciSparc entered into a termination agreement with Polyrizon
to terminate the Polyrizon Collaboration Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
August 13, 2024, we entered into the Polyrizon License. Pursuant to this agreement, we granted Polyrizon a royalty-bearing, exclusive,
sub-licensable right and license to the SCI-160 platform and received 320,000 ordinary shares of Polyrizon, pre-funded warrants to purchase
364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793 ordinary shares of Polyrizon, at an exercise price of
$4.38 per share. In addition, in consideration for the license, we will receive royalties from sales related to the SCI-160 platform and
income generated from it.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
December 30, 2024, pursuant to a share transfer agreement, or the Polyrizon Share Transfer Agreement, we sold all of the Polyrizon ordinary
shares and pre-funded warrants held by us, as well as an aggregate of 1,541,096 Polyrizon common warrants to third parties, for aggregate
consideration of $770,548. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
April 1, 2025, we entered into a securities purchase agreement with Polyrizon pursuant to which we participated in a private placement
of Polyrizon, and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and
Series A warrants to purchase ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant
to which we exchanged existing ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Acquisition of Wellution&#8482;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we
entered into the Wellution Acquisition Agreement with Merhavit M.R.M Holding and&#160;Management Ltd., or M.R.M, and the other parties
named therein, to acquire from M.R.M its rights to purchase, the Wellution&#8482; brand. In connection therewith, we incorporated a new
wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the new assets of the Brand. The Brand sells hemp-based products, including
hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other
beauty and hair treatment products that are all manufactured in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the closing
of the Wellution Acquisition Agreement for the Brand which took place on September 30, 2022, we paid $4.59 million for the Brand and issued
to M.R.M $15 million worth of warrants to purchase up to an aggregate amount of 82,418 of our Ordinary Shares, or the M.R.M Warrants.
The M.R.M Warrants had an exercise price of $182 per share and an exercise period of five years from the closing, until September 30,
2027.The M.R.M Warrants were exercisable during the exercise period upon the earlier of (i) an achievement of $100 million of gross sales
by the Brand in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;On March 26, 2024, M.R.M. agreed
with us to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Restructuring Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NewCo</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part of or independent to the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange,
while maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend
to explore other potential new opportunities, activities and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any restructuring and possible
listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses, regulatory
approvals, receipt of any necessary consents, final approvals from our board of directors and satisfaction of any closing conditions to
effectuate such corporate restructuring and listing of NewCo. There can be no assurance regarding the ultimate timing of the intended
restructuring and listing of NewCo or that they will be completed at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Strategic Transaction Opportunity
Engagement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we engaged
Rosario Capital Ltd. to identify potential opportunities for a strategic transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Proposed Acquisition of
AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
November 22, 2023, we announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated terms as
announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 91; Options: NewSection; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Pursuant
to the Restructuring Plan, on June 25, 2023, we entered into a securities purchase agreement with AutoMax, pursuant to which, at the closing
and upon the terms and conditions set forth in the AutoMax SPA SciSparc invested NIS 2,500,000 (approximately $690,000) in cash, in exchange
for ordinary shares of AutoMax based on a price per share of NIS 0.5. Following the closing, we held approximately 5.6% of the issued
and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, we and
AutoMax entered into a Merger Agreement, as amended on August 14, 2024, pursuant to which SciSparc Merger Sub Ltd., an Israeli limited
company and our wholly-owned subsidiary will merge with and into AutoMax, with AutoMax surviving as our wholly-owned subsidiary. Our Ordinary
Shares, as well as pre-funded warrants exercisable into ordinary shares, will be issued to AutoMax&#8217;s shareholders at the effective
time of the Merger, pursuant to the Exchange Ratio. Under the Exchange Ratio formula, immediately following the Merger, AutoMax&#8217;s
shareholders and M.R.M are expected to own approximately 49.99% of our share capital, on a fully-diluted basis, subject to certain exceptions,
and as further defined in the Merger Agreement, and our shareholders are expected to own approximately 50.01% of our share capital, on
a fully-diluted basis, subject to certain exceptions. The Merger has been unanimously approved by the boards of directors of both companies
and will be presented for approval by the shareholders of AutoMax. On August 14, 2024, the parties entered into the Merger Agreement Addendum,
pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November
30, 2024. On November 26, 2024, the parties entered into the Merger Agreement Second Addendum, pursuant to which the right to terminate
the Merger Agreement, if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, the parties
entered into the Merger Agreement Third Addendum, pursuant to which the right to terminate the Merger Agreement, if the Merger was not
consummated by March 31, 2025, was deferred to September 30, 2025, and the definition of &#8220;Exchange Ratio&#8221; was revised to remove
the rounding to four decimal places of the Exchange Ratio. The Merger is expected to close in the second quarter of 2025, subject to the
approval of our shareholders, approval of the AutoMax shareholders, including a separate approval by AutoMax shareholders who are not
controlling shareholders of AutoMax or us, and court approval, as well as other customary conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Loans to AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
January 14, 2024, we entered into, as lender, a bridge loan agreement with AutoMax, pursuant to which AutoMax received the Bridge Loan,
further to the previously-announced non-binding letter of intent for us to acquire AutoMax. On April 10, 2024, we signed the Merger Agreement
with AutoMax. On August 14, 2024, on November 26, 2024, and March 27, 2025, we and AutoMax entered into the Merger Agreement Addendum,
the Merger Agreement Second Addendum, and Merger Agreement Third Addendum, respectively. On June 9, 2024, we entered, as lender, into
the Amended Bridge Loan, pursuant to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate amount
of $2.4 million. On September 5, 2024, we entered into the Second Amendment, pursuant to which we extended an additional Loan amount to
AutoMax. &#160;During the month of September 2024, we provided AutoMax with the loan amounts due under the Second Amendment to the Bridge
Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on the closing date of the Merger, we will
be entitled to be paid the due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the Loan Amount,
accruing from the period beginning on December 1, 2024 and ending on the effective date of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 92; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Merger Agreement contemplates that at closing, we shall deliver to AutoMax the closing financing amount. In light of the Bridge Loan and
amendments thereto, no closing financing amount will be transferred. In consideration for the Loan Amount, AutoMax established a first
ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor of us.
The Bridge Loan amount, together with any accrued interest, may be repaid in part or in whole prior to the repayment date, contingent
on whether the closing of the Merger Agreement occurs. The repayment date shall be at the earlier date of: (a) the Closing, in which the
owed amount shall be deemed set-off against the closing financing amount; or (b) if the Merger Agreement is terminated in accordance with
its terms, within three months from such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On February 27, 2025, we announced that we had entered into the Additional
Loan Agreement with AutoMax where a $2 million loan was provided. The loan bears an 8% annual interest rate and will be repaid in equal
monthly installments of $50,000 and interest, with AutoMax retaining the option to make early repayment without penalties. The interest
on the loan will be cancelled as of the consummation of the Merger Agreement and AutoMax will continue to make monthly payments towards
the principal amount of the loan. As collateral, AutoMax pledged a first-ranking fixed charge on its subsidiary&#8217;s shares, in accordance
with a fixed charge debenture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax is a company in the
field of importing and marketing a variety of vehicles for personal use (including trade-in), this includes an array of vehicle sizes
such as: small; family sized; crossover, sedans, SUVs, as well as luxury vehicles and buses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initially AutoMax, under its
then corporate name Matomi Media Group Ltd., and its subsidiaries provided a variety of programmatic data-driven platforms, which focused
on two main activities of domain monetization and mobile digital advertising. These services were mainly for U.S. and Europe based advertising
agencies, app developers and domain owners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2018, AutoMax
completed a public offering of series A convertible loans, in the aggregate amount of NIS 103 million (approximately $24.5 million). Beginning
in the second half of 2017 through December 2019, AutoMax sold all its activities related to digital marketing. On January 8, 2020, following
a unanimous approval of the bondholders, AutoMax repaid the full debt, approximately NIS 101 million (approximately $27.9 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 9, 2020, AutoMax
entered into a share exchange agreement with Global AutoMax and M.R.M, or the Share Exchange Agreement. Upon the closing, on March 24,
2021, AutoMax issued to the shareholders of Global AutoMax 120,279,312 ordinary shares representing, upon issuance, approximately 52.53%
of the issued and outstanding shares of AutoMax, with additional issuances subject to fulfilling certain milestones, as detailed in the
Share Exchange Agreement. In exchange, Global AutoMax shareholders transferred all their shares to AutoMax. On March 28, 2023, following
successful completion of such milestones, AutoMax issued an additional 168,105,258 ordinary shares to its controlling shareholders, which
constituted approximately 41% of its issued and outstanding share capital following the issuance. Following the closing of the Share Exchange
Agreement, Global AutoMax became a wholly owned subsidiary of AutoMax. In addition, some of the key officers in Global AutoMax, who were
appointed as officers in AutoMax, were issued options to purchase up to 11,851,420 ordinary shares of AutoMax (adjusted to reflect the
5 to 1 reverse share split), subject to the terms of the company employee share incentive plan. On March 23, 2025, the said options expired.
As of the date of this Annual Report, the controlling shareholders of the AutoMax collectively hold approximately 55.65% of AutoMax's
issued and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">On June 19, 2022,
AutoMax entered into a joint venture agreement, or the Agreement, with Dalhom Motors Ltd., or Dalhom, pursuant to which, AutoMax and Dalhom
formed a jointly-owned subsidiary, Dalhom AutoMax, a special purpose company established for the purpose of importing and marketing of
Temsa Skoda Sabanc&#305; Ula&#351;&#305;m Ara&#231;lar&#305; A.&#350;,, or Temsa, buses in Israel. In addition, prior to the
closing, Dalhom AutoMax entered into a franchise agreement with Temsa for a period of three years, pursuant to which Dalhom AutoMax will
serve as a direct importer of Temsa buses in Israel. Furthermore, Dalhom AutoMax entered into a service and warranty agreement for a term
of three years, pursuant to which it will provide maintenance and warranty services for Temsa buses, as agreed upon in the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, AutoMax
Direct Import finalized entering into agreements with JAC, a manufacturer of private and commercial vehicles, for the direct import, distribution
and service of vehicles and spare parts manufactured by JAC in Israel, or the JAC Agreements. On December 27, 2024, AutoMax Direct Import
received its first shipment of vehicles manufactured by JAC, following regulatory approvals for direct importation. According to the JAC
Agreements, AutoMax Direct Import serves as a direct importer of JAC brand in Israel, and the JAC will provide AutoMax Direct Import with
vehicles and spare parts for the vehicles for marketing and sale in Israel, in accordance with annual business plans as agreed between
the parties. The JAC Agreement includes, among others, customary provisions regarding warranty for the vehicles by JAC, the supply of
spare parts, the duty to notify about malfunctions (recall) and compliance with other requirements required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax Direct Import will
adapt its existing showrooms for the purpose of selling JAC vehicles in the standards agreed in the agreement. The JAC Agreements are
for a period of three years, subject to AutoMax Direct Import&#8217;s compliance with sales and service network expansion goals determined
in the agreements, and will enter into force only when the appropriate European regulatory approvals are received for JAC vehicles. In
addition, JAC is entitled to terminate the agreement upon the occurrence of certain events provided in the JAC Agreements, as is customary
in such agreements, such as: (a) if AutoMax Direct Import substantially violates its obligations under the JAC Agreements or encounters
special circumstances that give justifiable reasons for early termination (including AutoMax Direct Import&#8217;s failure to meet its
sales goals, service network expansion goals or market share goals); (b) in the event of change of control in AutoMax Direct Import; and
(c) in the event of bankruptcy, moratorium, receivership, liquidation, or any other similar circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">As of the date of
this Annual Report, AutoMax engages in importing and marketing of vehicles in Israel (including trade-in). Within this segment, the AutoMax
engages in direct and parallel&#160;import of private vehicles and their marketing in Israel, and through joint ventures, in the direct
import buses to Israel of buses manufactured by Temsa, as well as in the purchase and sale of used vehicles (trade-in). AutoMax holds
direct and parallel&#160;importer licenses from the Ministry of Transportation, as defined in the Vehicle Services Licensing Law, for
37 vehicle brands of various models. As of the date of this Annual Report, AutoMax operates through ten sales branches located in Acre,
Haifa, Afula, Netanya, Ra'anana, Rishon LeZion, Ashdod, Jerusalem, Beer Sheva and Hedera. It additionally operates a storage system and
a system for preparing vehicles for sale. AutoMax has an international network of suppliers and manufacturers, located in Europe and North
America and China, that supply it with vehicles of different brands and models, tailored to order. AutoMax further has an import system
that consists of procurement, transportation and handling the procedure for releasing vehicles from customs, as well as vehicle storage
facilities in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax is authorized
by the Ministry of Transportation, to perform licensing inspections for the purpose of the initial registration of vehicles imported by
it. Additionally, AutoMax has been authorized by the Ministry of Transportation to import spare parts and to carry out various forms of
installations that involve changing the vehicle structure (such as installing towing hooks).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax was formed
under the laws of the state of Israel in February 2006, as a private company, under the name Cubeeffect Ltd. In November 2009, Cubeeffect
Ltd. changed its name to Adsmarket G.M. Ltd, and in July 2011 changed to Matomy Media Group Ltd. On April 18, 2021, the company changed
its name to AutoMax Motors Ltd. AutoMax&#8217;s ordinary shares were initially listed on the London Stock Exchange in July 2014 and in
February 2016 on the TASE. From November 2020 onwards, AutoMax ordinary shares have been traded solely on TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our intellectual property portfolio is comprised
of six granted U.S. patents, and pending patent applications in eight families, all of which are in the national phase of examination.
Of this portfolio, we have exclusively licensed one patent family from Yissum. Our intellectual property portfolio also includes.an application
to register the trademark CannAmide&#8482; pending in the United States.SciSparc has also been granted a trademark registration for Wellution&#174;
in Class 003 in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SciSparc has also been granted a trademark registration
for Wellution&#174; in Class 005 in the United States</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Internally Developed Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, we filed a
provisional application with the USPTO for the technology of proprietary sequences of anti-CD3 antibody and the utilization of the latter
in various autoimmune diseases, as well as in hepato-pathologies. The provisional application has been converted to a PCT and then entered
a National Status in December 2014 in the U.S., with the European Patent Office, or EPO, and in China and Canada. In the U.S. it received
a grant status in June 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2015, we filed a
provisional application with the USPTO for combinations of cannabinoids, n-acylethanolamines, and inhibitors of n-acylethanolamine degradation,
which, in April 2016 was converted into an international PCT application that subsequently entered national phase in the following state
entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to utilizing the potentiating effect of n-acylethanolamines
on cannabinoids for any cannabinoid amenable indication, including but not limited to analgesia and TS. The 20-year term of any patent
issuing from this application would expire in April 2036. In August and September 2021, the patent was granted in Australia and Japan,
respectively, and a further patent was granted in Australia in November of 2023. A patent was granted in Israel in August of 2022, and
three patents have been issued in the U.S., two in December 2021 and one in February 2022. In December 2022, we were granted a patent
from the EPO. A patent was issued in Canada in April 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we filed a provisional
application with the USPTO for combinations of opioids, n-acylethanolamines, and inhibitors of n-acylethanolamines degradation, which,
in May 2016 was converted into an international PCT application that subsequently entered national phase in the following state entities:
U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to potentiating effect of N-acylethanolamines on opioids
for opioid amenable indications. The 20-year term of any patent issuing from this application would expire in May 2036. In July 2021,
the first patent was granted in Australia and a second was granted in November 2023. A patent was issued in Japan in March 2023, and the
EPO granted a patent in November 2023. A patent was issued in Canada in April 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2016, we filed a provisional
application with the USPTO for the use of cannabinoids for potentiating the efficacy of antibiotics, which in July 2017 was converted
into an international PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and
China. The 20-year term of any patent issuing from this application would expire in July 2037. In November 2022, the USPTO issued this
patent called &#8220;Compositions and Methods of Potentiating Antimicrobials&#8221;. A patent was issued in Europe in May of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we filed
a provisional application with the USPTO directed to methods of treating OSA, which in January 2019 was converted into an international
PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and Australia. The 20-year
term of any patent issuing from this application would expire in January 2039. A patent was issued in Australia in February of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2019, we filed a
provisional application with the USPTO directed to compositions and methods for potentiating derivatives of 4-aminophenols, which in April
2020 was converted into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada,
China, EPO, Israel, India, Japan, Mexico, Russia, and the U.S. The 20-year term of any patent issuing from this application would expire
in April 2040.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, we filed a
provisional application with the USPTO directed to methods for maintaining microvascular integrity, which in August 2021 was converted
into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada, China, EPO, Israel,
India, Japan, and the U.S. The 20-year term of any patent issuing from this application would expire in August 2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In-Licensed Patents and Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2018, we entered
into an exclusive, worldwide, sublicensable, royalty-bearing license agreement with Yissum for a license to make commercial use of the
licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, or the Yissum
License Agreement. According to the Yissum License Agreement, we were required to pay Yissum an initial payment of $133,000, and shall
pay Yissum royalties at the rates of 3% of net sales, subject to the royalty reductions as described in the Yissum License Agreement.
All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and we shall hold and make use of the
rights granted. All rights in the development results shall be solely owned by us, except to the extent that an employee of the Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by us and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Intellectual Property Protection </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patent and
trademark protection, we intend to use other means to protect our proprietary rights, including pursuing marketing or data exclusivity
periods, orphan drug status, and similar rights that are available under regulatory provisions in certain countries, including but not
limited to the United States, Europe, Canada, Japan, and China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also seek regulatory approval
for our products for indications with high unmet medical need, great market potential, and where we have a proprietary position through
patents covering various aspects of our products, including but not limited to: composition, dosage, formulation, use, and manufacturing
process. Our success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers
to our competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing
applications, and licensing and acquiring new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see Item 3D &#8220;<i>Risk Factors-Risks Related to our Intellectual Property</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our portfolio of patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Country</b></p></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jul-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Oct-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THX-110<br/>
THX-210</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-Oct-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Oct-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210 </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Aug-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Country</b></p></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Mar-2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Jun-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Mar-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Jun-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 <br/>
THX-210</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jun-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Oct-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Aug-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Apr-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIODS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Apr-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Nov-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Country</b></p></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Mar-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be Ababdoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Mar-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2018</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTERS OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Jun-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Sep-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jul-2017</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Compositions comprising CB receptor agonists, uses thereof and methods for their preparation</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-Jun-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have an application to register the trademark
CannAmide&#8482; pending in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also been granted
trademarks for Wellution&#174; in Class 003 and Class 005 in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left">(1)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validation
states are not listed separately.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales and Transfer of Intellectual Property
Assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transaction with Former Subsidiary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we entered into
a share transfer agreement with our former subsidiary, Orimmune Bio Ltd., or Orimmune, and Karma Link Ltd., or Karma Link. According to
the agreement, we agreed to sell our interests in Orimmune to Karma Link, and also use our best efforts to transfer to and assign Orimmune
our rights in the Anti-CD3 technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2018, an additional
amendment to the transfer agreement was signed, or the Additional Amendment, between us, Karma Link and Orimmune, under which it was agreed
that Orimmune (and Karma Link) will be assigned certain rights in IP related to the licensed technology owned by us, subject to certain
conditions precedent. In 2021, we received the approval of the IIA to complete the assignment and we are now seeking to complete the transaction.
As of the date of this Annual Report on Form 20-F, the conditions precedent have not yet been completed and the assignment of the intellectual
property rights related to the licensed technology owned by us has not yet been transferred.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>MitoCareX </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2022, we entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, we
invested an initial amount of $700,000 in MitoCareX and agreed to invest over the next two years an additional $1,000,000, subject to
the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX.
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants and indemnification provisions and on March 31, 2022, the closing
conditions were met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, we announced
that MitoCareX has achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment of
MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The
system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this
milestone, we invested an additional $400,000 in MitoCareX and increased our share ownership holdings in MitoCareX Bio from 31.48% to
41.92%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2023, we announced
that MitoCareX successfully developed its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A
mitochondrial carrier proteins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 27, 2023, we announced
that MitoCareX achieved positive results with the development of its laboratory capabilities by establishing a variety of small-molecule
screening platforms. With this development, MitoCareX achieved its second milestone pursuant to the MitoCareX Agreement <span>and
as a result, on March 11, 2024 we invested an additional $600,000 </span>and increased our share ownership holdings in MitoCareX Bio from
41.92% to 52.73%<span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
September 26, 2024, we signed a non-binding letter of intent relating to the sale of our entire ownership interest in MitoCareX to a publicly-traded
company in the United States. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2025, we entered
into a securities purchase and exchange agreement, or the MitoCareX SPEA, together with MitoCareX, Dr. Alon Silberman and Prof. Ciro Leonardo
Pierri, as the Sellers, pursuant to which the Sellers will sell their stakes in MitoCareX to the Purchaser, N2OFF, Inc., a Nevada corporation,
or N2OFF, thereby resulting in MitoCareX becoming a wholly-owned subsidiary of N2OFF. The MitoCareX SPEA contains customary representations,
warranties and covenants by each of the parties. The closing of the MitoCareX SPEA is contingent upon, among other customary obligations,
obtaining approval of N2OFF&#8217;s stockholders by the requisite majority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the closing date of the
transactions contemplated under the MitoCareX SPEA, we will transfer and sell our stake in MitoCareX to N2OFF in consideration for a cash
payment of $700,000 and shares of N2OFF common stock, par value $0.0001 per share, or the N2OFF Common Stock, representing 16.75% of N2OFF
on a fully-diluted basis. The sale of our stake in MitoCareX is contingent upon the transfer of the other Sellers&#8217; stakes to N2OFF
in exchange for agreed to amounts of N2OFF Common Stock. Either party may terminate the MitoCareX SPEA if the closing date has not occurred
within ninety days of February 25, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing date
of the MitoCareX SPEA, the Sellers may receive such number of additional shares of N2OFF Common Stock, for no additional consideration,
that reflects an aggregate amount of up to 25% of the issued and outstanding capital stock of N2OFF on a fully-diluted basis, or the Additional
N2OFF Stock, which Additional N2OFF Stock, if the respective milestones are achieved as defined in the MitoCareX SPEA, will be duly issued
in installments based on the achievement of each milestone, as set forth in the MitoCareX SPEA, and will be allocated amongst the Sellers
as follows: 50% to us, 33.33% to Mr. Silberman and 16.67% to Mr. Pierri. The Sellers&#8217; eligibility to receive Additional N2OFF Stock
will terminate on December 31, 2028, such that if a specific milestone is not achieved and therefore the right to receive the respective
number of shares of Additional N2OFF Stock issuable upon the achievement of such milestone is not earned by December 31, 2028, the right
to receive the number of shares of Additional N2OFF Stock attributable to any such non-achieved milestone pursuant to the MitoCareX SPEA
will terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we started early
commercialization of our proprietary PEA oral tablets CannAmide&#8482;, we intend to build a global commercial infrastructure to effectively
support the commercialization of our main pharmaceutical product candidates, if and when we believe regulatory approval of a pharmaceutical
product candidate in a particular geographic market appears imminent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To develop the appropriate
commercial infrastructure, we will likely have to invest significant amounts of financial and management resources, some of which we expect
to commit prior to completing the regulatory process for our pharmaceutical product candidates. Where appropriate, we may elect in the
future to utilize strategic partners, distributors, or contract sales forces to assist in the commercialization of our pharmaceutical
products. In certain instances we may consider building our own commercial infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we entered into
a license and distribution agreement with SciSparc Nutraceuticals pursuant to which we granted SciSparc Nutraceuticals an exclusive license
to sell and market its PEA oral tablets, CannAmide&#8482; on Amazon Marketplace in Canada. Effective as of June 7, 2024, SciSparc Nutraceuticals
and we entered into an amendment to the license and distribution agreement to amend the term of the license and distribution agreement
to an indefinite term, unless terminated by either party upon 30 days advanced notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While
we believe that our scientific knowledge, technology and development experience provide us with competitive advantages, we face potential
competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop
and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based pharmaceutical,
a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called Unimed Pharmaceuticals,
with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment for chemotherapy-related
nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market, other pharmaceuticals
containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed by SVC Pharma LP and
Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole cannabis extract administered
as an oral spray. Furthermore, to the best of our knowledge, there are multiple companies that are working in the cannabis therapeutic
area and are pursuing regulatory approval for their product candidates. For example, GW, which markets Sativex, a botanical cannabinoid
oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval in the United States in June 2018 for Epidiolex,
a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and
various childhood epilepsy syndromes. In addition, GW is developing, among others, CBDV based therapy for ASD and therapy for neonatal
hypoxic-ischemic encephalopathy and schizophrenia. Zynerba is developing a transdermal formulation of cannabidiol for Fragile X and certain
refractory epilepsies and ASD. Skye is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and
other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for
systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx is developing
dronabinol for OSA treatment. Synendos is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed
pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. Synendos is developing small
molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders
caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor
antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101
(Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors, either alone
or through their strategic partners, might have substantially greater name recognition and financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in researching and developing pharmaceutical products,
obtaining FDA and other regulatory approvals of those products and commercializing those products around the world. They may also have
intellectual property portfolios that provide them with significant competitive advantages or create substantial barriers in our target
markets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently contract with
third parties for the manufacturing and testing of our product candidates for preclinical trials and clinical trials and also intend to
do so in the future. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates.
The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient and may eliminate the need to
directly invest in manufacturing facilities and additional staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our third-party manufacturers
have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our product
candidates to meet anticipated full scale commercial demands. To meet our projected needs for commercial manufacturing, third parties
with whom we currently work might need to increase their scale of production, or we will need to secure alternate suppliers. We believe
that there are alternate sources of supply that can satisfy our clinical and commercial requirements, although we cannot be certain that
identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, pharmaceutical
product candidates are subject to extensive regulation by the FDA. The FDC Act, and other federal and state statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion, marketing,
distribution, post-approval monitoring, reporting, sampling, and import and export of pharmaceutical drug product candidates. Failure
to comply with applicable U.S. rules and regulations may subject a company to a variety of administrative or judicial sanctions, such
as FDA refusal to approve pending NDAs, warning letters, product candidate recalls, product candidate seizures, total or partial suspension
of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical drug product
candidate development in the United States typically involves pre-clinical laboratory and animal testing, the submission to the FDA of
an IND Application, which must become effective before clinical testing may commence, and adequate, well-controlled clinical trials to
establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market
approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and
novelty of the product candidate or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nonclinical tests include
laboratory evaluation of an API or drug substance and drug product&#8217;s candidate chemistry, formulation and toxicity, as well as animal
trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the nonclinical toxicology
studies must comply with federal regulations and requirements, including GLP. The results of nonclinical testing are submitted to the
FDA as part of an IND along with other information, including information about product candidate chemistry, manufacturing and controls,
and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity,
may continue after the IND is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 30-day waiting period after
the submission of an original IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical
hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
In practice, a submitting party should contact the division after this 30 day period to ensure that the FDA has reviewed the IND to the
extent that they can assure there will be no hold placed on the IND if the FDA has not responded to the Company within this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the investigational product to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international standard meant to
protect the rights and health of patients to ensure the quality of the trial and to define the roles of clinical trial sponsors, administrators
and monitors. Clinical protocols and details of the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. Each protocol and any amendment involving testing of U.S. study subjects within the United States and subsequent
protocol amendments must be submitted to the FDA as part of the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may order the temporary
hold of a clinical trial at any time or impose other sanctions if the FDA believes that the clinical trial either is not being conducted
in accordance with FDA requirements, regulations or presents a potentially unacceptable risk to the clinical trial subjects. The trial
protocol and informed consent information for subjects in clinical trials must also be submitted to an IRB for approval. An IRB may impose
other conditions for the protocol and may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>505(b)(2) Regulatory Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505(b)(2) of the FDC
Act, or 505(b)(2), provides a regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug
products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from
studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference, or use from the person
by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of safety and efficacy for
an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants
to perform additional studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new
product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new
indication sought by the 505(b)(2) applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orange Book Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505 of the FDC Act
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section 505(b)(2) NDA is
an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required
for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a
right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In seeking approval for a
drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#8217;s
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products
with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential competitors in support
of approval of a 505(b)(2) NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any applicant who submits
a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product
that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires;
or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application
is submitted. This last certification is known as a Paragraph IV certification. Generally, 505(b)(2) NDA cannot be approved until all
listed patents have expired, except where 505(b)(2) NDA applicant challenges a listed patent through a Paragraph IV certification. If
the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use,
the 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although some of our product
candidates are based on repurposed drugs, there are at present no patents or other exclusivities listed in the Orange Book pertaining
to a product containing the active ingredient dronabinol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three-year exclusivity is
available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product,
such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence
trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity
period protects against FDA approval of 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter, three-year
exclusivity does not prohibit the FDA from approving 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year
and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NDA Submission and Review by the FDA</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful completion
of the required clinical and nonclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission
of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the time of the first submission of the
application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances.
One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates,
the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of preparing and
submitting an NDA is substantial, mainly due to the non-clinical and clinical trial costs. Under federal law, the submission of most NDAs
is additionally subject to a substantial application user fee; the fee in the financial year 2024 was $4,048,695.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has 60 or 74 days
from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination
that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug product
candidates are reviewed within 10 to 12 months, while most applications for priority review drugs are reviewed within six months. Priority
review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy
exists. The review process for both standard and priority review may be extended by FDA for three additional months to consider certain
late-submitted information, or information intended to clarify information already provided in the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also refer applications
for novel drug product candidates, or drug product candidates that present difficult questions of safety or efficacy, to an advisory committee,
which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA
may inspect the facility or the facilities at which the drug substance and drug product are manufactured. The FDA will not approve the
drug product candidate unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the
drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally
outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider
the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the
FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
requested information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA
may require a REMS plan to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides,
communication plans for health care professionals, and ETASU. An ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The
requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product candidate approval
may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product candidate
approvals may be withdrawn if compliance with regulatory standards is not maintained related to the manufacture, safety or effectiveness
or problems are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Clinical Trial Information</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials
of certain FDA-regulated product candidates, including prescription drugs, are required to register and disclose certain clinical trial
information on a public website (clinicaltrials.gov) which is maintained by the U.S. National Institutes of Health. Information related
to the product candidate, patient population, phase of investigation, study sites and investigator, and other aspects of the clinical
trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after completion.
Disclosure of the results of these trials can be delayed until the product candidate drug product or new indication being studied has
been approved. Competitors may use this publicly available information to gain knowledge regarding the design and progress of our development
programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track Designation and Accelerated Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has programs to facilitate
the development, and thus expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or
condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition.
These therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies&#8217;
benefits outweigh their risk. Under the Fast Track Program, the sponsor of a new drug candidate may request that FDA designate the drug
candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA
must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#8217;s request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDA&#8217;s accelerated
approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to
patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. Accelerated approval
may also be based on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely
to predict an effect on irreversible morbidity or mortality or other clinical benefit, considering the severity, rarity or prevalence
of the condition and the availability or lack of alternative treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In clinical trials, a surrogate
endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a
patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A
drug product that is approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
confirmatory or post-approval clinical trial(s) or registries to confirm the effect on the clinical endpoint. Failure to conduct required
post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market
on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior
review by FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to other benefits
such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections
of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA
approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s
time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track
designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial
process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Term Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After NDA approval, owners
of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of
the drug&#8217;s testing phase, the time between IND submission and NDA submission, and all of the review phase-the time between NDA submission
and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant did not pursue approval with
due diligence. The total patent term after the extension may not exceed 14 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For patents that might expire
during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent
term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is
reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension
is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advertising and Promotion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an NDA is approved, a
drug product will be subject to certain post-approval requirements. Products manufactured or distributed by us pursuant to FDA approvals
are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising,
promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase
4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. For instance, FDA closely
regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising,
off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs may be marketed only
for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established
in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and
FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires
clinical data similar to that in the original application. The FDA uses the same procedures and actions in reviewing NDA supplements as
it does in reviewing NDAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse Event Reporting and GMP Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adverse event reporting and
submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as
Phase 4 testing, REMS and surveillance to monitor the effects of an approved product candidate, or the FDA may place conditions on an
approval that could restrict the distribution or use of the drug product. In addition, quality-control, drug manufacture, packaging, and
labeling procedures must continue to conform with cGMPs after approval. Drug manufacturers and certain of their subcontractors are required
to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced
inspections by the FDA, during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers
must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product candidate approvals or request product candidate recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing or if previously unrecognized problems are subsequently discovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pediatric Exclusivity and Pediatric Use</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Best Pharmaceuticals for
Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for a drug if certain conditions
are met. Conditions for exclusivity include a determination by the FDA that information relating to the use of a new drug in the pediatric
population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement by the applicant
to perform the requested studies and the submission to the FDA; and the acceptance by the FDA, of the reports of the requested studies
within the statutory timeframe. Applications under the BPCA are treated as priority applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the Pediatric
Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise required
by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted with the exception of certain
oncological indications. The required pediatric assessment must assess the safety and effectiveness of the product candidate for the claimed
indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which
the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults
before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the pediatric studies
begin. Under PREA, the FDA must send a non-compliance letter requesting a response with 45 days to any sponsor that fails to submit the
required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition-generally a disease or condition with
a prevalence of fewer than 200,000 individuals in the United States. Orphan drug designation must be requested and granted before submitting
an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly
by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.
The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with an FDA orphan drug
designation is entitled to a seven-year exclusive marketing period in the United States for that drug product candidate for that indication.
During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease,
except in limited circumstances, such as a showing of clinical superiority to the product candidate with orphan drug exclusivity. Orphan
drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different
disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA
application user fee. In addition to the potential seven years of market exclusivity after approval, orphan drug designation status qualifies
sponsors for tax credits for qualified clinical trials and exemption from user fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Protocol Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A company may reach an agreement
with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size of clinical trials intended to
form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to evaluate the protocol within 45
days of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for
additional information. An SPA request must be made, and all open issues must be resolved before the clinical trial begins. If a written
agreement is reached, it will be documented and made part of the administrative record. Under the FDC Act and FDA guidance implementing
the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial
scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that were unrecognized
at the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the study sponsor fails to follow the
protocol that was agreed upon with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Controlled Substances</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CSA and its implementing
regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security,
recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA.
The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture,
import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent
the diversion of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA categorizes controlled
substances into one of five schedules-Schedule I, II, III, IV or V-with varying qualifications for listing in each schedule. Schedule
I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment in the United States and
lack accepted safety for use under medical supervision. Schedule I substances may be used only in federally approved research programs
and may not be marketed or sold for dispensing to patients in the United States. Pharmaceutical product candidates having a currently
accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with Schedule II
substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances presenting the
lowest relative potential for abuse and dependence. The regulatory requirements are more restrictive for Schedule II substances than Schedule
III substances. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist in
most situations and cannot be refilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following NDA approval of
a drug containing a Schedule I controlled substance, that substance must be rescheduled as a Schedule II, III, IV or V substance before
it can be marketed. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act, removed uncertainty associated with
timing of the DEA rescheduling process after NDA approval. Specifically, it requires DEA to issue an &#8220;interim final rule,&#8221;
pursuant to which a manufacturer may market its product candidate within 90 days of FDA approval. The new law also preserves the period
of orphan marketing exclusivity for the full seven years such that this period only begins after DEA scheduling. This contrasts with the
previous situation whereby the orphan &#8220;clock&#8221; began to tick upon FDA approval, even though the product candidate could not
be marketed until DEA scheduling was complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Facilities that manufacture,
distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular
location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required for importation and manufacturing
activities, and each registration authorizes which schedules of controlled substances the registrant may handle. However, certain coincident
activities are permitted without obtaining a separate DEA registration, such as distribution of controlled substances by the manufacturer
that produces them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA inspects all manufacturing
facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific
security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent
requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks
on all employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of
alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer (not a dosage form manufacturer
or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register, and the application is open for 30
days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of the Federal Register
publication is forwarded by DEA to all those registered, or applicants for registration, as bulk manufacturers of that substance. Once
registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances.
Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic
substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must
obtain authorization to destroy or dispose of controlled substances. As with applications for registration as a bulk manufacturer, an
application for an importer registration for a Schedule I or II substance must also be published in the Federal Register, which remains
open for 30 days for comments. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to
substances not already available from domestic supplier or where there is not adequate competition among domestic suppliers. In addition
to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II
substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics. In some
cases, Schedule III non-narcotic substances may be subject to the import/export permit requirement, if it is necessary to ensure that
the United States complies with its obligations under international drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For drugs manufactured in
the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be
manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific,
research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the United States each
year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing and procurement
quotas. The quotas apply equally to the manufacturing of the API/drug substance and production of dosage forms. The DEA may adjust aggregate
production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although
the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states may also
maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing
requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure to maintain
compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement
action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Europe/Rest of World Government Regulation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution
of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from
country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of whether we obtain
FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to
the commencement of clinical trials or marketing of the product candidate in those countries. Certain countries outside of the United
States have a process that requires the submission of a Clinical Trial Application, or CTA, much like an IND prior to the commencement
of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent
ethics committees in each country in which a company intends to conduct clinical trials pursuant to European Clinical Trials Regulation
regulations. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that
country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements and process
governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement vary from country to country, even though
there is already some degree of legal harmonization in the European Union member states resulting from the national implementation of
underlying European Union legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain regulatory approval
of an investigational drug under the European Union. regulatory systems, we must submit a MAA. This application is similar to the NDA
in the United States, with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the
European Union by using (i) the centralized authorization procedure, (ii) the Mutual Recognition Procedure, or MRP, (iii) the decentralized
procedure or (iv) national authorization procedures. The initial Sativex approvals were a consequence of an application under the de-centralized
procedure to the European Union member state of Spain acting as reference member state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Commission implemented
the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European
Economic Area, or EEA. This procedure results in a single marketing authorization granted by the European Commission that is valid across
the European Union, as well as in Iceland, Liechtenstein and Norway (forming together the EEA). The centralized procedure is compulsory
for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated
for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions
and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare human diseases) and (iv) advanced-therapy
medicines, such as gene- therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of
the applicant also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains a new
active substance which, on the date of entry into force of this Regulation, was not authorized in the Community; or (b) the applicant
shows that the medicinal product candidate constitutes a significant therapeutic, scientific or technical innovation or that the granting
of authorization in the centralized procedure is in the interests of patients or animal health at the European Community level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized procedure
in the European Union, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products
for Human Use, or CHMP, with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation
might be granted by the CHMP in exceptional cases, when a medicinal product candidate is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: (1) the seriousness of the disease to be treated;
(2) the absence of an appropriate alternative therapeutic approach, and (3) anticipation of exceptional high therapeutic benefit. In this
circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any Member State refuse
to recognize the marketing authorization by the reference member state in a decentralized procedure, on the grounds of potential serious
risk to public health, the issue will be referred to the Committee for the Mutual Recognition and Decentralized Procedures human. Within
a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the
procedure is submitted to the CHMP for arbitration. The opinion of the CHMP is then forwarded to the Commission, for the start of the
decision making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General
and the Standing Committee on Human Medicinal Product candidates or Veterinary Medicinal Product candidates, as appropriate. Since the
initial approvals of Sativex in the United Kingdom and Spain, there have been three &#8220;waves&#8221; of additional approvals under
three separate MRPs. Each of these procedures have been completed without any referral, and therefore without any delay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other countries outside
of the European Union, the requirements governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement
vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the other applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension
or withdrawal of regulatory approvals, product candidate recalls, seizure of product candidates, operating restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, most countries
are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control of narcotic substances,
including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to
our obtaining marketing approval for Sativex and our other product candidates in those countries. These countries may not be willing or
able to amend or otherwise modify their laws and regulations to permit Sativex or our other product candidates to be marketed, or achieving
such amendments to the laws and regulations may take a prolonged period of time. In that case, we would be unable to market our product
candidates in those countries in the near future or perhaps at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expanded Access to Investigational Drugs
in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investigational drug may
be eligible for clinical use outside the context of a manufacturer&#8217;s clinical trial of the drug. &#8220;Expanded access&#8221; refers
to the use of an investigational drug where the primary purpose is to diagnose, monitor, or treat a patient&#8217;s disease or condition
rather than to collect information about the safety or effectiveness of a drug. Expanded access INDs are typically sponsored by individual
physicians to treat patients who fall into one of three FDA-recognized categories of expanded access: expanded access for individual patients,
including for emergency use; expanded access for intermediate-size patient populations; and expanded access for large patient populations
under a treatment IND or treatment protocol. For all types of expanded access, the FDA must determine prior to authorizing expanded access
that: (1) the patient or patients to be treated have a serious or life threatening disease or condition and there is no comparable or
satisfactory alternative therapy; (2) the potential patient benefit justifies the potential risks of use and that the potential risks
are not unreasonable in the context of the disease or condition to be treated; and (3) granting the expanded access will not interfere
with the initiation, conduct, or completion of clinical studies in support of the drug&#8217;s approval. In addition, the sponsor of an
expanded access IND must submit IND safety reports and, in the cases of protocols continuing for one year or longer, annual reports to
the FDA. Expanded access programs are not intended to yield information relevant to evaluating a drug&#8217;s effectiveness for regulatory
purposes. If a patient enrolled in one of our clinical trials is not eligible or able to continue enrollment, we may be required to continue
to provide our product candidate to such patient through expanded access.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of pharmaceutical product
candidates in the United States will depend, in part, on the extent to which the costs of the product candidates will be covered by third-party
payors, such as government health programs, commercial insurance and managed health care organizations. These third-party payors are increasingly
challenging the prices charged for medical product candidates and services. Additionally, the containment of health care costs has become
a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government, state
legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic product candidates. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results. If these third-party payors do not consider our product candidates to be cost-effective compared to other available
therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do, the level of payment
may not be sufficient to allow us to sell our product candidates on a profitable basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription
drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D,
Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription
drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare
Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required
to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and
at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of
covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug
plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription
drugs may increase demand for product candidates for which we receive marketing approval. However, any negotiated prices for our product
candidates covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while
the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations
in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
non-governmental payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ACA was enacted in March
2010. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the law. The ACA may be modified,
amended or repealed at any time and may or may not be replaced with a different law or health care payment system. The ACA is expected
to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates, among other things,
the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements
under the Medicare Part D program. Since the enactment of the ACA, numerous regulations have been issued providing further guidance on
its requirements. The ACA continues to be implemented through regulation and government activity but is subject to possible amendment,
additional implementing regulations and interpretive guidelines. Several states have decided not to expand their Medicaid programs and
are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues are resolved could materially
affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and
Tricare. We are unable to predict the full impact of any potential modification, amendment, or repeal of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once approved,
and related treatments will be available from third-party payors, such as government health administration authorities, private health
insurers and managed care organizations. Third-party payors determine which medications they will cover and separately establish reimbursement
levels. Even if we obtain coverage for a given product by a third-party payor, the third-party payor&#8217;s reimbursement rates may not
be adequate to make the product affordable to patients or profitable to us, or the third-party payors may require co-payments that patients
find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely
to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our
products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical
and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available
or subsequently become available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities and
other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage
and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide
them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists
to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. Further, no uniform
policy for determining coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be sure that coverage
and reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement
will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing
approval. If coverage and reimbursement are not available, or if reimbursement is available only to limited levels, we may not successfully
commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of receiving
Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs,
Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report their average sales price,
which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid
Drug Rebate Program, effective April 1, 2016, that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved
under an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#8217;s best
price for the drug and inflation penalties which can substantially increase rebate payments. On December 21, 2020, CMS issued a final
rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including some changes to the treatment of value-based
purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For NDA drugs, the Veterans
Health Care Act of 1992 requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called
the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price
referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers to pay rebates on
these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information
to the government creates potential federal False Claims Act liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Further,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state
levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. We expect
that the pharmaceutical industry will continue to experience pricing pressures due to the trend toward managed healthcare, particularly
towards specialty pharmacy, the increasing influence of managed care organizations, and additional legislative proposals. For example,
CMS issued an interim final rule on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in
spending for Medicare Part B drugs without adversely affecting quality of care. This followed an Executive Order issued in September 2020
that directed the Secretary of DHHS to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221;
and high drug prices in the United States. Implementation of this interim final rule was blocked by a temporary restraining order and
preliminary injunctions through various court actions and CMS published a final rule on December 27, 2021 that rescinded the interim final
rule. Nonetheless, we expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing
controls and limit the growth of healthcare costs, including the cost of prescription drugs. It is unknown what form any such changes
or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect
that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the federal government to directly
negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing
or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">At
the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. On the federal level, the Trump Administration issued a final rule in 2020 for the safe importation
of drugs from Canada and other countries. Per this rule, the FDA authorized its first section 804 importation program, or SIP, a program
allowing the State of Florida to import certain prescription products from Canada. Section 804 (21 U.S.C. &#167; 384) of the Federal Food,
Drug, and Cosmetic Act provides a pathway for U.S. states and Indian tribes to allow importation of certain prescription drugs from Canada.
Programs under this pathway must significantly reduce the cost of these drugs to the American consumer without imposing additional risk
to public health and safety. As the first program of its kind, we have yet to see how this Program will be implemented and what specific
products will be imported. There is much opposition from the biopharmaceutical industry regarding this Program, but if Florida can execute
it as planned, it may signal a trend in the U.S. The practical implications of SIPs, and their implications for the biopharmaceutical
industry as a whole or our business in particular remain to be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
July 2021, the Biden administration issued an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple
provisions aimed at increasing competition for prescription drugs. The DHHS has released a Comprehensive Plan for Addressing High Drug
Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these
principles. While no legislation or administrative actions have been finalized to implement these principles, Congress is considering
legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations
on drug price increases and allowing Medicare to negotiate pricing for certain covered drug products. The impact of these legislative,
executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us
and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may
prevent us from being able to generate revenue, attain profitability, or commercialize any of the product candidates for which we receive
approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming
Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific
implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, we are unable to predict potential modification,
amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
the first key element, the IRA created a program for Medicare drug-price negotiation, enabling the Secretary of DHHS to negotiate the
prices of certain costly, single-source drugs or biologics within the Medicare program. Certain drugs and biologics are excluded from
this negotiation process, such as drugs that are less than 9 years, and biologics less than 13 years, from their FDA-approval or licensure
date, and drugs with an orphan designation as their only FDA-approved indication. The first set of these negotiated prices will not take
effect until 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; ">Second,
the IRA requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source
drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program.
This inflation-rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect
in 2022 as the starting point for measuring drug-price increases, with rebate payments required as of the beginning of 2023. DHHS will
start to send rebate invoices to drug manufacturers in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; ">Third,
the IRA restructures the Medicare Part D benefit to limit patients&#8217; out-of-pocket costs and rebalance the bearing of risk for Part
D plans and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay out-of-pocket costs for covered drugs once
they reach the catastrophic coverage level (when the policyholder&#8217;s out-of-pocket spending reaches $7,400). Other aspects of this
provision will take effect in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
bipartisan&#160;<i>Drug-Price Transparency for Consumers Act</i>&#160;was introduced to Senate on April 20, 2023, and the House of Representatives
on October 13, 2023 (S.1250 and H.R.5958, respectively). The Act is currently in committee. This Act would require that direct-to-consumer
advertisements for drugs and biologics include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable
under Medicare or Medicaid and for which direct-to-consumer advertisements are required to include information relating to side effects,
contraindications, and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, this
Act would amend the Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition
cost, or WAC, for a 30-day supply or typical course of treatment and clearly and conspicuously present such price information. If enacted,
the Act contemplates that implementing regulations would include the visual and audio components required to communicate the WAC appropriately
for the medium of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the
way the manufacturer may include a statement explaining that certain consumers may pay a different amount depending on their insurance
coverage. The Act would also subject advertisers to a penalty of up to $100,000 per violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
full implications of changes such as those discussed above, and their practical impact on biopharmaceutical pricing and reimbursement,
as well as advertising requirements and related costs, on the biopharmaceutical industry as a whole and our business in particular cannot
yet be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the marketability
of any products for which we receive regulatory approval for commercial sale may suffer if the government and other third-party payers
fail to provide adequate coverage and reimbursement. We expect that an increasing emphasis on cost containment measures in the U.S. will
continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time.
Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in Foreign Countries</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. For example, a member state of the European Union may approve a specific price for the medicinal
product candidate. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
product candidates will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product
candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As another example, in Canada,
for patented drugs, the Patented Medicines Prices Review Board (PMPRB) uses the median international publicly available ex-factory list
price (using prices in 11 pre-determined countries) as the maximum price the company is allowed to charge. The PMPRB is a quasi-judicial
body with a regulatory mandate to prevent pharmaceutical patentees from charging consumers excessive prices during the market exclusivity
period. This agency then monitors the prices charged by patentees for patented drugs on an ongoing basis. Under the Canadian Patent Act,
patentees are required to file price and sales information about their patented drug products at introduction and twice a year thereafter
for each strength of each dosage form of each patented drug product sold in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Health Care Laws and Compliance Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, our
activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the
CMS, other divisions of the DHHS (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney
offices within the Department of Justice, and state and local governments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal AKS prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing,
leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in whole or in
part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything
of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices.
There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions
and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory
safe harbor does not make the conduct per se illegal under the federal AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the ACA amended the intent requirement
of the federal AKS so that a person or entity no longer needs to have actual knowledge of the federal AKS, or specific intent to violate
it, to have violated the statute. The ACA also provided that a violation of the federal AKS is grounds for the government or whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes
of the civil False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
DHHS finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by excluding
rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or PBMs acting under contract with
Medicare Part D plan sponsors from the existing discount safe harbor under the federal AKS. The regulation reflects the first change to
the AKS discount safe harbor since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe harbors
were added. One of these new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under Medicare
Part D or a MCO for a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided certain
conditions are met. The other protects certain fixed-fee services arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to avoid, decrease or conceal an obligation to pay money to the federal government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented
a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
is false or fraudulent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises, any of
the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is
public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal
investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material
fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so that a person
or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated the statute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations,
require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated
on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians
and their immediate family members. The SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data
for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse
midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may be subject
to data privacy and security regulation by both the federal government and the states in which we conduct our business or target consumers.
HIPAA, as amended by HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission
of individually identifiable health information on HIPAA covered entities and their business associates, including mandatory contractual
terms and the implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards
directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health
information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted
by HIPAA, thus complicating compliance efforts. Most recently, fourteen states including California have adopted laws that regulate the
privacy and security of consumer personal information, and apply in instances where HIPAA and clinical trial laws do not. In addition,
other states such as Washington, have adopted laws that regulate the privacy and security of consumer health data which, again, apply
in instances where HIPAA and clinical trial laws do not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value
to physicians and other healthcare providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enforcement actions can be
brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the
name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal,
civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment,
additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of non-compliance with these laws, exclusion from government programs, refusal to allow us to enter into supply contracts,
including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our
operations, any of which could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to distribute product
candidates commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical
product candidates in a state, including, in certain states, manufacturers and distributors who ship product candidates into the state,
even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers
and distributors to establish the pedigree of product candidate in the chain of distribution, including some states that require manufacturers
and others to adopt new technology capable of tracking and tracing product candidate as it moves through the distribution chain. Several
states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with
the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities or register their sales
representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health care entities from providing
certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and
marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
FCPA regulates part of our business activities. The FCPA has two main provisions applicable to us: (a) the antibribery provisions, which
prohibit individuals and businesses from bribing foreign government officials in order to obtain or retain business; and (b) the accounting
provisions, which impose certain record keeping and internal control requirements on issuers, and prohibit individuals and companies from
knowingly falsifying an issuer&#8217;s books and records or circumventing or failing to implement an issuer&#8217;s system of internal
controls. Violations of the FCPA can lead to civil and criminal penalties, sanctions, and remedies, including fines, disgorgement, and/or
imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
antibribery provisions of the FCPA prohibits the paying, offering, promising, or authorizing payment or offering money or of anything
of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision
of such foreign official, political party, or candidate in his or her official capacity or to secure any improper advantage in obtaining
or retaining business. Under the statute, a company is liable when its directors, officers, employees, or agents, acting within the scope
of their employment, commit FCPA violations intended, at least in part, to benefit the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
accounting provisions of the FCPA consist of two primary components. First, under the &#8220;books and records&#8221; provision, issuers
must make and keep books, records, and accounts that, in reasonable detail, accurately and fairly reflect an issuer&#8217;s transactions
and dispositions of an issuer&#8217;s assets. Second, under the &#8220;internal controls&#8221; provision, issuers must devise and maintain
a system of internal accounting controls sufficient to assure management&#8217;s control, authority, and responsibility over the Company&#8217;s
assets. The accounting provisions do not apply only to bribery-related violations. Rather, the accounting provisions require that all
public companies account for all of their assets and liabilities accurately and in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company, its affiliates, and its and their operations around the world are subject to the FCPA because the Company is an &#8216;issuer&#8217;
as defined in the statute. The U.S. Department of Justice aggressively enforces the FCPA and has, at times, focused its enforcement attention
to the pharmaceutical sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grants from the IIA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts mainly with respect to our past activities (with respect to immunotherapy programs such as the Anti-CD3)&#160;were financed in
part through royalty-bearing grants from the IIA. As of December 31, 2024, we received the aggregate amount of approximately $1.1 million
from the IIA for the development of our abovementioned technologies. With respect to such grants, we are committed to pay royalties of
up to an aggregate amount of approximately $1.1 million relating only to technologies in our possession and excluding any royalties for
technologies that we sold to third parties. We are further required to comply with the requirements of the Innovation Law, with respect
to those past grants. In addition, any change of control and any change of ownership of our securities that would make a non-Israel citizen
or resident an &#8220;interested party&#8221; as defined in the Israeli Securities Law, 5728 &#8211; 1968 requires a written notice to
the IIA. Non-Israeli citizens and residents are required to execute an undertaking in favor of the IIA, in the form prescribed by the
IIA. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Innovation Law and regulations
thereunder restrict the transfer or licensing of such know-how inside or outside of Israel, and the transfer or licensing outside of Israel
of manufacturing or manufacturing rights of such products, technologies or know-how, without the prior approval of the IIA. None of our
current projects in the field of cannabinoid therapeutics are supported by the IIA, yet if eligible, we might apply for such support in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current Regulatory Status of SciSparc&#8217;s
Pharmaceutical Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The active ingredient in our
pharmaceutical product candidate SCI-110 is a Schedule I controlled substance. Other drug candidates in our portfolio are either not controlled
or as yet to be scheduled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidate SCI-110
is being developed, among others, for the treatment of TS. TS may be considered a serious condition with a potentially disabling nature.
Thus, it may be eligible for a fast-tracked submission. However, a request for eligibility may be filed by us later in the development
of this molecule. In June 2016, we submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In
a letter dated September 29, 2016, the FDA informed us that our request could not be granted at such time and is being held in abeyance
until and subject to us providing additional information pertaining to the overall prevalence of TS in both children and adults, and further
clinical data to support our scientific rationale for our request for orphan drug designation within 12 months. In September 2017, we
responded to such FDA letter within the designated time frame and provided the FDA with our articulated and reasoned responses including
documentation and clinical data that supports it. On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA
accepted that there is adequate scientific rationale for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing
clinical trials, suggesting that SCI-110 may provide benefit in treating TS. However, the FDA stated that it was unable to grant our request
and indicated that we did not provide adequate prevalence estimates, and any evidence to support our statement that only moderate to severe
TS patients would require pharmacological treatment. We further responded in January 2018 by providing the requested information. On January
23, 2020, following additional correspondence with the FDA, the FDA still did not grant us our request due to fact that we have not yet
provided adequate prevalence estimates. However, the FDA did agree with our position that we could potentially qualify for orphan drug
designation with respect to the moderate-to-severe TS sub-group population only rather than the entire population. After we had provided
additional prevalence estimates, the FDA raised a concern in its letter, dated December 7, 2020, about our ability to limit the use of
the pharmaceutical product to the subset of patients we are pursuing. Due to the fact that we disagree with this concern, we requested
a clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, we sent our response to the FDA. In
June 2021, we received a response from the FDA explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical study in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Canada</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NNHPD Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a non-traditional
class III Product License Application, CannAmide&#8482;, or TheraPEA, received Health Canada approval (NPN 80093504) from the NNHPD on
July 23, 2019. In the approval letter, the NNHPD confirmed that the application was in compliance with section 7 of the NHPR. The dosage
of 1 x 400 mg tablet 3 times daily was approved for the following use: &#8220;Studies show that PEA may be used as an anti-inflammatory
to help relieve chronic pain&#8221;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any labels used in the marketing
of TheraPEA must reflect the information outlined on the product license and must comply with the labelling requirements as per Part 5
of the NHPR. In addition, natural health products, such as TheraPEA, must be manufactured, packaged, labelled, imported, distributed and
stored in accordance with GMP as required by NHPR or in accordance with equivalent requirements if the natural health product is imported.
Furthermore, in accordance with Section 44 of the NHPR, each product for sale in Canada must comply with the finished product specifications
submitted to Health Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the NHPR, companies
are required to provide the NNHPD with the Canadian site information prior to commencing the importation and/or sale of the natural health
products in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes made in respect of
a licensed product require the submission of an amendment, notification or a new product license application as per sections 11, 12 and
13 of the NHPR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Organizational Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Nutraceuticals Inc.
is our majority-owned subsidiary, in which we have a 50.86% controlling stake and is focused on e-commerce operations of Wellution&#8482;,
a top- seller account of Amazon Marketplace, which sells hemp-based products. Brain Bright Ltd. is an inactive wholly-owned subsidiary.
We also own 100% of the issued and outstanding share capital of Evero Health Ltd., a company focused on the development and commercialization
of SCI-110 sleep technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, we invested
$1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 ordinary
shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind. As of April 23, 2025, following a reverse stock
split of Clearmind&#8217;s outstanding shares, we hold 7,692 ordinary shares of Clearmind, representing less than 0.2% of the outstanding
share capital of Clearmind.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 23, 2025, we also
hold 52.73% of MitoCareX Bio Ltd., an Israeli private company. See Item 4.B. Business Overview for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold a minority interest
in AutoMax of approximately 4.82% and a minority interest of approximately 1.14% of Jeffs&#8217; Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Property, Plants and Equipment </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our offices are located at
20 Raul Wallenberg Street,&#8239;Tower A, 2nd Floor, Tel Aviv 6971916, Israel, where we currently occupy approximately 120 square meters,
under a joint lease with a third-party for a total of 240 square meters. The lease ends on June 30, 2025. Our current monthly rent payment
is NIS 10,200 (approximately $3,300).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consider that our current
office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. However,
we are currently assessing our future needs and have not renewed our lease as of the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Litigation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with a joint
venture transaction, entered on May 15, 2020, by and between us, Capital Point and Evero Health Ltd., one of our subsidiaries, we issued
a warrant to Capital Point to purchase $340,000 of our ordinary shares, or the Warrant Shares, with an exercise price per ordinary share
equal to the closing price of our ordinary shares on the trading day on which the notice of exercise is actually received by us. Such
warrant was exercisable for 12 months starting from May 15, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 4, 2021, we received
from Capital Point a notice of exercise with respect to the Warrant Shares, which was rejected by the Company. On May 2, 2023, Capital
Point filed a lawsuit in the Tel Aviv-Jaffa District Court against us as the sole defendant in connection with the Warrant Shares. The
lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust enrichment under the
Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version), 1968. The lawsuit claims damages in
the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the lawsuit, liquidated
damages according to the provisions set forth in the warrant, and seeks as well for the court to order a mandatory injunction order for
us to issue a warrant to Capital Point to purchase $340,000 of our ordinary shares to Capital Point, the return of any unlawful profits
received by us and punitive damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 23, 2025, in connection
with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health
Ltd. As of the date of this Annual Report, we cannot predict the likelihood of our success in the lawsuit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, we signed
a settlement agreement regarding a lawsuit we filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against
six of our former directors, or the Defendants. The lawsuit included allegations of breaches of fiduciary duties under the Israeli Companies
Law, 1999, relating to a prior acquisition of a pain clinic network through a subsidiary of ours. As part of the settlement agreement,
we will be entitled to a $411,000 cash payment from the Defendants in exchange for our full dismissal of the lawsuit. The settlement agreement
includes the termination, effective as of February 5, 2024, of a disputed licensing agreement with Dekel. As part of the Settlement, Dekel
clarified, to our full satisfaction, that we will retain its exclusive global rights to our extensive IP portfolio, patents, know-how
and technologies and is released from all alleged commitments, claims and royalties related or arising out of the license agreement from
May 2015 with Dekel, including those related to claimed core technologies. Dekel will assume full and exclusive ownership of the patent
application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are
not related whatsoever to the Company&#8217;s pipeline and development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion and
analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report. This
discussion and other parts of this Annual Report contain forward-looking statements based upon current expectations that involve risks
and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking
statements as a result of several factors, including those set forth under Item 3.D. &#8220;Risk Factors&#8221; and elsewhere in this
Annual Report. We report financial information under IFRS as issued by the International Accounting Standards Board and none of the financial
statements were prepared in accordance with generally accepted accounting principles in the United States. Our discussion and analysis
for the year ended December 31, 2022 can be found in our Annual Report for the fiscal year ended December 31, 2023, filed with the SEC
on April 1, 2024 (File No. 001-38041).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following financial data
in this narrative are expressed in thousands, except for share and per share data or as otherwise noted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, we have generated revenues through our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand. Total revenues
recognized in the year ended December 31, 2024, amounted to $1,306 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
revenue from our drug development business from the sale of any pharmaceutical product candidates, and we do not expect to generate significant
revenue in this business within the next year at least. As of December 31, 2024, we had an accumulated deficit of approximately $75 million.
Our operating activities are described below under &#8220;Operating Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the year ended December
31, 2024, we have generated revenues in the amount of $1,306 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of goods sold </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of goods sold comprises
mainly purchase of products and transportation costs to our warehouse for the SciSparc Nutraceuticals business. In the year ended December
31, 2024, the cost of goods sold amounted to $800 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operating expenses
consist of five components - research and development expenses, sales and marketing expenses, impairment of intangible assets, general
and administrative expenses, and other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, research and preclinical studies, chemistry and formulations, regulatory,
professional and other related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of research and development expenses for the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">390</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,707</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,641</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our research
and development expenses will materially increase as we plan to continue clinical trials and develop new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales and Marketing Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sales and marketing expenses
consist primarily of Amazon fees, advertising costs, depreciation costs, storage and shipping costs, and management fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of sales and marketing expenses for the periods presented:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Advertising</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">576</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Storage and shipping</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,515</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,484</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, professional service fees for accounting, legal, bookkeeping, investor relations, regulatory expenses
and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of general and administrative expenses for the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">507</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">415</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,526</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,844</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the year ended December 31, 2024 to the year ended
December 31, 2023 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">683</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,641</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,844</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equity losses from the investment in MitoCareX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,164</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,883</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to holders of Ordinary Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,122</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
revenues for the year ended December 31, 2024 decreased by $1,573 thousand, or 55%, to $1,306 thousand, compared to $2,879 thousand for
the year ended December 31, 2023. The decrease is primarily due to operational difficulties which caused the Welllution<sup>TM</sup>&#160;brand
to be temporarily put offline from the Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Goods Sold</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our cost of goods sold for the year ended December
31, 2024 increased by $117 thousand, or 17%, to $800, compared to $683 thousand for the year ended December 31, 2023. This increase resulted
primarily from losses resulting from the revaluation of inventory.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Gross Profit</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our gross profit for the year ended December 31,
2024 decreased by $1,690 thousand, or 77%, to $506 thousand, compared to $2,196 thousand for the year ended December 31, 2023. This decrease
resulted primarily from the decrease in revenues.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses </i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the year ended December 31, 2024, amounted to $1,707 thousand, representing an increase of $66 thousand, or 4%, compared
to $1,641 thousand for the year ended December 31, 2023. The increase resulted primarily from an increase in expenses related to research
and preclinical studies which amounted to $211 thousand for the year ended December 31, 2024, compared to $101 thousand for the year ended
December 31, 2023.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses totaled $4,526 thousand for the year ended December 31, 2024, representing an increase of $682 thousand, or 18%, compared to
$3,844 thousand for the year ended December 31, 2023. The increase resulted primarily from an increase in share-based expenses and professional
and director fees that amounted to $419 thousand and $3,009 thousand, respectively, for the year ended December 31, 2024, compared to
$68 thousand and $2,594 thousand, respectively, for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sales and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sales and marketing expenses
totaled $1,515 thousand for the year ended December 31, 2024, representing a decrease of $969 thousand, or 39% compared to $2,484 thousand
for the year ended December 31, 2023. All sales and marketing expenses are generated by SciSparc Nutraceuticals, which owns the Wellution&#8482;
brand. The decrease resulted mainly from a decrease in Amazon fees, which were a result of the decrease in sales of goods by SciSparc
Nutraceuticals in 2024 compared to 2023. Other reasons for the decrease in sales and marketing expenses include the decrease in management
fees, advertising and depreciation costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income in the year ended
December 31, 2024, amounted to $1,270 thousand, through the sale of: (i) 320,000 ordinary shares of Polyrizon, (ii) pre-funded warrants
to purchase 364,931 ordinary shares of Polyrizon, and (iii) common warrants to purchase 1,541,096 ordinary shares of Polyrizon to third
parties, for aggregate consideration of $771 thousand. Also, we recorded a gain in the amount of $517 thousand from the remeasurement
of our remaining investment in such Polyrizon warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of intangible asset</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our impairment of intangible
asset totaled $1,344 thousand for the year ended December 31, 2024, representing an increase of $302 thousand compared to $1,042 for the
year ended December 31, 2023. The impairment in the year ended December 31, 2024 resulted from continued losses in the Wellution&#8482;
brand, similar to the loss on impairment recognized in the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating loss for the
year ended December 31, 2024, was $7,316 thousand, representing an increase of $501, or 7%, as compared to an operating loss of $6,815
thousand for the year ended December 31, 2023. The increase resulted primarily from the decrease in revenues and the increase in general
and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial Expense and Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expenses and income
consist of remeasurement of instruments measured at fair value, exchange rate differences, bank fees, loans interest and other transactional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial income
in the amount of $612 thousand for the year ended December 31, 2024, as compared to financial income of $2,219 thousand for the year ended
December 31, 2023. The decrease in financial income for the year ended December 31, 2024 resulted mainly due to a decrease in financial
income from the remeasurement of a warrant liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial expenses
for the year ended December 31, 2024, of $353 thousand, as compared to financial expense of $1,055 thousand for the year ended December
31, 2023. The decrease of financial expenses for the year ended December 31, 2024 resulted mainly due to a decrease in losses related
to changes in the fair value of securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total Comprehensive Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our total comprehensive loss
for the year ended December 31, 2024, was $7,472 thousand, representing an increase of $1,589 thousand, or 27%, as compared to $5,883
thousand for the year ended December 31, 2023. The increase resulted primarily from the increase in operating loss and a decrease in financial
income, net.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Liquidity and Capital Resources </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2004,
and through December 31, 2024, we have funded our operations principally with $76 million from the issuance of our securities in public
offerings and private placements. As of December 31, 2024, we had $1.5 million in cash, $10 thousand in trade receivables, $1,079 thousand
in other accounts receivable, $113 thousand in inventory, $517 thousand in short-term financial assets, and an additional amount of 20
thousand in short-term bank deposits. In the event that additional financing is required from outside sources, we may not be able to raise
such financing on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, operating
results, and financial condition would be adversely affected, and there is substantial doubt about our ability to continue as a going
concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,104</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,887</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,094</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,483</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(536</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,498</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $5,104 thousand during 2024 in comparison to $5,887 thousand during 2023. The decrease resulted primarily from a decrease
in finance income related to gains from the remeasurement of a warrant liability, and a decrease in inventory related to a revaluation
of inventory, offset in part by a decrease in losses from the remeasurement of investments in financial assets. Another reason for the
decrease in cash used in operating activities is the increase in the loss on impairment of intangible assets, which is a non-cash adjustment,
as well as the increase in share-based compensation costs, which are a non-cash adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $1,625 thousand during 2024 in comparison to net cash used in investing activities of $4,094 thousand during 2023. Net
cash used by investing activities during 2024 resulted mainly from a loan granted to a related party in the amount of $4,078, and an investment
in a company accounted for using the equity method in the amount of $600 thousand, offset in part by a divestment in short-term bank deposits
in the amount of $3,000 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities during 2023 resulted mainly from the investment in short-term bank deposits in the amount of $3,000 thousand, investment in
financial assets in the amount of $689 thousand, and an investment in a company accounted for at equity in the amount of $400 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $6,193 thousand in the year ended December 31, 2024, primarily consisted of proceeds from the issuance of share capital
in the amount of $6,225 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $8,483 thousand in the year ended December 31, 2023, primarily consisted of $5,552 thousand of net proceeds from the issuance
of share capital, pre-funded warrants and warrants, and by cash generated from the sale of a minority interest in the Wellution brand
in the amount of $2,985 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Wellution Acquisition
Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we
entered into the Wellution Acquisition Agreement, pursuant to which we acquired the Wellution&#8482; brand, or the Brand. We established
SciSparc Nutraceuticals, a wholly owned subsidiary, to hold the new assets, which is also a party to the Wellution Acquisition Agreement.
On September 30, 2022, we closed the acquisition of the Brand and paid $4.59 million for the Brand. In addition, at the closing we issued
the M.R.M Warrant to M.R.M (each as defined below), to purchase up to 82,418 of our Ordinary Shares. On March 26, 2024, M.R.M. agreed
with us to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Wellution Sales Agreement</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to which, at the closing, which occurred
on March 28, 2023, Jeffs&#8217; Holdings acquired from us 57 shares of common stock of SciSparc Nutraceuticals, which equals approximately
a 49% interest in our wholly owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup>&#160;brand, for a consideration
of $2.5 million in cash, and additional deferred cash payments of approximately $489 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the closing,
we and Jeffs&#8217; Brands undertook a mutual share exchange in the amount of approximately $288 thousand of ordinary shares from each
of us and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant
company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly,
we acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 ordinary shares from us having an aggregate
value of $288,238.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
transaction, which included an equity conversion of the financing amounts of approximately $700 thousand previously provided by the Company
to SciSparc Nutraceuticals for working capital, into shares of common stock at the price per share of the Wellution Sale Agreement, we
hold approximately 51% of SciSparc Nutraceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Wellution
Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into the Wellution Management Agreement for management
services of the Wellution<sup>TM</sup> brand by Jeffs&#8217; Brands, for a monthly fee of $20 thousand, which was reduced to $10 thousand
in 2024. Jeffs&#8217; Brands also received a one-time signing bonus in the amount of $51 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>At-The-Market Issuance
Sales Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2023, we entered
into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp., or the ATM Agreement, pursuant to which we may offer and sell
up to $1,729,964 of our ordinary shares. Between May 16, 2023 and August, 9, 2023, we sold approximately $4,779 of ordinary shares. On
August 9, 2023, the ATM Agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Underwritten Public
Offering</i><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
August 14, 2023, we closed an underwritten public offering, or the Public Offering, of 212,500 ordinary shares, at a purchase price of
$5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded
warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between us and Aegis, or the
Underwriter, on August 10, 2023. Pursuant to the terms of the Underwriting Agreement, we also granted the Underwriter a 45-day option
to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the Public Offering share price less
underwriting discounts and commissions.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
pre-funded warrants were exercisable immediately upon issuance and had an exercise price of $0.026 per share. Following the Public Offering
and as of April 23, 2025, the Company issued 25,000 ordinary shares in respect of the exercise of 25,000 pre-funded warrants.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>October 2023 Private
Placement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2023, we closed
a private placement transaction, or the 2023 Private Placement, pursuant to a securities purchase agreement and a registration rights
agreement with an institutional investor for aggregate gross proceeds of approximately $5 million (representing a 30% original issue discount
to the aggregate purchase price of $7,180,000), before deducting fees to Aegis, the placement agent and other expenses payable by the
Company in connection with the transaction. We sold units to the investors at a purchase price of $3.72 per unit, consisting of 1,930,108
pre-funded Ordinary Share purchase warrants to purchase up to 1,930,108 Ordinary Shares, and an additional accompanying pre-funded warrant
to purchase up to 1,930,108 Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pre-funded warrants were
exercisable immediately upon issuance and have an exercise price of $0.001 per share. Following the transaction and as of April 23, 2025,
we have issued 1,078,991 Ordinary Shares in respect of the exercise of 1,078,991 pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
January 14, 2024, we entered into, as lender, a bridge loan agreement with AutoMax, pursuant to which AutoMax received the Bridge Loan,
further to the previously-announced non-binding letter of intent for us to acquire AutoMax. On April 10, 2024, we signed the Merger Agreement
with AutoMax. On August 14, 2024, on November 26, 2024, and March 27, 2025, we and AutoMax entered into the Merger Agreement Addendum,
the Merger Agreement Second Addendum, and Merger Agreement Third Addendum, respectively. On June 9, 2024, we entered, as lender, into
the Amended Bridge Loan, pursuant to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate amount
of $2.4 million. On September 5, 2024, we entered into the Second Amendment, pursuant to which we extended an additional Loan amount to
AutoMax. &#160;During the month of September 2024, we provided AutoMax with the loan amounts due under the Second Amendment to the Bridge
Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on the closing date of the Merger, we will
be entitled to be paid the due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the Loan Amount,
accruing from the period beginning on December 1, 2024 and ending on the effective date of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Merger Agreement contemplates that at closing, we shall deliver to AutoMax the closing financing amount. In light of the Bridge Loan and
amendments thereto, no closing financing amount will be transferred. In consideration for the Loan Amount, AutoMax established a first
ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor of us.
The Bridge Loan amount, together with any accrued interest, may be repaid in part or in whole prior to the repayment date, contingent
on whether the closing of the Merger Agreement occurs. The repayment date shall be at the earlier date of: (a) the Closing, in which the
owed amount shall be deemed set-off against the closing financing amount; or (b) if the Merger Agreement is terminated in accordance with
its terms, within three months from such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
February 27, 2025, we announced that we had entered into the Additional Loan Agreement with AutoMax where a $2 million loan was provided.
The loan bears an 8% annual interest rate and will be repaid in equal monthly installments of $50,000 and interest, with AutoMax retaining
the option to make early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the Merger
Agreement and AutoMax will continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax pledged
a first-ranking fixed charge on its subsidiary&#8217;s shares, in accordance with a fixed charge debenture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>January 2024 Standby
Equity Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
January 21, 2024, we entered into a SEPA with YA, as amended on February 26, 2024. Pursuant to the SEPA, we will be able to sell up to
$20.0 million Ordinary Shares, at our sole option, any time during the three-year period following the execution date of the SEPA. Of
the $20.0 million eligible to be sold pursuant to the SEPA, as of April 23, 2025 we have sold 925,159 Ordinary Shares to YA pursuant to
the SEPA. Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price, which is defined
as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing on the trading
day immediately following our delivery of an advance notice to YA. Any sale of Ordinary Shares pursuant to the SEPA is subject to certain
limitations, including that YA is not permitted to purchase any shares that would result in it owning more than 9.99% Ordinary Shares.
We are not permitted to utilize the SEPA pursuant to the February 2025 Securities Purchase Agreements, as defined below, until all of
the convertible debentures have been paid off.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>February 2025 Securities Purchase Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2025, we entered
into securities purchase agreements, or the February 2025 Securities Purchase Agreements, with certain investors, pursuant to which we
sold and issued to the investors convertible debentures, or Debentures, in the aggregate principal amount of $4.2 million, or the Subscription
Amount, which are convertible into Ordinary Shares at a purchase price equal to 95% of the Subscription Amount. The Debentures, having
been issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding
principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an event of default for
so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at
the lower of (i) 110% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii)
95% of the lowest daily volume weighted average price of the Ordinary Shares during the 20 consecutive trading days immediately preceding
the conversion date or other date of determination, or the Market Price; provided that the Market Price may not be lower than the floor
price, which will be equal to 20% of the volume weighted average price of the Ordinary Shares on the day prior to the closing. At the
closing of the transaction, we issued to the investors 3,615,656 warrants which are exercisable into a number of Ordinary Shares equal
to the Subscription Amount applicable to the investors divided by a price equal to 130% of the volume weighted average price of the Ordinary
Shares immediately prior to the closing date, or $0.5532 per warrant. The warrants are exercisable for a term of five years from the issuance
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
entered into a global guaranty agreement, or the Global Guaranty Agreement, with one of the investors through certain of our subsidiaries,
pursuant to which such subsidiaries will guaranty its obligations under the Debenture with the lead debenture investor and other instruments,
agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
also entered into a registration rights agreement with the lead debenture investor, pursuant to which we have agreed to provide to the
lead debenture investor registration rights under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder,
and applicable state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the securities
purchase agreements with the investors, on February 25, 2025, we entered into a deed, or Deed, with AutoMax and three investors. Pursuant
to the Deed, SciSparc assigned part of the Subscription Amount in the amount of $2 million to AutoMax in lieu of making the payment under
the Additional Loan Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
to date primarily through proceeds from sales of our securities as well as exercises of warrants and options to purchase Ordinary Shares
or ADSs, as the case may be. We have incurred losses and generated negative cash flows from operations since August 2004. Since August
2004, we have not generated any revenue from the sale of pharmaceutical product candidates and we do not expect to generate revenues from
sale of our pharmaceutical product candidates in the next few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, our
cash, including short-term bank deposits, was $1,560 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash and cash equivalents
position is not sufficient to fund our planned operations for at least a year beyond the date of the filing date of this Annual Report.
The ability to continue as a going concern is dependent upon our obtaining the necessary financing to meet our obligations and repay liabilities
arising from normal business operations when they become due. While we have successfully raised funds in the past, there is no guarantee
that we will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms would
have serious consequences on our financial condition and results of operations. In addition, we started to recognize revenues from sales.
However, our pharmaceutical operations are dependent on our ability to raise additional funds from existing and/or new investors. This
dependency will continue until we are able to finance our operations through generating revenue from our products. These factors raise
substantial doubt about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we&#160;purchased
Wellution&#8482;, a business and brand which sells hemp-based products on Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part or independent of the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange, while
maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend to
explore other potential new opportunities, activities and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Restructuring Plan and
possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses,
regulatory approvals, receipt of any necessary consents, final approvals from our board of directors and shareholders and satisfaction
of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo. There can be no assurance regarding the
ultimate timing of the Restructuring Plan and listing of NewCo or that they will be completed at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
April 10, 2024, we signed the Merger Agreement with AutoMax. On August 14, 2024, November 26, 2024 and March 27, 2025, we and AutoMax
entered into the Merger Agreement Addendum, the Merger Agreement Second Addendum and the Merger Agreement Third Addendum, respectively.
For more information, see Item 3D &#8220;<i>Risk Factors-Risks Related to the Merger between SciSparc and AutoMax</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional financing sooner
than planned. Our efforts to commercialize our proprietary PEA oral tablets CannAmide&#8482; may not lead to any revenue or revenue at
the level at which we are expecting. Our future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This raises substantial doubts about our ability to continue as a going
concern.&#160;If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans
for, or commercialization efforts with respect to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Research and development, patents and licenses,
etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects-A. Operating Results-Operating Expenses-Research and Development Expenses, net&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects-A. Operating Results-Comparison of the year ended December 31, 2024 to
the year ended December 31, 2023-Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Trend information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trends impacting us are
described elsewhere in this Annual Report on Form 20-F, including in &#8220;Item 3.D. Risk Factors&#8221;, &#8220;Item 4.B. Business Overview&#8221;,
&#8220;Item 5.A. Operating Results&#8221;, &#8220;Item 5.B. Liquidity and Capital Resources&#8221;, and &#8220;Item 10.C. Material Contracts&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the anticipated
merger between us and AutoMax, if completed, is expected to significantly impact our future operational and financial profile. If the
Merger is consummated, we anticipate that our current business operations will continue while AutoMax&#8217;s current business activities
will continue to be carried out by AutoMax as a wholly-owned subsidiary of SciSparc. In the short term, we expect to incur transaction-related
expenses, including legal, advisory, and regulatory costs associated with the Merger. These expenses may continue to affect our financial
results until the closing or termination of the Merger. In the longer term, we expect the consummation of the Merger to occur on or before
September 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Critical Accounting Estimates</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 and the significant accounting judgments, estimates and assumptions used in the preparation of
the financial statements in Note 3 to our financial statements for the year ended December 31, 2024. We believe that the accounting policies
below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with IFRS. At the time of the preparation of the financial statements, our management is required to use estimates, evaluations,
and assumptions which affect the application of the accounting policy and the amounts reported for assets, obligations, income, and expenses.
Any estimates and assumptions are continually reviewed. The changes to the accounting estimates are credited during the period in which
the change to the estimate is made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, our
cash and cash equivalents totaled $1.5 million. In the period ended December 31, 2024, we had an operating loss of $7.3 million and negative
cash flows from operating activities of $5.1 million. Our current cash and cash equivalents position is not sufficient to fund our planned
operations for at least a year beyond the date of the filing date of the financial statements. The ability to continue as a going concern
is dependent upon our obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business
operations when they become due. While we have successfully raised funds in the past, there is no guarantee that we will be able to do
so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences
on our financial condition and results of operations. In addition, we have started recognizing revenues from sales. However, our pharmaceutical
operations are dependent on our ability to raise additional funds from existing and/or new investors. This dependency will continue until
we are able to completely finance our operations by generating revenue from our products. These above-mentioned factors raise substantial
doubt about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Intangible Assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately acquired intangible
assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets with a finite
useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the year ended December
31, 2024, we have reviewed indications of decline to our intangible assets, and have determined that there are signs of decline in the
value of the intangible assets and recognized a loss as a result of impairment in the amount of $1,344 thousand (as of December 31, 2023,
it was $1,042 thousand).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contingent Liabilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The evaluations of provisions
and contingent liabilities are based on best professional judgment, taking into consideration the stage of the proceedings, as well as
cumulative legal experience in the various topics. Whereas the results of the lawsuits shall be determined by the courts, these results
may differ from these evaluations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees and other service
providers are entitled to benefits by way of share-based compensation settled with company options to shares. The cost of transactions
with employees settled with capital instruments is measured based on the fair value of the capital instruments on the granting date. The
fair value is determined using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding
expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of the transactions
settled with capital instruments is recognized in profit or loss together with a corresponding increase in the equity over the period
in which the performance and/or service takes place, and ending on the date on which the relevant employees are entitled to the benefits,
or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at the end of each reporting
date and until the Vesting Period reflects the degree to which the Vesting Period has expired and our best estimate regarding the number
of options that have ultimately vested. The expense or income in profit or loss reflects the change of the aggregate expense recognized
as of the end of the reported period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the Black-Scholes
option-pricing model as a fair value method for our options awards. The option-pricing model requires a number of assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected dividend yield</i>
- The expected dividend yield assumption is based on our historical experience and expectation of no future dividend payouts. We have
historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Volatility </i>- The expected
volatility is based on fluctuations in the price of our Ordinary Share prices on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk free interest rate
</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s contractual term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of loan to AutoMax (a related party) </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into the Bridge
Loan with AutoMax, which is considered a related party, which amounted to $4.25 million as of December 31, 2024. The Bridge Loan was extended
in the context of an agreement for our acquisition of AutoMax, serving as an advance payment toward the transaction. The repayment terms
of the Bridge Loan are contingent on the completion of the Merger, with provisions for set-off against the closing financing amount upon
consummation of the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Evaluating the fair
value of the Bridge Loan was complex and required considerable judgment due to the significant estimates in management&#8217;s
assumptions, particularly regarding the involvement of a related party. The assessment of the recoverability of the Bridge Loan is
complex and subjective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Directors and Senior Management </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of April 23, 2025:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid"><b>Name</b></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 58%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Director </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technologies Officer</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Dayan<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">(1)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as determined by our Board of Directors, pursuant to the definition prescribed to such term under Nasdaq Stock Market rules)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Itschak Shrem </i>was
appointed to serve as our President in January 2022, prior to which he served as our Chairman from August 2020 to January 2022. Mr. Shrem
has more than 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment
banking, management and technology company. Prior to that, he spent 15 years at Clal Israel Ltd., where he served in various capacities,
including chief operating officer, and was responsible for capital markets and insurance businesses. In 1993, Mr. Shrem founded Pitango
Venture Capital Fund (formerly, Polaris) and served as a partner of Pitango Funds I, II and III. He has been the Managing Director of
Yaad Consulting 1995 Ltd. since 1995. Previously, Mr. Shrem served on the board of Tel-Aviv Sourasky Medical Center, the Weizman Institute
Eden Spring Ltd., Rail Vision Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as chairman of Sphera Funds Management
Ltd. Mr. Shrem holds a B.A. in Economics and Accounting from Bar-Ilan University and an M.B.A. from Tel-Aviv University.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amitay Weiss </i>has
served on our Board of Directors since August 2020 and as our Chairman since January 2022. Mr. Weiss served as our Chief Executive Officer
from August 2020 to January 2022. Mr. Weiss currently serves as chairman of the board of directors of Automax Motors Ltd. (TASE: AMX.TA),
as a director of Jeffs&#8217; Brands Ltd (Nasdaq: JFBR) and as an external director of Cofix Group Ltd. (TASE: CFCS). Mr. Weiss also chairs
and serves as director on the board of director of several public and private companies, including, Clearmind (Nasdaq: CMND), Maris Tech
Ltd. (Nasdaq: MTEK) and N2 OFF, INC.. (Nasdaq: NITO). In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as its chief
executive officer. From 2001 until 2015, Mr. Weiss served as vice president of business marketing &amp; development and in various other
positions at Bank Poalei Agudat Israel Ltd. from the First International Bank of Israel group. Mr. Weiss holds a B.A. in economics from
New England College, an M.B.A. in business administration from Ono Academic College in Israel, an Israeli branch of University of Manchester
and an LL.B. from the Ono Academic College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Oz Adler, CPA, </i>was
appointed to serve as our Chief Executive Officer in January 2022 and has served as our Chief Financial Officer since April 2018 and previously
held served as our VP Finance from March 2018 until April 2018 and as our Controller from September 2017 to March 2018. Mr. Adler has
experience in a wide variety of managerial, financial, tax and accounting roles. Mr. Adler currently serves on the board of directors
of numerous private, such as Polyrizon Ltd., and public companies, including Jeffs&#8217; Brands Ltd (Nasdaq: JFBR), Rail Vision Ltd.
(Nasdaq: RVSN) and Clearmind (Nasdaq: CMND), (FSE: CWY), and previously served as the chief financial officer of XYLO Technologies Ltd.
(Nasdaq: XYLO) from December 2020 to April 2021. From 2012 until 2017, Mr. Adler was employed as a certified public accountant at Kost
Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Mr. Adler holds a B.A. in Accounting and Business management from The
College of Management, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Adi Zuloff-Shani</i>,
PhD, has served as our Chief Technologies Officer since February 2016. Dr. Zuloff-Shani has more than 20 years of experience as a research
and development executive. Prior to joining us, and from 2012 to 2016, Dr. Zuloff-Shani served as a vice president development at Macrocure
Ltd. (Nasdaq: MCUR) where besides leading all research and development activities, she interacted and was involved with the activities
of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs. Dr. Zuloff-Shani
currently serves as the Chief Executive Officer of Clearmind (Nasdaq: CMND), (FSE: CWY). She has served as the Chairman of Orsus Therapeutics,
Inc. since November 2022, as a member of the scientific advisory board of N2 OFF, Inc. (Nasdaq: NITO) since October 2021 and as a director
of MitoCareX since May 2022. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amnon Ben Shay</i>
has served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between
January 2021 and January 2022. Mr. Ben Shay has been chief financial officer of Aerodrome Group Ltd since October 2022. Mr. Ben Shay previously
served on the board of directors of Azorim Investments and Building Development Company Ltd. (TASE: AZRM), Value Capital One Ltd. (TASE:
VALU) and B.G.I. Investments (1961) Ltd. (TASE: BGI). Mr. Ben Shay was chief financial officer of Hadar Hasharon Marketing and Distributions
Ltd. from February 2019 to October 2022. From February 2017 to January 2019, Mr. Ben Shay served as the chief financial officer of Fridenson
Air &amp; Ocean Ltd. From January 2014 to January 2017, Mr. Ben Shay served as the chief financial officer of Abetrans Logistics Ltd.
Prior to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to 2013. Prior to
the year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr. Ben Shay holds
a B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an accounting certificate
from The College of Management Academic Studies, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Alon Dayan</i> has
served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between January
2021 and January 2022. Mr. Dayan is the founder of L1-Systems Ltd. and has served as its chief executive officer since 2014 and is also
the founder of Viewbix Inc. (formerly known as Virtual Crypto Technologies Inc.) (OTC: VBIX), a company he served as chief executive officer
from 2018 to 2019. Mr. Dayan is currently director at Viewbix Inc. Prior to that, he served as a business development manager at Elbit
Systems Ltd. from 2006 to 2013. Mr. Dayan holds a B.A. in electronical engineering from Ariel University, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr.&#160;Moshe Revach</i>&#160;has
served as a member of our board of directors since September 2022. Mr. Revach also previously served as our director since August&#160;2020
until his resignation on March&#160;13, 2022. Mr.&#160;Revach has served as vice-counselor of the Ramat Gan municipality and has been
on its financial committee since March 2024. Mr.&#160;Revach serves as a director of L.L.N IT solutions, a wholly owned&#160;subsidiary
of the Jewish Agency for Israel, RPG Economic Society, ParaZero Technologies Ltd. (Nasdaq: PRZO), Plantify Foods Inc (CVE: PTFY), and
Jeffs&#8217; Brands Ltd (Nasdaq: JFBR). Mr.&#160;Revach previously served as a director of Biomedico Hadarim, and Jewish Experience Company
on behalf of the Jewish Agency and also served as deputy mayor of Ramat Gan, Israel from 2013 to 2023, while also heading the sports and
government relations departments in the Ramat Gan municipality. Mr.&#160;Revach holds an LL.B from the Ono Academic College, Israel, and
a B.A. in management and economics from the University of Derby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Liat Sidi</i> has served
as our Director since August 2020. Ms. Sidi serves as the manager of the accounting department for Foresight Autonomous Holdings Ltd.
(Nasdaq and TASE: FRSX) and has served as director for N2 OFF, Inc.. (Nasdaq: NITO) since November 2023. Ms. Sidi previous served as director
for Plantify Foods Inc (CVW: PTFY) from September 2023 to January 2024. Ms. Sidi previously served as an accountant for Panaxia Labs Israel
Ltd. (TASE: PNAK) from 2015 to 2020 and as an accountant for Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served as an accountant
for Feldman-Felco Ltd. from 2006 to 2010 and as an accountant for Eli Abraham accounting firm from 2000 to 2006. Ms. Sidi completed tax,
finance and accounting studies in Ramat Gan College of Accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Lior Vider</i> has
served as our Director since August 2020. Mr. Vider has served as investment manager at Finessa Capital since November 2023. Mr. Vider
previously served as chief investment manager for Impact Investment Management Ltd., from the Union Bank group, from 2007 to 2010 and
as chairman of the board of directors and a member of the group&#8217;s investment committee of Rahkia Capital Markets Ltd. from 2006
to 2007. Mr. Vider also served as a director at Endymed Medical Ltd. and Apollo Power Ltd. Mr. Vider founded and managed sponser.co.il,
a financial portal specializing in services for investors from 2005 to 2017. Mr. Vider holds a B.A. in industry and management engineering
from Shenkar College in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of eleven award winning and active physicians and scientists in the field(s) of: psychiatry and child psychiatry, TS, neurology,
Alzheimer&#8217;s disease, hospice and palliative medicine neurobiology, pharmacology and neuropsychopharmacology, organic and medicinal
chemistry, cannabinoids and drug discovery. We consult with the members of our Scientific Advisory Board on a regular basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Elon Eisenberg,</i>
is the Dean of the Faculty of Medicine at the Technion - Israel Institute of Technology. Prof. Eisenberg is a Professor of Neurology and
Pain Medicine at the Faculty of Medicine and holds the Otto Barth Family Academic Chair in Biomedical Science. Prof. Eisenberg graduated
from Sackler School of Medicine, Tel-Aviv University in Israel. Prof. Eisenberg completed a residency in Neurology, at Rambam Medical
Center, Haifa, Israel, and Neurology - Pain Fellowship at Massachusetts General Hospital, Harvard Medical School in Boston, USA. Prof.
Eisenberg has been the director of the Institute of Pain Medicine at Rambam Health Care Campus, Haifa, Israel, and the President of the
Israeli Pain Association. Prof. Eisenberg is currently the director of the Pain Research Unit at the Institute of Pain Medicine, Rambam
Health Care Campus. H Prof. Eisenberg&#8217;s main areas of research include mechanisms and treatment of pain with special emphasis on
neuropathic pain, CRPS, cancer pain, opioids and cannabinoids. Prof. Eisenberg has published about two-hundred articles, book chapters
and other manuscripts in various&#160;areas&#160;of&#160;pain.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. James Leckman, M.D.</i>
is the Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale University. Prof. Leckman is a well-known
child psychiatrist and patient-oriented clinical investigator. For more than 20, years he served as the Director of Research for the Yale
Child Study Center. His peers have regularly selected him as one of the Best Doctors in America. Dr. Leckman is the author or co-author
of over 430 original articles published in peer-reviewed journals, twelve books, and 140 book chapters. Dr. Leckman has a longstanding
interest in Tourette syndrome and Obsessive-Compulsive Disorder (OCD). His research on these disorders is multifaceted from phenomenology
and natural history, to neurobiology to genetics, to risk factor research and treatment studies. One area of active research interest
concerns the role of the immune system in the pathobiology of Tourette syndrome and other neuropsychiatric disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Michael Davidson
</i>currently serves, among other things, as Chairman of the Israeli Medical Centre for Alzheimer&#8217;s Disease Care and Research in
Ramat Gan and Chairman of the department of psychiatry at the Nicosia University Medical School. Prof. Davidson served as Chief Psychiatrist
at the Department of Psychiatry of the Sheba Medical Centre in Tel-Hashomer for six years. Prof. Davidson holds a secondary professorship
at the Sackler School of Medicine of Tel Aviv University and at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered
an international expert on Alzheimer&#8217;s disease and schizophrenia is the author of approximately 350 publications in scientific literature.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Daniele Piomelli</i>
serves as the Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry
at University of California, Irvine. Prof. Piomelli is also the founding director of the drug discovery and development unit (D3) at the
Italian Institute of Technology in Genoa, Italy, as well as the Editor in Chief of Cannabis and Cannabinoid Research of Cannabis and Cannabinoid
Research. Prof. Piomelli&#8217;s research has resulted in several contributions to the pharmacology of lipid based signaling molecules
including endocannabinoid substances and lipid amides. Prof. Piomelli is the author of more than 400 peer reviewed articles and books
and has received several awards and honors. Prof. Piomelli studied Pharmacology and Neuroscience at Columbia University, and the Rockefeller
University, and earned his degree of Doctor of Pharmacy from University of Naples.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Kirsten M&#252;ller-Vahl
</i>is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School, Germany.
Prof. M&#252;ller-Vahl is a specialist in both neurology and adult psychiatry. She serves as the head of the TS outpatient department
and over the past twenty-five years, Prof. M&#252;ller-Vahl has investigated more than 4000 patients with TS, both children and adults.
She serves on the scientific advisory board of the German Tourette Syndrome Association and is the current president of the European Society
of the study of Tourette syndrome (ESSTS), the national German Association for Cannabinoid Medicines (ACM) as well as the International
Alliance for Cannabinoid Medicines (IACM). Her scientific work related to TS includes a large number of clinical trials funded by the
EU (TS-EUROTRAIN: FP7-PEOPLE-2012-ITN, No. 316978; EMTICS: EU FP7-HEALTH-2011, 278367), by the NIMH (TIC-GENETICS (1R01MH115958-01), by
the German ministry of education and research (BMBF) (ONLINE-TICS: 01KG1421) and the German Research Foundation (DFG) (CANNA-TICS: NCT03087201).
At the 9th IACM Conference on Cannabinoids in Medicine in 2017 she received the &#8220;IACM Award 2017 for Clinical Research&#8221; for
her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine. Prof. M&#252;ller-Vahl has published
more than 180 scientific articles, is the author of several book chapters and the leading German textbook on TS, and co-editor of the
leading German textbook on cannabis-based medicine. She is author of several guidelines on TS including ESSTS guidelines and treatment
guidelines published by the American Academy of Neurology (AAN).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Weizman</i> is
a Professor of Child and Adult Psychiatry at the Sackler Faculty of Medicine of Tel Aviv University, a former Director of the Felsentein
Medical Research Center and the head of the Laboratory for Biological and Molecular Psychiatry and the head of the Research Unit at the
Geha Mental Health Center. Prof. Weizman&#8217;s research involves the investigation of brain mechanisms of mental disorders. Currently,
it focuses on neurodevelopmental disorders, the development of new strategies for treating psychotic disorders, and the psychopharmacology
of mental disorders. Prof. Weizman is the author of more than 760 original papers, five full books, 28 book chapters, and 60 review articles.
After completing his residency in Psychiatry, Prof. Weizman spent two years as a visiting scientist at the National Institute of Mental
Health in&#160;Bethesda,&#160;MD.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Michael H. Bloch, M.D.,
M.S.</i> graduated from Yale School of Medicine and completed his child and adult psychiatry training at Yale. His research interests
focus on studying Tourette syndrome, obsessive-compulsive disorder (OCD) and trichotillomania (TTM) across the lifespan and developing
better pharmacological treatments for children with depression, anxiety and ADHD. His research focuses on developing better treatments
for children and adults with these conditions particularly through clinical trials and meta-analysis. He has over 200 peer-reviewed publications
and is currently the Research Review Editor for the Journal of Child Psychology and Psychiatry. He also serves on the scientific advisory
boards of the Tourette Association of America and the TLC Foundation for Body-Focused Repetitive Behaviors. <i>Prof. Saoirse O&#8217;Sullivan,
PhD</i> received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow
where she began researching cannabinoid pharmacology through basic and clinical research. She was made Lecturer in 2007 and Associate
Professor in 2011 and Full Professor in 2019. Prof. O&#8217;Sullivan has over 40 peer reviewed articles, six reviews and three books chapters
on the topic of cannabinoid pharmacology, with specific interests on the cardiovascular and gastrointestinal effects of cannabinoids and
therapeutic potential of cannabis-based medicines. Prof. O&#8217;Sullivan&#8217;s research methodologies span from cellular and animal
models to human healthy volunteer studies and early phase clinical trials. In 2016, Prof. O&#8217;Sullivan was named the International
Cannabinoid Research Society Young Investigator of the year. Prof. O&#8217;Sullivan now runs an independent consulting company called
CanPharmaConsulting Ltd, and through this, acts as scientific advisor to Therapix Biosciences, Artelo Biosciences, Inc., CBD Science Group
PLC, FSD Pharma Inc., and Dragonfly Biosciences Ltd. She is the science lead for the Centre for Medicine Cannabis, working to shape the
UK&#8217;s new medicinal cannabis regime for patients. She is also secretary to the International Cannabinoid Research Society.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Mellar P. Davis, MD,
FCCP FAAHPM </i>is a Professor of Palliative Medicine, the Geisinger Commonwealth School of Medicine and a member of the Palliative Care
Department, and Section Head, Geisinger Medical System Danville, PA. He has been a member of the Geisinger Medical Staff since August
2016. In his role as Section Head, Dr. Davis is responsible for developing palliative care services throughout the Geisinger Medical System
including outpatient and inpatient services. In addition, Dr. Davis works with the Geisinger Hospice Services to develop and coordinate
care within the central region. Dr. Davis was a member of the Cleveland Clinic Palliative Care section, Taussig Cancer Institute and fellowship
director until joining the Geisinger Medical System. Dr. Davis was the co-chair of the Palliative Care Study Group of the Multinational
Association of Supportive Care (MASCC) and a past board member since 2010. Dr. Davis has been a Professor of Medicine in The Cleveland
Clinic Lerner College of Medicine, Case Western Reserve University, since 2009 and was elected as a Fellow to the American Academy of
Hospice and Palliative Medicine in 2010. Dr. Davis is Editor in Chief of Progress on Palliative Care. Dr. Davis&#8217; present duties
are as the Associate Editor in Chief of PC Fast Article Critical Summary for Clinicians in Palliative Care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Schroeder</i>
is the head of the Targeted Drug Delivery and Personalized Medicine Group, at the Technion, Israel Institute of Technology, and has translational
research experience with the development of liposome-based clinical systems. He is the author of 60 scientific papers in the field of
nanotechnology and medicine and is the inventor on 17 patents, and a recipient of 30 national and international innovation awards. Prof.
Schroeder is a scientific entrepreneur, starting multiple successful Technion spin-outs. Prof. Schroeder received three degrees in Chemical
Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took&#160;place&#160;at&#160;MIT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Yossi Tam</i>&#160;received
his B.Med.Sc., M.Sc., Ph.D. and D.M.D. from the Hebrew University of Jerusalem. He did his postdoctoral training at the National Institutes
of Health (NIH), and in 2014 he moved to the Hebrew University to head the Obesity and Metabolism Laboratory at the Institute for Drug
Research, where he focuses on targeting the endocannabinoid system for Obesity, Diabetes and the metabolic syndrome. Prof. Tam won major
national and international grants. He authored over 80 peer-reviewed papers in leading journals (such as Science, Nature Medicine, Cell
Metabolism, JCI, PNAS, Hepatology, Gastroenterology, Molecular Metabolism, to name a few), and three book chapters, with 5,412 citations
yielding an H-index of 36. In addition, Prof. Tam co-invented 14 patents that were commercialized to different pharmaceutical companies
for further clinical development and testing. Prof. Tam also serves as the Director of the Hebrew University&#8217;s Multidisciplinary
Center for Cannabinoid Research and a Scientific Advisory Board Member of several biotech companies, which develop a portfolio of non-psychoactive
cannabinoid-modulating medicines for unmet market needs. Prof. Tam&#8217;s research projects over the past twenty years have crossed subjects,
disciplines and methodologies, yet the main research interests remain focused on the different pathophysiological aspects of the endocannabinoid
system. Having a clinical background with basic science training, he has always been interested in how science can directly improve people&#8217;s
everyday lives. Thus, he has strived unceasingly to integrate his clinical curiosity and experimental knowledge, in order to deepen the
understanding of clinically relevant research questions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements for Election of Directors and
Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not a party to, and
there are no arrangements or voting agreements that we are aware of for the election of our directors and members of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our directors and senior management, as a group for the year ended December 31, 2024.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to us for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary/Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension,<br/> Retirement<br/> and Other <br/> Similar<br/> Benefits<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-<br/> Based<br/> Compensation<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">All directors and senior management as a group, consisting of 9 persons</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">157</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(1)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the directors and senior management&#8217;s payment of mandatory social benefits made by us on behalf of such officer. Such benefits may include, to the extent applicable to the executive, payments, contributions and/or allocations for savings funds, education funds (referred to in Hebrew as &#8220;<i>Keren Hishtalmut</i>&#8221;), pension, severance, risk insurances (e.g., life or work disability insurance) and payments for social security.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(2)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed based on fair value for Ordinary Shares options granted and estimated using the Black-Scholes option pricing model.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, the table below reflects the compensation granted to our five most highly compensated officers or directors during or with respect
to the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Annual Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Executive Officer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary/Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pension,<br/> Retirement<br/> and Other<br/> Similar<br/> Benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-<br/> Based<br/> Compensation<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler<br/> <i>Chief Executive Officer and Chief Financial Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">374</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani<i><br/> Chief Technologies Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">342</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem<br/> <i>President</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">299</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss<br/> <i>Chairman</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">299</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider<i><br/> Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
compensation includes the cost of our non-cash share-based compensation in 2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Services Agreements with
Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements and/or consulting agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. Most of these agreements are terminable by either party upon 30 days&#8217; prior written
notice. However, a longer 90 day notice period is required with respect to each of our executive officers. In addition, we have entered
into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount
and to the extent that these liabilities are not covered by directors and officers insurance. Members of our senior management are eligible
for bonuses each year, subject to a pre-determined target-based bonus plan, which is usually set during the first quarter of each calendar
year following the recommendation of our compensation committee and the approval of our Board of Directors. The annual bonuses are payable
upon meeting objectives and targets that are set by our Chief Executive Officer and compensation committee and approved annually by our
Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the terms
of our options and option plans, see Item 6.E. &#8220;Share Ownership<span style="font-variant: small-caps">&#8221; </span>below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by the Companies
Law, our compensation committee and Board of Directors approved, and recommended to our shareholders to approve, amended terms of compensation
of our Chief Executive Officer, Mr. Oz Adler, our President, Mr. Itschak Shrem, and our and Chairperson of the Board of Directors, Mr.
Amitay Weiss, as set forth below. Such terms are in line with our Compensation Policy and were approved by our shareholders on February
10, 2022. We intend to ask our shareholders to reapprove the Compensation Policy at the annual meeting to be held in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">President and Chairperson of the Board of Directors</span> - a monthly fee in the amount of NIS 52,500 (approximately $14,919) and an annual target bonus of up to six monthly salaries, or eight in the case of overachievement.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Chief Executive Officer </span>- a monthly fee in the amount of NIS 66,000 (approximately $18,755) and an annual target bonus of up to six monthly salaries, or eight in the case of overachievement, plus applicable pension, retirement and other similar benefits.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors&#8217; Service Contracts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have written agreements
with any director providing for benefits upon the termination of his/her employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Board Practices </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Governance Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law. However, pursuant to regulations promulgated under the
Companies Law, companies with shares traded on certain U.S. stock exchanges, including the Nasdaq, may, subject to certain conditions,
&#8220;opt out&#8221; from the requirements to appoint external directors and related rules concerning the composition of the audit committee
and compensation committee of the board of directors, other than the gender diversification rule, which requires the appointment of a
director from the other gender if, at the time a director is appointed, all members of the board of directors are of the same gender.
In accordance with these regulations, following our listing on the Nasdaq, in January 2022, we elected to &#8220;opt out&#8221; from these
requirements of the Companies Law. Under these regulations, the exemptions from such Companies Law requirements will continue to be available
to us so long as: (i) we do not have a &#8220;controlling shareholder&#8221;, as such term is defined under the Companies Law, (ii) our
shares are traded on certain U.S. stock exchanges, including the Nasdaq, and (iii) we comply with the director independence requirements
and the audit committee and compensation committee composition requirements under U.S. laws, including the rules of the applicable exchange,
that are applicable to U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer&#8221;, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement. As a foreign private issuer, we are exempt under the Exchange Act from, among
other things, the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information regarding
our corporate governance practices and foreign private issuer status, see &#8220;Item 16.G Corporate Governance&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors presently
consists of seven members. Nasdaq listing standards require that a majority of our Board of Directors be independent. These standards
provide, among other things, that a person will be considered an independent director if he or she is not an officer of the Company and
is, in the view of our board of directors, free of any relationship that would interfere with the exercise of independent judgment. We
believe that Mr. Vider, Ms. Sidi, Mr. Ben Shay, Mr. Revach and Mr. Dayan are all currently considered &#8220;independent&#8221; for purposes
of the Nasdaq rules. As such, our Board of Directors is comprised of a majority of independent directors as such term is defined in the
Nasdaq rules. Our amended and restated articles of association provide that the number of directors shall be set by the general meeting
of the shareholders provided that it will consist of not less than three and not more than 12 directors. Pursuant to the Companies Law,
the overall planning and management of our business is vested in our Board of Directors. Our Board of Directors may exercise all powers
and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible
for our day-to-day management and have individual responsibilities established by our Board of Directors. Our Chief Executive Officer
is appointed by, and serves at the discretion of, our Board of Directors. All other executive officers are appointed by the Board of Directors
or by our Chief Executive Officer, provided that he was authorized by the Board of Directors to do so. Their terms of employment are subject
to the approval of our Board of Directors&#8217; Compensation Committee (see &#8220;-Compensation Committee<span style="font-variant: small-caps">&#8221;</span>)
and of the Board of Directors (and in case the terms are not compatible with the provisions of the compensation policy, to our shareholders&#8217;
approval as well), and are subject to the terms of any applicable employment agreements that we may enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one third of the total
number of directors constituting the entire board of directors. At each annual general meeting of our shareholders, the election or re-election
of directors following the expiration of the term of office of the directors of that class of directors is for a term of office that expires
on the third annual general meeting following such election or re-election, such that at each annual general meeting the term of office
only one class of directors will expire. Each director holds office until the annual general meeting of our shareholders for the year
in which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier
pursuant to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least
65% of the total voting power of our shareholders at a general meeting of our shareholders in accordance with our amended and restated
articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
among the three classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class I directors consist of Ms. Liat Sidi and Mr. Amnon Ben Shay, and their terms will expire at our annual general meeting of shareholders to be held in 2027;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class II directors consist of Mr. Alon Dayan, Mr. Moshe Revach and Mr. Lior Vider and their terms will expire at our annual general meeting of shareholders to be held in 2025; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class III directors consist of Mr. Amitay Weiss and Mr. Itschak Shrem and their terms will expire at our annual general meeting of shareholders to be held in 2026.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended and
restated articles of association allow our Board of Directors to appoint directors to fill vacancies on our Board of Directors or in addition
to the acting directors (subject to the limitation on the number of directors and their qualifications), until the next general meeting
in which directors may be appointed or such appointment terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, nominations
for directors may be made by any shareholder holding at least 5% of our outstanding voting power. However, any such shareholder may make
such a nomination only if a written notice of such shareholder&#8217;s intent to make such nomination has been given to our Board of Directors.
Any such notice must include certain information, a description of all arrangements between the nominating shareholder and the proposed
director nominee(s) and any other person pursuant to which the nomination(s) are to be made by the nominating shareholder, the consent
of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that there
is no limitation under the Companies Law preventing their election and that all of the information that is required to be provided to
us in connection with such election under the Companies Law has been provided.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
Board of Directors must determine the minimum number of directors who are required to have accounting and financial expertise. Our Board
of Directors has determined that the minimum number of our directors of who are required to have accounting and financial expertise is
one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is
required to elect one director to serve as the Chairman of the Board of Directors to preside at the meetings of the Board of Directors
and may also remove that director as Chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her
relatives is permitted to serve as the Chairman of the Board of Directors, and a company may not (subject to a certain time-limited exemption,
as described below) vest the Chairman or any of his or her relatives with the chief executive officer&#8217;s authorities. In addition,
a person who reports, directly or indirectly, to the chief executive officer may not serve as the Chairman of the Board of Directors;
the Chairman may not be vested with authorities of a person who reports, directly or indirectly, to the chief executive officer; and the
Chairman may not serve in any other position in the company or a controlled company, but he or she may serve as a director or chairman
of a controlled company. However, and notwithstanding the foregoing, the Companies Law permits the shareholders of a company to determine,
for periods not exceeding three years from each such determination, that the Chairman or his or her relative may serve as chief executive
officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or his or her relative
may serve as Chairman or be vested with the Chairman&#8217;s authorities. Such determination of a company&#8217;s shareholders requires
either: (1) the approval of at least the majority of the shares of those shareholders present and voting on the matter (other than controlling
shareholders and those having a personal interest in the determination); or (2) that the total number of shares opposing such determination
does not exceed 2% of the total voting power in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may,
subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the Board of Directors, and it may,
from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise
expressly provided by the Board of Directors, the committees shall not be empowered to further delegate such powers. The composition and
duties of our audit committee and compensation committee, are described below. See &#8220;-Committees of the Board of Directors&#8221;
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Role of Board of Directors in Risk Oversight
Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. Our Board of Directors encourages management to promote a culture that incorporates risk management
into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management
meetings, and conducts specific strategic planning and review sessions that include a focused discussion and analysis of the risks we
face. Senior management reviews these risks with the Board of Directors focusing on particular business functions, operations or strategies,
and presents the steps taken by management to mitigate or eliminate such risks. The Board of Directors is assisted in its oversight role
by an internal auditor. The internal auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the
results of which are reported to our audit committee. See &#8220;-Committees of the Board of Directors-Internal Auditor&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leadership Structure of the Board of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law and our amended and restated articles of association, our Board of Directors is required to appoint one of its members to serve as
Chairman of the Board of Directors. Our Board of Directors has appointed Mr. Amitay Weiss to serve as Chairman of the Board of Directors,
effective January 10, 2022, and subsequently further named as the President of the Company, Mr. Itschak Shrem, the authorities of the
Chairman of the Board of Directors as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide, consistent with the Companies Law, that any director, and with respect to external directors (to the extent required
under applicable law - see the description of the External Directors Relief Resolution under &#8220;-External Directors&#8221; below)
&#8211; only subject to certain preconditions, may appoint another person to serve as his alternate director, provided such person has
the qualifications prescribed under the Companies Law to be appointed and to serve as a director and is not already serving as a director
or an alternate director of the company. The term of an alternate director may be terminated at any time by the appointing director and
automatically terminates upon the termination of the term of the appointing director. An alternate director has the same rights and responsibilities
as a director. To date there are no alternate director appointments in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies&#8221; are required to appoint at least two external
directors who meet the qualification requirements under the Companies Law. Pursuant to regulations promulgated under the Companies Law,
companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling shareholder,&#8221;
may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related
Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors (other than
the gender diversification rule under the Companies Law, which requires the appointment of a director from the other gender if at the
time a director is appointed all members of the board of directors are of the same gender). In accordance with these regulations, in January
2022, following our listing on Nasdaq, our Board of Directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint
external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of our
board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company. &#8220;Office holders&#8221; includes the chief executive officer,
general manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities
of any of the above positions regardless of that person&#8217;s title, and a director, or a manager directly subordinate to the chief
executive officer or general manager.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that constitutes competition with the company&#8217;s business;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 15, 2022, we filed
a lawsuit in the Economic Division of the Tel Aviv Court against six of our former directors, including our former interim chief executive
officer and executive chairman, which included allegations of breaches of their fiduciary duties (duty of care and duty of loyalty) under
the Companies Law. This lawsuit was settled in February 2025, pursuant to a settlement agreement entered into between the defendants and
us and thereafter approved by the court. See &#8220;Legal Proceedings&#8221; in Item 8.A below for additional information.&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Approval of Related Party Transactions under
Israeli Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at which the transaction
is first discussed, any direct or indirect personal interest that he or she may have and all related material information known to him
or her relating to any existing or proposed transaction by the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;personal interest&#8221;
includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder
with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest
in the matter.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction is an extraordinary
transaction, the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An office holder is not, however,
obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is
not considered an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not in the ordinary course of business;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law does not
specify neither to who within us nor the manner in which required disclosures are to be made. We require our office holders to make such
disclosures to our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, once
an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between the company
and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association provide otherwise
and provided that the transaction is in the company&#8217;s interest and is performed by the office holder in good faith. If the transaction
is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction.
Under specific circumstances, shareholder approval may also be required. Any director (and any person, in general) who has a personal
interest in an extraordinary transaction, which is considered at a meeting of the board of directors or the audit committee, may not be
present at this meeting or vote on this matter, unless the chairman of the relevant committee or board of directors determines that he
or she should be present in order to present the transaction that is subject to approval. If a majority of the board of directors or the
audit committee, as the case may be, has a personal interest in the approval of a transaction, then all directors may participate in discussions
of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder
approval is also required for such transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, all
arrangements as to compensation and indemnification or insurance of office holders require approval of the compensation committee and
board of directors, and compensation of office holders who are directors must be also approved, subject to certain exceptions, by the
shareholders, in that order. If shareholders of a company do not approve the compensation terms of office holders, other than directors,
the compensation committee and board of directors may override the shareholders&#8217; decision, subject to certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
disclosure requirements that apply to an office holder also apply to a &#8220;controlling shareholder&#8221; of a public company. Extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement
in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or
indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning
the terms of engagement of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an
employee, require the approval of the audit committee or the compensation committee, as the case may be, the board of directors and a
majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217; meeting.
In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the abovementioned approval every three years; however, such transactions not involving the receipt of services or compensation
can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to regulations promulgated
under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, that would otherwise
require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain determinations of the audit or
compensation committee and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other than
by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of
the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. The definition
a &#8220;controlling shareholder&#8221; is deemed to include any shareholder that holds 25% or more of the voting rights in a company
if no other shareholder holds more than 50% of the voting rights in the company. For the purpose of determining the holding percentage
stated above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#8217;s approval
are deemed as joint holders. According to the foregoing, the Companies Law recognizes a situation where there exists a &#8220;controlling
shareholder&#8221; regarding a particular matter or in relation to a particular transaction, although such shareholder would not be considered
to have a controlling interest on an ongoing basis or in any other case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising
its rights and performing its obligations to the company and other shareholders, including, among other things, voting at general meetings
of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of &#8220;related party&#8221; transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from oppressing and discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders,
additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
established two standing committees, both of which (the audit committee and the compensation committee) are mandatory (and to date comprised
of the same members and combined into one functional committee which resides as a unified committee). In addition, occasionally our Board
of Directors may form sub-committees for certain matters on an ad hoc basis, such as a pricing committee or a nomination and corporate
governance committee, with advisory powers only, operating under a framework and guidelines as outlined and defined in advance by our
Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to appoint an audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the corporate governance
rules of Nasdaq, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially
literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee, acting
pursuant to a written charter, consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay serves as chairperson of our audit committee.
All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC
and the corporate governance rules of Nasdaq. Our Board of Directors has determined that Amnon Ben Shay is an audit committee financial
expert as defined by the SEC rules and has the requisite financial experience as defined by the corporate governance rules of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Audit Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the Board of Directors to improve such practices;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) (see &#8220;-Approval of Related Party Transactions under Israeli Law&#8221;);</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether certain acts of an office holder not in accordance with his or her fiduciary duty owed to the company are extraordinary or material and to approve such acts and certain related party transactions (including transactions in which an office holder has a personal interest) and whether such transaction is extraordinary or material under the Companies Law (see &#8220;-Approval of Related Party Transactions Under Israeli Law&#8221;);</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deciding whether to approve and to establish the approval process (including by tender or other competitive proceedings) for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the process of approving of transactions that are not negligible, including determining the types of transactions that will be subject to the approval of the audit committee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an audit committee
charter setting forth among others, the responsibilities of the audit committee consistent with the rules of the SEC and Nasdaq listing
rules, including, among others, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering and making recommendations to the Board of Directors on our financial statements, reviewing and discussing the financial statements and presenting its recommendations with respect to the financial statements to the Board of Directors prior to the approval of the financial statements by our Board of Directors;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the Board of Directors in accordance with Israeli law;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our Board of Directors; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, reviewing regulatory authorities&#8217; findings, receiving reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommending to our Board of Directors if so required, and overseeing our policies and procedures regarding compliance with applicable financial and accounting related standards, rules and regulations; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">supervising the manner we implement the requirements of the Privacy Protection Law, 1981 and the Privacy Protection Regulations (Data Security), 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
is acting pursuant to a written charter, and consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay is the Chairperson of the
compensation committee. Our Board of Directors has determined that each member of our compensation committee is independent under the
corporate governance rules of Nasdaq, including the additional independence requirements applicable to the members of a compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our Board of Directors: (1) the annual base compensation of our executive officers and directors; (2) annual
incentive bonus, including the specific goals and amount; (3) equity compensation; (4) employment agreements, severance arrangements,
and change in control agreements/provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation,
compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a Compensation Policy. The Compensation Policy must be adopted by the company&#8217;s Board of Directors,
after considering the recommendations of the Compensation Committee. The Compensation Policy is then brought for approval by our shareholders
and is subject to special majority requirements. On February 10, 2022, our shareholders approved our new Compensation Policy, which expired
on February 9, 2025. We intend to ask our shareholders to reapprove the Compensation Policy at the annual meeting to be held in 2025.
The duties of the compensation committee also include the administration of the Company&#8217;s policy for recovery of erroneously awarded
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including
exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The Compensation
Policy must be approved (or reapproved) not longer than every three years, and relate to certain factors, including advancement of the
company&#8217;s objectives, the company&#8217;s business and its long-term strategy, and creation of appropriate incentives for executives.
It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations. The Compensation
Policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the knowledge, skills, expertise and accomplishments of the relevant office holder (director or executive);</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the terms offered and the average and median compensation of the other employees of the company, including those employed through manpower companies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of disparities in salary upon work relationships in the company;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also consider appropriate incentives from a long-term perspective and maximum limits for severance compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
is responsible for (1) recommending the Compensation Policy to a company&#8217;s Board of Directors for its approval (and subsequent approval
by our shareholders) and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders as
well as functions previously fulfilled by a Company&#8217;s Audit Committee with respect to matters related to approval of the terms of
engagement of office holders, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the compensation terms of the chief executive officer of the company need not be brought to approval of the shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
Board of Directors of an Israeli public company must also appoint an internal auditor nominated and supervised by the audit committee.
Our internal auditor is Mr. Daniel Shapira, who has been serving as our internal auditor since March 2006. Mr. Shapira is a Certified
Public Accountant and holds a B.A. degree in Economics and Accounting from Bar-Ilan University, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine whether a company&#8217;s actions comply with the law and proper business procedure. Our Chairman acts as the internal auditor&#8217;s
organizational supervisor. The internal auditor will submit his internal auditor&#8217;s work plan for the approval of our audit committee.
The internal auditor may not be an &#8220;interested party&#8221; or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the shares or voting rights of a company, any person or entity that has the right to nominate or appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not our employee, but the managing partner of a firm which specializes in internal auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter by the general
meeting of the shareholders. In case the remuneration of the directors is in accordance with regulation applicable to remuneration of
the external directors then such remuneration shall be exempt from the approval of the general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our amended and restated articles of association, a company may obtain insurance for any of its office holders for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of care to the company or to another person, including a breach arising out of the negligent conduct of the office holder;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon him or her in favor of another person concerning an act performed by such office holder in his or her capacity as an officer holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other insurable action in accordance with the Companies Law;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder relating to an administrative enforcement proceeding conducted with respect to such office holder including reasonable litigation expenses and attorneys&#8217; fees; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments to the party injured by the violation, in accordance with the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have liability
insurance providing total coverage of $5 million per claim and in the aggregate for the benefit of all of our directors and officers and
company coverage for securities claims. We also have an excess Side A difference in conditions policy providing a total coverage of $2.5
million per claim and in the aggregate for the benefit of all of our directors and officers for claims against them, which may operate
as a primary coverage in certain cases, subject to policy terms and conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and our
amended and restated articles of association provide that we may indemnify an office holder against:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court; However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on a company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking must detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder: (i) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (b) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (ii) in connection with a monetary sanction;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or charged to him or her by a court relating to an act performed in his or her capacity as an office holder, in connection with: (1) proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) a criminal charge of which he or she was acquitted; or (3) a criminal charge for which he or she was convicted for a criminal offense that does not require proof of criminal thought;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder relating to an administrative enforcement proceeding conducted with regard to such office holder, including reasonable litigation expenses and including attorneys&#8217; fees;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment to the party injured by the violation; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability or expense otherwise permitted as an indemnification by the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association allow us to indemnify our office holders up to a certain amount. The Companies Law also permits a company to undertake
in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her,
as described above, then the undertaking should be limited:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to categories of events that the board of directors determines are likely to occur in light of the operations of the company at the time that the undertaking to indemnify is made; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements, with each of our directors and with certain members of our senior management. Each such indemnification agreement provides
the office holder with indemnification to the fullest extent permitted under applicable law and up to a certain amount, and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings,
and to the extent that the directors and officers insurance do not cover these liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exculpation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance
an office holder from his or her liability to the company, in whole or in part, and for damages caused to the company as a result of a
breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
in its articles of association. A company may not exculpate a director from liability arising out of a prohibited dividend or distribution
to shareholders. Our amended and restated articles of association provide that we may exculpate any office holder from liability to us
to the fullest extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into exculpation
agreements with each of our current directors and executive officers undertaking to exculpate and release our office holders from any
and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability
incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would
not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly
(as opposed to merely negligently); (3) any action taken or omission committed with the intent to derive an illegal personal benefit;
or (4) any fine or forfeit levied against the office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Israeli Share Option Plan (2015); Israeli
Share Option Plan (2005) </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2005, we adopted the
Israeli Share Option Plan (2005), or the 2005 Plan, which was in force for a period of 10 years. Upon the expiration of the 2005 Plan,
we adopted the Israeli Share Option Plan (2015), or the 2015 Plan. There are no options outstanding under our 2005 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>We
no longer grant any awards under the 2015 Plan as it was superseded by the 2023 Share Incentive Plan, or the 2023 Plan, although previously
granted awards remain outstanding. Ordinary shares subject to outstanding options granted under the 2015 Plan that expire or become unexercisable
without having been exercised in full will become available again for future grant under the 2023 Plan. Our board of directors, or a duly
authorized committee of our board of directors administers the 2015 Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2023 Share Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 139.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2023 Plan was adopted
by our board of directors on December 28, 2023. The 2023 Plan provides for the grant of equity-based incentive awards to our employees,
directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of the Company
and to promote the success of the Company&#8217;s business. As of April 23, 2025, 953,787 Ordinary Shares were reserved and available
for issuance under the 2023 Plan.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares Available for Grants.&#160;</i>The
maximum number ordinary shares available for issuance under the 2023 Plan is equal to the sum of (i) 2,000,0000 shares and (ii) any shares
subject to awards under the 2015 Plan which have expired, or were cancelled, terminated, forfeited or settled in cash in lieu of issuance
of shares or became unexercisable without having been exercised, provided that no more than 1,013,787, Ordinary Shares may be issued upon
the exercise of Incentive Stock Options. If permitted by our board of directors, shares tendered to pay the exercise price or withholding
tax obligations with respect to an award granted under the 2023 Plan or the 2015 Plan may again be available for issuance under the 2023
Plan, unless determined otherwise by the Board. Our board of directors may also reduce the number of ordinary shares reserved and available
for issuance under the 2023 Plan in its discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Administration.&#160;</i>Our
board of directors, or a duly authorized committee of our board of directors, or the administrator, will administer the 2023 Plan. Under
the 2023 Plan, the administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan and any award agreements
or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the exercise price of
an option award, the fair market value of an ordinary share, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The administrator also has
the authority to approve the conversion, substitution, cancellation or suspension under and in accordance with the 2023 Plan of any or
all option awards or ordinary shares, and the authority to modify option awards to eligible individuals who are foreign nationals or are
individuals who are employed outside Israel to recognize differences in local law, tax policy or custom, in order to effectuate the purposes
of the 2023 Plan but without amending the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The administrator also has
the authority to amend and rescind rules and regulations relating to the 2023 Plan or terminate the 2023 Plan at any time before the date
of expiration of its ten year term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Employees.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2022, we had
3 full-time employees. On December 31, 2023, we had 3 full-time employees. On December 31, 2024, we had 2 full-time employees, our Chief
Executive Officer, who is also our Chief Financial Officer, and our Chief Technologies Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our current employees
and officeholders is represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations
with all of our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent
rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance
with relevant labor laws by the Israeli and Industry of Economy and which apply such agreement provisions to our employees even though
they are not part of a union that has signed a collective bargaining agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Share Ownership.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Action to Recover Erroneously Awarded Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Major Shareholders </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">The following table sets
forth information regarding beneficial ownership of our ordinary shares as of April 23, 2025 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors, and executive officers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors, and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as indicated in footnotes
to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown
to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each beneficial
owner&#8217;s address is c/o SciSparc Ltd., 20 Raul Wallenberg Street, Tower A, Tel Aviv, 6971916 Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Holders of more than 5% of our ordinary shares</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br/>
Ordinary <br/>
Shares <br/>
Beneficially <br/>
Owned<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent of <br/>
Class<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><span style="text-decoration:underline">Officers and Directors who are not 5% holders:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Itschak Shrem</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,536
</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(3)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amitay Weiss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,221 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(4)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Oz Adler</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,256 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(5)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dr. Adi Zuloff-Shani</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,756 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(6)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amnon Ben Shay</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,711 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Alon Dayan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,711 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liat Sidi</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,711 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lior Vider</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,711 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Moshe Revach</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,500 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(8)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">All directors and executive officers as a group (9 persons)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">381,113</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Ordinary Shares relating to options currently exercisable or exercisable within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 10,828,251 ordinary shares issued and outstanding as of April 23, 2025, plus ordinary shares relating to restricted share units, or RSUs, options and warrants currently exercisable or vesting within 60 days of April 23, 2025, which are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 340 Ordinary Shares; (ii) 50,000 vested RSUs; (iii) 25,000 RSUs vesting within 60 days of April 23, 2025; and (iv) options to purchase 1,196 Ordinary Shares at an exercise price of $169 per share, and an expiration date of January 3, 2028.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 25 Ordinary Shares; (ii) 50,000 vested RSUs; (iii) 25,000 RSUs vesting within 60 days of April 23, 2025; and (iv) options to purchase 1,196 Ordinary Shares at an exercise price of $169 per share and an expiration date of January 3, 2028.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 50,000 vested RSUs; (ii) 25,000 RSUs vesting within 60 days of April 23, 2025; (iii) options to purchase 1,196 Ordinary Shares at an exercise price of $169 per share; and (iv) options to purchase 60 Ordinary Shares at an exercise price of $5,460 per share. Mr. Adler&#8217;s options have an expiration date of January 3, 2028, to October 10, 2029, and a weighted average exercise price of $422.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 25,000 vested RSUs; (ii) 12,500 RSUs vesting within 60 days of April 23, 2025; (iii) options to purchase 6 Ordinary Shares at an exercise price of NIS 77,241 (approximately $20,876) per share; (iv) options to purchase 54 Ordinary Shares at an exercise price of $5,640 per share; and (v) options to purchase 1,196 Ordinary Shares at an exercise price of $169 per share. Dr. Zuloff-Shani&#8217;s options have an expiration date of February 16, 2026 to October 10, 2029, and a weighted average exercise price of $207.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 15,000 vested RSUs; (ii) 7,500 RSUs vesting within 60 days of April 23, 2025; and (iii) options to purchase 211 Ordinary Shares at an exercise price of $169 per share and an expiration date of January 3, 2028.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage
ownership held by any major shareholder during the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No major shareholders listed
above had or have voting rights with respect to their Ordinary Shares that are different from the voting rights of other holders of our
Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Record Holders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 23, 2025, there
were 30  holders of record of our Ordinary Shares,  eight of which have a registered address in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These numbers are not representative
of the number of beneficial holders of our shares nor is it representative of where such beneficial holders reside, since many of these
shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Change in Control Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not controlled by another
corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known
to us which would result in a change in control at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Related Party Transactions </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, and Dr. Adi Zuloff-Shani, our Chief
Technologies Officer. Each of these agreements contains customary provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. These
agreements are terminable by either party upon 30 days&#8217; prior written notice. In addition, we have entered into agreements with
each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent
that these liabilities are not covered by directors and officers insurance. Members of our senior management are eligible for bonuses
each year. The bonuses are payable upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually
by our Board of Directors that also set the bonus targets for our Chief Executive Officer. See Item 6.B. &#8220;Compensation-Employment
and Service Agreements with Executive Officers&#8221; and see the descriptions of exculpation and indemnification agreements and directors
and officers insurance arrangements in Item 6.A. &#8220;Directors and Senior Management&#8221; and Item 6.C. &#8220;Board Practices-Insurance,&#8221;
- &#8220;Indemnification&#8221; and &#8220;-Exculpation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
granted options to purchase our Ordinary Shares, and RSUs to our employees, officers, service providers and certain of our directors.
Such option and RSU agreements and may contain acceleration provisions upon certain merger, acquisition, or change of control transactions.
We describe our equity incentive plans under Item 6.E. &#8220;Share Ownership-Equity Incentive Plans.&#8221; If the relationship between
us and an executive officer or a director is terminated, except for cause (as defined in the various option plan agreements), options
that are vested will generally remain exercisable for 90 days after such termination.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Commercial Agreements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we entered
into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our
President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors. See Item 4.B. &#8220;Business
Overview- <i>Collaboration with Clearmind</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, we invested
$1.5 million in Clearmind in connection with its initial public offering on Nasdaq, in exchange for 230,769 common shares of Clearmind,
representing 9.33% of the outstanding share capital of Clearmind.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Polyrizon</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into the Polyrizon Collaboration Agreement with Polyrizon. Mr. Adler, our Chief Executive Officer and Chief Financial Officer, serves
as a director in Polyrizon. See Item 4.B. &#8220;<i>Business Overview - Polyrizon</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 13, 2024, we entered into a termination
agreement with Polyrizon to terminate the Polyrizon Collaboration Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, on August 13,
2024, we entered into the License Agreement for the out-licensing of our SCI-160 program with Polyrizon. Pursuant to the License Agreement,
we granted Polyrizon the Polyrizon License and <span>received 320,000 ordinary shares of Polyrizon, pre-funded
warrants to purchase 364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793 ordinary shares of Polyrizon, at
an exercise price of $4.38 per share. On December 30, 2024, we entered into the Polyrizon Share Transfer Agreement and sold all of the
Polyrizon ordinary shares and pre-funded warrants held by us, as well as an aggregate of 1,541,096 Polyrizon common warrants to third
parties, for aggregate consideration of $770,548. </span>See Item 4.B. &#8220;<i>Business Overview &#8212;</i>&#160;<i>Polyrizon</i>&#8221;
for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
April 1, 2025, we entered into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement
of Polyrizon and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and
Series A warrants to purchase ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant
to which we exchanged existing ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Jeffs&#8217; Brands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Wellution Sale Agreement with Jeffs&#8217; Brands and Jeffs&#8217; Holdings. See Item 5.B. &#8220;<i>Operating and Financial
Review and Prospects &#8212; Liquidity and Capital Resources</i>&#8221; for additional information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Oz Adler, our Chief Executive
Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands, Mr. Amitay Weiss, our
chairman of the board of directors and Mr. Moshe Revach, a member of our board of directors, are both directors in&#160;Jeffs&#8217;&#160;Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>MitoCareX</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2025, we entered
into the MitoCareX SPEA together with MitoCareX, the other Sellers, pursuant to which the Sellers will sell their stakes in MitoCareX
to N2OFF, thereby resulting in MitoCareX becoming a wholly-owned subsidiary of N2OFF. The closing of the MitoCareX SPEA is contingent
upon, among other customary obligations, obtaining approval of N2OFF&#8217;s stockholders by the requisite majority. On the closing date
of the transactions contemplated under the MitoCareX SPEA, we will transfer and sell our stake in MitoCareX to N2OFF in consideration
for a cash payment of $700,000 N2OFF Common Stock, representing 16.75% of N2OFF on a fully-diluted basis. Either party may terminate the
MitoCareX SPEA if the closing date has not occurred within ninety days of February 25, 2025. Following the closing date of the MitoCareX
SPEA, the Sellers may receive Additional N2OFF Stock, if respective milestones are achieved as defined in the MitoCareX SPEA. For more
information, see Item 4.B. &#8220;<i>Business Overview &#8212;</i>&#160;<i>MitoCareX</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Amitay Weiss and Liat
Sidi, our board members, also serve as board members of N2OFF. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2023, we entered
into the AutoMax SPA with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 22, 2023, we announced the signing
of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 14, 2024, we entered into the Bridge
Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 10, 2024, we signed the Merger Agreement
with AutoMax</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 9, 2024, we entered into the Amended Bridge
Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 14, 2024, we signed the Merger Agreement
Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 5, 2024, we entered into the Second
Amendment with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2024, we signed
the Merger Agreement Second Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2025, we entered
into the Additional Loan Agreement with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, we signed
the Merger Agreement Third Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 4.B. &#8220;<i>Business
Overview &#8212;</i>&#160;<i>AutoMax</i>&#8221; for additional information on commercial agreements related to AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss, our chairman
of the board of directors is the chairman of the board of directors of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Interests of Experts and Counsel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Consolidated Statements and Other Financial
Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 18. &#8220;Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Claims Against our Former Directors</i></b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 15, 2022, we filed
a lawsuit against our former directors in the Economic Division of the Tel Aviv Court, case number 34426-02-22, or the Lawsuit. The Lawsuit
named the Defendants and includes allegations of breaches of fiduciary duties (duty of care and duty of loyalty) of the Defendants under
the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Lawsuit challenged a transaction
approved by the Defendants in August 2018, to acquire, via one of our subsidiaries, Therapix Healthcare Resources, Inc., eight pain clinics
and a fully equipped laboratory from Anesthesia Services Associates PLLC. (d/b/a Comprehensive Pain Specialist), or the Transaction. The
Lawsuit claimed that the Defendants breached their fiduciary duties when approving the Transaction, causing us significant harm. The Lawsuit
claimed damages in the amount of NIS 13,114,200 (approximately $4.12 million), accounting for the amounts invested by the Company in the
Transaction and indirect expenses arising from the Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, we announced
that we settled this lawsuit, pursuant to which we received a settlement sum of $411,000 from the Defendants in exchange for our dismissing
the lawsuit, or the Settlement. The Settlement also includes the termination, effective February 5, 2024, of a licensing agreement, or
the Dekel License Agreement, with Dekel Pharmaceuticals Ltd., a company controlled by Dr. Shmulewitz. As part of the Settlement, we will
retain our exclusive global rights to our intellectual property portfolio, patents, know-how and technologies and are released from all
alleged commitments, claims and royalties related or arising out of the Dekel License Agreement, including those related to claimed core
technologies. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory
disorders and all such underlying intellectual property, which are not related to our pipeline and development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our Board of Directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board
of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The distribution of dividends
may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived
over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will
prevent a company from satisfying its existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See Item 10.E. &#8220;Taxation&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this Annual Report, has occurred in our operations since the date of our consolidated financial statements
included in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Offer and Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are listed
on the Nasdaq Capital Market, trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Plan of Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are traded
on the Nasdaq under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Selling Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Dilution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Expenses of the Issue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Share Capital </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Memorandum and Articles of Association </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this Annual Report. The information called for by this Item is set forth
in Exhibit 2.1 to this Annual Report on Form 20-F and is incorporated by reference into this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Material Contracts </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
material contract within the two years prior to the date of this Annual Report, other than contracts entered into in the ordinary course
of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221; above, &#8220;Item 4.B. Business
Overview&#8221; above, &#8220;Item 5.A. Operating Results&#8221; above, or &#8220;Item 7.B. Related Party Transactions&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of
war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_050"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Taxation. </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ISRAELI TAX CONSIDERATIONS AND GOVERNMENT PROGRAMS
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also contains a description of
material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference to its effect
on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative interpretation,
there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The discussion is not
intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our Ordinary Shares.
Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as well as any tax consequences
that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident companies
are generally subject to corporate tax, currently at the rate of 23% of a company&#8217;s taxable income. Capital gains derived by an
Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a corporation will be
considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the
control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Encouragement of Research, Development
and Technological Innovations in the Industry Law, 5744-1984</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Innovation Law,
research and development programs which meet specified criteria and are approved by a committee of the IIA are eligible for grants of
up to 50% of the project&#8217;s expenditure, as determined by the research committee, and subject to the benefit track under which the
grant was awarded. A company that receives a grant from the IIA, or a grant recipient, is typically required to pay royalties from the
revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a research
and development program funded by the IIA. Under the regular benefits tracks, the royalties are generally at a range of 3% to 5% of revenues
until the entire IIA grant is repaid, together with an annual accrued interest. Under the regulations of the Innovation Law, grants received
before January 1, 1999, bear no interest. Grants received before June 30, 2017, bear an annual interest rate that applied at the time
of the approval of the applicable IIA file, and that interest rate will apply to all of the funding received under that IIA approval.
Grants received from the IIA after June 30, 2017, bear an annual interest rate based on the 12-month Secured Overnight Financing Rate,
or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%. Grants approved after January 1, 2024, bear the higher
interest rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation to pay royalties
is contingent on actual income generated from such products and services. In the absence of such income, no payment of such royalties
is required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Innovation
Law also require that the manufacture of products developed with IIA grants be performed in Israel. The transfer of manufacturing activity
outside Israel is subject to the prior approval of the IIA (such approval is not required for the transfer of a portion of the manufacturing
capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outside of Israel in the applications
for funding, in which case only notification is required). It should be noted that the terms of the Innovation Law do not restrict the
export of products that incorporate the funded know-how. Under the regulations of the Innovation Law, assuming we receive approval from
the IIA to manufacture our IIA-funded products outside Israel, our liability to the IIA may be increased to between 120% and 300% of the
grants we received from IIA depending upon the manufacturing volume that is performed outside of Israel. For grant applications submitted
to the IIA after October 25, 2023, the maximum increased liability in connection with manufacturing outside of Israel is up to 150% of
the IIA grants, plus interest accrued thereon, instead of 300%.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the manufacturing is performed
outside of Israel, the rate of royalties payable by us on revenues from the sale of products manufactured outside of Israel will increase
by 1% over the regular rates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The know-how developed within
the framework of the IIA plan may not be transferred or licensed to third parties outside Israel without the prior approval of the IIA.
The approval, however, is not required for the export of any products developed using grants received from the IIA. The IIA approval to
transfer know-how created, in whole or in part, in connection with an IIA-funded project(s) to a third party outside Israel is subject
to payment of a redemption fee to the IIA calculated according to a formula provided under the Innovation Law that is based, in general,
on the ratio between the aggregate IIA grants and our aggregate research and development investments in the project that was funded by
these IIA grants, multiplied by the transaction consideration taking into account a depreciation mechanism (if applicable), and less royalties
already paid to the IIA. According to regulations promulgated under the Innovation Law, the maximum amount payable to the IIA in case
of transfer of know-how outside Israel shall not exceed six times the amount of the grants received plus interest, with a possibility
to reduce such payment to up to three times the amount of the grants received plus interest if the grant recipient undertakes to continue
the research and development activity in Israel for a period of at least three years after the transfer of knowhow, and maintain at least
75% of the research and development employees the company had for the six months before the know-how was transferred, subject to additional
conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transfer or licensing of know-how
to an Israeli entity is subject to the IIA prior approval and to an undertaking of the recipient Israeli entity to undertake all the transferor&#8217;s
obligations to the IIA and to comply with the provisions of the Innovation Law and related regulations, including the restrictions on
the transfer and licensing of know-how and the obligation to pay royalties, as further described in the Innovation Law and related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions under the
Innovation Law will continue to apply even after we repay the full amount of royalties payable pursuant to the grants. In addition, the
government of the State of Israel may from time to time audit sales of product candidates which it claims incorporate technology funded
via IIA programs and this may lead to additional royalties being payable on additional product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may impair
our ability to outsource manufacturing or research and development activities or otherwise transfer or license our know-how outside Israel
and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties or other payments
to the IIA. If we fail to comply with certain restrictions under the Innovation Law, we may be subject to mandatory repayment of grants
received by us (together with interest and penalties), as well as be exposed to criminal charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed, partially, through grants that we have received from the IIA. We therefore must comply with the requirements
of the Innovation Law and related regulations. Our total outstanding obligation to the IIA, respectively, including the interest accrued
through December 31, 2024, amounts to approximately $1.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures, including capital expenditures, in scientific research in the fields of industry,
agriculture, transportation or energy, for the year in which they are incurred. Expenditures are deemed related to scientific research
and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance.
Expenditures not so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time we may apply
the IIA for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance
that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Law for the Encouragement of Capital Investments, 5719-1959</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in
production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investment Law was significantly
amended effective April&#160;1, 2005 (which we refer to as the 2005 Amendment), further amended as of January&#160;1, 2011 (which we refer
to as the 2011 Amendment) and further amended as of January 1, 2017 (which we refer to as the 2017 Amendment). Pursuant to the 2005 Amendment,
tax benefits granted in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force
but any benefits granted subsequently are subject to the provisions of the 2005 Amendment. Similarly, the 2011 Amendment introduced new
benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However,
companies entitled to benefits under the Investment Law as in effect prior to January&#160;1, 2011 were entitled to choose to continue
to enjoy such benefits, provided that certain conditions are met, or elect instead irrevocably to forego such benefits and have the benefits
of the 2011 Amendment apply. The 2017 Amendment introduced new benefits for Technological Enterprises, alongside the existing tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital Gains</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gain tax is imposed
on the disposal of capital assets by an Israeli resident, and on the disposal of such assets by a non-Israeli resident if those assets
are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly
or indirectly, rights to assets located in Israel, unless a tax treaty between Israel and the seller&#8217;s country of residence provides
otherwise. The Ordinance, distinguishes between &#8220;Real Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Gain is the excess
of the total capital gain over Inflationary Surplus. Inflationary Surplus is computed generally on the basis of the increase in the Israeli
Consumer Price Index or, in certain circumstances, according to the change in the foreign currency exchange rate, between the date of
purchase and the date of disposal. Inflationary Surplus is not subject to tax in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain accrued by individuals
on the sale of our Ordinary Shares will be taxed at the rate of 25%. However, if the shareholder claims deduction of interest and linkage
differences expenses in connection with the purchase and holding of such shares or the individual shareholder is a &#8220;Significant
Shareholder&#8221; (i.e., a person who holds, directly or indirectly, alone or together with such person&#8217;s relative or another person
who collaborates with such person on a permanent basis, based on a written contract, 10% or more of one of the Israeli resident company&#8217;s
&#8220;means of control&#8221; including, among other things, the right to company profits, voting rights, the right to the company&#8217;s
liquidation proceeds and the right to appoint a company director) at the time of sale or at any time during the preceding 12 months period,
such gain will be taxed at the rate of 30%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain derived by corporations
will be generally subject to the regular corporate tax rate (23% in 2024).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual and corporate shareholder
dealing in securities in Israel for whom the income from the sale of securities is considered &#8220;business income&#8221; as defined
in Section 2(1) of the Ordinance are taxed at the tax rates applicable to business income- 23% for corporations in 2024 and a marginal
tax rate of up to 47% in 2024 for individuals, unless the benefiting provisions of an applicable tax treaty applies. Certain Israeli institutions
who are exempt from tax under Section 9(2) or Section 129(C)(a)(1) of the Ordinance (such as exempt trust fund, pension fund) may be exempt
from capital gains tax from the sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Capital Gains Taxes is
Applicable also to Non-Israeli Resident Shareholders</i>. A non-Israeli resident (whether an individual or a corporation) who derives
capital gains from the sale of shares in an Israeli resident company may be exempt from Israeli capital gain tax so long as the following
cumulative conditions are met: (i) the shares were purchased upon or after the registration of the securities on a recognized stock exchange,
outside of Israel (such as Nasdaq) (ii) the seller does not have a permanent establishment in Israel to which the derived capital gain
is attributed, and (iii) with respect to securities listed on a recognized stock exchange outside of Israel, such shareholders are not
subject to the Israeli Income Tax Law (Inflationary Adjustments) 5745-1985. However, non-Israeli corporation will not be entitled to the
foregoing exemptions if Israeli residents (a) have a controlling interest of more than 25% in such non-Israeli corporation, or (b) are
the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly and indirectly.
In addition, such exemption would not be available to a person whose gains from selling or otherwise disposing of the securities are deemed
to be business income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If not exempt, a&#160;non-Israeli&#160;resident
would generally be subject to tax on capital gain at the ordinary corporate tax rate (23% in 2024) if generated by a company, or at the
rate of 25%, if generated by an individual, or 30%, if generated by an individual who is a &#8220;Significant Shareholder&#8221;, at the
time of sale or at any time during the preceding&#160;12-month&#160;period (or if the shareholder claims a deduction for interest and
linkage differences expenses in connection with the purchase and holding of such shares). Individual and corporate shareholders dealing
in securities in Israel are taxed at the tax rates applicable to business income (a corporate tax rate for a corporation and a marginal
tax rate of up to 47% for an individual in 2024) unless contrary provisions in a relevant tax treaty applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a sale of shares
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to
Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder
who is a United States resident (for purposes of the United States-Israel Tax Treaty) holding the shares as a capital asset and is entitled
to claim the benefits afforded to such a resident by the United States.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt
from Israeli capital gains tax unless either: (i) the capital gain arising from such sale, exchange or disposition is attributed to real
estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the
capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment of the shareholder which is
maintained in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more
of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (v) such Treaty
U.S. Resident, if an individual, was present in Israel for a period or periods of 183 days or more in the aggregate during the relevant
taxable year. In any such case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent applicable;
however, under the United States-Israel Treaty, a U.S. resident would be permitted to claim a credit for the Israeli tax against the U.S.
federal income tax imposed with respect to the sale, exchange or disposition, subject to the limitations in U.S. laws applicable to foreign
tax credits. The United States-Israel Treaty does not provide such credit against any U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration may be subject to the
withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains
in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an
Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable
for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority
to confirm their status as non-Israeli residents, and, in the absence of such declarations or exemptions, may require the purchaser of
the shares to withhold taxes at source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either the purchaser, the
Israeli stockbrokers or financial institution through which the shares are held is obliged, subject to the above mentioned exemptions,
to withhold tax on the amount of consideration paid upon the sale of securities from the Real Gain at the rate of 25% for individuals
and 23% for corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the sale of securities
traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advance payment must be made
on January 31 and July 31 of every calendar year in respect of sales of securities made within the previous six months. However, if all
tax due was withheld at source according to applicable provisions of the Ordinance and regulations promulgated thereunder, the aforementioned
return need not be filed and no advance payment must be paid. Capital gains are also reportable on the annual income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A distribution of dividends
from an Israeli company to an Israeli resident individual, will generally be subject to income tax at a rate of 25%. However, a 30% tax
rate will apply if the dividend recipient is a Significant Shareholder (as defined above in this section) at the time of distribution
or at any time during the preceding 12 months period. If the recipient of the dividend is an Israeli resident corporation, generally,
such dividend will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within
Israel (although, if such dividends are subsequently distributed to individuals, the aforesaid will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-Israeli residents (whether
individuals or a corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our Ordinary Shares at
the rate of 25% or 30% with respect to a Significant Shareholder (as defined above) at the time of receiving the dividend or on any time
during the preceding twelve months. Such dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares
are registered with a Nominee Company (whether the recipient is a Significant Shareholder or not). For example, under the United States-Israel
Tax Treaty, the rate of tax withheld at source in Israel on dividends paid to a holder of our Ordinary Shares who is a Treaty U.S. Resident
is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by an Approval/Beneficial/Preferred Enterprise
(as defined under the Investment Law), that are paid to a United States corporation holding 10% or more of the outstanding voting capital
throughout the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more
than 25% of the gross income for such preceding year consists of certain types of dividends and interest. The aforementioned rates will
not apply if the dividend income was generated through a permanent establishment of the U.S. resident in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-Israeli resident who
receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such
income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other
taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) the taxpayer is not obligated
to pay excess tax (as further explained below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Excess Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals who are subject
to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax at
a rate of 3% on annual income exceeding a certain threshold NIS 721,560 for 2024, which amount is linked to the annual changes to the
Israeli Consumer Price Index(with the exception that based on Israeli new legislation such amount, and certain other statutory amounts
will not be linked to the Israeli consumer price index for the years 2025-2027)including, but not limited to income derived from dividends,
interest and capital gains. According to new legislation, in effect as of January 1, 2025, an additional 2% excess tax is imposed on Capital-Sourced
Income (defined as income from any source other than employment income, business income or income from &#8220;personal effort&#8221;),
to the extent that the Individual&#8217;s Capital Sourced Income exceeds the specified threshold of NIS 721,560 (and regardless of the
employment/business income amount of such individual). This new excess tax applies, among other things, to income from capital gains,
dividends, interest, rental income, or the sale of real property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-residents of Israel who
hold our Ordinary Shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of
our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax
is generally required to have been paid or withheld on these amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law presently does
not impose estate or gift taxes if the Israeli Tax Authority is satisfied that the gift was made to an Israeli resident individual in
good faith and on condition that the recipient of the gift is not a non-Israeli resident. If the gift giver is a non-Israeli resident
individual, then he should be exempted under the aforementioned capital gains tax exemptions provided for a regular sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE
CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &#8220;U.S. Holder&#8221; is a
holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien individual who is a
lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2)
a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that
is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United States
or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income for
U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision
over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; or
(5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our Ordinary Shares. This summary generally considers only U.S. Holders that will own our
Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences
to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder.
This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S.
Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including with respect to the TCJA
of 2017), and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change, possibly
on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS with regard to
the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders and, therefore, can provide no assurances
that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local, excise or foreign tax
considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank,
life insurance company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a
broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection with employment or other
performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our Ordinary
Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for
U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that
expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional currency
other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly
or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the U.S. federal income tax
treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares through a partnership or other pass-through
entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends Paid on our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder will be required
to include in gross income as ordinary income the amount of any distribution paid on our Ordinary Shares (including the amount of any
Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated
earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and
profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s tax basis for the Ordinary Shares to
the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal income
tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend
income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty
satisfies this requirement, and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends will not qualify
for the preferential rate if we are treated, in the year the dividend is paid or in the prior year, as a PFIC, as described below under
&#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder
has not held our Ordinary Shares for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend
date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days
during which the U.S. Holder has diminished its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding
period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Code section 163(d)(4)
will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property distributed, and for U.S.
federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included
in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible
in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such
U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain
or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of the Disposition of our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
Ordinary Shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s
tax basis for the Ordinary Shares in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent
determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency).
The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares will be long-term capital gain or loss if the
U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains
may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain realized by a U.S. Holder
on a sale, exchange or other disposition of our Ordinary Shares will generally be treated as U.S. source income for U.S. foreign tax credit
purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of our Ordinary Shares is generally allocated to
U.S. source income. The deductibility of a loss realized on the sale, exchange or other disposition of our Ordinary Shares is subject
to limitations. An additional 3.8% net investment income tax (described below) may apply to gains recognized upon the sale, exchange or
other taxable disposition of our Ordinary Shares by certain U.S. Holders who meet certain income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Passive Foreign Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: .5in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that we
would be deemed a PFIC for 2025. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections
of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value
of our Ordinary Shares. Accordingly, there can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our Ordinary Shares at a gain: (1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the Ordinary Shares, as the case may be; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to
each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for
that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each
such other taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the
tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would
be equal to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also
be subject to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held our Ordinary Shares while
we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain
a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. Therefore, the QEF election will not be available
with respect to our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders
are strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain adjustments
under the PFIC rules, U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their
net investment income (including dividends on and gains from the sale or other disposition of our Ordinary Shares), or in the case of
estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent
the U.S. Holder&#8217;s total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Consequences for Non-U.S. Holders of Ordinary
Shares </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally will not be subject
to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be subject
to U.S. federal income tax on a dividend paid on our Ordinary Shares or gain from the disposition of our Ordinary Shares if: (1) such
item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States and, if required by
an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2) in
the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present in the United States for 183 days or more
in the taxable year of the disposition and other specified conditions are met. Any dividend income or gain described in clause (1) above
will be subject to U.S. federal income tax on a net income tax basis in the same manner as a U.S. Holder and, with respect to corporate
holders, a branch profits tax imposed at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) may
also apply to its effectively connected earnings and profits (subject to adjustments). Any dividend income or gain described in clause
(2) above that is not effectively connected with the conduct by a Non-U.S. Holder of a trade or business within the U.S. generally will
be subject to 30% withholding tax (or such lower rate as may be specified by an applicable income tax treaty) net of certain U.S. source
capital losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if payment is made through a
paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related
person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable IRS Form W-8 (or a substantially
similar form) certifying its foreign status, or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup withholding
from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary Shares. In general,
backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will
not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding
is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that
the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Dividends and Paying Agents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Statement by Experts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>H. Documents on Display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports
with the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC will also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited interim financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at http://www.scisparc.com. Information contained on, or that can be accessed through, our website and the other websites referenced above
do not constitute a part of this Annual Report. We have included these website addresses in this Annual Report solely as inactive textual
references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_054"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. Subsidiary Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>J. Annual Report to Security Holders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. However, a substantial majority of our cash is held in current bank accounts that do not bear
interest. In the future, we intend to hold most of our cash in deposits that bear interest. Given the current low rates of interest we
receive, once we begin to hold most of our cash in deposits that bear interest, we do not expect to be adversely affected if such rates
are reduced. Our market risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following
paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our results of operations
and cash flow are subject to fluctuations due to changes mainly in NIS/U.S. dollar currency exchange rates. As of December 31, 2024, the
vast majority of our liquid assets are held in U.S. dollars, and the majority of our expenses is denominated in U.S. dollars. Changes
of both 5% and 10% in the U.S. Dollar/NIS exchange rate would decrease/increase our loss for 2024 by less than 1%, respectively. However,
these historical figures may not be indicative of future exposure, as we expect that the percentage of our NIS denominated expenses will
materially decrease in the near future, therefore reducing our exposure to exchange rate fluctuations. Our functional currency is the
U.S. dollar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not hedge our foreign
currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure
from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us
from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2024, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act.
Our internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with IFRS. We have a program for the review of our internal
control over financial reporting to ensure compliance with the requirements of the Exchange Act and Section 404 of the Sarbanes-Oxley
Act. Our internal control over financial reporting includes those policies and procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting
as of December 31, 2024. In conducting its assessment of internal control over financial reporting, management based its evaluation on
the Internal Control&#8201;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of December 31, 2024. Based on its evaluation, our management has concluded that our internal control over financial reporting was
effective as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable (we are exempt
from this requirement due to our status under the Exchange Act as a non-accelerated filer as of the current time).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the members of our
audit committee are &#8220;independent,&#8221; as such term is defined under Nasdaq rules. In addition, our Board of Directors has determined
that Amnon Ben Shay is an audit committee financial expert, as defined under the rules under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Ethics and Conduct is posted on our website
at http://www.scisparc.com. Information contained on, or that can be accessed through, our website does not constitute a part of this
Annual Report and is not incorporated by reference herein. If we make any amendment to the Code of Ethics and Conductor grant any waivers,
including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment or waiver on our website to
the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form 20-F. We have not granted any
waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Kost Forer Gabbay &amp; Kasierer
(a member of EY Global), served as our principal independent registered public accounting firm for each of the two years ended December
31, 2023 and 2024. Kost Forer Gabbay &amp; Kasierer (a member of EY Global) has served as our principal independent registered public
accounting firm since 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Kost Forer Gabbay &amp; Kasierer and/or other member firms of EY Global for all services, including
audit services, for the years ended December 31, 2023 and 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">155,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">155,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">281,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">267,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">(1)</td>
    <td style="text-align: justify">Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">(2) </td>
    <td>Includes professional services rendered in connection with the fees relating to our public equity offerings and related filings. &#160; Includes professional </td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">(3)</td>
    <td>services rendered in connection with the audit of our Israeli tax return report.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All of the services provided above were
approved by our audit committee and by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee charter
provides, among others, that our audit committee is responsible for: (1) pre-approving audit and non-audit services provided to us by
the independent registered public accounting firm; (2) reviewing and approving disclosures relating to fees and non-audit services required
to be included in the SEC reports; and (3) establishing pre-approval policies and procedures for the engagement of independent accountants
to render us services. Subject to the Board of Directors&#8217; and shareholders&#8217; approval, if and to the extent required by applicable
law, the audit committee shall have the authority to approve all audit engagement fees and terms and all non-audit engagements, as may
be permissible, with the independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer&#8221;, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on this &#8220;foreign
private issuer exemption&#8221; with respect to the following items:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160; &#160;</td>
    <td style="width: 24px; text-align: justify">&#9679;</td>
    <td style="text-align: justify">Quorum. While the Nasdaq rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s common voting stock, as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding common voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 15% of the voting rights present in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of any number of shareholders present in person or by proxy.</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px">&#9679;</td>
    <td style="text-align: justify">Shareholder approval.&#160;Although the Nasdaq rules generally require shareholder approval of equity compensation plans and material amendments thereto, we follow Israeli practice, which is to have such plans and amendments approved only by the board of directors, unless such arrangements are for the compensation of chief executive officer or directors, in which case they also require the approval of the compensation committee and the shareholders. In addition, rather than follow the Nasdaq rules requiring shareholder approval for the issuance of securities in certain circumstances, we follow Israeli law, under which a private placement of securities requires approval by our board of directors and shareholders if it will cause a person to become a controlling shareholder (generally presumed at 25% ownership) or if: (a) the securities issued amount to 20% or more of our outstanding voting rights before the issuance; (b) some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and (c) transaction will increase the relative holdings of a shareholder that holds 5% or more of our outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5% of our outstanding share capital or voting rights.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive Sessions</i>. The Nasdaq rules require that independent directors of a Nasdaq listed company must meet regularly in executive session (without members of management present), and such executive sessions should occur at least twice a year. In this regard we have elected to adopt the practices of our home country, Israel, which does not require independent directors to meet regularly in executive sessions separate from the full board of directors<i>. </i></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination of our directors</i>. Nasdaq rules require director nominations of a Nasdaq listed company to be made or recommended solely by independent directors and the director nominations process be addressed by a formal written charter or board resolution. We follow the requirements of Israeli law, which does not require us to have a formal written charter addressing the director nominations process. The nominations for directors, which are presented to shareholders by a board of directors, are generally made by the board of directors itself, in accordance with the provisions of the Companies Law. Nominations need not be made by a nominating committee of a board of directors consisting solely of independent directors or by a vote consisting solely of our independent directors in order to determine which persons shall be nominated for election by our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We otherwise intend to comply
with the rules generally applicable to U.S. domestic companies listed on Nasdaq. We may, however, in the future decide to rely upon the
&#8220;foreign private issuer exemption&#8221; for purposes of opting out of some or all of the other corporate governance rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-28374">adopted</ix:nonNumeric> an&#160;insider
trading policy governing the purchase, sale and other transactions in our securities that applies to our directors, senior management,
employees, consultants, contractors and other covered persons, including immediate family members and entities controlled by any of the
foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This policy prohibits, among
other things, insider trading and certain speculative transactions in our securities (including short sales, buying put and selling call
options and other hedging or derivative transactions in our securities) and establishes a regular blackout period schedule during which
directors, senior management, employees, and other covered persons may not trade in our securities, as well as certain pre-clearance procedures
that our directors and officers, our subsidiaries and/or affiliates must observe prior to effecting any transaction in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that this policy&#160;is
reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and listing standards applicable
to us. A copy of this policy&#160;is filed as Exhibit 11.1 to this Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY.</b>&#160;&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-15508"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors
recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and
employees. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-28375">Our IT general controls cybersecurity policies, standards, processes and practices are fully&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-28376">integrated</ix:nonNumeric>&#160;into
our risk management approach.</ix:nonNumeric>&#160;In general, we seek to address IT general controls cybersecurity risks through a comprehensive,
cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we
collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity
incidents when they occur.</p></ix:nonNumeric><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risk Management and Strategy</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the critical elements of our overall risk management approach,
our cybersecurity program is focused on the following key areas:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governance: As discussed in more detail under the heading &#8220;Governance,&#8221; our management oversees our cybersecurity risk management and interacts with our Sarbanes-Oxley Act, or SOX, advisor and  our Information Security advisor and other relevant members of management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative Approach: we have implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical Safeguards: we deploy technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery Planning: we have established and maintains comprehensive recovery plans that fully address our response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Education and Awareness: We provide regular, mandatory training for personnel regarding cybersecurity threats as a means to equip our personnel with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engage in the periodic assessment and testing of our policies, standards,
processes and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities,
including audits, assessments, tabletop exercises, threat modeling, vulnerability evaluation, and other exercises focused on evaluating
the effectiveness of our cybersecurity measures and planning. We are engaged with a subcontractor that monitors the IT system and cybersecurity,
including centralized patch management as part of their routine job functions. We regularly engage&#160;third parties&#160;to perform
assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our
information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported
to the board of directors, and we adjust our cybersecurity policies, standards, processes and practices as necessary based on the information
provided by these assessments, audits and reviews.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Governance</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management interacts with our SOX advisor and our Information
Security advisor and other relevant members of management.&#160;Our Information&#160;Security advisor&#160;is responsible for assessing
and managing cyber risk management, informs senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity
incidents and supervises such efforts. Our Information&#160;Security advisor&#160;has experience selecting, deploying, and operating cybersecurity
technologies, initiatives, and processes, and relies on threat intelligence as well as other information obtained from governmental, public
or private sources.&#160;The board of directors receives updates on IT general controls, and a set of policies and procedures that govern
how our IT systems operate and ensure the confidentiality, integrity, and availability of data as well as on cybersecurity risks, including
prevention of data theft, unauthorized access, operational disruption, and data breaches. Our management also receives prompt and
timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding
any such incident until it has been addressed. On an annual basis, our management discusses our approach to IT general controls and
cybersecurity risk management with our SOX advisor.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 23, 2025,&#160;we do not believe that we have experienced
any cybersecurity attack. Cybersecurity threats and cybersecurity incidents, if they occur, can materially affect or are reasonably likely
to affect us, including its business strategy, results of operations or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>
</div><div><a id="a_078"></a></div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements and the related notes required by this Item are included in this Annual Report beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. EXHIBITS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="9" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation by Reference</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/<br/>
Furnished</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999ex3-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Association of SciSparc Ltd.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269839&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 16, 2023&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023748901ex2-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020038984/ea130376ex4-2_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 24, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-4_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-6_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Share Purchase Warrant, pursuant to Securities Purchase Agreement, dated May 27, 2022</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 34%"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Promissory Note between SciSparc Ltd. and YA II PN Ltd, which includes the Repayment Schedule (Exhibit 1)</span></a></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390017004433/f20f2016ex4xii_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2017</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/f20f2020ex4-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exculpation Agreement</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023026713/ea176389ex10-3_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, dated March 22, 2023, by and between Jeffs&#8217; Brands Ltd and SciSparc Nutraceuticals Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 4, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex10-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby Equity Purchase Agreement dated January 21, 2024, between YA II PN Ltd. and  SciSparc Ltd.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-22_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the Standby Equity Purchase Agreement, dated as of February 26, 2024, between SciSparc Ltd. and YA II PN, Ltd</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390016017994/ff12016ex10v_therapix.htm">Israeli Share Option Plan</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-214458</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 4, 2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-7_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Share Incentive Plan (2023)</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024032202/ea020369701ex99-2_scisparc.htm">Form of Shareholder Support Agreement, dated April 10, 2024, by and between SciSparc Ltd. and each of the parties named therein.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 11, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024053324/ea020795601ex10-24_scisparc.htm">Loan Agreement, dated January 14, 2024, by and between SciSparc Ltd. and AutoMax Motors Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024053324/ea020795601ex10-25_scisparc.htm">Amendment to the Loan Agreement, dated June 9, 2024, by and between SciSparc Ltd. and Polyrizon Ltd.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024070407/ea021152801ex10-1_scisparc.htm">Exclusive Patent License Agreement, dated August 13, 2024, between SciSparc Ltd. and Polyrizon Ltd.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 19, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-4_scisparc.htm">Second Amendment to the Loan Agreement, dated September 5, 2024, by and between SciSparc Ltd. and AutoMax Motors Ltd.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282351</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 26, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex10-5_scisparc.htm">Loan Agreement, dated February 24, 2025 by and between SciSparc Ltd. and AutoMax Motors Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex4-1_scisparc.htm">Form of Convertible Debenture</a></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex4-2_scisparc.htm">Ordinary Shares Purchase Warrant</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex10-1_scisparc.htm">Form of Securities Purchase Agreement between SciSparc Ltd. and each of the investors listed on the Schedule of Buyers therein</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex10-2_scisparc.htm">Securities Purchase Agreement between SciSparc Ltd. and YA II PN, Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19 &#160; </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex10-3_scisparc.htm">Global Guaranty Agreement, dated February 25, 2025, by Brain Bright Ltd. and Evero Health Ltd. in favor of an investor.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001- 38041 </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025 </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20 &#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025017996/ea023226601ex10-4_scisparc.htm">Registration Rights Agreement, dated February 25, 2025, by and between an investor and SciSparc Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001- 38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025019407/ea023280701ex10-1_scisparc.htm">Securities Purchase and Exchange Agreement, dated February 25, 2025, by and among N2OFF, Inc., MitoCareX Bio Ltd., SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri.</a> &#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001- 38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 3, 2025</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024032202/ea020369701ex99-1_scisparc.htm">Agreement and Plan of Merger, dated April 10, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd.</a> </span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 11, 2024</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.23</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024069144/ea021145102ex99-1_scisparc.htm">Addendum to the Agreement and Plan of Merger, dated August 14, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; ">
    <td>4.24</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024113993/ea022624601ex2-4_scisparc.htm">Second Addendum to the Agreement and Plan of Merger, dated November 26, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4/A</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282351</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.25</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023748901ex4-25_scisparc.htm">Third Addendum to the Agreement and Plan of Merger, dated March 27, 2025, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex21-1_scisparcltd.htm">List of Subsidiaries</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023748901ex11-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023748901ex12-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023748901ex13-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023748901ex15-1_scisparc.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, independent registered accounting firm for the Registrant.&#160;&#160;</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024028859/ea020288201ex97-1_scisparc.htm">Clawback Policy</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 10%">101.INS</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 34%">Inline XBRL Instance Document.</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 8%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 6%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 18%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.SCH</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document.</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.CAL</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.DEF</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Definition Linkbase Document.</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.LAB</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Label Linkbase Document.</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.PRE</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>104</td>
    <td>&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCISPARC LTD.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date April 24, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 82 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: top; width: 90%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID&#160;<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-28377">1281</ix:nonNumeric>)</b></span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Financial Position</b></span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4 - F-5</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Comprehensive Loss</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Changes in Equity</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7 </b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Cash Flows</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8 - F-10</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></a></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11 - F-53</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 188; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: center; vertical-align: top; width: 33%"><img alt="" src="image_001.jpg" style="width: 61px; height: 72px"/></td>
    <td style="vertical-align: bottom; width: 34%"><b>Kost Forer Gabbay &amp; Kasierer</b><br/>
 144 Menachem Begin Road, <br/>
Tel-Aviv 6492102, Israel</td>
    <td style="vertical-align: bottom; width: 33%">Tel: +972-3-6232525<br/>
 Fax: +972-3-5622555 <br/>
ey.com</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-16842"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024
and 2023, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the
period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities, and has stated that
substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events
and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matters
communicated below are matters arising from the current period audit of the financial statements that were communicated or required to
be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter
in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 76%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 1 to the consolidated financial
    statements, the Company has incurred losses since inception, and expects to continue to incur losses for the foreseeable future. At December
    31, 2024, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for
    at least a year beyond the date of the issuance of the consolidated financial statements. Those factors raise substantial doubt about
    the Company&#8217;s ability to continue as a going concern.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determined the Company&#8217;s ability to continue
    as a going concern is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s future cash
    flows and the risk of bias in management&#8217;s judgments and assumptions in estimating these cash flows to conclude the Company would
    have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated financial statements.
    This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addressing the matter involved performing procedures
and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements.&#160;Our audit procedures
included testing the reasonableness of the forecasted revenue, operating expenses, and uses and sources of cash used in management&#8217;s
assessment of whether the Company has sufficient liquidity to fund operations for at least one year from the consolidated financial statement
issuance date. This testing included inquiries with management, consideration of positive and negative evidence impacting management&#8217;s
forecasts, the Company&#8217;s financing arrangements in place as of the report date, market and industry factors, we evaluated management&#8217;s
analysis of their impact on the forecasted cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assessed the adequacy of the Company&#8217;s
    going concern disclosures included in Note 1 to the consolidated financial statements.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fair value of loan to Automax (a related party) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 23%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><i>Description of the Matter</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><i>&#160;</i></p></td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: left; width: 76%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 24 to the consolidated financial
statements, the Company entered into a Bridge Loan Agreement with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), which is considered a related
party, under which the Company provided a total loan amount of $4,250 (the &#8220;Loan&#8221;) as of December 31, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluating the fair value of the Loan was complex and required considerable
judgment due to the significant estimates in management&#8217;s assumptions, particularly regarding the involvement of a related party.
The Company determined that the fair value of the Loan is a critical audit matter due to its materiality and the complexity involved in
assessing the fair value of the Loan under the unique terms of the agreement.</p></td></tr>
</table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 23%"><i>How We Addressed the Matter in Our Audit</i></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 76%">Our audit procedures related to the valuation of Loan to AutoMax at
fair value included the following, among others, engaging specialists with expertise in evaluating the assumptions used by management
in determining the fair value, assessing the methodology used in the valuation of the Loan, testing independent sourcing of key inputs
and assumptions, and developing independent estimates. The significant assumptions used to estimate the fair value of the Loan included
estimates of payment dates, credit spreads, volatility, share price, risk-free rate as of the valuation date, and loan cost were based
on an analysis of AutoMax&#8217;s credit portfolio and the trading data of its Series B bonds listed on the Tel Aviv Stock Exchange. This
analysis was conducted in order to derive an appropriate economic interest rate for the bridge loan. We examined the reasonableness and
adequacy of the disclosures related to the transaction within the financial statements.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-28378">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric></span></td> <td style="padding-bottom: 1.5pt; width: 20%">&#160;</td> <td style="padding-bottom: 1.5pt; width: 40%"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-16968"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv, Israel</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 24, 2025</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">A Member of EY Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2007.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28379">1,540</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28380">2,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Restricted deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28381">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28382">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28383">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-28384">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-28385">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-28386">1,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-28387">540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Investments in short-term financial assets</td><td>&#160;</td>
    <td style="text-align: center">24g</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28388">517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Bridge loan to related parties</td><td>&#160;</td>
    <td style="text-align: center">24a</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-28389">4,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-28390">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-28391">742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-28392">7,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-28393">6,445</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28394">1,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28395">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Investments in company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28396">952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28397">781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8, 24d</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28398">354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28399">659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28400">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28401">108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-28402">2,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-28403">4,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-28404">10,347</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-28405">11,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28406">816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28407">802</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28408">205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28409">185</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd">191</ix:nonFraction></td>
    <td style="white-space: nowrap">(*)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other short-term liability</td><td>&#160;</td>
    <td style="text-align: center">17e</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-28411">341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd">341</ix:nonFraction></td>
    <td style="white-space: nowrap">(*)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28413">37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28414">52</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28415">1,399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28416">1,571</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28417">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28418">24</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-28419">70,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-28420">64,526</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Reserve from share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: center">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-28421">5,746</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-28422">5,282</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-28423">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-28424">5,190</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: center">2d</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-28425">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-28426">497</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-28427">810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-28428">810</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-28429">74,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-28430">68,691</ix:nonFraction></td>
    <td style="white-space: nowrap">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-28431">8,154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-28432">7,614</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28433">785</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28434">1,973</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28435">8,939</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28436">9,587</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-28437">10,347</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-28438">11,182</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands (except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-28440">1,306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-28441">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-28442">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-28443">800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-28444">683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-28445">322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-28446">506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-28447">2,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-28448">1,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">21a</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28449">1,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28450">1,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28451">2,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: center">21b</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-28452">1,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">2,484</ix:nonFraction></td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">1,082</ix:nonFraction></td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of intangible assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28455">1,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28456">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">21c</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28457">4,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,844</ix:nonFraction></td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">5,427</ix:nonFraction></td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21d</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd" id="ixv-28460">1,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28461">7,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28462">6,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28463">8,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity losses from the investment in MitoCareX</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28464">429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28465">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28466">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">21e</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28467">612</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28468">2,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28469">7,832</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21f</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28470">353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28471">1,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28472">2,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-28473">7,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-28474">5,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-28475">2,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-28476">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-28477">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-28478">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28479">7,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28480">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28481">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Attributable to:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equity holders of the Company</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28482">6,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28483">5,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28484">2,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28485">1,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28486">761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28487">7,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28488">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28489">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Basic loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28490">1.28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28491">14.43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28492">14.82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Diluted loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28493">1.28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28494">14.43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28495">14.82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable to equity holders of the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> capital<br/> and<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserve<br/> from&#160;share-<br/> based<br/> payment<br/> transactions</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transactions<br/> with non-<br/> controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign<br/> currency<br/> translation<br/> reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-<br/> controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 32.5%; padding-bottom: 4pt">Balance at January 1, 2022</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28497">58,541</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28498">4,331</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28499">5,190</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28500">559</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28501">497</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28502">60,977</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28503">8,141</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 6%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28504">8,141</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28505">2,592</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28506">2,592</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28507">2,592</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28508">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28509">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28510">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28511">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28512">849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28513">897</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28514">897</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance at December&#160;31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28515">58,592</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28516">5,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28517">5,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28518">559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28519">497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28520">63,569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28521">6,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28522">6,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28523">5,122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28524">5,122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28525">761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28526">5,883</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28527">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28528">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28529">2,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28530">2,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of share capital in respect of investment in affiliate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-28531">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-28532">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-28533">288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of share capital, net of issue expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28534">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28535">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28536">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28537">94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28538">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28539">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28540">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance at December&#160;31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28541">64,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28542">5,282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28543">5,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28544">810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28545">497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28546">68,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28547">7,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28548">1,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28549">9,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28550">6,284</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28551">6,284</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28552">1,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28553">7,472</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of share capital, net of issue expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28554">6,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28555">6,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-28556">6,255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28557">105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28558">464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28559">569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28560">569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance at December&#160;31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28561">70,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28562">5,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28563">5,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28564">810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28565">497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28566">74,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28567">8,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28568">785</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28569">8,939</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">Loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28570">7,472</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28571">5,883</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28572">2,592</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile loss to net cash used&#160;in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to the profit or loss items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-28573">482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-28574">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-28575">187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28576">1,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28577">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Cost of share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28578">569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28579">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28580">897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Finance income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28581">897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28582">2,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28583">6,585</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Group&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28584">429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28585">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28586">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-28587">305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-28588">1,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-28589">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-28590">2,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-28591">829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28592">4,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Working capital adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-28593">535</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-28594">409</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" unitRef="usd" id="ixv-28595">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-28596">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-28597">397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-28598">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-28599">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-28600">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Increase in related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForIncreaseInRelatedParties" scale="3" unitRef="usd" id="ixv-28601">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-28602">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-28603">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-28604">77</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Decrease (increase) in inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" unitRef="usd" id="ixv-28605">629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-28606">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-28607">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-28608">136</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-28609">833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-28610">703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net cash used in operating activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28611">5,104</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28612">5,887</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28613">7,917</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 27pt">Withdrawal of (investment in) restricted bank deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28614">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28615">5</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28616">15</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Withdrawal of (investment in) short-term bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" unitRef="usd" id="ixv-28617">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-28618">3,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Sale (purchase) of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SalepurchaseOfPropertyAndEquipment" scale="3" sign="-" unitRef="usd" id="ixv-28619">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SalepurchaseOfPropertyAndEquipment" scale="3" unitRef="usd" id="ixv-28620">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in a company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28621">600</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28622">400</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28623">700</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Bridge loan to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" scale="3" unitRef="usd" id="ixv-28624">4,078</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28625">689</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28626">1,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Purchase of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28627">4,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28628">1,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28629">4,094</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28630">7,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Proceeds from issue of share capital (net of issuance expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28631">6,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28632">5,552</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28633">9,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Sale of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" scale="3" unitRef="usd">2,985</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Exercise of warrants (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-28635">2,770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of issuance expenses related to previous period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-28636">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Interest paid on lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28637">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28638">7</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28639">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Repayment of lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28640">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28641">47</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28642">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28643">6,193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28644">8,483</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28645">11,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28646">536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28647">1,498</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28648">3,301</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28649">2,076</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28650">3,574</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28651">6,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28652">1,540</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28653">2,076</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28654">3,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <span style="text-decoration:underline">Significant non-cash transactions</span>:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Right-of-use asset recognized with corresponding lease liability</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-28656">75</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-28657">102</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Investment in financial asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-28658">288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-20401"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-28659">74,975</ix:nonFraction> as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
cash and cash equivalents totaled $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28660">1,540</ix:nonFraction>. In the period ended December 31, 2024, the Company had an operating loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28661">7,316</ix:nonFraction> and negative
cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28662">5,104</ix:nonFraction>. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-20561"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_1" escape="true" name="sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" id="ixv-20573"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_2" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_3" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_4" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory" id="ixv-20594"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:OperatingTerm" id="ixv-28663">one year</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" id="ixv-20606"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-20624"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1" escape="true" name="sprcy:DescriptionOfAcquisitionOfASingleAssetCompany" id="ixv-20636"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" id="ixv-20685"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" id="ixv-20697"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" id="ixv-20737"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-20802"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory" id="ixv-20814"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28664">6</ix:nonFraction>-<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28665">50</ix:nonFraction></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-28666">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28667">33</ix:nonFraction>-<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28668">50</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-28669">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28670">7</ix:nonFraction>-<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-28671">15</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-28672">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c74" name="ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" id="ixv-28673">see below</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="ixv-20867"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-20882"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-20931"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify">3.</td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment of financial assets:</p>
</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of each reporting
period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes
between two types of loss allowances:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"/><td style="width: 48px">a)</td><td style="text-align: justify">Debt instruments whose credit risk has not increased significantly since initial recognition, or whose
credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit
losses within 12 months from the reporting date (12-month ECLs); or</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"/><td style="width: 48px">b)</td><td style="text-align: justify">Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit
risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument&#8217;s remaining
term (lifetime ECLs).</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial assets in
respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime
expected credit losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial asset in default
when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in
default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in
full.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_35" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_36" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_35"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_37" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_38" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_37"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_39" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_40" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_39"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-21270"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="ixv-21285"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-21297"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="ixv-21405"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-21495"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-21526"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-21582"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-21621"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-21644"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="ixv-21800"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="ixv-21813"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" id="ixv-21834"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" id="ixv-21877"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#8220;OPM&#8221;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest and
expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of new standards in the period prior to their adoption:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18, &#8220;Presentation and Disclosure
in Financial Statements&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In April 2024, the International Accounting
Standards Board (&#8220;the IASB&#8221;) issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;)
which replaces IAS 1, &#8220;Presentation of Financial Statements&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be classified
into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change the entity&#8217;s
operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other accounting standards,
including IAS 7, &#8220;Statement of Cash Flows&#8221; and IAS 34, &#8220;Interim Financial Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.</p></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-22054"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock" id="ixv-22064"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28674">1,383</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28675">1,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28676">157</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28677">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28678">1,540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28679">2,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-22122"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInventorieExplanatory" id="ixv-22132"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-28680">9</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-28681">73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-28682">104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-28683">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-28684">113</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-28685">742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-22190"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclourseOfAccountsReceivablesTableTextBlock" id="ixv-22200"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:Governmentauthoritiescurrent" scale="3" unitRef="usd" id="ixv-28686">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:Governmentauthoritiescurrent" scale="3" unitRef="usd" id="ixv-28687">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28688">449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28689">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-28690">350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-28691">275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivables in respect of downpayment on merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ReceivablesInRespectOfDownpaymentOnMerger" scale="3" unitRef="usd" id="ixv-28692">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-28693">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-28694">1,079</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-28695">540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="ixv-22290"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND JOINT VENTURES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $<ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-28696">700</ix:nonFraction>, and agreed to invest over the next two years, an additional $<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-28697">1,000</ix:nonFraction>, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28698">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-28699">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owns
<ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-28700">31.48</ix:nonFraction>% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-28701">400</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c85" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28702">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c86" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28703">41.92</ix:nonFraction>%.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND JOINT VENTURES  (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX - Joint Venture
    Transaction  (Cont.)</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-28704">600</ix:nonFraction> in MitoCareX and increased its share ownership in MitoCareX from <ix:nonFraction contextRef="c88" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28705">41.92</ix:nonFraction>% to <ix:nonFraction contextRef="c89" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28706">52.73</ix:nonFraction>%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInstallment" scale="3" unitRef="usd" id="ixv-28707">600</ix:nonFraction> installment to be deferred to March 25, 2024, and the $<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaid" scale="3" unitRef="usd" id="ixv-28708">600</ix:nonFraction> installment was paid on March
11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 26, 2024, the Company signed a non-binding letter of intent
relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#8220;N2OFF&#8221;) a publicly-traded company in the
United States which is a related party (the &#8220;Purchaser&#8221;). Pursuant to the terms of the letter of intent, initially, in exchange
for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-28709">27</ix:nonFraction>% of SciSparc&#8217;s ownership
in MitoCareX, SciSparc will receive cash consideration of $<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashConsideration" scale="3" unitRef="usd" id="ixv-28710">700</ix:nonFraction>. Subsequent to this first phase, SciSparc will transfer to the Purchaser
the remaining <ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchaserRemainingOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-28711">73</ix:nonFraction>% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser
equal to $<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RemainingPurchaserAmount" scale="3" unitRef="usd" id="ixv-28712">8,000</ix:nonFraction> and a valuation of MitoCareX equal to $<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RemainingPurchaserAmount" scale="3" unitRef="usd" id="ixv-28713">5,000</ix:nonFraction> (the latter of which includes the $<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashConsideration" scale="3" unitRef="usd" id="ixv-28714">700</ix:nonFraction>, in cash consideration for SciSparc&#8217;s
shares described above). The letter of intent also includes provisions for additional milestones that, upon achievement, may increase
the consideration paid by the Purchaser to SciSparc from $<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28715">5,000</ix:nonFraction> to $<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28716">7,000</ix:nonFraction>. The details of the full terms of this transaction are subject
to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company and the Purchaser have not closed the
sale of the ownership of MitoCareX and the Company still holds <ix:nonFraction contextRef="c94" decimals="4" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharePercentage" scale="-2" unitRef="pure" id="ixv-28717">52.73</ix:nonFraction>% of the issued and outstanding share capital of MitoCareX. See also
Note 25(d).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28718">429</ix:nonFraction> (for the year ended December 31, 2023
- $<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28719">210</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="ixv-22365"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsDate" scale="3" unitRef="usd" id="ixv-28720">700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28721">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28722">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfFirstMilestone" scale="3" unitRef="usd" id="ixv-28723">400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28724">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28725">781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfSecondMilestone" scale="3" unitRef="usd" id="ixv-28726">600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-28727">429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-28728">952</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory" id="ixv-22451"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Clearmind</span></i> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28729">1,500</ix:nonFraction> in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28730">230,769</ix:nonFraction> common shares of Clearmind, resulting in the Company holding <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-28731">9.33</ix:nonFraction>% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, <ix:nonFraction contextRef="c105" decimals="0" format="ixt:fixed-zero" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-28732">no</ix:nonFraction> par value, at a ratio of <ix:nonNumeric contextRef="c104" name="sprcy:ReverseShareSplitRatio" id="ixv-28733">1-for-30</ix:nonNumeric>. As a result, the Company holdings in Clearmind decreased from <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28734">230,769</ix:nonFraction> common shares to <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28735">7,692</ix:nonFraction>. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $<ix:nonFraction contextRef="c0" decimals="-1" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="3" unitRef="usdPershares" id="ixv-28736">1.38</ix:nonFraction> and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28737">11</ix:nonFraction> on its investment (for the year ended December 31, 2023 - $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28738">727</ix:nonFraction>). &#160;</p></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-22497"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AreaOfLease" scale="0" unitRef="sqm" id="ixv-28739">240</ix:nonFraction> square meters, whereby the Company occupies approximately <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AreaOfLease" scale="0" unitRef="sqm" id="ixv-28740">120</ix:nonFraction>
square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
<span style="-sec-ix-hidden: hidden-fact-94">three</span>-year term. The monthly lease fee was set at approximately $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MonthlyLeaseFee" scale="3" unitRef="usd" id="ixv-28741">3</ix:nonFraction>, linked to the NIS.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="ixv-22512"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-22522"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right of use asses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28742">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28743">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28744">181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28745">225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28746">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28747">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28748">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28749">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28750">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28751">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28752">203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28753">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28754">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28755">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28756">99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28757">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28758">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28759">106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28760">117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28761">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28762">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28763">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28764">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28765">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28766">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28767">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28768">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28769">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28770">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28771">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28772">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28773">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28774">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28775">47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28776">59</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28777">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28778">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28779">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28780">122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28781">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28782">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28783">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28784">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28785">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28786">225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28787">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28788">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28789">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28790">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28791">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28792">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28793">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28794">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28795">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28796">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28797">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28798">117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28799">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28800">28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28801">75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28802">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-28803">37</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-28804">52</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-28805">43</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-23049"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-28806">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentsOfAdditionalDeferredCash" scale="3" unitRef="usd" id="ixv-28807">1,120</ix:nonFraction> during the 12-month period following the closing of the Acquisition.
The Company paid an additional $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCostsValue" scale="3" unitRef="usd" id="ixv-28808">321</ix:nonFraction> as purchase costs.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28809">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-28810">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28811">1,344</ix:nonFraction> (as of December 31, 2023 -
$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28812">1,042</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="ixv-28813">7.8</ix:nonNumeric>
years (2023 &#8211; <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="ixv-28814">8.7</ix:nonNumeric>), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-28815">27.8</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-28816">13.8</ix:nonFraction>%) and a declining growth rate for the long term, reaching <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-28817">2</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-28818">2</ix:nonFraction>%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="sprcy:DiscountRatePercentage" scale="-2" unitRef="pure" id="ixv-28819">21.9</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="sprcy:DiscountRatePercentage" scale="-2" unitRef="pure" id="ixv-28820">20.6</ix:nonFraction>%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="ixv-23108"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28821">4,717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28822">1,042</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28823">486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28824">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28825">1,344</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28826">366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28827">1,479</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-28828">366</ix:nonFraction> (for the year ended December 31,
2023 - $<ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-28829">486</ix:nonFraction>).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-23177"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfTradePayablesExplanatory" id="ixv-23187"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-28830">608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-28831">538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetDebt" scale="3" unitRef="usd" id="ixv-28832">208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetDebt" scale="3" unitRef="usd" id="ixv-28833">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28834">816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28835">802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfOtherAccountsPayableTextBlock" id="ixv-23269"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="ixv-23279"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-28836">75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-28837">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-28838">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-28839">104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-28840">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28841">205</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28842">185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-23348"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" id="ixv-23366"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28843">1,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28844">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28845">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28846">449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28847">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-28848">4,239</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28849">6,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28850">5,344</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Investments in financial assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd" id="ixv-28851">871</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd" id="ixv-28852">659</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28853">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28854">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28855">191</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28856">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28857">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28858">123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28859">315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="ixv-23603"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison between
the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are presented
in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in short-term financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28860">354</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28861">354</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28862">517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28863">517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28864">659</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-28865">659</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28866">191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28867">191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-23860"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. <ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" id="ixv-28868">These contributions and contributions for compensation represent defined contribution plans.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28869">106</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28870">105</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28871">115</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-23919"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were <ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-28872"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-28873"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-28874">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2024, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
net carryforward tax losses are estimated to be approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:OperatingLossCarryforwardsTaxAmount" scale="3" unitRef="usd" id="ixv-28875">62,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-23986"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
<ix:nonNumeric contextRef="c0" name="sprcy:DekelLicenseAgreementDescription" id="ixv-28876">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AnnualInvestment" scale="3" unitRef="usd" id="ixv-28877">350</ix:nonFraction>. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $<ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalMilestoneAmount" scale="3" unitRef="usd" id="ixv-28878">75</ix:nonFraction>, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#8217;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#8217;s
share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $<ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentAmount" scale="3" unitRef="usd" id="ixv-28879">122</ix:nonFraction> out of a total estimated amount of
approximately $<ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28880">776</ix:nonFraction>. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $<ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28881">1,385</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $<ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28882">370</ix:nonFraction>.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital
Point (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-28883">340</ix:nonFraction> of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;).
The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint
venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary
of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company
unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue
to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="0" unitRef="ils" id="ixv-28884">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c2" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="6" unitRef="usd" id="ixv-28885">2.75</ix:nonFraction> million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-24143"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-24159"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-28886">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28887">10,828,251</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-28888">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28889">706,683</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to <ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28890">75,000,000</ix:nonFraction> ordinary shares with <span style="-sec-ix-hidden: hidden-fact-110">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, <i>inter alia</i>, a reverse split of the Company&#8217;s share
capital up to a ratio of <ix:nonNumeric contextRef="c172" name="sprcy:CapitalRatio" id="ixv-28891">30:1</ix:nonNumeric> (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28892">75,000,000</ix:nonFraction> ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-111">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be <ix:nonNumeric contextRef="c172" name="sprcy:ReverseSplitRatio" id="ixv-28893">26:1</ix:nonNumeric>, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-24280"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/> ordinary shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28894">706,683</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-28895">3,677,311</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultants" scale="0" unitRef="shares" id="ixv-28896">646,179</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectSEPA" scale="0" unitRef="shares" id="ixv-28897">5,798,078</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28898">10,828,251</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuances of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28899">923</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28900">1,423</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28901">13,858</ix:nonFraction> ordinary shares in respect
of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered into by and among Jeffs&#8217; Brands
and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also Note 25a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company issued <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28902">646,179</ix:nonFraction> ordinary shares to consultants in respect of services rendered in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-28903">105</ix:nonFraction></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-28904">10,210</ix:nonFraction> (the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of <ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-28905">136,388</ix:nonFraction> units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28906">12,885</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28907">74.88</ix:nonFraction> per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28908">123,504</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28909">73.29</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28910">68.38</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c181" format="ixt-sec:durwordsen" name="sprcy:IssuanceExpireTerm" id="ixv-28911">seven years</ix:nonNumeric> from the
date of issuance.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="ixv-24492"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28912">0</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28913">0</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28914">72</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28915">72</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28916">4.38</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28917">3.872</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28918">0.36</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28919">4.88</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28920">68.38</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28921">68.38</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-28922">192</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Less than $1 thousand</ix:footnote></td>
</tr></table></ix:nonNumeric>

<p style="margin: 0">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify">During
the year ended December 31, 2022, the Company issued <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28924">123,504</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28925">123,504</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28926">212,500</ix:nonFraction> ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28927">5.20</ix:nonFraction> per
ordinary share and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28928">37,500</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28929">5.174</ix:nonFraction> per pre-funded warrant,
for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-28930">1,300</ix:nonFraction>, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement,
the Company also granted the underwriter a 45-day option to purchase up to an additional <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28931">37,500</ix:nonFraction> ordinary shares solely to cover over-allotments,
if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $<ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28932">5,026</ix:nonFraction>, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of <ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28933">1,930,108</ix:nonFraction> units, each unit consisting of two pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;).
The Pre-Funded Warrants have an exercise price of $<ix:nonFraction contextRef="c189" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28934">0.001</ix:nonFraction>, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company issued <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28935">3,677,311</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28936">3,677,311</ix:nonFraction> Pre-Funded Warrants.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SaleOrIssueOfTreasuryShares" scale="3" unitRef="usd" id="ixv-28937">20,000</ix:nonFraction> of the Company&#8217;s ordinary shares (the &#8220;Advance Shares&#8221;). As of December
31, 2024, of the $<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-28938">20,000</ix:nonFraction> eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold <ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SaleOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-28939">5,742,785</ix:nonFraction>
ordinary shares for total proceeds of $<ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-28940">6,255</ix:nonFraction>. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of <ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePriceRate" scale="-2" unitRef="pure" id="ixv-28941">97</ix:nonFraction>% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#8217;s ordinary shares
during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $<ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-28942">5,000</ix:nonFraction> (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of <ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-28943">5</ix:nonFraction>% per annum, increasing to
<ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-28944">18</ix:nonFraction>% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InstallmentPayment" scale="-2" unitRef="pure" id="ixv-28945">10</ix:nonFraction>% of the original principal amount of the Promissory Note and accrued interest,
payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such notice against
an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment
amount shall also include a payment premium in the amount of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PaymentForPremiumPercentage" scale="-2" unitRef="pure" id="ixv-28946">5</ix:nonFraction>% of the principal amount of the installment payment. The Promissory Note
contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the
SEPA, the Company issued to YA an aggregate of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateIssuedAmount" scale="0" unitRef="shares" id="ixv-28947">55,293</ix:nonFraction> of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of
the commitment fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-28948">200</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-24717"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" id="ixv-24735"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28949">45</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28950">34</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28951">264</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28952">524</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28953">162</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28954">633</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28955">569</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28956">196</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28957">897</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span>The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span>issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-117">1,000,0000</span> Ordinary Shares. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-28958">6,851</ix:nonFraction> Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28959">169</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" id="ixv-24911"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying ordinary share price</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28960">129.74</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28961">174.98</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28962">0</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28963">0</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28964">133</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28965">134</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28966">2.00</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28967">1.46</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of Share Options (years)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-28968">6</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-28969">6</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-28970">158.34</ix:nonFraction> per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $<ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-28971">114.66</ix:nonFraction> per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end at
April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2024, share-based compensation in respect of Share Options of $<ix:nonFraction contextRef="c202" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28972">7</ix:nonFraction> was charged to the consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, the Company issued consultants <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28973">646,179</ix:nonFraction> ordinary shares in respect of services rendered. The shares were granted at a discount rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-28974">25</ix:nonFraction>% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $<ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-28975">105</ix:nonFraction>. </span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-25094"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-28976">7,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28977">166.28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-28978">6,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28979">350.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-28980">6,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28981">350.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-28982">7,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28983">166.14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-28984">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28985">144.55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-28986">7,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28987">166.28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-28988">5,869</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28989">165.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-28990">2.99</ix:nonNumeric> years and <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-28991">4.03</ix:nonNumeric> years as of December 31, 2024, and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NumberOfOptionsOutstanding" scale="3" unitRef="usd" id="ixv-28992">169</ix:nonFraction> - $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NumberOfOptionsOutstanding" scale="3" unitRef="usd" id="ixv-28993">21,179</ix:nonFraction> (inclusive) as of December 31, 2024, and 2023, respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">c.</td><td style="text-align: justify">Restricted Share Units:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: justify">On June 20, 2024, the Company granted <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-28994">530,000</ix:nonFraction> Restricted Share
Units (&#8220;RSUs&#8221;) to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s
discretion and taking into account personal tax implications and convert into <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConvertIntoOrdinaryShares" scale="0" unitRef="shares" id="ixv-28995">530,000</ix:nonFraction> ordinary shares of the Company. The RSUs vest on
a quarterly basis over a period of <ix:nonNumeric contextRef="c205" format="ixt-sec:durwordsen" name="sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" id="ixv-28996">two years</ix:nonNumeric>, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted
share price of the Company on June 20, 2024, which was $<ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28997">0.893</ix:nonFraction>.</td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: justify">On August 8, 2024, the Company granted <span style="-sec-ix-hidden: hidden-fact-118">530</span>,000RSUs to directors
and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account
personal tax implications and convert into <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConvertIntoOrdinaryShares" scale="0" unitRef="shares" id="ixv-28998">530,000</ix:nonFraction> ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of
<ix:nonNumeric contextRef="c206" format="ixt-sec:durwordsen" name="sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" id="ixv-28999">two years</ix:nonNumeric>, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August
8, 2024, which was $<ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29000">0.316</ix:nonFraction>.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="ixv-25336"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">RSUs granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-29001">1,060,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expiry of RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercise of RSUs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29002">1,060,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Total exercisable RSUs as of December
31, 2024, are <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29003">265,000</ix:nonFraction>. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $<ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29004">456</ix:nonFraction> was charged to the
Consolidated Statements of Comprehensive Loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-25407"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s Brand sells products
directly to customers mainly through the Brand&#8217;s online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024, the
allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right of return
asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" id="ixv-25423"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Purchased goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29005">798</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29006">672</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29007">301</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29008">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29009">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29010">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29011">800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29012">683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-29013">322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-25537"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="ixv-25547"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>a.</td>
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 61%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29014">390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29015">392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29016">436</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29017">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29018">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29019">264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29020">681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29021">719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29022">750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29023">211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29024">101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29025">703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29026">276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29027">254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29028">369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29029">104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29030">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29031">281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29032">1,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29033">1,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29034">2,803</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>b.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Sales and marketing expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Advertising</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29035">367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29036">576</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29037">363</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29038">495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">1,042</ix:nonFraction></td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">454</ix:nonFraction></td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29041">366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29042">486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29043">144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Storage and shipping</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29044">167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">145</ix:nonFraction></td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">91</ix:nonFraction></td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29047">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29048">235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c252" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29049">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29050">1,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29051">2,484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-29052">1,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>c.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29053">507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29054">415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29055">437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29056">419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29057">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29058">633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29059">3,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c254" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29060">2,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c255" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29061">2,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29062">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29063">86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29064">161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29065">158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29066">202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c261" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29067">162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29068">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29069">110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29070">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29071">197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29072">369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c267" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29073">1,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29074">4,526</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29075">3,844</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29076">5,427</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>d.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Other expenses (income):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Loss from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-29077">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c270" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-29078">1,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-29079">1,270</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>e.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c272" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29080">191</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29081">2,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c274" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29082">7,832</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Interest from loans to related parties and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29083">421</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c278" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29084">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29085">612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29086">2,219</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-29087">7,832</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>f.</td>
    <td style="font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29088">1,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29089">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c282" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29090">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29091">305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29092">1,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29093">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29094">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29095">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29096">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29097">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29098">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29099">353</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29100">1,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-29101">2,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 231; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-26347"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-26363"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_EarningsPerShareExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29102">5,824,972</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29103">7,472</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29104">407,681</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29105">5,883</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29106">175,953</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29107">2,592</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-29108">5,824,972</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29109">7,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-29110">407,681</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29111">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-29112">175,953</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-29113">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 232; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-26656"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried out
according to the results of the segment&#8217;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-26674"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO of
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29114">1,306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29115">1,306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29116">1,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29117">1,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29118">4,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29119">2,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29120">7,316</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equity losses from the investment in MitoCareX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromTheInvestment" scale="3" unitRef="usd" id="ixv-29121">429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-29122">259</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-29123">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-29124">7,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29125">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29126">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29127">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29128">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29129">5,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29130">1,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29131">6,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-29132">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-29133">1,164</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-29134">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-29135">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Drug Development Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the year ended December 31, 2024, the Company
recognized other income in the amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="0" unitRef="usd" id="ixv-29136">1,288</ix:nonFraction> as a result of a sale of an intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Online Sales Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="0" unitRef="usd" id="ixv-29137">1,344</ix:nonFraction> (as of December 31, 2023 - $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="0" unitRef="usd" id="ixv-29138">1,042</ix:nonFraction>).</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1"><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-size: 10pt">External</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29139">1,347</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-29140">1,347</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29141">1,347</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-29142">1,347</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29143">8,405</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-29144">118</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-29145">8,287</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-29146">109</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-29147">5,818</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-29148">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-29149">2,592</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29150">8,407</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29151">1,764</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29152">10,171</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29153">1,194</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29154">226</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29155">1,420</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29156">7,069</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29157">4,113</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29158">11,182</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29159">1,441</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29160">154</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-29161">1,595</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="ixv-27623"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_RelatedPartyBalancetextBlock-c0_cont_1" escape="true" name="sprcy:RelatedPartyBalancetextBlock" id="ixv-27639"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_RelatedPartyBalancetextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CurrentAsset" scale="3" unitRef="usd" id="ixv-29162">15</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CurrentAsset" scale="3" unitRef="usd" id="ixv-29163">121</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-29164">4,224</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-29165">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c326" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-29166">55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-29167">245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-29168">95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-27762"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-29169">63</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-29170">40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-29171">208</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SaleOfMinorityInterestInSubsidiary" scale="3" unitRef="usd" id="ixv-29172">2,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-27820"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29173">765</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29174">1,204</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29175">1,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-29176">120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-29177">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29178">157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29179">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29180">779</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c303" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestPercentage" scale="-2" unitRef="pure" id="ixv-29181">49</ix:nonFraction>% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution, for $<ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-29182">2,500</ix:nonFraction> in cash, and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DeferredCashPayment" scale="3" unitRef="usd" id="ixv-29183">489</ix:nonFraction> accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately <ix:nonFraction contextRef="c305" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-29184">51</ix:nonFraction>% of the share capital of SciSparc US.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, at the closing
of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides
management services to SciSparc US for the Wellution brand for a monthly fee of $<ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-29185">20</ix:nonFraction> and Jeffs&#8217; Brands received a one-time signing
bonus in the amount of $<ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmountReceived" scale="3" unitRef="usd" id="ixv-29186">51</ix:nonFraction>. The consulting agreement is for an undefined period of time and may be terminated by either party with 30
days advance notice. On November 2023 the monthly fee reduced to $<ix:nonFraction contextRef="c306" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-29187">10</ix:nonFraction> thousand. For the year ended December 31, 2024, the Company has
recorded management services expenses in the amount of $<ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-29188">120</ix:nonFraction> (for the year ended December 31, 2023 - $<ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-29189">220</ix:nonFraction>).</p></td></tr>
</table></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND
    BALANCES WITH RELATED PARTIES  (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_2" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $<ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-29190">288</ix:nonFraction> of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AcquiredOrdinaryShares" scale="0" unitRef="shares" id="ixv-29191">35,345</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired <ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AcquiredOrdinaryShares" scale="0" unitRef="shares" id="ixv-29192">13,858</ix:nonFraction> ordinary shares of the Company having an aggregate value of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValues" scale="3" unitRef="usd" id="ixv-29193">288</ix:nonFraction> which was adjusted from $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValueAdjusted" scale="3" unitRef="usd" id="ixv-29194">300</ix:nonFraction> according to the <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-29195">4.99</ix:nonFraction>% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#8217;s Brands on Nasdaq was $ <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ListedSharePrice" scale="0" unitRef="usdPershares" id="ixv-29196">2.57</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-29197">17</ix:nonFraction> on its investment (for the year ended December 31, 2023 -$<ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-29198">180</ix:nonFraction>).<br/>
<br/>
Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementAmount" scale="3" unitRef="usd" id="ixv-29199">63</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementAmount" scale="3" unitRef="usd" id="ixv-29200">40</ix:nonFraction>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c311" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="usd" id="ixv-29201">1.5</ix:nonFraction> million in Clearmind
in connection with its initial public offering on the Nasdaq Capital Market, in exchange for <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeOfCommonShares" scale="0" unitRef="shares" id="ixv-29202">7,692</ix:nonFraction> common shares of Clearmind, representing
<ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-29203">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind (see also Note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, the Company&#8217;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify">On August 13, 2024, the Company entered into the license agreement
(the &#8220;License Agreement&#8221;) of the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;), with Polyrizon Ltd. (the
&#8220;Licensee&#8221; or &#8220;Polyrizon&#8221;). According to the License Agreement, the Company granted the Licensee a royalty-bearing,
exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received
and will receive certain shares of the Licensee, reflecting an issue price of $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LicenseeIssuePrice" scale="3" unitRef="usd" id="ixv-29204">805</ix:nonFraction>, and royalties from sales related to and income generated
from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones
relating to the Assets. <br/>
<br/>
Pursuant to the terms of the License Agreement, the Company is entitled to up to $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MilestonesAmount" scale="3" unitRef="usd" id="ixv-29205">3,320</ix:nonFraction> based on the achievement of certain milestones, including <ix:nonNumeric contextRef="c312" name="sprcy:LicenseAgreementDescription" id="ixv-29206">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.</ix:nonNumeric> Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of <ix:nonFraction contextRef="c312" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfAggregateNetSales" scale="-2" unitRef="pure" id="ixv-29207">5</ix:nonFraction>%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. <br/>
<br/>
On October 31, 2024, following an initial public offering of the Licensee, the Company received <ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-29208">684,931</ix:nonFraction> units, of which (i) <ix:nonFraction contextRef="c314" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-29209">320,000</ix:nonFraction> units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-29210">4.38</ix:nonFraction> (<ix:nonFraction contextRef="c316" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-29211">960,000</ix:nonFraction> warrants in total); and (ii) <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-29212">364,931</ix:nonFraction> units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c318" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-29213">4.38</ix:nonFraction> (<ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-29214">1,094,793</ix:nonFraction> warrants in total). Altogether, the Company received <ix:nonFraction contextRef="c315" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-29215">320,000</ix:nonFraction> ordinary shares, <ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-29216">364,931</ix:nonFraction> pre-funded warrants to purchase one ordinary share of the Licensee, and <ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-29217">2,054,793</ix:nonFraction> warrants to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c320" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-29218">4.38</ix:nonFraction>. &#160; <br/>
<br/>
On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of <ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-29219">1,541,096</ix:nonFraction> Licensee common warrants to third parties, for aggregate consideration of $<ix:nonFraction contextRef="c322" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-29220">771</ix:nonFraction>. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; <br/>
<br/>
As of December 31, 2024, the Company holds <ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfWarrantsHolds" scale="0" unitRef="shares" id="ixv-29221">513,698</ix:nonFraction> warrants to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-29222">4.38</ix:nonFraction>. The warrants expire on <ix:nonNumeric contextRef="c323" format="ixt:date-monthname-day-year-en" name="sprcy:WarrantsExpireDate" id="ixv-29223">October 31, 2029</ix:nonNumeric>. The value of the warrants on December 31, 2024, is $<ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-29224">517</ix:nonFraction>.<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer, is a director
of the Licensee.</p>
</td></tr>
</table></ix:continuation><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 236; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND
    BALANCES WITH RELATED PARTIES  (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfRelatedPartyExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"><i>General Overview of Valuation Approaches used in the Valuation:</i>
&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-28052"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in">The warrants&#8217; fair value
was calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated,
in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29225">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c320" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29226">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29227">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c320" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29228">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c323" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29229">2.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c320" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29230">4.15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price of Polyrizon Ltd. ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29231">0.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c320" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29232">4.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29233">4.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c320" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29234">4.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-29235">517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-29236">1,399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, SciSparc and AutoMax
entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated
by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second
addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred
to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right
to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the effective time of the Merger (the &#8220;Effective Time&#8221;,
as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#8217;s share capital will be converted into the
right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;).
Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the
Company) are expected to hold together approximately <ix:nonFraction contextRef="c325" decimals="4" format="ixt:num-dot-decimal" name="sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage" scale="-2" unitRef="pure" id="ixv-29237">49.99</ix:nonFraction>% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate
number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of
the Company, together with the holders of the Company&#8217;s convertible securities, immediately before the Merger are expected to hold
together approximately <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage" scale="-2" unitRef="pure" id="ixv-29238">50.01</ix:nonFraction>% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject
to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;),
and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised
of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall
be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 237; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" id="ixv-28164"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 25:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"/> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#8220;Miza&#8221;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#8220;Target Assets&#8221;)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement is based on the approximate total $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EnterpriseValue" scale="3" unitRef="usd" id="ixv-29239">3,300</ix:nonFraction> (CAD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="sprcy:EnterpriseValue" scale="6" unitRef="cad" id="ixv-29240">4.5</ix:nonFraction> million) enterprise value of Miza, when including its $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-29241">1,000</ix:nonFraction> cash position, and an approximate $<ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-29242">11,600</ix:nonFraction> (CAD <ix:nonFraction contextRef="c331" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="6" unitRef="cad" id="ixv-29243">15.8</ix:nonFraction> million) value of the Company&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for <ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-29244">63,300,000</ix:nonFraction> common shares of Miza and up to <ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-29245">48,000,000</ix:nonFraction> Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately <ix:nonFraction contextRef="c333" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-29246">75</ix:nonFraction>% to a maximum of <ix:nonFraction contextRef="c332" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-29247">84.53</ix:nonFraction>%, will be active in both the pharmaceutical and supplement sectors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28, 2025, the Company entered into a second amendment (the &#8220;Miza Amendment&#8221;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.</p></td></tr>
</table></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 238; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-28213"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2025, the Company announced that it has reached a settlement
agreement (the &#8220;Settlement&#8221;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa
District Court against six of the Company&#8217;s former directors (the &#8220;Defendants&#8221;) case number 34426-02-22 (the &#8220;Suit&#8221;).
The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior
acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $<ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-29248">411</ix:nonFraction> cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#8220;License Agreement&#8221;). As part of the Settlement, Dekel clarified, to SciSparc&#8217;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#8217;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#8217;s pipeline and development program.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $<ix:nonFraction contextRef="c335" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-29249">2,000</ix:nonFraction> loan (the &#8220;New Loan&#8221;). The funding will support AutoMax&#8217;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $<ix:nonFraction contextRef="c336" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateLoanAmount" scale="3" unitRef="usd" id="ixv-29250">4,250</ix:nonFraction> (the &#8220;Previous Loans&#8221;). The Previous Loans were provided in lieu of SciSparc&#8217;s obligation to provide a $<ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateLoanAmount" scale="3" unitRef="usd" id="ixv-29251">4,250</ix:nonFraction> closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan, bearing an <ix:nonFraction contextRef="c338" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-29252">8</ix:nonFraction>% annual interest rate, will be repaid in equal monthly installments of $<ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaidOfMonthlyInstallments" scale="3" unitRef="usd" id="ixv-29253">50</ix:nonFraction> and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#8217;s shares.</p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company entered into securities purchase agreements (the &#8220;Securities Purchase Agreements&#8221;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#8220;Debentures&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NotionalAmount" scale="3" unitRef="usd" id="ixv-29254">4,200</ix:nonFraction> (the &#8220;Subscription Amount&#8221;), which are convertible into the Company&#8217;s ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221; and, as converted, the &#8220;Conversion Shares&#8221;), at a purchase price equal to <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePercentage" scale="-2" unitRef="pure" id="ixv-29255">95</ix:nonFraction>% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of <ix:nonFraction contextRef="c342" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-29256">8</ix:nonFraction>%, which will increase to an annual rate of <ix:nonFraction contextRef="c343" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-29257">18</ix:nonFraction>% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" scale="-2" unitRef="pure" id="ixv-29258">110</ix:nonFraction>% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" scale="-2" unitRef="pure" id="ixv-29259">95</ix:nonFraction>% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (<ix:nonNumeric contextRef="c341" format="ixt-sec:durday" name="sprcy:ConsecutiveTradingDays" id="ixv-29260">20</ix:nonNumeric>) consecutive trading days immediately preceding the conversion date or other date of determination (the &#8220;Market Price&#8221;); provided that the Market Price may not be lower than the floor price, which will be equal to <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" scale="-2" unitRef="pure" id="ixv-29261">20</ix:nonFraction>% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing of the transaction, the Company issued to the investors
<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfWarrantsIssued" scale="0" unitRef="shares" id="ixv-29262">3,615,656</ix:nonFraction> warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors
divided by a price equal to <ix:nonFraction contextRef="c345" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" scale="-2" unitRef="pure" id="ixv-29263">130</ix:nonFraction>% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or
$<ix:nonFraction contextRef="c344" decimals="4" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePricePerWarrant" scale="0" unitRef="usdPershares" id="ixv-29264">0.5532</ix:nonFraction> per warrant. The warrants are exercisable for a term of <ix:nonNumeric contextRef="c341" format="ixt-sec:durwordsen" name="sprcy:WarrantExercisableTerm" id="ixv-29265">five years</ix:nonNumeric> from the issuance date.</p></td></tr>
<tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr>
<tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">d.</td> <td style="text-align: justify"><span>On April 1, 2025, we entered
into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested
$<ix:nonFraction contextRef="c346" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-29266">100,000</ix:nonFraction> (out of an aggregate investment of approximately $<ix:nonFraction contextRef="c346" decimals="-6" format="ixt:num-dot-decimal" name="sprcy:AggregateInvestment" scale="6" unitRef="usd" id="ixv-29267">17</ix:nonFraction> million), in exchange for ordinary shares and Series A warrants to purchase
ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing
ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></td></tr>
</table></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 239; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE
    REPORTING DATE   (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px">&#160;</td> <td style="text-align: justify">The Company entered into a global guaranty
agreement (the &#8220;Global Guaranty Agreement&#8221;) with one of the investors (the &#8220;Investor&#8221;) through certain of the
Company&#8217;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#8217;s obligations under the Debenture with
the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.<br/>
<br/>
The Company
entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the
Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act
of 1933, as amended (the &#8220;Act&#8221;) and the rules and regulations promulgated thereunder, and applicable state securities laws.<br/>
<br/>
In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#8220;Deed&#8221;) with
AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $<ix:nonFraction contextRef="c347" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-29268">2,000</ix:nonFraction>
to AutoMax in lieu of making the payment under the Loan Agreement (the &#8220;Loan Agreement&#8221;) to which the Company entered into
with AutoMax on February 24, 2025.</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company announced it has signed a definitive
agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO)
(&#8220;N2OFF&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell <ix:nonFraction contextRef="c348" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-29269">4,961</ix:nonFraction> shares of MitoCareX to N2OFF for $<ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-29270">700</ix:nonFraction> and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFullyDilutedCapitalStock" scale="-2" unitRef="pure" id="ixv-29271">40</ix:nonFraction>% of the company&#8217;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#8217;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#8217;s control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to <ix:nonFraction contextRef="c350" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFullyDilutedCapitalStock" scale="-2" unitRef="pure" id="ixv-29272">25</ix:nonFraction>% of N2OFF&#8217;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFinancingProceeds" scale="-2" unitRef="pure" id="ixv-29273">30</ix:nonFraction>% of N2OFF&#8217;s financing proceeds over five years, up to a maximum of $<ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-29274">1,600</ix:nonFraction>. N2OFF has also committed to investing $<ix:nonFraction contextRef="c351" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-29275">1,000</ix:nonFraction> in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of <ix:nonFraction contextRef="c340" decimals="2" format="ixt:num-dot-decimal" name="sprcy:RestrictedStockGrantPercentage" scale="-2" unitRef="pure" id="ixv-29276">5</ix:nonFraction>% of N2OFF&#8217;s capital stock, vesting over <ix:nonNumeric contextRef="c341" format="ixt-sec:durwordsen" name="sprcy:VestingPeriod" id="ixv-29277">three years</ix:nonNumeric>. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - -
- -</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">F-53</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>













































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="ifrs-full:CurrentWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-8" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-9" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-10" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-11" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-12" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-14" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-15" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-16" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-17" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-18" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-19" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-20" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-21" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-22" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-23" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-25" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-26" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-27" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-28" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-29" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-30" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-31" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-32" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-33" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-34" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-35" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-36" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-37" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-38" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-39" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-40" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-41" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-42" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-43" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-44" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-45" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-46" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-47" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-48" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-49" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-50" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-51" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-52" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-53" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-54" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-55" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-56" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-57" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-58" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-59" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-60" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-61" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-62" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-63" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-64" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-65" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-66" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-67" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-68" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-69" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-70" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-71" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-72" name="sprcy:AdjustmentsForIncreaseInRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-73" name="sprcy:AdjustmentsForIncreaseInRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-74" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-75" name="sprcy:SalepurchaseOfPropertyAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-77" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-78" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-79" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-80" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-84" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-87" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-89" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-90" name="sprcy:LeaseholdImprovementsMainlyRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-91" name="sprcy:ReceivablesInRespectOfDownpaymentOnMerger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-92" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-93" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c108" id="hidden-fact-94" name="sprcy:OptionToExtendLeaseTerm">P3Y</ix:nonNumeric>
<ix:nonFraction contextRef="c114" id="hidden-fact-95" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-96" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-97" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-98" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-99" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-100" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-101" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-102" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c159" id="hidden-fact-103" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-104" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c159" id="hidden-fact-105" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-106" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-107" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-108" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-109" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-110" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-111" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-112" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-114" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-115" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-116" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c198" decimals="0" id="hidden-fact-117" name="ifrs-full:NumberOfSharesIssued" unitRef="shares">10000000</ix:nonFraction>
<ix:nonFraction contextRef="c206" decimals="0" id="hidden-fact-118" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="pure">530000</ix:nonFraction>
<ix:nonFraction contextRef="c269" id="hidden-fact-119" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c271" id="hidden-fact-120" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-121" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c276" id="hidden-fact-122" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-123" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c279" id="hidden-fact-124" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c280" id="hidden-fact-125" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c278" id="hidden-fact-126" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-127" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-128" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-129" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-130" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-131" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-132" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-133" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c293" id="hidden-fact-134" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c293" id="hidden-fact-135" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c295" id="hidden-fact-136" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c295" id="hidden-fact-137" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c297" id="hidden-fact-138" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c297" id="hidden-fact-139" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c326" id="hidden-fact-140" name="sprcy:CurrentAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c328" id="hidden-fact-141" name="sprcy:CurrentAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c326" id="hidden-fact-142" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c328" id="hidden-fact-143" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c329" id="hidden-fact-144" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c326" id="hidden-fact-145" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c327" id="hidden-fact-146" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c328" id="hidden-fact-147" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c329" id="hidden-fact-148" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-149" name="sprcy:SaleOfMinorityInterestInSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-150" name="sprcy:SaleOfMinorityInterestInSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-151" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-29432">0001611746</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-29433">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-29434">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="sprcy-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact ix_4_fact ix_5_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-109" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_7_fact ix_8_fact ix_9_fact ix_10_fact" toRefs="ix_4_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-11</xbrli:startDate>
    <xbrli:endDate>2024-03-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-21</xbrli:startDate>
    <xbrli:endDate>2023-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-13</xbrli:startDate>
    <xbrli:endDate>2019-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-04-11</xbrli:startDate>
    <xbrli:endDate>2017-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-27</xbrli:startDate>
    <xbrli:endDate>2022-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dc5kA5J/7v3cgprmjEDX50MSDBw7v3azgA==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-15</xbrli:startDate>
    <xbrli:endDate>2022-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-18</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-02</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-22</xbrli:startDate>
    <xbrli:endDate>2023-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PreFundedUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-30</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-20</xbrli:startDate>
    <xbrli:endDate>2024-06-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-08</xbrli:startDate>
    <xbrli:endDate>2024-08-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-10</xbrli:startDate>
    <xbrli:endDate>2022-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-31</xbrli:startDate>
    <xbrli:endDate>2024-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-13</xbrli:startDate>
    <xbrli:endDate>2024-08-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:SaleOfStockAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-30</xbrli:startDate>
    <xbrli:endDate>2024-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea023748901ex2-1_scisparc.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of SciSparc Ltd.&rsquo;s (the &ldquo;Company&rdquo;) share capital and provisions of the amended and restated articles of association
(the &ldquo;Articles&rdquo;) are summaries and do not purport to be complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration number and purposes of the Company</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registration number with
the Israeli Registrar of Companies is 51-358165-2. Our purpose as set forth in our Articles is to engage in any lawful activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Type and class of securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share capital
consists of 75,000,000 ordinary shares, of no par value (the &ldquo;Ordinary Shares&rdquo;). All of our outstanding Ordinary Shares have
been validly issued, are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preemptive rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are not
redeemable and are not subject to any preemptive right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer of shares</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our fully paid Ordinary Shares
are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our Ordinary
Shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership
by nationals of certain countries that are, or have been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liability to further capital calls</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Election of directors</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our board
of directors must consist of at least three (3) and not more than eight (8) directors, including, if applicable, two external directors
appointed as required under the Companies Law 5759-1999 (the &ldquo;Companies Law&rdquo;). Other than our external directors (if any),
our directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible,
of one third of the total number of directors constituting the entire board of directors. At each annual general meeting of our shareholders,
the election or re-election of directors following the expiration of the term of office of the directors of that class of directors is
for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2020 and
after, at each annual general meeting the term of office only one class of directors will expire. Each director, holds office until the
annual general meeting of our shareholders for the year in which his or her term expires and until his or her successor is duly appointed,
unless the tenure of such director expires earlier pursuant to the Companies Law upon the occurrence of certain events or unless removed
from office by a vote of the holders of at least 65% of the total voting power of our shareholders at a general meeting of our shareholders
in accordance with our amended and restated Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further<FONT STYLE="background-color: white">,&nbsp;our&nbsp;</FONT>shareholders&nbsp;<FONT STYLE="background-color: white">approved
an approval mechanism similar to a mechanism that exists in the Delaware Generate Corporate Law, which requires an affirmative vote of
the board of directors (by 75% of the members) in addition to the approval of our shareholders in order to amend such provisions.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the board of directors shall not
be permitted to act, other than for the purpose of convening a general meeting of the Company&rsquo;s shareholders for the purpose of
appointing additional Directors. For further information on the election and removal of directors see &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&rdquo; of the Company&rsquo;s annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contested election</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, in the
event of a contested election, our board of directors in its discretion, will set the method of calculation of the votes and the manner
in which the resolutions will be presented to our shareholders at the general meeting. In the event that our board of directors does not
or is unable to make a determination on such matter, then the directors will be elected by a plurality of the voting power represented
at the general meeting in person or by proxy and voting on the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend and liquidation rights</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our Ordinary Shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions
are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&rsquo;s Articles
provide otherwise. Our Articles do not require shareholder approval of a dividend distribution and provide that dividend distributions
may be determined by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court approval;
as a company listed on an exchange outside of Israel, however, court approval is not required if the proposed distribution is in the form
of an equity repurchase, provided that we notify our creditors of the proposed equity repurchase and allow such creditors an opportunity
to initiate a court proceeding to review the repurchase. If within 30 days such creditors do not file an objection, then we may proceed
with the repurchase without obtaining court approval. In each case, we are only permitted to distribute a dividend if our board of directors
and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our Ordinary Shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exchange controls</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a
state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder meetings</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such
time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors
is required to convene a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our
board of directors or (ii) as a company listed on an exchange in the U.S., one or more shareholders holding, in the aggregate, either
(a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 10% or more of our outstanding
voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel, a matter relating to the appointment
or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting
of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date
of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting
of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">amendments to our Articles;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">appointment or termination of our auditors;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">appointment of external directors;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">approval of certain related party transactions;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">increases or reductions of our authorized share capital;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">mergers; and</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the exercise of our board of directors&rsquo; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual general meeting or extraordinary general meeting be provided to shareholders at least 21 days
prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with
office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must
be provided at least 35 days prior to the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting rights</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting rights</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All our Ordinary Shares have identical voting and
other rights in all respects.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Quorum requirements</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Articles,
holders of our Ordinary Shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at
a general meeting. The quorum required for our general meetings of shareholders consists of at least two shareholders, present in person
or by proxy, holding at least fifteen percent (15%) of the voting rights of the Company. A meeting adjourned for lack of a quorum will
be adjourned for one day at the same time and place, or to such other day, time or place if such is stated in the notice of the meeting.
At the reconvened meeting, if a quorum is not present within a half an hour, any number of shareholders present in person or by proxy
will constitute a lawful quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Vote requirements</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6. Directors, Senior Management
and Employees</FONT>&mdash;C. Board Practices&mdash;Approval of Related Party Transactions under Israeli Law&mdash;Disclosure of Personal
Interests of a Controlling Shareholder&rdquo; of the Company&rsquo;s annual report on Form 20-F. Certain transactions with respect to
remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Approval of Related Party Transactions under Israeli
Law&mdash; Disclosure of Personal Interests of an Office Holder&rdquo; of the Company&rsquo;s annual report on Form 20-F. Another exception
to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization,
of the company pursuant to Section 350 of the Companies Law, which requires the approval of the majority of the shareholders voting their
shares, other than abstainees, holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting
deed and voting on the resolution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Articles amendment</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to amend the Articles,
in addition and prior to the approval of a general meeting of shareholders, the approval of the board of directors with the affirmative
vote of at least three-quarters (3/4) of the directors then in office and entitled to vote thereon is required in order to approve any
amendment to the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Access to corporate records</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our Articles, our
financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel
Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring
shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has
not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modification of class rights</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our Articles, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be amended by adoption
of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance
with the rights attached to such class of shares, as set forth in our Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisitions under Israeli law</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Full tender offer</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s shareholders for the purchase of all of
the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a tender offer is not accepted
in accordance with the requirements set forth above, the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Special tender offer</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already
another holder of at least 25% of the voting rights in the company. Alternatively, such an acquisition may be approved pursuant to a private
placement approved by the company&rsquo;s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or more of
the company&rsquo;s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made
by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting
rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject
to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability of the offer, or shall
abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the
board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding
the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such
person&rsquo;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the
target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the
purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Merger</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements described under the Companies
Law are met, by a majority vote of each party&rsquo;s shares, and, in the case of the target company, a majority vote of each class of
its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to
the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger,
the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the
shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in
concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders (as described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash;Approval of Related Party Transactions under Israeli
law&mdash;Disclosure of Personal Interests of a Controlling Shareholder&rdquo; of the Company&rsquo;s annual report on Form 20-F).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would have
been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain
shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the value to&nbsp;the parties to the merger
and the consideration offered to the shareholders of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders
of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Majority Board Approvals</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, at least
three-quarters (3/4) of our serving directors are required to vote in favor of certain transactions which may have a significant effect
on the Company&rsquo;s structure, assets or business, including mergers acquisitions, consolidations and issuance of equity securities
or debt securities convertible into equity in each case that would reasonably be expected to result in change of beneficial ownership
of above than fifteen percent (15%) in the Company, material changes to the principal business of the Company and any resolution to transfer
the headquarters of the Company outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approval of business combinations</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles restrict certain
business transactions with any shareholder and/or its affiliates and/or investors for a period of three years following (i) with respect
to any shareholder of the Company holding fifteen percent (15%) or more of the voting power of the ordinary shares as of September 15,
2022, the effective date of the Articles, and (ii) with respect to all shareholders of the Company, each time as such shareholder and/or
any of its affiliates and/or investors become(s) (other than due to a buyback, redemption or cancellation of shares by the Company) the
holder(s) (beneficially or of record) of fifteen percent (15%) or more of the issued and outstanding voting power of the ordinary shares.
The restricted business transactions include mergers, consolidations and dispositions of assets with an aggregate market value equal to
10% or more of the Company&rsquo;s assets or outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Borrowing powers</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in capital</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution
duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the
declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board
of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forum for adjudication of disputes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our Articles,
the federal district courts of the United States of America, shall be the exclusive forum for the resolution of any complaint asserting
a cause or causes of action arising under the U.S. Securities Act of 1933, as amended, including all causes of action asserted against
any defendant to such complaint. The competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or
proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer
or other employee of the Company to the Company or the Company&rsquo;s shareholders, or (iii) any action asserting a claim arising pursuant
to any provision of the Companies Law or the Securities Law 5728-1968. The Company retains the ability to consent to an alternative forum
in circumstances where the Company determines that its interests and those of its shareholders are best served by permitting a particular
dispute to proceed in a forum other than the federal district courts or State of Israel, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer agent and registrar</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
transfer agent and registrar is Vstock Transfer LLC (&ldquo;Vstock&rdquo;). Vstock&rsquo;s address is 18 Lafayette Place, Woodmere, New
York 11598 and its telephone number is (212) 828-8436.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.26
<SEQUENCE>3
<FILENAME>ea023748901ex4-25_scisparc.htm
<DESCRIPTION>THIRD ADDENDUM TO THE AGREEMENT AND PLAN OF MERGER, DATED MARCH 27, 2025, BY AND BETWEEN SCISPARC LTD. WITH AUTOMAX MOTORS LTD., AND SCISPARC MERGER SUB LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.25</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum no. 3<BR>
<I>to<BR>
</I><U>AGREEMENT AND PLAN OF MERGER</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>&nbsp;</U></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This addendum, dated March 27, 2025 (the &ldquo;<B>Effective
Date</B>&rdquo;) constitutes addendum no. 3 (the &ldquo;<B>Addendum</B>&rdquo;) to that certain Agreement and Plan Of Merger dated April
10, 2024, as amended by Addendum No. 1 dated August 14, 2024, and Addendum No. 2 dated November 26, 2024 (hereinafter together, the &ldquo;<B>Agreement</B>&rdquo;),
by and between, SciSparc Ltd., an Israeli limited company (the &ldquo;<B><I>Parent</I></B>&rdquo;), SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of Parent (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), and AutoMax Motors Ltd., an Israeli limited
company (the &ldquo;<B><I>Company</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63.8pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Parties wish to modify and amend certain provisions set forth in the Agreement, all as further stipulated
herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE,</B> the parties hereto agree
to amend the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify; padding-right: 35.4pt"><U>Amendment of End Date</U>:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">Notwithstanding
Section 9.1(b) of the Agreement, the End Date shall be extended from March 31, 2025, to September 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify; padding-right: 35.4pt"><U>Amendment of Exhibit A &ndash; Certain Definitions:</U></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The definition
of &ldquo;Exchange Ratio&rdquo; shall revised as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&ldquo;<B><I>Exchange Ratio</I></B>&rdquo;
means, subject to Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;&lrm;</FONT>1.5(h), the result of the following
calculation <STRIKE>(rounded to four decimal places)</STRIKE>: the number of the Parent Outstanding Shares divided by 0.5001 multiplied
by 0.4749 divided by (the number of the Company Outstanding Shares less the number of the Company Ordinary Shares set forth in the Parent
Ownership Certificate); so that, in any event, immediately following the Effective Time, holders of Company Outstanding Shares (other
than the Parent) and Parent Pre-Funded Warrants issued hereunder will hold together 49.99%, minus the Finder Fee, of the Parent Outstanding
Shares, immediately following the Effective Time, all which shall be calculated in accordance with the example of the calculation set
forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;&lrm;</FONT>1.6(a) of the Parent Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify; padding-right: 35.4pt"><U>General</U></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.1.</TD><TD STYLE="text-align: justify">Any and all provisions, terms and/or conditions contained
in the Agreement shall continue in full force and effect, unless and to the extent otherwise expressly provided herein which provisions
will supersede any such provisions of the Agreement. In the event of a conflict or inconsistency between the terms of the Agreement,
previous addendums/amendments (if any), and the terms of this Addendum, the terms of the latter shall govern and prevail.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.2.</TD><TD STYLE="text-align: justify; padding-right: 4.25pt">This Addendum shall be deemed for all intents and purposes an integral part of
the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.3.</TD><TD STYLE="text-align: justify; padding-right: 4.25pt">Terms used but not defined herein shall have the meanings assigned to such terms
in the Agreement. </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Signature page to follow]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF,</B> the undersigned have
caused this Addendum to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white"><B>SCISPARC LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; width: 35%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white"><B>SCISPARC
    MERGER SUB LTD.</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white"><B>AUTOMAX
MOTORS LTD.</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Tomer Levi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Name: </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Tomer Levi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Yaara Alfi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Name: </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Yaara Alfi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>4
<FILENAME>ea023748901ex11-1_scisparc.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 11.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCISPARC LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>INSIDER TRADING POLICY</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AND GUIDELINES WITH RESPECT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTAIN TRANSACTIONS IN COMPANY SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Date: April 23,
2025</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 161.4pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This Insider Trading
Policy (the &ldquo;<B>Policy</B>&rdquo;) provides guidelines to directors, officers, employees and other related individuals of SciSparc
Ltd., an Israeli company (the &ldquo;<B>Company</B>&rdquo;), with respect to transactions in the Company&rsquo;s securities. The Company
has adopted this Policy in order to ensure compliance with securities laws and to avoid even the appearance of improper conduct by anyone
associated with the Company. Failure to comply with these procedures could result in a serious violation of the securities laws by you
and/or the Company and can result in both civil penalties and criminal fines and imprisonment. We have all worked hard to establish the
Company&rsquo;s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.
The appearance of insider trading can cause a substantial loss of confidence in the Company and its shares on the part of the public and
the securities markets. This could result in an adverse impact on the Company and its shareholders. Accordingly, avoiding the appearance
of engaging in share transactions on the basis of material undisclosed information can be as important as avoiding a transaction actually
based on such information. The Company has appointed its Chief Financial Officer, or in his or her absence, the Company&rsquo;s Chief
Executive Officer (the &ldquo;<B>Compliance Officer</B>,&rdquo; as the case may be), as the Company&rsquo;s Insider Trading Compliance
Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If any provision
of this Policy contradicts the provisions of securities laws and regulations applicable to the Company, including, without limitation
under Israeli law, then the provisions of such securities laws and regulations shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">I.
<U>Applicability of Policy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This
Policy applies to all transactions in the Company&rsquo;s securities, including ordinary shares, options and any other securities the
Company may issue from time to time, such as preferred shares, warrants, notes, and convertible debentures, as well as to derivative
securities relating to the Company&rsquo;s shares, whether or not issued by the Company, such as exchange-traded options and debt securities.
It applies to all officers of the Company, all members of the Company&rsquo;s Board of Directors, and all employees of, and consultants
and contractors to, the Company and its subsidiaries/branches who receive or have access to Material Nonpublic Information (as defined
below) regarding the Company (collectively, &ldquo;<B>Company Affiliated Persons</B>&rdquo;). Company Affiliated Persons, members of
their immediate families (which include spouse and minor children), members of their households, other family members living with them
or who are supported by them, are sometimes referred to in this Policy as &ldquo;<B>Insiders</B>&rdquo;. This Policy also applies to
any trust or other estate in which an Insider has a substantial beneficial interest or as to which he or she serves as trustee or in
a similar fiduciary capacity, and to any trust, corporation, partnership or other entity which the Insider controls, including venture
capital partnerships.&#9;This Policy also applies to any person who receives Material Nonpublic Information from any Insider.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any person covered
by this Policy who possesses Material Nonpublic Information regarding the Company is an Insider for so long as the information is not
publicly known. Any employee can be an Insider from time to time, and would at those times be subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Policy imposes
additional restrictions upon Insiders who have routine access to Material Nonpublic Information, referred to as &ldquo;<B>Access Insiders</B>.&rdquo;
Access Insiders are: (1) members of the board of directors, (2) the executive officers, (3) the controller, and (4) the investor relations
department of the Company. In addition, other employees of the Company who have routine access to Material Nonpublic Information as determined
by the Compliance Officer, who were notified that these additional restrictions apply to them shall also be Access Insiders until otherwise
determined by the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II.
<U>General Policy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">It is the policy
of the Company to oppose the unauthorized disclosure of any nonpublic information acquired in the work-place and the misuse of Material
Nonpublic Information in securities trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">III.
<U>Specific Policies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>1.  <U>Trading
on Material Nonpublic Information</U>.</B> Unless otherwise permitted by this Policy, an Insider must not (a) purchase sell, gift or otherwise
transfer any securities of the Company while they possess Material Nonpublic Information about the Company or (b) purchase, sell, gift
or otherwise transfer any security of any other company, while they possess Material Nonpublic Information about the other company that
they obtained in connection with their employment by or service to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>2.  <U>Tipping</U>.</B>
No Insider shall disclose (sometimes called a &ldquo;<B>Tip</B>&rdquo;) Material Nonpublic Information to any other person (including
family members) where such information may be used by such person to his or her profit by trading in the securities of companies to which
such information relates, nor shall such Insider or related person make recommendations or express opinions on the basis of Material Nonpublic
Information as to trading in the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>3.  <U>Confidentiality
of Nonpublic Information</U>.</B> Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure
of such information is forbidden. In the event any officer, director or employee of the Company receives any inquiry from outside the
Company, such as a stock analyst, for information (particularly financial results and/or projections) that may be Material Nonpublic Information,
the inquiry should be referred to the Compliance Officer, and to the other appropriate Company officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">IV.
<U>Potential Criminal and Civil Liability and/or Disciplinary Action</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>1.  <U>Liability
for Insider Trading</U>.</B> In the United States and many other countries, the personal consequences to an Insider of illegally trading
securities while in possession, or on the basis of, Material Nonpublic Information can be quite severe. In the United States there are
substantial civil penalties and criminal sanctions which may be assessed for insider trading. Civil penalties are a payment of a penalty
of up to three times the illicit windfall. In addition, Insiders may be subject to criminal fines of up to $5,000,000 and up to twenty
years in prison for engaging in transactions in the Company&rsquo;s securities at a time when they have knowledge of Material Nonpublic
Information regarding the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If you are located
or engaged in dealings outside the U.S., be aware that laws regarding insider trading and similar offenses differ from country to country.
Employees must abide by the laws in the country where located. However, you are required to comply with this Policy even if local law
is less restrictive. If a local law conflicts with this Policy, you must consult the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If securities transactions
ever become the subject of scrutiny, they are likely to be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
in any transaction an Insider should carefully consider how the transaction may be construed in the bright light of hindsight. If you
have any questions or uncertainties about this Policy or a proposed transaction, please ask the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>2.  <U>Liability
for Tipping</U>.</B> Insiders may also be liable for improper transactions by any person (commonly referred to as a &ldquo;<B>Tippee&rdquo;</B>)
to whom they have disclosed Material Nonpublic Information or any person to whom the Tippee discloses such Material Nonpublic Information
regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in
the Company&rsquo;s securities. The civil penalties and criminal sanctions for tipping by an Insider are the same as the ones for an Insider
conducting insider trading, even if the disclosing person did not profit from the trading. The U.S. Securities and Exchange Commission
(the &ldquo;<B>SEC</B>&rdquo;), the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) and the stock exchanges use sophisticated
electronic surveillance techniques to uncover insider trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>3.  <U>Possible
Disciplinary Actions</U>.</B> The seriousness of securities law violations is reflected in the penalties and criminal sanctions such violations
carry. These violations may also create negative publicity for the Company and a director&rsquo;s resignation may be sought, or an officer
or other employee will be subject to possible Company disciplinary action including ineligibility for future participation in the Company&rsquo;s
equity incentive plans or termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">V.
<U>Individual Responsibility</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Every Company Affiliated
Person has the individual responsibility to comply with this Policy against insider trading, regardless of whether the Company has recommended
a trading window to that person or any other Insiders of the Company. The guidelines set forth in this Policy are not intended to provide
a conclusive solution for all circumstances, and appropriate judgment should be exercised in connection with any trade in the Company&rsquo;s
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An Insider may,
from time to time, have to forego a proposed transaction in the Company&rsquo;s securities even if he or she planned to make the transaction
before learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego
anticipated profit by waiting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">VI.
<U>Applicability of Policy to Inside Information Regarding Other Companies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Civil penalties
and criminal sanctions, and termination of employment, may result from trading on inside information regarding any other company obtained
in connection with employment by or services performed to the Company. Further, no person shall purchase, sell, gift or otherwise transfer
any security of any other company, including another company in the Company&rsquo;s industry, while in possession of Material Nonpublic
Information if such information is obtained in the course of the Insider&rsquo;s employment or service with the Company, or that of a
family member. All employees should treat Material Nonpublic Information about any other company with the same care required with respect
to information related directly to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">VII.
<U>Dissemination of Company Information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The prohibition
of the disclosure of Material Nonpublic Information applies to all contacts made within and outside the Company. Care should be taken
to prevent the disclosure of Material Nonpublic Information during all contact including phone calls and casual conversation. If in doubt
about whether information falls into the category of Material Nonpublic Information, then the information should not be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Prior to disclosure
to any third party, any officer, director or employee of the Company who is aware of any Material Nonpublic Information concerning the
Company that has not been disclosed to the public should report the intention to disclose such information promptly to the Compliance
Officer and obtain approval to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">VIII.
<U>Definition of Material Nonpublic Information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Material Nonpublic
Information is information which is material, and that has not been disclosed or otherwise made available to the general public by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">It is not possible
to define all categories of material information. Generally, information should be regarded as material if a reasonable investor would
consider it important in making an investment decision regarding the purchase, sale, gift or otherwise transfer of the Company&rsquo;s
securities or the information, if made public, would likely affect the market price of the Company&rsquo;s securities. Either positive
or negative information may be material. Information may be material even if it relates to future, speculative or contingent events and
even if it is significant only when considered in combination with publicly available information. Nonpublic information can be material
even with respect to companies that do not have publicly traded stock, such as those with outstanding bonds or bank loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">While it may be
difficult under this standard to determine whether particular information is material, there are various categories of information that
are particularly sensitive and, as a general rule, should always be considered material. If any Insider has questions as to the materiality
of information, he or she should contact the Compliance Officer for clarification. Examples of information which is deemed to be material
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Financial results;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Projections of future earnings or losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>News of a pending or proposed merger or acquisition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>New product or project announcements of a significant nature;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Expansion or curtailment of operations or the gain or loss of a substantial customer;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The initiation, suspension and results of the Company&rsquo;s clinical and pre- clinical trials and any other material information
relating thereto;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Changes in control of the Company or major changes in senior management;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant new joint ventures, alliances, or strategic partnerships or material developments in existing arrangements;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Impending bankruptcy or financial liquidity problems;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant product defects or modifications;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant pricing changes;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Events regarding the Company&rsquo;s securities (e.g. stock splits, repurchases, or changes in dividend policy);</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Changes in auditors or auditor notification that the Company may no longer rely on an audit report;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">A significant purchase or sale of assets or disposition of a subsidiary or division;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">New equity or debt offerings, significant borrowings, or other material financial transactions;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant litigation exposure due to actual or threatened litigation;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant actions by regulatory bodies;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Receipt, cancellation or deferral of significant purchase orders;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Proposed payment of a dividend; and</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Any of the above with respect to a subsidiary, or other affiliate of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Nonpublic information
is information that has not been previously disclosed to the general public and is otherwise not available to the general public. It is
important to note that information is not necessarily public merely because it has been discussed in the press, which will sometimes report
rumors. You should presume that information is nonpublic unless you can point to its official release by the Company in a Regulation FD-compliant
method, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Information contained in publicly available documents filed with securities regulatory authorities (e.g., filings with the SEC);</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">2.</TD><TD STYLE="text-align: justify">Issuance of press releases; or</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">3.</TD><TD STYLE="text-align: justify">Meetings with members of the press and the public.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">IX.
<U>Additional Circumstances Where No Exceptions Apply</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There are almost
no exceptions to the prohibition against insider trading. For example, it does not matter that the transactions in question may have been
planned before the Insider came into possession of the undisclosed material information, regardless of the economic loss that the person
may believe he or she might suffer as a consequence of not trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As noted above,
the definition of Insiders, to which this Policy applies, includes immediate family members of Company Affiliated Persons. Although immediate
family is narrowly defined, a Company Affiliated Person should be especially careful with respect to family members or to unrelated persons
living in the same household.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Finally, there are no limits on the size
of a transaction that will trigger insider trading liability; relatively small trades have in the past occasioned investigations and lawsuits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">X.
<U>Trading Window</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The period beginning
two weeks before the end of the last month of each calendar quarter and ending two Trading Days following the date of public disclosure
of the financial results for that quarter, is a particularly sensitive period of time for transactions in the Company&rsquo;s shares from
the perspective of compliance with applicable securities laws. This sensitivity is due to the fact that directors, officers and certain
other employees will, during that period, often possess Material Nonpublic Information about the expected financial results for the quarter.
As used herein, the term &ldquo;<B>Trading Day</B>&rdquo; shall mean a day on which the Nasdaq Capital Market is open for trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Accordingly, to
ensure compliance with this Policy and applicable federal and state securities laws, it is the Company&rsquo;s policy that all directors,
officers and employees refrain from conducting transactions involving the purchase, sale, gift or otherwise transfer of the Company&rsquo;s
securities other than during the period (the &ldquo;<B>Trading Window</B>&rdquo;) commencing at the close of business on the second Trading
Day following the date of public disclosure of the financial results for a particular fiscal quarter or year and continuing until the
day that is two weeks before the last day of the last month of the next fiscal quarter. As a courtesy to the persons subject to this Policy,
the Company may provide advance notice before the Trading Window opens.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">From time to time,
the Company may also notify that directors, officers, selected employees and others are required to suspend trading because of developments
known to the Company and not yet disclosed to the public. In such event, such persons are advised not to engage in any transaction involving
the purchase, sale, gift or otherwise transfer of the Company&rsquo;s securities during such period and should not disclose to others
the fact of such suspension of trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The purpose behind
the self-imposed Trading Window period is to help establish a diligent effort to avoid any improper transaction. It should be noted, however,
that even during the Trading Window, any person possessing Material Nonpublic Information concerning the Company may not attempt to &ldquo;beat
the market&rdquo; by trading simultaneously with, or shortly after, the official release of Material Nonpublic Information. Although there
is no fixed period for how long it takes the market to absorb information, out of prudence a person aware of Material Nonpublic Information
should refrain from any trading activity for at least two full Trading Days following its official release, whether or not the Company
has recommended a suspension of trading to that person.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>NOTWITHSTANDING
THESE TIMING GUIDELINES, IT IS ILLEGAL FOR ANY PERSON TO TRADE WHILE IN POSSESSION OF MATERIAL NONPUBLIC INFORMATION, INCLUDING SITUATIONS
IN WHICH THE PERSON IS AWARE OF MAJOR DEVELOPMENTS THAT HAVE NOT YET BEEN PUBLICLY ANNOUNCED BY THE COMPANY. TRADING IN THE COMPANY&rsquo;S
SECURITIES DURING THE TRADING WINDOW SHOULD <U>NOT</U> BE CONSIDERED A &ldquo;SAFE HARBOR&rdquo;, AND ALL DIRECTORS, OFFICERS AND OTHER
INSIDERS SHOULD USE GOOD JUDGMENT AT ALL TIMES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XI.
<U>Inquiries</U></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All Insiders should
review this Policy carefully and contact the Compliance Officer if they have a concern that a contemplated transaction in the Company&rsquo;s
securities might not conform with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XII.
<U>Rule 10b5-1 Trading Plans</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 213.85pt; text-align: right; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The trading restrictions set forth in this Policy,
do not apply to transactions under a previously established contract, plan or instruction to trade in the Company&rsquo;s securities entered
into in accordance with Rule 10b5-1 trading plan that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">has been submitted to and pre-approved by the Compliance Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">includes a &ldquo;Cooling Off Period&rdquo; for</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9675;</TD><TD STYLE="text-align: justify">directors and officers that extends to the later of 90 days after adoption or modification of a Rule 10b5-1
trading plan or two (2) business days after filing the Form 20-F or Form 6-K with financial results covering the fiscal quarter in which
the Rule 10b5-1 trading plan was adopted, up to a maximum of 120 days; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9675;</TD><TD STYLE="text-align: justify">employees and any other persons, other than the Company, that extends 30 days after adoption or modification
of a Rule 10b5-1 trading plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">for directors and officers, includes a representation in the Rule 10b5-1 trading plan that the directors
or officers is (1) not aware of any material nonpublic information about the Company or its securities; and (2) adopting the Rule 10b5-1
trading plan in good faith and not as part of a plan or scheme to evade Rule 10b-5;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">has been entered into in good faith at a time when the individual was not in possession of material nonpublic
information about the Company and not otherwise in a blackout period, and the person who entered into the Rule 10b5-1 trading plan has
acted in good faith with respect to the Rule 10b5-1 trading plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">either (1) specifies the amounts, prices, and dates of all transactions under the Rule 10b5-1 trading
plan; or (2) provides a written formula, algorithm, or computer program for determining the amount, price, and date of the transactions,
and (3) prohibits the individual from exercising any subsequent influence over the transactions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify">complies with all other applicable requirements of Rule 10b5-1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Compliance Officer may
impose such other conditions on the implementation and operation of the Rule 10b5-1 trading plan as the Compliance Officer deems necessary
or advisable. Individuals may not adopt more than one Rule 10b5-1 trading plan at a time except under the limited circumstances permitted
by Rule 10b5-1 and subject to pre-approval by the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Although non-discretionary
Rule 10b5-1 trading plans are preferred, discretionary Rule 10b5-1 trading plans, where the discretion or control over trading is transferred
to a broker, are permitted if pre-approved by the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The actual transactions effected pursuant to a
pre-approved Rule 10b5-1 trading plan will not be subject to further pre-clearance for transactions in the Company&rsquo;s shares once
the Rule 10b5-1 trading plan or other arrangement has been pre-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Revocation of Rule 10b5-1
trading plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Rule 10b5-1 trading plan will
be subject to the prior review and approval of the Compliance Officer. Revocation is effected upon written notice to the broker. You should
note that revocation of a Rule 10b5-1 trading plan can result in the loss of an affirmative defense for past or future transactions under
a Rule 10b5-1 trading plan. You should consult with your own legal counsel before deciding to revoke Rule 10b5-1 trading plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An individual may only modify
a Rule 10b5-1 trading plan outside of a blackout period and, in any event, when the individual does not possess material nonpublic information.
Modifications to and terminations of a Rule 10b5-1 trading plan are subject to pre-approval by the Compliance Officer and modifications
of a Rule 10b5-1 trading plan that change the amount, price, or timing of the purchase or sale of the securities underlying a Rule 10b5-1
trading plan will trigger a new Cooling-Off Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Company reserves the right
to publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification, or termination of a Rule
10b5-1 trading plan and non-Rule 10b5-1 trading arrangements, or the execution of transactions made under a Rule 10b5-1 trading plan.
The Company also reserves the right from time to time to suspend, discontinue, or otherwise prohibit transactions under a Rule 10b5-1
trading plan if the Compliance Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation,
or other prohibition is in the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Compliance of a Rule 10b5-1
trading plan with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Rule 10b5-1 trading plan are the sole responsibility
of the person initiating the Rule 10b5-1 trading plan, and none of the Company, the Compliance Officer, or the Company&rsquo;s other employees
assumes any liability for any delay in reviewing and/or refusing to approve a Rule 10b5-1 trading plan submitted for approval, nor the
legality or consequences relating to a person entering into, informing the Company of, or trading under, a Rule 10b5-1 trading plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If required, an SEC Form 144
will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote
at the bottom of the Form 144 should indicate that the trades are in accordance with a Rule 10b5-1 trading plan that complies with Rule
10b5-1 and noting the expiration date of such Rule 10b5-1 trading plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">During an open trading window,
trades differing from Rule 10b5-1 trading plan instructions that are already in place are allowed as long as the Rule 10b5-1 trading plan
continues to be followed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The transactions prohibited
under this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other
arrangement or trading instruction involving potential sales or purchases of the Company&rsquo;s securities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 213.85pt; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XIII.
<U>Certain Other Exceptions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">For purposes of
this Policy, the Company considers that the exercise of share options for cash under the Company&rsquo;s share option plans or the purchase
of shares under employee purchase plans in effect at the time of the adoption of this Policy and that may be adopted in the future (but
<U>not</U> the sale of any such shares) is exempt from this Policy, since the other party to the transaction is the Company itself and
the price does not vary with the market but is fixed by the terms of the option agreement or the plan. Accordingly, cashless exercises
of options are subject to the Policy when they involve the sale of shares into the public marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Gift transactions
of securities for family or estate planning purposes, where securities are gifted to a person or entity subject to this Policy, are not
deemed to be transactions for the purposes of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XIV.&nbsp;<U>Additional
Information for Directors, Officers and Certain Employees with Routine Access to Material Nonpublic information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This Policy imposes
additional restrictions upon Access Insiders, because of their routine access to Material Nonpublic Information.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>1.  <U>Preclearance
of Trades</U>.</B> The Company has determined that all Access Insiders should refrain from trading in the Company&rsquo;s securities,
even during the Trading Window, without first complying with the Company&rsquo;s &ldquo;preclearance&rdquo; process. Each Access Insider
should contact the Compliance Officer prior to commencing any trade in the Company&rsquo;s securities. At the time of executing a trade
in the Company&rsquo;s securities, such individuals will be responsible for verifying that the Company has not imposed any restrictions
on their ability to engage in trades. If the individual has not completed the trade within ten (10) trading days of notification of the
intention to trade, then the individual must again notify the Compliance Officer that he or she intends to execute a trade and re-verify
the nonexistence of any restrictions on such trade. For the avoidance of doubt, this paragraph shall not apply to a Qualified Plan, after
it has been set up.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Before each transaction
in the Company&rsquo;s securities by a Company each officer and director should contact the Compliance Officer regarding compliance with
Rule 144 under the U.S. Securities Act of 1933, as amended (&ldquo;<B>Rule 144</B>&rdquo;), which contains guidelines for the sale of
privately issued shares and sales by affiliates of the Company, if such sales are not covered by an effective registration statement,
to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>2.  <U>Rule
144 and Section 16 Matters for Directors and Officers</U>.</B> Directors and principal officers of the Company must also comply with Rule
144, or another applicable exemption from registration. The practical effect of Rule 144 is that directors and officers who sell the Company&rsquo;s
securities may be required to comply with a number of requirements including holding period, volume limitation, manner of sale and SEC
filing requirements. The Company may provide separate memoranda and other appropriate materials to its directors and officers regarding
compliance with Rule 144. In addition, if the Company is no longer considered a &ldquo;foreign private issuer&rdquo;, the directors and
officers who trade with Company securities have to report of purchases and sales of shares through the filing of Form 4s with the U.S.
Securities and Exchange Commission. The Company will advise such persons if they are subject to the requirement to file a Form 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XV.
<U>Specific Requirements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">1.  <B><U>Speculative
Trading</U></B>. No Insider may engage in transactions of a speculative nature at any time. All Insiders are prohibited from short-selling
the Company&rsquo;s securities or engaging in transactions involving the Company&rsquo;s based derivative securities. A short sale, for
these purposes, means any transaction whereby one may benefit from a decline in the price of the Company&rsquo;s securities. &ldquo;<B>Derivative
Securities</B>&rdquo; are options, warrants, stock appreciation rights or similar rights whose value is derived from the value of an equity
security, such as the Company&rsquo;s common stock. This prohibition includes, but is not limited to, trading in the Company&rsquo;s based
put and call option contracts, transacting in straddles, hedging or monetization transaction with respect to the Company&rsquo;s securities,
and the like. In addition, no Insider shall engage in a transaction with respect to securities of the Company if he or she owns the security,
but does not deliver it against such sale (a &ldquo;short sale against the box&rdquo;) within twenty days thereafter, or does not within
five days after such sale deposit it in the mails or other usual channels of transportation. The above does not derogate from Insiders&rsquo;
right to hold and exercise options or other derivative securities granted under the Company&rsquo;s employee share option or equity incentive
plans as long as such exercise is not prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">2.  <B><U>Margin
Accounts and Pledges</U></B>. Securities held in a margin account may be sold by the broker without the consent of the owner thereof if
such owner fails to meet a margin call. Similarly, securities pledged as collateral for a loan may be sold if the owner thereof defaults
on the loan. In case of an owner who is subject to this Policy, these sales may occur at a time when such person is aware of material,
non-public information or otherwise not permitted to trade such securities. Therefore, this policy prohibits holding any Company securities
in a margin account or pledging any Company securities as collateral for a loan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">3.  <B><U>Post-Termination
Transactions</U>.</B> If an Insider is aware of Material Nonpublic Information at the time such Insider&rsquo;s association with the Company
is terminated, whether by the Insider or the Company, the Insider may not trade in Company securities until such information is no longer
material or until two Trading Days after such information has become public. In addition, if the Company is not in a Trading Window at
the time such association with the Company is terminated, the Insider may not trade in Company securities until two Trading Days after
the next announcement of quarterly earnings or of the material, non-public information.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">4.  <B><U>Ad
hoc Restrictions</U></B><I>.</I> The Compliance Officer has the authority to impose restrictions on trading in the Company&rsquo;s securities
by appropriate individuals at any time. In such event, the Compliance Officer will notify the affected individuals, either personally,
by email or by voicemail, to inform them of the restrictions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">5.  <B><U>Open
Orders</U></B>. Any Insider who has placed a limit order or open instruction to buy or sell the Company&rsquo;s securities shall bear
responsibility for canceling such instructions immediately upon becoming in possession of Material Nonpublic Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-indent: -36.05pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XVI.
<U>Interpretation and Amendment</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 215.25pt; text-align: right; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Compliance Officer
shall have the authority to interpret and update this Policy and its Schedules and all related policies and procedures. In particular,
such interpretations and updates of this Policy, as authorized by the Compliance Officer, may include amendments to or departures from
the terms of this Policy, to the extent consistent with the general purpose of this Policy and applicable securities laws.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 215.25pt; text-align: right; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">XVII.
<U>Acknowledgement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Please sign the attached acknowledgement form and return it
to the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If you have any questions with respect
to this Policy, please contact the Company&rsquo;s Compliance Officer, at Oz@scisparc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 161.45pt; text-align: center"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><B><U>ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">I have received, read and understand the Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities of SciSparc Ltd., a copy of which is attached hereto, and agree to comply with the provisions thereof.</Font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">Date:__________</TD>
  <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>ea023748901ex12-1_scisparc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) OR 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Oz Adler, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">1.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have reviewed this annual report on Form 20&ndash;F of SciSparc Ltd. (the &ldquo;Company&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">2.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">3.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">4.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">5.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 60%">Date: April 24, 2025</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt; text-align: justify; width: 40%">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ea023748901ex13-1_scisparc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2024 (the &ldquo;Report&rdquo;) by SpiSparc Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section
1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in">(1)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">(2)</TD>
    <TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 60%">Date: April 24, 2025</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: justify; width: 40%">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>ea023748901ex15-1_scisparc.htm
<DESCRIPTION>CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 33%; vertical-align: bottom"><IMG SRC="ex15-1_001.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 34%; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Kost Forer Gabbay &amp; Kasierer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">144 Menachem Begin Road, Building A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel-Aviv 6492102, Israel</P>
</TD>
  <TD STYLE="text-align: left; width: 33%; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972-3-6232525</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +972-3-5622555</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">ey.com</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We consent
to the incorporation by reference in the following Registration Statements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Registration Statements (Form F-3 Nos. 333-269839, 333-266047, 333-248670,
and 333-255408) of SciSparc Ltd., and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Registration Statements (Form S-8 Nos. 333-225773 and 333-278437)
pertaining to the Therapix Biosciences Ltd. Israeli Share Option Plan (2015) and SciSparc Ltd. 2023 Share Incentive Plan, respectively,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">into our
report dated April 24, 2025 with respect to the consolidated financial statements of SciSparc Ltd. included in this Annual Report (Form
20-F) of SciSparc Ltd. for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt; text-align: left">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Kost
    Forer Gabbay &amp; Kasierer</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel Aviv, Israel</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kost
    Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 24, 2025</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">A member firm of EY Global</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( #T# 2(  A$! Q$!_\0
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M2\ZN-J6Z*.PI5ZTXQA.M6E"/PPE5J.$?*,'/D7R@O4_J_"8 '3U [_R/3BG
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>sprcy-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:54 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.trpx.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:sprcy="http://www.trpx.com/20241231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.trpx.com/role/ConsolidatedBalanceSheet" id="sprcy_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatement" id="sprcy_r_ConsolidatedIncomeStatement">
        <link:definition>995302 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0" id="sprcy_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>995302 - Statement - Consolidated Statements of Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ShareholdersEquityType2or3" id="sprcy_r_ShareholdersEquityType2or3">
        <link:definition>995303 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ConsolidatedCashFlow" id="sprcy_r_ConsolidatedCashFlow">
        <link:definition>995304 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/General" id="sprcy_r_General">
        <link:definition>995305 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantAccountingPolicies" id="sprcy_r_SignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" id="sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
        <link:definition>995307 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/Cash" id="sprcy_r_Cash">
        <link:definition>995308 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/Inventory" id="sprcy_r_Inventory">
        <link:definition>995309 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OtherAccountsReceivable" id="sprcy_r_OtherAccountsReceivable">
        <link:definition>995310 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVentures" id="sprcy_r_InvestmentinAssociatesandJointVentures">
        <link:definition>995311 - Disclosure - Investment in Associates and Joint Ventures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InvestmentinFinancialAssets" id="sprcy_r_InvestmentinFinancialAssets">
        <link:definition>995312 - Disclosure - Investment in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/Leases" id="sprcy_r_Leases">
        <link:definition>995313 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/PropertyandEquipmentNet" id="sprcy_r_PropertyandEquipmentNet">
        <link:definition>995314 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/IntangibleAsset" id="sprcy_r_IntangibleAsset">
        <link:definition>995315 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TradePayables" id="sprcy_r_TradePayables">
        <link:definition>995316 - Disclosure - Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OtherAccountsPayable" id="sprcy_r_OtherAccountsPayable">
        <link:definition>995317 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/FinancialInstruments" id="sprcy_r_FinancialInstruments">
        <link:definition>995318 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilities" id="sprcy_r_EmployeeBenefitLiabilities">
        <link:definition>995319 - Disclosure - Employee Benefit Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TaxesonIncome" id="sprcy_r_TaxesonIncome">
        <link:definition>995320 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens">
        <link:definition>995321 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/Equity" id="sprcy_r_Equity">
        <link:definition>995322 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactions" id="sprcy_r_ShareBasedPaymentTransactions">
        <link:definition>995323 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/RevenuesandCostofRevenues" id="sprcy_r_RevenuesandCostofRevenues">
        <link:definition>995324 - Disclosure - Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLoss">
        <link:definition>995325 - Disclosure - Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/LossPerShare" id="sprcy_r_LossPerShare">
        <link:definition>995326 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OperatingSegments" id="sprcy_r_OperatingSegments">
        <link:definition>995327 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties" id="sprcy_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>995328 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod" id="sprcy_r_SignificantEventsduringtheReportingPeriod">
        <link:definition>995329 - Disclosure - Significant Events during the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EventsAftertheReportingDate" id="sprcy_r_EventsAftertheReportingDate">
        <link:definition>995330 - Disclosure - Events After the Reporting Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/AccountingPoliciesByPolicy" id="sprcy_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesTables" id="sprcy_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/CashTables" id="sprcy_r_CashTables">
        <link:definition>996002 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InventoryTables" id="sprcy_r_InventoryTables">
        <link:definition>996003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OtherAccountsReceivableTables" id="sprcy_r_OtherAccountsReceivableTables">
        <link:definition>996004 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables" id="sprcy_r_InvestmentinAssociatesandJointVenturesTables">
        <link:definition>996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/PropertyandEquipmentNetTables" id="sprcy_r_PropertyandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/IntangibleAssetTables" id="sprcy_r_IntangibleAssetTables">
        <link:definition>996007 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TradePayablesTables" id="sprcy_r_TradePayablesTables">
        <link:definition>996008 - Disclosure - Trade Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OtherAccountsPayableTables" id="sprcy_r_OtherAccountsPayableTables">
        <link:definition>996009 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/FinancialInstrumentsTables" id="sprcy_r_FinancialInstrumentsTables">
        <link:definition>996010 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables" id="sprcy_r_EmployeeBenefitLiabilitiesTables">
        <link:definition>996011 - Disclosure - Employee Benefit Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EquityTables" id="sprcy_r_EquityTables">
        <link:definition>996012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsTables" id="sprcy_r_ShareBasedPaymentTransactionsTables">
        <link:definition>996013 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/RevenuesandCostofRevenuesTables" id="sprcy_r_RevenuesandCostofRevenuesTables">
        <link:definition>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables">
        <link:definition>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/LossPerShareTables" id="sprcy_r_LossPerShareTables">
        <link:definition>996016 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OperatingSegmentsTables" id="sprcy_r_OperatingSegmentsTables">
        <link:definition>996017 - Disclosure - Operating Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/GeneralDetails" id="sprcy_r_GeneralDetails">
        <link:definition>996019 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesDetails" id="sprcy_r_SignificantAccountingPoliciesDetails">
        <link:definition>996020 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" id="sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable">
        <link:definition>996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofCashTable" id="sprcy_r_ScheduleofCashTable">
        <link:definition>996022 - Disclosure - Cash - Schedule of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofInventoryTable" id="sprcy_r_ScheduleofInventoryTable">
        <link:definition>996023 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable" id="sprcy_r_ScheduleofOtherAccountsReceivableTable">
        <link:definition>996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" id="sprcy_r_InvestmentinAssociatesandJointVenturesDetails">
        <link:definition>996025 - Disclosure - Investment in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable">
        <link:definition>996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/InvestmentinFinancialAssetsDetails" id="sprcy_r_InvestmentinFinancialAssetsDetails">
        <link:definition>996027 - Disclosure - Investment in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/LeasesDetails" id="sprcy_r_LeasesDetails">
        <link:definition>996028 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/PropertyandEquipmentNetDetails" id="sprcy_r_PropertyandEquipmentNetDetails">
        <link:definition>996029 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable" id="sprcy_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/IntangibleAssetDetails" id="sprcy_r_IntangibleAssetDetails">
        <link:definition>996031 - Disclosure - Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable">
        <link:definition>996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofTradePayablesTable" id="sprcy_r_ScheduleofTradePayablesTable">
        <link:definition>996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable" id="sprcy_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
        <link:definition>996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" id="sprcy_r_ScheduleofCompanysFinancialInstrumentsTable">
        <link:definition>996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable" id="sprcy_r_ScheduleofDefinedContributionPlansTable">
        <link:definition>996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dWPfPvA7idgTsx7K7UvePg2rVOumdRjhIw==] CSR-->
      <link:roleType roleURI="http://www.trpx.com/role/TaxesonIncomeDetails" id="sprcy_r_TaxesonIncomeDetails">
        <link:definition>996038 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
        <link:definition>996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EquityDetails" id="sprcy_r_EquityDetails">
        <link:definition>996040 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofShareCapitalTable" id="sprcy_r_ScheduleofShareCapitalTable">
        <link:definition>996041 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable">
        <link:definition>996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>996043 - Disclosure - Equity - Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails" id="sprcy_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>996044 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" id="sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable">
        <link:definition>996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" id="sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable">
        <link:definition>996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" id="sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofRSUtransactionTable" id="sprcy_r_ScheduleofRSUtransactionTable">
        <link:definition>996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" id="sprcy_r_ScheduleofCostofSalesandGrossProfitTable">
        <link:definition>996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
        <link:definition>996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" id="sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
        <link:definition>996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/OperatingSegmentsDetails" id="sprcy_r_OperatingSegmentsDetails">
        <link:definition>996052 - Disclosure - Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofOperatingSegmentsTable" id="sprcy_r_ScheduleofOperatingSegmentsTable">
        <link:definition>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable">
        <link:definition>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable">
        <link:definition>996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" id="sprcy_r_SignificantEventsduringtheReportingPeriodDetails">
        <link:definition>996059 - Disclosure - Significant Events during the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/EventsAftertheReportingDateDetails" id="sprcy_r_EventsAftertheReportingDateDetails">
        <link:definition>996060 - Disclosure - Events After the Reporting Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.trpx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
  <xs:element name="ScheduleOfCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCashAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
  <xs:element name="ScheduleOfCompanysFinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
  <xs:element name="ScheduleOfExpensesDueToShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfFairValueForShareOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ScheduleOfRsuTransactionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRsuTransactionAbstract"/>
  <xs:element name="ScheduleOfCostOfSalesAndGrossProfitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOperatingSegmentsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract1"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract"/>
  <xs:element name="a2024Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2024Abstract"/>
  <xs:element name="CostOfGoodsSoldAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSoldAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract2"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="BSalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BSalesAndMarketingExpensesAbstract"/>
  <xs:element name="CGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="DOtherExpensesIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DOtherExpensesIncomeAbstract"/>
  <xs:element name="EFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EFinanceIncomeAbstract"/>
  <xs:element name="FFinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FFinanceExpensesAbstract"/>
  <xs:element name="ContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContinuingOperationsAbstract"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract3"/>
  <xs:element name="IssueOfShareCapitalNetOfIssueExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
  <xs:element name="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
  <xs:element name="AdjustmentsForIncreaseInRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForIncreaseInRelatedParties"/>
  <xs:element name="SalepurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SalepurchaseOfPropertyAndEquipment"/>
  <xs:element name="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
  <xs:element name="DisclosureOfInvestmentFinancialAssetsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
  <xs:element name="DisclosureOfOtherAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
  <xs:element name="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
  <xs:element name="DescriptionOfAcquisitionOfASingleAssetCompany" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
  <xs:element name="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
  <xs:element name="DisclosueOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="DisclosureOfInventorieExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInventorieExplanatory"/>
  <xs:element name="DisclourseOfAccountsReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
  <xs:element name="DisclosureOfTradePayablesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfTradePayablesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
  <xs:element name="DisclosureOfIssuedAndOutstandingShareCapital" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
  <xs:element name="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
  <xs:element name="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
  <xs:element name="OperatingSegmentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsTablesTable"/>
  <xs:element name="OperatingSegmentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsTablesLineItems"/>
  <xs:element name="RelatedPartyBalancetextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RelatedPartyBalancetextBlock"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
  <xs:element name="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
  <xs:element name="LeaseholdImprovementsMainlyRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseholdImprovementsMainlyRate"/>
  <xs:element name="CashScheduleofCashDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashScheduleofCashDetailsTable"/>
  <xs:element name="Governmentauthoritiescurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_Governmentauthoritiescurrent"/>
  <xs:element name="ReceivablesInRespectOfDownpaymentOnMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
  <xs:element name="InvestmentsDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsDate"/>
  <xs:element name="InvestmentAchievementOfFirstMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfFirstMilestone"/>
  <xs:element name="InvestmentAchievementOfSecondMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfSecondMilestone"/>
  <xs:element name="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
  <xs:element name="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
  <xs:element name="DepreciationOfIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
  <xs:element name="CreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFromOthers"/>
  <xs:element name="WarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsLiability"/>
  <xs:element name="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
  <xs:element name="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
  <xs:element name="ShareIssuedToAConsultants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareIssuedToAConsultants"/>
  <xs:element name="IssuanceOfShareCapitalInRespectSEPA" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
  <xs:element name="IncomeStatementsLocationsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IncomeStatementsLocationsDomainDomain"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
  <xs:element name="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
  <xs:element name="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
  <xs:element name="ExternalRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExternalRevenues"/>
  <xs:element name="EquityLossesFromTheInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromTheInvestment"/>
  <xs:element name="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="CurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CurrentAsset"/>
  <xs:element name="SaleOfMinorityInterestInSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfMinorityInterestInSubsidiary"/>
  <xs:element name="KeyManagementPersonnelCompensationManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_KeyManagementPersonnelCompensationManagementFees"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
  <xs:element name="OperatingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingTerm"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
  <xs:element name="InitialInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestment"/>
  <xs:element name="AdditionalInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInvestment"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingSharesPercentage"/>
  <xs:element name="AdditionalInstallment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInstallment"/>
  <xs:element name="InstallmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaid"/>
  <xs:element name="CashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashConsideration"/>
  <xs:element name="PurchaserRemainingOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaserRemainingOwnershipPercentage"/>
  <xs:element name="RemainingPurchaserAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RemainingPurchaserAmount"/>
  <xs:element name="IssuedAndOutstandingSharePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharePercentage"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinFinancialAssetsDetailsTable"/>
  <xs:element name="ShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareCapitalPercentage"/>
  <xs:element name="SharePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePerShare"/>
  <xs:element name="ReverseShareSplitRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReverseShareSplitRatio"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeasesDetailsLineItems"/>
  <xs:element name="AreaOfLease" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AreaOfLease"/>
  <xs:element name="OptionToExtendLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OptionToExtendLeaseTerm"/>
  <xs:element name="MonthlyLeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MonthlyLeaseFee"/>
  <xs:element name="IntangibleAssetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetDetailsTable"/>
  <xs:element name="PaymentsOfAdditionalDeferredCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentsOfAdditionalDeferredCash"/>
  <xs:element name="PurchaseCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCostsValue"/>
  <xs:element name="GrowthRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrowthRatePercentage"/>
  <xs:element name="LongTermPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LongTermPercentage"/>
  <xs:element name="DiscountRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DiscountRatePercentage"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsTaxAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingLossCarryforwardsTaxAmount"/>
  <xs:element name="DekelLicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DekelLicenseAgreementDescription"/>
  <xs:element name="AnnualInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AnnualInvestment"/>
  <xs:element name="AdditionalMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalMilestoneAmount"/>
  <xs:element name="InstallmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentAmount"/>
  <xs:element name="EstimatedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EstimatedAmount"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsTable"/>
  <xs:element name="CapitalRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalRatio"/>
  <xs:element name="ReverseSplitRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReverseSplitRatio"/>
  <xs:element name="IssuanceOfAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfAggregateShares"/>
  <xs:element name="AggregateUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnits"/>
  <xs:element name="AggregateUnitsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnitsPerShare"/>
  <xs:element name="IssuanceExpireTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpireTerm"/>
  <xs:element name="WarrantsAndExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAndExercise"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePerShare"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateGrossProceeds"/>
  <xs:element name="CommitmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CommitmentAmount"/>
  <xs:element name="SaleOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfOrdinaryShares"/>
  <xs:element name="SharePriceRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePriceRate"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestRate"/>
  <xs:element name="InstallmentPayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPayment"/>
  <xs:element name="PaymentForPremiumPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentForPremiumPercentage"/>
  <xs:element name="AggregateIssuedAmount" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateIssuedAmount"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="FairValueOfShareOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOptionsGranted"/>
  <xs:element name="OrdinarySharesGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGrantedDiscountRate"/>
  <xs:element name="NumberOfOptionsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOptionsOutstanding"/>
  <xs:element name="ConvertIntoOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConvertIntoOrdinaryShares"/>
  <xs:element name="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
  <xs:element name="OperatingSegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsDetailsTable"/>
  <xs:element name="OperatingSegmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsDetailsLineItems"/>
  <xs:element name="SaleOfStockDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfStockDomainDomain"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="InterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPercentage"/>
  <xs:element name="DeferredCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DeferredCashPayment"/>
  <xs:element name="BonusAmountReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmountReceived"/>
  <xs:element name="AcquiredOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AcquiredOrdinaryShares"/>
  <xs:element name="AggregateValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValues"/>
  <xs:element name="AggregateValueAdjusted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValueAdjusted"/>
  <xs:element name="ListedSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ListedSharePrice"/>
  <xs:element name="ComprehensiveLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLossOnInvestment"/>
  <xs:element name="CooperationAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CooperationAgreementAmount"/>
  <xs:element name="ExchangeOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeOfCommonShares"/>
  <xs:element name="OutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingShareCapital"/>
  <xs:element name="LicenseeIssuePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LicenseeIssuePrice"/>
  <xs:element name="MilestonesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MilestonesAmount"/>
  <xs:element name="LicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LicenseAgreementDescription"/>
  <xs:element name="PercentageOfAggregateNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfAggregateNetSales"/>
  <xs:element name="NumberOfUnitsReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfUnitsReceived"/>
  <xs:element name="NumberOfWarrantsHolds" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfWarrantsHolds"/>
  <xs:element name="WarrantsExpireDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsExpireDate"/>
  <xs:element name="AggregateNumberOfOutstandingOrdinarySharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
  <xs:element name="EnterpriseValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EnterpriseValue"/>
  <xs:element name="EventsAftertheReportingDateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EventsAftertheReportingDateDetailsTable"/>
  <xs:element name="AggregateLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateLoanAmount"/>
  <xs:element name="RepaidOfMonthlyInstallments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RepaidOfMonthlyInstallments"/>
  <xs:element name="PurchasePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePercentage"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
  <xs:element name="ConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsecutiveTradingDays"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
  <xs:element name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfWarrantsIssued"/>
  <xs:element name="VolumeWeightedAveragePricePerWarrant" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePricePerWarrant"/>
  <xs:element name="WarrantExercisableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantExercisableTerm"/>
  <xs:element name="AggregateInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateInvestment"/>
  <xs:element name="PercentageOfFullyDilutedCapitalStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfFullyDilutedCapitalStock"/>
  <xs:element name="PercentageOfFinancingProceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfFinancingProceeds"/>
  <xs:element name="RestrictedStockGrantPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RestrictedStockGrantPercentage"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VestingPeriod"/>
  <xs:element name="IncomeStatementsLocationsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_IncomeStatementsLocationsAxis"/>
  <xs:element name="SaleOfStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_SaleOfStockAxis"/>
  <xs:element name="AccumulatedDepreciationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationMember"/>
  <xs:element name="AdvertisementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdvertisementMember"/>
  <xs:element name="AmazonFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmazonFeesMember"/>
  <xs:element name="August2023FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_August2023FinancingRoundMember"/>
  <xs:element name="AutoMaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxMember"/>
  <xs:element name="BusinessDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BusinessDevelopmentExpensesMember"/>
  <xs:element name="ChemistryAndFormulationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ChemistryAndFormulationsMember"/>
  <xs:element name="ClinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClinicalStudiesMember"/>
  <xs:element name="CostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostMember"/>
  <xs:element name="DebenturesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DebenturesMember"/>
  <xs:element name="DepreciationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DepreciationMember"/>
  <xs:element name="DirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DirectorsMember"/>
  <xs:element name="DrugDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DrugDevelopmentMember"/>
  <xs:element name="ExchangeRateDifferencesNetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeRateDifferencesNetMember"/>
  <xs:element name="FinanceExpenseInRespectOfLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpenseInRespectOfLeasesMember"/>
  <xs:element name="FinanceExpensesFromInterestAndCommissionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
  <xs:element name="FreightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FreightMember"/>
  <xs:element name="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
  <xs:element name="InitialPublicOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialPublicOfferingMember"/>
  <xs:element name="InterestFromLoansToRelatedPartiesAndDepositsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
  <xs:element name="InvestorRelationsAndBusinessExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestorRelationsAndBusinessExpensesMember"/>
  <xs:element name="IssuanceExpensesRelatedToWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
  <xs:element name="JeffsBrandsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_JeffsBrandsMember"/>
  <xs:element name="June2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022WarrantsMember"/>
  <xs:element name="LeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseMember"/>
  <xs:element name="LossFromSaleOfPropertyAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
  <xs:element name="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
  <xs:element name="ManagementFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ManagementFeesMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MergerAgreementMember"/>
  <xs:element name="MitoCareXBioLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXBioLtdMember"/>
  <xs:element name="MitoCareXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXMember"/>
  <xs:element name="MizaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MizaMember"/>
  <xs:element name="N2OFFMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_N2OFFMember"/>
  <xs:element name="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
  <xs:element name="October2023FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_October2023FinancingRoundMember"/>
  <xs:element name="OfficeEquipmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeEquipmentsMember"/>
  <xs:element name="OfficeMaintenanceRentAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
  <xs:element name="OnlineSalesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesMember"/>
  <xs:element name="OnlineSalesSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesSegmentMember"/>
  <xs:element name="OverAllotmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OverAllotmentMember"/>
  <xs:element name="PreFundedUnitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PreFundedUnitsMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedWarrantsMember"/>
  <xs:element name="ProfessionalAndDirectorsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProfessionalAndDirectorsFeesMember"/>
  <xs:element name="PurchasedGoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasedGoodsMember"/>
  <xs:element name="RegulatoryExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryExpensesMember"/>
  <xs:element name="RegulatoryProfessionalAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
  <xs:element name="ResearchAndPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndPreclinicalStudiesMember"/>
  <xs:element name="RightOfUseAssesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightOfUseAssesMember"/>
  <xs:element name="SEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SEPAMember"/>
  <xs:element name="SciSparcMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SciSparcMember"/>
  <xs:element name="ShareBasedPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentMember"/>
  <xs:element name="StorageAndShippingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StorageAndShippingMember"/>
  <xs:element name="SubsequentEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SubsequentEventsMember"/>
  <xs:element name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TwoThousandTwentyThreePlanMember"/>
  <xs:element name="WagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WagesAndRelatedExpensesMember"/>
  <xs:element name="OtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
  <xs:element name="SegmentReportingRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SegmentReportingRevenueAbstract"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
  <xs:element name="SignificantEventsDuringTheReportingPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
  <xs:element name="SignificantEventsDuringTheReportingPeriodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
  <xs:element name="SignificantNonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantNonCashTransactionsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>sprcy-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://www.trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatementAlt0" roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://www.trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://www.trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://www.trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <calculationLink xlink:role="http://www.trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dWPfPvA7idgT2G5jJFWOF0aiji1vw3/lWQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_FinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="sprcy_Governmentauthoritiescurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_NetDebt" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_Accruals" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherPayables" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_OtherReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_CreditFromOthers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_WarrantsLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>sprcy-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://www.trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://www.trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://www.trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_General" roleURI="http://www.trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://www.trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Cash" roleURI="http://www.trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Inventory" roleURI="http://www.trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://www.trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVentures" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVentures"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://www.trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Leases" roleURI="http://www.trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://www.trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAsset" roleURI="http://www.trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayables" roleURI="http://www.trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://www.trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstruments" roleURI="http://www.trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncome" roleURI="http://www.trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Equity" roleURI="http://www.trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://www.trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShare" roleURI="http://www.trpx.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegments" roleURI="http://www.trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://www.trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://www.trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_CashTables" roleURI="http://www.trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InventoryTables" roleURI="http://www.trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://www.trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesTables" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://www.trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://www.trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayablesTables" roleURI="http://www.trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://www.trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://www.trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityTables" roleURI="http://www.trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://www.trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShareTables" roleURI="http://www.trpx.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://www.trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" roleURI="http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://www.trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://www.trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://www.trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCompanysFinancialInstrumentsTable" roleURI="http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://www.trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofRSUtransactionTable" roleURI="http://www.trpx.com/role/ScheduleofRSUtransactionTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_GeneralDetails" roleURI="http://www.trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesDetails" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LeasesDetails" roleURI="http://www.trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://www.trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://www.trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://www.trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityDetails" roleURI="http://www.trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsDetails" roleURI="http://www.trpx.com/role/OperatingSegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://www.trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.trpx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Inventories" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_SharePremium" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_WarrantLiability" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RetainedEarnings" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="31" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_OtherEquityInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ParentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVentures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EventsAftertheReportingDate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="sprcy_DisclosureOfInventorieExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="sprcy_RelatedPartyBalancetextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_LeaseholdImprovementsMainlyRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="sprcy_CashScheduleofCashDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_FinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_Inventories" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_Governmentauthoritiescurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentsDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="sprcy_OfficeEquipmentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="sprcy_RightOfUseAssesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="sprcy_CostMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="sprcy_AccumulatedDepreciationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_NetDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="sprcy_CreditFromOthers" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_WarrantsLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_ShareIssuedToAConsultants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofRSUtransactionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dc5kA5J/7v3cS/u/uWbQWug36cM43Ghkxg==] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="sprcy_PurchasedGoodsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="sprcy_FreightMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="ifrs-full_CostOfSales" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AdvertisementMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AmazonFeesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_DepreciationMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_StorageAndShippingMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ManagementFeesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ExchangeRateDifferencesNetMember" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceCosts" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_EquityLossesFromTheInvestment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_CurrentAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="sprcy_OperatingTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXBioLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MinimumMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MaximumMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InitialInvestment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_AdditionalInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_OutstandingSharesPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_AdditionalInstallment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InstallmentPaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_CashConsideration" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_RemainingPurchaserAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_IssuedAndOutstandingSharePercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="sprcy_InitialPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_SharePricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ReverseShareSplitRatio" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_LeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_AreaOfLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_OptionToExtendLeaseTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_MonthlyLeaseFee" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_IntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ifrs-full_OtherIntangibleAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_PurchaseCostsValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_GrowthRatePercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_LongTermPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_DiscountRatePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_DekelLicenseAgreementDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_AnnualInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_AdditionalMilestoneAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_InstallmentAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_EstimatedAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_PreFundedUnitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_OverAllotmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_June2022WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_August2023FinancingRoundMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_October2023FinancingRoundMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="sprcy_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_CapitalRatio" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_ReverseSplitRatio" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ServicesExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_GrossProfit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateUnits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateUnitsPerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_IssuanceExpireTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_WarrantsAndExercise" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_PurchasePricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateGrossProceeds" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_CommitmentAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_SaleOfOrdinaryShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_SharePriceRate" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_InterestRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_InstallmentPayment" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_PaymentForPremiumPercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateIssuedAmount" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_DirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="sprcy_TwoThousandTwentyThreePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_FairValueOfShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_NumberOfOptionsOutstanding" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_ConvertIntoOrdinaryShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/OperatingSegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_SaleOfStockAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain_0" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_JeffsBrandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MergerAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SaleOfStockDomainDomain" xlink:to="sprcy_InitialPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="sprcy_PrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_InterestPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_Cash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_DeferredCashPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_BonusAmountReceived" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ServicesExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AcquiredOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateValues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateValueAdjusted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ListedSharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ComprehensiveLossOnInvestment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_CooperationAgreementAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentInvestments" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ExchangeOfCommonShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_OutstandingShareCapital" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_LicenseeIssuePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_MilestonesAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_LicenseAgreementDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_PercentageOfAggregateNetSales" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_NumberOfUnitsReceived" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_PurchasePricePerShare" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_NumberOfWarrantsHolds" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_WarrantsExpireDate" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MizaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_EnterpriseValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/EventsAftertheReportingDateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="sprcy_DebenturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="sprcy_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AutoMaxMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SciSparcMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_N2OFFMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_LoansReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_AggregateLoanAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_RepaidOfMonthlyInstallments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NotionalAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PurchasePricePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_ConsecutiveTradingDays" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_NumberOfWarrantsIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_WarrantExercisableTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_InvestmentIncome" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_AggregateInvestment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PercentageOfFinancingProceeds" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_RestrictedStockGrantPercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VestingPeriod" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.trpx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12gTitle" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>sprcy-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to equity holders of the company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Profit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments to the profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Decrease in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash for immediate withdrawal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract_lbl" xml:lang="en-US">Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Total inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl" xml:lang="en-US">Investment in Associates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl1" xml:lang="en-US">Investments in company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Investment in Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property and equipment, net at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl1" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US">Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsPayableAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="sprcy_OtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl" xml:lang="en-US">Investments in financial assets at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitmentsAbstract_lbl" xml:lang="en-US">Contingent Liabilities, Commitments, Claims and Liens [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssuedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Balance at January 1, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Balance at December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Received common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl3" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl4" xml:lang="en-US">Number of shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl5" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl5"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xml:lang="en-US">Share-Based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of Share Options , Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of Share Options, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract_lbl" xml:lang="en-US">Schedule of RSU transaction [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="sprcy_ScheduleOfRsuTransactionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Balance, January 1, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Balance, December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalInformationAbstract_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_AdditionalInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl" xml:lang="en-US">Income Statements Locations [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract_lbl" xml:lang="en-US">Significant Events during the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_SignificantEventsDuringTheReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Events After the Reporting Date [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short-term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Investments in short-term financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Bridge loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Investments in short-term financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other short-term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Engaged in a mutual share exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax Income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issuance of share capital in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl" xml:lang="en-US">Issuance of share capital, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Impairment to its intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Withdrawal of (investment in) restricted bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Withdrawal of (investment in) short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issue of share capital (net of issuance expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Invested amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl1" xml:lang="en-US">Gross cash proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl" xml:lang="en-US">Payment of issuance expenses related to previous period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl" xml:lang="en-US">(a) Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Investment in financial asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Equity losses from the investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl1" xml:lang="en-US">Equity losses from the investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Finance income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl" xml:lang="en-US">Increase in related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US">Sale (purchase) of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investment in a company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl" xml:lang="en-US">Bridge loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest paid on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterestMember_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl" xml:lang="en-US">Leasehold improvements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl" xml:lang="en-US">Leasehold improvements mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl" xml:lang="en-US">Goods in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_Governmentauthoritiescurrent_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl" xml:lang="en-US">Receivables in respect of downpayment on merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsDate_lbl" xml:lang="en-US">Investment date March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl" xml:lang="en-US">Investment following achievement of first milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl" xml:lang="en-US">Investment following achievement of second milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl" xml:lang="en-US">INVESTMENT IN FINANCIAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl" xml:lang="en-US">Schedule of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDebt_lbl" xml:lang="en-US">Open debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued vacation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract1" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsLiability_lbl" xml:lang="en-US">Warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_WarrantsLiability_lbl0" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Companys Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">EMPLOYEE BENEFIT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Expenses in respect of defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, Issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants (Note 18h</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareIssuedToAConsultants_lbl" xml:lang="en-US">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Underlying share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Underlying ordinary share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl2" xml:lang="en-US">Share price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of the ordinary shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Expected life of Share Options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2024Abstract" xlink:href="sprcy-20241231.xsd#sprcy_a2024Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2024Abstract_lbl" xml:lang="en-US">2024:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2024Abstract" xlink:to="sprcy_a2024Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">2023:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of RSU transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0" xml:lang="en-US">Granted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Expiry of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercise of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">REVENUES AND COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSoldAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostOfGoodsSoldAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract2" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl" xml:lang="en-US">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_BSalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">b. Sales and marketing expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BSalesAndMarketingExpensesAbstract" xlink:to="sprcy_BSalesAndMarketingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">c. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DOtherExpensesIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_DOtherExpensesIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DOtherExpensesIncomeAbstract_lbl" xml:lang="en-US">d. Other expenses (income):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DOtherExpensesIncomeAbstract" xlink:to="sprcy_DOtherExpensesIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EFinanceIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_EFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EFinanceIncomeAbstract_lbl" xml:lang="en-US">e. Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceIncomeAbstract" xlink:to="sprcy_EFinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FFinanceExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_FFinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FFinanceExpensesAbstract_lbl" xml:lang="en-US">f. Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FFinanceExpensesAbstract" xlink:to="sprcy_FFinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ContinuingOperationsAbstract_lbl" xml:lang="en-US">Continuing operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Basic loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl" xml:lang="en-US">Basic loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract3" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Loss (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Diluted loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl" xml:lang="en-US">Diluted loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">OPERATING SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExternalRevenues_lbl" xml:lang="en-US">External</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl" xml:lang="en-US">Segment loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl" xml:lang="en-US">Equity losses from the investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRevenueExpense_lbl" xml:lang="en-US">Finance expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Segment Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Segment Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RelatedPartyBalancetextBlock_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RelatedPartyBalancetextBlock" xlink:to="sprcy_RelatedPartyBalancetextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CurrentAsset_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl" xml:lang="en-US">Management fees (see also note 25a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl0" xml:lang="en-US">Warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl" xml:lang="en-US">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">EVENTS AFTER THE REPORTING DATE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US">Other expenses (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostMember_lbl" xml:lang="en-US">Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostMember" xlink:to="sprcy_CostMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationMember_lbl" xml:lang="en-US">Accumulated Depreciation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationMember" xlink:to="sprcy_AccumulatedDepreciationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeEquipmentsMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightOfUseAssesMember_lbl" xml:lang="en-US">Right of use asses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightOfUseAssesMember" xlink:to="sprcy_RightOfUseAssesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOptionsMember_lbl" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasedGoodsMember_lbl" xml:lang="en-US">Purchased goods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FreightMember_lbl" xml:lang="en-US">Freight [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share-based payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory, professional and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research and preclinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl" xml:lang="en-US">Chemistry and formulations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdvertisementMember_lbl" xml:lang="en-US">Advertising [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdvertisementMember" xlink:to="sprcy_AdvertisementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmazonFeesMember_lbl" xml:lang="en-US">Amazon fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DepreciationMember_lbl" xml:lang="en-US">Depreciation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationMember" xlink:to="sprcy_DepreciationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StorageAndShippingMember_lbl" xml:lang="en-US">Storage and shipping [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageAndShippingMember" xlink:to="sprcy_StorageAndShippingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ManagementFeesMember_lbl" xml:lang="en-US">Management fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ManagementFeesMember" xlink:to="sprcy_ManagementFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl" xml:lang="en-US">Professional and directors&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl" xml:lang="en-US">Business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryExpensesMember_lbl" xml:lang="en-US">Regulatory expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl" xml:lang="en-US">Office maintenance, rent and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl" xml:lang="en-US">Investor relations and business expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl" xml:lang="en-US">Loss from sale of property and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl" xml:lang="en-US">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl" xml:lang="en-US">Interest from loans to related parties and deposits	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl" xml:lang="en-US">Exchange rate differences, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl" xml:lang="en-US">Issuance expenses related to warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl" xml:lang="en-US">Finance expense in respect of leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl" xml:lang="en-US">Finance expenses from interest and commissions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DrugDevelopmentMember_lbl" xml:lang="en-US">Drug Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesMember_lbl" xml:lang="en-US">Online Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xml:lang="en-US">Other related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US">Classes of ordinary shares [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingTerm_lbl" xml:lang="en-US">Operating term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestment_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInvestment_lbl" xml:lang="en-US">Additional investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInstallment_lbl" xml:lang="en-US">Additional installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaid_lbl" xml:lang="en-US">Installment paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashConsideration_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl" xml:lang="en-US">Purchaser remaining ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RemainingPurchaserAmount_lbl" xml:lang="en-US">Purchaser equal valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl" xml:lang="en-US">Issued and outstanding share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl0" xml:lang="en-US">Share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePerShare_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReverseShareSplitRatio_lbl" xml:lang="en-US">Reverse share split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary shares par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AreaOfLease_lbl" xml:lang="en-US">Area of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl" xml:lang="en-US">Option to extend lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MonthlyLeaseFee_lbl" xml:lang="en-US">Monthly lease fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_Cash_lbl1" xml:lang="en-US">Cash payment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl" xml:lang="en-US">Additional deferred cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCostsValue_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Acquisition of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrowthRatePercentage_lbl" xml:lang="en-US">Growth rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LongTermPercentage_lbl" xml:lang="en-US">Long term, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DiscountRatePercentage_lbl" xml:lang="en-US">Discount rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl" xml:lang="en-US">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl" xml:lang="en-US">Carryforward tax losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl" xml:lang="en-US">Milestone payments, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AnnualInvestment_lbl" xml:lang="en-US">Annual investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalMilestoneAmount_lbl" xml:lang="en-US">Additional milestone amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentAmount_lbl" xml:lang="en-US">Installment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EstimatedAmount_lbl" xml:lang="en-US">Estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Capital purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalCommitments_lbl" xml:lang="en-US">Capital warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Units received (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalRatio_lbl" xml:lang="en-US">Capital ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReverseSplitRatio_lbl" xml:lang="en-US">Reverse split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US">Services rendered amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ServicesExpense_lbl0" xml:lang="en-US">Services expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl" xml:lang="en-US">Issuance of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnits_lbl" xml:lang="en-US">Number of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnitsPerShare_lbl" xml:lang="en-US">Units per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpireTerm_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsAndExercise_lbl" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US">Purchase sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfOrdinaryShares_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePriceRate_lbl" xml:lang="en-US">Share price rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestRate_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPayment_lbl" xml:lang="en-US">Installment payment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentForPremiumPercentage_lbl" xml:lang="en-US">Payment for premium percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateIssuedAmount_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Commitment fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl" xml:lang="en-US">Fair value of share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl" xml:lang="en-US">Ordinary shares granted discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl" xml:lang="en-US">Share options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl" xml:lang="en-US">Conversion of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US">Vest over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercisable of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIntangibleAssets_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DeferredCashPayment_lbl" xml:lang="en-US">Deferred cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl" xml:lang="en-US">Other fee expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmountReceived_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AcquiredOrdinaryShares_lbl" xml:lang="en-US">Acquired ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValues_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValueAdjusted_lbl" xml:lang="en-US">Aggregate values adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ListedSharePrice_lbl" xml:lang="en-US">Listed share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl" xml:lang="en-US">Loss on investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CooperationAgreementAmount_lbl" xml:lang="en-US">Cooperation Agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeOfCommonShares_lbl" xml:lang="en-US">Exchange of Common Shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingShareCapital_lbl" xml:lang="en-US">Outstanding share capital, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LicenseeIssuePrice_lbl" xml:lang="en-US">Licensee issue price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MilestonesAmount_lbl" xml:lang="en-US">Milestones amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl" xml:lang="en-US">Aggregate net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfUnitsReceived_lbl" xml:lang="en-US">Number of units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US">Aggregate consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl0" xml:lang="en-US">Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfWarrantsHolds_lbl" xml:lang="en-US">Warrants holds (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsExpireDate_lbl" xml:lang="en-US">Warrants expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl" xml:lang="en-US">Aggregate number of the outstanding ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EnterpriseValue_lbl" xml:lang="en-US">Enterprise value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl" xml:lang="en-US">Cash position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Loan amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateLoanAmount_lbl" xml:lang="en-US">Aggregate loan amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl" xml:lang="en-US">Monthly installments (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US">Aggregate principal amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePercentage_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl" xml:lang="en-US">Volume weighted average price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl" xml:lang="en-US">Volume weighted average price during consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConsecutiveTradingDays_lbl" xml:lang="en-US">Consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl" xml:lang="en-US">Volume weighted average price of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfWarrantsIssued_lbl" xml:lang="en-US">Number of warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl" xml:lang="en-US">Volume weighted average price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantExercisableTerm_lbl" xml:lang="en-US">Warrant exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentIncome_lbl" xml:lang="en-US">Investing amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateInvestment_lbl" xml:lang="en-US">Aggregate investment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl" xml:lang="en-US">Percentage of fully diluted capital stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl" xml:lang="en-US">Percentage of financing proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Financing proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl" xml:lang="en-US">Restricted stock grant percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl" xml:lang="en-US">asis of presentation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dS6SLkh98Dq2fjc4Ib+yx1EkzTCJcnrN+A==] CSR-->
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl" xml:lang="en-US">The operating cycle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl" xml:lang="en-US">Consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl" xml:lang="en-US">Acquisition of a single asset company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl" xml:lang="en-US">Investment in joint arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">Investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US">Finance income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl" xml:lang="en-US">MitoCare X Bio Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXMember_lbl" xml:lang="en-US">MitoCareX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialPublicOfferingMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialPublicOfferingMember" xlink:to="sprcy_InitialPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseMember_lbl" xml:lang="en-US">2021 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIntangibleAssetsMember_lbl" xml:lang="en-US">Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssetsMember" xlink:to="ifrs-full_OtherIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israeli [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Pre-Funded Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PreFundedUnitsMember_lbl" xml:lang="en-US">Pre-Funded Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitsMember" xlink:to="sprcy_PreFundedUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022WarrantsMember_lbl" xml:lang="en-US">June 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_August2023FinancingRoundMember_lbl" xml:lang="en-US">August 2023 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_August2023FinancingRoundMember" xlink:to="sprcy_August2023FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OverAllotmentMember_lbl" xml:lang="en-US">Over Allotment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_October2023FinancingRoundMember_lbl" xml:lang="en-US">October 2023 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_October2023FinancingRoundMember" xlink:to="sprcy_October2023FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SEPAMember_lbl" xml:lang="en-US">SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DirectorsMember" xlink:to="sprcy_DirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Common shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xml:lang="en-US">Restricted Share Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesSegmentMember_lbl" xml:lang="en-US">Online Sales Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesSegmentMember" xlink:to="sprcy_OnlineSalesSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_JeffsBrandsMember_lbl" xml:lang="en-US">Jeffs&#8217; Brands [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MergerAgreementMember" xlink:to="sprcy_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MizaMember_lbl" xml:lang="en-US">Miza [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SubsequentEventsMember_lbl" xml:lang="en-US">Subsequent Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxMember_lbl" xml:lang="en-US">AutoMax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SciSparcMember_lbl" xml:lang="en-US">SciSparc&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DebenturesMember_lbl" xml:lang="en-US">Debentures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DebenturesMember" xlink:to="sprcy_DebenturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_N2OFFMember_lbl" xml:lang="en-US">N2OFF [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_N2OFFMember" xlink:to="sprcy_N2OFFMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US">Components of equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesTable_lbl" xml:lang="en-US">Operating Segments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesTable" xlink:to="sprcy_OperatingSegmentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xml:lang="en-US">Classes of property, plant and equipment [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeDomain_lbl" xml:lang="en-US">Range [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashScheduleofCashDetailsTable_lbl" xml:lang="en-US">Cash - Schedule of Cash (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="sprcy_CashScheduleofCashDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_lbl" xml:lang="en-US">Schedule of Cash [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US">Carrying amount [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl" xml:lang="en-US">Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xml:lang="en-US">Levels of fair value hierarchy [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Company&apos;s Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems_lbl" xml:lang="en-US">Schedule of Company&apos;s Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl" xml:lang="en-US">Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_lbl" xml:lang="en-US">IncomeStatementsLocationsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsDomain_lbl" xml:lang="en-US">Segments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsDomain" xlink:to="ifrs-full_SegmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl" xml:lang="en-US">Operating Segments - Schedule of Operating Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US">Schedule of Operating Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xml:lang="en-US">Categories of related parties [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xml:lang="en-US">Investment in Associates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_lbl" xml:lang="en-US">Classes of ordinary shares [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl" xml:lang="en-US">Investment in Financial Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US">Investment in Financial Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsTable" xlink:to="sprcy_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsTable_lbl" xml:lang="en-US">Intangible Asset (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsTable" xlink:to="sprcy_IntangibleAssetDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Asset [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xml:lang="en-US">Geographical areas [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="sprcy_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US">Classes of share capital [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xml:lang="en-US">Types of share-based payment arrangements [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsTable_lbl" xml:lang="en-US">Operating Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsTable" xlink:to="sprcy_OperatingSegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsLineItems_lbl" xml:lang="en-US">Operating Segments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfStockDomainDomain_lbl" xml:lang="en-US">SaleOfStockDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockDomainDomain" xlink:to="sprcy_SaleOfStockDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems_lbl" xml:lang="en-US">Significant Events During the Reporting Period [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_SignificantEventsDuringTheReportingPeriodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Classes of financial instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable_lbl" xml:lang="en-US">Events After the Reporting Date (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US">Events After the Reporting Date [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AcquiredOrdinaryShares_lbl0" xml:lang="en-US">The number of shares acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInstallment_lbl0" xml:lang="en-US">The amount of additional installment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInvestment_lbl0" xml:lang="en-US">The amount of additional investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl0" xml:lang="en-US">Adjustments for increase in related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0" xml:lang="en-US">Adjustments for losses from remeasurement of investment in financial assets&#xd;
  to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Adjustments for group&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateInvestment_lbl0" xml:lang="en-US">aggregate investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateIssuedAmount_lbl0" xml:lang="en-US">Aggregate issued amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateLoanAmount_lbl0" xml:lang="en-US">Aggregate loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl0" xml:lang="en-US">Aggregate number of the outstanding ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnits_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnitsPerShare_lbl0" xml:lang="en-US">Per share of aggregate units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValueAdjusted_lbl0" xml:lang="en-US">The amount of aggregate values adjusted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValues_lbl0" xml:lang="en-US">The amount of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AnnualInvestment_lbl0" xml:lang="en-US">Amount of annual investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AreaOfLease_lbl0" xml:lang="en-US">Area of Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmountReceived_lbl0" xml:lang="en-US">Bonus amount received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CapitalRatio_lbl0" xml:lang="en-US">Capital ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashConsideration_lbl0" xml:lang="en-US">Cash consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CommitmentAmount_lbl0" xml:lang="en-US">Commitment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl0" xml:lang="en-US">Amount of comprehensive loss on investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl0" xml:lang="en-US">Represents the share of restricted share units convert into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CooperationAgreementAmount_lbl0" xml:lang="en-US">Cooperation Agreement amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFromOthers_lbl0" xml:lang="en-US">The amount of credit of others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CurrentAsset_lbl0" xml:lang="en-US">The amount of current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DeferredCashPayment_lbl0" xml:lang="en-US">Deferred cash payments amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl0" xml:lang="en-US">Dekel license agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">The amount of depreciation of intangible asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Description of accounting policy cost of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in Consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in operating cycle Explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for acquisition of a single asset company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl0" xml:lang="en-US">The description of accounting policies for basis of presentation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">The entire disclosue of cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about defined contribution plans explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of expenses due to share-based compensation explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value for share options granted explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl0" xml:lang="en-US">The tabular disclosure of inventories.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl0" xml:lang="en-US">The disclosure of the investment financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">Disclosure of detailed inforamtion about issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl0" xml:lang="en-US">The disclosure of trade payables explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of accounts receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DiscountRatePercentage_lbl0" xml:lang="en-US">Percentage of discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl0" xml:lang="en-US">Represents the par value of effect of potential dilutive ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EnterpriseValue_lbl0" xml:lang="en-US">The amount of enterprise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl0" xml:lang="en-US">Equity losses from the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeOfCommonShares_lbl0" xml:lang="en-US">Number of shares exchanged.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExternalRevenues_lbl0" xml:lang="en-US">Amount of external revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_Governmentauthoritiescurrent_lbl0" xml:lang="en-US">Represent the government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialInvestment_lbl0" xml:lang="en-US">Initial investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentAmount_lbl0" xml:lang="en-US">Amount of installment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaid_lbl0" xml:lang="en-US">The amount of installment paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPayment_lbl0" xml:lang="en-US">Installment payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestPercentage_lbl0" xml:lang="en-US">Interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestRate_lbl0" xml:lang="en-US">Interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl0" xml:lang="en-US">The amount of investment following achievement of first milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl0" xml:lang="en-US">Investment following achievement of second milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentsDate_lbl0" xml:lang="en-US">The amount of investment date,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceExpireTerm_lbl0" xml:lang="en-US">Issuance expire term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfAggregateShares_lbl0" xml:lang="en-US">The issuance of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl0" xml:lang="en-US">Number of issuance of share capital &#8211; in respect of January 2024 SEPA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0" xml:lang="en-US">The amount of issue of share capital, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl0" xml:lang="en-US">Issued and outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0" xml:lang="en-US">The amount of compensation to key management personnel in the form of management fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl0" xml:lang="en-US">The leasehold improvements rate used for mainly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LicenseAgreementDescription_lbl0" xml:lang="en-US">The description of the license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LicenseeIssuePrice_lbl0" xml:lang="en-US">The amount of licensee, reflecting an issue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ListedSharePrice_lbl0" xml:lang="en-US">Amount of listed shares price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LongTermPercentage_lbl0" xml:lang="en-US">The percentage of long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MilestonesAmount_lbl0" xml:lang="en-US">Milestones amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MonthlyLeaseFee_lbl0" xml:lang="en-US">Monthly lease fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl0" xml:lang="en-US">Represents the amount of options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl0" xml:lang="en-US">Number of Other Equity Instruments Vested in Share based Payment Arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfUnitsReceived_lbl0" xml:lang="en-US">Number of units received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfWarrantsHolds_lbl0" xml:lang="en-US">Number of warrants holds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfWarrantsIssued_lbl0" xml:lang="en-US">Number of warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0" xml:lang="en-US">The amount of net operating loss carryforward tax as of the reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl0" xml:lang="en-US">Option to extend lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl0" xml:lang="en-US">Ordinary shares granted discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingShareCapital_lbl0" xml:lang="en-US">Percentage of outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentForPremiumPercentage_lbl0" xml:lang="en-US">Payment for premium percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl0" xml:lang="en-US">Represents the amount of payments of additional deferred cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl0" xml:lang="en-US">Percentage of aggregate net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl0" xml:lang="en-US">Percentage of financing proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl0" xml:lang="en-US">Percentage of fully diluted capital stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseCostsValue_lbl0" xml:lang="en-US">The amount of purchase costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePerShare_lbl0" xml:lang="en-US">The purchase price is the price an investor pays for an investment, and the price becomes the investor&apos;s cost basis for calculating gain or loss when selling the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePercentage_lbl0" xml:lang="en-US">Represents the purchase price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl0" xml:lang="en-US">Purchaser remaining ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl0" xml:lang="en-US">The amount of receivables in respect of downpayment on merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RemainingPurchaserAmount_lbl0" xml:lang="en-US">Remaining purchaser amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl0" xml:lang="en-US">Repaid of Monthly installments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl0" xml:lang="en-US">Restricted stock grant percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReverseShareSplitRatio_lbl0" xml:lang="en-US">Reverse share split ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReverseSplitRatio_lbl0" xml:lang="en-US">Reverse split ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl0" xml:lang="en-US">The amount of sale of minority interest in subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SaleOfOrdinaryShares_lbl0" xml:lang="en-US">Sale of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl0" xml:lang="en-US">The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareCapitalPercentage_lbl1" xml:lang="en-US">Share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareIssuedToAConsultants_lbl0" xml:lang="en-US">Number of share issued to consultants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePerShare_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePriceRate_lbl0" xml:lang="en-US">Share price rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VestingPeriod_lbl0" xml:lang="en-US">Vesting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares during the consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares of preceding the closing of trading day.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares on the day prior to the closing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl0" xml:lang="en-US">Volume weighted average price per warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantExercisableTerm_lbl0" xml:lang="en-US">Warrant exercisable term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsExpireDate_lbl0" xml:lang="en-US">Warrants expire date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl1" xml:lang="en-US">Salepurchase Of Property And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfAggregateShares_lbl1" xml:lang="en-US">Issuance Of Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl0" xml:lang="en-US">Financial assets, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DirectorsMember_lbl0" xml:lang="en-US">Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DirectorsMember" xlink:to="sprcy_DirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StorageAndShippingMember_lbl0" xml:lang="en-US">Storage And Shipping Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageAndShippingMember" xlink:to="sprcy_StorageAndShippingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightOfUseAssesMember_lbl0" xml:lang="en-US">Right Of Use Asses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightOfUseAssesMember" xlink:to="sprcy_RightOfUseAssesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">CGeneral And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl1" xml:lang="en-US">Number Of Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl0" xml:lang="en-US">Income Statements Locations Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl0" xml:lang="en-US">Segment Reporting Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateInvestment_lbl1" xml:lang="en-US">Aggregate Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContinuingOperationsAbstract_lbl0" xml:lang="en-US">Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1" xml:lang="en-US">Adjustments For Losses From Remeasurement Of Investment In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl1" xml:lang="en-US">Receivables In Respect Of Downpayment On Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FFinanceExpensesAbstract_lbl0" xml:lang="en-US">FFinance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FFinanceExpensesAbstract" xlink:to="sprcy_FFinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SEPAMember_lbl0" xml:lang="en-US">SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SciSparcMember_lbl0" xml:lang="en-US">Sci Sparc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl2" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl1" xml:lang="en-US">Investment Achievement Of First Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl1" xml:lang="en-US">Leasehold Improvements Mainly Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl1" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl1" xml:lang="en-US">Payments Of Additional Deferred Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCostsValue_lbl1" xml:lang="en-US">Purchase Costs Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AnnualInvestment_lbl1" xml:lang="en-US">Annual Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl0" xml:lang="en-US">Research And Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl1" xml:lang="en-US">Restricted Stock Grant Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1" xml:lang="en-US">Key Management Personnel Compensation Management Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl0" xml:lang="en-US">Notional amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashConsideration_lbl1" xml:lang="en-US">Cash Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl0" xml:lang="en-US">Other finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl0" xml:lang="en-US">Operating Segments Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValues_lbl1" xml:lang="en-US">Aggregate Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl2" xml:lang="en-US">Investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ListedSharePrice_lbl1" xml:lang="en-US">Listed Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl0" xml:lang="en-US">Chemistry And Formulations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl0" xml:lang="en-US">Interest From Loans To Related Parties And Deposits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OverAllotmentMember_lbl0" xml:lang="en-US">Over Allotment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl1" xml:lang="en-US">Repaid Of Monthly Installments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl1" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Disclosure Of Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl1" xml:lang="en-US">Sale Of Minority Interest In Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl0" xml:lang="en-US">Loans received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for restricted cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExternalRevenues_lbl1" xml:lang="en-US">External Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares Of During The Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxMember_lbl0" xml:lang="en-US">Auto Max Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1" xml:lang="en-US">Description Of Accounting Policy For Consolidatedfinancialstatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Cost Of Sales Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsecutiveTradingDays_lbl1" xml:lang="en-US">Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaid_lbl1" xml:lang="en-US">Installment Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl1" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0" xml:lang="en-US">Finance Expense In Respect Of Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DeferredCashPayment_lbl1" xml:lang="en-US">Deferred Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Current restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInvestment_lbl1" xml:lang="en-US">Additional Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EnterpriseValue_lbl1" xml:lang="en-US">Enterprise Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Adjustments For Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl1" xml:lang="en-US">Effect Of Potential Dilutive Ordinary Shares Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesMember_lbl0" xml:lang="en-US">Online Sales Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasedGoodsMember_lbl0" xml:lang="en-US">Purchased Goods Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateLoanAmount_lbl1" xml:lang="en-US">Aggregate Loan Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1" xml:lang="en-US">Issue Of Share Capital Net Of Issue Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl1" xml:lang="en-US">Comprehensive Loss On Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl1" xml:lang="en-US">Option To Extend Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeOfCommonShares_lbl1" xml:lang="en-US">Exchange Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0" xml:lang="en-US">Impairment loss recognised in other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Operating Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:to="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0" xml:lang="en-US">Disclosure Of Significant Events During The Reporting Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterestMember_lbl0" xml:lang="en-US">Other equity interest [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl1" xml:lang="en-US">Investment Achievement Of Second Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl0" xml:lang="en-US">Gain On Sale Of Patent License Netnet Of Polyrizon Ltd Holdings Sold Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentForPremiumPercentage_lbl1" xml:lang="en-US">Payment For Premium Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl0" xml:lang="en-US">Cash advances and loans made to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_ScheduleOfCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAndExercise_lbl0" xml:lang="en-US">Warrants And Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl0" xml:lang="en-US">Other cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MizaMember_lbl0" xml:lang="en-US">Miza Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPayment_lbl1" xml:lang="en-US">Installment Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseMember_lbl0" xml:lang="en-US">Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsDate_lbl1" xml:lang="en-US">Investments Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValueAdjusted_lbl1" xml:lang="en-US">Aggregate Value Adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Schedule Of Companys Financial Instruments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:to="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl1" xml:lang="en-US">Adjustments For Increase In Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_October2023FinancingRoundMember_lbl0" xml:lang="en-US">October2023 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_October2023FinancingRoundMember" xlink:to="sprcy_October2023FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsExpireDate_lbl1" xml:lang="en-US">Warrants Expire Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl0" xml:lang="en-US">Current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0" xml:lang="en-US">Payment Of Issuance Expenses Related To Previous Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl0" xml:lang="en-US">Tax rate effect of foreign tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SubsequentEventsMember_lbl0" xml:lang="en-US">Subsequent Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Fair Value Was Calculated Using The Black Scholes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl1" xml:lang="en-US">Equity Losses From The Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl1" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIntangibleAssets_lbl0" xml:lang="en-US">Other intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInstallment_lbl1" xml:lang="en-US">Additional Installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfWarrantsIssued_lbl1" xml:lang="en-US">Number Of Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of depreciation and amortisation expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0" xml:lang="en-US">Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareCapitalPercentage_lbl2" xml:lang="en-US">Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Disclosue Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1" xml:lang="en-US">Description Of Acquisition Of ASingle Asset Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostMember_lbl0" xml:lang="en-US">Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostMember" xlink:to="sprcy_CostMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestment_lbl1" xml:lang="en-US">Initial Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl1" xml:lang="en-US">Dekel License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1" xml:lang="en-US">Description Of Accounting Policy Foroperatingcycle Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plans Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl1" xml:lang="en-US">Consideration paid (received)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CooperationAgreementAmount_lbl1" xml:lang="en-US">Cooperation Agreement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_Governmentauthoritiescurrent_lbl1" xml:lang="en-US">Governmentauthoritiescurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0" xml:lang="en-US">Option life, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingShareCapital_lbl1" xml:lang="en-US">Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXMember_lbl0" xml:lang="en-US">Mito Care XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl0" xml:lang="en-US">Cost Of Goods Sold Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrowthRatePercentage_lbl0" xml:lang="en-US">Growth Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsLiability_lbl1" xml:lang="en-US">Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0" xml:lang="en-US">Losses From Remeasurement Of Investment In Financial Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl1" xml:lang="en-US">Services expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfWarrantsHolds_lbl1" xml:lang="en-US">Number Of Warrants Holds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RelatedPartyBalancetextBlock_lbl0" xml:lang="en-US">Related Party Balancetext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RelatedPartyBalancetextBlock" xlink:to="sprcy_RelatedPartyBalancetextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl0" xml:lang="en-US">Exchange Rate Differences Net Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information To The Items Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnits_lbl1" xml:lang="en-US">Aggregate Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantExercisableTerm_lbl1" xml:lang="en-US">Warrant Exercisable Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Other Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl1" xml:lang="en-US">Percentage Of Aggregate Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AreaOfLease_lbl1" xml:lang="en-US">Area Of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl2" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Other Equity Instruments Vested In Share Based Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Revenues And Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value For Share Options Granted Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value For Share Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares On The Day Prior To The Closing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FreightMember_lbl0" xml:lang="en-US">Freight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesSegmentMember_lbl0" xml:lang="en-US">Online Sales Segment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesSegmentMember" xlink:to="sprcy_OnlineSalesSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract_lbl0" xml:lang="en-US">BSales And Marketing Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BSalesAndMarketingExpensesAbstract" xlink:to="sprcy_BSalesAndMarketingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalMilestoneAmount_lbl0" xml:lang="en-US">Additional Milestone Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LicenseAgreementDescription_lbl1" xml:lang="en-US">License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl1" xml:lang="en-US">Percentage Of Financing Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClinicalStudiesMember_lbl0" xml:lang="en-US">Clinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfUnitsReceived_lbl1" xml:lang="en-US">Number Of Units Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of interests in investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl1" xml:lang="en-US">Disclosure Of Inventorie Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0" xml:lang="en-US">Office Maintenance Rent And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1" xml:lang="en-US">Operating Loss Carryforwards Tax Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MergerAgreementMember_lbl0" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MergerAgreementMember" xlink:to="sprcy_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfOrdinaryShares_lbl1" xml:lang="en-US">Sale Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CommitmentAmount_lbl1" xml:lang="en-US">Commitment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl1" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareIssuedToAConsultants_lbl1" xml:lang="en-US">Share Issued To AConsultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl1" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingTerm_lbl0" xml:lang="en-US">Operating Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PreFundedUnitsMember_lbl0" xml:lang="en-US">Pre Funded Units Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitsMember" xlink:to="sprcy_PreFundedUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentIncome_lbl0" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateIssuedAmount_lbl1" xml:lang="en-US">Aggregate Issued Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0" xml:lang="en-US">Sale or issue of treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl1" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DOtherExpensesIncomeAbstract_lbl0" xml:lang="en-US">DOther Expenses Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DOtherExpensesIncomeAbstract" xlink:to="sprcy_DOtherExpensesIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl1" xml:lang="en-US">Convert Into Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl1" xml:lang="en-US">Fair Value Of Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReverseSplitRatio_lbl1" xml:lang="en-US">Reverse Split Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0" xml:lang="en-US">Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl2" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DiscountRatePercentage_lbl1" xml:lang="en-US">Discount Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXBioLtdMember_lbl0" xml:lang="en-US">Mito Care XBio Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl0" xml:lang="en-US">Loss From Sale Of Property And Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdvertisementMember_lbl0" xml:lang="en-US">Advertisement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdvertisementMember" xlink:to="sprcy_AdvertisementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl0" xml:lang="en-US">Significant Non Cash Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitments_lbl0" xml:lang="en-US">Capital commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl0" xml:lang="en-US">Current trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentMember_lbl0" xml:lang="en-US">Share Based Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl0" xml:lang="en-US">Business Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIntangibleAssetsMember_lbl0" xml:lang="en-US">Other intangible assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssetsMember" xlink:to="ifrs-full_OtherIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl1" xml:lang="en-US">Ordinary Shares Granted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation rate, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MilestonesAmount_lbl1" xml:lang="en-US">Milestones Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParentMember_lbl0" xml:lang="en-US">Parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl1" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investments other than investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl1" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0" xml:lang="en-US">Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPercentage_lbl1" xml:lang="en-US">Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LicenseeIssuePrice_lbl1" xml:lang="en-US">Licensee Issue Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl2" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EstimatedAmount_lbl0" xml:lang="en-US">Estimated Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RemainingPurchaserAmount_lbl1" xml:lang="en-US">Remaining Purchaser Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl0" xml:lang="en-US">Other related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0" xml:lang="en-US">Issuance Expenses Related To Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EFinanceIncomeAbstract_lbl0" xml:lang="en-US">EFinance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceIncomeAbstract" xlink:to="sprcy_EFinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl1" xml:lang="en-US">Aggregate Number Of Outstanding Ordinary Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0" xml:lang="en-US">Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CurrentAsset_lbl1" xml:lang="en-US">Current Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclourse Of Accounts Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationMember_lbl0" xml:lang="en-US">Accumulated Depreciation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationMember" xlink:to="sprcy_AccumulatedDepreciationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0" xml:lang="en-US">Finance Expenses From Interest And Commissions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl0" xml:lang="en-US">Current inventories in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Three Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2024Abstract_lbl0" xml:lang="en-US">a2024 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2024Abstract" xlink:to="sprcy_a2024Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MonthlyLeaseFee_lbl1" xml:lang="en-US">Monthly Lease Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DebenturesMember_lbl0" xml:lang="en-US">Debentures Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DebenturesMember" xlink:to="sprcy_DebenturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AcquiredOrdinaryShares_lbl1" xml:lang="en-US">Acquired Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePriceRate_lbl1" xml:lang="en-US">Share Price Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Trade Payables Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Of The Assets At Annual Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of redesignated financial assets and liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl1" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Sales And Gross Profit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePercentage_lbl1" xml:lang="en-US">Purchase Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl1" xml:lang="en-US">Disclosure Of Investment Financial Assets Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_N2OFFMember_lbl0" xml:lang="en-US">N2 OFFMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_N2OFFMember" xlink:to="sprcy_N2OFFMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl1" xml:lang="en-US">Issued And Outstanding Share Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmountReceived_lbl1" xml:lang="en-US">Bonus Amount Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRevenueExpense_lbl0" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022WarrantsMember_lbl0" xml:lang="en-US">June2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfStockAxis_lbl0" xml:lang="en-US">Sale Of Stock Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFromOthers_lbl1" xml:lang="en-US">Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryExpensesMember_lbl0" xml:lang="en-US">Regulatory Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpireTerm_lbl1" xml:lang="en-US">Issuance Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl4" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl1" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl1" xml:lang="en-US">Descriptionof Basisofpresentationofthefinancialstatements Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePerShare_lbl1" xml:lang="en-US">Share Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0" xml:lang="en-US">Proportion of ownership interest in associate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedWarrantsMember_lbl1" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Non-current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl2" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares Of Preceding The Closing Of Trading Day</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalRatio_lbl1" xml:lang="en-US">Capital Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DrugDevelopmentMember_lbl0" xml:lang="en-US">Drug Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl0" xml:lang="en-US">Professional And Directors Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Depreciation Of Intangible Assets Other Than Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Intangible Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeEquipmentsMember_lbl0" xml:lang="en-US">Office Equipments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Disposals, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnitsPerShare_lbl1" xml:lang="en-US">Aggregate Units Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmazonFeesMember_lbl0" xml:lang="en-US">Amazon Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices Of Share Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LongTermPercentage_lbl1" xml:lang="en-US">Long Term Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestRate_lbl1" xml:lang="en-US">Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl4" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialPublicOfferingMember_lbl0" xml:lang="en-US">Initial Public Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialPublicOfferingMember" xlink:to="sprcy_InitialPublicOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl2" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl1" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl0" xml:lang="en-US">Restricted share units [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ManagementFeesMember_lbl0" xml:lang="en-US">Management Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ManagementFeesMember" xlink:to="sprcy_ManagementFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReverseShareSplitRatio_lbl1" xml:lang="en-US">Reverse Share Split Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of accrued expenses and other liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of all instruments on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl1" xml:lang="en-US">Volume Weighted Average Price Per Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0" xml:lang="en-US">Regulatory Professional And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDebt_lbl0" xml:lang="en-US">Net debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VestingPeriod_lbl1" xml:lang="en-US">Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect SEPA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_August2023FinancingRoundMember_lbl0" xml:lang="en-US">August2023 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_August2023FinancingRoundMember" xlink:to="sprcy_August2023FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl0" xml:lang="en-US">Other fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl0" xml:lang="en-US">Transfers of research and development to entity, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOptionsMember_lbl0" xml:lang="en-US">Share options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0" xml:lang="en-US">Investor Relations And Business Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl1" xml:lang="en-US">Purchaser Remaining Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_JeffsBrandsMember_lbl0" xml:lang="en-US">Jeffs Brands Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DepreciationMember_lbl0" xml:lang="en-US">Depreciation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationMember" xlink:to="sprcy_DepreciationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0" xml:lang="en-US">Disclosure of associates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0" xml:lang="en-US">Categories of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentAmount_lbl1" xml:lang="en-US">Installment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Companys Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>sprcy-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Apr 24 20:36:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://www.trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://www.trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://www.trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://www.trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_General" roleURI="http://www.trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://www.trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Cash" roleURI="http://www.trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Inventory" roleURI="http://www.trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://www.trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVentures" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVentures"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://www.trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Leases" roleURI="http://www.trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://www.trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAsset" roleURI="http://www.trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayables" roleURI="http://www.trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://www.trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstruments" roleURI="http://www.trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncome" roleURI="http://www.trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Equity" roleURI="http://www.trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://www.trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShare" roleURI="http://www.trpx.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegments" roleURI="http://www.trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://www.trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://www.trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_CashTables" roleURI="http://www.trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InventoryTables" roleURI="http://www.trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://www.trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesTables" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://www.trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://www.trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayablesTables" roleURI="http://www.trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://www.trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://www.trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityTables" roleURI="http://www.trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://www.trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShareTables" roleURI="http://www.trpx.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://www.trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" roleURI="http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://www.trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://www.trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://www.trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCompanysFinancialInstrumentsTable" roleURI="http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://www.trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofRSUtransactionTable" roleURI="http://www.trpx.com/role/ScheduleofRSUtransactionTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" roleURI="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_GeneralDetails" roleURI="http://www.trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://www.trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesDetails" roleURI="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LeasesDetails" roleURI="http://www.trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://www.trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://www.trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://www.trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityDetails" roleURI="http://www.trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsDetails" roleURI="http://www.trpx.com/role/OperatingSegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://www.trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_WarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ParentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfShareCapitalNetOfIssueExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="AdjustmentsForIncreaseInRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="SalepurchaseOfPropertyAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="SignificantNonCashTransactionsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVentures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="DisclosureOfInvestmentFinancialAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableAbstract" xlink:to="DisclosureOfOtherAccountsPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EventsAftertheReportingDate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAcquisitionOfASingleAssetCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="DisclosureOfInventorieExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="DisclourseOfAccountsReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesandJointVenturesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesTablesTable" xlink:to="InvestmentinAssociatesandJointVenturesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="DisclosureOfTradePayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfIssuedAndOutstandingShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesTable" xlink:to="OperatingSegmentsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyBalancetextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:to="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="LeaseholdImprovementsMainlyRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashScheduleofCashDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_FinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_Inventories" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="Governmentauthoritiescurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ReceivablesInRespectOfDownpaymentOnMerger" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentsDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentAchievementOfSecondMilestone" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentAchievementOfFirstMilestone" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CostMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="AccumulatedDepreciationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="OfficeEquipmentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="RightOfUseAssesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="DepreciationOfIntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_NetDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ShareIssuedToAConsultants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="IssuanceOfShareCapitalInRespectSEPA" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHEdGawgUi5SQ7dAE2Io5c+733Zhked1fegGDPSq10wtplqsqjy7Or9y2vY1HPMdFh02Q5FLb9ZPNgQauTbbmkgCFCVh7h3+ftlIy8xOCljMF2cQkx86gbnNEjGbIxm51d1nZ3Oz+36dWPfPvA7idgTs6mBntLbHi7k0HEjmYRztg==] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="a2024Abstract" xlink:href="sprcy-20241231.xsd#sprcy_a2024Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="a2024Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofRSUtransactionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="PurchasedGoodsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="FreightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="ifrs-full_CostOfSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryProfessionalAndOtherExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AdvertisementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AmazonFeesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="DepreciationMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="StorageAndShippingMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ManagementFeesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossFromSaleOfPropertyAndEquipmentMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InterestFromLoansToRelatedPartiesAndDepositsMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ExchangeRateDifferencesNetMember" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IssuanceExpensesRelatedToWarrantsMember" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpenseInRespectOfLeasesMember" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpensesFromInterestAndCommissionsMember" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="AResearchAndDevelopmentExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BSalesAndMarketingExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_BSalesAndMarketingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="BSalesAndMarketingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BSalesAndMarketingExpensesAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="CGeneralAndAdministrativeExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DOtherExpensesIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_DOtherExpensesIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="DOtherExpensesIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DOtherExpensesIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EFinanceIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_EFinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="EFinanceIncomeAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EFinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="FFinanceExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_FFinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="FFinanceExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FFinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ContinuingOperationsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="EquityLossesFromTheInvestment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="CurrentAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="SaleOfMinorityInterestInSubsidiary" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="KeyManagementPersonnelCompensationManagementFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="OperatingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesandJointVenturesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="srt_MinimumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="srt_MaximumMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="InitialInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="AdditionalInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="OutstandingSharesPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="AdditionalInstallment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="InstallmentPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="CashConsideration" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="PurchaserRemainingOwnershipPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="RemainingPurchaserAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="IssuedAndOutstandingSharePercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="InvestmentinFinancialAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="InitialPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ShareCapitalPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="SharePricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ReverseShareSplitRatio" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="AreaOfLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="OptionToExtendLeaseTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="MonthlyLeaseFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_OtherIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="PaymentsOfAdditionalDeferredCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="PurchaseCostsValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="GrowthRatePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="LongTermPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="DiscountRatePercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="OperatingLossCarryforwardsTaxAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="DekelLicenseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="AnnualInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="AdditionalMilestoneAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="InstallmentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="EstimatedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="June2022WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="August2023FinancingRoundMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="October2023FinancingRoundMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="PreFundedUnitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="OverAllotmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="CapitalRatio" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ReverseSplitRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ServicesExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_GrossProfit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IssuanceOfAggregateShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateUnits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateUnitsPerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IssuanceExpireTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="WarrantsAndExercise" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="PurchasePricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateGrossProceeds" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="CommitmentAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="SaleOfOrdinaryShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="SharePriceRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="InterestRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="InstallmentPayment" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="PaymentForPremiumPercentage" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateIssuedAmount" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="TwoThousandTwentyThreePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="DirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="FairValueOfShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="OrdinarySharesGrantedDiscountRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOptionsOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ConvertIntoOrdinaryShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/OperatingSegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsTable" xlink:to="OperatingSegmentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MergerAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="SaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockAxis" xlink:to="SaleOfStockDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockAxis" xlink:to="InitialPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="InterestPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="DeferredCashPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ShareCapitalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="BonusAmountReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ServicesExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AcquiredOrdinaryShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateValues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateValueAdjusted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ListedSharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ComprehensiveLossOnInvestment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="CooperationAgreementAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentInvestments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ExchangeOfCommonShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="OutstandingShareCapital" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="LicenseeIssuePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="MilestonesAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="LicenseAgreementDescription" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="PercentageOfAggregateNetSales" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="NumberOfUnitsReceived" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="PurchasePricePerShare" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="NumberOfWarrantsHolds" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="WarrantsExpireDate" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateNumberOfOutstandingOrdinarySharesPercentage" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="SignificantEventsduringtheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MizaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="SignificantEventsDuringTheReportingPeriodLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="EnterpriseValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ShareCapitalPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.trpx.com/role/EventsAftertheReportingDateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="EventsAftertheReportingDateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="DebenturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SciSparcMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="N2OFFMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_LoansReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="AggregateLoanAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="RepaidOfMonthlyInstallments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NotionalAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PurchasePricePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ConsecutiveTradingDays" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="NumberOfWarrantsIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePricePerWarrant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="WarrantExercisableTerm" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_InvestmentIncome" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="AggregateInvestment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PercentageOfFullyDilutedCapitalStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PercentageOfFinancingProceeds" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="RestrictedStockGrantPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VestingPeriod" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> % # 2(  A$! Q$!_\0
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MS/#^B6OAS0K32K-<16Z!<XY9N['W)YK3K-N[*04444@/BW7O^1BU/_K[E_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SCISPARC LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A, 2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12gTitle', window );">Title of 12(g) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">10,828,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Oz Adler<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">oz@scisparc.com<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A, 2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-7175777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12gTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(g) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection g<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12gTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024
and 2023, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the
period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted deposit</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Bridge loan to related parties</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in company accounted for at equity</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">10,347<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other short-term liability</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and premium</a></td>
<td class="nump">70,886<span></span>
</td>
<td class="nump">64,526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve from share-based payment transactions</a></td>
<td class="nump">5,746<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrants</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Foreign currency translation reserve</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Transactions with non-controlling interests</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(74,975)<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to equity holders of the company</a></td>
<td class="nump">8,154<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">8,939<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 10,347<span></span>
</td>
<td class="nump">$ 11,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(322)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">7,316<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment in MitoCareX</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">5,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total comprehensive loss</a></td>
<td class="nump">7,472<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the Company</a></td>
<td class="nump">6,284<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit loss</a></td>
<td class="nump">$ 7,472<span></span>
</td>
<td class="nump">$ 5,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital and premium</div></th>
<th class="th"><div>Reserve from share-based payment transactions</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Transactions with non-controlling interests</div></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 58,541<span></span>
</td>
<td class="nump">$ 4,331<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (60,977)<span></span>
</td>
<td class="nump">$ 8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance of share capital in respect of investment in affiliate</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of share capital, net of issue expenses</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">64,526<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
<td class="num">(7,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of share capital, net of issue expenses</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 70,886<span></span>
</td>
<td class="nump">$ 5,746<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="nump">$ 8,154<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 8,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfShareCapitalNetOfIssueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issue of share capital, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfShareCapitalNetOfIssueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance income, net</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance income, net</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="num">(535)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForIncreaseInRelatedParties', window );">Increase in related parties</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">629<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(668)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Working capital</a></td>
<td class="nump">136<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,104)<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Withdrawal of (investment in) restricted bank deposits</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Withdrawal of (investment in) short-term bank deposits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SalepurchaseOfPropertyAndEquipment', window );">Sale (purchase) of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Investment in a company accounted for at equity</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties', window );">Bridge loan to related parties</a></td>
<td class="num">(4,078)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,861)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="num">(4,094)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of share capital (net of issuance expenses)</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants (a)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid on lease liability</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,193<span></span>
</td>
<td class="nump">8,483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the beginning of the period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the end of the period</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Investment in financial asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForIncreaseInRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase in related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForIncreaseInRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses from remeasurement of investment in financial assets

  to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for group&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset recognized with corresponding lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SalepurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SalepurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantNonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantNonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $74,975 as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
cash and cash equivalents totaled $1,540. In the period ended December 31, 2024, the Company had an operating loss of $7,316 and negative
cash flows from operating activities of $5,104. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">7-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify">3.</td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment of financial assets:</p>
</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of each reporting
period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes
between two types of loss allowances:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"></td><td style="width: 48px">a)</td><td style="text-align: justify">Debt instruments whose credit risk has not increased significantly since initial recognition, or whose
credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit
losses within 12 months from the reporting date (12-month ECLs); or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"></td><td style="width: 48px">b)</td><td style="text-align: justify">Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit
risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument&#8217;s remaining
term (lifetime ECLs).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial assets in
respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime
expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial asset in default
when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in
default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in
full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract', window );"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory', window );">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#8220;OPM&#8221;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest and
expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of new standards in the period prior to their adoption:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18, &#8220;Presentation and Disclosure
in Financial Statements&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In April 2024, the International Accounting
Standards Board (&#8220;the IASB&#8221;) issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;)
which replaces IAS 1, &#8220;Presentation of Financial Statements&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be classified
into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change the entity&#8217;s
operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other accounting standards,
including IAS 7, &#8220;Statement of Cash Flows&#8221; and IAS 34, &#8220;Interim Financial Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant judgements and assumptions made in relation to interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,383</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">157</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">INVENTORY</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER ACCOUNTS RECEIVABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivables in respect of downpayment on merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,079</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Investment in Associates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Investment in Associates and Joint Ventures</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND JOINT VENTURES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid on March
11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 26, 2024, the Company signed a non-binding letter of intent
relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#8220;N2OFF&#8221;) a publicly-traded company in the
United States which is a related party (the &#8220;Purchaser&#8221;). Pursuant to the terms of the letter of intent, initially, in exchange
for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute 27% of SciSparc&#8217;s ownership
in MitoCareX, SciSparc will receive cash consideration of $700. Subsequent to this first phase, SciSparc will transfer to the Purchaser
the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser
equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700, in cash consideration for SciSparc&#8217;s
shares described above). The letter of intent also includes provisions for additional milestones that, upon achievement, may increase
the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full terms of this transaction are subject
to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company and the Purchaser have not closed the
sale of the ownership of MitoCareX and the Company still holds 52.73% of the issued and outstanding share capital of MitoCareX. See also
Note 25(d).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $429 (for the year ended December 31, 2023
- $210).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">952</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Investment in Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory', window );">INVESTMENT IN FINANCIAL ASSETS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Clearmind</span></i> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company holdings in Clearmind decreased from 230,769 common shares to 7,692. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $1.38 and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $11 on its investment (for the year ended December 31, 2023 - $727). &#160;</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the investment financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately 240 square meters, whereby the Company occupies approximately 120
square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
<span style="-sec-ix-hidden: hidden-fact-94">three</span>-year term. The monthly lease fee was set at approximately $3, linked to the NIS.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right of use asses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(181</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(106</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">59</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $37, $52 and $43, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSET</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 -
$1,042).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 7.8
years (2023 &#8211; 8.7), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of 27.8% (2023 &#8211; 13.8%) and a declining growth rate for the long term, reaching 2% (2023 &#8211; 2%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of 21.9% (2023 &#8211; 20.6%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,344</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $366 (for the year ended December 31,
2023 - $486).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE PAYABLES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">816</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">205</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,239</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,248</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Investments in financial assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">871</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison between
the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are presented
in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in short-term financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">659</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">659</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">EMPLOYEE BENEFIT LIABILITIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">106</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">105</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">115</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2024, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
net carryforward tax losses are estimated to be approximately $62,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#8217;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#8217;s
share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.</p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital
Point (the &#8220;Capital Point Warrant&#8221;) to purchase $340 of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;).
The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint
venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary
of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company
unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue
to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,828,251</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to 75,000,000 ordinary shares with <span style="-sec-ix-hidden: hidden-fact-110">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, <i>inter alia</i>, a reverse split of the Company&#8217;s share
capital up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-111">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/> ordinary shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">706,683</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,677,311</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">646,179</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">5,798,078</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">10,828,251</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuances of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued 13,858 ordinary shares in respect
of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered into by and among Jeffs&#8217; Brands
and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also Note 25a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company issued 646,179 ordinary shares to consultants in respect of services rendered in the amount of $105</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.872</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.36</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.88</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Less than $1 thousand</td>
</tr></table>

<p style="margin: 0">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify">During
the year ended December 31, 2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement,
the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments,
if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;).
The Pre-Funded Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company issued 3,677,311 ordinary shares in respect of the exercise of 3,677,311 Pre-Funded Warrants.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $20,000 of the Company&#8217;s ordinary shares (the &#8220;Advance Shares&#8221;). As of December
31, 2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold 5,742,785
ordinary shares for total proceeds of $6,255. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of 97% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#8217;s ordinary shares
during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest,
payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such notice against
an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment
amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note
contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the
SEPA, the Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of
the commitment fee of $200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">524</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td>
    <td>&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span>The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span>issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-117">1,000,0000</span> Ordinary Shares. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying ordinary share price</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129.74</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174.98</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of Share Options (years)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end at
April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2024, share-based compensation in respect of Share Options of $7 was charged to the consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, the Company issued consultants 646,179 ordinary shares in respect of services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $105. </span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,013</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">166.28</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">144.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,869</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">165.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was 2.99 years and 4.03 years as of December 31, 2024, and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,179 (inclusive) as of December 31, 2024, and 2023, respectively.</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left">c.</td><td style="text-align: justify">Restricted Share Units:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: justify">On June 20, 2024, the Company granted 530,000 Restricted Share
Units (&#8220;RSUs&#8221;) to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s
discretion and taking into account personal tax implications and convert into 530,000 ordinary shares of the Company. The RSUs vest on
a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted
share price of the Company on June 20, 2024, which was $0.893.</td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: justify">On August 8, 2024, the Company granted <span style="-sec-ix-hidden: hidden-fact-118">530</span>,000RSUs to directors
and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account
personal tax implications and convert into 530,000 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of
two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August
8, 2024, which was $0.316.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">RSUs granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,060,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expiry of RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercise of RSUs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,060,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Total exercisable RSUs as of December
31, 2024, are 265,000. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $456 was charged to the
Consolidated Statements of Comprehensive Loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">REVENUES AND COST OF REVENUES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s Brand sells products
directly to customers mainly through the Brand&#8217;s online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024, the
allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right of return
asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Purchased goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">672</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalInformationAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory', window );">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>a.</td>
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 61%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">390</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,803</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>b.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Sales and marketing expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Advertising</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">454</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Storage and shipping</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>c.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,526</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,844</td><td style="padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>d.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Other expenses (income):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Loss from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,270</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>e.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(191</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,205</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,832</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Interest from loans to related parties and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(612</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>f.</td>
    <td style="font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">353</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,824,972</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">407,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">175,953</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,472</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">407,681</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">175,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">OPERATING SEGMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried out
according to the results of the segment&#8217;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO of
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equity losses from the investment in MitoCareX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Drug Development Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the year ended December 31, 2024, the Company
recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Online Sales Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-size: 10pt">External</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">8,405</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">8,287</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">109</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(5,818</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,592</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">8,407</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,764</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">10,171</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,194</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">226</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,420</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7,069</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,113</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">11,182</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,595</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">765</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution, for $2,500 in cash, and additional deferred cash payments of approximately $489 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately 51% of the share capital of SciSparc US.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, at the closing
of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides
management services to SciSparc US for the Wellution brand for a monthly fee of $20 and Jeffs&#8217; Brands received a one-time signing
bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30
days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2024, the Company has
recorded management services expenses in the amount of $120 (for the year ended December 31, 2023 - $220).</p></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $288 of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 ordinary shares of the Company having an aggregate value of $288 which was adjusted from $300 according to the 4.99% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#8217;s Brands on Nasdaq was $ 2.57, and the Company has recorded a loss in its statements of comprehensive loss of $17 on its investment (for the year ended December 31, 2023 -$180).<br/>
<br/>
Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $63 and $40, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $1.5 million in Clearmind
in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing
9.33% of the outstanding share capital of Clearmind (see also Note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, the Company&#8217;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify">On August 13, 2024, the Company entered into the license agreement
(the &#8220;License Agreement&#8221;) of the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;), with Polyrizon Ltd. (the
&#8220;Licensee&#8221; or &#8220;Polyrizon&#8221;). According to the License Agreement, the Company granted the Licensee a royalty-bearing,
exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received
and will receive certain shares of the Licensee, reflecting an issue price of $805, and royalties from sales related to and income generated
from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones
relating to the Assets. <br/>
<br/>
Pursuant to the terms of the License Agreement, the Company is entitled to up to $3,320 based on the achievement of certain milestones, including (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction. Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of 5%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. <br/>
<br/>
On October 31, 2024, following an initial public offering of the Licensee, the Company received 684,931 units, of which (i) 320,000 units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (960,000 warrants in total); and (ii) 364,931 units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (1,094,793 warrants in total). Altogether, the Company received 320,000 ordinary shares, 364,931 pre-funded warrants to purchase one ordinary share of the Licensee, and 2,054,793 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. &#160; <br/>
<br/>
On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of 1,541,096 Licensee common warrants to third parties, for aggregate consideration of $771. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; <br/>
<br/>
As of December 31, 2024, the Company holds 513,698 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. The warrants expire on October 31, 2029. The value of the warrants on December 31, 2024, is $517.<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer, is a director
of the Licensee.</p>
</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"><i>General Overview of Valuation Approaches used in the Valuation:</i>
&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in">The warrants&#8217; fair value
was calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated,
in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price of Polyrizon Ltd. ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,399</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, SciSparc and AutoMax
entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated
by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second
addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred
to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right
to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the effective time of the Merger (the &#8220;Effective Time&#8221;,
as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#8217;s share capital will be converted into the
right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;).
Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the
Company) are expected to hold together approximately 49.99% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate
number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of
the Company, together with the holders of the Company&#8217;s convertible securities, immediately before the Merger are expected to hold
together approximately 50.01% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject
to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;),
and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised
of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall
be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodAbstract', window );"><strong>Significant Events during the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 25:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#8220;Miza&#8221;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#8220;Target Assets&#8221;)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement is based on the approximate total $3,300 (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of the Company&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28, 2025, the Company entered into a second amendment (the &#8220;Miza Amendment&#8221;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.</p></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsDuringTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsDuringTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events After the Reporting Date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENTS AFTER THE REPORTING DATE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2025, the Company announced that it has reached a settlement
agreement (the &#8220;Settlement&#8221;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa
District Court against six of the Company&#8217;s former directors (the &#8220;Defendants&#8221;) case number 34426-02-22 (the &#8220;Suit&#8221;).
The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior
acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $411 cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#8220;License Agreement&#8221;). As part of the Settlement, Dekel clarified, to SciSparc&#8217;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#8217;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#8217;s pipeline and development program.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $2,000 loan (the &#8220;New Loan&#8221;). The funding will support AutoMax&#8217;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4,250 (the &#8220;Previous Loans&#8221;). The Previous Loans were provided in lieu of SciSparc&#8217;s obligation to provide a $4,250 closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan, bearing an 8% annual interest rate, will be repaid in equal monthly installments of $50 and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#8217;s shares.</p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company entered into securities purchase agreements (the &#8220;Securities Purchase Agreements&#8221;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#8220;Debentures&#8221;) in the aggregate principal amount of $4,200 (the &#8220;Subscription Amount&#8221;), which are convertible into the Company&#8217;s ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221; and, as converted, the &#8220;Conversion Shares&#8221;), at a purchase price equal to 95% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) 110% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) 95% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (20) consecutive trading days immediately preceding the conversion date or other date of determination (the &#8220;Market Price&#8221;); provided that the Market Price may not be lower than the floor price, which will be equal to 20% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing of the transaction, the Company issued to the investors
3,615,656 warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors
divided by a price equal to 130% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or
$0.5532 per warrant. The warrants are exercisable for a term of five years from the issuance date.</p></td></tr>
<tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr>
<tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">d.</td> <td style="text-align: justify"><span>On April 1, 2025, we entered
into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested
$100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and Series A warrants to purchase
ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing
ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px">&#160;</td> <td style="text-align: justify">The Company entered into a global guaranty
agreement (the &#8220;Global Guaranty Agreement&#8221;) with one of the investors (the &#8220;Investor&#8221;) through certain of the
Company&#8217;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#8217;s obligations under the Debenture with
the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.<br/>
<br/>
The Company
entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the
Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act
of 1933, as amended (the &#8220;Act&#8221;) and the rules and regulations promulgated thereunder, and applicable state securities laws.<br/>
<br/>
In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#8220;Deed&#8221;) with
AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $2,000
to AutoMax in lieu of making the payment under the Loan Agreement (the &#8220;Loan Agreement&#8221;) to which the Company entered into
with AutoMax on February 24, 2025.</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company announced it has signed a definitive
agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO)
(&#8220;N2OFF&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell 4,961 shares of MitoCareX to N2OFF for $700 and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to 40% of the company&#8217;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#8217;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#8217;s control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to 25% of N2OFF&#8217;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive 30% of N2OFF&#8217;s financing proceeds over five years, up to a maximum of $1,600. N2OFF has also committed to investing $1,000 in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of 5% of N2OFF&#8217;s capital stock, vesting over three years. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - -
- -</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors
recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and
employees. Our IT general controls cybersecurity policies, standards, processes and practices are fully&#160;integrated&#160;into
our risk management approach.&#160;In general, we seek to address IT general controls cybersecurity risks through a comprehensive,
cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we
collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity
incidents when they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our IT general controls cybersecurity policies, standards, processes and practices are fully&#160;integrated&#160;into
our risk management approach.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory', window );">asis of presentation of the financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory', window );">The operating cycle</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements', window );">Consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany', window );">Acquisition of a single asset company</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory', window );">Restricted deposits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investment in joint arrangements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments accounted for using the equity method</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">7-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify">3.</td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment of financial assets:</p>
</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of each reporting
period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes
between two types of loss allowances:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"></td><td style="width: 48px">a)</td><td style="text-align: justify">Debt instruments whose credit risk has not increased significantly since initial recognition, or whose
credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit
losses within 12 months from the reporting date (12-month ECLs); or</td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 168px"></td><td style="width: 48px">b)</td><td style="text-align: justify">Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit
risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument&#8217;s remaining
term (lifetime ECLs).</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial assets in
respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime
expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial asset in default
when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in
default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in
full.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings (loss) per share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit liabilities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in Consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in operating cycle Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for acquisition of a single asset company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAcquisitionOfASingleAssetCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of accounting policies for basis of presentation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory', window );">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">7-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,383</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">157</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosue of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfInventorieExplanatory', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInventorieExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInventorieExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock', window );">Schedule of Other Accounts Receivable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivables in respect of downpayment on merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,079</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounts receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclourseOfAccountsReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems', window );"><strong>Investment in Associates and Investments in Investees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">952</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right of use asses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(181</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(106</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">59</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of Fair Value of the Intangible Asset</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,344</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfTradePayablesExplanatory', window );">Schedule of Trade Payables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">816</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfTradePayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfTradePayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">205</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,239</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,248</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Investments in financial assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">871</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Companys Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison between
the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are presented
in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in short-term financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Investments in financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">659</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">659</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets and financial liabilities that have been redesignated during the transition to IFRSs. [Refer: Financial assets; Financial liabilities; IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 29<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_29&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory', window );">Schedule of Defined Contribution Plans</a></td>
<td class="text">These contributions and contributions for compensation represent defined contribution plans.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">106</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">105</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">115</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about defined contribution plans explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,828,251</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital', window );">Schedule of Issued and Outstanding Share Capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/> ordinary shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">706,683</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,677,311</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">646,179</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">5,798,078</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2024</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">10,828,251</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.872</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.36</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.88</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Less than $1 thousand</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed inforamtion about issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock', window );">Schedule of Expenses Due to Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">524</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock', window );">Schedule of Fair Value for Share Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying ordinary share price</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129.74</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174.98</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate (%)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of Share Options (years)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,013</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">166.28</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">144.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,869</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">165.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of RSU transaction</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">RSUs granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,060,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expiry of RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercise of RSUs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,060,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses due to share-based compensation explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value for share options granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock', window );">Schedule of Cost of Sales and Gross Profit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Purchased goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">672</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalInformationAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of Additional Information to the Items of Profit or Loss</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>a.</td>
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 61%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">390</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,803</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>b.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Sales and marketing expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Advertising</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">454</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Storage and shipping</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>c.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,526</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,844</td><td style="padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>d.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Other expenses (income):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Loss from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,270</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>e.</td>
    <td style="text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(191</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,205</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,832</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Interest from loans to related parties and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(612</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>f.</td>
    <td style="font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">353</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,824,972</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">407,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">175,953</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,472</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">407,681</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">175,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingSegmentsTablesLineItems', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Operating Segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO of
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equity losses from the investment in MitoCareX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug <br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online <br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-size: 10pt">External</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">8,405</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">8,287</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">109</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(5,818</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,592</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">8,407</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,764</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">10,171</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,194</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">226</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,420</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7,069</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,113</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">11,182</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,595</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RelatedPartyBalancetextBlock', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Benefits to Key Management Personnel</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">765</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in">The warrants&#8217; fair value
was calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated,
in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price of Polyrizon Ltd. ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,399</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RelatedPartyBalancetextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RelatedPartyBalancetextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="num">$ (68,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(7,316)<span></span>
</td>
<td class="num">(6,815)<span></span>
</td>
<td class="num">(8,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (5,104)<span></span>
</td>
<td class="num">$ (5,887)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingTerm', window );">Operating term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife', window );">Leasehold improvements, description</a></td>
<td class="text">see below<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeaseholdImprovementsMainlyRate', window );">Leasehold improvements mainly</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRatePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseholdImprovementsMainlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The leasehold improvements rate used for mainly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseholdImprovementsMainlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash - Schedule of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInventoriesInTransit', window );">Goods in transit</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total inventory</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInventoriesInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInventoriesInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_Governmentauthoritiescurrent', window );">Government authorities</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ReceivablesInRespectOfDownpaymentOnMerger', window );">Receivables in respect of downpayment on merger</a></td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Related party</a></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">$ 1,079<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_Governmentauthoritiescurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_Governmentauthoritiescurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReceivablesInRespectOfDownpaymentOnMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables in respect of downpayment on merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReceivablesInRespectOfDownpaymentOnMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2024</div></th>
<th class="th"><div>Mar. 11, 2024</div></th>
<th class="th"><div>Nov. 25, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaserRemainingOwnershipPercentage', window );">Purchaser remaining ownership</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RemainingPurchaserAmount', window );">Purchaser equal valuation</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (429)<span></span>
</td>
<td class="num">$ (210)<span></span>
</td>
<td class="num">$ (109)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OutstandingSharesPercentage', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInstallment', window );">Additional installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentPaid', window );">Installment paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RemainingPurchaserAmount', window );">Purchaser equal valuation</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharePercentage', window );">Issued and outstanding share</a></td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional installment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of installment paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaserRemainingOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchaser remaining ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaserRemainingOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RemainingPurchaserAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining purchaser amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RemainingPurchaserAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance at beginning</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsDate', window );">Investment date March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance at ending</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfSecondMilestone', window );">Investment following achievement of second milestone</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfFirstMilestone', window );">Investment following achievement of first milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment following achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment following achievement of second milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment date,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Invested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,251<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharePricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ReverseShareSplitRatio', window );">Reverse share split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Invested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReverseShareSplitRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse share split ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReverseShareSplitRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AreaOfLease', window );">Area of lease</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OptionToExtendLeaseTerm', window );">Option to extend lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MonthlyLeaseFee', window );">Monthly lease fee (in Dollars) | $</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AreaOfLease', window );">Area of lease</a></td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of Lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MonthlyLeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly lease fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MonthlyLeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OptionToExtendLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to extend lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OptionToExtendLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember', window );">Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentsOfAdditionalDeferredCash', window );">Additional deferred cash</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseCostsValue', window );">Purchase costs</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of intangible asset</a></td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Amortized over period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment to its intangible asset</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful life</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GrowthRatePercentage', window );">Growth rate, percentage</a></td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LongTermPercentage', window );">Long term, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DiscountRatePercentage', window );">Discount rate, percentage</a></td>
<td class="nump">21.90%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation expenses</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrowthRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrowthRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LongTermPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LongTermPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentsOfAdditionalDeferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payments of additional deferred cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentsOfAdditionalDeferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Loss on impairment of intangible asset</a></td>
<td class="num">(1,344)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill', window );">Depreciation of intangible asset</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at ending</a></td>
<td class="nump">$ 1,479<span></span>
</td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Payables - Schedule of Trade Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Schedule of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Open debts</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued vacation</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties', window );">Related parties</a></td>
<td class="nump">4,239<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">5,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Investments in financial assets at fair value</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Company's Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDefinedContributionPlansAbstract', window );"><strong>Schedule of Defined Contribution Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Expenses in respect of defined contribution plans</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDefinedContributionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDefinedContributionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingLossCarryforwardsTaxAmount', window );">Carryforward tax losses (in Dollars)</a></td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IL', window );">Israeli [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingLossCarryforwardsTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforward tax as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingLossCarryforwardsTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DekelLicenseAgreementDescription', window );">Milestone payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AnnualInvestment', window );">Annual investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalMilestoneAmount', window );">Additional milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentAmount', window );">Installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EstimatedAmount', window );">Estimated amount</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Capital purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Capital warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">&#8362; 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AnnualInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AnnualInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DekelLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dekel license agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DekelLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EstimatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EstimatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CapitalRatio', window );">Capital ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ReverseSplitRatio', window );">Reverse split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services rendered amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,251<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Purchase sale (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CommitmentAmount', window );">Commitment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SaleOfOrdinaryShares', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,742,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharePriceRate', window );">Share price rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentPayment', window );">Installment payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentForPremiumPercentage', window );">Payment for premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateIssuedAmount', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Commitment fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember', window );">Pre-Funded Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember', window );">SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CommitmentAmount', window );">Commitment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">1,094,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember', window );">June 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceExpireTerm', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member] | Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember', window );">October 2023 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember', window );">October 2023 Financing Round [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,677,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,677,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate issued amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share of aggregate units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CapitalRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CapitalRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installment payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance expire term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentForPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentForPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReverseSplitRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse split ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReverseSplitRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePriceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePriceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAndExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAndExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, Issued and outstanding</a></td>
<td class="nump">10,828,251<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Issued and Outstanding Share Capital (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at January 1, 2024</a></td>
<td class="nump">706,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants', window );">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants (Note 18h</a></td>
<td class="nump">3,677,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultants', window );">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</a></td>
<td class="nump">646,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectSEPA', window );">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</a></td>
<td class="nump">5,798,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at December 31, 2024</a></td>
<td class="nump">10,828,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectSEPA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital &#8211; in respect of January 2024 SEPA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectSEPA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share issued to consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.38%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.872%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price ($) (in Dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 68.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 20, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfShareOptionsGranted', window );">Fair value of share options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.66<span></span>
</td>
<td class="nump">$ 158.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesGrantedDiscountRate', window );">Ordinary shares granted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value of the ordinary shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOptionsOutstanding', window );">Share options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember', window );">Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.74<span></span>
</td>
<td class="nump">$ 174.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConvertIntoOrdinaryShares', window );">Conversion of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement', window );">Vest over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.316<span></span>
</td>
<td class="nump">$ 0.893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Exercisable of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value of the ordinary shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member] | Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConvertIntoOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the share of restricted share units convert into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConvertIntoOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Other Equity Instruments Vested in Share based Payment Arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares granted discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) - Share Options [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Total</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) - Share Options [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Fair Value for Share Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying ordinary share price (in Dollars per share)</a></td>
<td class="nump">$ 129.74<span></span>
</td>
<td class="nump">$ 174.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life of Share Options (years)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_a2024Abstract', window );"><strong>2024:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Share Options , Share Options outstanding at the beginning of the year</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the beginning of the year</a></td>
<td class="nump">$ 166.28<span></span>
</td>
<td class="nump">$ 166.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options cancelled during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options cancelled during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 144.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Share Options, Share Options outstanding at the end of the year</a></td>
<td class="nump">6,802<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the end of the year</a></td>
<td class="nump">$ 350.23<span></span>
</td>
<td class="nump">$ 166.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options exercisable at the end of the year</a></td>
<td class="nump">6,802<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options exercisable at the end of the year</a></td>
<td class="nump">$ 350.23<span></span>
</td>
<td class="nump">$ 165.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_a2024Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_a2024Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of RSU transaction (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfRsuTransactionAbstract', window );"><strong>Schedule of RSU transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Balance, January 1, 2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">RSUs granted</a></td>
<td class="nump">1,060,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Expiry of RSUs</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercise of RSUs</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Balance, December 31, 2024</a></td>
<td class="nump">1,060,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRsuTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRsuTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember', window );">Purchased goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember', window );">Freight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember', window );">Advertising [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember', window );">Amazon fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">454<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember', window );">Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember', window );">Storage and shipping [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember', window );">Management fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember', window );">Loss from sale of property and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember', window );">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="num">(1,287)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember', window );">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember', window );">Interest from loans to related parties and deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(421)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember', window );">Exchange rate differences, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember', window );">Issuance expenses related to warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember', window );">Losses from remeasurement of investment in financial assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember', window );">Finance expense in respect of leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember', window );">Finance expenses from interest and commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BSalesAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BSalesAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DOtherExpensesIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DOtherExpensesIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FFinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FFinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic loss per share, Weighted number of shares</a></td>
<td class="nump">5,824,972<span></span>
</td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">175,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument', window );">Basic loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Effect of potential dilutive ordinary shares, Weighted number of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare', window );">Effect of potential dilutive ordinary shares, Loss (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share, Weighted number of shares</a></td>
<td class="nump">5,824,972<span></span>
</td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">175,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument', window );">Diluted loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the par value of effect of potential dilutive ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Segments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingSegmentsDetailsLineItems', window );"><strong>Operating Segments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember', window );">Online Sales Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingSegmentsDetailsLineItems', window );"><strong>Operating Segments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments - Schedule of Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">7,316<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromTheInvestment', window );">Equity losses from the investment in MitoCareX</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax Income (expense)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">7,472<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">10,171<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">4,873<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromTheInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity losses from the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromTheInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DeferredCashPayment', window );">Deferred cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFeeAndCommissionExpense', window );">Other fee expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BonusAmountReceived', window );">Bonus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Engaged in a mutual share exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AcquiredOrdinaryShares', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateValues', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateValueAdjusted', window );">Aggregate values adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ListedSharePrice', window );">Listed share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CooperationAgreementAmount', window );">Cooperation Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExchangeOfCommonShares', window );">Exchange of Common Shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OutstandingShareCapital', window );">Outstanding share capital, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LicenseeIssuePrice', window );">Licensee issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MilestonesAmount', window );">Milestones amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfAggregateNetSales', window );">Aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in Shares)</a></td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,251<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Aggregate consideration</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage', window );">Aggregate number of the outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Engaged in a mutual share exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AcquiredOrdinaryShares', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ComprehensiveLossOnInvestment', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage', window );">Aggregate number of the outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,054,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfWarrantsHolds', window );">Warrants holds (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsExpireDate', window );">Warrants expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AcquiredOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AcquiredOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of the outstanding ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValueAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate values adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValueAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus amount received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of comprehensive loss on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CooperationAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cooperation Agreement amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CooperationAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DeferredCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DeferredCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LicenseeIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of licensee, reflecting an issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LicenseeIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ListedSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of listed shares price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ListedSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfUnitsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfUnitsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfWarrantsHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants holds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfWarrantsHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfAggregateNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfAggregateNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expire date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CurrentAsset', window );">Current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CurrentAsset', window );">Current assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract', window );"><strong>Schedule of Transactions with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions', window );">Research and development expenses</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SaleOfMinorityInterestInSubsidiary', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of research and development to the entity in related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfMinorityInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of minority interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfMinorityInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Schedule of Benefits to Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_KeyManagementPersonnelCompensationManagementFees', window );">Management fees (see also note 25a)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_KeyManagementPersonnelCompensationManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_KeyManagementPersonnelCompensationManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details) - Warrants [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems', window );"><strong>Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">2.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EnterpriseValue', window );">Enterprise value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Cash position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember', window );">Miza [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of enterprise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsDuringTheReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events After the Reporting Date (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Feb. 25, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfWarrantsIssued', window );">Number of warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,615,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePricePerWarrant', window );">Volume weighted average price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,251<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RepaidOfMonthlyInstallments', window );">Monthly installments (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Aggregate principal amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePercentage', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay', window );">Volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays', window );">Volume weighted average price during consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing', window );">Volume weighted average price of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investing amount (in Dollars)</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateInvestment', window );">Aggregate investment (in Dollars)</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfFullyDilutedCapitalStock', window );">Percentage of fully diluted capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfFinancingProceeds', window );">Percentage of financing proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Financing proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RestrictedStockGrantPercentage', window );">Restricted stock grant percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember', window );">AutoMax [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateLoanAmount', window );">Aggregate loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember', window );">SciSparc&#8217;s [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateLoanAmount', window );">Aggregate loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember', window );">N2OFF [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfFullyDilutedCapitalStock', window );">Percentage of fully diluted capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investing amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing', window );">Volume weighted average price of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember', window );">Debentures [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember', window );">Debentures [Member] | Top of Range [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfFinancingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfFinancingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfFullyDilutedCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfFullyDilutedCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RepaidOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repaid of Monthly installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RepaidOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RestrictedStockGrantPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock grant percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RestrictedStockGrantPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares during the consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares of preceding the closing of trading day.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares on the day prior to the closing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercisable term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !J'F%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !J'F%J:+P'-\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( !J'F%IGXP"_T 8  *<A   8
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M,4LGX&$^ 7^\^Q.\ RP%BPW?921=9F=#J;3D'H=1U>]EV2_JZ7="HP\ P_<
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M>JCG9 PWM,9V6L_*^,%*\$1E8"7\)#_FS@OUEWQW"J1"44:*0W1C3L ZI[W
M[<HW6:&^#19N<([M.+>1$NML]N!(.V\\8-46UB <V\GXD0O*UFF56*.7<AAC
M(LOKC&+,C:)U*KNC+@@.&+4E[YW:VFFWV)MH\,SDIBP >"H%CY7Q6E58"LZJ
MWC(/MP[<4#OD.V#45M[P%=OY>A%%NV17GB\MZ8I%YE-4K//S)% #U]W4F>S\
MT!_U$ PWK,7'L+8LI%5)+05[W,E\_YD?D%6/-SQ>4E'<CZA-T6LY;@Q'QVP(
MM4K68!7XL"?QXP;&V%[*WO[4TM"+U"#41MU0R8X"W".T@2<^II3M/[S .A;#
M$>["TV U\L*^5Z[!)SZF?-W;=-4G SUB0_T*Q5#.FLSZRUF<<ZU]K]+0P[73
M0^V09S2*50'.5HPN3?0<[MT=)E2LBSO8#!0%6'FG5#\M[WFOX.FDN [M/%=:
M7B^ N[_@T>E$A9'?5S9=E!?+GXE8,Y708KI2W3D? C6'HKRK+;](OBUN+Q^Y
ME#PI/FZHJF!%;J!^7W$N7[_D'=0WYN/_ 5!+ P04    "  :AYA:S6UZW? %
M  #.&   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;+U9:V_;-A3]*X17
M#"VPQ"+UM.<8:/S8"JQ;D+3;@&(?:(FVA4JD2]).\N]'RK)DBQ2;8L6^Q'J<
M>WG/Y>7E$3-Y9/RSV!(BP5-94'$SV$JY&P^'(MV2$HMKMB-4O5DS7F*I;OEF
M*':<X*PR*HLA\KQH6.*<#J:3ZMD=GT[87A8Y)7<<B'U98OY\2PKV>#. @].#
M^WRSE?K!<#K9X0UY(/+C[HZKNV'C)<M+0D7.*.!D?3-X"\=+%&J#"O%G3A[%
MV3705%:,?=8W[[*;@:<C(@5)I7:!U<^!S$A1:$\JCB^UTT$SIC8\OSYY7U;D
M%9D5%F3&BK_R3&YO!LD 9&2-]X6\9X^_DII0%6#*"E']!8\UUAN ="\D*VMC
M%4&9T^,O?JH3<68 HQX#5!N@KD'08^#7!G[7P.\Q"&J#X*4CA+5!^-(1HMH@
MJG)_3%:5Z3F6>#KA[!%PC5;>]$4U796U2G!.=64]2*[>YLI.3F>,"E;D&98D
M P]2_:BRD0*P-9BQ4A7K5E?1@8#?F!#@"GQ\F(/7K]Z 5R"GX,.6[06FF9@,
MI8I%>QRF];BWQW%1S[@0@?>,RJT "YJ1[-+!4)%HF* 3DUOD]#@GZ37PX4\
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M"\I2AQ:48\Y::8#<TN 6BSP]'FXHD0 8SU3WYL] ;-4N"K"4/%_M)=:26S)
M7%4[!J_5#CQ7DX_YT5OEY(TU,\>HXO/9OT;&[%M0P75@I,8*2_IRTRH.Y%8<
M\[S8Z_.X_S\[_HNR8T'9LF.%]69'JY7+)^W&C]P;OQ+N]R0MU*=9OL[MAXG#
MLR/2DO!-=9@M5%O?4WD\U&B>U@?F*!@O476,VWDS0^,YLCQ?(&5@>7X+QTMH
M>:Y8G<[DNV_@^&WE:=B&>CSI?X_Y)J<"%&2MPO:N8Y48?CP\/]Y(MJL.>U=,
M2E96EUN"55EH@'J_9DR>;O0 S;\PIO\"4$L#!!0    ( !J'F%I9=EYW- 8
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M.PN5 ,4T.^7M0''N3G%NI^+&S[1*,T[KO71S?!>Y<S7GCO+4Z/1S@:2 >,9
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M 0&&&2=D1],A36V'HEY@UH4(QFR(:M#Y65ZC+KX5:-CWT$'S8D:F+6L%K(.
M:4ZA)'0S7(7H!E"!:D+*DA6:/$?AB\B0*)J6Y4(=PJ_<,&=: 6U=4FBE;H)+
MJU)CZ0"!+ :]?21$"V@RH_'84IK(/&3:Z*A$V-*!4$VM\LARCLH"<TG6LB;Q
M'R1@#.KE&E]SV9%.+.< ZFWX0J'Q/"[;90T:/6G H9V966GYD])AT02 $9>$
MO#@>9L>/9DV]81B2>.]LT$L5$?@61505-%YO8Q0CTUJ#O3$R09.XPS 4YX\X
M(XHU GPK'#6X47)3]!":;6*2.D#7X2BQ=4ZZ+GO4^Y4(Y!<#)^Z?3=(-6X73
MIN_Y'XT*[C;GA)!S)Q*>8N@^H K#;L(7CSVX33O.J\ 3I2<W=8I:3DWMM[9U
M'-"+RY[";(HX:T:8YLLCS2WI-;=P.JJH[*AS<>?JLJW=MEIVX_=0+XYZH;W3
M$H$(0K8+ @!;)7_&5D?M!4VB.4/M%'=S&)2^[!^AFC+/ &,7N*LM>)R :VA[
MM%6C_HA:XX1*TSTF\-#QRZ:QT/T2713%"D=/D-L.FL3!)!1/-#\S=#!L@A_L
M5'!"HECO.]6T95Z:6C<^/ES;\SHR2,DW;6<-&*HIGD2?(&$K8G^&S8^UA=^$
M1(*Y\QU-9G++L9\%)WYV)TFOD;&#?W*QD&RGH%_+V7,OT1[B%SL'C3!5(APJ
MSFM?#)K8E(^2_BKHBQYT025FH9!8HV@C2K87OT9H'%7I0N+]]8)-)\-V(@ZS
M9U<Q[SN,+3J,)7/G#-[YH'NN&54W$D%0:0KA0:N18$P"@B9H+E7@Z >6S!=A
M!&X-^10(+1QJ\;6GE&+U+R39L[_Q$;AUR76#E:_@Z!B3^4/91UO9_?4;]DZZ
M#.-1D$0K#Z ;;4;SAGGG8!1B3< *8= YS@RH4C#%-KJ_L2&<-;HC&/1<=B>:
M)&3AOMIM\*\%76;LU0]QH\<NZL:]&U.@<!7NA:E7PKYX>=J][:Z>Y_'&=;L\
MWEM_YG8E44)*++%U,GIU/& VW@7'']Y4X?XU-=Z;,CS2U8"PM #?EP8 ;GZ0
M@NY"_N)_4$L#!!0    ( !J'F%J97GAX'B@  (Z%   8    >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULQ3W;<MM&EN_]%2C-SI1=1=&6E*MBNTJVXXRF',<;
M.[,/6_L  DT28Q!@T(!DY>OW7/L"@)2<V:JMVLU8)-!]^O2YW_CLMNT^N:VU
M??9Y5S?N^<FV[_>73YZX8FMWN5NV>]O -^NVV^4]_-EMGKA]9_.27MK53\Z?
M/OWFR2ZOFI,7S^BS]]V+9^W0UU5CWW>9&W:[O+M[:>OV]OG)V8E^\&NUV?;X
MP9,7S_;YQGZP_6_[]QW\]<2O4E8[V[BJ;;+.KI^?7)U=OOP*GZ<'_EG96Q?]
M.\.3K-KV$_YQ73X_>8H V=H6/:Z0P__<V%>VKG$A .-W6?/$;XDOQO_6U=_0
MV>$LJ]S95VW]7U79;Y^??'>2E7:=#W7_:WO[=ROG^1K7*]K:T7^S6W[VJXN3
MK!A<W^[D98!@5S7\O_EGP4/TPG=/#[QP+B^<$]R\$4'Y.N_S%\^Z]C;K\&E8
M#?]!1Z6W ;BJP4OYT'?P;07O]2\^5)NF6E=%WO3955&T0]-7S29[W]9545GW
M[$D/F^"C3PI9\"4O>'Y@P;/S[.>VZ;<N^[$I;9DN\ 2@\R">*X@OSX^N^-H6
MR^SB;)&=/SW_ZLAZ%_[(%[3>Q9\[<O;?5RO7=T N_S-W>E[[J_FUD84NW3XO
M[/,3X!%GNQM[\N)O?SG[YND/1R#_RD/^U;'57WRX_NG=]9OK5U?O/F97KU[]
M\MN[C]?O?LK>__+V^M7UCQ_FP#V^X+M?/OZ8G5^>9O>LG'W<VFS=UL#"B*H\
M8&VO6-OF-]:LK 5&V^_KRI99T0+KNMXV?7V754W6XQI5DS=%E=>9Z_/> G?W
M#A;NLKRNL[WMJK9T&6&NZ6VYR(:FMLYE+;S;W5;.\FOE,LN7V<L<EL_:M3Z?
M$YO#WX<VNL1CN - (/P9PF]@N7W>P0&JAD[:E?"T!;[LM]GUFU\_+++<995S
M SRRNJ/=KJ\^O%P2DEZUNWW>W/WM+]^=GWW[@YO=R_B],K\7"BC F.M1QE1N
MYN154P+-TN&CC0!NEY&,@T7Z5G%A$*I]UZZK/@/LUBTL5<'V+AL<7ANA:&@*
M19G]#%(>-MG9?MO*#K-H F##_1C T&\?7F=Y4](%WN3U8/F9#@BD9)!PK\;"
MAW X6'UP^/@CP=#3IT\?+V#[PN[[['8+*)D]\8I! EW4Y41WQ5U1V\NY#Y4"
M!$$&::2QV1U L,Q DKP"L@2B+7'APV1"U'OT,5/ !AW">9"P 9*"H$ &Z;=Y
M3ZB!E?L.>"F0C][EHP_#RE5EE7?PPF,"%9_$=7)9"3@)$%QL*WL#[R/"3+P"
M? E7V3KD';AW)(X.]1(0%-S$#2R<KP!%G>V'K@'J[-H=T 701G/3UC<$-A,Z
M+@H?PIU92_>+2^&'^:JJJ_X.E\O7:Z [O%-GC2[9;^'J-UM:==_>VBYK;^ _
M\7I+D+4H%A!;-RW=' .IZ $<V$Z.!\SF@!'P(?@3:0/ R?#MGHF_4"3!-H0+
M(B!Y8CFZRWLD!"(9_E%8I!EZ"N\?_WV[K8JMWPMI:M6#R0- (G)L V*+H'5#
ML37Z6&'!7G!'N&E$JKB4?!13@C(=2XK<O^;R'0/H" @1G^,C'R#?=%&6"@/H
M13!US)Q\!U)%%@_T+!+])[CN_3*+E6H%I\]/Z0N09G5.^$0(X>/&Y21T^(,-
MH-"I@(*'0$: -87[(F6:>*'T78#=UA780W0^ &4] ' "TKUG7V;OVN94^1"W
M@YTL"B@ZEHMP#W0MXHZ6MK\/2'>CA[*F!=;N^ZY:#3TRV"(KJPYX Q0?' [E
M&/]%7)AGB/.F/P9%(F;A<R,;.[PO. 8L3+P;P13OKV)7OMJV-3#4F-R #5,%
M@3>"]POB4HB368D$G=VB)0XZOFK@;TL0ZI9!SJL<HMMN 2\'#KC,WO*-3Y<Y
M^$X&(J_)*CK#G6%2(1T-VF63HW&OU(:@'UYFCDH\;>"K@61 DE9(<<L,=- ;
MT9?P>3%T<(,%GQ-8!FS_QG_(^F,]\W2*_X5AH5*Q8/5/D:)8H;8$!P4U.W]O
M >!V5Q4@;&ZJKFT(VDHE4XQ\5HA6+[0I!UP#!7+"1++O;\L/2_,:L)1WK)7/
MG_X 2IW^=?8#$H=\^!_R$>AKD!: Y:KW9@Z;&Q7Z=9/C/AAPHX!_B0C+:]<F
MK$(6"0,8(V4%\@((2/0P"SZUA.9W,M%.LBQ85#>@FURV:]'& ;OKA@4>>\>H
M7801!A<QW ,$$BC%JP*XE>F--3[*9.!E5("]JO_+[+>]J*;\V/-&GE\$(0W\
M _89$89J4F!^H8+)8BM4"62!=O0!*V(06A];P&6LI<.SB_%29@<>+*"GJ(<2
MA"(:0.C$5KMAM\ EJV8_]&P^DD#M 9O(QX#G O>FN^K;#4,+R@7.Z/4,R$!B
M<!(=BO>BLU[+MT,/R[NE^3@Z()E0I.)LR=Z'BT\,J%NA9J%'1=7.7 4MX]]:
M9M=KP2=I@R-(F=M^[@YP,V;BNF*SJT+>N&8K@ZXDO+$02G.]4EUR8KZ"1 (8
M?-@)&S(KU2W9VXI,N&"XCS7;C+0<&R!S<.&=[=N.11Y<#89*2K&BJBY;Y_ ?
M\@^R*?D:Y(QPL )>762;MBUO*]#JN%%IU[;#S?O\,]L>P/%[M#[EL,!(L#N*
MG[("L[1C(\Y^!@>4/%8WAQ4R[O#D>&.@H5N@K3_0W5@OLU]! '<5N56E)3T
MCL$5;COZ&&\<(-ZJ>4M>$9#S%I!Q"CIGYQ]\M++]+7I]8".#5;WC, D9?>*@
M/&9S 5ZOVV8S>IOL<N"?' QMU.IP(!)#P"2-7\&;!88MU[6 A6+F\>RI" %
M&L!8>O?.@@Q/Q*<7].T:F ^T6U[HO==HY&;Y!HXD4AD.A.L"*Y85"**\0Z-T
M@_>KD. 9_]6"2H;-@2 WZGC]8_(9$V;T@9E5>>@(\(*B\Y>R5F2QBR2FT,Y
M-$I @_+?LBH@=RUX7$V\[T(V)8I"[Z"^,V3PE[:H'!NE*Q XM(M7#!1S9#1U
MEMB'E0-H@&H'GC")4;$Z2(7F'3VL$.EAS)F>!TP@N'X+N+I6%.I'R0HH.3G.
MD*#%<T$X&4<^Q 'S[GJO;#Y] 315NO.,/.W%]#3G"KAXZ7#>"/3PX?\A\)%\
M:E=UM9$-$"[\.I99<%$<.=!7XU-&41;CA8/(GMHK>_:>V;:D/_#N?!""85G$
MFR[@=4#<(/:91%X\HD>(83!&FB&Q97-^Q?A7A%*]X^(2902, L*4/%=X&>-9
MV<5B>H,A3!3OS>&AA:@3?6('$@#( +%FY!2IYIA7&$ D02LLA'$(S7K.D=0'
MGG#J&\+C '.TLZI9]5Q-CY; +F(NNC6;>*$9JT#R5J;;>PW48N2_0V<UVP]=
ML46!1ZXKW@ZBCB*>@0 CS:;XP%7S.E *V3QE68F+,'>C@0C8#IJ]T&6VC07K
MX6L45Y!OD%T4L@J]9*^B12JR]EJP4L%:I+#$2-205'[(3LOLMZ:4^$_RQ2(*
M"1'EB%OF]Q55&'@BDC;!WL][MGE\T$J12H%A^.8TIE^X.F#O-';A$4",BQ<6
MI%],Z3.^<":^<&#V /H$[F7V$T4[B WFPAV)=V:"K:#FNU+I\6W&L1&-!'SN
M(U8( NL>I!L/_,>1=5G%RGQJ7#)GP9F5AR:B-F62O$F!R(]>NB-5,0O* U"T
M4+D1R =P:] (='=@P:$G5["!L$.+EDQ"?Q ,L8HCQ91?@8JH.MK^RP";HVY#
MKLCMMJWMGXH;)AM,">,+HXAS@4!-[XPS.F8*WP,H54*.&JJ0A%%@YWNWG:+%
M2$CRH*,<D9J9(34?7<<H7Y]OK(1V:5N %?WFZ<6R=V2SVWPL@T%EN &M0:%\
M"B*PR0C0H 8VW\=NNM<F'%.!4^YKZY_-+H"5-F!3XZ7,N:QNY@"<]0#Y2\FX
M10ACIC$QXT]!"F>;EYREVMK:YRH81H +K[25O1 6ET2 UZ#3*1+7C6PXO/28
M_>YW#%E7=E;E3)G@7"6[Q".\!51[=?X'.8"DL'VH<RQY\6H#()%9P7R0:*ZL
M"M2(S%%3UH&6A3N:1\,<^^L;*7YF51X\7=3P,BW,U0RQPJ8+,DAK+D>Y45%H
M%SBYYP@E@K]G(PETV^6!+Y.K,2(98PWH8]I)J)D$/5BX2(9 ^,-N8#.K1',%
M#TO!B?B;2&"*(J0;!C=.3;3(+-B 3NG55/:0Y'>G?7L*_Y-ACATD!'RHEO0R
M>QUMS>YY7<C>E&?%]#ZZ#*>8#S<KSB-KEFIP=CW48*FN1U8\A:^:!ES'3,*K
M3G+B[M+\-?L9Z MP\U?S-E]%2/WF].NGV<6%05D]]!@4O+B0CWX17WKHP#HD
MR9-<Q[>G9U]G9U^;M^A@8P@?$0>R0X2=LYA#AMVST^S (^S9"R[@3J>'ST:'
MIZB%[?3@[-M3&.)1:O.3/4&5.>V>T*PR(B0J*0X $D;SP"M\RW;@+MORL5%K
M!F^-XA$QPJ-3, -&E[)(*$MXDI8#IJY*O!X1)R%JR2EID%/VEJ4.'@Q\5)!>
M%#4YM4WIB5"-Q*F-"T!1T E,/^0"U-3\L)8*B.L!M%OM**254&(,$*<&$11"
M0MZ!.$&T7]+?)/8X^*GD1W0L,H#U-V%<F=Y;A_Y5D[R*H=H0W_H7^@P]0%X%
M_^PR^Q"22S[85XT?,XD I] BNS:Q\Z1FU8-DQPPL\?X'(K/FB")1O(U"?<OL
M1Q019<4^3&R1DB;DP.7&-I2%F#G[(A)!1;ZO^KQ&?)H2M&W=,M>*.&2"4XSC
M,4;5&&12 'XP65+.H4#"?6O$KS* (28APE3+U/-NU26BBQE"*'YDIN+>5EZ3
M\$VCU1;>W0SDL\LQ?2(+ + <3V< ^ 4V&H.'$G\G2I/"0LT$IP<X,X^8$[/K
MR^P3X"B<0!)\P0I4&HZ"-E&^@V-:+(;P5CH4&#%&#JP7,(4AFYZ2(9$/650=
M:#7,6A3T 9>K!/05>=?=D?6Q0]&@N0&$ -9$#EB:Z_7LHX< PDH96SJY\&@E
M>7&1*"S";3D4W@^<?8=$K)E^KD'3+:@+U@D1C]7,CX[-;B^"^$O #= B1?29
M1?%D\5>+5/:O!])_&$8W:U2HK+HJI]*7HPLY^B^G??[9?T6:6,,C4;*TJ]PG
M4)&P/)I,2620%<K,:6/Q3 *T;"6UKR(!K]BB!"%&QY@_ TOR%;4DA=4TT(@/
MG,JK4EU!/D"(7O->J,2;C4OHN_;9<7-,BBRS>IF]\312-:#<!XZE8\CXS80]
MQI^DYOBPQ^S4O#R/KGY?#S.^?N8+G.9E_=3OGU;B1&+6[GNR:"<<<$#F:]W1
MN.@MR10)ZJ<!0)'673F/Y5BJ>"7,1JF XT )K/KX!HYZJG%V+"JL+#J0]5V5
M7YK3V6I"KPAW;6EKHK1=WN0;<F1&B/J!@AJGFDK7M$>@6[+KW(%+6)K\,5@O
MHR.-=6[00AR$ VEY^0# ,0,*Y$ &ZQP!9.2I4=BPA97KFLO,4'K-G@3UK:B>
M^/MCYW/9!HM9J'X/KD$D!;HMK##:F+\]9;NV1NMHG]_Y@(-XZ'GM[5T*K,G5
M1M^*D!EZU!=H0BRSJW5/P01B.!,QG 9'1\1$KDQO-VUW-[H**E,-T35 %!]^
M>D=1G);*]SB,*5"CD#,:GV6/#BC>!RQ&=L0R^R4NDEO/F8*+I#P1+8D*#)Z;
MM@"9<!?2CB#:1_R#%NX7LOHZ*UN*1+0A $HJ.RD:,*P1T7B/_'Q\+)9X&-F5
M:%1QMY"$NUAMN?=3 U%I8H.K K FY3CP9B1BS.H!['8_#I@#K\;4GOE*HPF>
M@Y;;62MFBT@AEB\1CJ;4Q+F^&;@.1\M'9#\EEC'LU4%"F"LAI'A._$SYK\'G
M1NXQRI>F>)S]J+&QZ!XPODH'FD@1[X2!U$$&O$R2,;"#G2Y7MB;!=[X"4R1@
MG?Q09>AZS.D/H +@RX<!:Y2L0=16-U1"EZ0\[&YERY)B.?Y[7X)8AM#9%DE!
M)>_BRP$V4NP.:]V-RQ&PO-T+JJTM-US,Y[$)/G:%-5E8@<OES'/X-V.VNM\W
M8S-RL^W%:; ( $D[OQ^F AQ:-Y7;HE]TC@[_*(DX=5&FW#GRST-UP>6,_DZ3
MW9&6"I',T?*4(P=;&YVW'U++@LNZT1Z23*NOPN+\1UU'YC2[E+=8S\$4D<1/
MYV%4Q#T$3BE8;VQ%Y!N#U9!XEHKKA\(81^\68(+TD].."POP22QYG$&2WYU*
M6_[MLRHT\!=094EAL[!FJ%N@GH[\;GS76O&,00*L.L%H4X>K@W65<W$^V@M=
M2?FHNZ6Y&+O/#W6=-4+%*29RRCM+A5X@/\3O]_%OK""[I0K<U'2?V,:AZ(PE
MX1=)MQC0D@N\!N3 *&EZ"]QQM^>L20H9>$9SENTM-C%(R1*1$I-B2S&LSI*Y
MGM8>2@WLC!9#2&D]$Z\'3,[!VAELI=(H*6TCV9!:1B.%B$XK&Y<@Z]#LU8RO
M.-=2AR7Z$2D&]C@[U_HS3Z+^6MF>>W1V?DJ/9#^^>NL>$UO,&2GSF/L36$/6
MC1<SBC:\A0>A[L_@1>V&J$M%S^:]%S!_@/>IJ(1"X1A@ZZN=9<Q,^[&BVK\9
MU\9,'=+H_3C[Y\#6KB7>NP<N0.;3HIWO$^]S#C,8.IU'@<)OYG$Q\G<EL^8X
M&)DJKD8[8+D8+I9AWDDB<\ 7*IY]]Q33-Y@H!Z.A', >_'M[BS&V!874;(=R
MEFI I73V(8!P>@%P*^"P"L<D!49U.=DN_XZ+M35DIY7&VZ23"JR2ZA/Z>R,#
M(/+ADA,SJNF*43@OS5=Q""8J?2(1-/O-$>_Z\L ;G!FM6!O&T:)4F+*!]2>#
M-M3M./6DO=-SS*9/*A4\O:+6GBXD96%?ZK+ZDB+I(TR5STS-F3GJ1,U8Q>2?
MW7]C]RHOL/[Z+\#2_"'\G8UUYPAO"4# U ?#7H?#BT>N5>+@6+<5NUOWNEA?
M'S628RY)+.7$P8ZM98/6LJ13>FZ ]!8!59GE]*FWZ2/;*D1]0D\0<3/M43DX
M8K=!>YQZ#PI+/9OP!]O2B)ZH_"4!,(8A;(V*'%[W*XO8]B^N*+3$#@Y9>XL#
M;B=7QW-L@_+?*"M1R#E3VPV9Q5B#3/K7Z_? K>8;<!'7:UBI3R.'<0!Y)E;<
MS$4\L$F.*U[7E,^10!P5T?DT0M*@0ZKM>,.5]%U(<BK30UF4W87E'E;US<AU
M6'/I3RS^1!H+0%&>BWI/80_U,VB)OK9<'(" 2U:\8\E/6;XH8(\KRAOI_8&^
M!MV3-[8=7'W'>3(&$U,DMC]%,*DE9F5GSX0,3>1<#KXYB>( U%?5#ITC*1QZ
M<]*R<?4)E8K1R<!8E-964A*+%LB;3]VP[POI3W38_"LM6]A)D*Y+>1R.QVIN
M8W(J5L#<^D5:Y":O:FZ%!*ZD,\/A#'<.(=41)(AOR?T0; NY*8P3(B[@<1T*
M(!@)!A.#H.TV8;NVFR["+@U9(Y39H4*^(A^D>=N3$C/VTGR[)%F,/>R'N.-5
MVX#-TE,F$_A:"V-#GS!8,6;5]M2GPT&()T&AA#Y+Z7X*1!1]@Q%G'VT!NFW)
ML0DMFE)^+,](L0L@C*K4J!IC776N-YJ<4I*:VRS-2$1%66L] /R-#TICI3]\
M9 0@O?NWA!+A.<<:1W8R:;:,"8?]#RG?T*SDZWF39%:-@7W,S4=X[JAT5L)O
M*;I14MR+ ^F&TE)B[$BCQ&O261O7M-_%-V.^ ZY1JRGGW!^Q2X'-.Z3=/L:&
MU=PCF73E.S.%AY,+ I,8IR5V&&$WJBRK!5&/%>AX:9Y?(8*!]CZ0DR+&OXP4
M71P,G(N,QL[A >,(XW+HS#!S$^$D5L0TH3JO=[PE=-@*8JKTJ$IZW&9BLQQ]
M? AU\NT2!9I)]QR=+A 6;(^&:NZ3H**;1H<<O15=SC+;4?.6S3OJ_,.0;*@Y
ML5%9RV5X+/YX9)B9>PM2).S(Q?1@T#08YHSK7G(MW9Y4OU!E5!,''U$,WU&J
MVU)!")Y 9#W2ZX+<@4,G>EB\U@30&W6[?(%^W&AS>>S+3(=ZF*A$GFO\F\B_
MXT8_+4KD$C!R1#:C$G\J[$G6J5Q\%HR48)M8T6$_T(RC$^#0?HICT!-K2D\T
MV7VCAH=4KL][%_,L:PX%XUZV72?)ZP?Y%,>].3UD"^><K<>]C#^O?)%T(44@
MM^U0EVAE>)%(UAUUD88H\SZON"!&0L&)_N6P"4D]=/TC;:-Z99=WGV ALHXP
MN=OT/DP:MT)QR=G\,1#T5-M@''B?5E_%>Y/%TN>?L/HB3PJ*;8A3C3K<?/K=
MA#0TP[Z(V@_RE;,R,R'/I@_*4SMR*$OL:LPW:-_* ]*D,+87/*HCS)HX/A?U
ME_F3BV<[AUZZ5RP<8C&%-QZ]SUOYC1:\)C\POZ A)T^;D_V$@A4S*A/CP;LC
M3"7564:B4' _C@TUJ0:E?MWQ[OZ^HEDZOL0H@J6Q:TPV@!F78(OC;O@-%69)
M,QF";A!!V*QV1S1/CB39M7G#2GH*2\0VF9K#1_?@PJXX0#B@Y.%\ 9&O+;9-
M]?L0JV>*7L*E<0T5FX9)[9S,T1#SV0U8&5TAKDO4FK2$6OAX'KF-I']PEW^N
M=ESL3UJ3725MQ37M"CUE6H"F#DCU#@XCF+PT-).GP=>O$T=X3F2:43]#%YUI
M9-U4KJAQ3!.//.*B#A&8<+X:5:&/U8\D][8"2@']GO;88X0<KX=>-3Q806,?
M<4^"VJ_@A'6'FAXNS5M<)3O+3K/_'%I4=21C7?9H:#BA;LO'7/1,\IOIBGML
MN?6S"&&#B#71F92USV'M:[X(IDV*#O^>[.8;/@01"I6GJ^B:Y@?NZ&X78;<D
M>N8Q&*TD3$*4]VB.KN5&!^=)Z4O6?+S,]L! U-$JA28["_XDN\X(_J3M];CE
MYL.>::N?JA'MJN!F91P!%Y)OJ:(^UN'8B;%,K>@**\&'8;HB?) &ZCQG! F&
MSX3Q-/1&KC5683 >V)N4F, (5Q@,0N$2_D+:D49)*RS1(6WODL(/:;XGY(%\
M;:PJ5>DR&\&=I.#V6)V,"@]KD9TD^>,+NAS]+5/,J-TCSN=1+_#LF(K881T5
M A\O(XP*KCG6%28I4:0&CK4?.IP'Y\903]PF=(KU;KSD\ DB5"+[O09:(RWA
M-$!6+B;V!\D>"I3!ET%8W7OEY@NN/#U76OGLJ\I-FK?.?%M96AV=L$Z8Y0+L
MMF+-XUF*S#$P,X>^JKFEXC6NQ!$1ND+ /U8AQ!U._O)-?/E!190S!\$>/ YB
MV29Q'$9E\X<.F"OU(3-/-S"I.S(O0;"S@,X98DR"$95CD1'!5!(''+4''G0>
M4&)>IT-)B,!U,J +[B(=& VJ)C6HJD9XBXZ9D#0--\!::AVH$^^(Y'UPU_%%
M*\^U&+;FT"R'*=$,<.UB+**/GI\F&52..5-\9A E&(TCXRZ @3DG7UST[V$B
M#,"*MV909(=0^2=Q)C+<PTR"5"A2&25/_5*_:USD2[VZ''.EEAI,&O5' . A
M?WD8I7<7(Q+>V6QXVN,AH"9J-)-. -5W\=;.A%!F$O318773P&+R0OSU3&M8
MU.1[??4A.SM?Z-PT,#P(-H9U1@I+YD13'N;^E(?F6A+%*\D)"D&,OPOWZ/O$
M4C@"SBA0F.](&>SS.[J!TG^*CTL'Z@"N>D>W\/LR^X##$TY9QDOF/YEG,%\6
M#@*Q;N]L'$@TDM#266N=HT"^YM_!0!T:;?,-;+JCR.D4!N='VG%9YZFHHP0V
MG6NWS(X\=)E,0+"''S1D5823C:I2IF&8*)P<1R*I\97?H7^*MANYVVFD5-ID
MJ!D1+$(D&B/]F>HR<^> 8N67]S^'TU^Q,II<P'2TV'B.X+T'-)-\98C0\ S7
MJ'M[[:W-.80L'WP1J6Z;1J+\8#EIM2O:#I5ERY4=6L$4%?%&63FI?$N&44GF
MA:)S0,]/PFE-%$E%CN>PLH/C.DH_6]YR=N8LFSPR4"J0U<J24$%?BT\ND64R
M.A[A/^6*_VEY!-I[@MC?-B4GI2>[NO')@AACX1YF\7NT-% 11 WR]-B-P$&G
MTV8M$YL;<6M4"C5/N>8*5B^.)CTFZ/YJZZU2:C/L5MR[-D-1K&W E#,X#&#'
MK:\W%/IYUWJ,I&1$?8Q47\KAC;(EA3=:("E%X<?1<NX"&BH7PNN@U[#U*@2+
M_#>+R%FC@4;,+WZ1+EAWALK)K/C2=K(4&>-*<0OE[E)\5YQR1*_JTA'%/E*)
M($0=T?EC3E+JLC0$,;H;E#;<*M4GZ03CJ5OH*RDH1#0)LR]&ZO_(G?C=XB96
M96(&H&][6",*:NL(E!GE%0\9H\J*:# YA^;(&5.+6?CR"2-Q+$)]>#@&4(8>
M8C"1!?P!^\10VX^4GRS$_IH,D*QH^B2Z"Y*<:-6?I#?#EK[/77&IR9D10O%E
MABM!MJEV.UM61.IQZ1[%1.VMO )R ,/4+@8!UN4OJ5'*^1EA3-*YOD,8%X0T
M$10(^R)=C[K^_:9S'?NT<()UN7*P7#854A2]*F/17 '&(H*##1G+K .#0.WT
M1Z@Q'B/I,[5<'OY*0GHZ<L*L[MCD5=4AIJJ\-BZW.SJR65W@6_JQ$:R+]^+-
MEXD0#"XI4F2]98+>XA]/*%@-(N#IVQIX<UQ;-5Z:Q29RZ723+-XDC'D?+Q&/
M<]'J%'9F\N FU!3(. 2C!B*X*5#+# +#'WJ/\V)4A#*0TO4S")<9_-^/PLD:
M?T\KTN*X-U7Z(O6C7)*W3N4M Z3<<!/NAU ,;$=KX\R%(]\2EO2/$$R/8S)H
M18AJQIE1.'>5*P#Z6XL>G<X8I3*^2%F3J2"S3,8J.[%I@L'18=\S3]C7]C>U
MY9;RPQH><+E:; NG >D+3KG)CK4%UU8^ BK\I!^ D-'IO51BU7*XBXL6HF&_
MI$%T*%":3/694(D >&N3'VUH8C'6[1V*]N7<9;%JF\%Q_HJ-QE,=R8D7.Y*(
M/B064X9X<%0[V)(LYQA,VMJQPXP>U9MZO<.BD(:;8_01JZ15G>@!:,Y*$PB&
M<&'@5GC>XM@&DC(\')^\0KN@M!3%?(_3\7@-VCD0)55,( %+3!MT/9(6AR!I
M>Y-<!KO[X &0Z1M^(H"&>B4S2W3T9/RZ;,726A]0[J/OIA7V<^LPS^E,SLBU
M'#7'AK$ %(7<4\P;$-2!/NMI<I*,Y\+(=NA]G?LUF*L/YN+;X.B'5Q?TVQU2
MYO8V+D &E$1?77&4[TWX:1T9$>N[5\*T,#.>?S7_XR5OB>P [=5N=((UCY&"
MSQ]&P/K#!_<2\HAF<Z9:J>AC>X4: +2<'C,]%"7:<IL&J!%L:S*4KW/MT-'L
MYMVJ+2D2/DV):OA5X_KC'U())9VDZR-()20ZYI2(-TS*-6HO^#66V;#D@4OC
MGJEZ%"KGV@1_?3K [>R;0#&\SNRLO3NZKUKF!/&\,1-*)DB-_2,'@0J:C7X<
MZ^Q[GN,:IE(EX,GZ\G-+ODC4B*S*75"IH8*4N\A)OTKP74-0VCH7I4U1,,8V
M'8:C>#/1+(A+;)M!CUK+9M9"5][]IPQ3 C@#",N!U?4FX&1V$'3%+B4_GO:/
M1#-\6V]QT*^]["33["6FS+3FTYZVZU,\82C^57Q%%0=A,!!#9[B3B10[MI+L
M$6>AZ8HRR'R,$/\G5#94=\(SRR7!0CULMUK&_X9M<V=E3ZLK+28L+!1I9.H-
M'5Y #]TY5*OE_:I)D.3^F6'QD# <2O8.K+[L^\>CZ2\8!)I@[0# 8Q;"@$,A
MWE]926F<\))48W.5K(L BG[)Q)? 8]$&?6NB;Q]IOP>-TK ^)(P]7V"_DK@/
M5?:V+Y:/LU@4^Q]>4*[Q<Q$F]+4(\,7] CH_%;WPH2&[:'1+T2@<<273!AAJ
M%"LJ7S-(KR\XI)S+,R+C\*<;*YJ]H&'#!4[!#-YM2-6.(RQD7"- <!<K7_?5
MD1][Y4W, Z?V(8&D92VE"//05I_[4!PSKHDRE7$T\%!S7 H23[L9,TV-6+PC
M?4&9_L[;W;-B!2>Q:!,-ER9(AB&MMYP1-TEP%5DB_&8)ELM1,)?+0?V8O]EI
M?J@UDQEB$D0+S)L*W9[&@H[FAK5K,T:NGR^13!1C]T[GB9$$BY:Y9R#JU8?L
M(E*1:=LR&TQHOI+JC.80<H:UV^DO=W#<FTP@*EFGH %I_4A@>4>7*O6#[XHZ
M[R8RM26(3BT".-$PPEW4>82>9]O09!/M8_3%?).!B6K#^)F(U %K#L$009V>
M\*$ S+V)($B+A >#Y':2O Q#$7U>4UQ0HV^EBG-RUE!MZ)U7O)/YMZ> CO7X
M5(1$TC0IBL(4N5,-R5>NH\3TJW246)B+'-L#X?0,O\8+/OJ@(C\Q33EPO&HR
MV^T &W&T7._2ER;\8;MVX>-VZZ&C(&/'%0>:4SA6(D3]_\PP<3 ,?XIA[4DK
M#4YJ;IC!(+($/.W')A**GO!H^$DNU<BJB>Z[P.S !4H 66[0L#WZT"N<A%NE
MY@.].#>ZV#E(I([=%Q*)P#+3FUL>1*1.&\+WI@@\:*&.YA6/?OI 6K/8*Z-!
M$)X8/,G>3W0F6+0SIT_U >;H=7[T^ (/;#7!YM@/E^LS@3G=0LV;_X>K/:#;
MEMD-_\)"T[?T8W_1OZGQ@W^25@&O^3<OUWZN?-;ZNEM/V0V%VZF+ A626/;Q
M)A1'EDI+3L2)JTH=!U9^K:]=X40R5Z"U01&QVZ[J>_Q5FO:6M-7<1@(&99QT
M5<*K=.*5=L?M&5CPV-;MYBYNS9!9:^/L$HT8Q^)I9Z)\]$S,A#K23BN0Z?PO
MG%[R,X\(U:3TF^LWOVB>,AKLQ@G?2I 4F<UNJP.LL8JXH]BXD=&RM]@V0S^W
MDHSW M(V8^OV9<>N1%U3@1/_:IXO*T67EWZ.FRL2:-:S]D0@?/1VJ,2GGUK.
MKG;Y']AGW+?4+OR;CZ".]Z8H.F9N4\][$>U)]4!YZ+SD'US5TMB+IPCA]SQ;
M@9U$74I&R<J<&O]F.IDM$CWR\S2C_H2$M2?3UD=>.&O)9"B.S$]FK,HX,B(7
M+#"O[T9%=GE2L]SY&\0P?UX'PR412VT!QG0JMA*)VH'YF_3K36(/QA<E\#@X
M^#?7@U%R+3D5+>6D-I;2IW.HT8Y<N<4EMO]'8?C9G'EZ,<.>)Q)23#/F5F])
M"58S_05>_FD9%!TR"S4]=F7=?,%#) PI)LX_4K0T5[3=:\ &Y9KTE]AETFPR
M\4=!P!]!J'8ZE$@GKHZP+[82S=S,>3)=J+@(OY'$]4R&$ZO@@>&%4.O]F!."
M-CMX+HI;L1S!B;7.#^N;R7W&L[_4HY(REC#SRM_K=6/\Z!+ENU2YCZ81YSS8
MGSTSN,(=_9)T2B[BV8DXG?O9QM"O@U2((643-1)J..*ZR<8MP _:_] !4CCB
MYHXXTF3\'5(,:=.U_&N2H<$^4D1$WJ'8?E3+X'_9E'YT.?K-YW4<T,<$,]W/
M*@R+P;QGI3_,R+]06I$%@^3AJ%QWS3;4&F1*_'-1@I.%C#-2K8-#B5@%ZB]B
M8VZ]QVQ7U81Q<,3.4G(E:@7#&31SCV*Y6%8%0M7_L- :;JKM'&5F6>Q.4<)A
M/WER$<>K."<2VE9# 7-*)6P-H>D7_:3>#^RU<R<F\T4R$#>Z/KJW9?99M+WG
M(R#_L:)GW1=^(5:'L0YCJY=^3)NBZ^SM['F F>C...8DL]4U7L=;QU>'D9?*
MN6=/^A?/GE0._E/ _W?M+?S7;:WM7^=]_N(9D/;&OB)%3\;E\Y.SD^A3%%7/
M3Z[.+J_.3Y[ F^'Q%\_V@/&?\VZ#5%C;-;SZ=/GMUR<L+?2/OMWCDMFJ[8&/
MZ)];FP,UX@/P_;IM>_T#-[AMNT\$WHO_!5!+ P04    "  :AYA:_D4UPBP+
M  "T&P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;,U96V\;-Q9^GU]!
MJ$#1 K9\2=($3F) \2514#M&Y&P?%OM S5 2XQER0G(DJ[]^OW/(N2A1O=V7
MQ0)I+<V0Y_J=[QQ2;S;6/?B54D$\5J7Q;T>K$.JSHR.?KU0E_=C6RN#-PKI*
M!GQURR-?.R4+WE251Z?'Q[\=55*;T?D;?G;GSM_8)I3:J#LG?%-5TFW?J=)N
MWHY.1NV#SWJY"O3@Z/Q-+9=JIL*7^L[AVU$GI="5,EY;(YQ:O!U-3L[>/:?U
MO. ?6FW\X+,@3^;6/M"7:?%V=$P&J5+E@21(_%FK"U66) AF?$LR1YU*VCC\
MW$J_9M_ARUQZ=6'+/W015F]'KT:B4 O9E.&SW7Q0R9\7)"^WI>?_BTU:>SP2
M>>.#K=)F6%!I$__*QQ2'O[/A-&TX9;NC(K;R4@9Y_L;9C7"T&M+H [O*NV&<
M-I2467!XJ[$OG,_TTNB%SJ4)8I+GMC%!FZ7XV!1+A#[X W'E@X;WR@MI"C'Q
M2%]- ?7BBU>%T$:$E1)W3M7228ZT7?"C:VVDR;4LQ2Q@/XM[<Q1@-*D^RI.!
M[Z*!IW]AX,FIN+$FK+RX,H4J=@4<P=O.Y=/6Y7>G3TJ\5/E8/#LY$*?'I\^?
MD/>L"^$SEO?L_R.$XI^3N0\.</[7OFA&6Y_OMY5*_,S7,E=O1ZAAK]Q:C<Y_
M_NGDM^/73T3B>1>)YT])/Y]-W]].KZ<7D]M[,;FX^/3E]GYZ^UY\_'+Y_N;J
M]GZ&2,SNIS>3^ZN9F-Q>BLEL]N7F[G[ZZ78FOLRN+L7T5MQ_N!)WGZ_N)I\G
M]$)\NN9'U]/;R>W%=/*[F-UC/XO;Y_[3!MY^NK\2S\X.Q?_84C&-*:Z=S97W
ME%Y9U^66<$+/?0^A3/80JFVI<ZV (%IT8:M:FJU820\&*!0_7-@2O$J+O[9X
M$YN5SE=8MHY+*NO#4(-0BP4X4=AHDZQ(G0?#YA9K_F1 9BR[0Y_OT'>6R7$/
M[;/L4%QJSP8+0)?L<4**4H$H1:GE7)<Z;,_$'RL%!A9Y<B$A_KVS32VT%XV1
M\U)EP0IJ++K<@EB#<N"[Z$*QHT-7-<4ED)A6%SY:5R@G(*/"D\;%G=]9<H#N
M@]BT=C2>:Q*[<\?^P=>Y=8XCFI&RL;A?R:07]4DU0\$BT?P,F=0&IBK$.-#*
M8:8VMBF+E @K:KFE/U&^L&M%D?*ZTJ6$V?"6V6&CPZI[ZE7>.#([YJ,QA1=&
M$8300$F8G0=)4< _[]'"84Z[=RW+AO6RK=2<#NWB$!ZGI1R\=C%R;VRE<Z',
M6CMK*!;CF#5L1RPE_C,V2Y @V#IIO,PCC;'GP)9@1H$"B$:OU$"NE[KHXMUE
M-49P;]AC7*G3%@11C6AC58%T.^T?N!2RF-4N9I9L['U82Z<)3Q[ZG%Z3S(6S
MU0 /6,D,^O-/KTY/7K[V]  :V!<22.ET.CHW!L:ON&(P/L2=MCP#+/H\4T#I
M'RI/L2DP-BWTV0[J8VGB]<J6R&5)9(#@Q7*HY%=+V6[9?VV9!3AW7LP!7M0J
M'K"[""WF%Z3&Y%V6/:J7$8GEI(!VXVN4DR4Y3I6271EN(J=19#7DIO:3]OO6
MF!ACB%+\"@LI?67#2I*EM0S("<4P@.K46MO&"[\"=M*6%.^LPKA"PBFVEPD3
M+1<NI&[!2VBFW8<1#2@@ LL.]&(B_N.>; >NVO=(+$13$\P,T@\8)A;D)CS?
M<F'EN:H#X4G8U+5K8(/,K6RA2O$+>75Z_/K3W0U_.GG]ZYBMTJ9NB"MLHF$L
MSF+,5+21!:D#H1Z5R[5/WSD9<C D.+64CN.L'FO@$#:O+24Q,EKWL-2+WO]D
M[ %7S>'"*=43%11DW:X"%5(HJ-QJ51;C;#[^;EX9F!*C7?\XJ.QK%9E3WQH-
MA0"VP8 ?<P=ZE@]*J+]2$;F$.1/!_ZY5U43\.XKW=,M("7$'++4.7F9MEZ/.
M2_2'\FF; C=8H%69)FVFV!C4\UA<H#:7RC-9]IH&QKM>1]O54$3:%JV!.4N@
M=^VN"(X'M=UQFSMZDM!%,^NC2822H[A(?T.?B/@#NQL&KM+K@@B4_&#]8!3$
MK!P837S4D,$ ^+!=<>0K="GD#(>:V"%HBR-39/$5QY$VB2Q:.L<CS _!9>V#
M^')72\X9]1@&>-DJM!\*(_7XQE/-SNFH2-3P.X!?BKR4N@+TIET(6ZHH]8,J
M]<K&:./("<]4AH_E8"-TE=1*T&-7F"Z"HIJ'!UA;,7G*)2+I=SLW[#^RCHET
MULR]+C1Z2D0'/9<+"-44S-W1#-Q*JV+;RGK8=WUF3N7W8.P&)BUCDEJ?VMZS
MB?TV0AVL<]!BV=8@J0[Y(+SD)6*/4ZYG6'GU'3B9!0^RW<8!(7ML6\B*G&H[
M$-F">?41$T+8=BG7+F\JH!*!@R"NW=+;UL1=BY+DZ#1$+=#MX "PU,ZJB)Y\
MH&P"RK:ML-B5 LPC,WAD5K$5,:I8!2@H5P77A:;+ 5\S32S2M+C@Q@@$H\"H
MC&>:NR0%,8(D+<T21"IJC;!SV!8@%^:XT"4]=L!O#>::0SB@&;X8$^:87LL$
MA%@Y5&(T^45#NN%CF!R"]_5.U^I+@M#HFCA@=S/8H,?YW>6QY#(*3O]P6'S4
MTS ;=P35D<JNG-KZV/<PR!F;PH'Y"1O9@WB! N2X!^;/",)!Z]UIJUGCF1IX
M&E,14K0LLG=0^<KH;XU*?-^V13*/1M2=Q=PY_9Z>ZE-7C5 'E! J-M7.:1#E
M,T4R-Y45?/2:BVK>A/0,S,0C ?F\P'@8W_=E2>]2*RL2CT.R]BL>+/NL1 .'
M!F$E!<^Z#"O (8@"*!=DK.<NL9B-/=^G$(-#>ML%AG^&<?1A=^1N<RDK-0 ,
MN0367DM,]9# W9P.:*7E$Q'":M2& & *C!3^NY8%4ZQ+L85;LH@S!*CW^O-,
MG+PZ$&G4N8OGH!@> EZO Q/.WFN+-!HQC4^@J.3KEU@U4QI,#$O#GOX.)9MU
MAKZS^-.-6KQI,GO7SENQT(O_QD[QM)V=JB2RU93%"1[-MI24-E@A3O;K0["?
M4#!NC25X@81@/=5!!;[C$PL?&EPZMG)Q<_KQ#$V+JXD:6&/:>0CN[!O">C5.
MT<0 :HJC X8<[>/Y(F([SFR0RRYQM#0=88J&_"38#!<2X]=#;P<=?H=?B/=Q
MW@&N$'>P1G]H(,[6"\W=&"? 2.^^F<=OXVP:8F_IQLAB!\A]!SLLU((I&S#F
M:VHB^W0)X),C3"][W.#[BN621NP.)- S>)1]Q\WQ(APO^M 65D7Z0/'KQ39U
M@NX@P=E+]G!8.,>>RYA/:ZKR/XQ^.SG\8#>83QU.T]S(XHZ_%W%186HC+D>K
M _=1O#/NMM:DMD.G6FQ?6IYP?K&((I,3Y6JM?/S8'?RI93^F&<=P*TTAHP.O
M-E2%20+<^_6 SKHT4J8QF(R%F8!T.W9DG;YD^%C<6*<LN\O<U,R'0W\/9^JT
M;9_&O(%F8O@(9R1?L,"@FFZW<+2)J2:?N84/)OF."0^R'IA4 "^[FIX-8WLA
M_4I<8SSM>(*\IPW/GG<[F,YT-:C^S^ULOJ_X57>YP& TIN%S:-J116ZFT7&I
M#8__% B:0:%%?)18[K8B7F>_C".99F?G:8I4=)^!0N89"6K*+4YXTI7;CN!I
M0TU].U! TV#<79LD%5E4\8*NT.9?:=R"CKXDQSLW(N16:N!I5H]>1H)I6;H/
M^6!%=W#:2>K?SF-W9X3M.!#26:C87U7[+KR/!K^D5,HM^?<B'N=,B#^J=$^[
MGZ0F\9>8?GG\/>M&NB7Q;:D6V'H\?OEB%*]RVB_!UOR[S-R&8"O^N%(X!3I:
M@/<+:T/[A11T/]2=_QM02P,$%     @ &H>86G*60/9& @  %@4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&ULC51-;]LP#+WG5Q#:L%,;?R8-LL1
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MMM.,.BA*$T#G2R'T?F$N:'IR_ =02P,$%     @ &H>86M>4P7#$!P  '!0
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MSM[NC[K_O_.9L1HY\]MK;GNCD]>-4AT=FX)'XK2'0C%"/XK>V<\_C?='']Z
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ME02PZV_PTE_4-]0$ZY#&$LH''PT2PL7-3UO=MZJ5JG--J9V\)N$1VZZ;U08
M;AP(=MA6.!Y5Z6OY#%S.Z"M(]05$_EG5R9Q+'5#5-5QO0',<7/"41F$&Z?O(
M<S^2^3F/;;&=H/-"%$/FUZ91AGH,KE_ZO\GW[?'HB+WOGOEBNL2I>T?C[KES
ME<)%)_-MA9%?ZY/AY ?!@,JWP>P"S,'A/P/S8B+;8OL_B(?RX$T\$Q@]V@O9
M:^_\P\X7FTSHA?LNA5<2RC+_\::YVWSZ.O=??-KE_KL98KR@UYE4S+%U-#C8
MZS'MOT7Y'U85[OO/3%F\[[C+1&!HT+0 S^<*Q57]H .:#X)G?P%02P,$%
M  @ &H>86O@[)L+H P  QP@  !D   !X;"]W;W)K<VAE971S+W-H965T,30N
M>&ULG59M;]I($/XK(S=7M1+!;R3D!9 ((2K2A48EU^ITN@^+/> 5]JZ[NX;D
MW]_LVKQ$):BZ+WA?9IYY9F9GAMY&JI7.$ V\%+G0?2\SIKSQ?9UD6##=EB4*
MNEE(53!#6[7T=:F0I4ZIR/TH""[]@G'A#7KN[$D->K(R.1?XI$!71<'4ZQWF
M<M/W0F][\(TO,V,/_$&O9$N<H?FK?%*T\W<H*2]0:"X%*%STO6%X<]>Q\D[@
M.\>-/EB#]60NY<IN)FG?"RPAS#$Q%H'19XTCS',+1#1^-IC>SJ15/%QOT1^<
M[^3+G&D<R?P'3TW6]ZX\2''!JMQ\DYLOV/AS8?$2F6OW"YM:MA-YD%3:R*)1
M)@8%%_67O31Q.%"X"MY1B!J%R/&N#3F6]\RP04_)#2@K36AVX5QUVD2."YN4
MF5%TRTG/#"9BC=I0E UP 0]<,)%PEL-0:S2ZYQNR827]I,&[J_&B=_#""!ZE
M,)F&L4@Q?0O@$[D=PVC+\"XZB7B/21OBL 51$'5.X,4[CV.'%_\OC^&?X5P;
M18_EWV/.U]"=X]"V@&YTR1+L>U0A&M4:O<''#^%E<'N">&='O',*?3"9?A_/
MGA_'TV>83.%A,AU.1Y/AGS"<S<;/LV-L3^(=9SO]^CR&JYMS.&T-1CDR1>\Q
MA:\"IG*-Q1P5A%V7IJ@%)D,8R:)DXI7";"..*9R%K8L@L&&WUUQP8P-?5O.<
M)R 7"U1<+&EQ@/Z(*4^(.$P$/8-/'S]<15%PN[MW^_#V,S"259@@E7@*41RT
MNI?7D,BBH,K7&2/_WN"V2%A3X5I[#9TMVTSFJ3V^;L?Q'U;)J4/"2FZ([2%*
M&V:_0H.5SKESF)HFT&-R>$1DRG3*?L*H@7ID:D5MUU)W!)@@229@ADFE*#8$
M/'Y),B:6"!55DW)B^K684YO81N)Q>M\$80?TH)A8+2IE8&9DLOH-D!]_M[<@
MA^F,ZJJ+6P?>)5*D56*=8Q3#-2J-381TF7-C0\&IC+C6E94A#1H%VM#"!4'1
MAYI_DY,6" DE4[!F>84M8,:B,NK7%B<\I_B=QT&;:M-9LQEK'4N6MDG<<TPQ
MH0&E;0*4+-YY#D9"MW5Y'3ETLD9]IO9ZVVMJ2TTF:Q=+Q1-\F^U]6C=,TPMO
MQU?[C&Y9T@T]3G+>A2V7VA&V<:+(&+3-R'$@AE2*F9UY:ZSEW!,BK%<R"&A[
MZJ],K>I9&%HN+O;[#O?I-]1C.(>S;M3]W(9C7<H_&"X%JJ4;H9JH5L+4<V9W
MNIO2PWHX[<7K$4\/?LF%AAP7I!JTNQ<>J'ILUALC2S>JYM+0X'/+C/YIH+("
M=+^0TFPWUL#NO\O@/U!+ P04    "  :AYA:,*TQ-ZD"  "Z!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q]5$UO&C$0O>=7C#923H3]@'R4P$J0
M4#52TD0A;0]5#V9W8*UX[:UM6/CW'7N!@D2XL+9GWIOW;&;ZM=(?ID"TL"J%
M-(.@L+;JA:')"BR9::L*)45F2I?,TE;/0U-I9+D'E2),HN@Z+!F70=KW9Z\Z
M[:N%%5SBJP:S*$NFUR,4JAX$<; ]>./SPKJ#,.U7;(X3M#^J5TV[<,>2\Q*E
MX4J"QMD@&,:]4=?E^X2?'&NSMP;G9*K4A]L\YH,@<H)08&8= Z//$N]1"$=$
M,OYN.(-=20?<7V_9OWKOY&7*#-XK\8OGMA@$MP'D.&,+8=]4_0TW?JX<7Z:$
M\;]0-[DQ)6<+8U6Y 9."DLOFRU:;>]@#W$:? )(-(/&ZFT)>Y0.S+.UK58-V
MV<3F%MZJ1Y,X+MVC3*RF*"><39^0+)E^:(G+G839!C=J<,DGN#B!9R5M86 L
M<\P/"4(2L5.2;)6,DI.,#YBUH1.W((F2[@F^SLY9Q_-U3CJ#W\.IL9H>_\\Q
MDPU%]SB%:XB>J5B&@X#^\0;U$H/TXCR^CNY.".SN!'9/L:=/X^%D/#FFZC3N
M^\O[&+[T+J$A@!<)PTIS 9N[:X$M$.Y563&Y!I06->9G7%H%#&RM+M?(- AW
M/<#F&I%ZS-+?SA9 3>YRE&4"&/4XJ!FPJM)JQ:D!4*PAZ4;4.0L*0HG$;%I0
M%U1@NCZHJK)L47&Z_D-TG$1G!VA?<0]X<7Z;Q#=WA@K/>(;$SJ6/YYQ>D6?6
M*7I' <,E7[;@T6B&H@WO>Z4+1E4EJ,IW/9G&E469-]YH#.0Y=Q$FSFQ!YH\]
M9+C73R7JN9\:!C*UD+9IK=WI;C -FW[\G]Y,M6>FYUP:NNX90:/VS54 NID4
MS<:JRG?G5%GJ=;\L:+BB=@D4GREEMQM78#>NTW]02P,$%     @ &H>86MGA
MY+%+ P  [P<  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULE57;;M-
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M+4OSVJ&T 69_)80^&/: ]OU,_P!02P,$%     @ &H>86M "X1KL!@  _1
M !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULI5A-;^,V$+WK5Q!N4;2
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M2A:X,&"K/!=F/46EZW$8A]N%;_(A<[P034:E>, [='^4"T.SJ$5)98Z%E;H
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MWZ0A%MPN8_4;)0]0UEXS@@G@3D>B=1WEVQ(]B.C]1/4#/,V&QL,\CZ ';]6
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MFZ@837CZWKCJ7JH,W#,'PB^-?')&=A@X!U22%!H= &7X5<PT81D&#DQ70"E
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M PPG[ B4'M7N6.9)5J"BOOO+/GJ)S^#]R()#"*)SYTLN\?4JI!:WR+%%.B3
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M/.R!KC\?ZH-5E7MEGRM+'P#N=D5?7*A9@9XOE++M@0-TWW#3_P%02P,$%
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M*VNA:[&4#JDK0269D,*INLX54KK>D0NK^)5X3A+^\<.KZ73\]K8]P&],WK[
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M',>-WS,\:=L6&@/3>&_[:.\IX_YI@6X50A^^L_[^R9_Z*9S:WJ%Y*- 3M"U
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M" 14+C!0/SS"%0@1B+R,'R,GGDH&X.G\R/X^>O=>]M3"E19?.7--@=]@Q.!
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MCFAH"GMD^C-P5%CDH/M]*RLDCPF M6OH4L$)_?;Q;98W99;7=7:3UX/F=SK
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M3;XC^WIT4-^1K^W,)B;96**G+%+CS<PEK%7^!)35T9;&2HP7Z^P;!GY^=0_
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M-G$ /0'7?!!GA/939!G#7LTB0BJ%G-R,X3OEOP87LKO#REFKXDGV@W79!O>
M;G_:T(2+.)L;N X2X%44(X05]'2ZLE71>><;4);\J9/;P1)T/:;T>V !T.7]
M@%46K8'55C>40AU%XO1AH\N27'?NN4M!+[U'=X^H8#GOZLL!5E(T!G.=Q@E)
M6";F&-5>ESM.YG:GN<[>5ICABA487,Z2.G\U)JN[C5U6='?[7LP:C0 0MW/K
M883*H'93F3T:FA?HWQE%YJ=&U)0Z1^X8G[)SE9#?<09)(*6\@WTT/26>@#6
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M_4+M ]SY5BE[,/P%_8N8_P%02P,$%     @ &H>86MAO"D0^ @  \P0  !D
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M"8TWH/V%UFXW\0?T]USQ!U!+ P04    "  :AYA:7(6RWX,"  "1!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R55-MNVD 0?><K1FY4M5(:7PDD
M!4N0I)>'J(CT\E#U8;$'O(J]Z^ZN<?+WG5V#2R6"U!?O;<Z9,P-G)JU4C[I
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M3=#@8C3T0'4#H#L863O3K:0A"[MM03,3E0V@][649G^P"?HIG/X!4$L#!!0
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MFDKLA.D5-WK'>775R_1O>#_L;IDJ:Z&!8T&IP?GEA0>J'R"]863K1)M*0R/
M;2N:N:AL )T74IJ]82\8IWCR!U!+ P04    "  :AYA:[2\*P'D%  "K"P
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MF>%J. R<[L-U;*8=+G?A<XG;M#1^ ]9KC1.Q'G@'F_OYR5]02P,$%     @
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M.!M^-'!^?7$%TH"EF?/+:\H>^*ZJ5Z)Y.@K^1J$!W0(#+0_64]3]$@47>KV
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M/2< L%\!]%+OX+KJ!Q^:9:<+\/G1\6X,J4&<U"#>PCT"[UJ#!Q56X@0 \0N
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MK:ZPAQN@*0@S0-_/.%?/)\9 UT%=_@-02P,$%     @ &H>86A!.J/\! P
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M9;+JR%<-!%V79YHY%?*$5%ZF\I0,3 7(YTM*Q>M '9.:<W?X'U!+ P04
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M:;!;N&&)_1R4#<#]A93F>6);1O>'R/X 4$L#!!0    ( !J'F%J^?_#&V@(
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MCH7\G\2>),#N$V!/J4?7= >LD)M7(%R)E#(B"(RN:ZOC-3KJ!-E%?A#JN\-
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M@X2Y2)B'A/E(6 ""U5)DN$^1H8I>I0A;$!KS;2+;TD ).#4-D# +";-+V*B
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MJOFH%J!:B&H1JL6HEJ!:2FEB*FI=*LH;/=%FN^>]_:"AS?8JRY-QB/9X4,U
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MHC &^ON*Z]QV&Q.@?X_3WU!+ P04    "  :AYA:((U=FZ$#   ."P  &0
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MV9/ISHH70-$1=*5KXCD5LL+6S5B^FH I SF_H%1L.VJ!ZAWF_P=02P,$%
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M#OAEO7-*++1)$D>/<1*7U5,B"U[$J[3>@B0JCT>4ZSS;K=;U@Y7-GIY))0'
MX$<M%Z"B,2PT]8N1R4P -P^=M@-4@)JMH*(Q+#250)FM!'!5HG\'J*#=UG-F
MZWT#MR8K2BV]SFDRZ]X!*I#I00"G!Q_2D@MZRD9*)UDDLMHR.^P"M(WR.BJ;
M9OUM5L1E3\BA%@=0T1@6FDKUT2:3<!/1B2&'NZ,D[I:2KY&2!#(E"> ZQ DA
MUV[4.7-I*^1&Y /FF^MK)!:!3"P".+%@W_:W5I'/<[*(ETL1RH*@HA'/8)BB
M%A-0T1@6FKISJ<Q+0K@UZ+0P#5'S"E0TAH6F$BCSBA N6_2'*0QP>@#>ANWN
MGS-;;TL8<[1^.F1R$,(EAE/W6 Q1ZPFH: P+3:509A$AG$6<LL=B:*@+Z+4#
M^# #+OR&@W7T:X=2D8<]Y86BV"FS/(@PH<>>HSR/TA[M!1]@L >AJG4L-)5<
MJ=9#N+9P<A"B%A)0T1@6FDJAS!1".%,X*0A'*&SSA1T)B(6&Z@.UNH)5:OFP
MO_K ]_6'G&]X5.SRIBL[6XH;7U4HK%]5BQZ'98Y(C.D+853UCXK&L-!4RH^V
ME(<+$B>',&HE A6-8:&I%,J$(803AI-"V/#XKKX:<6LPLBU7[T8S6 5!1QE^
M)O7Y#*X;:).H0DQPM>7S.O82$8H])7@8?ZB#H*(Q+#256RG=9W!)X-08FZ'6
M E#1&!::2J&4^[/3=H:'8FS6+@+H4M5@HA?6#29'N]"JIR^E]FR8U&YN<?'+
M*F&U#BBRNDU</QW1$V>HJ^^H: P+3659:OT9O/I^<IRA*GI4-(:%IE(H%?WL
MM/5W,,X:".7GJO1?8( /,T!IF@[6T7H]JT2W^HY4GC-8>7ZQOW[F\T1HR7@9
M\\47^I4<OS9Q.SWZK;X-SU?UKRH6(HYW:=G\N-3AW>:7&V_IQ5W]>X7:^XQ>
MW)O>%^?\\E./VB<W]L6];1SABQ&^Z1/[XGU]C*D\U>8G)S]&^2H6UYR$+\5I
M6^=5221O?L6Q>5%FV_I7!Q^SLLPV]9]K'BUX7AF(SY=95KZ\J YP^"W-Z_\#
M4$L#!!0    ( !J'F%KOP:DA7@,  %<,   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;*U7:V_3,!3]*U9 :)/&TN;1QV@CK0T()$ 39?#92]S&FF,'
MVUG'O^?:R4(?7E58OZQ^W'M\S_'US=UD+>2]*@C1Z+%D7$V]0NOJRO=55I 2
MJTM1$0X[2R%+K&$J5[ZJ),&Y=2J9'_1Z [_$E'O)Q*[=R&0B:LTH)S<2J;HL
ML?P](TRLIU[?>UKX1E>%-@M^,JGPBBR(OJUN),S\#B6G)>&*"HXD64Z]Z_Y5
M.C;VUN ')6NU,4:&R9T0]V;R*9]Z/1,08233!@'#SP.9$\8,$(3QJ\7TNB.-
MX^;X"?V#Y0Y<[K B<\%^TEP74V_DH9PL<<WT-['^2%H^L<'+!%/V+UJWMCT/
M9;72HFR=(8*2\N87/[8Z;#CT!\\X!*U#L.L0/>,0M@[AL0Y1ZQ!991HJ5H<4
M:YQ,I%@C::P!S0RLF-8;Z%-NKGVA)>Q2\-/)9Z$4NB$2+0HL"7J+%I!8><T(
M$DOTM2[O8 M&=E<AS'-D/6X5R1'E2!<$S459U1K;:P33'<2SE&A,F3H'[-M%
MBLY>GZ/7QO5[(6H%@&KB:R!BPO&S-NA9$W3P3-#] 'T17!<*O><YR;<!?%"@
MDR%XDF$6'$1,27:)POX%"GI!Y AH?KQ[Z'!/CW</#K )NTL-+5[X#-X<Q*&\
MIGR%H#Y(>S7JRJ5S@Q.Y<4S)N5(5SLC4@YJBB'P@7O+F57_0>^?2Z)1@Z8G
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M1!H#V%\*>)?MQ!S0_2^1_ %02P,$%     @ &H>86C160K]8 @  NP<  !D
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M=#@X+GAM;+59;6^;.AC]*Q:;IE9:!S:OZ=)(;=AT*[5:M6SW7FFZ']S$2=
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MB"JMJDVVOKR2&D/SBL1T$C-(S"0QB\3L1VSV+*^TZ6ATD%?DC"Z)>23FDUA
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MD)A.8L;UT=_/T281.9]%8C:).23FDIA'8CZ)!206DEA$8C&$=7)*'>V#JBZ
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M@^WNC.(K)PWDVN#$4X]/UUQ-KL<'F]XZ.JN!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M=,J8TKIYUO8<C.4]!__M#4KE[.!$0SL34,U -1/5+%2S4<U!-1?5/%3S42U
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M@UJ#%[]]TQL&G[JR^)IDR2N1[64X:C,<'6./9\A(59J[!Y/!&HMGB:70$'C
M<JRA\U+7E$-':8OQ.A[B95GO)NBY213LFR3/3<+@HK794S-HU0R.JIG3^JY@
M=9&*F4=\G@8P:<:^4UTM-,L8=H0N34>)NP^!=-V,P7-5'R\&3Z3_O[,Z/?Y.
MM2Q K5S7T225E3!US6A7Z\8VP<;F&L"3=6QX5Z[.^W]IZFYY0]6*X8OCL$3*
MX/P#QJ[J#E1/C"Q=35Y(@Q7>#7-LVJ"L >XOI33;B770_@V(_P!02P,$%
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M#:#O"RG-KF,GJ)YVX[\!4$L#!!0    ( !J'F%J)R%#,6@4  (TN   9
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M #1@2!!4[\&=]Y&W?D]Y[2_$X[]02P,$%     @ &H>86I>*NQS     $P(
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M2P$"% ,4    "  :AYA:1L=-2)4   #-    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !J'F%J:+P'-\@   "L"   1
M              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M !J'F%J97)PC$ 8  )PG   3              "  >0!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ &H>86F?C +_0!@  IR$  !@
M     ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M !J'F%J)D88TT0,  +X)   8              " @2L/  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  :AYA:]\>-;N(&   ]'P  &
M            @($R$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ &H>86LUM>MWP!0  SA@  !@              ("!2AH  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !J'F%I9=EYW- 8  +TH
M   8              " @7 @  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  :AYA:J*(ZY,H)   Z-0  &               @(':)@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &H>86A*]D,S9
M"0  G!<  !@              ("!VC   'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( !J'F%J97GAX'B@  (Z%   8              "
M@>DZ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  :AYA:
M_D4UPBP+  "T&P  &               @($]8P  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ &H>86G*60/9& @  %@4  !D
M     ("!GVX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !J'F%HPK3$WJ0(  +H%   9              "
M@7N"  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ &H>8
M6MGAY+%+ P  [P<  !D              ("!6X4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  :AYA:'U2LY<$&  !O$   &0
M        @('=B   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( !J'F%J#ND..2@(   4%   9              " @=6/  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ &H>86GEP1B1J @  2P4
M !D              ("!5I(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  :AYA:T +A&NP&  #]$   &0              @('WE
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !J'F%J< M&;
M> 0  )0*   9              " @1J<  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ &H>86E>+SJX* P  ?@8  !D
M ("!R:   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  :
MAYA:.U[0"AL0  #Z*0  &0              @($*I   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !J'F%K'KU_W"PX  /0E   9
M          " @5RT  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ &H>86G$K4J3A"   G!<  !D              ("!GL(  'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  :AYA:T#/6S;0%   @
M#0  &0              @(&VRP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( !J'F%H-NZ)>J 4  -8+   9              " @:'1
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ &H>86M<S
MX1AO P  E0<  !D              ("!@-<  'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    "  :AYA:<;(8<YP%  #/#0  &0
M    @($FVP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M !J'F%K-;<0W[@X  &LI   9              " @?G@  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ &H>86C%I!S6D!0  2 P  !D
M             ("!'O   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  :AYA:'8*_0' .  #H)0  &0              @('Y]0  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !J'F%H\I3,X$0(
M -T$   9              " @: $ 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ &H>86DDG;.K% P  R@D  !D              ("!
MZ 8! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  :AYA:
MH43N#O,I  #+E   &0              @('D"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( !J'F%HU)]5*Q (  !D&   9
M      " @0XU 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ &H>86@X'"5=* @  '04  !D              ("!"3@! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  :AYA:V&\*1#X"  #S!
M&0              @(&*.@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( !J'F%I<A;+?@P(  )$%   9              " @?\\ 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ &H>86O3G'O[>
M @  _@8  !D              ("!N3\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  :AYA:Y5Y/O $#  !]!P  &0
M@('.0@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !J'
MF%I8M#VWE@(  "8&   9              " @09& 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ &H>86A3/=7-! @   04  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( !J'F%K4B"I8-04  ,@-   9
M  " @:)9 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M&H>86F[\GABG @  T04  !D              ("!#E\! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  :AYA:[2\*P'D%  "K"P  &0
M            @('L80$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( !J'F%IDHA0[W0(  * &   9              " @9QG 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ &H>86E8 KG&U P
M&0D  !D              ("!L&H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  :AYA:5&)35=($   .#   &0              @(&<
M;@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !J'F%I2
MY( ^10,  )0,   9              " @:5S 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ &H>86JA$K_T2 @  M@0  !D
M     ("!(7<! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !J'F%IQJU!3<@D  (5_   9              "
M@>^& 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ &H>8
M6O/K_M=L P  (PP  !D              ("!F) ! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  :AYA:K"+<MXH&  !&0@  &0
M        @($[E $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( !J'F%J%8E-&<P(  .\&   9              " @?R: 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ &H>86A/ S 9P @  D 8
M !D              ("!IIT! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    "  :AYA: (%S,WP'  "L.P  &0              @(%-H $
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( !J'F%I7OP#9
M@00  %\8   9              " @0"H 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ &H>86F1O]TL! P  LPD  !D
M ("!N*P! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  :
MAYA:2\!R&5\"  !&!@  &0              @('PKP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !J'F%H+9O;FC0(  #0'   9
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M970W,RYX;6Q02P$"% ,4    "  :AYA:GJN6XK4%   A&0  &0
M    @(&)P@$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M !J'F%I;E[2%BQ,  ,I@ 0 9              " @77( 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ &H>86K=K91-" @  N04  !D
M             ("!-]P! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    "  :AYA:J'N;[/H"  ";!P  &0              @(&PW@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !J'F%H@C5V;H0,
M  X+   9              " @>'A 0!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ &H>86@A.3DG<#   ;+P  !D              ("!
MN>4! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  :AYA:
MO!G[4?@"  #!"   &0              @(',\@$ >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( !J'F%KEV@UI]0(  "4(   9
M      " @?OU 0!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ &H>86B(8_MU7 P  6PP  !D              ("!)_D! 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  :AYA:<BW;YXL"   ;!P
M&0              @(&U_ $ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    ( !J'F%H>1-5/* ,  ),-   9              " @7?_ 0!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ &H>86I4]IA0L
M#0  5W,  !D              ("!U@(" 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    "  :AYA:[\&I(5X#  !7#   &0
M@($Y$ ( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( !J'
MF%HT5D*_6 (  +L'   9              " @<X3 @!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ &H>86F$_LYMR!0  _1P  !D
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M=#DR+GAM;%!+ 0(4 Q0    ( !J'F%K)7NMZ@@,  .8)   9
M  " @6(Y @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @
M&H>86HG(4,Q:!0  C2X  !D              ("!&ST" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-"YX;6Q02P$"% ,4    "  :AYA:.^X39O +   ,J   &0
M            @(&L0@( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4
M Q0    ( !J'F%IN.ASD9P,  "X6   -              "  =-. @!X;"]S
M='EL97,N>&UL4$L! A0#%     @ &H>86I>*NQS     $P(   L
M     ( !95(" %]R96QS+RYR96QS4$L! A0#%     @ &H>86GJ>8^^9!@
MYCT   \              ( !3E," 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( !J'F%KZ,(1HN0(  .0W   :              "  11: @!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !J'F%HJHF7Z20(  !4V
M   3              "  05= @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !G &< 2!P  ']? @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>352</ContextCount>
  <ElementCount>400</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Investment in Associates and Joint Ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InvestmentinAssociatesandJointVentures</Role>
      <ShortName>Investment in Associates and Joint Ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Investment in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InvestmentinFinancialAssets</Role>
      <ShortName>Investment in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TradePayables</Role>
      <ShortName>Trade Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Employee Benefit Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EmployeeBenefitLiabilities</Role>
      <ShortName>Employee Benefit Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/RevenuesandCostofRevenues</Role>
      <ShortName>Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</Role>
      <ShortName>Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995326 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995327 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OperatingSegments</Role>
      <ShortName>Operating Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995328 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995329 - Disclosure - Significant Events during the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod</Role>
      <ShortName>Significant Events during the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995330 - Disclosure - Events After the Reporting Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EventsAftertheReportingDate</Role>
      <ShortName>Events After the Reporting Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/Cash</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/Inventory</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/OtherAccountsReceivable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables</Role>
      <ShortName>Investment in Associates and Joint Ventures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/InvestmentinAssociatesandJointVentures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/IntangibleAsset</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Trade Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TradePayablesTables</Role>
      <ShortName>Trade Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/TradePayables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/OtherAccountsPayable</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/FinancialInstruments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Employee Benefit Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables</Role>
      <ShortName>Employee Benefit Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/EmployeeBenefitLiabilities</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/Equity</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/RevenuesandCostofRevenuesTables</Role>
      <ShortName>Revenues and Cost of Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/RevenuesandCostofRevenues</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/LossPerShare</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Operating Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/OperatingSegments</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996019 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/General</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Cash - Schedule of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofCashTable</Role>
      <ShortName>Cash - Schedule of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable</Role>
      <ShortName>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Investment in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investment in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable</Role>
      <ShortName>Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Investment in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/InvestmentinFinancialAssetsDetails</Role>
      <ShortName>Investment in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/InvestmentinFinancialAssets</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/Leases</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/IntangibleAssetDetails</Role>
      <ShortName>Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable</Role>
      <ShortName>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofTradePayablesTable</Role>
      <ShortName>Trade Payables - Schedule of Trade Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable</Role>
      <ShortName>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable</Role>
      <ShortName>Financial Instruments - Schedule of Company's Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable</Role>
      <ShortName>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/TaxesonIncome</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/EquityTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Issued and Outstanding Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Equity - Schedule of Warrants??? Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity - Schedule of Warrants??? Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofRSUtransactionTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of RSU transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable</Role>
      <ShortName>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable</Role>
      <ShortName>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable</Role>
      <ShortName>Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/OperatingSegmentsDetails</Role>
      <ShortName>Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/OperatingSegmentsTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofOperatingSegmentsTable</Role>
      <ShortName>Operating Segments - Schedule of Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants??? Fair Value was Calculated using the Black???Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Warrants??? Fair Value was Calculated using the Black???Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Significant Events during the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails</Role>
      <ShortName>Significant Events during the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea0237489-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Events After the Reporting Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trpx.com/role/EventsAftertheReportingDateDetails</Role>
      <ShortName>Events After the Reporting Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trpx.com/role/EventsAftertheReportingDate</ParentRole>
      <Position>95</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0237489-20f_scisparc.htm">ea0237489-20f_scisparc.htm</File>
    <File>sprcy-20241231.xsd</File>
    <File>sprcy-20241231_cal.xml</File>
    <File>sprcy-20241231_def.xml</File>
    <File>sprcy-20241231_lab.xml</File>
    <File>sprcy-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="899">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>118
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0237489-20f_scisparc.htm": {
   "nsprefix": "sprcy",
   "nsuri": "http://www.trpx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0237489-20f_scisparc.htm"
     ]
    },
    "schema": {
     "local": [
      "sprcy-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sprcy-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sprcy-20241231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sprcy-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sprcy-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 272,
   "keyCustom": 128,
   "axisStandard": 19,
   "axisCustom": 2,
   "memberStandard": 29,
   "memberCustom": 55,
   "hidden": {
    "total": 155,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 117,
    "http://www.trpx.com/20241231": 35,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 352,
   "entityCount": 1,
   "segmentCount": 86,
   "elementCount": 881,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 899,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/cyd/2024": 3,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.trpx.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.trpx.com/role/ConsolidatedIncomeStatement",
     "longName": "995302 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.trpx.com/role/ShareholdersEquityType2or3",
     "longName": "995303 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.trpx.com/role/ConsolidatedCashFlow",
     "longName": "995304 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.trpx.com/role/General",
     "longName": "995305 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.trpx.com/role/SignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements",
     "longName": "995307 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "shortName": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.trpx.com/role/Cash",
     "longName": "995308 - Disclosure - Cash",
     "shortName": "Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.trpx.com/role/Inventory",
     "longName": "995309 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.trpx.com/role/OtherAccountsReceivable",
     "longName": "995310 - Disclosure - Other Accounts Receivable",
     "shortName": "Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.trpx.com/role/InvestmentinAssociatesandJointVentures",
     "longName": "995311 - Disclosure - Investment in Associates and Joint Ventures",
     "shortName": "Investment in Associates and Joint Ventures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.trpx.com/role/InvestmentinFinancialAssets",
     "longName": "995312 - Disclosure - Investment in Financial Assets",
     "shortName": "Investment in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.trpx.com/role/Leases",
     "longName": "995313 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.trpx.com/role/PropertyandEquipmentNet",
     "longName": "995314 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.trpx.com/role/IntangibleAsset",
     "longName": "995315 - Disclosure - Intangible Asset",
     "shortName": "Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.trpx.com/role/TradePayables",
     "longName": "995316 - Disclosure - Trade Payables",
     "shortName": "Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.trpx.com/role/OtherAccountsPayable",
     "longName": "995317 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.trpx.com/role/FinancialInstruments",
     "longName": "995318 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.trpx.com/role/EmployeeBenefitLiabilities",
     "longName": "995319 - Disclosure - Employee Benefit Liabilities",
     "shortName": "Employee Benefit Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.trpx.com/role/TaxesonIncome",
     "longName": "995320 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens",
     "longName": "995321 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.trpx.com/role/Equity",
     "longName": "995322 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.trpx.com/role/ShareBasedPaymentTransactions",
     "longName": "995323 - Disclosure - Share-Based Payment Transactions",
     "shortName": "Share-Based Payment Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.trpx.com/role/RevenuesandCostofRevenues",
     "longName": "995324 - Disclosure - Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss",
     "longName": "995325 - Disclosure - Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.trpx.com/role/LossPerShare",
     "longName": "995326 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.trpx.com/role/OperatingSegments",
     "longName": "995327 - Disclosure - Operating Segments",
     "shortName": "Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "995328 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod",
     "longName": "995329 - Disclosure - Significant Events during the Reporting Period",
     "shortName": "Significant Events during the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.trpx.com/role/EventsAftertheReportingDate",
     "longName": "995330 - Disclosure - Events After the Reporting Date",
     "shortName": "Events After the Reporting Date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.trpx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.trpx.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.trpx.com/role/CashTables",
     "longName": "996002 - Disclosure - Cash (Tables)",
     "shortName": "Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.trpx.com/role/InventoryTables",
     "longName": "996003 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInventorieExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInventorieExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.trpx.com/role/OtherAccountsReceivableTables",
     "longName": "996004 - Disclosure - Other Accounts Receivable (Tables)",
     "shortName": "Other Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables",
     "longName": "996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)",
     "shortName": "Investment in Associates and Joint Ventures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.trpx.com/role/PropertyandEquipmentNetTables",
     "longName": "996006 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.trpx.com/role/IntangibleAssetTables",
     "longName": "996007 - Disclosure - Intangible Asset (Tables)",
     "shortName": "Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.trpx.com/role/TradePayablesTables",
     "longName": "996008 - Disclosure - Trade Payables (Tables)",
     "shortName": "Trade Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.trpx.com/role/OtherAccountsPayableTables",
     "longName": "996009 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.trpx.com/role/FinancialInstrumentsTables",
     "longName": "996010 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables",
     "longName": "996011 - Disclosure - Employee Benefit Liabilities (Tables)",
     "shortName": "Employee Benefit Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.trpx.com/role/EquityTables",
     "longName": "996012 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.trpx.com/role/ShareBasedPaymentTransactionsTables",
     "longName": "996013 - Disclosure - Share-Based Payment Transactions (Tables)",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.trpx.com/role/RevenuesandCostofRevenuesTables",
     "longName": "996014 - Disclosure - Revenues and Cost of Revenues (Tables)",
     "shortName": "Revenues and Cost of Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables",
     "longName": "996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)",
     "shortName": "Additional Information to the Items of Profit or Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.trpx.com/role/LossPerShareTables",
     "longName": "996016 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.trpx.com/role/OperatingSegmentsTables",
     "longName": "996017 - Disclosure - Operating Segments (Tables)",
     "shortName": "Operating Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996018 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:RelatedPartyBalancetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:RelatedPartyBalancetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.trpx.com/role/GeneralDetails",
     "longName": "996019 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c64",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.trpx.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996020 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
     "longName": "996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.trpx.com/role/ScheduleofCashTable",
     "longName": "996022 - Disclosure - Cash - Schedule of Cash (Details)",
     "shortName": "Cash - Schedule of Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.trpx.com/role/ScheduleofInventoryTable",
     "longName": "996023 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInventorieExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInventorieExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable",
     "longName": "996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "shortName": "Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "sprcy:Governmentauthoritiescurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "sprcy:Governmentauthoritiescurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
     "longName": "996025 - Disclosure - Investment in Associates and Joint Ventures (Details)",
     "shortName": "Investment in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "sprcy:InitialInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "sprcy:InitialInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
     "longName": "996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)",
     "shortName": "Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "sprcy:InvestmentsDate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
     "longName": "996027 - Disclosure - Investment in Financial Assets (Details)",
     "shortName": "Investment in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:SharePricePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-1",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.trpx.com/role/LeasesDetails",
     "longName": "996028 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c106",
      "name": "sprcy:AreaOfLease",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c106",
      "name": "sprcy:AreaOfLease",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.trpx.com/role/PropertyandEquipmentNetDetails",
     "longName": "996029 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.trpx.com/role/IntangibleAssetDetails",
     "longName": "996031 - Disclosure - Intangible Asset (Details)",
     "shortName": "Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:PaymentsOfAdditionalDeferredCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
     "longName": "996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "shortName": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.trpx.com/role/ScheduleofTradePayablesTable",
     "longName": "996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)",
     "shortName": "Trade Payables - Schedule of Trade Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "shortName": "Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "longName": "996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable",
     "longName": "996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)",
     "shortName": "Financial Instruments - Schedule of Company's Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable",
     "longName": "996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "shortName": "Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.trpx.com/role/TaxesonIncomeDetails",
     "longName": "996038 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "sprcy:OperatingLossCarryforwardsTaxAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "sprcy:OperatingLossCarryforwardsTaxAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
     "longName": "996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.trpx.com/role/EquityDetails",
     "longName": "996040 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c173",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c172",
      "name": "sprcy:CapitalRatio",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.trpx.com/role/ScheduleofShareCapitalTable",
     "longName": "996041 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
     "longName": "996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "shortName": "Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
     "longName": "996043 - Disclosure - Equity - Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "shortName": "Equity - Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
     "longName": "996044 - Disclosure - Share-Based Payment Transactions (Details)",
     "shortName": "Share-Based Payment Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c200",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
     "longName": "996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c209",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c209",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
     "longName": "996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c212",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.trpx.com/role/ScheduleofRSUtransactionTable",
     "longName": "996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of RSU transaction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
     "longName": "996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "shortName": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c214",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "longName": "996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "shortName": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherFinanceIncomeCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "longName": "996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.trpx.com/role/OperatingSegmentsDetails",
     "longName": "996052 - Disclosure - Operating Segments (Details)",
     "shortName": "Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable",
     "longName": "996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)",
     "shortName": "Operating Segments - Schedule of Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996054 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c303",
      "name": "sprcy:InterestPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c303",
      "name": "sprcy:InterestPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c326",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c326",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
     "longName": "996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
     "longName": "996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c320",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c320",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
     "longName": "996059 - Disclosure - Significant Events during the Reporting Period (Details)",
     "shortName": "Significant Events during the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:EnterpriseValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:EnterpriseValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
     "longName": "996060 - Disclosure - Events After the Reporting Date (Details)",
     "shortName": "Events After the Reporting Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c344",
      "name": "sprcy:NumberOfWarrantsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237489-20f_scisparc.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sprcy_AResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "a. Research and development expenses:",
        "label": "AResearch And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "sprcy_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AccumulatedDepreciationAbstract0",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AccumulatedDepreciationMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Depreciation [Member]",
        "label": "Accumulated Depreciation Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AcquiredOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AcquiredOrdinaryShares",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ordinary shares (in Shares)",
        "documentation": "The number of shares acquired.",
        "label": "Acquired Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of intangible asset",
        "label": "Acquisitions through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ifrs-full_AdditionalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information to the Items of Profit or Loss [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdditionalInstallment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional installment",
        "documentation": "The amount of additional installment.",
        "label": "Additional Installment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional investment",
        "documentation": "The amount of additional investment.",
        "label": "Additional Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdditionalMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone amount",
        "label": "Additional Milestone Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in inventory",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in other accounts receivable",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income, net",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of intangible asset",
        "verboseLabel": "Impairment to its intangible asset",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "sprcy_AdjustmentsForIncreaseInRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdjustmentsForIncreaseInRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in related parties",
        "documentation": "Adjustments for increase in related parties.",
        "label": "Adjustments For Increase In Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "documentation": "Adjustments for losses from remeasurement of investment in financial assets\r     \n  to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Losses From Remeasurement Of Investment In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments to the profit or loss",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities:",
        "verboseLabel": "Adjustments to the profit or loss items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Adjustments for group\u2019s share of losses of company accounted for at equity, net.",
        "label": "Adjustments For Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Cost of share-based payment",
        "verboseLabel": "Share-based compensation",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Working capital",
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "sprcy_AdvertisementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AdvertisementMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising [Member]",
        "label": "Advertisement Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "documentation": "Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate investment (in Dollars)",
        "documentation": "aggregate investment.",
        "label": "Aggregate Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateIssuedAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateIssuedAmount",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares",
        "documentation": "Aggregate issued amount.",
        "label": "Aggregate Issued Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateLoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateLoanAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate loan amount (in Dollars)",
        "documentation": "Aggregate loan amount.",
        "label": "Aggregate Loan Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateNumberOfOutstandingOrdinarySharesPercentage",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of the outstanding ordinary shares",
        "documentation": "Aggregate number of the outstanding ordinary shares.",
        "label": "Aggregate Number Of Outstanding Ordinary Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateUnits",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units",
        "documentation": "Number of shares issued.",
        "label": "Aggregate Units"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateUnitsPerShare",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units per share (in Dollars per share)",
        "documentation": "Per share of aggregate units.",
        "label": "Aggregate Units Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValueAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateValueAdjusted",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate values adjusted",
        "documentation": "The amount of aggregate values adjusted.",
        "label": "Aggregate Value Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AggregateValues",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "documentation": "The amount of aggregate value.",
        "label": "Aggregate Values"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r235",
      "r251",
      "r286"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r238",
      "r254",
      "r289"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r281",
      "r290",
      "r294",
      "r302"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "sprcy_AmazonFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AmazonFeesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amazon fees [Member]",
        "label": "Amazon Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "sprcy_AnnualInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AnnualInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual investment",
        "documentation": "Amount of annual investment.",
        "label": "Annual Investment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AreaOfLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AreaOfLease",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of lease",
        "documentation": "Area of Lease.",
        "label": "Area Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r129",
      "r163",
      "r167"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_August2023FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "August2023FinancingRoundMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Financing Round [Member]",
        "label": "August2023 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "AutoMaxMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax [Member]",
        "label": "Auto Max Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "sprcy_BSalesAndMarketingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "BSalesAndMarketingExpensesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "b. Sales and marketing expenses:",
        "label": "BSales And Marketing Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "sprcy_BonusAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "BonusAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Bonus amount received.",
        "label": "Bonus Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [member]",
        "verboseLabel": "Bottom of range [Member]",
        "netLabel": "Bottom of Range [Member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r350"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r231"
     ]
    },
    "sprcy_BusinessDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "BusinessDevelopmentExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development expenses [Member]",
        "label": "Business Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CGeneralAndAdministrativeExpensesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "c. General and administrative expenses:",
        "label": "CGeneral And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital warrant",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_CapitalCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities, Commitments, Claims and Liens [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CapitalRatio",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital ratio",
        "documentation": "Capital ratio.",
        "label": "Capital Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r46",
      "r82",
      "r85",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r148",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r85",
      "r91",
      "r93",
      "r94",
      "r148",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/IntangibleAssetDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash consideration",
        "netLabel": "Cash payment (in Dollars)",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansMadeToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bridge loan to related parties",
        "label": "Cash advances and loans made to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/GeneralDetails",
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at the beginning of the period",
        "periodEndLabel": "Cash at the end of the period",
        "terseLabel": "Cash",
        "verboseLabel": "Cash for immediate withdrawal",
        "netLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r105",
      "r123"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CashConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "documentation": "Cash consideration.",
        "label": "Cash Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal of (investment in) restricted bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal of (investment in) short-term bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashScheduleofCashDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CashScheduleofCashDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash - Schedule of Cash (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/LeasesDetails",
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/LeasesDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "sprcy_ChemistryAndFormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ChemistryAndFormulationsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry and formulations [Member]",
        "label": "Chemistry And Formulations Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsDomain",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesDomain",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "sprcy_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical studies [Member]",
        "label": "Clinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "sprcy_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount (in Dollars)",
        "documentation": "Commitment amount.",
        "label": "Commitment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CompanysShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Company\u2019s share of losses of company accounted for at equity, net.",
        "label": "Companys Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_ComprehensiveLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ComprehensiveLossOnInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investment",
        "documentation": "Amount of comprehensive loss on investment.",
        "label": "Comprehensive Loss On Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "sprcy_ConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ConsecutiveTradingDays",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate consideration",
        "verboseLabel": "Consideration",
        "label": "Consideration paid (received)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "sprcy_ConsolidatedStatementsOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ConsolidatedStatementsOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ContinuingOperationsAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations:",
        "label": "Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConvertIntoOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ConvertIntoOrdinaryShares",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of shares",
        "documentation": "Represents the share of restricted share units convert into ordinary shares.",
        "label": "Convert Into Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CooperationAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CooperationAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cooperation Agreement amount",
        "documentation": "Cooperation Agreement amount.",
        "label": "Cooperation Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CostAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost:",
        "label": "Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CostMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost [Member]",
        "label": "Cost Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of goods sold",
        "terseLabel": "Cost of goods sold",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r34"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CreditFromOthers",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "The amount of credit of others.",
        "label": "Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "sprcy_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "documentation": "The amount of current assets.",
        "label": "Current Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r118",
      "r192"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInventoriesInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInventoriesInTransit",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods in transit",
        "label": "Current inventories in transit"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current investments",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r120",
      "r192"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r308"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r309"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r309"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r307"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r307"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r307"
     ]
    },
    "sprcy_DOtherExpensesIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DOtherExpensesIncomeAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "d. Other expenses (income):",
        "label": "DOther Expenses Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DebenturesMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debentures [Member]",
        "label": "Debentures Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DeferredCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DeferredCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash payments",
        "documentation": "Deferred cash payments amount.",
        "label": "Deferred Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DekelLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DekelLicenseAgreementDescription",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments, description",
        "documentation": "Dekel license agreement description.",
        "label": "Dekel License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r258"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "sprcy_DepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DepreciationMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation [Member]",
        "label": "Depreciation Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DepreciationOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "documentation": "The amount of depreciation of intangible asset.",
        "label": "Depreciation Of Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48"
     ]
    },
    "ifrs-full_DepreciationRatePropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRatePropertyPlantAndEquipment",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates",
        "label": "Depreciation rate, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements, description",
        "label": "Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "documentation": "Description of accounting policy cost of sales.",
        "label": "Description Of Accounting Policy Cost Of Sales Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForConsolidatedfinancialstatements",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated financial statements",
        "documentation": "The description of the entity's accounting policy changes in Consolidated financial statements.",
        "label": "Description Of Accounting Policy For Consolidatedfinancialstatements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit liabilities",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and expenses",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency and foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint arrangements",
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Description of accounting policy for investments other than investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Description of accounting policy for restricted cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForoperatingcycleExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The operating cycle",
        "documentation": "The description of the entity's accounting policy changes in operating cycle Explanatory.",
        "label": "Description Of Accounting Policy Foroperatingcycle Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAcquisitionOfASingleAssetCompany": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DescriptionOfAcquisitionOfASingleAssetCompany",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of a single asset company",
        "documentation": "The description of the entity's accounting policy for acquisition of a single asset company.",
        "label": "Description Of Acquisition Of ASingle Asset Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of Share Options (years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "asis of presentation of the financial statements",
        "documentation": "The description of accounting policies for basis of presentation of the financial statements.",
        "label": "Descriptionof Basisofpresentationofthefinancialstatements Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Weighted number of shares",
        "label": "Dilutive effect of all instruments on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sprcy_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DirectorsMember",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosueOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash",
        "documentation": "The entire disclosue of cash and cash equivalents.",
        "label": "Disclosue Of Cash And Cash Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Disclosure of accrued expenses and other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS",
        "label": "Disclosure of additional information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefits to Key Management Personnel [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
     "presentation": [
      "http://www.trpx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates",
        "label": "Disclosure of depreciation and amortisation expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
     "presentation": [
      "http://www.trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plans",
        "documentation": "Disclosure of detailed information about defined contribution plans explanatory.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plans Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.trpx.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT LIABILITIES",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING SEGMENTS",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EVENTS AFTER THE REPORTING DATE",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information to the Items of Profit or Loss",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Due to Share-Based Compensation",
        "documentation": "Disclosure of expenses due to share-based compensation explanatory.",
        "label": "Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Share Options Granted",
        "documentation": "Disclosure of fair value for share options granted explanatory.",
        "label": "Disclosure Of Fair Value For Share Options Granted Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.trpx.com/role/RevenuesandCostofRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES AND COST OF REVENUES",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Companys Financial Instruments",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefits to Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSET",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails",
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Intangible Asset [Line Items]",
        "terseLabel": "Intangible Asset [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfInventorieExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfInventorieExplanatory",
     "presentation": [
      "http://www.trpx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "documentation": "The tabular disclosure of inventories.",
        "label": "Disclosure Of Inventorie Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfInvestmentFinancialAssetsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN FINANCIAL ASSETS",
        "documentation": "The disclosure of the investment financial assets.",
        "label": "Disclosure Of Investment Financial Assets Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "sprcy_DisclosureOfIssuedAndOutstandingShareCapital": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://www.trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued and Outstanding Share Capital",
        "documentation": "Disclosure of detailed inforamtion about issued and outstanding share capital.",
        "label": "Disclosure Of Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU transaction",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Exercise Prices of Share Options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Segments",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfOtherAccountsPayableTextBlock",
     "presentation": [
      "http://www.trpx.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Disclosure Of Other Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, Net"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value for Share Options Granted [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Financial Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "label": "Disclosure of redesignated financial assets and liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets and financial liabilities that have been redesignated during the transition to IFRSs. [Refer: Financial assets; Financial liabilities; IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.trpx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT EVENTS DURING THE REPORTING PERIOD",
        "label": "Disclosure Of Significant Events During The Reporting Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVentures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Associates and Joint Ventures",
        "label": "Disclosure of associates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS",
        "label": "Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant judgements and assumptions made in relation to interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TradePayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/OtherAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "sprcy_DisclosureOfTradePayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclosureOfTradePayablesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Payables",
        "documentation": "The disclosure of trade payables explanatory.",
        "label": "Disclosure Of Trade Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclourseOfAccountsReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DisclourseOfAccountsReceivablesTableTextBlock",
     "presentation": [
      "http://www.trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Receivable",
        "documentation": "The disclosure of accounts receivables.",
        "label": "Disclourse Of Accounts Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DiscountRatePercentage",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate, percentage",
        "documentation": "Percentage of discount rate.",
        "label": "Discount Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r258"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231",
      "r282"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231",
      "r282"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "sprcy_DrugDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "DrugDevelopmentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Development [Member]",
        "label": "Drug Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "sprcy_EFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EFinanceIncomeAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "e. Finance income:",
        "label": "EFinance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.trpx.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EffectOfPotentialDilutiveOrdinarySharesLossPerShare",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Loss (in Dollars per share)",
        "documentation": "Represents the par value of effect of potential dilutive ordinary shares.",
        "label": "Effect Of Potential Dilutive Ordinary Shares Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDefinedContributionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses in respect of defined contribution plans",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r34",
      "r175"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EnterpriseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EnterpriseValue",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise value",
        "documentation": "The amount of enterprise.",
        "label": "Enterprise Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r19",
      "r107",
      "r110",
      "r127",
      "r128",
      "r129"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to equity holders of the company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "sprcy_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromTheInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EquityLossesFromTheInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity losses from the investment in MitoCareX",
        "documentation": "Equity losses from the investment.",
        "label": "Equity Losses From The Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r235",
      "r251",
      "r286"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r232",
      "r248",
      "r283"
     ]
    },
    "sprcy_EstimatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EstimatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amount",
        "label": "Estimated Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingDateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "EventsAftertheReportingDateDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ExchangeOfCommonShares",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Common Shares (in Shares)",
        "documentation": "Number of shares exchanged.",
        "label": "Exchange Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeRateDifferencesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ExchangeRateDifferencesNetMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences, net [Member]",
        "label": "Exchange Rate Differences Net Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($) (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExternalRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ExternalRevenues",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External",
        "documentation": "Amount of external revenue.",
        "label": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FFinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FFinanceExpensesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "f. Finance expenses:",
        "label": "FFinance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FairValueOfShareOptionsGranted",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options granted",
        "documentation": "Fair value of share options granted.",
        "label": "Fair Value Of Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee (in Dollars)",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "sprcy_FinanceExpenseInRespectOfLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FinanceExpenseInRespectOfLeasesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense in respect of leases [Member]",
        "label": "Finance Expense In Respect Of Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromInterestAndCommissionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FinanceExpensesFromInterestAndCommissionsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses from interest and commissions [Member]",
        "label": "Finance Expenses From Interest And Commissions Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "negatedTerseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments in financial assets at fair value",
        "label": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company's Financial Instruments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Company's Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial and lease liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r339"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r290"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r290"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r290"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r290"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r290"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r242"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "sprcy_FreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "FreightMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freight [Member]",
        "label": "Freight Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]",
        "label": "Gain On Sale Of Patent License Netnet Of Polyrizon Ltd Holdings Sold Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in financial asset",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r184",
      "r195",
      "r197"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r184",
      "r195",
      "r197"
     ]
    },
    "sprcy_Governmentauthoritiescurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "Governmentauthoritiescurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Represent the government authorities.",
        "label": "Governmentauthoritiescurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Gross proceeds (in Dollars)",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "sprcy_GrowthRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "GrowthRatePercentage",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate, percentage",
        "label": "Growth Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israeli [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "ILS",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS [Member]",
        "label": "Israel, New Shekels"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r231"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment loss (gain)",
        "label": "Impairment loss recognised in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "negatedLabel": "Loss on impairment of intangible asset",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IncomeStatementsLocationsAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Locations [Axis]",
        "label": "Income Statements Locations Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IncomeStatementsLocationsDomainDomain",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementsLocationsDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "verboseLabel": "Tax Income (expense)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r37",
      "r38",
      "r39",
      "r66",
      "r124",
      "r162"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "verboseLabel": "Units received (in Shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r281",
      "r290",
      "r294",
      "r302"
     ]
    },
    "sprcy_InitialInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InitialInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "documentation": "Initial investment.",
        "label": "Initial Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InitialPublicOfferingMember",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Member]",
        "label": "Initial Public Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r306"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r306"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r306"
     ]
    },
    "sprcy_InstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InstallmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment amount",
        "documentation": "Amount of installment amount.",
        "label": "Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InstallmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment paid",
        "documentation": "The amount of installment paid.",
        "label": "Installment Paid"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InstallmentPayment",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment payment, percentage",
        "documentation": "Installment payment.",
        "label": "Installment Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IntangibleAssetDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r85"
     ]
    },
    "sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InterestFromLoansToRelatedPartiesAndDepositsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest from loans to related parties and deposits\t[Member]",
        "label": "Interest From Loans To Related Parties And Deposits Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid on lease liability",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "sprcy_InterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InterestPercentage",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "documentation": "Interest percentage.",
        "label": "Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InterestRate",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, percentage",
        "documentation": "Interest rate.",
        "label": "Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r337"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory",
        "terseLabel": "Inventory",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r178"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Investments in company accounted for at equity",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r125",
      "r164"
     ]
    },
    "sprcy_InvestmentAchievementOfFirstMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentAchievementOfFirstMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of first milestone",
        "documentation": "The amount of investment following achievement of first milestone.",
        "label": "Investment Achievement Of First Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAchievementOfSecondMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentAchievementOfSecondMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of second milestone",
        "documentation": "Investment following achievement of second milestone.",
        "label": "Investment Achievement Of Second Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ifrs-full_InvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing amount (in Dollars)",
        "label": "Investment income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investment income, such as interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r337"
     ]
    },
    "sprcy_InvestmentinAssociatesandJointVenturesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Joint Ventures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesTablesLineItems",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandJointVenturesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesTablesTable",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Joint Ventures (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentinFinancialAssetsDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsAccountedForUsingEquityMethodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentsDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestmentsDate",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment date March 31, 2022",
        "documentation": "The amount of investment date,",
        "label": "Investments Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestorRelationsAndBusinessExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "InvestorRelationsAndBusinessExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and business expenses [Member]",
        "label": "Investor Relations And Business Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpensesRelatedToWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuanceExpensesRelatedToWarrantsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses related to warrants [Member]",
        "label": "Issuance Expenses Related To Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpireTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuanceExpireTerm",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire term",
        "documentation": "Issuance expire term.",
        "label": "Issuance Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuanceOfAggregateShares",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of aggregate shares",
        "documentation": "The issuance of aggregate shares.",
        "label": "Issuance Of Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of exercise of October 2023 pre-funded warrants (Note 18h",
        "documentation": "Issuance of share capital \u2013 in respect of exercise of October 2023 pre-funded warrants.",
        "label": "Issuance Of Share Capital In Respect Of Exercise Of Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectSEPA": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuanceOfShareCapitalInRespectSEPA",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of January 2024 SEPA (Note 18(i))",
        "documentation": "Number of issuance of share capital \u2013 in respect of January 2024 SEPA.",
        "label": "Issuance Of Share Capital In Respect SEPA"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfShareCapitalNetOfIssueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssueOfShareCapitalNetOfIssueExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital, net of issue expenses",
        "documentation": "The amount of issue of share capital, net of issue expenses.",
        "label": "Issue Of Share Capital Net Of Issue Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "IssuedAndOutstandingSharePercentage",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding share",
        "documentation": "Issued and outstanding shares percentage.",
        "label": "Issued And Outstanding Share Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital purchase",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "sprcy_JeffsBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "JeffsBrandsMember",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffs\u2019 Brands [Member]",
        "label": "Jeffs Brands Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "June2022WarrantsMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Warrants [Member]",
        "label": "June2022 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_KeyManagementPersonnelCompensationManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "KeyManagementPersonnelCompensationManagementFees",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees (see also note 25a)",
        "documentation": "The amount of compensation to key management personnel in the form of management fees.",
        "label": "Key Management Personnel Compensation Management Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel [Member]",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "sprcy_LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LeaseMember",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Lease [Member]",
        "label": "Lease Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeaseholdImprovementsMainlyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LeaseholdImprovementsMainlyRate",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements mainly",
        "documentation": "The leasehold improvements rate used for mainly.",
        "label": "Leasehold Improvements Mainly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "sprcy_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r128"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r128"
     ]
    },
    "sprcy_LicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LicenseAgreementDescription",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, description",
        "documentation": "The description of the license agreement.",
        "label": "License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LicenseeIssuePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LicenseeIssuePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensee issue price",
        "documentation": "The amount of licensee, reflecting an issue.",
        "label": "Licensee Issue Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ListedSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ListedSharePrice",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listed share price (in Dollars per share)",
        "documentation": "Amount of listed shares price per share.",
        "label": "Listed Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount (in Dollars)",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LongTermPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LongTermPercentage",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term, percentage",
        "documentation": "The percentage of long term.",
        "label": "Long Term Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossFromSaleOfPropertyAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LossFromSaleOfPropertyAndEquipmentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from sale of property and equipment [Member]",
        "label": "Loss From Sale Of Property And Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "LossesFromRemeasurementOfInvestmentInFinancialAssetsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets [Member]",
        "label": "Losses From Remeasurement Of Investment In Financial Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ManagementFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ManagementFeesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees [Member]",
        "label": "Management Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "sprcy_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement [Member]",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MilestonesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones amount",
        "documentation": "Milestones amount.",
        "label": "Milestones Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXBioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MitoCareXBioLtdMember",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCare X Bio Ltd [Member]",
        "label": "Mito Care XBio Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MitoCareXMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX [Member]",
        "label": "Mito Care XMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MizaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MizaMember",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miza [Member]",
        "label": "Miza Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "sprcy_MonthlyLeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "MonthlyLeaseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly lease fee (in Dollars)",
        "documentation": "Monthly lease fee.",
        "label": "Monthly Lease Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "sprcy_N2OFFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "N2OFFMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "N2OFF [Member]",
        "label": "N2 OFFMember"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]",
        "label": "Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open debts",
        "label": "Net debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r239",
      "r255",
      "r281",
      "r290"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r112",
      "r114"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r119",
      "r192"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Non-current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount (in Dollars)",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofRSUtransactionTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted",
        "verboseLabel": "Granted shares",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r349"
     ]
    },
    "sprcy_NumberOfOptionsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfOptionsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options outstanding",
        "documentation": "Represents the amount of options outstanding.",
        "label": "Number Of Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable of shares",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of RSUs",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of RSUs",
        "label": "Number of other equity instruments expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, January 1, 2024",
        "periodEndLabel": "Balance, December 31, 2024",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest over period",
        "documentation": "Number of Other Equity Instruments Vested in Share based Payment Arrangement.",
        "label": "Number Of Other Equity Instruments Vested In Share Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Share Options , Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Number of Share Options, Share Options outstanding at the end of the year",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140",
      "r143"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options exercisable at the end of the year",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Share Options, Share Options cancelled during the year",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sprcy_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2024",
        "periodEndLabel": "Balance at December 31, 2024",
        "terseLabel": "Received common shares",
        "verboseLabel": "Shares issued",
        "netLabel": "Issuance of ordinary shares",
        "label": "Number of shares issued (in Shares)",
        "totalLabel": "Ordinary shares (in Shares)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Issued and outstanding",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sprcy_NumberOfUnitsReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfUnitsReceived",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units (in Shares)",
        "documentation": "Number of units received.",
        "label": "Number Of Units Received"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfWarrantsHolds": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfWarrantsHolds",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants holds (in Shares)",
        "documentation": "Number of warrants holds.",
        "label": "Number Of Warrants Holds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "NumberOfWarrantsIssued",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued (in Shares)",
        "documentation": "Number of warrants issued.",
        "label": "Number Of Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_October2023FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "October2023FinancingRoundMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2023 Financing Round [Member]",
        "label": "October2023 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "sprcy_OfficeEquipmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OfficeEquipmentsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipments Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OfficeMaintenanceRentAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OfficeMaintenanceRentAndOtherExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance, rent and other expenses [Member]",
        "label": "Office Maintenance Rent And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OnlineSalesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales [Member]",
        "label": "Online Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OnlineSalesSegmentMember",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales Segment [Member]",
        "label": "Online Sales Segment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingLossCarryforwardsTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingLossCarryforwardsTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses (in Dollars)",
        "documentation": "The amount of net operating loss carryforward tax as of the reporting date.",
        "label": "Operating Loss Carryforwards Tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingSegmentsDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingSegmentsDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingSegmentsScheduleofOperatingSegmentsDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments - Schedule of Operating Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingSegmentsTablesLineItems",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Abstract]",
        "label": "Operating Segments Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingSegmentsTablesTable",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OperatingTerm",
     "presentation": [
      "http://www.trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating term",
        "label": "Operating Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OptionToExtendLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OptionToExtendLeaseTerm",
     "presentation": [
      "http://www.trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend lease term",
        "documentation": "Option to extend lease term.",
        "label": "Option To Extend Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OrdinarySharesGrantedDiscountRate",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted discount rate",
        "documentation": "Ordinary shares granted discount rate.",
        "label": "Ordinary Shares Granted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "verboseLabel": "Ordinary Share [Member]",
        "netLabel": "Common shares [Member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "sprcy_OtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Assets",
        "verboseLabel": "Assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash position",
        "label": "Other cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26",
      "r33",
      "r122"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in short-term financial assets",
        "verboseLabel": "Investments in financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other short-term liability",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts receivable",
        "terseLabel": "Other accounts receivable",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_OtherEquityInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterestMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_OtherFeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other fee expenses",
        "label": "Other fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses (income)",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r175",
      "r176"
     ]
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset [Member]",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "verboseLabel": "Investments in short-term financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties [Member]",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r237",
      "r253",
      "r288"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r240",
      "r256",
      "r291"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r240",
      "r256",
      "r291"
     ]
    },
    "sprcy_OutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OutstandingShareCapital",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding share capital, percentage",
        "documentation": "Percentage of outstanding share capital.",
        "label": "Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "documentation": "Outstanding shares percentage.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OverAllotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "OverAllotmentMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Allotment [Member]",
        "label": "Over Allotment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares par value",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParentMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "sprcy_PaymentForPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PaymentForPremiumPercentage",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for premium percentage",
        "documentation": "Payment for premium percentage.",
        "label": "Payment For Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PaymentOfIssuanceExpensesRelatedToPreviousPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of issuance expenses related to previous period",
        "label": "Payment Of Issuance Expenses Related To Previous Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentsOfAdditionalDeferredCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PaymentsOfAdditionalDeferredCash",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional deferred cash",
        "documentation": "Represents the amount of payments of additional deferred cash.",
        "label": "Payments Of Additional Deferred Cash"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "sprcy_PercentageOfAggregateNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PercentageOfAggregateNetSales",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net sales",
        "documentation": "Percentage of aggregate net sales.",
        "label": "Percentage Of Aggregate Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfFinancingProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PercentageOfFinancingProceeds",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of financing proceeds",
        "documentation": "Percentage of financing proceeds.",
        "label": "Percentage Of Financing Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfFullyDilutedCapitalStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PercentageOfFullyDilutedCapitalStock",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fully diluted capital stock",
        "documentation": "Percentage of fully diluted capital stock.",
        "label": "Percentage Of Fully Diluted Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "sprcy_PreFundedUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PreFundedUnitsMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Units [Member]",
        "label": "Pre Funded Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "verboseLabel": "Pre-Funded Warrant [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing proceeds (in Dollars)",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromChangesInOwnershipInterestsInSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from contributions of non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (a)",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of share capital (net of issuance expenses)",
        "verboseLabel": "Invested amount",
        "netLabel": "Gross cash proceeds (in Dollars)",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sprcy_ProfessionalAndDirectorsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ProfessionalAndDirectorsFeesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and directors\u2019 fees [Member]",
        "label": "Professional And Directors Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow",
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "terseLabel": "Income (loss)",
        "verboseLabel": "Loss",
        "negatedLabel": "Profit loss",
        "negatedTerseLabel": "Loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r25",
      "r97",
      "r108",
      "r111",
      "r163",
      "r166",
      "r192",
      "r196"
     ]
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r113"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity holders of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r175",
      "r176",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "terseLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r337"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Property and equipment, net at beginning balance",
        "periodEndLabel": "Property and equipment, net at ending balance",
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r116"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r115"
     ]
    },
    "sprcy_PurchaseCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PurchaseCostsValue",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "documentation": "The amount of purchase costs.",
        "label": "Purchase Costs Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in financial assets",
        "label": "Purchase of interests in investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in a company accounted for at equity",
        "label": "Purchase of investments other than investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "sprcy_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PurchasePricePercentage",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "documentation": "Represents the purchase price percentage.",
        "label": "Purchase Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PurchasedGoodsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased goods [Member]",
        "label": "Purchased Goods Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaserRemainingOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "PurchaserRemainingOwnershipPercentage",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser remaining ownership",
        "documentation": "Purchaser remaining ownership percentage.",
        "label": "Purchaser Remaining Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r350"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r350"
     ]
    },
    "sprcy_ReceivablesInRespectOfDownpaymentOnMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ReceivablesInRespectOfDownpaymentOnMerger",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables in respect of downpayment on merger",
        "documentation": "The amount of receivables in respect of downpayment on merger.",
        "label": "Receivables In Respect Of Downpayment On Merger"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r232",
      "r248",
      "r283"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "sprcy_RegulatoryExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RegulatoryExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory expenses [Member]",
        "label": "Regulatory Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryProfessionalAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RegulatoryProfessionalAndOtherExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory, professional and other expenses [Member]",
        "label": "Regulatory Professional And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RelatedPartyBalancetextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RelatedPartyBalancetextBlock",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "label": "Related Party Balancetext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized over period",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sprcy_RemainingPurchaserAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RemainingPurchaserAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser equal valuation",
        "documentation": "Remaining purchaser amount.",
        "label": "Remaining Purchaser Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RepaidOfMonthlyInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RepaidOfMonthlyInstallments",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly installments (in Dollars)",
        "documentation": "Repaid of Monthly installments.",
        "label": "Repaid Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "sprcy_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and preclinical studies [Member]",
        "label": "Research And Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "verboseLabel": "Engaged in a mutual share exchange",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r177"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r233",
      "r249",
      "r284"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r234",
      "r250",
      "r285"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r241",
      "r257",
      "r292"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and restricted deposits",
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Units [Member]",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "sprcy_RestrictedStockGrantPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RestrictedStockGrantPercentage",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock grant percentage",
        "documentation": "Restricted stock grant percentage.",
        "label": "Restricted Stock Grant Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r177"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Total",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r121",
      "r149",
      "r160",
      "r165",
      "r170",
      "r171",
      "r173",
      "r175",
      "r176",
      "r192"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cost of Sales and Gross Profit [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ReverseShareSplitRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ReverseShareSplitRatio",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse share split ratio",
        "documentation": "Reverse share split ratio.",
        "label": "Reverse Share Split Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ReverseSplitRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ReverseSplitRatio",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split ratio",
        "documentation": "Reverse split ratio.",
        "label": "Reverse Split Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RightOfUseAssesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RightOfUseAssesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asses [Member]",
        "label": "Right Of Use Asses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Right-of-use asset recognized with corresponding lease liability.",
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "sprcy_SEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SEPAMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA [Member]",
        "label": "SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfMinorityInterestInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SaleOfMinorityInterestInSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "documentation": "The amount of sale of minority interest in subsidiary.",
        "label": "Sale Of Minority Interest In Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SaleOfOrdinaryShares",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of ordinary shares",
        "documentation": "Sale of ordinary shares.",
        "label": "Sale Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale Of Stock Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfStockDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SaleOfStockDomainDomain",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SaleOfStockDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase sale (in Dollars)",
        "label": "Sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "sprcy_SalepurchaseOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SalepurchaseOfPropertyAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale (purchase) of property and equipment",
        "documentation": "The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.",
        "label": "Salepurchase Of Property And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "verboseLabel": "Sales and marketing expenses",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information To The Items Of Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfCompanysFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Companys Financial Instruments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfCostOfSalesAndGrossProfitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Sales And Gross Profit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDefinedContributionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfDefinedContributionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Of The Assets At Annual Rates Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfExpensesDueToShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses Due to Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfFairValueForShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value For Share Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Intangible Asset Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://www.trpx.com/role/RevenuesandCostofRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of Sales and Gross Profit",
        "label": "Schedule Of Revenues And Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRsuTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfRsuTransactionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU transaction [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Fair Value Was Calculated Using The Black Scholes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices Of Share Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SciSparcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SciSparcMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SciSparc\u2019s [Member]",
        "label": "Sci Sparc Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails",
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r132",
      "r163",
      "r185",
      "r198"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://www.trpx.com/role/OperatingSegmentsDetails",
      "http://www.trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://www.trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r132",
      "r169",
      "r185",
      "r198"
     ]
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services rendered amount (in Dollars)",
        "verboseLabel": "Services expenses",
        "label": "Services expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareBasedPaymentMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment [Member]",
        "label": "Share Based Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareCapitalPercentage",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "Share capital percentage",
        "documentation": "Share capital percentage.",
        "label": "Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital in respect of investment in affiliate",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "sprcy_ShareIssuedToAConsultants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "ShareIssuedToAConsultants",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to consultants (Note 18(e), and Note 19 (a) (3)",
        "documentation": "Number of share issued to consultants.",
        "label": "Share Issued To AConsultants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedIncomeStatement",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from the investment in MitoCareX",
        "terseLabel": "Equity losses from investment in MitoCareX",
        "verboseLabel": "Equity losses from the investment",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r161",
      "r168"
     ]
    },
    "ifrs-full_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options [Member]",
        "label": "Share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share options."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharePriceRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SharePriceRate",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price rate",
        "documentation": "Share price rate.",
        "label": "Share Price Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposit",
        "verboseLabel": "Short-term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsDuringTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantEventsDuringTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsDuringTheReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantEventsDuringTheReportingPeriodLineItems",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events During the Reporting Period [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantNonCashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SignificantNonCashTransactionsAbstract",
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Significant non-cash transactions:",
        "label": "Significant Non Cash Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r236",
      "r252",
      "r287"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StorageAndShippingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "StorageAndShippingMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Storage and shipping [Member]",
        "label": "Storage And Shipping Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates mainly",
        "label": "Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SubsequentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "SubsequentEventsMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "sprcy_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://www.trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://www.trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://www.trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [member]",
        "verboseLabel": "Top of range [Member]",
        "netLabel": "Top of Range [Member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r350"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts payable",
        "terseLabel": "Other accounts payable",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge loan to related parties",
        "label": "Current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet",
      "http://www.trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade payables",
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party",
        "label": "Receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Transfers of research and development to entity, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of transfers of research and development to the entity in related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "sprcy_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails",
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "sprcy_VestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "VestingPeriod",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "documentation": "Vesting period.",
        "label": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price during consecutive trading days",
        "documentation": "Volume weighted average price of ordinary shares during the consecutive trading days.",
        "label": "Volume Weighted Average Price Of Ordinary Shares Of During The Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price",
        "documentation": "Volume weighted average price of ordinary shares of preceding the closing of trading day.",
        "label": "Volume Weighted Average Price Of Ordinary Shares Of Preceding The Closing Of Trading Day"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price of ordinary shares",
        "documentation": "Volume weighted average price of ordinary shares on the day prior to the closing.",
        "label": "Volume Weighted Average Price Of Ordinary Shares On The Day Prior To The Closing"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "VolumeWeightedAveragePricePerWarrant",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price per warrant (in Dollars per share)",
        "documentation": "Volume weighted average price per warrant.",
        "label": "Volume Weighted Average Price Per Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "sprcy_WagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "WagesAndRelatedExpensesMember",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and related expenses [Member]",
        "label": "Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantExercisableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "WarrantExercisableTerm",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercisable term",
        "documentation": "Warrant exercisable term.",
        "label": "Warrant Exercisable Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "sprcy_WarrantsAndExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "WarrantsAndExercise",
     "presentation": [
      "http://www.trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and exercise",
        "label": "Warrants And Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsExpireDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "WarrantsExpireDate",
     "presentation": [
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expire date",
        "documentation": "Warrants expire date.",
        "label": "Warrants Expire Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "WarrantsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable",
      "http://www.trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants liability",
        "verboseLabel": "Warrants",
        "label": "Warrants Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.trpx.com/role/EventsAftertheReportingDateDetails",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://www.trpx.com/role/ShareholdersEquityType2or3",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants [Member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options exercisable at the end of the year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options cancelled during the year",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Weighted average exercise price, Share Options outstanding at the end of the year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://www.trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "verboseLabel": "Warrants fair value",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "verboseLabel": "Fair value of the ordinary shares granted",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://www.trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://www.trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($) (in Dollars per share)",
        "verboseLabel": "Underlying ordinary share price (in Dollars per share)",
        "netLabel": "Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)",
        "label": "Share price per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "sprcy_a2024Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.trpx.com/20241231",
     "localname": "a2024Abstract",
     "presentation": [
      "http://www.trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024:",
        "label": "a2024 Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_29&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "A14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_A14&doctype=Appendix&subtype=A",
   "URIDate": "2024-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0001213900-25-035115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-035115-xbrl.zip
M4$L#!!0    ( !J'F%HF03@[V5$% ,]^*@ :    96$P,C,W-#@Y+3(P9E]S
M8VES<&%R8RYH=&WLO6MSVTBR-O@=OP+K.3.G.Y:2)5F6;SU^ERU1W9RQ)1U2
M[I[>-][8 (&BB#$(<%" 9/:OW[S4#2 H43)UQXD3TS() H6JK*R\//GD3__K
MVS3QST4NXRS]^W]O;V[]MR_2,(OB].SO_]T=[O?[__V_/GH__5\;&_XO(A5Y
M4(C('\W]_6PZ&X:Q?YH'J1QG^=3_H9C^Z&_XDZ*8O7_Y\N+B8C.$:V08YT)F
M91X*B1_X&QOJ=ONYP)N]]T\GI=^=Y?[.KK^S]?[5WOO7K_TOI_OPCYW7?/FD
M@$'"0%/Y7MWS[R_4<YJ>\<)<6Z9%/C?7?AOER:84X>99=OY2??D2GK)K?E#F
M.;S]LE^H;ZL_F4=+KIY'E0LC$3=?"%]4+RQR<R'.(EV<Y6<OX8N7Q7PF\.J=
MC:U7&Z^V]6]$N&04\$7EYO$XEQOC,DGX<JFOQ\_I(47P+4NS*;\D/F3GS4OS
M(W,7F>WN;+]I'N;.UM:KE^H*\X-ORZ[=AFO3)$[%OWX>?+*7%\W7VTM?%EKP
M@@)$%X>[M;&UL[&]X]QD Z:A<B,]+9?=9_OUQM9;9V[ARJ^7O"E^/0JDT)?+
M6>X($%Y?Y+-O*)8TI=L[]LXRMZ\Y#N2(;@H?5E:LE!NXZ'+Q2OU-]?)ET@.#
M??<2OM47XA=13235=7LO^4OWTOBRQ4YE$:2AF8)OR247_^L33)B]LCZY%Z_H
MTNUW[]Z]I&_-I;+I.KCE]LM_??XT#"=B&FPLC$3&U__5\O&@'GJ!^D@$T4?/
MQ__[J8B+1'ST?WK)?WC>3U-1!'Z8I85(87T+\:UX23\DU;@A_E/&YW]_L<_?
M;YS""KYX"?=\R3?]:91%\X\_1?&Y+XMY(O[^8@Q7OO>WMV:%?QI/A?2/Q(4_
MR*9!VN$/.OY0Y/'X!?T*!_ 2__O3[+HW^.!/@_PL3M_[>.D6W._EK'9/U-N'
ML4A :P_*1&R<!&<"5;0[WHLX*B;XO*V_OEAXD0T9_RG@RUGQP1]E>23RC2*;
MO?=_3H+PJ[\#SY59$D?FRU%6%-E4?[^MOW_Q\6]_V=[;^J"&M3"XEPNC6^>\
MZ&?79^=[[_S!1V'9")+X##X*03Q$#E,X^OCEJ'_:._"'I]W3WO"GEZ.&E;FU
M9P][^U\&_=-^;^AWCP[\WK_V?^T>_=+S]X\_?^X/A_WCHSL>T._=X:_]HU].
MCX\Z_@%:":]WW]WE$.Y\]0^/!Y_]G^)O[],L/2JG\-.0U<NW8B#&?W\1;KWP
MTV *3P93XOU!%L(U:4&*Q8_!+HB_G6_LO'VU^^K%1S@C#W]Z6;G5QR<\=Y?/
M&1_Z.#]D*+P?95DR"I(D*T;9MZ8I'8BS6(*]@(;"L #C%3^LSO$NON.[-[N[
M'^K3[ ]ZO_2'IX/N*6P9WLJ?>T>G_LF7P?!+%_XX/?9AK^&WWO;.#Z,?_>.!
M_\,9_.?0/_VUYSO[T.S![OXI?KW][M7N$UW!T<?C02N@JPIH-TW+(!F(69;7
MY/*UDLN]1;GL'AU]Z7X"\3PY'C2*H[_]"F31VW[]0_2\I?$PR_UB(OQQ+,,@
M\><BR,%9CL A7GTAWT>@-S:F<,$$UV\C"N8;>*,-D3:MZ G<+XMZ:70 /ZLN
MZ=YUY*?IL=4G[I-W6QS2N_T!(VI\Z)L7'P]$**8CD?NOMNNRU+G^,66?=PB?
MR.K3WN*)M;.[>&+5__T4I:W5?=?2?12(BO%H;M)_[Y:?RW D'PW[I.@NU8$>
MG,>M#FRE\EI2.9R(),%8:9#.&^3R]=9RN1S^VOOT"=VLD^[1'Y>(ID?'<RN:
M'V&:I['$0+9_&"?"/\HVWZ]^(/72(B[F^$.X%HZWZCIMO_BXM;6]\>KMUN["
MJ?<T9_.:$Z=]H[0X@F_LY+W9YBC"?G]XTAWL^Y].#S99?=S/)/X4?_RA]RT(
M"WH#/QO[N1FY'TA?SD08CV.PZ>+4CPOIA9,@AU_^" .^A4'R_VZ^CM/J</]=
MRB(>S^]^T3_2.9J0CUN=G;_]Y>W.]IL/DB<N3HO,ZZ5G22PG[W%N8+O!!,YF
M21P&HT0\T4T!DHR./\[,-8\*$9T%^2S/SE7BJ6I]\R;JIV&6PR%A(PS[?/%^
M%E4-\=<[+S[V91Z(I+Z1](3<84P.MM0_RCR641QJL8G=-_'!;\KRLR"-_Z1_
MW])>>A "<CVMV8VB7$BI_O,I3L6V7>9WKTC@=K;\05 F_N]@9X@43J8S?UC<
MLP[]SI?<<5[R#;WD:78!'F6WX^_\),O9QS3ZZ27^US],LBR_UW<=W?!U]^'/
MXQS>*ZUN7%C44Y'XW?/X?,'DN]F33C)9!,G_&\\6M<3NBX][[]YLO]O>N[:K
M7M=?2FWA&)I4EWYKOJHZBM</2U>IH:*:FN6@J.)9D/CBFPC+(CY'U3Z.0R&?
MJ9+:KL2$X!LPE4Y$+K,T%4G5M-O>WF)_\$^_&R7BOK?I_B068[]GUO&8UC&_
MX^P4[.W+G8[J!./.R46PN'/W7GS\O]^]V:G/Y\;*M_Z4A4%R,LG21G\&M.XK
ML,W?O'[SYLU])H1@QGK3(+[6G-6$DGZO]G3U)=^^^)C]^?_(,):S( \1@G&O
MK[KJ"ZY@&FSO/$;;8*6WW''?\G$;!\O?=YEQ\.Z&QL'R)RTW#O:V;F@<;*_3
M.-C;7F8<W+59@(<;_%0D8H9:L^/W-E"S^$$:O00'YC (93S%N%)*^M2#SWW'
ME%!!/E^I)Y_UTQ.V(H9PT.9Q$<-MBLP?"14J$+F(T.&K?^;-RER6&&6!;^"W
MY!ARHAMF#]-JW1 &=P13?]MO<$_!%6?"+I\J7T^55YVJL\I4W?LL%1CG@;=+
MDED0$6#X!?@-UQZ"@Q<SL*\P2Y)@)@5,GOK+? 5G>0C/PB%_^_ "U&*1ZV>>
MB[R(P>K1;\#@,;HFJJ'37NW\=0%C-F*,V>9KBT)KU!4P@K2":1L'H!?F[Z]Z
M41?_!O/"1QN"!G%511!._# )I&2]AP^!_Q11T^AW_FI7I?F*!_-^>8"2X0_G
MTU&6_(!>U1-ZNR,50J;%$]_"29">P0>I?S&)X1.[H^MO#?^37RJZ13:#-X0W
M.LOAT(QP0V3Y>S\_&_VPL[7;V7GUMK/S^O6/5=F^Y?==-3BA]-Q\>^>,Q+MZ
MWN^\^'B<@TP$^=P?3H(<'YEF/ECH_GF0E&)9C* J,LL$Y+O"54I8658=,W3O
M]3KG<7@RV#>O4S=Y;O)Z:QO9*9PLUXUJ@] O6GU: GIJ2U3C!B@%X+X<!3(*
M_K-@YNX'LQ@L5O]SD'\51<.F>4GGCCJ+GJA] -.L= B<]KGP8^D'H$XP?XS:
M-!O!+RF4WFQ542KXB5M5YG']- +-60AZ6[;-\=VSLD!4/YT^DO2,UM2>FIE8
MRE+D)JU%AR]?%2H9A%4(L^DTP^V5P>D22#VK89))H?\Q(Y 67'I.UMMH3I\&
M!,93J[;Y5&=?Z8O#/&#9JR@,\.4C$<;3()%_?]$_.JQ"TF"M-J*LV%"7++J-
M^S3W0YQZ/BF.[9J"H0G'I2"3LTQC?B"O<U73[+[XN+W5>;N#!Z9)W>OA?O0O
M/8LZO.*> WGK^(Q(>Z*K>5G%!Y93?("[_:<4:8B'AJVMH$H8_H%3\,%/Y */
M[1TL^5"?:)MMSRD#J55Z6#ONA?.VBVK3W).>LM7P$#9>\,7, )<->)2+X.O&
M2("4POO-Z'W=V^\UW!Y?S!VB,\V5Y6M^N%NS<COE*@]#L(R2!N483@2L,/SJ
MJQ^S G4@&'C2>1?@4VY\3;,+4+PBD'!X14I;TXZ,Q#A.&:&!=3[^[M9KK8J=
M,Q0.OB>C=>,T$OA[0HJ\^/@'_%[!QGSUY.ME#G^'"?XGSN]036^?9K>J.<'J
M/<H6[#,#([^;5[UK.44QBJ4ZM4D:4WV28Z3&@$S5%1TOOH9DIUD!G_RGC-%,
M (-MC.%$OI'T&RVY5_C4BCVG;6J4;_P,\7Q/1LZKC[M2^'DTUTV;_Y8E95K
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MM>L(V:R&0+C5I^+C;O4!**1L"J'-)5(0;&Z.@V(\R[ +,<8^*'[$R2TP4G%
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MQJ.X[#=93KN SQ7U8VL5KJ3U6Q.O-?%N?RM,A2B4-*.1HU PH+*#W&AVNUW
M(IS-DKEQ:UKKI=71MR28F&D]8XP4?)'";<0^RZ&V0$A2-8"ZH^R32W#4=?1T
M(V2Z%>!6@-<CP+,RER5++Z,&!-K77.)0YF0W8%=:%MLX/<^2<XP#(5!P+'*Z
MH"%T1"4<G,J$9_Q#C,=2%3WX/V-'*:+MQ]_VTW"SXP=89X#>^T+] 6P*_+6I
MF*!?,TP47GD_,VC&067,V$F7TVB(=N=+<2<%8-<'$2?GL_"K02VV^ZG=3]_A
MSF;G!!7VSY)L!-(OPBS-IG'H^K:MA+42]AT29L,6""0016P"%6ASN/5_K:"U
M@G;#$:B2!_3$J0@,@V[J/,=TI=9J%N"R4@2N$H##\'<N$AU<QFA]6OAEBB8'
MHY[@",>(=^X$(L"TP'1HEHZ3&#8!/$.5$5B(Z"S("U,=]SF.(A#77B#A)32<
MDR"I95+$&V-0R86]G;K7&*R7=O.TF^>F(U#H6A14!?O#6 7NE#)7X;DD_D\)
M=FW1QHA;,;OI")R,!?I=E+H49ZU$M1)UTQ$DI@J#:E5;06H%Z:9^"EIWB(C.
M<LEE1CF;>7&J:U#ZA9CZKS;]?XI*LTQ_PS_8] >Q_.H?\N_KQ2OTP]W-RH]4
M]+1>0^\47-.O7F_ZQQR*5< [MP3Y/(;WH^Z\&H5A[R/!B@6O/I#-E5*;=Y8-
M>UQU,->J8]UKZUB;ZUC/VS+61[X/3IOJY;":SE/\2EBW'\4AN]+D_&+ROAS]
M6^&X%$-'BBPP_'<.&E(B)8O"7Q:$2+-NL%:^A%C!0LXPH(I'L!01/T9!?H:I
MZ(BZIQQN\%' .8:;)0AY9L@^!_'G'1^T)VE=%$#$#(03K$7DEV+,&-:@(*HM
MF?M1/*8"TT(C[S)9!4$KJ'^M!M.S$[7I_Y&5/I<V4J5<+N"^Y0ST_?(*5%33
M[GQBE2<C&F"H>-,'65%WAT/H)K 46(9V(7Q53<IR@M0^M;SZ.&%75L5W+IOU
M' ,Z@<Q2//:(00QIN6#1SLH 6X<*H==A51$C!B]7QI[]T@U$0(4O.-EE?L9&
M50C_(LRKEULK!BO"8L77Y)\'>9R51#,6)IFD.,04[J0+$K.R:"H YP >/HN1
MH/RX(#IG=A+8Z((8I##F%@L==?-(-S$,J:Z%%&H.]8_-A%LF%!-0[&@9(>B&
M39]3\9"VSYZ]--24XZS$ &I44F UIMI22@W,+]FVF[#DEWV_A!H 98($*#"Q
M5L334-TB8I2I5E$P[4\1?!5>FOG9*-%%_I1NAG^&I,WIEP1X)L&Z?, =6P^)
M); L)C@&3'\XS >=JM+W76:=#F@Y9/+!6^1@3\4Y'T9)</$09&I%XHU7:R7>
M()*-(=:0YO.*_^7?#HO&@]A IXA QG?5B@KT7)C'(Q%Y<#!F%[YB[E33HLME
MF/();27WMX&4&6@Q5(B$PP^P*.8<-"0AFF$?E;#;V!1<8%5@E7E!3K-PK1[/
M*/>*1I?5<7=@1YWQKKA@)L_:>TE1X)XJ)I0S8=?[@-]G<6^K:@1=9( ?@G4(
MGT996+)6&,<);QDX5,P3A[W]V]L^=Z1]^7]U3 8$/_XXH+49V%P5\BG:R,&^
M/K-HXA1]HC=@M4*S]=/+^..M4M$\<=*&FY7O/P-L[.]"*ZCK40N3I"K&5\T]
MDIG &&@$JL?(= 87;3ZJ&6PH4JI:<G1/4(XEQ?O09(S'V+V]\,'J1)@C7*@+
M:A6='+NB>!K3H4W.KW$1V7"\$,QS8,@O*) 88M)C\0E(RY=H^F(2^'IAV"*:
M?A$7W!#1>[[![S;.O7S_D<23DTN0"2*'3+'X$*Q.D%13<JB!O2AN-NC36+N!
M?E(*O\\QG +7C&,2G%8D6Y%<220Y@E-5G:E0,!NB(T)8;1$H2(VE'1J7S$/
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M$>>41,Y5W5=4<@T9,6R:SBV1"")TABD73/&DN689-R=[[F!=J>['T9 :@:>
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MJB"V!N"V @]^#1/%*!'3V!E"5X.KP7%6YK&O) *"(K!A>"(FJ6@UIXPXX@.
M7P192SA,<Y7<_NTO;W>VWWR0S6U.=#LW/+UP?/" JDKT+(*4X-2<:30'L&MM
M<E^E,)9XN*#:1UPQTV50,;HUL<E2-EW-6!Y$=)GS?R7)$0=B8R(H861XH@Z<
ME*+$XVH%^DKPJ,4 <*.U[F!5G9BOFB 5*B=M0>&.Y8;&L[<<NZX3UJR7FQ:
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MR9AYF$V/R*KQ>3W:R&<OJ =+%:S7H&")U-3T-[Q$TT9YR6R[4S1-&,,9*^J
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M=VWR="%YNKWUE+.GSV(3@+;^1YD*L.^V]SJ6CA7MI8!"(@+I@I$;8XG^MD3
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M8VJ]I<.$VZMS(>8=NHQS..SEA7%ND!XJ%?[5NUJV+N,<I"$*]\.!M8:XR)%
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M=,R]NV/) ?J%;1E'*L Q/,R9U&*(P!LUY/@L3+@3\#/"YD4BA-N\K0E[+@U
M(MZB.\]:'^R@@9@*R0^O9S9/NG4F>\?F^BU<*/?==X,E_.D,2YC"$C[Y)<,2
MWF)9_5R-[&P\D%I>?>6WLT/NU[],7\*\@GD(8.PLZU0SXS]BQ\X+[B$L.);
MOJ%Z"03DI9W'U$U#8 MN)>4<V7FEG5?:OV/:&FX>LOAEA"<BN)0T6%I>]*<*
M>'Z$=-K/=66?(Z.?<I=@R@OFKY:$);4',(7>#*$8M3*>B,(K,C=1\F[GDGTB
M.]QMVG)=2$G!OGXVZF>C_N_DOL XU]?]/J: 9RNG6CL3A ;EQBUG/-4(=:2S
M4K<\+]/S,OV!3\ 49"5KQ6T*2A<E^!OIZ!1O(VDR=:X'_ON\",^+\(<]@4-
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M=*?_0"/G&<YYAG.^=\P'T?/5 QZ:=8,4% AQH_[UHF 2P!.SD9R41DHK4$R
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MB@UAD9HT=; ^<*,3I0<=O<A=,V*/WOAPDTYO2R;Y;6*D73'K%+X;D#XG)U=
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M!<++1J9D76*.;/_.<V$(>W_QBRW"EI&N$R8A/](].*M&5 RWX)%U1Y@4U<S
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MXGAM.1O,(7=JTA#\MDA@LW+0G[B")3S/P7BN%Z=&YKY92HHB=EC"GI!X,C&
MS6W.7=>MH_9;SV^9)4I(FVYXR2G$,JLZO-(3)H;PL VG<!7(%NW]X4D]<%%6
M-9>-P3_0B'*YOB#E<!GL-^F?MM-ZB?U;UNRK2S:2A0,:O(GP%Z)VU9:"^'>P
MGH"I+9F+>9B[-"E-ED F3:@>ZY6KEC8,(U2,KP8B :J1+:S)XZ 54Y4UM[@P
MRG%@MGT-8T":7B-3DZE6"784K/#E18TF=:59<@M2>YR]0>!%PO8$M1;.!@U9
M$TE-[S;PYD50.V<ZR\R4^'G^4K!W)6,]Q.J%G")!X;^*)8R$%L_*@'M1+5;R
M>KD<%]VUB0J9O?<S&/1!QY7#>*#>[ \+7**]6-P.X^V+@P\F>K>D'P"M'J&D
M1@$IC6 :S 'WM+34J$SRG&F77?!2"E^& ;N/XC2<9%FOSJ0SAA!L8\.3@3U+
M<4U\ )>/0,/M*>W7'M(V%]Y#%M%L)FS =V6K1*[C[ Z-B:1WWL[MNZ!TF2I)
MC:1"WJ6,Z*/71?L$5I.AQ\1.<\0.'+:(7<UN3\=%DOJR"=2D+UI$7]G.D-_N
MBI/T5JFG1Z?4TS3U]/B4>OI]B/H[QP-B<F*D-!;[9JW*2 )50<%W'$V;F)BS
MEO]/-\>]N*<8$7@E4TV?R]7?B@.6@FRX:'YTKS;AY0W*!37(*)A[@HP32044
MPV&-.I\M[G&] L6V ,#9<J>AIQD;Z8;:]=N$L[  E"#9728!K%/8@X;P[2C)
MPI)"!L6\K R$.JW<%52_4D900EKD\47IZD_*Q*8E5]&UTF])JALJ#_(.\J[+
M&$_:[FZ+CZ2F;81LD6 [4!Z2X$A$3Z!V>4M11 8(K:W[IJZ^_KG(?WSYJB"(
M)>HJUL15%DVQ)+Y1DX!3@=1%9*5HUQR% 8YCC]K:IEU;77QN- 2D$&*4 ]8R
MTGO^ 9AH*X786>Q@9^.4>ZYWR._Y'O 9=".M3)/6Z,MF*VGKXQ!XPC.^ID0/
MF3=)37#&L.*HB&+(<JZ-TME!LW LU(?6XOHG;"FRD!X4D5OL1X@7-.XM^M@9
M$;'K,PEN\HBYVFMQP/YSI\@UH6B1& *<%/A! W7H]*B]6Y!KB!SLL"D4";W>
M-H 7A)>S:#KJ2P_^XK 9,2PL;*X6]VVE-@F02VQ'L]@QYF'9#B3_',B(*T#Q
M)RY@%'DB[](Q10C)RGAAX-&YU2%< 71XPBX O)U^5^ D*JXCM_<()8X!/"2'
M"Z3U,[_7;G7D[3"\/B4GG]?PT [4K,?^VK!'$KGI&<V2Y)4'.5KD<3;8%%62
MN.&$(Z)5[AV2^I.:=B2D_"47V;3D+/!DW:_M@CV0S8,Q<SFEL"+S&CG0(F+@
MZ:3V,,E \:C0_\#W+M?-,P!5<Z78A+6 N#6# (84HZM.SB=X_6+<82YQ8PP^
MTULTTPXP09Y)H#8+]6W%2V)(A,'E^@5!0RI@WK1%;C\$7<$_*2,GM5E2' !?
M583&\_SH#>6?Z@&2U^$JU+J?<1#=9CB-XJO89LY!Y)VD^P&@ROD_]^R>^KAI
M(O(<(9+B!+"E$(;9==C RX.FT%8-X\5Q(2JYT6V]UB?9-55DQBH_8]U5:2KA
MSD<8G[_!:LVBU4IJ:L9N#5? 7I"_FQVG0U3-FIK<\5BC.4)AA@1XQBB@8E"L
MB^*1T>[B,-<HZ\9II$+[<!U27MU'#:V\B#1%')5$S*1*@E])V.3A'U6#,J'+
MF%*X:NIKW.;T )]2R&+(#35E +$>Y#"=YU^:.%N?)BM-8/2<*1&7M(?$9J6T
M ER#]H!OG#5FBDQM+FD+<[#C<8140#'W=2XVCD1<;*K"'FF@LF.#-[=R:7$R
M/=ZI0XY#9?2=24^HZ!1HF[2GA/NL!JMJQ_4.^B1<H\U&2JL;_ZGSZ"!B5?>#
M58F#BY*2$XR>K+U$4DB=).ITT6C$.XJ>I25C:5\89R7L>5.2F2#VI1:K>Y K
MB8F7Z&?9:>Z)RQYA79^4SK])Z4#O?W!*QXWJW92.-^*/*)UX@_^[E<YQ#^J#
M4CJSC>C_=J4C6/+6%YF619MS>Y.N 0#;KZ=K<J]K,M$USI._*['T&P.,BGPH
M$((W8/C V%URO2-*W)AU4D]8]/CE4?"I*?5!-6X1+*6/C<32-;5*R^A,765'
M:B-]'&^+O @@=R%IWEV(KU+#GE_("5?J&Y37P7B&07\*X442N\B7X+V"S'NA
M0WB$.J%2YOH?W70K8ZC/0'5B^45:)2%Q,*YU$3=%_=_H\_:9R=#<MM:C3<U?
M8LSZ#D)Q)-D?N7M)DZ .^(@/Z"!Y,Y%?1_2J:)QC3W''%2[1L9N6=$XS@#'I
MO;;ZI. -DNMX-G(=LR0R$(N RHB!G>IMWDO6E=2A2(8$%M/?7W("8W,HO^5(
MX/R"2XHA=@(ZXV,> &?4A=*GI]GM$@ )"DKN],O,+_&(JB:H2SP)R8]#8B5D
M$O\RJAMG3,D5844[4"'[<61FI\2C5)3&L9D<,#4ZK=D,@ZN5+H7B:18@!F5+
MVMLSD26'..PJ+=Y 9&B1HKEP>Q9+J9* J(0FM+PI$:4DM!NCR6YO+"3MCK@7
MHC>C7)^*B'^U_/CC4WY\FA]_<LJ/_SY$7>'[C^(B.I,U&YFL:CIP4UER9\:^
M.G5E9Z!2C+PG9A5.)J(,X:]^-0FYI#2:H[ '8H*O)NN<&Z2:3\[=N#7PX;@0
MF+*\FM%R'5'A^HE0;FI^9DEE7*S3H_R'#I>"Z2X/H"^4Y([V3NWG1H\KS9B^
M(Q^XIAJ"LXLZX&P<L]"R_D+K3)5S+Z8K:(I28DWNEH=TB .0&WM8$N[%?IL,
M<X2=:*M']1JK-ZPV;%XSL+G+B)/RTR/">*8P_MUJ)]Z#VJR) 9E17 &V]$6G
MF70[A,Z2.5KLZ$ZDSS7;@65J#P,0[(]9CQG!FI?]AE! ?*O;J>OI@PU"S,DB
M-<8P;J:8GM&PC>&D2:/=14WE_MNP[9)2%X=/HDN2VTWJ5G6_U\&\7_O]U=9H
MR5QRPMQ\I4D8X[>^1M[K_M\64=! 6;6#6&MS2,U1=E>97R=96"<3YO?BTH<7
MOR 2GWV[O%16VK&42/S9X4.&KU@AT@B,U!YK0C>5(_9\T5Y?7QQ V< N-Y3T
MZV:]'E6"JZLT:OC"I+9!63;_8GZ'3?.SZQ49#5RQ<#LQ5'ZES=5]?/1D9+>^
M+TGZVXV;FR5K9%>[+QS;;[D;.*G:B'5>1R,8]]IRPQF+BV9GW,UJ3;P,!_]E
MV,0OU\WR=7;OY<LO[Q?S@"'2!1(5C=WR"-@8>$BK/,Q>T[@"?L$:6VOD@7H.
M%F7?-[5U1?<'#A,INB6A68UP>2.Z(C @TM*[^<I0JU.W8!.U DC1NF<:B<'A
MH.570[U3>"MNOJ9. 'B3UC\UXEP>!9CY6,^?Z<ZE/+M^I"7,2(S'^=WXU^PF
M?ULJ-F4<H9J8[+I.T /<0#W4P;+<.K+(("X)5+3N?VS-2'$XZ6FQ1JZMJ83D
MM;')4O5,-JG#6=<_>V@L;8IRWYG01;\+6+<*. >2>6"9"PO^"KKL@U!</PEF
M&Z)ZT/BU%FX?LD0@<!O0;NL5(58D3&OKQW974VZE/GB#8*\C9]PYAV(FTNO\
M*D8W) !R1K--HGYWZ())#5>S,.R&N>BZ*J+#HQ4X)B@5=L1U1O'F26(]:1)"
M!Q3#[<E+"%L'#D8\R_+]&L<<O:^N)3QSJ8;$+Y,,J?AUB6Z>\:_$]$+O+F5N
MBSFKBUL ')).G2I71G;!J:^Y;IA-ZFW3;H/?MYM(=(J,D>*_.@Y$BK?+RWE!
M.CX<!'+8[_E7L:Z;Z#9D#ORN,[Y3&,$397^$&B,8-. [6J^GU\_X[DN0_]/K
M[4@O8N9M#I0CAEMB;W&&V/5FD,6\1XRS8/W1 E1O9G,$LL=F:MVJ:8/W5%3S
M_D\OC^#M@N5/3L'R:;#\Z2E8_CL] M8MSVJ_RNO-]C)8>(I6FP$UER!A?94&
M:R+3.5I=<7/!1NX#=1;CG.1!->VN>A8/!186#!7VM<0,XBK_F[&UHOGKHSX*
M!E>D;KT/ 4DQ%>5URZM.PH'*Z^HU=0SE[%NAW-N-$ .(+\_5[[NK50BZHP/)
MZ0CR?.@6HQEXGDVRE3=UE<6"]7H*ELYW#5]XB<-J--^:IEZ1SP#75&[OY NZ
MP5,.%'^19*.^MWT+9DFFYQ1T7[H2B7Z -I5^RR\CR*TJS,R0U*:+$>\]#SJD
M>1OEOB%!C87V!.;>UBNA<)\\4\P<HH5L_9<2?G/M)8I+*<$:8PDV6QK9A_:R
M%OI$DH9#D?HUXNM<$&BG,G76!W-S7-@/EAJ]3@44_%_>E)'6*%F!<+>C?S-*
M%Y^LS+G%E"W8,!<G,<1[P?S3>[;1N2MA&8S;+44WVHO_\\F#3]Y^ -=-M;ND
MCS[XHUVH!-Y0;H=PG^A/]J<A6% T^3#@G[_XA.Z%_]SU^E;B_Z%8LNK-< %]
M(E?'KM(/R0N3;%NND]Q5QS__2+[P[-//GLU_=#8X*SUG36L6\%BS.DN9GQO^
MK\?4_@.+_&_>9?S_D\_I7DZV^^RTW_^._79@ON$@[TGSH+R+"6#%]9"F(2B(
MRGN=YOB=).%W+PEZWO42ELBN._VG3?[=;_*VZ_JY\#"WYZ;=?LA5A_^3ANRP
M3\N^J\-7NDVS=%\]B<7O7BP<<Q+RR5Q7;TA*H_!]K)RO9C\^+'O"S#T41Y&&
M3AKEHQ&=4<6P)K]<$3O\.TY+6IVWKR>^J7M,P,P,,\.3 RD%<1(#F-;0#U_0
MOTZ"]GL7-(^! 2A3=51(1L: )+3EHJDLFPUXP3EL%$0?FL5^HI[./URI^6US
M3D:ME&90,\V@IGE[#LIP2*E#.=V^M:/NZ_H7O99*3+%:*4Y4YE*=MZ! 87$$
M."GCDH4;P)-&F6,/*@&VMF#0*%;-^T"\>X]!VML6Q.T929;[:3/NIT5D<$/A
MH<7A:)E<VI^3I)2L1!+469REE*@;[5K$==G6;;E&M.Q4JR9(WDECLVT$ 7=2
M>E%OQ6DUD*0%0;.R+J^UO!RF&S1K0E'!%3442F4M*U(0>>#:&E#0KG&(8+@)
M 8;NY,UVW1T$FC8%UQ'BLS*6L=27Y7J%*,2""@D(LR=RG\Z.M+EA3*PCLEFE
M\$Z"E\+UW&YVR=300TJUV5S2@IL)PY.&.G2#)Z=,-I<**.BB<P%JY:6+@+*@
M?R)E*MSR*_2) 5-VSV87E8$?"H_LRBC19&XA8!X>)&:<PR6E[OAVQ0J=S?R!
MD&O85%.,65](IE:@5279,L4F?W3"88$]XFI8CBV_F73NW$J0[0=UXQK0.'8>
MMQ20MP!8NNM=$6^7;'YZ2C9/D\V?GI+-O_-#$&$WKDBZ*2]5-70=7 4]0E=+
M0J#FR*'3-E+&]^;:JDF!=D>LN'G))9FBRN(S*4U*CFQD/Z7\()'8:E$F?2)K
M.P']4+0B#L8O#YRG2[M-F,Z6,[![@Q_RX"")WG1\*C%/_$VPT1;$9$Q#(.[F
MDO@&BFRAO=V"*U\MZ.!RAPWN"L+("$L,QERXZ"6N$U2>CM4_79NSR[LW$);9
M?MWL^K)F3B9)27"UX*Y0U U"KJR%#F]NIF194!X2H"':^B %M01W'^X91NCD
M=(>6UJIYZM#LBBRU%^+4R&0&U(N,J=E@$+O:]KPD8ZN2^1+FBOE"8 0/<Z_Z
MFJ_O9=?W@CY?&IKXJ (X^_VU_GP GLU/7(D^:/W&L>[-&WI]"D(S9)LOR.I@
MJ%'2,R@E(E;*UX%++ ^G<<<XG6RUQ'@#:-165.H15-!!6-0@[_P" "@:0A$]
M;],MB#30,83$42AEP[K6-^^"FJ-7$PAH=56V!$O#3(AA,"_HUFSKW90/8=1X
M*CUI#@5J?9 .M9,?1GW XVT-JZ^+F\TM;OCSJY=#$3FUA?S=&#WDB1T# ]$'
M(E9J/Z+FF&,+N1Z).@VDK4F4UR#))/557U!Q%&GEI?D*L8 J/G27.RS+45.H
M:Y>5$S%!BA2^H6CR<WX9VFX*")9<JN?Y-X!N*6F9@M? =4[CU?;S9D(G8@O;
MU<1Y\J\Z.:U#3E&,1P^^L.ASN<9O'GY19*4AHKK#734]D$,95M-H%^M",*F&
M(5H2=OJHP,N2IZ5-W8ICFW;1_8R6U+'@N% 64Z.%^0>?<3>!RXVSXMAF@LHZ
MW9*X'10%I<J<5B#.@PHA?<&]J>EH#-<6OS8H-A+ ?1A/NU.*(E_!-D/;$K1.
M C&CYHEWX18CO&4[#(3KY3WNC*=*>P/X,5S]LJO#MMS(=@);!,(G/ZRH7X%#
MC_"?<:,NZAJ@*13@0(78(( L^_:::.,KXNH:<!1V=147?-]GMP>FC1.<TY^Q
MY29,C+0"U7\36P]DM[=^BF$/R&D]_'+.,D<QJ0$ZT1BSX %SN-=BM$R(-*'<
M/WZE_DOH#D9PW5R4J0A^M$-LCV_+ Q3L)IBRP7$XW9D4NV0C2=>&Z-L0!P3!
M3\W4.+)>7L$OJ1R)NL[ZBK C%_;SR_+PDKJ?PW^[MJ;S)!\-[P&]77XO/L6I
M?SVR[<5][K]N5OS(X3RCVT<OG=$>SHR)OAU'Q%AAX5L, "A47Q%/;%6GD%81
M/8PTMWDK?=D,S&<1%0[Z$@5G_9I;?CRRV"0^Z=;,#4 G%+Y-"J7K'<51-RA1
M!H*NE]T:SE\&3X5NYSKM_6D\\1EZ4J9@^ )];_UAZ>O1BV1=\7%M!152/T+%
M2)A-MK2FI63-46BKT=$Y(E!2L]K>J7CT8ML$I=^L]8J+G (Z8OY6;&RFYFG4
MB,]AT^OT>-&E5AH60;PW]D U(P'#M8<_3UJJ\"F)O"-L3Y'<OFN#_[W:HP^=
M4/97#DD[X9:#H1>>:D1HK)B4K#A:<F1$T,:S^Q#!/M!Q>1CCOO-OK?);1@GQ
MB.//I"M*#0JVAM*#A+L<FJ"0G<G#;;QG+H!57^ZM<!OSY,+P@5L'.=[.S!#P
MCBB(T%Q<[JRS7=Z5R:&EETD!N=AK]%HVGTH&G%TPV%M'T091Y:[/4,<N;,@*
M!U@0A2:)C3)FM(0XFT*"(I] !XBZI>MD.DS:I[&)=4<4H60U$T&9^00T:S%X
M]EL]V1[)C]6I/^M(L>K9B(J6ZNBSQ#Y'=?N2'H4 "\_BL)6^BN0.8R25A$0!
M:)>TMEP[BJ4;P_@?"3S,6%%F+=U A_-K6B:_:9SBES2%?7J*TT_C])^=XO0?
MA&#_N@$X\?\\[4\+^A=I)FI1>^AZ]5D=W:!L9C7,73?2?Z!N:J2"I?9& Q"9
M0WO!'1B)FFKC!'>\PWVED0>*02XEVI"P*J,,H92-,<:?J_V:'JQD()&P1'JD
ML^$RF.N#P8[M%P"F 9/5V@71":PF)336P0V)M2H57^$"XXC8KBX9OQW@(TF,
MZCKY5B;LG^7Z@(HR= 12_H$S\]S)C5R\2N=U)&9. G>7=<M=9OS.ANR,B!I.
M(*GX&#+W- SY_'4?/DG (>-O "S9?0O^@1+_#&C6&N:YM,HUJ@VT 03DTBXO
M+[NAQ>*V.(N#,RZPT9K FD>@CTLR7!(>W 4[ +9.-#%T)SJ/!XB^N2+ZWO7\
M_HO5"'+:B7!&(CQ$W#O>2]D[2!&;O[ FC29:/P\R]?U@T@A3GRSL!-'&MFCN
M[ZPZBLSQ^WALY3G-?8PUV:GVGY>2+7,RH^@T;XC,93.1N=_2P)Q1^RI#OX>8
M%P%7>.<\!B- Z70@Q[,)0YH-C8V;AH>P7Z3'"P&#5)0JXC^^[! 1.MW#%"S#
M0M6>(X,<+@:*<MPYPM,8CDG5:>5S.;I7IVP5=)G61GP8JZJA(URM-1<@3(Y7
M9L=H)H0LY(0(;5F<""^<<*<4>J\B--]V^<6^["D*KR%[^1K*C$F/!)D:L>=E
M"3*H8>%I-D@;[M6U36P8[>L7."A55@RI*E2U?&%S?NP:=HYKUBYIDJ*[LK0\
M3WQ^/BM(\NHT+YMP5?9TLL*B#9R.2)C^U&"9F\,QY+-M.1A_75UE_%I4O7M\
M=*]D9\LC)SO]D7C=MP.G<$'4:W33TR*;2&8BD786C5@8IU%/H';; Q/ VN45
MYI:"/'TM7Q'*2IR\%8.WH9RTW'$IT8:#R!75I^L1H*P\?Z]2KDNC#*7+,8@6
M&"9_NJ2:@3#('<7]-D$L&.''#'R5,AT9[.RKKJGD\=Y$K:F BN6"IYE)\(BS
M?RDP@SYX0 YW0!4I.DL%PI#O\V#%;>ME_);^F\NO]GU;5^EAE>T0UAR_-A0$
M7=?"# 36*=$R'<%Q#%*[HQPM5+$D"R_?$Y0(ZP,A,P%.33QM#.3@D!$C*,8$
M]#<J1\[WP=:*I_L("/"":-*NZ@CU[#>_86@+P4SVPB2J723BHSRM>CU_/VM/
M, 2W$B CT'E]&<Y6"G?=ZWVJU55O8MZ.T4O7@)9 I(VJR:V [;>W7CX W?E3
MG1_C@<\TF9+6B+";2(UK08]RWL+AR4(])K(>][AQK4%H?G"8)%3C(#!T*>]T
MMB&2&U$,\5DC<'#%=%^'J_^,T@Q:*RIHEZOD5,J'!1/(2N"1^5KNUV5ON&X1
M9"]K2=MW#,RR'_:00(WXL]9/I=D\^828%?'ZQ?X@T7PN64$U6;T)7[BJAS?A
M7V;>XHBOQ#7C48Z"@?+:.+3VCFN3M*1\G59JL*MK!E@SS"_\2%QZZ J3!H!K
MTMW 4J[2D1Q&5"_32PL,8$-CO2 W"@3KZ%8Q]-!PR0X0G6\,_CS[+LVMW):
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MLOVS5ON$EUYUVC5/WL]5N4[EX4RKZ4 A/)3KH%;_\S_PD+L04-27O]"0;,>
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M;PM62,60G/=1$'D.Z@[1!X<,U6T)W'/?LE/AD,QC;&V!.A^Z41=A+[CS@WY
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M]:UW1_/=(B@1%I-/TZ<X.D_ MP">^"NIS/Q[MP/HLSLZX8'!HI&CPA:*$B.
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M$T+?9._R Z_F'HYN06@)U5GFQN?>C2?\/@K%"J,.#B1&^Q9;UM>VT5+_%D4
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M$+SI7X2)@%LO G2!V$Z 2L)'9(?(^;;F%?H6.:GDN0:WG9R)8?R]7+]G[Z+
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MO_"HO/^3\>L?!*M@4<QF4OL^&EI:7[/2(TDL5&"$%\H"ARMWO9[Y\B"7&".
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M]_ @N>]!MXLWR*-^#J;FH*U(#5&W$ZAC2C(K8:XCR;7SC'"5J<.]YR3*W#R
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M#)B()$W1X5?*TS#2BUO*S234*2-H-YD0Q[YH!-=[Z["NSF$T#%>R>K'LO,Y
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MBREQ3.$J)T6P9)3 J59&EB_/O&6U2LG!CE-)I5F1>#?J^?-V.R6\;R(J*^=
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M8X/4)>51&@A#$=N\W#-J2\W=DQB<A7N;93UYUTF)B'[G-^@N*K/9O<;&KT2
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M:&Z]NS)A<!&A]Z%UD?\GK*3Y^8V<%4:%T]):Q/0N:[?>V/5<F2Y;;JAWW'V
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M04;$.C2I;0]1H8#;PV<5%2\) #^^2R0@9_H[E%A'LDJ)>!-3FNP#@(8=;3J
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M;(92W*E6@(=+?^+,?+XUP.)$[$O[FNEDV05<K2HQC^!^FPI6:=E5X!S9HO"
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M8?0Z(+@%?;*HB5787\ O>[HAN!R.1UBB=0]L$^"^7)9:[B+(:+0_1&YO9C>
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MU"(5/3F?C006=_ZW#<[1Q:+<#H'^VDE5EW@RE)14^=+:KN; +QV<6.10Y(L
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M[^#"Y&,;B] *C:4^ N&I<PGOY'!EB")%F 9"$QL7<J.%)!:!<;;]M2;!S3C
M&1UBLS(#KZ;GZW39QC%;MI&43E>#"8OC*G,\6/HJ40TT1"6$*)T0Y!GOQUX_
MH-X%#$5+($X@.>T;!!+=+51.N0&VP+U ]^_=?\B9X[<OGO%F(#R/'DYF$78[
MJO:;J>#IN_+31:V%C)K3% E[1*]+[TWY".M*_=B  C*Y-J=F1NXZ:RR4:2L>
MMJ0?-/H%)X5Y=0KU ;$I&G+'4.V?P_J>.D['#D(96O-K\RF,YII 4\7Y&HFQ
M4XZ^H!4#B2K>MY,84Q10&651#SS:_8+ "=Z&11W+7D:>8T[6I3^\T6GKRG1&
M8H<#DRE$C.%5<C:_/%=U];XDFCFU6X;?B0BF./NP:T*#H#4QP9 )#$PLGHBN
MBKK5AMNB! H#]C9"(;[VUK4EOD\RV>0!NSG[:285KBY?=1@$=DL<5O2R02E1
M""7P:$/$OHVY#JV-.IJ-7T*2_NA8P)\IX']]+.#_;G:!AG^&*9+;9EHB/BPA
MY0X^'N%%Q;>8HQP*J5TY:(9O%3NEXM?;Z+LI0E6^#R@=#!6GGH9JFL<?&WY\
M_7SG-T>30 #<;)O=@8:K(Q'K3<W^(1"*S07_V"TO&,O?1Z?&?Z-$>P;!R#A)
M"59. 4ST"9^4?B- KT4,G(HR_F=EK(]3CA_M_GXQ= S)C,$^U<F).(>TN(F,
M1L0R.4]1U(MPON$6[+8EC@>>,EF*"'<"D(^*_G-,@Z$P[W^/U_G'SCM;2P$H
MBI1L! ^03RB;@ IZJ6._!-[X0IV)WH_"0+.I8J\<Z:7[:V:_L./I!REYF%/W
M:M":RZ[AUIG FFI_CCFN5J3K-9C^&?]\Y'K9A[FLRJL):%W?CR0(#>F9O*@+
M#*7P91MI\&0\:@%TKN1&KR:OJ@S> .,3RKC? ??9\0@C_$PB=^GV>>\'F=*(
M7+HGE+I@A7]X\>PY7$FPKV5^&GL-R9E-,](P*3]G:"PU"0ZN!2J$$\](XO5L
MM*+/9@E*_0@-R#%7G+H6U JG1.4B-"[ G N5\,#@?1%XIYQSXH_BFG@3V1/"
M4&Y59$WK*@TX[;1D@/-)ZW.Z=4,F?H&.*!]OPE_6I&O<M<&/'1ON<57GCPCT
M/-B!3^QQ#;<MQ.*]"\5[3FJ2UIX?0LKU* 0=+'X9@[*?EXMR@Z+S@S,B,G@8
MZW"RIXAEC6,!,_\<\[:K5,5/DTIF[MBPA<3%B%8W[&W9BHF!B;CCL:%D3=AX
M+1=MH-&(;$;I'"UC3I/PG[WI\PO(PE^KTVC:G-VDS5GK1I'UDX8^)HD$'A;[
M 0V8PN3=CL[0F)5>^$+]!;FPJJ@59F^P8%3MK@A.%(:Y.,=9M*@K1F0%"7FD
MNKT#NJ2M2.&X0KNFXM>FUB5/DW,?NCZ+&\%BN?(5.,[I052;4>F$Q,P+U"8V
M73 N,[CS>D[/]M$S"R63 <H"<V&!*=%J/&Y#EW'*AZ\=RF]DB<9^9.UX?GAV
M<O;-D[/0GJS?]!^?SD$* Y1P)/;!_-W%-M0]0_:L8)J%,?NYPCQ-WZ!X>BB\
MFRUIGRI]?LIS37H*FT)'FOL),^DGE"B%'ANZ+O+<!$)E@)\JEA=!%EH$SQN6
MX!Y&<&J#$75J!,S>EQ>_580C-NN.4Q6:K *DZ/VH]:L]#>.R/!]<0J:TE?XC
M4I8G25Q6$Y!CF55SO8\GO8CA*E18ZG:!JP:Y4V(YFQ%R]BLS$ 7K+G2XR-$T
M'Z  H68V1D5KB652,6,B7&]\@0.PB']MO2*6#KA9G!#66#>9H)W<AH,$UG*0
MR[C@+@M"F.ZT:RC:&AN\IN3"@.@.E8;5.>EJ]!:M0]?9 3@$O>"J*["TJ/^+
M(+KRCBQ%I&^'^&G!+\2(1RKT^_O%6((!*@&^3>>0A=TEFT9>@,M1E [P%Q_V
MS,/D=TU<RY&+:C*2%=O:R+$C:KV(8U3N'/:-OZVJZ (>-(5]*<LI;K:2G'<4
M,7=25;8%/Q92[V?F5R3!.(*A )0(5RC)%=[2KS3JWH?9H!TN=I9G.WFKH5V\
MY[)@[Y). JN!O*RXE3H/;XU#5^X7KVUPE?VN3%SKKKI8$UM,E.M6#B%_E/DP
MLX0/"7Q7VS&(20Y$>38]^B0F@#H+OS35WX_(UY'Q:?9.5@A-OUGP5J0>FT66
M?Q(8AZB9ZL"QX952+]X6 ,&0>%<$_19LA"K=QZ::Z(J:0&H,QI8*L>4S]V:2
M]@L5^I$/JA:D)M@&#N_YHTJ?1#H5O!WSJS':PH/&+W3?LC62G,-I=LV!?-TY
M2=B^;@/,X64;L)!$,^!/Y<$5=;KE*=DWN;#?9!2(Q\MV<_=@SX Z+)B+Q9N9
M=8GH5<^*GFY]P'D?XY)O.HOFCYGLNF/&H"@3%#PB;:1M<RZYVANJ(OTHBXXT
MVW&[_X**X-?'BN!,1?#QL2+XN]D%AU)1,9J7W(.PON4NPBURKLJL1#2)#R3)
M1I M7<6<A(E1M3/WHB(WAI/OUCD2 )GBD"LU?@S^IN8I%P^9(DV)<PP0<655
M V--!Y/%K:Q@$/.8CK],"'&(.C7F,I38-".N$<GQ>,/JKLNR!529/8&];S4E
M\)WK1@[ERD.$DB.^R&.L>%T_\DAW=%E"4E'XQ\5?B^M6EK7POO'*%]= F6'1
M*S#"^_O?;Y&D+81<R.+^[>H/TCV47XP*?J9Q3PD6MWXEXG=]PC2;.'%I6P@+
MMIB^HM/L)>?[\.48TP'CCS)5$_3*;"#(V3W)*;)Z,1I,6L25/ 2C)@?SY-H!
M??0F+*I:4J6A)@I5GX"NT-427$4AG.%J:8 CJZG1N"\:P#1#F\C4%TV#M)36
M<+ ^W)Q)-@1<Q'5*76N1IX?B1 '_682%KB=O':G16#/AL[=@"'CH8G8^[%D2
M!GRB4\9MRS%,&#?6VK;2F/"45)Q0BVK6%X\>.ZT!C$1C']T -$V.4AKXXJO0
M"/,,@,\Z9,-_!-#R=<3DW7EU^NST]>E=X94/K#R<CCV0BLUF4K',5<@\2IS:
MM9K@ %A7O3!529]>TJJK9@F\D0WQ7_M[<"\,&28?5VFP$UN%Y0=L251;-!Z1
M[I<=D4+6H3I0MY>_]57C1]#O3ZVE$N7",J%0BY ;/H,6I;)<S:T=OT:]'=]M
M9>2!VKCD@#SZ1G2OMB]C$P6)YE%!@=/]>;*5"FVU ]Z&K@[J@!(>F+3PL $J
M2-&5V/(V):Q5U6^41-"'\CM^TBMZ-<C+R9,:M@O'J.!<\#G^HI>A?2\/(7%2
M<&&>3^X?O)4UX3<)9:76RH"/L1D</X1[9_(VL1<Q=L\P\0/S>"59*DIFDHQ]
M^G4T.C!/&+<"LAKN^(KRZ_3'3GY+1@W>L;0^]N1D3=LN(L;9>L>'^@'CM^=J
MI-U.&0C9B!Y=87Z$\=KAZ?0CY+!;T9/9,H_MM6L(_VMYXHJ+"S@9$#/Q2PIZ
M;T/VB(0SYUUOV<+2O<3>R\<L3&^WX#G/+5!TU/=M>"(EBK$76K<DJHE#,"Y9
M=_UE.:^) %1=Z4*[OC 7 HCY^N')UX\"FVQHE$/E5^QOTH!!2$;_9'0]>U>'
M*<&,22A"TK-A9UWWF,%O &33WVE8]]D=XG)!#1)8RKA-NAT8D^_*\<$5(9/J
M)?/N!N'S0*3*UU833:Z4B:]#U7K2IDQB,Z"=V=#Y-VJ)Z<IML5<]R7Z8;<5R
MR<NBS6TIC Y0@^\C>0JM(*+0O"JXD:[I03H;I'INMAY1UHI42";OXS[)XFA:
M5<R7(NBXHB^!%+Z"&EQ53U,=N.1GUM#\(HZZ5T,<.:U%4)71'VSHL8E@9*JZ
MB^K26^9,IW4>7$]AT9I43G%9#=7C&@TJ-@HP22Z=$^:J]U[(D'[@3&&.D6YU
M46W&EVN9MR',_!Q9QOQC"65 SUU#W3&K,P%G<:NK8AP1##H9^4BW0%O2Y#$5
M$+GVT8Z/AKI!*364R,(H;#VMZ[D#D47D$0 =FKFN=!]_.:RMP$711RY]_G-
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MU]"MKG2?NCC.AL#:FB7A!^3R#M,IFFTS6:<\"]L6=H8:<>)KQ7?.KQU?AW>
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M;V@>ZF@W[3ZAO9MJ3A ?SP;/^5OA L$IDOKRK1I:6#5LS$;$O"KRQ,N[P?Y
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MGE(^?^#B0S^YM;$OOZ=9//%_X=&+WGDV(U'WAX9OB0I__^6\)_UT^1SM'R3
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MT#*M'_Q'T6,;,C/]]$Z<KNI7Z#OH+-(A$6":X6HI14$6Q2.@@PH6W#J.2&B
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M1IT]=X,XK5(8</'@O=S3BM74NIB9GC/##5X5'V <"MNAPS$+$,:*640 N7D
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MD]_-V>G$O/^I!2;/N@*3]0*3X[VNP.0><,(9>ME2D862D75"IMR+#BQS!_#
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MM^;PV./SW7,]J7/)FS!#=+SPWPS>#][XOY ^TB"W;/9--4?@=3$9"!HG/FH
MYD*-4JK.\))@$>H0/80VP*-C'F,N)K>\!KXZNT<U;NG5EVUG;A!;R<2\"H!#
M7H =L$R >9\M4ZVP1&36NYZG@'9(KQ.&91R1YHJ($7NR+>NJOW4!\"6C-H=.
MQDH0X 507V'K<WZ2I5R:?P+? @->PL72P.%HS,$)KWOXLS\K%PO6J?Q3&EE(
M>_.K61CKOU!CLP!^;)%^Q&#*F#_"WJ3^A/*6D4R:0!H"G]>V,AXK$LRX7=K\
MN@+]]<AM+;4]=1Y$+DA/-1^4R]-1.QICBJ9%^K?(:;\E7$"%2=-=:A^I?9E
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M8_VDN0//! ;>(^+L#G.L_X6+QLF_)[9>H-)<>&Q:8TCSCL8JO?HJ 5O)B86
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M\>=DA2LJQJ-U4<'"P946.W/I#TT6;)^-L6M8'YV8Z,3$;BQZATR&'4/[Z&1
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M(F\@?/,%D?E'EC6_A.+A%[R)BO24+OB__4Z[L1B2F9;#/<B@_7U7Q7E0<7Y
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M\W?7Q"=5&Z: B-;X![,)!M=2#B2;O?@L9.>;[5+0*S<]'_%DJ))_:D>:9-)
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M15J0+)66(!A >&@.E&/^&_KZ%"+BFX+!-OV^)4 <H)2%YWX"N,%%N&<MQNF
M;[+!9F-%=<#?XX90YOG9T?$7!59=POXE&HM$S;CC"G&"$XBQHNL0)K:Z2/#Z
MV4D<\&IV7,C#2=Y-%SY3XKIG*IBI>/?L1*AE=*$0B,Z.4F#3$Q0XL(8U2(7C
MEU6NDMK49-BHSM*V6$X5G9P=D>M);4S*NE"<64ITC1M4HYI:_=,0=Z_'ZI6S
MET<OGUP^I5(7_ D) ]>!PK-(^;S*_JMRG7<%MZ#>);$=L<SWFRY9D*5D7:PA
MC(9T"1&2VI>M7'Y_<,^(@QTT+6!:>89=?G8T=80"CI#T]UN,TEN_(CA2_@99
M;<[2E#0DO["XMH,'9V$^J@:I#M JD&H\XE=A]9==1[_Q!.8U^G9KV^]EJI-*
M*!_+>_BJN$%",3N>#U[/4(5;//!>88#@I6SZ\#T'ZT_I+@@ [OC5JV?_AM*@
MQ[XF2]NV75\R.UDNRYH\39>.%O@J>6+,(/Q#VQQH[URH'2#-') '&J*$R<(E
M>?+EBQWZ'VI;2]8"[,SA>T[31,,?,4:@34H1,(0)PFB"9TPJ^^PEIU4-Q_T<
M:D!5(B.:>JY'S:_U'374-N(92K[O7])-F5+6+?J ]@:3HK@H%)GP2N5+_#J.
MF(CJI/UJO$?OWYV=GKQ[$^\R40E95R^]U(>S_VK:6XE4,%L2=\M>]97!%EU9
MEQ;>ND545H&4(%2=_BV><KHJZW@_3]!%1C)A#_P.?CV+MU ""$%A)+UD^BT^
MD[H1W/#E<JW+,ISZ5&$$\!7 EP \3$SS= K5_^>-W1#+!,#_X4*XZ W\GT%;
M5-9WH )##<L X5(WB!A9D*9EC"P/FS$UKKF"4LR.R@0DV28LR[AZTV;*):)3
M?'M)J!#(FZJ+%>@E4RP$B(>W(;5)ZNNZWIA-ZOF _$T,"9NJ.']@J[3$G=,M
M0O.<&96:UZ%+,Y&B'SJ+B @2S7;M$2I(T#/J)J0*VERM&;Y%<IH)ED,_C)M!
M\8RTUU7/1(*+7>74,IK,$+W9H#"%9^([\07^7N].T\::!'(!K1U=$G_&V;\_
MA:N%"&9F^2//APA==KYUK76"MVH:O@CUVEO(1-Q"P&X80U^R,>1/5+R1_=9:
M+Y6SMU0R\"UEHJK%P0]\0($+X86]KE8;8W&YZMI;<%@&8OZQ\O:AH9] K2 "
MXRZ"E-9G@SS^BMKS2K$, S+ 2\\H0Y[9FX^@\HDK\6,'<<YSII;-U68KTXM3
M"Y),ZX1]D\AL*FIT2[X$*87OO[] (R'CBT%B3UP1 <#L@S!]@QW*T4RL]W?=
MI7(U[!I2Z$+1@,@-B"[M(NZIWT)W^[PW"Q?[3.PI@?,NB>950:5Q :*IP3T2
M"57 L5:DD!"LC^=]!58D4(+_HB3O!G=2(KUY="L9XJ2X)#I?8%-$SK$<G*QD
M9O/).C:0YKSF:NCK*I\ ;.Y#,FCHP*W (7"KE]LB3UTUOL84<")D&+TNK@W$
M[KBRRNY)OLDYU).E0,C*=;@L9\L,DW2JK<;+9R*28>\%WU16_ RQI%WSH2&,
M*V#BD($4%4(^0YR"(&$[LH*8 8>8<U@67+> )>KEK#F:YM!3EW6[3PPBN7![
MW7*QMV_4:3%8\..,9*LZ*S0ND47FN0"=E]T+E(H,(6<I8Z,/0_&.+MM$F /\
M(W1GHV0U;+6_,V:YXG$$R5Q;AR-6AFZS1-VD"JQ*I+30I#FTI?N54EI(WU*B
MEE>R)*^MJ19NV.96:[Q^O6/J/ACHM$SX+(RSSV(0GYB/?_F8CY_(QW_QF(__
M\]^$DVVPT#%G)(I95N3K@-(^][XI^]R1$FSS7EBR-Q+5XLNU#:R;J(/(7O=8
M=?,WAL7 +F:5&_[H$4)V"RE92U87.;MCFSHW>R16S\UJ4A(%:ID>LFJ12T-X
MW?M%23$D#6/Q1%8U**'GX!U_YE<C/B0J5"#8R.X2@PUU)4-B5ZS0;O5AEF)[
M"%!Z/2B;2!^][W;KS>PDAX=.!;[CZ&#)&^-RN<Q&$\P?@XH\C5['HG0M?QP7
MX3E[DCT>G!B=?$\80B\@8]M77$_SU=&+;.X;#;(3,>+9><$EN/11R%3_A;88
M^W85GQU'Q%8:A<G2UCICRK+6;A:$B4^C>!*-3K(%3XDL[?B++[^>/?_JQ5-%
M FJ(ZMNV7112ZLH5*?T:'9M.<%R15>^95N?Z5FH+86&Z# TUMZ="+,)O]JDB
MV2^#:]DTM@FS.81S=1_4V2 PI+R=F8XR#,*$N^U#86J?K:D\GDH=@2ZH.O.Z
M4*<+U]Z%\>O^0QBRI;,M#6HE@!Q2MEY=]OAJ.A ?:KHEMQ(9N:LXME)5L%HQ
M'8V5:[[89SKH+3"*M>^? 37]UZF[\T(0'61.HTMMNZ&IV)7[-4/8IXC2H JN
MWT@'D5:M@I-9!>J"V*,@KR%DJMC=:'6U8NJTQI ,."7OD=-!_$@*/0S;2\S>
M9^<9>C?[NU[@T0S";S3E';:IJ]9H@-QR":9BD!X#C'\[:\+?=ZL[^*@LXKZA
M*M\A$#]%4BJ+-\#P*]2[C\=GW6Z%.IY15*GEE%T_[K9W5RA1(YP.3=X&R!N&
M"I=Q?BA=<^&BN7OP=&*;#QQ"&==HS[@BQ44:@@;55==$PQR'?DXEI?2(D\4"
MT<GX].\I&$&",)QS, ).7Q01J#<B71A]G\W*A=\L:B9N%6*:%M_.@E3*DX%G
M:DQ4?".T568Z6^[PQ@(LI#=&5Y2*5BD3X8T4.*)IFVXJ"U D2P>:$;HJ<_NW
MPF*O;RC2H.K>.#3(U?,OY'QPO83)1 + .7?3Q7V)NF5"[+ORWQ0539:1KX^U
M6N#<(N' H.I1\[V!2E=?63<)9*364)S?G.'<I-6HU3/Q&KEM+((=?@U)3JX^
MEQC>*<^N\Z35ON*O,-,E&1=]I@(D:3-Y$:F;:6_0SM\0XT"L91[O06?S&P33
MYLQZG3AK;)3FYH]"",#R4_2,:+ )@\?M("LH4BD@D3:+]!-0N<0UVZJ-BCH3
M)'F4/'& #]K/OC15EY[ 3G^D4'W^XO#H)7EZGXEL?T^=3N)-%28-6L\S2SB^
MLQ+P$V&PQ-_?G13,9_+LF56/<EPM%0OF+@H?J_A#B%PFB_U0W<VJE23I^<0D
M?%+'MMF!Y1P B-U[.N7*VN-T)O&%P&)LR2HBVJ?K>(K@7)6]BFT"%47A0(TP
MV1E0FVID:8SMI/V=S.FU8M;EYL3L'_6'BF@'8/Y-%T[NJ9 ,]U5(8E>$MP*N
M5ZK"Y+BDEHUK/3CHY?LL<9XT:U=ILNWWLW\^DQMQPEUVV6QWA[2P(Z6P(7/3
M\L2-'=S*- SJ6RO:9_/EIO(J22%MT8!(]6)2201T+J2Y\(''L<WX?"*88!PH
M6;#9"LA/M2\N?N>C$++Q'X4F"#XY['XW#X59IS!UW@%XMA(,=C-[!9)8L=[3
M.](7CI_K-]07B08^D4BGMLZ==%RA/H DV_EA*2E&YJ:VS95^NHC-]/(TH%#3
M(Y'UTAH&%B?JFSM]/B8H,;9?RB\$B4COXAU=D1C\X@]R$CX39>*&<4$5>@LF
M5*"K8M 4X7Z_!Y\B7OA$?H/M^(%1AT; R,5+4"3A9(#G\5<D3%R1*=Z&/%6)
M3A]3:7GEN]*J>RD0;.?S*/Y'^<^4VCD,[SDG*0,]4/"="M[)!/"V;3]H#D2R
M]]8A+)Z]YWPCF##XG@>]]@\*' %[IF D/)#U;"T+S@8>:,&3/'-A/DD%Y2A=
MXSLN30=?1MNX:82SC,9[R.*.;E3@B2#TT1@ZLVYN6G:NVJECPT-_^7CE9!@H
M7?<W+EKWN_E6.CV.B404[ZC0?*O$%I IV44'[?)@0RGRK18TR_:LU/>,CRD[
MV54T#J0S0V\(KQU?6@Z7I(@8'X(7Q6A88'"ZW($G2:2M<(NS[RC28FIP\-J<
MM]:#C8!6Y$YZ_2'R5V[+N#141#=/X'>NTG@"-!R<"1B:T2M:.-1M_E*#:^#9
M<97_\F7QXNCHZ>'L1S:%/1E/W:>(!<\+O5WD/O^Q9_GS2LU\8I+RB\<DY422
M\LO').6?_R:03WY9(S3=EXT,J?X;Q1T/$'><O?<).1)_IY*R #J62,'Y5X1U
MJBGY2/D/A/<NHA>R!?R(ZS@(W)^L")* W[=2^/BNHG@<^]DW%>)K/\ZW+4&(
MCI_SKV9/+@Z/G[T\PH^_/WQW^/+5RZ\*Q8O&7ZWNG@IWU)Q)(79=QW6-7$JK
ME(4PC.@[C.+1PDV'1XOG[T 3,P'0D+@ZCBYURIM18LC2)S2%X7@ 1TZCY!&4
M@'Z+!9(_E_!1ZNR##V)@';:.1TKKAH0*<S23V6 FJ61:HK$R@T$_#*Z'(;N)
M"EI9F?0%8[+*Y. HDV?6&F.BCZ0F)N.6'AX_J9Y25QFT&MNN*A2!G+8+3CR*
M<?XN9;I1.JBQ7N@[MXAHO09WMP6?770/=B#V/ID[6N*]_K > _8T\Y4"Z F;
MRO8((IE \9?S^"O.<04R$! L^?GDM!!RG>='!PO*2#&ZGX):W! ) #X^^JG(
MA"N$*T*M2JUQO'CU?!<O"4J.<4'4^F83V9VIN#021A&.N3E'4:OU9L5.#RA3
M]X$(>!7U#- #HB&Q$\A>N5O4W(ZG;7+C6\BA=@VH O"[.'W?3W=U%S1U1@7I
MN[7UB_>+K*U3K:5.8@D 42"QU&P6^HKLI[Q[2W2PHE"M*^+!3HBP"=Q1,"]V
M4@)2N;I((N.9U<>X:G5C9 (I+*+"CWY)5J*O!Y%!,Z<,+-9&4XG*IA_4'!Q)
M :KDTTHNFR#[KJ768Z!%T88^^LOQT5%Q='1$/?/B5K6\CX_6G>@TY8++\KN&
M2I1H$C<EI*N]ZY&6(T<_IV]RJ6))(7U"9+8()9' KIAP7;:4+YXCX/;\98)>
M%?SA;T.- BNR/]?,]>J! L2/R>9!Y7)<F+3M+!L(FR2IH* D@H9MF:(@GNB8
M*UZBM=* J@ R88=R,.;6'U0/SR:)6J@R5?L'*ZF$43OLKZ)W8&&)EF8U.E$G
M$,2)D5I[TVT>.($0BD=Y6U4GI\6X3 ,IULG+X:@'+/G,]RQ-=Q^+'%];SQM[
M&)36#E1<4!CW4 J@1 Z99,[X"3\*VG!U7([SR7M<(+8<)MZ?S6_?G 8HFQSI
M_4#:;/UZZZ%OI06*-11^[$$TT29: 9#2,"889+#0G#67M7GD02GA3J&!MXP%
MN^.*I+I$T2=S>VJ[8;9;]C2Y]S 4;DU_2PRY]W2H]T52A,CG,I5>X8<T@3>[
M.(,J2K"?&A0YE7H+8;))"G665ZJ#^PAU+*.4O<+4"/]S64WPZ,"(U*'2!Y1(
M'G2J04[4GU:'#N$D0HX1V]>VB;V2)$7&O7;,NO"%YLHADW,&96UVOJ_[*+"T
M-G*"[7Y5[AHJ-U;A,UAFZ5\C#/(\?1?NE;W)*SA!P6S4EELNTP-53H:1!!WB
MH_U!Z\5*WRY W K&G19!> -8/[BJ]W/]["T?\:J?"4#L'1>-?M-2R<R3\[?G
M[[YY2A0?O=T(K3RTSN^,*%TYQLDXE@-MLDHT9<( \80YSE)=W/$Q:?T#1Z!F
M8N>IIGK6Y<=Z'1T^?@1#8HF.[0ZJ6&H&21B@SIT%"X:-OU.Q85\?*$%]N&P7
M=\H([Q0RT10)\:CB?X8F"*]8):@@O$VZ0(DO5WVD-#.7;V*"BUVGV7-I;8Y,
M=0]&\< =TB62)+"I+7-_HB&S=)?-&=F(X"$-9+2Y:(=$>*JKEM[,S9"DYPT]
M#<>"-I#W'RB9D!XX#.8L"9_'Z\XX88"ZIOH[UX.1)%,(:$<.Z*7VO+=X)+=D
M10$@6DOAM"+]T1/H]HK+\KBM2]L+\\_:/IM\(86^%^D&/!0KZ--2$5\^IB(F
M4A%?/:8B_A1G'2_GS*7G;/E'>2M%S-2TNH8E]LX9F(]6OUG](YNK 'FV-+NH
M11,8J(\)4I0<RC7+B-I(:\D%!2-]*+G&NB6]Z9EDZ^1P*'KFVYR9BD*LIV\O
M"HEC4.%MKX&WK:+@GU2'5X=LQ_Q(/0-AXY\U2.%$#?(=VXY/BQ1XR*EB_D[+
M(SK-%??BFR?Q7G9-16&;I0"I#)DV^93"E:.G6;MVFP_>1'WO0%(G_W5!FOJZ
MOJPI_S-%;X)@6;2GN!: 3B#AJ6%T?3#"'A041=>'O4KP(P$ENRGO\'][A$^V
MS(N0R 3Q\"@/=@!QP^^U0G3BAVSTO^(!I$ KIUOF\F]8UO.ROP:79",U40AC
MH5P+;R*>D$*^T%71S6F8_I(S$\2JQ!#8,BLL5X;,5#=8A!7'V0JN29%_B0>G
M'CA,1/Y-1<$DBJ514 I<$$JR>47E<-$]G LV/5[\]0QLL.A_F^4&"Z:\D^JC
MN@G<6#BK9K!DH4'I=7L=I%[9 =@@)_L^6WC/^B.]<,B\[=IRP6E,RZ<T=S@9
M0=G3O+C8-1Q9T"I^"6[/Q<$%6Q2;]-R(01IK#)J>N?AZO=Z0)R*=?39<_L-.
M3B(,8L\?) *.HB)1:)$CL$E5$\[-0-UF-.4OR;R/3]\*(PJ7GK;K-1G(20HS
M%7'7]BC0H--ZN=-&.OJ*H!5\]ER&]):WS:R)AZ6]75& )#IF.RXB65?1$4%?
MA:4<2A>$H8/IX_Y@^)W#I9N8'Y]XG5UPHX@&>\5-(*U5!^$L42Y,D9EJ%B]O
M=177-:$/G8P@3LA^6Y4+;1M[98PQR-RE*(;5#U9T."C]$= 2ENIX#R[O#NC_
MLA\T ^L>-XR=[]8[J6(2DB2:.*\)RE_+N>14YG47O\S$Q9.-HJG'E#8HVPK_
M2;/UJQIDU%X& KI/4:*1J',PLJ:J%GUJ-3;?DJ0@&;BJ%JGZP3T6 L)B63*2
M^'O.[%&E8V&/D\\6"J<D?LG4-0MY1.W6H4.U!.'$J\G9ONJB\[Y(18XN-<'Q
M\'Z[JBX1MPG@E8L"2#,+1$U>K\6EO5,=2Y*J=Z*J%PYN(P-!$BZ-"X7EU$$:
MY;U,Y19_O>S*'1'B4>EY>LVNHXAFK]LSC[=N3-SVX+7W,$B<Z*6(9S/ ($OU
M>*4W#ZW<$5NN3%R#/IA"CH_TXR1H<;HHDC02X_Y)-R3*P*FO*FG@",V=%&Y>
ML)=!/*TS+>%%OWG;0T!#]RQ064\(%LJ_1SLQW/\ JU^V%N+*?> %^#Z)R %S
M6UP!*_B2;4EQ;5N&;L1+.?G\WOKQ[6G9Q^T@4_,9,/0.#7?!/DM$"]"=[2TW
MSO':*-Q"5RX6])@?&Y5:J%FXG=2'/6.ZZ2@@Y6EM/3DGS0%Z6LDR!V$PPL$M
M^  $'V22R%N\/?U1,A@31[*\F[*$9F8)W?N:V> U11*C O\(J<O3C.LGI=R,
M;2E;!D6++.N/U>)@655)"F9A?*7SRX\WN,OB<7WP LR['RSCH=<[,*2M BN)
M.0O\:$V.:+_V47H6YLA,TS1.^3%#-T;@6##WR=$H.4#.Z0[Y([IES=PP,R5)
M))&DX=HN 0<NQ3095Z8,YS9)[!42L5=\:AILM.3@A.S4*QF,%P5Z=!^X.)U'
M'-VIZ(Q A1LLR@BS<&7W:FG8"#=MO2 Z%L$)P!N+X@N0LED;!=15J5*)<%1Q
M'ZJ[_94YCY?!#!U:*< 7C7L[*,LXV$.('<!8N<NKDKIW3)_I*".G;T#M>A(N
MS/"T8ZTGJ%H,#WQ0<Y /2.9<FI)*U* \(#JH;"M> PI'_SVK-<LY<GJY84;)
M3HJ):"*Q6['=TG:!?CT^G0_^$'U_=G[BBDH3Q8SL5%#AJGZ%=E 4>;DWCB-,
M!!KIV!+L5('#PM9"LK"?7U>,YEQ4V!:<2Q=[D(HA%609,Q6SWTA.7'N=HX&G
M-:Z!DE]7)8<=I^03PA4-RLHZ!SI'H!(:?%T+M13YK##'6#+Q7^.))6?V%K7<
M3!:0C+YY7'I*4K:=\7!I(&<\Q43%Q,0W*%6-@U822=P/M/ZANAZ>.Q<GWJ V
M=>].1!/_7_]:2?R,7/&5^5QE1FDX&H@+RUURJI];#IC&K9N;:%RJX$;$P3^0
M@GE$Y$T#VC<\VI-X/'%21!_(4!&K@WF^@:E&6*]H,GZ@ORVJ&\X[J@(*2\ Q
M.U%M^'9J7"P[;WI+NFDUC8#/M5'FC+HWQ[?>89^<;D90;[QG?3'V:X/'R'MN
M#;H$G6MG[4,- \&('_!]&%[ #";&1XTO\3 .$?[].(2\RE@7]L<A9K\:AWCH
M$O83\[E?/>9S)_*YKQ[SN7_N6S .MJJ!\6,T3>->2Q&W6H3@G"H;Z\%QKKV2
MTU<O=D2!WU3LP.7M=)1G\(NCHV>NC3NG";?]WJJ7(EC9#[HV96ZX$C,6HGV(
MO]^59:'F6#HLHKY'F? 9/:R:).M3-J3<-[]-!._I=;U:=%5CU<"2)3_3ZA&C
MZGO"Q50LJ.,ZI*S"4\[T@JJQ;)J=]. 9U'2QY9Y^KV7UB4H91)Q+60BD;UQ4
MN77=K!D71+@>6MWKMM_4VW(EW;I;UDDULS>EM%FO_ *T 15X$@M6]$RLP<F
MR^JZ7"WQ-YA#O_9._G@\_31/LMPZM%+@%#+9,UEKBIZ8\Z4=C[Y-^:U "0@<
M'37"*M<UN=8(J8J:O_CI_/S'=^_YB H-:7QP"])P5]-(1>G/CHZ_*@BC7\(J
M\,?;=0]RZ;1%N2T9%6B7@YABT6DIKG:#@C+.==$^5V086\-)_JNP:]<H,J$@
M%2]*1YQB6]2T\_?*)JY$M$-KK<=/W\47PKI>W-9+:>*9NF!)6\D^[4&O#5KX
MU!!+O3#%$6S,FH=Q\Z=G#]YZR$+VTKWPTAI\45B%3@$[ 7,VK7NM<\S1'5&M
M7>\C.='R6^%,M4YIMRG5EQ44T44F$.,V028/ ZQ09&#5L(UO_?[L_9O3[X<<
MFI.B5V(5>1+3V]*"H;Q!IPZ;I7$$(]7+_+E)K)"HHP6-9Q4"5^QK+_[B_Q,O
M6&@<3$"E0=O,XP6C:E+@;)(GRI!3RJ=J#B&^.E"X)+4(W,\<1I'SJQUZDE#N
M>3?/QG<X.YF(Q_"Z(B/;\_!-1=C*6)_ZH% (GP.F.,WTK+A:L6)R9\Q&4B:$
M;-WVUN[8+Y5TC^#J&/.^-0!N[5B"7_@)%XP5"CN9&MWQ8A^M)=VK[PYU);CO
MH1@!2SJME)2(8V-]E0?*@H7#"CNL? 8HJ4Y9[G%TV870/F4Y@8 '_R3#B@23
MU"LL/M P%5AU9TA=>?\\U0\LRG5YI5HS-0*AI()&Q*D'"+<)YA9+V77G^:T4
M6==7U8<T&CD\85G)L1?F%9W(0K:'K#($#_(@_-RZ<CMI)3SG]$(6-?X"YY+*
M.G9D3;J,Q]OG[0NZ;'<<%^&R=E30(9H!*#'?$_JM(_R\+>_P2V[]RIPN)._B
MYAN]$2AC^ L<P*2(530[(,4@VK;7Z+2B1:3"^"KXQ/@84F^'Z,,C+:;(UJ6S
MN$7W*16N*C5.HP*(OVGJ4KSQ1;M!ARE:,KE05]R4;LN4;),K9^7\[/8#-V.+
M*#R@J#9'_PM91HHJ12N7#T7I.U%O$<['&+CB(]]6X4F7R6CA[,\EV2I76WKA
M;YC+WE-@<Y'C .6&C2XX<%WP7,*_.Y>';D^\11<;WCS>*)*;LEL!*]5'>4=X
M(6DW;D =D)X9\SVR:WP%Q28!X$NNWKS=5.[DD=$Z ?^0RJ:%1O<0W2Q"NB&N
M9!;U\K"K?V8K" ._S'J=.HDC1XY]N4'Y!]><B%6*&WR7 H![J+Q-N]ZTJUV#
M9(N[^U<[*FI#Z8VJ>Z)VOBFA0[.OE=S-K%WO5E?:=W9?@B\^ZZ^:;0OC:4W3
MVHFKL\?!2[T6J!B8<M=*I&L\:J[T>.3QA;&C-R+@%:?PL47IW]ZX3H>JRKG(
M,%RB?=>6=E]W7G?: XYG%'8>]+.(XE8HS>,QB';X6KG*]17NV0Z6FF&VM)8[
M-*0!VV'Y.5#6&6/%4 DO$PAQ<(-ZN8$T449X 7"1#"YWO<6T*H*96W\=<X:/
M#;!"C2&T?*JX\<A5VUT)<\BBNHR7&&%[,@M\ET\Q:-G.U:6)IGE71]4I% V^
M7;*ZW2."!GIFM#"NT8K@EA("<]HCWWDYOJVCYFY;1A)>L;MR18:%X.A4U*8/
M<8'[=D64T4!5&E=%TS8'3I8,EKM(Z)W1I'WKQ^6NEV0]JCAW8BYN(;=)A#(Q
M35HG)XVGUS&NT6ZKY8,D/&DWL('7*#$F*FU>,J$;KTJ4!B=1&=4_=77514DD
M@D+Q1_4,E&=+M$+._F.&]V%KPLQ=??!RZ*P1%#GS%E$?E-W6* Y\"7!2N&2Z
M4KQAUV^S&[Y/Q[+.NW)$\,L)%%,B2K)QM*Q>?KT\NM;FQAXVSCA^=:2E &;\
MWNQM<1 S1/PF7R*!!GY1J(16 H;N(!S<Y8^%.=6T!"CC,A;S!UW="1Y[.+N
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M2TIW]W#VKB1ONQ@8-?Z1&:=^]*JU?B$9'_([+O$Q1H.ZDVUB/I::B7CE^_Z
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MZ?4@'L[EB7C_&6B@D^GJQ[J8,]>92:E%%@8[C >IJK)S';C3R(^YR#&"@HO
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MZMWT,"D>B1]3?G51"Y#4 @IKRHAU)2-6 #SON)K&GZ!;9NCD#+-Q,'3F%N<
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MX(Z_G/]KO4$OT5<)1[;=,7/\,;;#9]-:B[JI#4,[.'0SE_A3N$0]/-C=K$!
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M<WK17^, EIOJ2S\,,VPEYP&!9]-0E#8P"2,8 .=#QC"Z_6D4"6UZ,$T?^,W
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M;SZ._S$8?*713UN'+9M1?PI Z,5XB3')IL1/#T@I.+.4@MJ_C1@_ \J&/U!
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MX3=FI[5I*,]&AN&Y(89'IDI\H.ZH9C)?]97D<K>J_))5RR^?4FNT<V!_8=,
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M41)>\Q#VVVLRMN7P1Q]L?,YRQVMMF3/X]"EKS'Y:FGW#,$W1/N=],$:'6HS
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M!J2VTQA"S5Z>FF]XIQ398I=P*;\1[TCLQXG5A<K*'PSL>#0ZVF-I8]+91:L
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MUUQ^0+*TN5;S?XL0S]D&=")"]*8C*Y6/NRX3C4-$TT@$M:&X-XZJZ38MTJS
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MRH=0GQU@$Q7D:9CN;KJI+T5V\>HRO8S+-,\.E*G?ZL+L['CMI@NSY^UN;S_
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MH$1BW.A4F4G,,)Y?<F3(0/!/8["'*^.%@!^0&S,OO(7(D%%HEO#?_ZKACQ1
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MTJ12-$>*D7,)*G>=0,G$YI6@*&F/IGE=D@BY.^OG%;J6AVPJTJK:V$LSW,7
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M&Y 7/^8+OPY!U!\TB#H4BOC.]A#-2.#)?AG>O.;RTQEV0/9!.T-N;QEGC!'
MVIV'#:6'C MN=)#7&B1*&BFCSHQYL/7,_.#=L"%X-+CROP\]@X$0I]6Z0=*1
M;4QFTJ-]L"&PK#FO^3S'G-*8VLJ@9S%&81-CNWJBKK@N%2.8EO52B9UEIX$(
M!IS1C48+6(?_A"LS4ST&)AN$0XKT<!N^_#;8G/LTB056(%FN<G3E4_*_6S"
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M-US!+]J\T?[.M]RYG_V[-^#P?6=PIX<"JMSYY@B4__F V)/O$-F,&];^O,&
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MY_ ?.OU(F22G4E4X!LA?O %)%HEZ2<E+-)LP=LZ*5%IJUER7PN*N\AJH'NY
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MLF3&^%*254)X&ZL5S$L*XW(@$H*4GF1@Z@']P 0$%@OX2UGF,XSBE>''=^_
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MJ\E"..#2E!4V5@I+" BK=([=N@G:^R*OT[FL+41X[XSLD)2*Q&%5<'X+10/
MOVF"<VJP+M8[65>?+V*D7.H23K4PJQS>H+,3LC.HX _<=F/C[K%[A64[]0$Q
MX6<P5%6#8L>9WZG"_X2S6)=)J;>[=;FYJSMF)^?-6TY%=[K:J>_2!VY\5=,(
M?@%L/2D^A2$-.918XB"9[+KPM(?A)(7T**M3T%)A%C5?#[\KWKKU.M<J4EE
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MT09PR0V8PE$')_(H)&B=1.0Y6*UY"Y*1## P-&K)_Q&[OM^:OX$_D:FFZ2>
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MS(GN<[&;]Y?N64?0-NYAM]OV&GIW)V[<F!!0V-H1$BN!7\ZGOY6955))2$:
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M2O'CV25O04G(!)6/6H +MMUIC.*A(2_:K3&@2N%>R*M@'_F$.0@]03D54Q9
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M/.IS5D"< T=T]!1C6WHD6&>M5%<::,3\8' G$06R [W>H2<0DH(C!YT2T)@
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M(LXI0.)AUN 8;XGA_,6,HHB%Z!Q2;#P_'*7E]@)!7)&ON>Q.D?<4G],Y; G
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MZ%KH#<A^-]G7 6$LSE3@H9I^+XMLZ0@LP[?C79MN!B4Z5$SFSY2A] 2"2OE
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M3B!J^W#LR9EV87"[]3NS+=T9V]JMP1S'(!LU7M]E\@#FPC@/>(90\P\CB-<
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M%HSY,1>F;_=RCS6W'E]S'&-&8D-Q,$[8L':6Z-ASE@!.^%@#*&0XW&>1*9?
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MN[G^\*O83?OXQO=K6RM@F_VJ0@BH56QL5<6_TPKDMY1.V>&Q)?73F<\=8[A
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M&N9BSL:YV?.&)/%69H]@B!1D<34W?/9H^*2W;[7<]-FGZ9/>QM7W8OQ\0EV
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MQ*:6O8A-TI5GST!/W7!)6\;5WXJ,RYZ+D[85D_;6-]+9^BS':W*8KI2#0*G
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M53<E77[]N)??..[E-X][^:U,+G_%U/#M;-]-\3"@4J)1K+0VZ6@]+'Y(_3
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M(? &T'%Z<B*'A;_\[6=\6CX?*C=%YVZK6?^:=DTYU[0SRQ:VZ+U^;KDUSL+
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MRZ*.0=7402D]AG6PO,!4+)S:*F;4'H,%K=2,X\"Z0Y/#-_!:?6\DU0GVTWE
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M%7@ZM])6D(20DJ>8\>-]^2DEH;(WB9SGF ZBLE^U]49J$M'"%T[,F_2;,_*
MD:CK+$V,-X28SDHGIL;4&NZAE.[7+Z63&7:MG-Z,\,]+9ZVS:N6T-LZP.$FM
M%1'H(SWEL&F]L( FP(DYH LB74/S,%0&7Q0(N*J:C_>@\2IU^H&GO^12:2T=
M_:4=-:M23<SVL*9>?&/N8$H/(2V]INU8H63Z/*^$/N>+>BB>J#4B6/R6#'5+
MPB]472=AJD@G8S;*H+-H(20(,/J[.?)+1Y39R$],F87Y(#Q"0Q!.NJ(FNY &
MC)"D6J:C1C ^>FJ?<]4PJ6FW$0XSU=XLRX_D_1H15DC)?@SA _/H:E(:9/+2
M($L,")Y[O:K,@?,8PJ59<&"S.!A-,-I*;5S(EWAT!(>8\+Q6\2// Y]JN0ES
M4BU8,L0UZT83ON/U89D76C9+KE!/:>8KQ&8L-4(<WF%UW</$\K3?W4BJAX_^
M@=3U@>SBST3H)<>-=UJ0'DV^&+31Y VMOTG]T>3E(E?TW'%IVZSP\E)%G#HA
M^@S)66PV^,6,9R#*L-PQN6:QIT)-V&(X?//0=5&2I:I^G_00;4>C2(?*GX4-
M1+W9<S$,"G[G(=O#BQ 7<\N;QXV+HNI*BO9!+@2+Q-#1@"O(3!0-M(K61-(]
M\3FTT%72,&5%O/!;06M("XK ;^$OQ[JQ.N+52:FF?47TY!BA=9:$TG2S-J-K
MV11=RXDSE2Q]8=TGYN_4YD\V;U:??ZJ]S4BJ$F0/@S1)5[]F'A1 ]FS_B#2[
M-W$(UQRZH1;_,%=B[^@IT,4*>VY&E\?QC6;HS>/510F2*ACZ=^D#+40GTDZ.
MY:7IREK)QR%%5S*I*P?5=Z3?ET@$8!<#FQO"ES!BV-TXXNG4*79J8*N#J3:"
MV#ZB08@K,&<Z S>47K_9PK($ED$M-L\3WV6M!LPFW,UC\D4Q:D-Q;U)$M2C?
M-T3!R0*RD?,:YD<T&(OKRZ%P!&2.;-D6$R 2K;SVM8O'8G!(G99C,BEW\U![
M49Q::Z.GIE*,#)6BX-L02B>R'IG #B-2HS'H60*<=_<Q\]F:][]G<1#&6",C
M-!PUT/-"&E@-1DJ-*[W-5$7].)X 4/;,9>JSY@!4YJ,5D#F9U7(99FR L.I"
MZK@BJ!^%%90&GC'4+B@P.+%LCNX^8:X"P^-KA'4A&_OB7;B6S-&^B>21Z0UD
M=%W-KF]LY#'-@$D3T4Z=N33*13^MBE2[*NSZ%S4P4F!5X0G-&\UXM<E"M/!O
MC:*CDMQ$48*D*A68<O],)]$%N$.7  ;I@H%;L@DRR^"2WTA3:J;?")\>N?!E
M>C =N*5'.HA5#.3ZT%IJJ67\9D^:"C=LA>UWNVTK;%8K[*!MA6U;8=M6V+85
MMFV%W9]6V+([80>[=\+V"^Z$_4HS&J*7K_"FZ,:ST0Z<H9U32@8[S]OT]/1E
MMS&E[(?7^^K4E<B65, +QR0)=#"ATO@>V!*Y*V_V>$.6K<)OR[[15"3 $ %W
M/5>F<(I3\,&4$NJ8-%3.&HWB:<RKKVRL8D*/CK"<]+]H<7B1,J. @O>B*K>T
M!.)C8,E&5S!OY$JL%["KC^$_9LB")P<Y7]4T[DG_:_XAU.^UDP0"NJ%<1V@)
M.%'<\S)YW#L]6JL?BR3?O#GO#1FM"I[0#YFWF;LC0:\T0C&, @L+?H]=QV/&
MD$]BE9,:XI#!K9FN,YZKP26$. ].WC4%^FDH9B]C&7ICR+0J^LB;0MV0Z JS
M.5:8&5GFR$8N!G?[%[V,Q5!'RMS0/DF:^9DA%>+C7/M74^PVB2F<I *2&2[%
MNGB-, #2K\E:XT_%+@].&DV)OQ_UCPI?ZF?+\4!M+:PX<WD93TU?B'1]UETU
MD DL^)$&-2))^<$O9O X?-/OGG;Z@\M._^SL[7*G\_RG]%Y<-H:3^V0-$X4]
MOQU)HC_E:?'I]7[*/BRAMCX&JN1#TUOG9T?4=CRUW)"N2INR]HL73X]M/SH6
M'\CR-Q(9^PW$X5(V!Q* XX3O'L,K8L_A;Y^!-DP/: /U=BX-3;G@Z^/5.SAO
MU [.CJ[/N@M;V.UF,RDG6Z2(KUS-?85:6]:1PL7F!\EAE>^%*D5-2L-:[X"!
M_B 5^@DT*&@$TITW<*"H.?&<0\[">4_U_.AZ,,A_JNO.*S_')_Q\C?G_&#@J
ME*]==76;,^)EH\CX(O/ UW#B5:.V<+F2$_->WBIFVY3#+KK-Y;"K7!Q6%%MM
MHT@7WWTG\)3B /9%A06Z^UL*FU[TFD3C0%#7%QMRZ46_43OH'5WWSIK%I8/&
M<BG<W:K3*II+\_#@)T0PPQE3& 4*?#Y"<5<5F1EBN3A=&? FJ+L@> '[_V:*
M_N?=^-:++._1&0HT_/!?3C2Y]:B)THE8<C'I,P;W,V0,1WGXSPN(VB73I9:!
MQAG'Q\Z/XXECVPP^PO][/(8[/[X"OC\6V9*M[GYI<_Q"E/>0HQ=YZUDW#(E4
M$=W*9CL!1RA$-+.-Q4B7.1?I(JA%%L@H%P<D).S$-^E>86I-"*G"CTY*U:PE
MDUD)O! XUK-Y1\,0O\6"D1,R^ZTA&R,PK$L@BGIT3=M%D\*]FQ=^;4B 555U
M:0'-3BJ2+PJ]Z'8"%CHVAC9%M6 R5(,(*V!/#GOF185()Y')K-&$D#./F6>K
MH+]LWUGL.(,[IID(SA,.,:2">_YA:E]+.L 9K'Q*$Q=245Q]07RT+"Z%:,H*
M7(>H^!?ZF:H:^6P.&;JE&+ H+.,EV43 LI),]>VHKQJIK^(DD37C%\H>I%0B
M%F=:3ZJ*1=EZ45([=?ZWII(@YWO?,]W<I/3_U===+:E!9%H.+!6]%8_E;VC>
MBH&K4#[WR=!:-9_'F;]K(U6S3M. ..J&CNLA.\9RY:]Q5L_<2_3W+QFF9*RH
MG9>Z9&XZSXE)*5O;X5W6>K,=%?_S64./S*.A@QE[[VAI<!"G3@0G"#K&L!DH
M29\G\D5*GBMAJ85P&[/T$%_JHH#SP=F(9?=QEVQ';<DO59#T(F4)=''N5PI;
MRR#SEFP@V<NHK&XG2&68N>TEC*NYQD:\4B:^)@ !/1HJ+8KCYXR<J85#*,4#
M@ ;X9#&^ /X%WG*6M"GK?Q-%_P0TZ"V0ZA(CT-+L0!,X86_&3*ZG074-=^,O
MOJ>ZX#A%EF,4Y7UERB*Z;,OT2C-,OM=F$25"0(PT3]HP]\1$RB?IM^"RJMQF
MB0F>#*;D(*X\OH&Z.$#761?82^XJ$>0(VQ?1U$H-YV+D!*-XBN,E1_0+DN^:
M"SL2H4V4U[&GACCB"N"9>.4GQNTX\Z/+%H3-!<P.A3[2GB2^V$F5/9'HM^.1
MPJK(_ XU,AN+OY>8Z1/G<<*#39IEY7(K+.0]Q<H9YW^$LP%52:,7N6&&.]/_
MU$D'E<8Q98)PJ(@QQK(L'A-S0AF'X*@W%C9G'T?6#_4GJN>2>&W:1.S ";^'
M)H8ML",MA0[)V[8S=JL'*BB48/N,7Y@T!/&*&=J-9-[A!!2^6(HT8/B-</XD
MV"1^X%A\%5>/&0)<20)>S]^%,6OO$8W?Q8K,@!FK;,>:.NDV; VHO+VNU[;7
M9;77G;;M=6U[7=M>U[;7M>UU;7O=0C'X+AUZQ;;7?91&[ZT7@D-.2=)2_/8U
M+]*]]:M!K_76RV)1MRYO71$ Z!A% 94ZZ(6F*_(R3MX,17Y&; AK[#B48SV'
MK)C443J7U#IDZ>/:*%;)XSO*3_;EI?:\[77YN;&*N0;S%YA&G(IGOF<LR=]I
M09^9&V<@D?+X"X_89.7V%B$L90'1?'B+TFI@W1-4T$+L:TF.+YH$?OPXF4^K
MT:P.*ES!MXF@R^(L I&="^P-XBL53."HA;+S-@;FYY2J)G;(D*^J%>*]RH)B
M0L-FPTC7\2LQ$H=6R!/:'-H.^T0ISQLX$2S0*J]EM#F4D+?(,C]E[;^%<+Y<
MR3?$0CBNT4#0N%"A?JMJC:EO,Y<"X_ HZY$ !N>D^Z_(L%4;%;7P5EYXT?R\
MVO+6X?,6P2_RP<5)ZHEJOL,EUM3)ZS71+PIFL?.6Q2I@,8SDU\9C[^<MQ/FJ
MPJ0@C _%F##O%3O!EP5SV$51KD(_9W7($B/%<&BN'#7I9'FH)J$ET]05G[@5
M_4M>6)$IH;$ 5!3MZ7]?);=#\]%Y8D;@A(3]+(H8$,N)U[+X>NF!<KU#W\5R
MW9GUHH#>!4HV/E?T^-!<$N'8:'\5]0]QA*4L*-I.S)MQ1(#>%!$PM(B G"TS
MYTH15D_$'N%.YSAGA,YU,LD"#HIO?I&EM-%&XS%O.$E6C?47AAQOPV&NP-]3
MH.%S%9@E.^XKB:P&;KPJF!LO*^'&.R_IW:$QFPOAIXZAS7"@,EDG"-B3/P()
M^V+:#+&L"0K=G'/PL5-HPW#1V+1] FSWDQ$_5/"E 6:[. T6ZZFP"4J#0\>/
MZ5$SG%TD!C6,7CIF&(\FN"*J]+84OEK"]W).YPN5"KNPA-6+-ZH*4S6'Q'O=
M@FG\JK7I*K#IAHVVZ=:+A5=NYO5Z1:<*NY6HEIMYHTHD %"\SNN*I,YSRI@H
MW!6A7AZRTN3\HM&"71>9A+1\IMV<=;6H\.;7[BQ59FC8T6AD2;"P$QK=H7_&
MQF-)&&"+@M+#TB2%I[\/(?_=?%4RJE.5?)"C@31E@B/%B,D7'#C5I X.']+"
M:]8@1:?+>X7ERU=JD-OTF%ZV>/^V;Z24AC7TGS350< *TOEUY[WB'+;'JY#%
M1:><>X7EG%>[KOGXWI">'\AJY\G"B$9J[BV;#IEM$TRW^KL9BN9K.QG"-4%+
M0\:/.IN3DA%[%#*!9[T(N!GA.A.F1A)NF3";LG,:G;^R4$JOZ-1WKS!LH95'
M]=YY<FR&%?)$-4Z6^#+F?:'U?>F\F>IQ$HG6.8940E$;]3Z<\!JB*G/"R=(&
M]@-K25IF[&S6I]1O^Y2R^I3.VCZEIM)WV[S4-B\USWEMFY>:W;QT .35[-"(
MVXS6 +V)!N@2/GCRMC*:K*%W[FSWWKG=1P/E]D.*KCOL'4+A8?/;?OIU\O9[
MIJ>U$0&D[0-2]%]TE6&OP'GA*_HE%G-C<TBIIN^Y+X;(?!Y^"++H4K9>8Y!.
M#SH=U*2";(J0A;+132O/4Q'<>9:;6$^$?X1X?[^^BK:'7M%%:KW+EL]> 9_)
MZK^))5I/QPR!4LTP'F*Y*E908';-=37@+X[-^6P%MDB]4,>1Y,5LSI7![3S<
MZP>T'(\YE ?2E^51*6!D$118WC7JTRH[YC".%G9+:_;=U"=_A76\"M'1+[KV
MK]<6_[TVT:%XTHG" B2 Y%'X"<C,IGD:R3/](>R+<P0\=V:]S-L%CF<B0@UA
M$/LQ(@!3T8 +TLK%3_OPP&CB!#9\.8A>*F_EJH?-BRXV['</@,W+BE ,3C9@
MRY+<O31:;D9L88;AP7PT7X!36@_5%UV.V"\0:3<G[$*"M"M'NV!MW)A#C =L
MAA6SWJ,A4,QI9!%6&%@(K8#@N68:[V,!K8$7[V+.C%=<;5)%9>H+M9T05Q)C
MJ4)H#%GTS+#(X1D<MY<9(T,LO;+R!X0W"P*D7SBZ36-0SM<*X"4VUM'/&>-J
M4;#RCM7ED]RTJ?8+].R'6"K(;"!4= >X.^'3G(R $?Y(JNT(?D(VR:H81T*G
MYQGZ\YS0Q/[PXRQF2U?]:" YU,8WWTDU5WR.$,F\7Y#]29V,?AK*F2_"$+7H
M:-_ .WI]<PJW/-$,*B45>/_7FU[_F#YB?GCW*7S+71LI^%=)_3T5^D77/?8'
M!\QFPT+9; L60U]=?Y@A>0Q9-A>?;<-$LJ%#C?U+]J:ZEP,V!;<&E2L?_X>C
M22*X3<Y&)P?-0T57:O8+G *9TW!">J1ACL=T?1G=YL8BB)GV?6LV<QTQX"!T
MIO #GY,W R,(;2^0O;<?O]V;5RDXK"QBQ?%*V50I2<K()L_RZH/KH:JBT^3]
M N=%YD5!P^9C$,TA'V^4SO5YH.''5NQ&E.%+A2T4>  5F/L!358 [7W9!27]
M$L+?P\BT8W9B_L-_QK$8'9J" 5+>PO_B;,=.BCQ7+82/&@4"%\OA]<8XL!3'
M;Z%5(T=QP3_X-&?>6LVG;(3)F WY-A"RL><ZWQ$'8:Y:6<,V2.V8TSOQ&<9C
M#HV6B\Y0]P\!"*?Y)1^GS2CGDJ@$#JN^S*,>?BFZ%*#?E@(</'!4)K^L0(YZ
M):Q4=+:_7PTF3?9MHCTD'$."@%%^73H"R7OLMH1'=L(P9HN04 H:YI7UX0V*
MSOGVKZI!GE@*[:#;JH9RQ; H8/&V';850)8I ;)$GTDZK#[W<"1<8R7X24;W
MZFMH2AX4G8<<'$(>LOEF0*U80^O-@+6IJE=<2STH.@DZ*"P)NEK:1QN(^FQ)
MK*R#^=3FG/!/4=")^;!TE$'UV#[--""*SF0.J@$>66% B-&S!E8/:?A.[;VG
MKJGP*1:-2:T==-#KK*%]3G5&P1K$544GVP;5)-MNEJ&LZ@U/!C8\\?R#0P4/
M\"19)61WN(9V-$ 4K;PS06<6$V5D=H'>X80@LH-';*D*S!'FV5R7_\!;/\(3
M4UN@D5J@OH;DU5B= 5]73Q:Y//7%(4% <P@?*CCM+,$HZYB/OF]S@%L6/#DC
M/&-,NH2&RQZI7CU@+L^3JZ*-=<&(%N4E ^5ET**\9*&\G+<H+QM B<C%50M@
MTH*]M& O33-E6["7%NRE!7NI/\SYVL!>SG<'>SFK#.QE4'05VZ %>ZF"M\_K
MY.V[\1@\PR@]G7'E8/1#K%P8%%TT-Z@&UF5QP+.7-6(&1).!]JA/EZV&4WDL
MDL6_3FC. A:B"ZBB&FHZ;CHV-O/%/&>'RA:P2@)+/64 @6'=YHB1U% @LM0_
M/Z;/IRHI1"6F6)!XE$?Y;8_>(9OMZ1&12\.Q+%KXT H=BF10U2<<S%\LZ9*G
M)XIOI&,EH3.-W<CR&%CL[LN)\:"P;F&3\(UC7.84SA<+5;/VA!D;"AW9<2 S
M\X3W;058^QH'(15TJ ECHK@#6WHI\^.G(T;84XS#?PQQZ.Q)'/C0\KX'\2P:
MO?"R6/#RGW"R$/[-]]C<<T_,6SFCC*"HLW;%BV]'<1 PZGVPGBS'Q3UU, )&
M>X;-&4,FF.R15H+G/8XC4'U\;1UQ4SB8"<\"/LY;_$)Y(DG%.E^":)G07L=7
MF'X(;RFD2F2,O1G/CHLCU>*0I?&(>1!M:7YC7P50T56(@T.H0FR^[KZH4W=C
MLAGHPVZ(YFY0XJ+H0L1!886(*]4Y.%3$'\BU-AO":JB&@ M47(CE>,;0CR:H
M)#F\^\])G1;-'0+5X''U9VE:3_L+CHU4PP9 T?K4":T^0+W3CAI(0'H^1 F/
MW1CPC>$+4%L01H;-L'N)VM#F5&SRLB%E$L3L22U[#4I); !^Q@]ZO@<2)=E\
MDG.@3F[U+:$ZX7,AIQ[Q)H.2.WQ!\$:NZ7C':>C82=/'B?D^NQPSL[#"FE&[
MJH^/5&WCJ*/Y7)#T<:-IL_8,L/5J9,E\XRSP1XS9RB@0S\6G93SI593AG19=
M 3HX!-2?YNO!RSKUX*VLHK;,V'.$S0MV[O[D[PLE^=/"QNVM;3YT5IT\SB-!
MIR4T%D4?'T8LQ)]HVK/--SRS)QZ+K:=>R,*W4C[JC\9/*$^5WIU6-CXVN:)N
M(E[\14NXZV-WLL9YZ<WD2THY<;@*=MIRQX=T5*HZ*ZV-EA9D&ZH,<'D)(%>
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MF$<.)7*&JAGE'\4=(.+,S5*$0<L<6>$$9)D7AWR$,*\B/$9'E0X)"&4N"ZU
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M"TN.<$Z.0PXI<+4#+AT*0;!*B6VY082=,[":,"9\J  ]T:F/(Z=IFV.X*3\
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M7;1'EDL*G>[F>E2(Z'2)V"%%8E"\COO=&]B\RWZ)]]LVI;:+:;!/60W0R.#
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M>:85S2UFH_6LUD3;].*>@9YIPW3"Q3C2"270X J%3 F;P3WQ?\/EDI(&RY'
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M@\W2FN,7[H>";)0F!3.:QR"[S;-F]TQ>FKT*%X=A)O 3,K67.G3YGYA$QJY
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MFD$(6W@9G,:#DR 98?V^8^BG8_8O]XIZ?T%X@=1\M:)F<V\ESNMK:^.J8L7
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M8-Z7*BL"V+2\#FENL6<@"Y:JZJ9M[TEF2E%'<=@%D.U]%4!NWHTQDU;%+)1
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M&XX[_Q"K#K#B#S YY0$V=I_@+VFP]@0+KFY]"_2 ]))8 ZHGVD[!<Z"VBW-
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MTU<L?WD5<[@<%H(CW9V ?"P$DZHTGBQPUW&9!H@>+]3@:M,%Z:O1GN4/0&4
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M3+)!_TKF%&>0S6$9')2?_=O5YGLO!^QERVK29OFL41C^FC;*A6D[P2/'AK7
MC=>=/9B:*&^IL:J]>%^?V6QRIOT\>]94E<%/^'_/L!G_K(5C\\Y^^Q5^7I:E
MGQU(H/5W13,DD$Q_FR@.YG- /Z,*;D@&<Z03_!_X[INIOUD:PI]]<=1SZ=G4
M\8XVQEK44^GDGC$))-F4;DR'27+W\?3@8T4GZS=P/YNCMWD#K]ZWF%UJR(,<
MX[*'SZW$Z@)'+JY0%^\M&AK14R6/*1Y[7&F]QMF?OAF2ONFG1T)8Z:-NU#>E
MYE-R7=-*K&N..?2V4<_D',NH(A7'MIB"SAA65"Q#*%J)QS"J$,8A+:;X,MT;
M<*DFSXKQA (B317-DEX4W24?;$J2HRDZN&'*HZ9KCL:P)P#=>>J45IS@%<XS
MR/K3,TU9U\!1LR3=M(NNO]OD&64KP L9*8D,E 'BO&R%J'>Z9TIE*[7;@E+4
M,",WMVF0WC>MLN7HMJ 5SD=O#-K;U.Z>EB<:>@U$M)CM\(BH;BJ&+3FF#[PP
M5RS2,-3GR.:FK3G[5A_9LG);,+I='W7D,JJ/Y(Z&7,5 MXN!7OT4)S'8>DQ2
MM>D4=@O(CTWASX,/\227H'85%DNHG[)E;K;03QW$:JZ"O8<;N"ROLU,MIBJ&
M+&_0>@M=V:V/>JW-)OL[B52O9\[./:H>>9\)$(@J]F2N3MR"/?VD#F]:]A1T
MTD[CP[?I0K051N4A+J;X(.VU;;LA ?%#)HXIO2J6I1B%1TJ2>V^=LOG_R9?>
M+=W2U[I_@VR8 D+M8/+=3J:5>;5/<W>3J8J+128+MNR%K?ULO7_IV8I%%>5%
M"$B\>WL'MGMSR4TE9_.P61^5?Z8<5DPS43-ML1E3;-?B4YS,J:11.S[]A=E*
M/S^IP#7%GX#KN9E+_BP%-W$JY5;)LS*(?B[N7@IB\5D(G0.%'1ODXGZE(%<;
MO*\$-7;E/^67/"O4&A:SYVQ"ZD0'[;)GA*!!-H"&]*P%Z[R\1_UZ4NW8+!J"
M-W"@B+*#7/)"*4C50V2[DML6*_.NR^$7;GQH7K$"EB-,S-E,(QSF8X?Z&63#
M24PO.OWZ2$X?YCOVQ&]RKZ=?)<L3"?9PQ\&2(<[8W%S)4Z6+CR$&7*K%''>Z
M^&]Y9+N*3Q2G4!0XO:"[>19%^=MTBF?-;N,&K29-[6QVTT]*?H_,V6V4HM6D
M O+F%N5HJ7J\?G44H,:H5JME!C$*/_)?KNUHT[?%4^?PD-_H:=*$Z;I8]?_6
M01]M^=PSQYS3L_T//!+09Z^:ZCSC_9J_@*7 Q<&>*Q-X*O[BYT=@^.I#!.Z]
MXH5J =J+9S0UH_[K*.;S<[FK&;&04; 2(Y1'GRHS37_[L.G5><Y=^P_CE*J/
M3O[G]+=?\6YK'5)_]2CC4]-T#(0/X/+V5^<O[Y.Z]'.F?] 59 P8X=_O\USI
M'9OH"KB94XVI_I(#R^$O4"/9] 33D_X;=P9WG43_1M>@)CR$K!),_WL6Q[0)
M0W\Y*,S\P7D].?YIT>?\G[,SZ;/&=/6#]$UY BUVS_[M8F(/MGV[]5'Z!_8J
MP?.ELS-Q):E6?G' Z0INH)8<LX-Z^-DF/V4[Y+/HFR;:T/71Y[/@^WMO_E%Z
M>)O#.X\MY1$+4&Y \W+JW)A(ADXG>-6OWF5$(<)<\VBSBE:/%E-^G#TRT/=P
MXSF1/;C>7LQZD:9!Z@28'1*B^(<'UXLOLN!FL?*V&^E>J*+'T?W%]?VW\=V%
M].7A\EP:WUQ*UP_WTOWW3_?7E]?CN^NK^]]^?8S9!\6MZ.;VX>I>>KB5+FYO
M[F^_7%^.'ZXNI<_7-^.;B^OQ%^G^ 3[X>G7S4-#*:!'?[R\QF.\\FZZM&*HM
MG;"?$X;;#F<M2JKB**<[)<PJR0@IXXB?P<#.F>-!9+DL:A)=:O9$-S$!>CN]
M4BP#46Z^,8O&25[]G,,A1 -6 E91K]WIXZ&=CQ$19Q],3%U7YC;L<^]?JTR'
M]2XH*(9ZQ*P5#^S+\Y]Y'JM":"59_G#&A6)A#:SSU1=2G^=2OMS>WTO?KNZD
M^S_&=U?+ZXG8G8=D=683F(WBLE)4 G9[S&\Z [C]"G66&V.5\R 7-TO4>KV
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M>C,O[!A*YGUX9A5!ZW"KVS(UDMP],QL;&Q!9)-$& 38.R>Q/_S*K<+-(@@?
M*@B]L]VV1 )5F5E9F;^\RLA!&3DH(P?E-L3<1ADYD!%9;%1K^6*+[=.+3J7:
M3ET+6B+)!^9WSEARY_2B6:G5>!,[2W[GP.]\N8T5-+5*K9LZ)[.,')0H7JYW
MU=8X'NU[W&RFCH65 +"0HG,$"+B-/91;9<A):L$Y@MC09(M63X"V>+R!Z-'I
M9KR?%''"Y'835)OE!%7>!-5..4%55/DN)Z@6<H)J;+9U_%ZKGBJ>VB:COI,8
M4?E =-4AHWO5<A;\J90*@8MLCEZ3A2W/D_=>BH=%KKQ.N]X PI;S7K>=]]H4
M8=[KTT/_ZV/_\ND6CBE5')_Z7^"(PMG][?;I)^7A^@L]N*!<G@(MLB8Y8>\S
MDDT:PGY2M5&F5LA3N!<@%><SS6X.,J>>1QFV6;BVT#JT[^#_1C7$)U7'7GKX
ME4^Z.?R^2>>PSH7KGA!3-#C%Z'"4\5YE@W0X4\5BBP#+Q$);_V- M1A!(F*?
MG=#SAA!O1>N#:6-1TG<BYVBG ';D^\O!M_;A8].KJG!WC4,78O^-P^S_L/E!
MF5(V@ZR'7\B"II"  C' IZ$9._3O<V+9IF$075 IRX 6%)]AN_>TMT<*IL+?
M#B%*H<A9*'+)EFC5.6&U93HW [10,T8$;_:SWCSR.?S61Z6'O+AT+0NC6ZJ7
M2K$RF,=MHL/CY#KN13O6K T4_B453,QYW*J :P1V6CL^#\<DGGG>]E;$X.V"
M?U"*0]2U.'M]EQ$U7M]R)I0T3IT.8<<"-QZ\7G+P0,>B5AZ+ QV+78KE=CT6
M6"17YP6Z#\G";',T#G:7'5RH#B%)>YW)^LHSF;HQ&O\H2D.JPU] (>0=/6TI
MX[Q-3(VKUWD) F^3/ZE%N?'F13DUJ9J')=6QYQ5LH=^_FL;9\(WI^%9Y,-*2
MJEV2*BVI.F^>5(>WT4/+ ?34<'OC <O+J[PA-;DJ^9Q,=#V:3%U($6H?POC<
M.M,0=&!K,PY2'O*#N0=;<PA4;[U9LB@=B_8;0;PKB[JG%]Q<W;?)H=1&13<;
MQV1EJO(!VIZ4J44'3BUZSBZU*);0^&2IALT.IOV).*^$&)%$&#CI>V<Y;O.&
M:$92!V,1AR-H=!G<K"3EG6$ZBF8,=1<E5E%G.-35!KUI#RWM&3ZH&<I7TR%*
MO3E\+UH.TR&86J8V;1-?SZ*?T+^):BD$;/_1<LN@,L-G?_H*G"F6S6X/E!<F
MR6[K$F6@</MUI/7^'X@-FF(X551C!!=4T&#*GT6[.O]DK6F\771WC^#M?LTJ
MZ?4V)I:-)12,$'UC%.FS]61>P_7H+*(IO=$[,9WWTCN]:/.:,VQ1IK\A0"\&
M,YH2,*,#-E"3US"R:,S8;V!83LRHH;;=C+"FYH8PJ"KVC<-^C3/-,"T@$YC\
M;&XZVOZV^VQK(TVU%L6'('IE7./ &I-E'J& #<9WGGC=>M)U:SP&LI7N!-9Q
MP%^O6X)KVTIV:W5::@FNO15P;9@3N'9K,,4 <M!_-EWG%[*X"ZH([OWZ@;T1
MMJU?$X79NO7J00O_B$'&FF.#$"C?R2)2-1$63"CO0I1MI%ED"&NRQ4;4]N%D
M":N5L)I !"YAM1)6>W.PVCX^X=2TG#.@Q4QY]BZW-8YN@2LN]@/M^#?FI3E#
MP))>K)302.?KV5PW%X3XMD0ZEZAQ>M%IEZ5+A^7Y?MA@YCQO8C\XT LEUP_*
M]?U R,RY3N<'];:#@X]1CK7Q:HG+V#KA22N?'$YO_B#O@>5BI*_R" ^A,B:8
MWV(3HL"1-A6#9K&TL!>;I'#?H>T4ALYNUESAKV](RBS(3AMK1S<KJ[>"U&8#
MK&?#.LPQ+EFW/<B^NLC].%47Y4U<O,5(=!-?FK:#867:!?7L6;5IUNF"C823
M5!<<%RD .E(RWC,JIM/F.(*CU2FUN1!^_TX<[)U>=,NF &*X\+LPL%L]O>AT
M>!.NRE#\VPS%CY9"\?"OC)J!#PSEACQ;KFHME'J#]<VL*,Z4*"C9JK%0:,R#
M5GHXI@([5"<681XTK1CYF8S']O_[O]UZK?-WY9-%.YQC!B[OYS^9.@J$K=P:
MPW/E'?ZV7OT[K/_2I#^B/ZC]_7U%416#O.J+,SRA\.[7*?![H9BO!OPES#E#
M^X'SGHHR=RW;56&)L.37J3:<PA,=NBN,7M-*%EBB.S<-^D.$W=BJX6R,-%8/
M8Q,'%01L46.?ZOL;KRCADA5U^(>K(7W&ECF+$0[VX&)8-;!R;/HGQP0U1OYP
M51U7I\[GEOD#-(Y#=/S*AKDTL0$C]2U\03^M"A071K% C07*Z:P>T4Y .1)7
M3^"W-)>UTU]C:8"1;7NLL%?Q#*1SJ#W.56NH?'MDS,'/V,IOH#%<?'8%=Z7\
M90,E]KN-+U5[FDX[TZRR5G79X<5]#^$Q%2HXJ.KPQ\#5$1D3"R4"?^O;M)3W
M<69GL4/&["MO!;C+K:ZB!O"ZN\QL$/(A%G[AP4'>S"UM2&#+J$78YORZ,9!H
MS7B!'YEP.I$NKZ;U';\V5.>:H^H5C^.OJ@V4T6C]V%A[(=Z!F $%ICJFF-KP
M89T]^YF %C/P(?#A.W5!=93R#F7.TR#W=#W]8#V^'CE7^C:[*D!4X?&X=OR:
MQQ/Z<I &9 W^./F8B*A.B3ZB/A-(,BR?=["'Y@R6[YUO^'M$S"OA><?WF*X#
MVS-8KH]+O*JZ5:N([10U*%T&M37L<*,WL$OS%9\8U7+>(YTPFUDQD898)E&O
M^]J>L83E'P$/0<?#<C'3%P02+D^;?FT,?#)48Q@M YQ;Y$4S71LX!H+]HHV8
M!$1V?JX\+V)*$5FP)!,H*/@AD"("YI._[,1F<>D_JP:]JOP6UY50B:=D*BZ(
M>V=$5PFJ"Z^QV''=<%I;NVIFNKE+1HKMM7/S]**UW(/OK_[NV8P1C] )J3Q'
M@RTSPR*T"3-[Q7WDEL?-JN$%';_M3Y;/066EX1*3WKCQ@SRW79WJP<C+EJP-
M[K.]$V*?1-+_;&*]:#@2('YJ D45W(G*,SZ$_EP-M.28T*.RZ1[9S^VA_8UO
M".D;(S@=,\U&=7#-2JK272HM3)CAW"DKC$2+# G<"*"'X,"3,P?$0K&!\<C'
M9]-P;=_@"-5F%A1@A_,3OK!/7_3@K2O=IMO<<WFN/*%4<J1(T6S&70,>"A:$
MAE;3',Z".:)G&:F %)O!_??,+%90QWCE@CXC&C*)%FTOF%7>J)Z,U 4(].@%
MAS9@= OD[%P98+GV"\WV8]<H$C(J3R#L[I"I\4U4W:\)S?YRU<&>1LMRY0]:
MPCN1G:+%<JICY *)Z7W5/@'Y0Y=RI/#.J5]+N+T,[M<0YM%;P%8$ZO*#;,J[
M\6;"-)2SC5O:KX'*3EOJ\8-/[\_97+8 \H@!'M'$:?Z K>"VB=Y;FS^[Y:2_
M5CGICS?IKUOD27_;2%8YIJ\<T[=Y3)\0^&HY^&[?P7=T!6N'WRG*.S@E3^?O
M-TW!8_)Q(&E<+7C)@J#=)T+63Y>KB39/D11$]%.%%E:%$=:>]#2?O34"J+%"
M$4B,0C'KC!K^Z]&?N+6[P@.K@$DX@5N-@G/@;;H.8E=,#8).G*H&W'A;V[_[
M=3W%RGWK!<3DVEO E38>@V>.\_0&!JW6UZE4IC(C>R#E]>YRL3[N W@.CI6U
M\)$]"NL3%5'J<1KJ,1=O"2#TZ)6@(L*@L-RAR]!3E@7AX5DJ"!?:%CXW&>CJ
M+0*1LA>$'(8)U-U?-5CXC2KU-,G0=1!A!3%@B"/ZA82ACW[\8ZI9H^@'%&TV
M(R.- 5_P8O07S*AL@34Q'%)23?1%0JK\@$CZ=(CJ%AYYWWO\P.,3PP8#ME<C
M;+>]7T4Y#VJDT:HT.$TRESC/#RZMQ"W2[3OA".:X<YQBTZAT6SRQ7]YYW"M^
M82$S19U,+#(!L5!>T)'9?.YWSSOM^Z^B+E.ZW,1>8\6Y#H,.+&CAA^OR67S?
M>V>Z/31!0GGA)M4_</Y13+_VYI;:]MXRYZ:%#QV,!Z\&L>RI-E_;F&$]2MUK
MG5XTSWN\**+I/U[1M9GFA%$(3V%2*$RC"BS RFP:UP'96X'FZ!KE,-.U@=K$
M,QNH2>_, M6^JO9(_8/*QE_6D[2^*\+_A:Z''E<:C> >69 #3"KA'-PV"/4Y
M)T<KC)M$X"LE@*]4!50UO7BP]-QV0!J#0"3>&A:9$L-&PM+/972%>\.%HN_[
M J\;&+?&"V$1F73' M&^91H@!W%[6O"TM.C6ALW6=C_\!]@L(G==+LR%LP5/
MV+_OK'-E\*?2'^G$BEW!@91?3C4R5JY_^"; 8#P&\;.HW+#?W;"8'MAWWN\J
M"$33BWZJ:K!AP[\,GDW5HE!TT)T _L(LU^AMR'[BF4+1-@5;Y./L;23O^-F#
MK#1P+]:F$ZW[(N88'=+Y)-MU]L@RU8A%GCOT#-;7I!FQ7YASL(#IV>S'<XXN
M=3C:,\T856A,CCT %!V[YJ_@7/1'FO(?5S?'XS/0NX:V[GP\D>'4,'5S@@UO
M@V. I^LWHMDV_ZOWH*:U$8LUPFFZH^\\Y$&D,0>X]/"8T1\PRS,\?=&T "ZM
M@N0 V>.\5Z[E)S:@3K=7Q7(H@983V/!&G!AP($:Q\ TP< ZD#(U=GKAMZ>;N
M<VD$KP_>SN*.Z6X,?F-&2I'U2]X]RVB_)=>K_/:%%9\Q<$[TA?2R&PVXUKB*
MCYDN9!.?&K5:C%.MW>85A)9(Z%*UUW$)'.;:.<=;AKM(IVV!C% =GW  *6:=
M@04/JFWN/NO:$!4:L2+P@V>">SDP>$E\)PY%MP*@!&VZM>2I56N[^M4^I#08
M7](4KJW\:N#GZ46GTN[5ETGD9X0%3G7DWK((V(@VH3EU)]OL+)TOQW8V"!/-
MHEE&Z;RV>A6\Z=YY8UFK!-E%T42VI4RC8+.1(EO:*KZ;C-;NU\.*:TH)GZ"^
M0P!E*V-S1?0EE_SU\?D10RW4$IN!$&KKS+>D=_,)O9OM?!^E[SKFG?J#B3>3
M[.?WYSX/5H=KWI"4Y^-,Y2G;D^V<*;C^^^X$_J;4&KR$HR6O!^Y'M%!#L.LD
M:N=_\7Z[9.-'-/(9>X07 ,+K]_'R]@P(AQF($TN=Q3P'-D0N++R@=_:]J2\L
M[4^XB;XXHW/Z^9/X"HCW#07N93\)V_]2)/LZ"5DNK3].#5B=0;/(PX\")13+
M7*BZLSA[A@L%'E8Y ;- =Q%=J6!A@;=A*N^T#(Q:O3XAO3>S?2H<8H;+O:4W
M+[IUGA_@(TG>)Y?<"IH/>$+3W,$:\G\"A\X"]6,DT'1_0WCWCW4TD1BF#CK*
MC<"4FZS ^L[VNK^ 6WQA'(A<:Z<W3R^ZU64+D#F^C#>:'RBSX7&Q:@#\C&:
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M6YK#/1UK,W'C_30V\&!OI_$W3SRP;TCJ^#T(_T6KUJBT>[R\\:.IQYT;/1U
M/<)I6*4>L;8E((J'9\#BUR*^]<1Q0J3EC/8<P'6?C=3%&6(Q9\2([\1GYS5]
MS15\*[Y*L%$3&$<OB12R!0>U"DYT]:;!DUK-WLB:_3I/_49GP9!1GY7WW*B:
MQ8H$G#NX]5V+@>"P6=H@X9HVXKDU;,=R:=+.9Q8B2Z=8:'.8Y:3I\^SSJ0[1
M57#G_&;*134(UI\DCN0Y6^"*9@&Q[HA';1?0+ML%\-H%],IV 66[@+)=0-DN
MH&P7(%6[@*TK_NO[WT?\3#GZ[]IYO:49V#'ZXC-U='1E\((MB>"Y8##@S>L5
M V"46AU.,<_$#H.3P0<^@MEP<1++O<LCOR][RJ!IZMG.7EXD\UY8L-5T$8H@
M(20*+I)-X0=P6M&7Q(@O;?&)#F8 C"BZ!O>ZSN;(XV>IOM 7L1Z5S\1Y)<0X
MF=%,<.;D#[4Y-=N]SGZST%BFH=OS0I$>A/(:SH Y V=J1N"2&6%]TH**6HX;
M73_C.?TPYL#)B;@X@_$73Q(TV@.,,X>Y6VWEHP.B7JU?U3\.I/\DT:7!M?UJ
M)&I!TR_4_OXXG)H(JPSN[_R.JH[ZG98:(53'&NAZC4HMH)5#*[IL\%(HG;#[
M ]'-5XKJT("3U_SOA>H9,JJ<! 5NJO=#6F.!C72)Y?7)AL/QSDLZP+1"VOH/
M3T<D(8$^VR*TOILV>W!(V#DDDB$ 7Y_1+"S[8U+BN$;JX5*.\QSI+-WHV:59
MS0R,4][6N&$/]\F."+G,Y>VTN6,MKS3L$POG=8$^H_+NKTLCZ8(9CFE*/OBS
M,]>.\MQE/N9.D&5X76 7R"&H.7_S?3O,AJ,0YH IHR3^M3X;KMXZO=AJ).:6
MA!*, SO$U#+G0/N@'-A[ZEGLR?Z6E1<34\&I51HY;AD-]LKR&$6RI[%7%MO>
MK\'N]N!CY_2BLUSC*,BLM"S/178D[1Z I/E.?#N]>-#L[V=CS(\*YG_0M&BQ
MCLVV#8]B/,8MWL ._89'#["_/;B,+8O/.5$8"8^.0&1MT-S-VN;9]H>_3RZ^
M&12R0#>);L";,6&.EPKG_B+2H=A6\24BE6'_*@[7ZE7,"=LFR-RH@6%PWEC.
M^I#P7 A&V57A>Q%N%K"YP*K4@E0(N8^(OYD#,F]5YNT;.!894+.9\U&("+J?
MOA)!$H\O[=+DKC1:_-P5*8Y!8[]AOWF2N8T)F U.:\[=3LB*L1LG.<+'@@T.
MS;/3WS3?P:%]N,)U>.#&QA9JM*4:S6W667,5D(X)YFMARO*,=76+=FBXH[_F
M=+N@ 0N__TIL:)?WE4?WF9K@&/A0;FU+);K&.LSB7,9(!V\VI?*,-UDTNIUW
M\17!X\.V$=^6QXC"@W[W*C=IUV_5T>RQ/X!O[+4J"":-CJB;]!S&EI/[CA;7
M!T73G-E^\5E[\9[@F(+K-Q'T*,?]0"5*0II%_$P8GT:,["Q#&';F/:42YP;H
MIQ?MQ8^0><]"_J8F]9( %*:18:0;3-,_-('D1AASLM06)BD1F( ,Y\6=\:;/
MT0;QM!$*?MN?%,9_CC:._ARCB8;)"DK=V8PVZP"A\A8=%C_@YX(QIXX9MKCS
M/Y*8--9>M]OE)CA+J[0)'I>3W#:-)VEI3_%MG\!K6#M3+WFX1??LS=9DG?Y:
M.V^853>DVN_)@?8;W\PRCQ_)W(D1I"7]>>RS@#P9CUF_239FSXQ1*ZJ.KH,/
MXKL\M50Y 4*-60.;9 >#)"?>?U3>J>_9SMA,B:4.>F%CL;AZ#EKK^3J9#6=U
M(F)T$LB_7_BQOK%_8BQMT&R1UI<LS[]>$JL8:?PO/^"7 XU]0K$R^O7X)Z+=
M".AO8Z2M>-D(U@Q?Z-\LT6LL.J""Y?+&F&92;CCP0DH8;\/O%39]PXOZP+[Q
M<8I?Z[G5P-=Z:]>NC&%K#[^^+Q2">*G?MN-@ZXT.#NOF=]I_!QK"97E<-QKE
MR@TM:[0W"JTO-D%]U4DXWB39!G+#* G:-P.=G(4RTG37&WJBV<J[B,GD=Q=B
M&;5H(KUGA1PQ"3#')S%9#K@89+.$G^3W &0'B/:*P2DIEL9*R=:+%D^"3G:1
MH!V0]>SEIPM>=_6\NF:B<*2)S!Y"L$X$3O@B\'?EW?/[I&4=W&$1R]K7 9LE
MFZD9OX<VFVP3M,*C?=VBLJ".'5^5)9151$.!;IZJ+R1NCF!.%ACY</G0*_K5
M!(,::6?[VZ#M)_UKVON+'73B&9W0Z=M4GRNV]B-L0TG[[]&TKLCC:?<"_P4K
MGTEG$Y$78H1/.U?@0L0)W ZM<:/=9=AS"6%[.WDFK'?,B,S17</D2^_;,4WB
M!EK?Z^W[2*>BL\Z^=#X'BHGEZ@1>^NXQUAZVWGY>V2!V585.YLG,^S]YR^*?
M3EG\PRG^:56+7/PCG-26I4);G7")JH*VS^QFMD<TJ_L1A[*/M2&XI=<O"#RS
M.0U@J#WXZ<7W-(?Y"9[]28<+()K;76LW19GHN%]U4@:%2$J])4(-TN/MYZ^W
M-[>7_:]/RO6O>'24JV\/MU\_*T\_72L/U_>#AR?\V_WUP^W@:E/9T?XEP?3?
MK?9Y!Y4T%U>G/]2H8?)1.6,?I5OQS\'S1:&##1L[87_(/BKPLPNV<I<7$U -
MPW3ANAZQ$B(-U"+:ECBJ#)31V;/&O >=. [S*S#%S)_Y<Z?]J2JWM[?*K_ C
M%[V*6V-X'@+S\.NPB[7JM35D=46C".;O0?5/IF4B:L+LT@":\)Y-AUJHACI2
M_5(.B_C31EF[S#FMV&!U3A3P9[/F_#8/T?XOIF+/-71.6#-N=?2B4AJ$_6K1
M0</^L^#_#8E+I4!!!3H&N\SKH(S=%FB<#S_]G2XP0!:_NK!'_XMH3Z/8^0-4
M8B[.$W 0%ASO^2T[B/<TC=![J1UIQ"%GW;TRF^!SC=8O]:VHX9XN_-JC[9=Y
M+;G>7?:OM@ 04LZ#6;_4Z""8H1I?:I,FW*T>!/.>H=KTJ6''#3R6>(:($0EA
MH32OY\)^[7AH6/Q2M:=]8X3_P0@YK"@V\V8=5YHUVC".QY4A/ [.INWUY,&S
MJ1HQ(=O0/:11VW]K[/RFVPI.?:U5VKM)6'*UV\X<XJUVK8PU8+6M<TXCGD#(
M8KU<DHB>RCJXRZ[1DDWGOPQN.<V=L-@601>\0RL,S&0A[:#8%B-4>&O2"R^J
M^OF]I#:(PC%;9#6;.-X,%>6*8YF<M$3WC<1@7?<W;*UQS*WA;-PN;HN_-;H3
M!GE-\(*CH&+DDDO,0P@[\F-#]VB$)3(5GB)[*\?"L])N&AEA;\;^\E1O^QG_
M(#Y,L;.P$3P$:U ]J#ELL4SAQF#AM $Y7-.TZC2<ZLN2)KR*;[\^%H%X!OG#
M^UR=HH5TEL(BTL$Y,(#H<?#6&YA'#N?+"FQY@G^E#<U4!3O<SUS6A7N+T$]C
MY^9<T2E<6X/SS?;I18?3VYVU IRI/_R];'.0MPD\[+?ZSNE%%PP(SCBQ2A#3
M5!FJ#NQ[-KT@3L(N9MDU\[D>) 90Y%IVE1]F#G3]^/OJ;"HO'8*E3"U%8JG"
MZ/N_"E*FO+MDG:,5R\/R<HE8*_SP3=&N:;4@K2/PT#@S?^+K8?L:$74$*H7.
M:*![8SOC#ONFB0A ,[8L>G+CJ0KXD)]=>)B?EU!!#PV+&#U'DP4RT#C#^0 @
M9GZT/G@J;';F.A@+?[4T((H1\2@\6R/H-$FO6).J4^)UQ?#<P40JEF$JV##
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M<LQY8!.##.@+2K!%<+VC2S G!O,9F/X,".VEM](+-*@(1QVBZS0Q.=)F9*E
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M'H)OEC;1KM,XO5B50Y&@H_\&]'_I*Q03R^_#N'S%$Y]8*]M-]]=^W=3]W=Z
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MA2L+/2$N#)Z,M*MB+(TC.^V:&$OCR%2[+L;2.#9Z6PP;O<7+VQ##1N<> S%
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MFG*PL:43EOC20=DN.S(C#=N%&I+9E1V)$9;M,;NU"BSL9')72XF=Y'-7'P#
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MEJ5=O<)BP*5,258,T9,@"VF9@O6M*1C[TF$I*#$F? E4F)B6A@?I@=#.5/=
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MWS3)'&JJN83)@9;6# :D..D_&$C6_91LVH@_3XAS@ZGL3OF;/N6!K\71RO]
MUP"+'YLSD'.D:9_P#Q09G!S1N 8H*X2@5WYB+DV<+D11)((P'U&C !\H(+&%
M)JXWD'9$\36)HC^W-A?<B%FY**3>K4+_B".RNB9(5B$+812;^>Y(O^TC]>^Y
MM>\F!AY_N;[IQ'GR=D?Y/1UEQ*U\5 +O3NZ;/KF>1*;6%G>NR]"_;[H77:W]
MRQ=QA(82Z-<D<4(1R9[NQ>4L!BHZ)ZD^V%'#-TT-GH(=EB1+T<D"#DWYNT+X
MCJL(4DWW1G0K$?AM:4.W#*1ZGA_77)D= 7S3!'!0\Z$ZD%#HV6$LZ55Y;D1
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MP$[5#UWS%1K%:?[4Y;@D'*;F1H5P%3GS8F08Z J^^WRER^ =NV?>\5R3R>$
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M1&90Y@&JD2!K.&*UDA%WWLN^E9'D1I+WLM F/ONDU$UN22_X'&.]N/"DK*V
M-PY)@!I!(V/W<\4IEV!.WH-;W8$6A8J9(W,:J"_($'2/]B):T_M[BIK^*T;-
MD\EX(7B>3N-/CB'$W4A&)$:XU2FGW,4MPHHT-RD4;J(I?!%-DO>EDFY"$F;9
ML!3)'ND>Q$40WC&=T^P^1=Z4$\IRDR&(K)=<8:A-Y!WPZGT@4B@IA5A"C<@H
M2,D$)Y,B7A#,,D-F6D?,>XJ8<*6(:8^XRCT?$YQ$'$-VRQ& 8&?R>7;G8.G.
MP3XELQ2/R^6TCPXT1&*PA6COZ]P]//Q3<A^?60LZF,2/GSY9?WKD\0$OBF6
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M:RID,6_1I"K/;\#!GY:JRG#G,U.!Q"\KBZ=Y/%JHC\ JLZI<)#6\#"F$_YV
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M"Y8T' 2#- BA\ + ;HRAWQX>53\\3II*9L*7T.-2T[(^[>1KO47-+95\Q4+
MH*4J8UWZ!R"100Z#2*VS(71W.98K+@VX?]=\J%]_[XO@6+^T:D@#\L+ACK=K
MH$PPF?@JPSEC+PV$$'0VUB5ZZ[$UZO^KU]X14:)1#MARHP2:$V;S@/HD]JG-
MY&ZKEBYL:FIAH@$OI9T6U\-$96A+QAZ,2>+P:YXV,J#&>KU! N")QS['HDB/
M'GPX^)A?M[-*/RVBUVW@,RG7<#1[0L!B; '2Y2O5FV&]6!A"SR"DQV,=Z]P%
M9%)L%_S>-'1E7(\$V;5.%3P(&/06BOEW<\V:!)(UE]I490(MB0.4D;'OB+$3
M8<4(A10X4(ZO7=,V&O5>"E8Y,T;Z2@7TYTH2+F4"G[$:PQD!I2R$*>XY:^W(
MP<?JQX_ORB3@86)T=<;UVC,&_-UK0DB8FK>G"(L8<>-QR)"S])DY&W")*K3M
M2#@TM!G!Y*R)L%L:Q#[+.,E[)YBK6)C9ZR7"Y6B'[B[IH,NE[4<R$0Q:48\Y
MB<\VE="?@BR_5@;?_]$,_IE! %/_);+RDW2_474?DYPI']+]/8ZTUB"IUK]K
ME$5Z/G,5FNE1G4>IW4F/9! %YMTS)"8F HDSM4C@89MCJBE\BQ469H7EOCK%
M$EP!",80"=P$!@ 7 $9P$Z9AJ$R24*<#'-('<6GQ#CD0@1"Z?!R( =,D()GF
MRDG!$V@:W)KS6BQH+)5)#/#-'*;A7R8+:U::B"KI&^YUGL!IBHR[/H>,#Q+S
M$ \8N02N[+OL&$T_8!2STI04"S$675$R/XZ4-9I5JY XN(N,I0=62X2XG!T*
MEE<W 8S%(T"CW6D$'A5J(K@AY;ZQ,YY"_VJ!] ,Q@Q'RO&8$[T00RJR\U>9I
MU$%_<-#G=4CQ4&GS:WLE(HXDGE>'>GPJL&RC MT/*XJ\>_ZBT/B#%GU><II9
M5 ==@GW3)%$DC)3IO.;08ZSL4:BCT%S8*  =,*B4L(,IRC7RZ/A=1<@J>5V-
MZ/(IW>RJ2+=)_QW#(%587\44NB7=<6!5^;^L9=K"\68F[U8V6]CF'Y4*%.#,
M=YI0<$[9,=#Z*X%TP&!+4JFD=[NM;O_?ZXS7V%L3#D<X-H'"FHG9V GT;7\2
MZ >!-1GYW %.GB'AJAD?6R>"O*T:2+%&H(E@],_*A &:@=2QUD*>Z-$:HBAX
M7H2<ZO/>N[!E3M4UU+51[XN;>FMG]/T!^=JW!KWQF.CKC^'9_*!>MX,I?""R
M8-NO,6BA+,#@TV><S$Z4.=A)JX-Y:X?'H3_OOBJ?1Y;SS),Y26/$!KBAL03?
MR]Z5M,L\G$3,MRZZ,W:M[GR0G Z1V\&GTE[INWE"MZR2_\T,TV#*E89V/@M,
M0R!/]?$,,AZ))I:JBFD/&)_V8<O1*3FWNE4#,[JQG>>#S<J57_!T\LNW=YBX
MU^ZXN.[PW3UG@9M2Y,E=,Z^W%3X>@M9YZI^A5:Y V=\,_Z5V3=;(\&^(79^)
ME[#S-GQV +W+]Y6]"4V]=2U97/E;4-.IQQE>=R#X(](/79?;T!*^:A!YF'PZ
MNH7+E/2[!_/Z;JL;YVW[F"1AV#-?'"/CJY/5I''YIFR^P4AXH0SP&_5_H_ZK
M0_TN%U#91R^BIF>7P+]3PE930N?*&EYT_E,L7 RMX6C\.Q.\E4Q@10$4:.?L
MFK]5E-.Y@+PXRKU]17TG'6P&5NX]C)EGB-\P\#IAX!NE@I*.[[Y9[]X2#+Q]
M16WU+.",AS2T.?6SLX#U6IO=,?TP LV^^W=X[R]\-GR<OL4='[C ?,3OTG(W
M&*/$9Y7L%B-_F[)X#YJ;R-LX=T.DF5IS/91MC1<HZ6O^ F5A_ZWK9::1&OZR
M47\M0?\B\O]02P,$%     @ &H>86@I=17K$#0  F0X   T   !I;6%G95\P
M,#$N:G!GI=1G4-/=M@?@A&( Z24J"'F1(DB5W@01:2("KQ2ID28E!D0$@H0$
M"T5I"H*5(D7$@!$Q@!AZ)(I*AT 0,(D*!('\14*4)!P]Y\RY7^Z'._>L_6G/
M^LV:>6;O6=M3VY] TL><7)U 8# 8=/KW 6W/@!S^W/ZK^C/DOYT!WNX&R8B
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M=K65,K]49^J3$M3<=9Z3=XM=/_)83#@*VU=E%X;_I4!,I<"^_TWTH]39+3W
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MO@%U)8J4<[VHQ6O?N#5Y(M5:&?%T5*I7VU/T:=-^_K3T*;-Z)>X%XI;$8N^
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M^?U[. %.DLI5UQ3Q1H*'N&@?3=%Q0'AFI.3I;+$.;'@;<9/4Z 18FWY.Q ;
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M<7^L$'!%IRB-N0'TN3WSI?BJV*UZ^%(57;5T^_]NZ4>XG\(:3C-G;6D'+$R
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M\)1?!F$E3[)7DH&TM<9DQZLN[&AS*, 6KIRRO(\1B 21Y5*JU8[[F\E4QTL
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MJ?5W?*TK[D]KXD 19VIS1EPIPC&]AF%,7$2TF&%7>I=B:KK*EY-]:0'O=5M
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M(TQF6L:7"A(4M!61&2/K:P/&C19?LQC<]4'5Y<+U+4W*(/CG#T.\+LZ8"E#
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M S,1  3B.WY\V-C3PF. QWKVL+D[),>5(__*''KBNL8.%H==DJ0Y.ZP=@M]
MZ7TONI4!(RCN4>0GM1Z\H[$#)G.'XWZR95]9@K9\79E W@Y5:5[A#HW&&)C,
M'8XQL&5?&8.V@"D@W9A&X.;+.R]$N/B!=,FAXNBC3[P;*+Q*F7T)MB9K<[N3
MO!=U&M*"9KNFX&JT/^V._CE.@XWS_LH@QC25$9ZA;8)HAARUZ6@QV]!J-5SE
M8(\!JDR.P[&TCI QKKX6$E+:<0!=01-WC:U6=G*P V3M7C:&-4ZFML(<_WY(
MVR/HJ"Z7"TR[W;IYL,3<%,I73O.+N641>IC<TXJNT:5_;G]1]#&AH0G8?EB%
MHDOA.(YQWP$*Y/<)9TC%225YHP=9 8B;+T"AV:M9?:-AWYZ<XQ:1+$;4ZLYS
M+6<)1COGO2;4(:<!=$RGT$-0[;:7!5A@[@Z#(M$_J-6B>*U:%+U+IA"/#&4R
MGP*1%FA7:F,K'@HRQ.[K#3,U3J(8UV"PUPO#YLK0H,3]4E$087>YQ%%*;/(\
MS'-;R,@%=EY_R&!P#Z<1ET(-Y-.%!Z+)J#0JRXGC4A7,>+5:F4\H->6X<.MS
MK'LN8DZT1978K2_'54BFBV&7EVBP<<GW*96J*[,9<VI5* G6K8YCJ%D1Y30X
MS&5&5Y,WGCFT"8]UR?;Q.1X88Y%-R2_77OTXZ'!*+W1E9W+-%QS.K;& D4DK
MFF[C CQFE%]&:Q;0$.VPZ!AW*"<EK6J*94?*^$)RA*Q?CY:5?&D\N0H!L(A(
MX@SW#J')/23#$U$ORB>L78^]$;41E>/0%1@Q1-T]O5ODM !8-MH7#:L$U+B[
MQR+JU.7K94A/C[);M$ X6$44Q^^B6:,]HQV31[,PE1@=$]8PQ+KZ\/55] 3Q
M_G0MFG%<#GK8&<\=8)@I]$D< JUJ "*^66!0LT:1_Z]F?W?K.$E3E&P8E0WT
M2+.^:8,9&I8RTG<+/*-Z0WD_\"1XR.C/:?QFX#5A"#7'-PE9(V'?)@:)VTF0
MNPBYFUEX!]:$?9>.46\ [OH$$S+EVJF1[:XNEC+T8CXDJPAC<N6A5YTLQ:D7
M+8)H5>=')<%(-.1X%:4B'Z%KH2/>O@@2Y*<U+ 7B[E0("_,EIQ=WSN<\SW_'
M'Q./OC\6W73&T1;%_*S&:VC.] R%G]=<VT Y/.'4[QM+"W76T=[\P6]]9AH2
M6*NXVEF&[N.]15"8=/+S-LK]D/9IJI1<OEL[,U;VN:>L+%A4=( 9[?;#"A>D
MN?-I,B$5*FX#*2,S("4UZ>Z PSYF/V54CL2G^X*"U9HP,WM$B;="Y\\H\0.,
M;A(JD=(O+]EV[2P-Y=EI+K-3TS1D R;[^"CPF;]4%?ZF:\16(]P?[=>874"[
M">F]$I25\S3-EI9BQU4IO9GGS')P!WV\FW35XMQW_AHMLA#M\ 9PB;\Y;TI-
MUN&1']?UC9JCQ[T+HB J!PF;L\4B_X*^=.WBYVE,UFJ>6QXO;Y)X&1!SN(JQ
MF07!Y,#Z\NCG0MLA6EUF3EX^>327W_6QV,>/ZQ4&,HR>3K]]HG:3:$;74(4"
M*(PU*4::6F"#]@-"/ 8&K:$Q(%H*$"O=^80"E3>7" 2-TFHBV;QJ0WM7E*V)
MH[ *R9=L&E>2Q97"893*BSFCRA1,]@YA+!C$J8R$"GOO*O5+8'"]X_!CN\.@
MZW.[ER$'-U1YS:L(VLVI7;]7DSOBB1?2[@/X*4C7MRBDZ7XW7F(NE:I&XZ7.
MBH,;I( 1I=VO/FHIVE3R\M@[A-M0.%1Y^[VP7QZ:WS38B[#.Z E*GQ"*FH;N
M>O>38M!QDIN,!>A0!S2_=' B2#/;[F_HY9KPL,J/9.);XCB*D/-,+7DN)V\M
M"HJQ](# :L0R7XZH@$&*P<D;BIPZW(3FJQAJW(!;#/"I%_I9+H X\N[(A.G+
M W4S3SP<X/DC2M(U^HP1F?15L"2?D[\6[QI>.HNBS MO*;!&XXHU.-VG'?:M
MLWQ98WD>S9@LW]=9)MM^Q?*LSK+LE=4:.\HYH+UHLX8-H,@=E[IJCX9=<QL0
MYUYOV[)K3RECD;FK6,0N09N/*?(<V /A![)C[.JU)E\F?O: 7I.?HHCVR& :
M[&C,AG460W4*ZKUKRJS.<E]D1(95,F0LQ%79T^M%8^9<F%#0@I15?"5U8[=]
M* N_O!VGZHTK'RV]+$Q=:I^*WE!!QRW%/[=Z8.PI&GQ4/HA3H:8;DSVT<S*6
M-_<Z32N+N'<'[RP"AAXD]F$-BK"XV;94X70SA2L"M"4J'XGQ9I-%9%O(!1 M
M/J'T*4Z^[G;EZT8XQOQQ"&-G)&#I0/^Q=1(")6YP]=$BDBPMTE(=:9E)?^)J
M9<O4X,O$?$D.=.1*BVSJC@/$PY3($2C@I4!-@7E[PW4<+BXWVR1^S(,IV+(:
M^WAPVHQED"9[)0N)ZJLI]"1.TW@S7^;'MV5%LFB[3F9E.-Q-/3$%!DH(5P'G
MC+=N5-,A[/H93:26KJ0,5@;6KISTNLA=[_9>1\$<.=&CNW<)):49*4BN)A;6
M)U:?%6-*UT2@(11L:@ !=XT4'+Y5#="'*0"7???1O#-;DKP$T6JVH;&O+MSU
MER!=7T:EOFJRL+CI:&'761:LZ_U(C[+%KK[\7L7V17/CIU,#;DBB47YG1Q%0
MM$!7WU3^SJX9:5^ZC=:TQ(LXH2A&C\$B*X$XYPGE8H6B,L?\,YD.70#U%X%R
MG=#"Z:<@#.<);,4\<C-S[&<ZNINX<@X09:]I*PJ9.8)!3)T'G6R9$2NHLVV(
M!*^AUYB<.23I+T5/ ?]%\$*Y]/!#KA#R3;Z,WJ PQ?1ON7$4AM$>SI01 -\>
M87:>JZ<C"'$>B(R@_7+L7V9A6-()$!:^"&+D_V$5/[ZI/B\$7_UM+_C>X4W&
M8GI?_WC6107>+Q @3JP6\?>^ VI3@(,W/U7QP][]E,3_^>Y,I[#I<"XNO9#5
MW)!R/F^]T<7=V)=7=SIE2H>;A$SS>>NUT]HC +.MNKV'2C9YE\\B8W:NQ'IS
M46F_]SRJ7N4OAJYDD"[J]C(*64P,R10I>E[51KV,\A*<P.+<>G@8Q5MEC^);
M"Z1/FJ;>ORZ(7#!9##D^FC6E-:F.),<#K*B6S(PE8M48LJ:9.LVQY&V %=,0
MF#!L:_!4:?0\*[ &=ZWT>LX8Q2?L>AO"/3''O259C"C!(GR,'U$2T="*EZ5K
MHEQ:D5FXFM!V@;U#N-U]H,K;!ZKZY6&L4*+-H+V<LC;A,77]%&BL3WP&DP"K
M7J0)VGK!KG>B;9>L3=ZE-Z:F-)X<(4>+-/C+CJ?+Z!;A+?+)+>PL?HJV!:;M
M/+I&R:J=H-2#! ,=;T++25I4PJ<^O2?N69;C$3<Q29P?OVRNG((WJRU'2;&7
MRO^C_O2T>L-G9T<B@_YT7!F +$OU?=M[XS7EP.\@0?+Z-7JOP&F.+&XF2K0G
M@,M; UI<Q,EG'$2K BC\&A%?;V'=I9=F;.!UMZ#52\K!W/OY<9U0K6H\W;LS
M2/JZ'P"+0[TVB3-X E3[*Z>'VA ]<(1@* VR:*!1 II3*.8\%S.F25HY-OM/
M,1' SX2-+$']<[&V&#6R?!CK5:<.(;!G0Y;TS%\'Z+'JG1<D.+T.R!F?QI'\
M0N\;R^4-4^?J[Y47('U1FZ[ND!]'"TW*:@_FUELUIJ^.S(#W$%.N;%6&X=4J
M,#XAH2<[/ .56__1>2BVFA\*8$MUQ^.(6J@+A11/+:3LX:$/M9#]JM,C8]O9
MG/4TB'H= MEZLDV1#U_/DR?_F*0!KO  +C=;<A_-=YIH\3$AAWUK%*N09Z8F
MX!HD3>?J;:>^F-*YWE18'L>VL2!8Q)WCG!E>MWT6(X'_H4_=-A'/> IWC6[F
M7.<&L<^.2)HC.R0D43#MV\,1 I.S31PA,(\0F%.%P#P"?ZDI=0CPESX M[+;
M5!.CB@D7Q>^8QOYX%+G3$M+OEX3V9*LR%856K\^7GW%>&R$G=_:W8\FYE98\
M1Q1FGA9H\V I8=<^</I&V'>OKM4BUZ9G!"J'<Y61$FG_&*X?V6""%LC!5 F;
M>SBK?OBJ452RR06'0<(UYD)7#9IQGLUTO_:B^W429ZOU288)MQ@3C^ AB'+C
MPNZUKXG=R9N*+K49JP BD]S&V M'8#, 5ESO^3I, B)QO8!0-=JU(V@$"@=Q
M,Y:Z9V5]PV3NNNE;.Q^U49)M!4VJ603N]@F?SXU2[45K.*#4%1[M-1"RV.M,
MT1+J"3+#Y:KAH5XQ1[)LNVWU$:1!U-#6"GSHT+<H6GF+#;E"6GH-TY_E1XL6
M66< 3_V&S%8)^*5!AT8LOB8P=.+TQ4!6(\!N+\IE%\T-?7<7JB!@K.E)S(G;
M1P'I8U!*R*80/O8)"31+_!;Y\2H*R,"749$[/D_HST=D!9KX=1Q)'V(LNC1F
MZ-6C?F?J3DY@.5SG6';4L=P\)1QB:<&!(@VF[IQY/>>-]Y+78UJ +JE(N<4M
MZ7"A XEAYOM$83L$@8I6^:^U3O/VGMUE&1M1;3'/4)C@#1*BUUW9N.<E3P![
ML&?1%;W10&[ 5+83D[& .I.I^SC_\5VVW88!2APA-G"YF9@2@2*&-5"S M!5
M,BD,HZKTI-FU06!19)]T_/XSL,&&!$W6<9*F*-F<;[9A_(+0"8J(G/,2N23S
M0HN1,"$G8VBI U%JNVQ7*&%SQY!U+4Y<61V=& B_-+9):XII4IVF=EJ2TYUI
MQCG1*DPPVQKK96*:"NR7J^,V/1=!Y$7DKAZ6S>NCQ>XGM4N#^2KJ6[1 .%A%
M-$>MQ1,178T5Z]?F85P.69"WB P2^(268S!X(2-C"5(I6U&K!;U0\ 9;E.]<
MIS.TC3%QF?)DY6 9H,4,N[( *:;&E""ER2+DE&(JH?8(3FM.PUSD6@.>UJ<X
M\CM0@&Y1-258.K#-7D89T/PXM0X%C1FD9<$U.8-B;,_;$; QFEQH3<H721T
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MK8=F[8O-'J1,\%9I0)LV<_6%^G2;IZ]5F] ,?>5DD9OL(0S\^7*)$G*SD\K
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M4A8E&W/ #O[RA@[_X&%$Y_[_ 5!+ P04    "  :AYA:^UQ\M<?9  #"I0H
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M4_ID#O#Y"OM;8H#%"W3M!0GZW@NWN/1A<RM@*)BW!<SA&<&8>]V.ZOEPRM$
MP*VFYVA!MQJ1T)HT2G!=9,2DD;C[R&A@Q[,A"&2 ;><&6))2 R(5J6"IS'#D
MUP3VZY;8Z3$6FJ;;1Y-$490UIT39@Y<\@W9IX&.?A0138393C?ZJA7G6[9#/
MVV'[R\V\2 2HU2^CQ>W]HP9%6L9\=3F?-QY0N*H! .06O(HWUK'4]T2>A'_%
MY?L-?1)&T[/<8#(&=@Y./6J<>D6U2)(E^&1?#\;,-I)U,Q69+A<Z*4IYX)][
M)+91XOALV$J0!(-E.Q;JM&_T!M&GV,-1D-J"/\B0I\&4+FD!DF1''VZOJ7U
MS(3M>AO2)(27>)-@ZC:A[P36<9(%:?[OR!\3BRE(&!&1S](L-WIQ&@]]K FX
MCC8XTCRDT4WYA\AC7[ZA]F\Y(O*Y(=_0+_:#LC46[(=E/RY9BO!YO<.!A-P>
M&][-@*LCRM!^C4MU"/Q>T[LAKNVHD9*DL\O@:I>)R"[#NVO08Z.JR;!V&\-=
MYA@9K37=,DJ:1(Z8%@GESID#\7S^\ND_1[9>SG$Y12*WBT(Z\-?9?8KCK(.F
MY@_#8W(8B9;!8X@'X$>1$M._UU;?E2(C2NI+*3_/W2>#BMXQD;S<@:+D2(=[
M_F:_^WR>'^+8?PY"=ZEEVRF!*QG72IO-K0^0UUE3WDU_LPX#CF/R:5SS:!!G
M>,'SJQ/.*5 @KP9IXKN<O4K/JV8W[8E?G8#.NJCQ6K!G$0YV[^T&$!HL(\:U
M>:%#E"R"GS9%Y<<#\CR:2%T1'*SB1E^8' 88)2B$@J$F_OB8J,\#BQ8@E*.O
M3_C-8O;KZ7:S"0.R?<'"\(":OO/8M<>M:]&EU(N;HM$@ 2B3MP80A4R B8O1
MID]DY$JE].L5TZEI3$&>"8#U6SX&*OH7[U?2G!C*+IS<.[73H?<6JF@D<:4X
M3Q"A(YLJIT/K]*USL!1;\631 U@T.W,(&SV*-,P4?3"Y3S5B)$(N3X@^;WHS
M6QJ6^2!.<"#/ZU0$Z;VQ*S9 8 ^/CG3U3VI0[^S::-)X;'<@CE^+/'I[=;</
MF1Q'1+5LUR#)?K0)&D#8K8 LB6JHHFVY-O"6CCT.- )O9=RQCK[E1WG /DZ#
M940C8IJAOI%_$WB/0<AJAX "V)Q*R#M08VIU7M0UP\SIE7WU2Z[3 7F6>@&:
M?(78\;F#DF\.DM%WCNR9H[-5H2 !)(N.G)[6UQ/LJ<]B#V&OP'6&%O3UZ!/M
M QK [0*OH[.%&WU CX.U>]#Q@P/45!+1H<S=Q*&+J,N0%50*J[;@UH)*JA)D
M-:=N;07<X"<<IL3.*"'Z;8 30OW*;97V%C+<6J=J8J3O;6@CNDE7B@NMRH:'
M0=<P4-,3=QUT&NRPAM]T%2<9.;&NK]:;,-YA?(XCO BR].IE@Z/4_2LP;8+<
M0E*7+ DXRU:H:-9F*8)@TQ0+=90:<<CJ>J%R(%Z2CB/L7\11E@2/6_I>@ :<
M2DY'&O[CU@X=/#LTI4GCN%)T@?@^$.L$_K!N*U.10UF+5?:QQ[?>SW%R$:\W
M<40-YLEBYKT4J!Y'\WCM7DOJ4^3Z!*Y-F<QB]%YHO8L(Y5_#X[0##.H*THPS
MG?*<;P)B=I.AUD$&X_94D. :D')29.__8I;!GK[AXW;I-XCK@?P0>L$Z=__<
M!%BB3X'>];5)O_DR3\F?#CC,$VDXQUYC6.<1:O7Q908A^VA 3D*QL.I0$<SL
M"-ZN]NNS0SI$%V97?_\XGOV(1K/9P_C\XVQT?G.%9A-4_/K;R<WEU<,43:[1
M[-LK=#&YO1_=_?@-_',7.T$T,PYUJ5-79CB?KKP$%^H!]-Y!31'D'8.2,@T#
MG35#1;LAV3K&@% 4HFOE48<]YFZ[?L1)T7<Z3M,M=I]:4DF$ZX*?"EHT )DW
M8';-9)NEF9<_#1XL3G7DWRC^V<8@^W.BJ&M0$,+E$!!1T_[&[SLOVGK)#IV]
M072>@T27/JH ,P3(R&EYQ'>)YY@V1.\%$OA<10"2!$!&C.BI7IYVG&C=.3F#
MQ1%*69M? ^O/>F>]5K%[&3FB4O?Y-RA@'T$?PKIS_%U_'->M;"\C1537GOZ5
M*1MB:L0),2VHMC_ ^V?*^_>.[Z1D=/Q>P/C\6\KVE <\>A5$N7&7OO[\!?![
MB&@(&3%_$$AA4H>\A/N?+?__T%-^E[S_4>3_@(/E*B/V.5'[WA(_X+47T!00
M[**'V.M;&HBQH"\*JK,*(VJ25QD%]5KT/PO'1\FC3D;C+/J#ER0>#5#CZA@\
M>RDYAH;S(AT?2]C,*AN<A][\TPEI'M-GO?E@Z#X)YO2#V]C'XF,KN'/E:%B7
M.V2.(TO[I5]<@ET3+K'>'[T4^_?>CEY&S @"4C($'6X<_; *YBN:\R&=)%.<
M/ 5SG);6\V7@W\79WPG-P6)W'=.*7?$R"E@NP10H3Y3[F3E6$<XG*%,;=/"3
M<SHZ*H9'_/A#NFB!0GOC"@%$<J9*HAGH45"=7F[Q+&9T,YG36W7R^SQQJ&T,
MD$G?($]*#0C4V%W+WA#I#F4QXI<0WR6\M[<'$(B"ADS9V>51ZLC_>5N$VY-5
M<K#@W,7YMA+B/H-&&TFJT')P#[&N8.O*5VO*,*DR=$@3>9$OXC3;NQ=.6!/Z
M1I6V ;:VCR>BT[Y7BY9W4X<RD9MYRDEFSBDYV*#CXTGGS#XJ?D:^2B>+490%
M?A!N,V+J\,\_73[,T"#%?0ZN5IID.ILVI%K"XYJB@']#7'^F ?.F75OZC9?M
M>FSI8D>4GC?)@=SY9;.,CF-5K#.X>9:0)D%FY1_/0QV*K]&;QL\Q%Q3A9<SS
M5.6W+XIL[K"7@!LFFD@1.W95O#M2$F'M*VT%;2*[1")8#;GBR!=*]%<ESM-.
MZJCA0+QZP<D\2#%UN^+B>J 8BR-A'!WLUR/JZ%UB^L]WIV=?.U-CQZ+_*$$?
M&KKO2/.1Z,QR-.3EPR%<C(<V=,#NJA-DI1T9T_45>DR!':W6;ZNJ/N*L1"J^
M.PYEJAYL]_ZU@- RD63EI'M(MYPWVMJW*^D&X%6GF!(-?^W#]"/*JI;@-QIF
MDA(Y8!6LZ!Z#R]*+Y>\DN$.8-H#=GZ0ZTCN$$U>W*:C#@]\H@H-A+?)^@":Q
MW'M@*?B!K?L<%&'+;]1!R_\##25;NQS^'O 3CK;NW[XWQW4;=-D87:*TBJ_R
M!\+EU<C^EX,)1)*(L XXT8RM/>NC;)^AH;J!/=_=>=DVP;-XML)!<KV-<HO
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M%<G(D;U73/P@\I)= :(WJ&CQ"_:AM]@VR39B5E7S[A))5N]XLLW2S(L(TY9
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M]RN5W&DG1VQ#K>V=Q"/>>7P)?-SO1"2 5ZL+O6VY<Q;TQN2)W9@T%!8XUOO
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MB,C0V:CV'\.]PU&R7[Q/U:=H_>"*Z^C>"WQM [3>RGEBF=KP4NMS_Q7:D,^
M,S<*^<Q;G(=SLBV'Y:6KBSA* Y\=5.)(4ZJ'[=SJ\8/Q96X'\AV:\Q^"EC62
M<9NK9"2<6+?*S<D#IDESR3:P-Q",MW"]OMR"0(NFEEK/-,B@:$SC1//6L+GO
M3:1V6 .ZG1EV8-IWNQ]HQ,[GFOB1-H=(7BXFI14I^-];8@70)'H-30*0MEPM
M##YMN6*RUE&5]^6)HZ:JZ&;T@.<X>,(^^P,+<"$?$9U&W_Z3_]#P9,) &DG@
M[C3;!['N'*']$C[P??$XD&J<D/MBHWVF,^S3U.V-XYCQ'JS3DVOSNITD16HS
MFIJ4YNYO'K'A3E<&PJJG,--A@J6-SD<L&V-&TMBMH28F0E62O0PV!PTZ5O*]
M48%=/+N^5^,33AYC.TZ?MK$:VB':%]-/.ZVS^R28TW7+?C!98_6&KN]-#TE0
MKJX-_1):RD)6-R1\.*7.23@NXO4FP2M,MOPG/([F\=K=Q8J4 )A$,3)R9$8C
M_R5+&@X>XMPF44'F#=E\[:MZ/5%.,X1.-V&0/5#[4OM8+&SL=GL6$R&MY<4^
M+MZ$I?1SQ"QJZ$)>*BGPYV'I7.T35=U[>5IX\;YQS*-M<V"'5RER*F0W:8VT
M*ANOJ$@ ?O24B*]QC!3-LO=]7F'AJ4D1V7?W)8?1JR!"EW$8>DE*[;Q<!*\_
M7\:?6JMKFM6A2(ZJ>VG)M7!_55D-+KN@)%_LD]D"VG0"QG+7D8UIV&=]W%#G
MS2R^>LEPY+,.C8(;Q:W=ASD*Z9 &/+)B[EF,,/L^%W4S^A$@]E$I"CX*4CY;
MVV5\&T?9*MRQSJZQ[E)NMG)=S;L^O*R0=_Y5(>4%KFEO()VM9#I7RELPP0Z!
M<9>86.HT>HG IT@H[,RT$HT-<TH34")+$<Q]6::=ALUOHY!@?9.73;++<9_Z
M\)WAA0T& Q ZM.*>!SY1#"^(QEOCDO3^#2LM2[H<7V0]J^[(!LK&TUX1^'7.
MR AG>DP\DS&QS&(DV<<&R\XS>SNU2&:43A95)-XE7N DP?ZA7I*'W;1UXSCB
MIH6<]AA*O_@:S1N:R7V<C::$N! ;G=EW"]6ZB-,L9:==78 <-G1]F#DDH262
MABA5\B6LOU#.\,.0JL;$NI@DH_F_MT'*L),6123+PMH7\?HQB/)ZVZWY39V9
M-;T1[$I1]4^Z-%''OGM1+E[X_:UOK-7WR%ZYVRG#T3[$;;2FD3YI'M[#4B@=
M9@J^]0AR B^<Q7G.S'>G9U\[6TS=*05X<-69:-GZ8=W]0DR!F)CJ188O:(]T
M;UBJ+Y9^>&@=KODQQ>2_-\$"W^9EZ?Q16HX^"]9X.-M-=TH!5DAGHF5%9=,L
M6+-4"%LV @K)$- KI#<LU5=(/SRT>M_X(8F?LQ6M<6L<72=LZMBI+*)!EJ&=
M?<IJ%+\1A7LYM\)5K*_L<.D,+0.];N(\(8.QN 4-W5=P;9(@K<Q:),@02MJ]
MJ.5,YPNH"B=G>T=T&:0L!YW5TI8T=NMO$1,A\_X7'\O7-\A)6RT%KD2@?*[V
MD3DCEF:5>6VNXP3R/JF=$H@G)JU4&=PTI;!73=JB;IQCM3A@C\"9]T(1?;58
ML*J\9 P<+*/BMPYK)JC) +":U13)BB1X+TR]P7M7].3:*'G0/F6[#!UEFBE:
M@?S"2Y+=(DZ>O<1/2=]&SS1U>G)LWVJ0)+W\K#Y&9!6QD&6<2J^AX+*'M<M-
MD%.LA1^6QO$E_H3).6Q.5=]HF6"6H>X2I_,DV!@D"&CMQK$AU4*.+!0G"'&:
MQ1$NKS#3-\BO6L$=G'2EQ)E7.ARPS @315N;C&7-9NZ#*QL4R#R5[#-1GC+W
M09825G.1EJ(Y65]C5Q>=^Z5@M)_(VX.EIFL0TGYEO=XK@2%D)&R5B"@'D&C.
MEOL#EWS&" F'[5PGHFR,KY$*Z$#>D+F 9%(63\Q.D^\]SD:B;;9RO+0;P[<Z
MTP]7L7.Q2OA<"54TIPZ!M/D+]>*Y;+T>L+,3J(H&]\$!"FJDIXGBF701%0)_
M!-60:OW\V3;I;H6&\FXOXO4ZR/TISJ E&!K"F79(1@N4GEE9QP&$BLAEUPR,
M%,[0WCLVCN:TRBZ^Q/E_Q]'==OV(DV;5\ARY[G25&5D@KR[-:-1\DQFPC^$!
M:8>+AK8S9Q#,<TYS0D7AZA^C($M14J0T8DZNO-EKX+!U&%G:OQ ME)S),_Y:
M$]>9,*NA6[:;YC-]@/R7AYSE4U\V9F*;J#!_X6^;B@$Z"X-V @9QZ@6PS L:
M21?ZRK<PQ<E3,,>IZSO<YK@ MV8-$F19?HJOR'80^3C9'WJ'</71*L:ZYA=-
MN.>%J;5)"^@0IM0J.7]P*?YY\?BT0[9#C] U68R6RP0OO0R+_ S*'(?B]@"9
M#86$*/(9TN_I6P"O;-&L& "2SU ICGH60_F$+;W%^ZZ8=:I[:5!OY#Y#<)T
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M\LHFXF*00#X%@UJ0QRD#6059<"F$[W!&L\GHFG_J/MR[&93TM+K((YRQI%^
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MVOK(2?!]'&[7N)%^KTR66W.M3!;W";&"J<]EML(7(3D#1DM:Q,FCO[KT=IJ
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M=501JH4-;MEN<D)WWX47@]M#%Y#1&1C,64L?J[H ?]\WRB');K.ZC4$"NS0
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MQHM?^GV.48X@?D[R9];'JKXI-Y!12&\&EEC7C!B]R;:JV42(_H ^,R@'A'Q
M1;%IFZQX\;R #C%U_J"L)6T^,L:_T3T;*;L-X4^0B*R6VLT0VBEV;G><-@&I
MDMJD+@ <3."ASD@AT!S^S[_]R/]+":>M6'>8L&)'R4'40/T)B/\,?RII2S99
M\T2VN^J[^-A/1PC!*LJ?2:6#&L!M\%STUQ7RHIHC^]""FS^?" >Y.7!^L:^W
M8OSK[56U/V3E:;79P.E-<]9BU8I\D*_4>=X/5^!C71T/$A:^D5'\;.W)A<E^
MVHC/L-4AO\.[9:U,C'L%J^M/B%;=,V046BDS!'YIZV?$&GE\K.DC.S@_U6R<
MMW6UH31W'T"J->'-B6I/V$XH&_[$R703-OOPBX-JPT\.6 M-)LH*2'V9_<1D
MLZ]*PB-'R,.)]_NUS&G]O2[@[70XULT1W 6\8'/!GE3L(Q*G^H&R%45YEYSF
M1^Z\5#2+IM'^W=M=MA&'XT?*OGK(3O &%]Y>-HP#W4CR%;LLQ="0+TCKU%A6
MG6<*,31X-9RP]MBM%:NZB"=QK[+HX@]Q\]XTS9'F*ZZ(A_=NP5M+O7T9\C;&
M[Y/XB,WT=ZH:R^<J*V,%OF-MQ^)&E'<W>(^TAQPBKN^OW,:RWJZ/+7L=ESG3
M-_OVBEO*/LY(/=+P;'0&&[@SJH[D$)@84X^=P;EG*B?+#_/>^+4LW$^@KT-K
MFSC,L*T\O;%[)L+@#7$[\5&P*>=S[Y(T^WNGT'<W]1'Z+N,4Z[$1$GJ?7<SU
MS0M"B:<"S2,-:UK\S]"9*;2R^T(TU!Y+GIFPL(X^$U[COG,*%J$VB?&'Y-T@
MFC++\AAC1EYU8N8]K.^!]'(>C-XB:"M_Z972FF;K+4?D=4J8-0'Y\D:HB[<;
MJT6>0T:2B_)]51X;L1R_T0TMGMU'-&^J3HA:-D:]&2V#'\O8R6%ZA40B9'R#
M%BXIRS8$K,P5JG3-T8[%.N8%X6:[RIJGJZILBIQ;Y:O2+=7FB6S,ELBB'8S;
M)E\K:QA"!L,B/^[][_^NW>CMGU[ @S%;Y&OE*OGY*ZWDS46\%;+7O[)_8I8\
MK+,[5ZPH/E086$V?*-OOSQ1&NRZG:)$;LSN?;4 .M<<DX,RIDSG[W 5D@7!U
MLZ.8;HXM&])]G>4\NO$48;79=/U(*SJ2G/7$GA$;-[:I<'.-<A.Q=5"W-V5;
MQ<6K?:-L)37<>PNV3WT>LE^V=;&!XT_\CEMY8+* /M2"J-S&49SYLC-NG3*?
MC#!>Q5>5C)JH2NW'#*D2ND?G^ER  \?-B6TB_%RG5S5JFA<M1'+P^AZ1=J -
M[\7+&/)>R ?7@ >+V*U<IA?VL:YAPB$>)E+0HH>,5\(];HS!6R0\8@WA*KBF
M6\J&D<,S2<(^N<2LFHJ@+HEJV."_42PLC(7MY#.]"G1-_Z"[S\6&*694GVC7
MM-G4Q<'W]N;]R$YT))D^SO.N*[([*\29;5IB9(&R+YC& Q6!68.(PDYQ1U-N
M$+75RD+=1)/XM<WD#(&A3*Q>7.NM?,!"'DG%-M;IJFK:]1;@B!KQBWOZHWV_
MJS9_N#>E)L?=$)H@.7 "3!=N^-Q#\!KRI3^3==M<GR%##,W9.^"/50WO,_9S
M#H'@.N*Y800%?JUO=^?]!0#/(]JKYF!9$D\ J]A >+7Y82/6NOLT^HE^EN F
M+IW8F4 Q+85&KB/:-Z?-CG[X<6!+!1(Q3R^W>KH@>OY-8GP45>^=+:KIZR4@
M=?P+YG^/15/(?]RQ<<H;45I0+[PVN VZ^R2_D4C#ORHT#&6W7M1%Y!=1<$W$
M2!CYTJFV[[.F:*JM-*-EXI=L2BUGW+RC8[@8 'P,EL,#?!@:F)]6ZREPXV N
MC+DB\RZ7\^8!XS"1J=!0E(2]7 &QF?T//"W/3,%B@^2  $$M]5Z>'35;-HHB
MMY7 2QZ2'/@/M".+?#Y,X]HRY7/$ACB]X%L3" \TORG9MMT+>^=#=62O8;8V
M*2!UMW7Q<(3?W[+)C3DF.O+B]2D^P#0'_062P2?8G_@WP'"O/T* ?$/H4G2*
MRXC*O58N,@?)[:/FZ-EHP([27!_I?=751X"+D/V>TS &''[:]E8/E<1)SHZ.
MMNI5.-D87[ O&-3E,E,N_J5REK"1CYJ/65'S$$^=;<AOQ^93G8$W?_XBV3+"
M(LZ5ZQ[23RB(DT=!?9$GR@R)^)?';!'CO&U[A:X!9J6JB]@W;)L]''=9K34+
ML10*30;7!Q-DS3^/'FDL8J9$-,<@;SSV!=&;,'@/&+G_P\1_;$/41+[#LQHG
M.?Q)%KF+96[D8)EEXN;H?MG>T/U45B=[!9@Y;;W*>LMX#L2((S#O4<)$< GV
ML;1S>BNRS&?N9*"@$M67J<&[F/1/GU\T2+KWL6ZH-DTV(C2>#S#^:=Z?/FG)
M:61N *>%KDE'<NF:OTE"0C'6L6'RU(:LI>&DX*X%/UQE7\@U0,V1L3-AGQ,7
MLPA/DP_;+=VTZ^UMU8*1*MM=%SL>*]D/O(,0UE#RZ2!0\9"IYPB\8/EGN"E4
M?8A-G?C2@E*X9TAC/,.S19K\$/W GD/UH2X:D708%TA!=2?,[388NF46;+QA
MG&XB-+^#H&+2#(?%RR+?)EA8_XV _"3P,F69C+ ,TBM^'WX(=RY/J=A7I3\,
M>P1B0&7W'/.\LK)@D;^'58Q+YP?;FV6V^P90YIYL[BXYA,H>3"_C7;"7_X !
MF\1M+"8_X;4I3)88[5O"7'+_V)D2=9WW@241]37CYVH\&3%2P+@:/E7/;)'P
M-L?VJ:HY$J.,H0YJ6?Q">-04B$$"\V+V\32>F; $4(Q -V71%C$@"++A4J!S
M1^,>2]S!&L(M8* F!T"Y]#5@8$0O 9MKQ(%-W%8F<<5]FQ61(#:FP ^LUU+$
M#1QXA=VQB'&P]P;B3>RXZ0GXM #5?CSV@* '"1T(PF:J%CO,PJ8CU1)JY<BF
MZ,(>CMTF;#M_J,(&\U50S .;')YX8;1NP7:\H!S+ZB)>;9X*]EJ 'Z& 5]VT
M7XH=^UM51EIF3 ]BM=M5WP7$MZ8J"I\QNF2O"*,O_PCF;1,7+;/ES.@=H+7G
MP2F]B9C$AI.RS^)2YG# ;O0D6L6$=-2I 3;7GM/.N0<AC^(5XDML,'[?#!@,
MHJA+#2"%;R#,HZCI/:WWSMTA6X)C%2)JV0&^1[2_C0=ND;*#.9PU+0>SWFJ\
MP7"UI$()O0>I:(%;QYN $3_N>7"PCKGNI5E*!D) 610.;0^!CDSG*\!]>UO3
M[;',:?Y[5H/9RCEA-\9D]>)("(=4>OM?HJB,P,[GEE7Q"?AYO6DK,'*_>_/N
M%\A9>"T^2;[+;RYFLJ>+R[<>Y@I_@4OF[L/M*NS!*":ND;]FY1'\LU SD, G
M<!6.L @FSW8G-ZQ)'8SL*VUER)0,=HY4/YKF.)Y6CHC6_5F%DZ//8HAG^S3&
M22JYJ\49WQ9AE_"$ 38.8P7.A/GY<\Q7C% PMMU_T].7K&1#X'8L6C=56=*=
MF470_1GJST1BX)@)&6U%_J GLM=T8#;%=^",Y7F 5;V'?D:;+46-@IDJE_&T
MSY,LBD;,@8N?JEU^LS_4E7B%-E^RHMR=?#8NF/.=ZDH*HR^W>A%>; WR,/:<
M%.)L!A@<3UZ41)(?KS- >QR)W",4'V2U=A)HSQ+Q>N281*F?VYK]*^ZDE!-!
M7S%=<[MC6A@W=95"2\$->Q^SY)R*$=LXQU@!Y1G$U>J;@94A_49C1S(E SK!
MY21^@:II#'FQB=[&;?HSJ2H?P: 3UO!@X1]Z@<L[UG=@OL(0]8@#B[ =7**L
M<VT8;OPQ UT[?)"\X9C'(K9SE7P]?ZG*]FEWX@H 4\N<LA7-A/X#RBKR!3H8
MMD6\-KXP7ARZII<(0#,>19%!]=WEJ>+QC <CZDGB9FT\'R$Q)%_X>D  E2>"
ME2'$H>;=FM\HW#8W99=I+H,>5F -%*^8L-&-TR8RL-N@3@1Y> [R#Q"1UR\_
M08QO(&^S\X7D60EG"AYMQ? Z9:&J,]TB$!C=BR@\8^7 /4,61M&$KLSP?V&/
MU(B ?>6^(/"HQ;5Z6CEP"]W"*+K0A4EO@M074>W1SD58\B:W"$_KM8+8@]R9
M*S:FT[:JF63SYC[[X=> ^V]M[@#0D(6\NL;&($?:[ ?)&F4BJ>FAJEM1YP$W
MK3)" .-)C)8:A@XHE)[["C)$RISKI+Z(!]$<#,F4=Y!:-_K+T<&&;3(\_**\
M(?MYF#(+Q,S+=<Y%/U%5H^JXDI 19B7$FF5^XJ2!,U/3<#?ZJ>%QB!H(<Q2+
MGA$$RD"?CX@:WNM8AR;^1'CK<@=91] .Y&OH8U7?UG1?'",,D>I9":ZI@^BT
MG&AX#S_C"0DRCS<AS7J[RG..BYOMS.H7DZT\NM('A-YIDH 9V94#0;1LAOAU
MSEI 0AA3IU>/$2#XE;8<3#_NPNEB(T';'A<=0)@?'U.6R0G+('V:OCDHB1A6
M/M[6U892]^._/S%;U8T=>:(?[L7C9<D_+0X)($_+<;<[<903V,1<2;EK/;A+
M@]F!W@(-AI]H(A*Q 0(+VCXN'@/3Y95,<EO.+2/YQ!Y@4">DF8#Y<I#]>$45
M[,TSXL$R!0X^491F-1CNJ0Z!*'%'L9*V<,H7$D^)_R-3)5%!?\M. F<^,^ND
MON)QA%V/![JI]K0Q\&.J6E4QX 5R!$H]T-EDN\UQ)TQ$CQD4N:B%J>C[$RU)
M0W<[^(L+B 9M)?0$ZUX,%OFC;4 UEH"V/H34ZB\,F]Z./@EN?=W'.NK&K+]1
MB-)C:WO]O:1U\U0<(AY2JC.I56]2J>X+>E+%\.B>K C1(.CJ!H:AD:]QS<0O
MWTOK\@NM'VD==[L96(^#Q(>\(PG%J/><*/*,1C,_GM6)<DM^.NK%II>?W\6A
MV^N3L5X"+(B+#=N$^!A.K]2S^R8K\O56!LP8, ^^\M2L"VP6%19D8(9@OW\]
M_-@F(\ \RDFGBGSS9P.WSL>H#5UI<.@F'!7+T!?\'-EF)2P!##<> +O5C4@A
MO3OL"G"5%)5[1GAKZ8=HH#WA=;71-XB-"]LLN+E%V19B./%R=T@<3> 1LEZ
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M@GHF\F]? [.$B)9W?DW;K-C1_*9D6WJ?B<#*ZM@]MWKH<A.OB%P2)T5'G61
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M?[_JXU)+VD2RZU*@IP@KH3M$PCIQ'_"^*L6CS@V0(@&PA/.<M9?N#3Q-V<Z
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MJHM_5N7G-O]+M8/(C>:._=]_6P)9B#E292(%:2)I$T%<9+])\H31)^H#!+Z
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MNGW&O0Z\JAGYJ99]?D:.EW R8]_- =[3 G<HA_8P*F<4JV- J'M\^CY\7PE
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M#;B,LH#C.#GM+E(UU./"!'4WHOKASH67I?%L1$@@[=%U7V<Y5;"0\A4GZMJ
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M5/I]]:XK[@TA#3"XNLEV3#\8_'Y3/9908?6F%&^I=0V_=\;6#G1FH^0Z!(5
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MU>QF,VT:-!30:0I^2-\_U=7Q\>G]D6TGVC3L9?; -AW_4Y3#S XBT-$GK?@
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M0A^=!_Y]-T"R3QEX@/B)8DYQZC-."1@3I&SS2\ XY5?V\R14$T#%E88!?<_
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MAZ[X^_#O1#)W2^.25E@&]C*2.F#J0'<M <BB6EZ7^@E,E@4\5=$_4P>ZX2O
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M@R'N11"*A/GTV?::Q.O M7H%J\"#KPQTF4$1SU#ZH(<C=C@9JB\F!^-PNTV
M\ETH!8N8F5$\3R;B%5D\EW"?462-V'(()D7G%D0B!\ZJYT SY?"=*CV2UA'7
M(TY6-LX-26F9@&,AF[GA#:!E*X3KZ147<O:PTA":0)@PB=L0"Z9YC<E>BKWM
MNP$$XL=WR7;K4;813IQ3"LTH ILM@M(2W91C&#>%H2D$>^C[CACE+O:2'T/$
MS(SL-8R"A55Z*?NL2"D_T\ZVIJ_M/S4B2_&([#45F:[4]1_AL;(Z-V!*])7B
M$=EERD'B-4 8])7M/S7Z2O&(G'" *+I'(+4M FN27 #[;(7I8+5#@1^SAGC
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MTP;*-.14!:<]JAE*\2GS^ 1O?QUX[-]7N3*Q&YQHVA\[\JA"72GN\"L=\C'
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M]G.VL1[*;@67QT3GRSO'(U'Z ^W:8</5QT]P8[SEE.X?51ZV^+Z.AON.47(
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M7*R=B$\YX[$_/C0]ORBU+R.UM8Z"@HIH,QA6#D+5/51[.--NN(J$E'Z.'FX
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MS: [$@W0FTA@@^?UWIBCF+EL3%,)%25FBFD_9'4L<A11YRY$ <Z?UXI=D.@
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M+FAT;5!+ 0(4 Q0    ( !J'F%JN0]'CKS,  (8E 0 >              "
M 1%2!0!E83 R,S<T.#DP,65X,3$M,5]S8VES<&%R8RYH=&U02P$"% ,4
M"  :AYA:&[%OBL$&   7)0  '@              @ '\A04 96$P,C,W-#@Y
M,#%E>#$R+3%?<V-I<W!A<F,N:'1M4$L! A0#%     @ &H>86B6$)557 P
MD0P  !X              ( !^8P% &5A,#(S-S0X.3 Q97@Q,RTQ7W-C:7-P
M87)C+FAT;5!+ 0(4 Q0    ( !J'F%H=[&=@G 0  'X5   >
M  "  8R0!0!E83 R,S<T.#DP,65X,34M,5]S8VES<&%R8RYH=&U02P$"% ,4
M    "  :AYA:\U5_3K\D  #KQ@  '0              @ %DE04 96$P,C,W
M-#@Y,#%E>#(M,5]S8VES<&%R8RYH=&U02P$"% ,4    "  :AYA:?((&YJ0)
M   8.0  '@              @ %>N@4 96$P,C,W-#@Y,#%E>#0M,C5?<V-I
M<W!A<F,N:'1M4$L! A0#%     @ &H>86@I=17K$#0  F0X   T
M     ( !/L0% &EM86=E7S P,2YJ<&=02P$"% ,4    "  :AYA:)E8Q4T<C
M   PJ@$ $@              @ $MT@4 <W!R8WDM,C R-#$R,S$N>'-D4$L!
M A0#%     @ &H>86@M ELEQ#P  ,LD  !8              ( !I/4% '-P
M<F-Y+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  :AYA:'/X' N%=  !M
M_P4 %@              @ %)!08 <W!R8WDM,C R-#$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( !J'F%K[7'RUQ]D  ,*E"@ 6              "  5YC!@!S
M<')C>2TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ &H>86I:&L"N+7@
M03@& !8              ( !63T' '-P<F-Y+3(P,C0Q,C,Q7W!R92YX;6Q0
52P4&      T #0": P  &)P'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>ea0237489-20f_scisparc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sprcy="http://www.trpx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sprcy-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-25</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-21</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-04-11</startDate>
            <endDate>2017-04-11</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PreFundedUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:SaleOfStockAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-12-30</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-12-30</startDate>
            <endDate>2024-12-30</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-18</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-28343">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-28344">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-28345">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-28346">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-28347">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-28348">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-28349">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-28350">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-28351">001-38041</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-71">SCISPARC LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-28352">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-93">20 Raul Wallenberg St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-97">Tower A, 2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-28353">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-28354">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-28355">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-110">Oz Adler</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1" id="ixv-28356">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-28357">3-7175777</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1" id="ixv-28358">oz@scisparc.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-123">20 Raul Wallenberg St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-127">Tower A, 2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-28359">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-28360">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-28361">IL</dei:EntityAddressCountry>
    <dei:Security12gTitle contextRef="c0" id="ixv-28362">Ordinary Shares, no par value</dei:Security12gTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-165">SPRC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-28363">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-28364"
      unitRef="shares">10828251</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-28365">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-28366">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-28367">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-28368">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-28369">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-251">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-28370">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-28371">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-28372">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-28373">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-28374">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-15508">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our board of directors
recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and
employees. Our IT general controls cybersecurity policies, standards, processes and practices are fully&#160;integrated&#160;into
our risk management approach.&#160;In general, we seek to address IT general controls cybersecurity risks through a comprehensive,
cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we
collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity
incidents when they occur.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-28375">Our IT general controls cybersecurity policies, standards, processes and practices are fully&#160;integrated&#160;into
our risk management approach.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-28376">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-28377">1281</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-16842">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Opinion on the Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024
and 2023, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the
period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-28378">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-16968">Tel Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28379" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28380" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28381" unitRef="usd">20000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28382" unitRef="usd">65000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-28383" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c2" decimals="-3" id="ixv-28384" unitRef="usd">10000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c3" decimals="-3" id="ixv-28385" unitRef="usd">22000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-28386" unitRef="usd">1079000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-28387" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-28388" unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-28389" unitRef="usd">4224000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-28390" unitRef="usd">113000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-28391" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-28392" unitRef="usd">7503000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-28393" unitRef="usd">6445000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-28394" unitRef="usd">1479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-28395" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c2" decimals="-3" id="ixv-28396" unitRef="usd">952000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c3" decimals="-3" id="ixv-28397" unitRef="usd">781000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-28398" unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c3" decimals="-3" id="ixv-28399" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-28400" unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-28401" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-28402" unitRef="usd">2844000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-28403" unitRef="usd">4737000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-28404" unitRef="usd">10347000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-28405" unitRef="usd">11182000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-28406" unitRef="usd">816000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-28407" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-28408" unitRef="usd">205000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-28409" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c3" decimals="-3" id="ix_0_fact" unitRef="usd">191000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="-3" id="ixv-28411" unitRef="usd">341000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c3" decimals="-3" id="ix_1_fact" unitRef="usd">341000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28413" unitRef="usd">37000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28414" unitRef="usd">52000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-28415" unitRef="usd">1399000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-28416" unitRef="usd">1571000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28417" unitRef="usd">9000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28418" unitRef="usd">24000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-28419" unitRef="usd">70886000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-28420" unitRef="usd">64526000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-28421" unitRef="usd">5746000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-28422" unitRef="usd">5282000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c2" decimals="-3" id="ixv-28423" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c3" decimals="-3" id="ixv-28424" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-28425" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c3" decimals="-3" id="ixv-28426" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c2" decimals="-3" id="ixv-28427" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c3" decimals="-3" id="ixv-28428" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-28429" unitRef="usd">-74975000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-28430" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-28431" unitRef="usd">8154000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="-3" id="ixv-28432" unitRef="usd">7614000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-28433" unitRef="usd">785000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c3" decimals="-3" id="ixv-28434" unitRef="usd">1973000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-28435" unitRef="usd">8939000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-28436" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-28437" unitRef="usd">10347000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-28438" unitRef="usd">11182000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-28440" unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c4" decimals="-3" id="ixv-28441" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c5" decimals="-3" id="ixv-28442" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-28443" unitRef="usd">800000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="-3" id="ixv-28444" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c5" decimals="-3" id="ixv-28445" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="-3" id="ixv-28446" unitRef="usd">506000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c4" decimals="-3" id="ixv-28447" unitRef="usd">2196000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c5" decimals="-3" id="ixv-28448" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-28449" unitRef="usd">1707000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-28450" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-28451" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-28452" unitRef="usd">1515000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="-3" id="ix_2_fact" unitRef="usd">2484000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c5" decimals="-3" id="ix_3_fact" unitRef="usd">1082000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-28455" unitRef="usd">1344000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-28456" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-28457" unitRef="usd">4526000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ix_4_fact" unitRef="usd">3844000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ix_5_fact" unitRef="usd">5427000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherIncome contextRef="c0" decimals="-3" id="ixv-28460" unitRef="usd">1270000</ifrs-full:OtherIncome>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-28461" unitRef="usd">-7316000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="-3" id="ixv-28462" unitRef="usd">-6815000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c5" decimals="-3" id="ixv-28463" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-28464" unitRef="usd">-429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-28465" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-28466" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-28467" unitRef="usd">612000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-28468" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-28469" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-28470" unitRef="usd">353000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-28471" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-28472" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-28473" unitRef="usd">-7486000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="-3" id="ixv-28474" unitRef="usd">-5861000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="-3" id="ixv-28475" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-28476" unitRef="usd">-14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="-3" id="ixv-28477" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="-3" id="ixv-28478" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28479" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28480" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28481" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-28482" unitRef="usd">-6284000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-28483" unitRef="usd">-5122000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-28484" unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-28485" unitRef="usd">-1188000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-28486" unitRef="usd">-761000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28487" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28488" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28489" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-28490"
      unitRef="usdPershares">1.28</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-28491"
      unitRef="usdPershares">14.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-28492"
      unitRef="usdPershares">14.82</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-28493"
      unitRef="usdPershares">1.28</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-28494"
      unitRef="usdPershares">14.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-28495"
      unitRef="usdPershares">14.82</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c6" decimals="-3" id="ixv-28497" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-28498" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-28499" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-28500" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-28501" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c11" decimals="-3" id="ixv-28502" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-28503" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-28504" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c20" decimals="-3" id="ixv-28505" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c21" decimals="-3" id="ixv-28506" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28507" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c15" decimals="-3" id="ixv-28508" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c21" decimals="-3" id="ixv-28509" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c5" decimals="-3" id="ixv-28510" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c15" decimals="-3" id="ixv-28511" unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c16" decimals="-3" id="ixv-28512" unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c21" decimals="-3" id="ixv-28513" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-28514" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c23" decimals="-3" id="ixv-28515" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c24" decimals="-3" id="ixv-28516" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c25" decimals="-3" id="ixv-28517" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c26" decimals="-3" id="ixv-28518" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-28519" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-28520" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-28521" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-28522" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c37" decimals="-3" id="ixv-28523" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c38" decimals="-3" id="ixv-28524" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c39" decimals="-3" id="ixv-28525" unitRef="usd">-761000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28526" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c35" decimals="-3" id="ixv-28527" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c38" decimals="-3" id="ixv-28528" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c39" decimals="-3" id="ixv-28529" unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-28530" unitRef="usd">2985000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost contextRef="c32" decimals="-3" id="ixv-28531" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c38" decimals="-3" id="ixv-28532" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c4" decimals="-3" id="ixv-28533" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c32" decimals="-3" id="ixv-28534" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c38" decimals="-3" id="ixv-28535" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c4" decimals="-3" id="ixv-28536" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c32" decimals="-3" id="ixv-28537" unitRef="usd">94000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c33" decimals="-3" id="ixv-28538" unitRef="usd">102000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c38" decimals="-3" id="ixv-28539" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-28540" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-28541" unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-28542" unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-28543" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-28544" unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-28545" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-28546" unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-28547" unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c47" decimals="-3" id="ixv-28548" unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-28549" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c53" decimals="-3" id="ixv-28550" unitRef="usd">-6284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c54" decimals="-3" id="ixv-28551" unitRef="usd">-6284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c55" decimals="-3" id="ixv-28552" unitRef="usd">-1188000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28553" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c48" decimals="-3" id="ixv-28554" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c54" decimals="-3" id="ixv-28555" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c0" decimals="-3" id="ixv-28556" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c48" decimals="-3" id="ixv-28557" unitRef="usd">105000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c49" decimals="-3" id="ixv-28558" unitRef="usd">464000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c54" decimals="-3" id="ixv-28559" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-28560" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c56" decimals="-3" id="ixv-28561" unitRef="usd">70886000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c57" decimals="-3" id="ixv-28562" unitRef="usd">5746000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c58" decimals="-3" id="ixv-28563" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c59" decimals="-3" id="ixv-28564" unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c60" decimals="-3" id="ixv-28565" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c61" decimals="-3" id="ixv-28566" unitRef="usd">-74975000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c62" decimals="-3" id="ixv-28567" unitRef="usd">8154000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c63" decimals="-3" id="ixv-28568" unitRef="usd">785000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-28569" unitRef="usd">8939000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28570" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28571" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28572" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-28573" unitRef="usd">482000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c4" decimals="-3" id="ixv-28574" unitRef="usd">538000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c5" decimals="-3" id="ixv-28575" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-28576" unitRef="usd">1344000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-28577" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-28578" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-28579" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-28580" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-28581" unitRef="usd">897000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c4" decimals="-3" id="ixv-28582" unitRef="usd">2205000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c5" decimals="-3" id="ixv-28583" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c0" decimals="-3" id="ixv-28584" unitRef="usd">429000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c4" decimals="-3" id="ixv-28585" unitRef="usd">210000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c5" decimals="-3" id="ixv-28586" unitRef="usd">109000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c0" decimals="-3" id="ixv-28587" unitRef="usd">305000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c4" decimals="-3" id="ixv-28588" unitRef="usd">1048000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c5" decimals="-3" id="ixv-28589" unitRef="usd">770000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-28590" unitRef="usd">2232000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c4" decimals="-3" id="ixv-28591" unitRef="usd">829000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c5" decimals="-3" id="ixv-28592" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c0" decimals="-3" id="ixv-28593" unitRef="usd">-535000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c4" decimals="-3" id="ixv-28594" unitRef="usd">-409000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c5" decimals="-3" id="ixv-28595" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-28596" unitRef="usd">25000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c4" decimals="-3" id="ixv-28597" unitRef="usd">-397000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" id="ixv-28598" unitRef="usd">20000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="-3" id="ixv-28599" unitRef="usd">-8000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c5" decimals="-3" id="ixv-28600" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <sprcy:AdjustmentsForIncreaseInRelatedParties contextRef="c0" decimals="-3" id="ixv-28601" unitRef="usd">15000</sprcy:AdjustmentsForIncreaseInRelatedParties>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c0" decimals="-3" id="ixv-28602" unitRef="usd">12000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c4" decimals="-3" id="ixv-28603" unitRef="usd">55000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c5" decimals="-3" id="ixv-28604" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="-3" id="ixv-28605" unitRef="usd">629000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c4" decimals="-3" id="ixv-28606" unitRef="usd">-74000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c5" decimals="-3" id="ixv-28607" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c0" decimals="-3" id="ixv-28608" unitRef="usd">136000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c4" decimals="-3" id="ixv-28609" unitRef="usd">-833000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c5" decimals="-3" id="ixv-28610" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-28611" unitRef="usd">-5104000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-28612" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-28613" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-28614" unitRef="usd">45000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-28615" unitRef="usd">-5000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-28616" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" id="ixv-28617" unitRef="usd">3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c4" decimals="-3" id="ixv-28618" unitRef="usd">-3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <sprcy:SalepurchaseOfPropertyAndEquipment contextRef="c0" decimals="-3" id="ixv-28619" unitRef="usd">-8000</sprcy:SalepurchaseOfPropertyAndEquipment>
    <sprcy:SalepurchaseOfPropertyAndEquipment contextRef="c5" decimals="-3" id="ixv-28620" unitRef="usd">8000</sprcy:SalepurchaseOfPropertyAndEquipment>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-28621" unitRef="usd">600000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-28622" unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-28623" unitRef="usd">700000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties contextRef="c0" decimals="-3" id="ixv-28624" unitRef="usd">4078000</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-28625" unitRef="usd">689000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-28626" unitRef="usd">1500000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-28627" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-28628" unitRef="usd">-1625000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-28629" unitRef="usd">-4094000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-28630" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="-3" id="ixv-28631" unitRef="usd">6255000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c4" decimals="-3" id="ixv-28632" unitRef="usd">5552000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c5" decimals="-3" id="ixv-28633" unitRef="usd">9005000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c4" decimals="-3" id="ix_6_fact" unitRef="usd">2985000</ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c5" decimals="-3" id="ixv-28635" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c5" decimals="-3" id="ixv-28636" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-28637" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-28638" unitRef="usd">7000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-28639" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-28640" unitRef="usd">54000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-28641" unitRef="usd">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-28642" unitRef="usd">70000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-28643" unitRef="usd">6193000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="-3" id="ixv-28644" unitRef="usd">8483000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-28645" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-28646" unitRef="usd">-536000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-28647" unitRef="usd">-1498000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-28648" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28649" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c31" decimals="-3" id="ixv-28650" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c14" decimals="-3" id="ixv-28651" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28652" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28653" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c31" decimals="-3" id="ixv-28654" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c0" decimals="-3" id="ixv-28656" unitRef="usd">75000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c4" decimals="-3" id="ixv-28657" unitRef="usd">102000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c4" decimals="-3" id="ixv-28658" unitRef="usd">288000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0" id="ixv-20401">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d; or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#x2019;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#x2019;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
board of directors (the &#x201c;Board&#x201d;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $74,975 as a result of recurring operating losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company&#x2019;s
cash and cash equivalents totaled $1,540. In the period ended December 31, 2024, the Company had an operating loss of $7,316 and negative
cash flows from operating activities of $5,104. The Company&#x2019;s current cash and cash equivalents position is not sufficient to fund
the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Definitions and Meanings:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Companies that are controlled by the Company, as defined in IFRS 10, &#x201c;&lt;i&gt;Consolidated Financial Statements&lt;/i&gt;&#x201d;, and whose accounts are consolidated with those of the Company (if active).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Associates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An entity over which the Company has significant influence, as defined in IAS 28, &#x201c;&lt;i&gt;Investment in Associates and Joint Ventures&lt;/i&gt;&#x201d; and is not a Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related Parties&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As defined in IAS 24, &#x201c;&lt;i&gt;Related Party Disclosures&lt;/i&gt;&#x201d;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Accounting Standards issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Financial Reporting Standards issued by the IASB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c64" decimals="-3" id="ixv-28659" unitRef="usd">-74975000</ifrs-full:RetainedEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28660" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-28661" unitRef="usd">-7316000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-28662" unitRef="usd">-5104000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-20561">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;7-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;3.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Impairment of financial assets:&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company evaluates at the end of each reporting
period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes
between two types of loss allowances:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 168px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Debt instruments whose credit risk has not increased significantly since initial recognition, or whose
credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit
losses within 12 months from the reporting date (12-month ECLs); or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 168px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit
risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument&#x2019;s remaining
term (lifetime ECLs).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has short-term financial assets in
respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime
expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company considers a financial asset in default
when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in
default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in
full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
Company&#x2019;s Brand sells products directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory contextRef="c0" id="ixv-20573">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;</sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory>
    <sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory contextRef="c0" id="ixv-20594">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory>
    <sprcy:OperatingTerm contextRef="c0" id="ixv-28663">P1Y</sprcy:OperatingTerm>
    <sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements contextRef="c0" id="ixv-20606">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-20624">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <sprcy:DescriptionOfAcquisitionOfASingleAssetCompany contextRef="c0" id="ixv-20636">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;</sprcy:DescriptionOfAcquisitionOfASingleAssetCompany>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-20685">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="c0" id="ixv-20697">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0" id="ixv-20737">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-20802">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;7-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory contextRef="c0" id="ixv-20814">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;7-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c65" decimals="2" id="ixv-28664" unitRef="pure">0.06</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c66" decimals="2" id="ixv-28665" unitRef="pure">0.50</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c67" decimals="2" id="ixv-28666" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c68" decimals="2" id="ixv-28667" unitRef="pure">0.33</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c69" decimals="2" id="ixv-28668" unitRef="pure">0.50</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c70" decimals="2" id="ixv-28669" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c71" decimals="2" id="ixv-28670" unitRef="pure">0.07</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c72" decimals="2" id="ixv-28671" unitRef="pure">0.15</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c73" decimals="2" id="ixv-28672" unitRef="pure">0.15</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife contextRef="c74" id="ixv-28673">see below</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c0" id="ixv-20867">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0" id="ixv-20882">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-20931">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;3.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Impairment of financial assets:&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company evaluates at the end of each reporting
period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes
between two types of loss allowances:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 168px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Debt instruments whose credit risk has not increased significantly since initial recognition, or whose
credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit
losses within 12 months from the reporting date (12-month ECLs); or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 168px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit
risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument&#x2019;s remaining
term (lifetime ECLs).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has short-term financial assets in
respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime
expected credit losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company considers a financial asset in default
when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in
default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in
full.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-21270">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c0" id="ixv-21285">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0" id="ixv-21297">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0" id="ixv-21405">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-21495">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-21526">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-21582">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c0" id="ixv-21621">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-21644">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c0" id="ixv-21800">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c0" id="ixv-21813">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
Company&#x2019;s Brand sells products directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock contextRef="c0" id="ixv-21834">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock>
    <ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory contextRef="c0" id="ixv-21877">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Judgments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount rate for a lease liability:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#x2019;s conditions and restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective control:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#x2019;
meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining the fair value of share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#x201c;OPM&#x201d;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest and
expected dividend yield.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates and assumptions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal claims:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#x2019;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#x2019;s familiarity of and proximity to the circumstances, and also on the legal counsels&#x2019; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disclosure of new standards in the period prior to their adoption:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18, &#x201c;Presentation and Disclosure
in Financial Statements&#x201d;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In April 2024, the International Accounting
Standards Board (&#x201c;the IASB&#x201d;) issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;)
which replaces IAS 1, &#x201c;Presentation of Financial Statements&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be classified
into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change the entity&#x2019;s
operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other accounting standards,
including IAS 7, &#x201c;Statement of Cash Flows&#x201d; and IAS 34, &#x201c;Interim Financial Reporting&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-22054">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CASH&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;157&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-22064">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;157&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c75" decimals="-3" id="ixv-28674" unitRef="usd">1383000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c76" decimals="-3" id="ixv-28675" unitRef="usd">1866000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c77" decimals="-3" id="ixv-28676" unitRef="usd">157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c78" decimals="-3" id="ixv-28677" unitRef="usd">210000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28678" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28679" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0" id="ixv-22122">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <sprcy:DisclosureOfInventorieExplanatory contextRef="c0" id="ixv-22132">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInventorieExplanatory>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c2" decimals="-3" id="ixv-28680" unitRef="usd">9000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c3" decimals="-3" id="ixv-28681" unitRef="usd">73000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:FinishedGoods contextRef="c2" decimals="-3" id="ixv-28682" unitRef="usd">104000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c3" decimals="-3" id="ixv-28683" unitRef="usd">669000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-28684" unitRef="usd">113000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-28685" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-22190">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receivables in respect of downpayment on merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <sprcy:DisclourseOfAccountsReceivablesTableTextBlock contextRef="c0" id="ixv-22200">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receivables in respect of downpayment on merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclourseOfAccountsReceivablesTableTextBlock>
    <sprcy:Governmentauthoritiescurrent contextRef="c2" decimals="-3" id="ixv-28686" unitRef="usd">78000</sprcy:Governmentauthoritiescurrent>
    <sprcy:Governmentauthoritiescurrent contextRef="c3" decimals="-3" id="ixv-28687" unitRef="usd">62000</sprcy:Governmentauthoritiescurrent>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-28688" unitRef="usd">449000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-28689" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-28690" unitRef="usd">350000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-28691" unitRef="usd">275000</ifrs-full:CurrentPrepaidExpenses>
    <sprcy:ReceivablesInRespectOfDownpaymentOnMerger contextRef="c2" decimals="-3" id="ixv-28692" unitRef="usd">187000</sprcy:ReceivablesInRespectOfDownpaymentOnMerger>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-28693" unitRef="usd">15000</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-28694" unitRef="usd">1079000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-28695" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="c0" id="ixv-22290">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN ASSOCIATES AND JOINT VENTURES &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MitoCareX - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid on March
11, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 26, 2024, the Company signed a non-binding letter of intent
relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#x201c;N2OFF&#x201d;) a publicly-traded company in the
United States which is a related party (the &#x201c;Purchaser&#x201d;). Pursuant to the terms of the letter of intent, initially, in exchange
for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute 27% of SciSparc&#x2019;s ownership
in MitoCareX, SciSparc will receive cash consideration of $700. Subsequent to this first phase, SciSparc will transfer to the Purchaser
the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser
equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700, in cash consideration for SciSparc&#x2019;s
shares described above). The letter of intent also includes provisions for additional milestones that, upon achievement, may increase
the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full terms of this transaction are subject
to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company and the Purchaser have not closed the
sale of the ownership of MitoCareX and the Company still holds 52.73% of the issued and outstanding share capital of MitoCareX. See also
Note 25(d).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $429 (for the year ended December 31, 2023
- $210).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;952&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <sprcy:InitialInvestment contextRef="c79" decimals="-3" id="ixv-28696" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:AdditionalInvestment contextRef="c80" decimals="-3" id="ixv-28697" unitRef="usd">1000000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c81" decimals="4" id="ixv-28698" unitRef="pure">0.5001</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:InitialInvestment contextRef="c82" decimals="-3" id="ixv-28699" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:OutstandingSharesPercentage contextRef="c83" decimals="4" id="ixv-28700" unitRef="pure">0.3148</sprcy:OutstandingSharesPercentage>
    <sprcy:AdditionalInvestment contextRef="c84" decimals="-3" id="ixv-28701" unitRef="usd">400000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c85" decimals="4" id="ixv-28702" unitRef="pure">0.3148</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c86" decimals="4" id="ixv-28703" unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:AdditionalInvestment contextRef="c87" decimals="-3" id="ixv-28704" unitRef="usd">600000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c88" decimals="4" id="ixv-28705" unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c89" decimals="4" id="ixv-28706" unitRef="pure">0.5273</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:AdditionalInstallment contextRef="c90" decimals="-3" id="ixv-28707" unitRef="usd">600000</sprcy:AdditionalInstallment>
    <sprcy:InstallmentPaid contextRef="c91" decimals="-3" id="ixv-28708" unitRef="usd">600000</sprcy:InstallmentPaid>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c92" decimals="2" id="ixv-28709" unitRef="pure">0.27</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:CashConsideration contextRef="c92" decimals="-3" id="ixv-28710" unitRef="usd">700000</sprcy:CashConsideration>
    <sprcy:PurchaserRemainingOwnershipPercentage contextRef="c93" decimals="2" id="ixv-28711" unitRef="pure">0.73</sprcy:PurchaserRemainingOwnershipPercentage>
    <sprcy:RemainingPurchaserAmount contextRef="c93" decimals="-3" id="ixv-28712" unitRef="usd">8000000</sprcy:RemainingPurchaserAmount>
    <sprcy:RemainingPurchaserAmount contextRef="c94" decimals="-3" id="ixv-28713" unitRef="usd">5000000</sprcy:RemainingPurchaserAmount>
    <sprcy:CashConsideration contextRef="c95" decimals="-3" id="ixv-28714" unitRef="usd">700000</sprcy:CashConsideration>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="c96" decimals="-3" id="ixv-28715" unitRef="usd">5000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="c97" decimals="-3" id="ixv-28716" unitRef="usd">7000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <sprcy:IssuedAndOutstandingSharePercentage contextRef="c94" decimals="4" id="ixv-28717" unitRef="pure">0.5273</sprcy:IssuedAndOutstandingSharePercentage>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c83" decimals="-3" id="ixv-28718" unitRef="usd">429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c98" decimals="-3" id="ixv-28719" unitRef="usd">210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0" id="ixv-22365">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;952&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sprcy:InvestmentsDate contextRef="c5" decimals="-3" id="ixv-28720" unitRef="usd">700000</sprcy:InvestmentsDate>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-28721" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c31" decimals="-3" id="ixv-28722" unitRef="usd">591000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:InvestmentAchievementOfFirstMilestone contextRef="c4" decimals="-3" id="ixv-28723" unitRef="usd">400000</sprcy:InvestmentAchievementOfFirstMilestone>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-28724" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c3" decimals="-3" id="ixv-28725" unitRef="usd">781000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:InvestmentAchievementOfSecondMilestone contextRef="c0" decimals="-3" id="ixv-28726" unitRef="usd">600000</sprcy:InvestmentAchievementOfSecondMilestone>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-28727" unitRef="usd">-429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c2" decimals="-3" id="ixv-28728" unitRef="usd">952000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory contextRef="c0" id="ixv-22451">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 8:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN FINANCIAL ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Clearmind&lt;/span&gt;&lt;/i&gt; &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#x201c;CMND&#x201d; and the Frankfurt Stock Exchange under the symbol &#x201c;CWY.&#x201d; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company holdings in Clearmind decreased from 230,769 common shares to 7,692. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $1.38 and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $11 on its investment (for the year ended December 31, 2023 - $727). &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c99" decimals="-3" id="ixv-28729" unitRef="usd">1500000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c100"
      decimals="0"
      id="ixv-28730"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssued>
    <sprcy:ShareCapitalPercentage
      contextRef="c101"
      decimals="4"
      id="ixv-28731"
      unitRef="pure">0.0933</sprcy:ShareCapitalPercentage>
    <ifrs-full:ParValuePerShare
      contextRef="c105"
      decimals="0"
      id="ixv-28732"
      unitRef="usdPershares">0</ifrs-full:ParValuePerShare>
    <sprcy:ReverseShareSplitRatio contextRef="c104" id="ixv-28733">1-for-30</sprcy:ReverseShareSplitRatio>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c102"
      decimals="0"
      id="ixv-28734"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c103"
      decimals="0"
      id="ixv-28735"
      unitRef="shares">7692</ifrs-full:NumberOfSharesIssued>
    <sprcy:SharePricePerShare
      contextRef="c0"
      decimals="-1"
      id="ixv-28736"
      unitRef="usdPershares">1380</sprcy:SharePricePerShare>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-28737" unitRef="usd">11000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-28738" unitRef="usd">727000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-22497">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 9:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately 240 square meters, whereby the Company occupies approximately 120
square meters for the Company&#x2019;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
&lt;span style="-sec-ix-hidden: hidden-fact-94"&gt;three&lt;/span&gt;-year term. The monthly lease fee was set at approximately $3, linked to the NIS.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <sprcy:AreaOfLease contextRef="c106" decimals="0" id="ixv-28739" unitRef="sqm">240</sprcy:AreaOfLease>
    <sprcy:AreaOfLease contextRef="c107" decimals="0" id="ixv-28740" unitRef="sqm">120</sprcy:AreaOfLease>
    <sprcy:MonthlyLeaseFee
      contextRef="c108"
      decimals="-3"
      id="ixv-28741"
      unitRef="usd">3000</sprcy:MonthlyLeaseFee>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-22512">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right of use asses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January&#160;1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Depreciated cost at December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $37, $52 and $43, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-22522">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right of use asses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January&#160;1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Depreciated cost at December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c109"
      decimals="-3"
      id="ixv-28742"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c110"
      decimals="-3"
      id="ixv-28743"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c111"
      decimals="-3"
      id="ixv-28744"
      unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c112"
      decimals="-3"
      id="ixv-28745"
      unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c113"
      decimals="-3"
      id="ixv-28746"
      unitRef="usd">2000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c115"
      decimals="-3"
      id="ixv-28747"
      unitRef="usd">75000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c116"
      decimals="-3"
      id="ixv-28748"
      unitRef="usd">77000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c113"
      decimals="-3"
      id="ixv-28749"
      unitRef="usd">1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c114"
      decimals="-3"
      id="ixv-28750"
      unitRef="usd">21000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c115"
      decimals="-3"
      id="ixv-28751"
      unitRef="usd">181000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c116"
      decimals="-3"
      id="ixv-28752"
      unitRef="usd">203000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c117"
      decimals="-3"
      id="ixv-28753"
      unitRef="usd">12000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c118"
      decimals="-3"
      id="ixv-28754"
      unitRef="usd">12000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c119"
      decimals="-3"
      id="ixv-28755"
      unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c120"
      decimals="-3"
      id="ixv-28756"
      unitRef="usd">99000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c121"
      decimals="-3"
      id="ixv-28757"
      unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c122"
      decimals="-3"
      id="ixv-28758"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c123"
      decimals="-3"
      id="ixv-28759"
      unitRef="usd">106000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c124"
      decimals="-3"
      id="ixv-28760"
      unitRef="usd">117000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c125"
      decimals="-3"
      id="ixv-28761"
      unitRef="usd">4000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c126"
      decimals="-3"
      id="ixv-28762"
      unitRef="usd">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c127"
      decimals="-3"
      id="ixv-28763"
      unitRef="usd">28000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-28764"
      unitRef="usd">33000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c125"
      decimals="-3"
      id="ixv-28765"
      unitRef="usd">1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c126"
      decimals="-3"
      id="ixv-28766"
      unitRef="usd">4000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c127"
      decimals="-3"
      id="ixv-28767"
      unitRef="usd">106000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-28768"
      unitRef="usd">111000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c129"
      decimals="-3"
      id="ixv-28769"
      unitRef="usd">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c130"
      decimals="-3"
      id="ixv-28770"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c131"
      decimals="-3"
      id="ixv-28771"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c132"
      decimals="-3"
      id="ixv-28772"
      unitRef="usd">40000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c133"
      decimals="-3"
      id="ixv-28773"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c134"
      decimals="-3"
      id="ixv-28774"
      unitRef="usd">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c135"
      decimals="-3"
      id="ixv-28775"
      unitRef="usd">47000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-28776" unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c136"
      decimals="-3"
      id="ixv-28777"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c137"
      decimals="-3"
      id="ixv-28778"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c138"
      decimals="-3"
      id="ixv-28779"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c139"
      decimals="-3"
      id="ixv-28780"
      unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c142"
      decimals="-3"
      id="ixv-28781"
      unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c143"
      decimals="-3"
      id="ixv-28782"
      unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c109"
      decimals="-3"
      id="ixv-28783"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c110"
      decimals="-3"
      id="ixv-28784"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c111"
      decimals="-3"
      id="ixv-28785"
      unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c112"
      decimals="-3"
      id="ixv-28786"
      unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c144"
      decimals="-3"
      id="ixv-28787"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c145"
      decimals="-3"
      id="ixv-28788"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c146"
      decimals="-3"
      id="ixv-28789"
      unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c147"
      decimals="-3"
      id="ixv-28790"
      unitRef="usd">65000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c148"
      decimals="-3"
      id="ixv-28791"
      unitRef="usd">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c149"
      decimals="-3"
      id="ixv-28792"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c150"
      decimals="-3"
      id="ixv-28793"
      unitRef="usd">47000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c151"
      decimals="-3"
      id="ixv-28794"
      unitRef="usd">52000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c121"
      decimals="-3"
      id="ixv-28795"
      unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c122"
      decimals="-3"
      id="ixv-28796"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c123"
      decimals="-3"
      id="ixv-28797"
      unitRef="usd">106000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c124"
      decimals="-3"
      id="ixv-28798"
      unitRef="usd">117000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c152"
      decimals="-3"
      id="ixv-28799"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c153"
      decimals="-3"
      id="ixv-28800"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c154"
      decimals="-3"
      id="ixv-28801"
      unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-28802" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="-3" id="ixv-28803" unitRef="usd">37000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="-3" id="ixv-28804" unitRef="usd">52000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="-3" id="ixv-28805" unitRef="usd">43000</ifrs-full:DepreciationExpense>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-23049">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 11:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INTANGIBLE ASSET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 30, 2022, the Company
announced the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace account (the &#x201c;Brand&#x201d;),
American food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 -
$1,042).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 7.8
years (2023 &#x2013; 8.7), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#x2019;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of 27.8% (2023 &#x2013; 13.8%) and a declining growth rate for the long term, reaching 2% (2023 &#x2013; 2%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of 21.9% (2023 &#x2013; 20.6%).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $366 (for the year ended December 31,
2023 - $486).&#160;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:Cash contextRef="c2" decimals="-3" id="ixv-28806" unitRef="usd">4540000</ifrs-full:Cash>
    <sprcy:PaymentsOfAdditionalDeferredCash contextRef="c0" decimals="-3" id="ixv-28807" unitRef="usd">1120000</sprcy:PaymentsOfAdditionalDeferredCash>
    <sprcy:PurchaseCostsValue contextRef="c2" decimals="-3" id="ixv-28808" unitRef="usd">321000</sprcy:PurchaseCostsValue>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-28809" unitRef="usd">4861000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c0" id="ixv-28810">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-28811" unitRef="usd">1344000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-28812" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c0" id="ixv-28813">P7Y9M18D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c4" id="ixv-28814">P8Y8M12D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sprcy:GrowthRatePercentage contextRef="c0" decimals="3" id="ixv-28815" unitRef="pure">0.278</sprcy:GrowthRatePercentage>
    <sprcy:GrowthRatePercentage contextRef="c4" decimals="3" id="ixv-28816" unitRef="pure">0.138</sprcy:GrowthRatePercentage>
    <sprcy:LongTermPercentage contextRef="c0" decimals="2" id="ixv-28817" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <sprcy:LongTermPercentage contextRef="c4" decimals="2" id="ixv-28818" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <sprcy:DiscountRatePercentage contextRef="c0" decimals="3" id="ixv-28819" unitRef="pure">0.219</sprcy:DiscountRatePercentage>
    <sprcy:DiscountRatePercentage contextRef="c4" decimals="3" id="ixv-28820" unitRef="pure">0.206</sprcy:DiscountRatePercentage>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c0" id="ixv-23108">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c31" decimals="-3" id="ixv-28821" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-28822" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-28823" unitRef="usd">486000</sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-28824" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-28825" unitRef="usd">1344000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-28826" unitRef="usd">366000</sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-28827" unitRef="usd">1479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="c155"
      decimals="-3"
      id="ixv-28828"
      unitRef="usd">366000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="c156"
      decimals="-3"
      id="ixv-28829"
      unitRef="usd">486000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-23177">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 12:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRADE PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;816&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <sprcy:DisclosureOfTradePayablesExplanatory contextRef="c0" id="ixv-23187">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;816&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfTradePayablesExplanatory>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c2" decimals="-3" id="ixv-28830" unitRef="usd">608000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="-3" id="ixv-28831" unitRef="usd">538000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:NetDebt contextRef="c2" decimals="-3" id="ixv-28832" unitRef="usd">208000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt contextRef="c3" decimals="-3" id="ixv-28833" unitRef="usd">264000</ifrs-full:NetDebt>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-28834" unitRef="usd">816000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-28835" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <sprcy:DisclosureOfOtherAccountsPayableTextBlock contextRef="c0" id="ixv-23269">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 13:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;205&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfOtherAccountsPayableTextBlock>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="c0" id="ixv-23279">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;205&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c2" decimals="-3" id="ixv-28836" unitRef="usd">75000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c3" decimals="-3" id="ixv-28837" unitRef="usd">48000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:Accruals contextRef="c2" decimals="-3" id="ixv-28838" unitRef="usd">130000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c3" decimals="-3" id="ixv-28839" unitRef="usd">104000</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c3" decimals="-3" id="ixv-28840" unitRef="usd">33000</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-28841" unitRef="usd">205000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-28842" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-23348">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification of financial assets and financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,239&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,248&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Investments in financial assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison between
the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2024, and 2023, which are presented
in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Investments in short-term financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#160;&#160;&#160;&#160;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x202f;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#x2019;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#x2019;s
financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Foreign currency risk:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory contextRef="c0" id="ixv-23366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,239&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,248&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Investments in financial assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28843" unitRef="usd">1560000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28844" unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-28845" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-28846" unitRef="usd">449000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-28847" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-28848" unitRef="usd">4239000</ifrs-full:NoncurrentReceivablesDueFromRelatedParties>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c2" decimals="-3" id="ixv-28849" unitRef="usd">6248000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c3" decimals="-3" id="ixv-28850" unitRef="usd">5344000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c2" decimals="-3" id="ixv-28851" unitRef="usd">871000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c3" decimals="-3" id="ixv-28852" unitRef="usd">659000</ifrs-full:FinancialAssetsAtFairValue>
    <sprcy:CreditFromOthers contextRef="c2" decimals="-3" id="ixv-28853" unitRef="usd">75000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers contextRef="c3" decimals="-3" id="ixv-28854" unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-28855" unitRef="usd">191000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28856" unitRef="usd">48000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28857" unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" id="ixv-28858" unitRef="usd">123000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" id="ixv-28859" unitRef="usd">315000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c0" id="ixv-23603">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison between
the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2024, and 2023, which are presented
in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Investments in short-term financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#160;&#160;&#160;&#160;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x202f;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-28860" unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c157"
      decimals="-3"
      id="ixv-28861"
      unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-28862" unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c157"
      decimals="-3"
      id="ixv-28863"
      unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c3" decimals="-3" id="ixv-28864" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c161"
      decimals="-3"
      id="ixv-28865"
      unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-28866" unitRef="usd">191000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c162"
      decimals="-3"
      id="ixv-28867"
      unitRef="usd">191000</sprcy:WarrantsLiability>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c0" id="ixv-23860">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 15:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EMPLOYEE BENEFIT LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Employee benefits consist of short-term
benefits and post-employment benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Post-employment benefits:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#x201c;Severance Pay Law&#x201d;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#x2019;s liability is accounted for as a post-employment benefit. The computation of the Company&#x2019;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#x2019;s salary and employment
term which establish the entitlement to receive the compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Defined contribution plans:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Expenses in respect of defined contribution plans&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;106&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory contextRef="c0" id="ixv-28868">These contributions and contributions for compensation represent defined contribution plans.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Expenses in respect of defined contribution plans&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;106&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-28869" unitRef="usd">106000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c4" decimals="-3" id="ixv-28870" unitRef="usd">105000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c5" decimals="-3" id="ixv-28871" unitRef="usd">115000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-23919">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 16:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TAXES ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax rates applicable to the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2024, 2023, and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The assessments of the Company are
deemed final through the 2016 tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward tax losses and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has accumulated tax losses
since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company&#x2019;s
net carryforward tax losses are estimated to be approximately $62,000.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c163"
      decimals="2"
      id="ixv-28872"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c164"
      decimals="2"
      id="ixv-28873"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c165"
      decimals="2"
      id="ixv-28874"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sprcy:OperatingLossCarryforwardsTaxAmount contextRef="c2" decimals="-3" id="ixv-28875" unitRef="usd">62000000</sprcy:OperatingLossCarryforwardsTaxAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-23986">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 17:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with Dekel Pharmaceuticals Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#x201c;Dekel License Agreement&#x201d;). The Dekel License Agreement became effective
in August 2015.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#x201c;Amendment&#x201d;), which encompasses the Company and Dekel&#x2019;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#x2019;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#x2019;s field of activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#x2019;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#x201c;Yissum&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#x201c;Yissum License Agreement&#x201d;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#x2019;s
share in such joint patents shall be automatically included in the Yissum License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agreement with Hannover Medical School:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#x201c;MHH&#x201d;) to conduct during 2018 a phase IIb clinical
trial titled &#x201c;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#x201d; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Agreement with Yale University:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 2, 2023, Capital Point Ltd. (&#x201c;Capital Point&#x201d;) filed with the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a suit against the Company, case number 2050-05-23 (the &#x201c;Suit&#x201d;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit challenges a certain warrant issued by the Company to Capital
Point (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340 of ordinary shares of the Company (the &#x201c;Warrant Shares&#x201d;).
The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint
venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary
of the Company, as further described in the Company&#x2019;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company
unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue
to Capital Point the Warrant Shares.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <sprcy:DekelLicenseAgreementDescription contextRef="c0" id="ixv-28876">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</sprcy:DekelLicenseAgreementDescription>
    <sprcy:AnnualInvestment contextRef="c0" decimals="-3" id="ixv-28877" unitRef="usd">350000</sprcy:AnnualInvestment>
    <sprcy:AdditionalMilestoneAmount
      contextRef="c166"
      decimals="-3"
      id="ixv-28878"
      unitRef="usd">75000</sprcy:AdditionalMilestoneAmount>
    <sprcy:InstallmentAmount
      contextRef="c167"
      decimals="-3"
      id="ixv-28879"
      unitRef="usd">122000</sprcy:InstallmentAmount>
    <sprcy:EstimatedAmount
      contextRef="c167"
      decimals="-3"
      id="ixv-28880"
      unitRef="usd">776000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c168"
      decimals="-3"
      id="ixv-28881"
      unitRef="usd">1385000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c169"
      decimals="-3"
      id="ixv-28882"
      unitRef="usd">370000</sprcy:EstimatedAmount>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c2" decimals="-3" id="ixv-28883" unitRef="usd">340000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="0" id="ixv-28884" unitRef="ils">10000000</ifrs-full:CapitalCommitments>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="-4" id="ixv-28885" unitRef="usd">2750000</ifrs-full:CapitalCommitments>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-24143">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 18:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,828,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Reverse Share Splits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#x2019;s share capital
to 75,000,000 ordinary shares with &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, &lt;i&gt;inter alia&lt;/i&gt;, a reverse split of the Company&#x2019;s share
capital up to a ratio of 30:1 (the &#x201c;Third Reverse Split&#x201d;). Following the implementation of the Third Reverse Split, the Company&#x2019;s
authorized share capital was adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt; ordinary shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;706,683&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issuance of share capital &#x2013; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,677,311&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Share issued to consultants (Note 18(e), and Note 19 (a) (3)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;646,179&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of January 2024 SEPA (Note 18(i))&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,798,078&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,828,251&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capital management in the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional issuances of ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 22, 2023, the Company issued 13,858 ordinary shares in respect
of the stock purchase&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;agreement entered into by and among Jeffs&#x2019; Brands
and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo&#x201d;) (see also Note 25a).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company issued 646,179 ordinary shares to consultants in respect of services rendered in the amount of $105&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 2022 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Financing Round&#x201d;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 66%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.872&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    share price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.36&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.88&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    fair value ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Less than $1 thousand&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify"&gt;During
the year ended December 31, 2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 14, 2023, the Company closed
an underwritten public offering (the &#x201c;2023 Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#x201c;Aegis&#x201d;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement,
the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments,
if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;).
The Pre-Funded Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company issued 3,677,311 ordinary shares in respect of the exercise of 3,677,311 Pre-Funded Warrants.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 2024 Standby Equity Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;), as amended on February 26, 2024, with YA II PN, LTD (&#x201c;YA&#x201d;),
which provided for the sale of up to $20,000 of the Company&#x2019;s ordinary shares (the &#x201c;Advance Shares&#x201d;). As of December
31, 2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#x201c;Commitment Amount&#x201d;), the Company has sold 5,742,785
ordinary shares for total proceeds of $6,255. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of 97% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#x2019;s ordinary shares
during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice to YA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#x201c;Pre-Paid Advance&#x201d;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#x201c;Promissory Note&#x201d;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest,
payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such notice against
an equal amount of the monthly installment amount, at the Company&#x2019;s option. If the Company elects to pay in cash, the installment
amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note
contains the Company&#x2019;s customary representations and warranties and events of default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, pursuant to the
SEPA, the Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of
the commitment fee of $200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-24159">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,828,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c2"
      decimals="INF"
      id="ixv-28886"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-28887"
      unitRef="shares">10828251</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c3"
      decimals="INF"
      id="ixv-28888"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-28889"
      unitRef="shares">706683</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c170"
      decimals="0"
      id="ixv-28890"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:CapitalRatio contextRef="c172" id="ixv-28891">30:1</sprcy:CapitalRatio>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c173"
      decimals="0"
      id="ixv-28892"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:ReverseSplitRatio contextRef="c172" id="ixv-28893">26:1</sprcy:ReverseSplitRatio>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c0" id="ixv-24280">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt; ordinary shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;706,683&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issuance of share capital &#x2013; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,677,311&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Share issued to consultants (Note 18(e), and Note 19 (a) (3)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;646,179&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of January 2024 SEPA (Note 18(i))&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,798,078&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,828,251&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-28894"
      unitRef="shares">706683</ifrs-full:NumberOfSharesIssued>
    <sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants
      contextRef="c0"
      decimals="INF"
      id="ixv-28895"
      unitRef="shares">3677311</sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants>
    <sprcy:ShareIssuedToAConsultants
      contextRef="c0"
      decimals="INF"
      id="ixv-28896"
      unitRef="shares">646179</sprcy:ShareIssuedToAConsultants>
    <sprcy:IssuanceOfShareCapitalInRespectSEPA
      contextRef="c0"
      decimals="INF"
      id="ixv-28897"
      unitRef="shares">5798078</sprcy:IssuanceOfShareCapitalInRespectSEPA>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-28898"
      unitRef="shares">10828251</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c174"
      decimals="0"
      id="ixv-28899"
      unitRef="shares">923</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c175"
      decimals="0"
      id="ixv-28900"
      unitRef="shares">1423</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c176"
      decimals="0"
      id="ixv-28901"
      unitRef="shares">13858</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c0"
      decimals="0"
      id="ixv-28902"
      unitRef="shares">646179</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ServicesExpense contextRef="c0" decimals="-3" id="ixv-28903" unitRef="usd">105000</ifrs-full:ServicesExpense>
    <ifrs-full:GrossProfit
      contextRef="c177"
      decimals="-3"
      id="ixv-28904"
      unitRef="usd">10210000</ifrs-full:GrossProfit>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c178"
      decimals="0"
      id="ixv-28905"
      unitRef="shares">136388</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c178"
      decimals="0"
      id="ixv-28906"
      unitRef="shares">12885</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c178"
      decimals="2"
      id="ixv-28907"
      unitRef="usdPershares">74.88</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c179"
      decimals="0"
      id="ixv-28908"
      unitRef="shares">123504</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c180"
      decimals="2"
      id="ixv-28909"
      unitRef="usdPershares">73.29</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c181"
      decimals="2"
      id="ixv-28910"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:IssuanceExpireTerm contextRef="c181" id="ixv-28911">P7Y</sprcy:IssuanceExpireTerm>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c0" id="ixv-24492">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 66%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.872&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    share price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.36&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.88&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    fair value ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Less than $1 thousand&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c0" decimals="2" id="ixv-28912" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c4" decimals="2" id="ixv-28913" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c0" decimals="2" id="ixv-28914" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c4" decimals="2" id="ixv-28915" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c0" decimals="4" id="ixv-28916" unitRef="pure">0.0438</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c4" decimals="5" id="ixv-28917" unitRef="pure">0.03872</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-28918"
      unitRef="usdPershares">0.36</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c4"
      decimals="2"
      id="ixv-28919"
      unitRef="usdPershares">4.88</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-28920"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c4"
      decimals="2"
      id="ixv-28921"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c3" decimals="-3" id="ixv-28922" unitRef="usd">192000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c182"
      decimals="0"
      id="ixv-28924"
      unitRef="shares">123504</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c183"
      decimals="0"
      id="ixv-28925"
      unitRef="shares">123504</sprcy:WarrantsAndExercise>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c184"
      decimals="0"
      id="ixv-28926"
      unitRef="shares">212500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c184"
      decimals="2"
      id="ixv-28927"
      unitRef="usdPershares">5.2</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c185"
      decimals="0"
      id="ixv-28928"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c185"
      decimals="3"
      id="ixv-28929"
      unitRef="usdPershares">5.174</sprcy:PurchasePricePerShare>
    <sprcy:AggregateGrossProceeds
      contextRef="c184"
      decimals="-3"
      id="ixv-28930"
      unitRef="usd">1300000</sprcy:AggregateGrossProceeds>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c186"
      decimals="0"
      id="ixv-28931"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c187"
      decimals="-3"
      id="ixv-28932"
      unitRef="usd">5026000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c188"
      decimals="0"
      id="ixv-28933"
      unitRef="shares">1930108</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c189"
      decimals="3"
      id="ixv-28934"
      unitRef="usdPershares">0.001</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c190"
      decimals="0"
      id="ixv-28935"
      unitRef="shares">3677311</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c191"
      decimals="0"
      id="ixv-28936"
      unitRef="shares">3677311</sprcy:WarrantsAndExercise>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="c192"
      decimals="-3"
      id="ixv-28937"
      unitRef="usd">20000000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <sprcy:CommitmentAmount
      contextRef="c192"
      decimals="-3"
      id="ixv-28938"
      unitRef="usd">20000000</sprcy:CommitmentAmount>
    <sprcy:SaleOfOrdinaryShares
      contextRef="c192"
      decimals="0"
      id="ixv-28939"
      unitRef="shares">5742785</sprcy:SaleOfOrdinaryShares>
    <ifrs-full:GrossProfit
      contextRef="c193"
      decimals="-3"
      id="ixv-28940"
      unitRef="usd">6255000</ifrs-full:GrossProfit>
    <sprcy:SharePriceRate
      contextRef="c194"
      decimals="2"
      id="ixv-28941"
      unitRef="pure">0.97</sprcy:SharePriceRate>
    <sprcy:CommitmentAmount
      contextRef="c195"
      decimals="-3"
      id="ixv-28942"
      unitRef="usd">5000000</sprcy:CommitmentAmount>
    <sprcy:InterestRate
      contextRef="c196"
      decimals="2"
      id="ixv-28943"
      unitRef="pure">0.05</sprcy:InterestRate>
    <sprcy:InterestRate
      contextRef="c197"
      decimals="2"
      id="ixv-28944"
      unitRef="pure">0.18</sprcy:InterestRate>
    <sprcy:InstallmentPayment contextRef="c2" decimals="2" id="ixv-28945" unitRef="pure">0.10</sprcy:InstallmentPayment>
    <sprcy:PaymentForPremiumPercentage contextRef="c0" decimals="2" id="ixv-28946" unitRef="pure">0.05</sprcy:PaymentForPremiumPercentage>
    <sprcy:AggregateIssuedAmount
      contextRef="c0"
      decimals="0"
      id="ixv-28947"
      unitRef="shares">55293</sprcy:AggregateIssuedAmount>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-28948" unitRef="usd">200000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-24717">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 19:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The cost of share-based payment recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;524&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;569&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;196&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;897&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The 2005 and 2015 ESOP and 2023 Plan of the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#x201c;2023 Plan&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span&gt;The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. &lt;/span&gt;Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#x201c;Share Options&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board approved
to reserve for &lt;span&gt;issuance under the 2023 Plan &lt;span style="-sec-ix-hidden: hidden-fact-117"&gt;1,000,0000&lt;/span&gt; Ordinary Shares. &lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 3, 2022 (the &#x201c;2022 Grant Date&#x201d;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2022 General Meeting&#x201d;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;February&#160;10,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January
    3,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying ordinary share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129.74&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;174.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;134&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of Share Options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end at
April 21, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;During the year ended December 31,
2024, share-based compensation in respect of Share Options of $7 was charged to the consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2024, the Company issued consultants 646,179 ordinary shares in respect of services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $105. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2024:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life of the Share Options outstanding was 2.99 years and 4.03 years as of December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,179 (inclusive) as of December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Restricted Share Units:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 20, 2024, the Company granted 530,000 Restricted Share
Units (&#x201c;RSUs&#x201d;) to directors and officers, pursuant to the Company&#x2019;s RSU Plan. The RSUs will vest at each recipient&#x2019;s
discretion and taking into account personal tax implications and convert into 530,000 ordinary shares of the Company. The RSUs vest on
a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted
share price of the Company on June 20, 2024, which was $0.893.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 8, 2024, the Company granted &lt;span style="-sec-ix-hidden: hidden-fact-118"&gt;530&lt;/span&gt;,000RSUs to directors
and officers, pursuant to the Company&#x2019;s RSU Plan. The RSUs will vest at each recipient&#x2019;s discretion and taking into account
personal tax implications and convert into 530,000 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of
two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August
8, 2024, which was $0.316.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,060,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expiry of RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,060,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Total exercisable RSUs as of December
31, 2024, are 265,000. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $456 was charged to the
Consolidated Statements of Comprehensive Loss.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock contextRef="c0" id="ixv-24735">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;524&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;569&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;196&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;897&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-28949"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c210"
      decimals="-3"
      id="ixv-28950"
      unitRef="usd">34000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c211"
      decimals="-3"
      id="ixv-28951"
      unitRef="usd">264000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-28952"
      unitRef="usd">524000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c210"
      decimals="-3"
      id="ixv-28953"
      unitRef="usd">162000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c211"
      decimals="-3"
      id="ixv-28954"
      unitRef="usd">633000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c209"
      decimals="-3"
      id="ixv-28955"
      unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c210"
      decimals="-3"
      id="ixv-28956"
      unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c211"
      decimals="-3"
      id="ixv-28957"
      unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c199"
      decimals="0"
      id="ixv-28958"
      unitRef="pure">6851</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c200"
      decimals="0"
      id="ixv-28959"
      unitRef="usdPershares">169</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock contextRef="c0" id="ixv-24911">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;February&#160;10,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January
    3,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying ordinary share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129.74&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;174.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;134&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of Share Options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c212"
      decimals="2"
      id="ixv-28960"
      unitRef="usdPershares">129.74</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c213"
      decimals="2"
      id="ixv-28961"
      unitRef="usdPershares">174.98</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c212"
      decimals="2"
      id="ixv-28962"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c213"
      decimals="2"
      id="ixv-28963"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c212"
      decimals="2"
      id="ixv-28964"
      unitRef="pure">1.33</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c213"
      decimals="2"
      id="ixv-28965"
      unitRef="pure">1.34</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c212"
      decimals="4"
      id="ixv-28966"
      unitRef="pure">0.02</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c213"
      decimals="4"
      id="ixv-28967"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c212"
      decimals="0"
      id="ixv-28968"
      unitRef="pure">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c213"
      decimals="0"
      id="ixv-28969"
      unitRef="pure">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c200"
      decimals="2"
      id="ixv-28970"
      unitRef="usdPershares">158.34</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c201"
      decimals="2"
      id="ixv-28971"
      unitRef="usdPershares">114.66</sprcy:FairValueOfShareOptionsGranted>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c202"
      decimals="-3"
      id="ixv-28972"
      unitRef="usd">7000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c203"
      decimals="0"
      id="ixv-28973"
      unitRef="shares">646179</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:OrdinarySharesGrantedDiscountRate contextRef="c0" decimals="2" id="ixv-28974" unitRef="pure">0.25</sprcy:OrdinarySharesGrantedDiscountRate>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c204"
      decimals="-3"
      id="ixv-28975"
      unitRef="usd">105000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-25094">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2024:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-28976" unitRef="pure">7013</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-28977"
      unitRef="usdPershares">166.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c2" decimals="0" id="ixv-28978" unitRef="pure">6802</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-28979"
      unitRef="usdPershares">350.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-28980" unitRef="pure">6802</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-28981"
      unitRef="usdPershares">350.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c31" decimals="0" id="ixv-28982" unitRef="pure">7060</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c31"
      decimals="2"
      id="ixv-28983"
      unitRef="usdPershares">166.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-28984" unitRef="pure">47</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-28985"
      unitRef="usdPershares">144.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-28986" unitRef="pure">7013</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-28987"
      unitRef="usdPershares">166.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c3" decimals="0" id="ixv-28988" unitRef="pure">5869</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-28989"
      unitRef="usdPershares">165.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c0" id="ixv-28990">P2Y11M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c4" id="ixv-28991">P4Y10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <sprcy:NumberOfOptionsOutstanding contextRef="c2" decimals="-3" id="ixv-28992" unitRef="usd">169000</sprcy:NumberOfOptionsOutstanding>
    <sprcy:NumberOfOptionsOutstanding contextRef="c3" decimals="-3" id="ixv-28993" unitRef="usd">21179000</sprcy:NumberOfOptionsOutstanding>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c205"
      decimals="0"
      id="ixv-28994"
      unitRef="pure">530000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sprcy:ConvertIntoOrdinaryShares
      contextRef="c205"
      decimals="0"
      id="ixv-28995"
      unitRef="shares">530000</sprcy:ConvertIntoOrdinaryShares>
    <sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement contextRef="c205" id="ixv-28996">P2Y</sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c205"
      decimals="3"
      id="ixv-28997"
      unitRef="usdPershares">0.893</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <sprcy:ConvertIntoOrdinaryShares
      contextRef="c206"
      decimals="0"
      id="ixv-28998"
      unitRef="shares">530000</sprcy:ConvertIntoOrdinaryShares>
    <sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement contextRef="c206" id="ixv-28999">P2Y</sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c206"
      decimals="3"
      id="ixv-29000"
      unitRef="usdPershares">0.316</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c0" id="ixv-25336">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,060,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expiry of RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,060,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="c0" decimals="0" id="ixv-29001" unitRef="pure">1060000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-29002" unitRef="pure">1060000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c207"
      decimals="0"
      id="ixv-29003"
      unitRef="pure">265000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c208"
      decimals="-3"
      id="ixv-29004"
      unitRef="usd">456000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0" id="ixv-25407">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;20:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;REVENUES AND COST OF REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s Brand sells products
directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the Company&#x2019;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024, the
allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right of return
asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Purchased goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock contextRef="c0" id="ixv-25423">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Purchased goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock>
    <ifrs-full:CostOfSales
      contextRef="c214"
      decimals="-3"
      id="ixv-29005"
      unitRef="usd">798000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c215"
      decimals="-3"
      id="ixv-29006"
      unitRef="usd">672000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c216"
      decimals="-3"
      id="ixv-29007"
      unitRef="usd">301000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c217"
      decimals="-3"
      id="ixv-29008"
      unitRef="usd">2000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c218"
      decimals="-3"
      id="ixv-29009"
      unitRef="usd">11000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c219"
      decimals="-3"
      id="ixv-29010"
      unitRef="usd">21000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-29011" unitRef="usd">800000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="-3" id="ixv-29012" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c5" decimals="-3" id="ixv-29013" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c0" id="ixv-25537">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;21:- &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;a.&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 61%; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;436&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;b.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Sales and marketing expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Advertising&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Amazon fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;454&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Storage and shipping&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Management fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;c.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;d.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Other expenses (income):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Loss from sale of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 25b)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;e.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(191&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,205&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Interest from loans to related parties and deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(421&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;f.&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses from interest and commissions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;353&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassified&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0" id="ixv-25547">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;a.&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 61%; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;436&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;b.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Sales and marketing expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Advertising&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Amazon fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;454&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Storage and shipping&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Management fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;c.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;d.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Other expenses (income):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Loss from sale of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 25b)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;e.&lt;/td&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(191&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,205&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Interest from loans to related parties and deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(421&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;f.&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses from interest and commissions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;353&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassified&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c220"
      decimals="-3"
      id="ixv-29014"
      unitRef="usd">390000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-29015"
      unitRef="usd">392000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-29016"
      unitRef="usd">436000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-29017"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-29018"
      unitRef="usd">34000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-29019"
      unitRef="usd">264000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c226"
      decimals="-3"
      id="ixv-29020"
      unitRef="usd">681000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c227"
      decimals="-3"
      id="ixv-29021"
      unitRef="usd">719000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c228"
      decimals="-3"
      id="ixv-29022"
      unitRef="usd">750000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c229"
      decimals="-3"
      id="ixv-29023"
      unitRef="usd">211000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c230"
      decimals="-3"
      id="ixv-29024"
      unitRef="usd">101000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c231"
      decimals="-3"
      id="ixv-29025"
      unitRef="usd">703000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c232"
      decimals="-3"
      id="ixv-29026"
      unitRef="usd">276000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c233"
      decimals="-3"
      id="ixv-29027"
      unitRef="usd">254000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-29028"
      unitRef="usd">369000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c235"
      decimals="-3"
      id="ixv-29029"
      unitRef="usd">104000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c236"
      decimals="-3"
      id="ixv-29030"
      unitRef="usd">141000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-29031"
      unitRef="usd">281000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-29032" unitRef="usd">1707000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-29033" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-29034" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c238"
      decimals="-3"
      id="ixv-29035"
      unitRef="usd">367000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c239"
      decimals="-3"
      id="ixv-29036"
      unitRef="usd">576000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c240"
      decimals="-3"
      id="ixv-29037"
      unitRef="usd">363000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c241"
      decimals="-3"
      id="ixv-29038"
      unitRef="usd">495000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c242"
      decimals="-3"
      id="ix_7_fact"
      unitRef="usd">1042000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c243"
      decimals="-3"
      id="ix_8_fact"
      unitRef="usd">454000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c244"
      decimals="-3"
      id="ixv-29041"
      unitRef="usd">366000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c245"
      decimals="-3"
      id="ixv-29042"
      unitRef="usd">486000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c246"
      decimals="-3"
      id="ixv-29043"
      unitRef="usd">144000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c247"
      decimals="-3"
      id="ixv-29044"
      unitRef="usd">167000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c248"
      decimals="-3"
      id="ix_9_fact"
      unitRef="usd">145000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c249"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">91000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c250"
      decimals="-3"
      id="ixv-29047"
      unitRef="usd">120000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c251"
      decimals="-3"
      id="ixv-29048"
      unitRef="usd">235000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c252"
      decimals="-3"
      id="ixv-29049"
      unitRef="usd">30000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-29050" unitRef="usd">1515000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="-3" id="ixv-29051" unitRef="usd">2484000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c5" decimals="-3" id="ixv-29052" unitRef="usd">1082000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c220"
      decimals="-3"
      id="ixv-29053"
      unitRef="usd">507000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-29054"
      unitRef="usd">415000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-29055"
      unitRef="usd">437000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-29056"
      unitRef="usd">419000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-29057"
      unitRef="usd">68000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-29058"
      unitRef="usd">633000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c253"
      decimals="-3"
      id="ixv-29059"
      unitRef="usd">3009000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c254"
      decimals="-3"
      id="ixv-29060"
      unitRef="usd">2594000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c255"
      decimals="-3"
      id="ixv-29061"
      unitRef="usd">2468000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c256"
      decimals="-3"
      id="ixv-29062"
      unitRef="usd">108000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c257"
      decimals="-3"
      id="ixv-29063"
      unitRef="usd">86000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c258"
      decimals="-3"
      id="ixv-29064"
      unitRef="usd">161000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c259"
      decimals="-3"
      id="ixv-29065"
      unitRef="usd">158000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c260"
      decimals="-3"
      id="ixv-29066"
      unitRef="usd">202000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c261"
      decimals="-3"
      id="ixv-29067"
      unitRef="usd">162000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c262"
      decimals="-3"
      id="ixv-29068"
      unitRef="usd">128000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c263"
      decimals="-3"
      id="ixv-29069"
      unitRef="usd">110000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c264"
      decimals="-3"
      id="ixv-29070"
      unitRef="usd">80000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c265"
      decimals="-3"
      id="ixv-29071"
      unitRef="usd">197000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c266"
      decimals="-3"
      id="ixv-29072"
      unitRef="usd">369000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c267"
      decimals="-3"
      id="ixv-29073"
      unitRef="usd">1486000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-29074" unitRef="usd">4526000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-29075" unitRef="usd">3844000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-29076" unitRef="usd">5427000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c268"
      decimals="-3"
      id="ixv-29077"
      unitRef="usd">-17000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c270"
      decimals="-3"
      id="ixv-29078"
      unitRef="usd">1287000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-29079" unitRef="usd">1270000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncome
      contextRef="c272"
      decimals="-3"
      id="ixv-29080"
      unitRef="usd">191000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c273"
      decimals="-3"
      id="ixv-29081"
      unitRef="usd">2205000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c274"
      decimals="-3"
      id="ixv-29082"
      unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c275"
      decimals="-3"
      id="ixv-29083"
      unitRef="usd">421000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c278"
      decimals="-3"
      id="ixv-29084"
      unitRef="usd">14000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-29085" unitRef="usd">612000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-29086" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-29087" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="c281"
      decimals="-3"
      id="ixv-29088"
      unitRef="usd">1204000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c277"
      decimals="-3"
      id="ixv-29089"
      unitRef="usd">18000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c282"
      decimals="-3"
      id="ixv-29090"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c283"
      decimals="-3"
      id="ixv-29091"
      unitRef="usd">305000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c284"
      decimals="-3"
      id="ixv-29092"
      unitRef="usd">1046000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c285"
      decimals="-3"
      id="ixv-29093"
      unitRef="usd">770000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c286"
      decimals="-3"
      id="ixv-29094"
      unitRef="usd">8000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c287"
      decimals="-3"
      id="ixv-29095"
      unitRef="usd">9000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c288"
      decimals="-3"
      id="ixv-29096"
      unitRef="usd">15000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c289"
      decimals="-3"
      id="ixv-29097"
      unitRef="usd">22000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c291"
      decimals="-3"
      id="ixv-29098"
      unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-29099" unitRef="usd">353000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-29100" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-29101" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-26347">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 22:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,824,972&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;407,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175,953&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,824,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;407,681&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;175,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share Options to employees, officers, directors and consultants; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable warrants to investors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c0" id="ixv-26363">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,824,972&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;407,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175,953&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,824,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;407,681&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;175,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-29102"
      unitRef="shares">5824972</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-29103" unitRef="usd">-7472000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="INF"
      id="ixv-29104"
      unitRef="shares">407681</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c4" decimals="-3" id="ixv-29105" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="INF"
      id="ixv-29106"
      unitRef="shares">175953</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c5" decimals="-3" id="ixv-29107" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-29108"
      unitRef="shares">5824972</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-29109" unitRef="usd">-7472000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="INF"
      id="ixv-29110"
      unitRef="shares">407681</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c4" decimals="-3" id="ixv-29111" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="INF"
      id="ixv-29112"
      unitRef="shares">175953</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c5" decimals="-3" id="ixv-29113" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-26656">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;23:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OPERATING SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies the principles
of IFRS 8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#x2019;s management determined that it has two reportable segments &#x2013; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The review of the CODM is carried out
according to the results of the segment&#x2019;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO of
the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug &lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online &lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,316&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equity losses from the investment in MitoCareX&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug &lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online &lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Drug Development Segment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the year ended December 31, 2024, the Company
recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Online Sales Segment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Year
    ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,287&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Company&#x2019;s share of losses
    of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,194&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;226&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c0" id="ixv-26674">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO of
the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug &lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online &lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,316&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equity losses from the investment in MitoCareX&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug &lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online &lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Year
    ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,287&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Company&#x2019;s share of losses
    of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,194&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;226&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c294"
      decimals="-3"
      id="ixv-29114"
      unitRef="usd">1306000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c0" decimals="-3" id="ixv-29115" unitRef="usd">1306000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c294"
      decimals="-3"
      id="ixv-29116"
      unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-29117" unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c293"
      decimals="-3"
      id="ixv-29118"
      unitRef="usd">4873000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c294"
      decimals="-3"
      id="ixv-29119"
      unitRef="usd">2443000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-29120" unitRef="usd">7316000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:EquityLossesFromTheInvestment contextRef="c0" decimals="-3" id="ixv-29121" unitRef="usd">429000</sprcy:EquityLossesFromTheInvestment>
    <ifrs-full:InterestRevenueExpense contextRef="c0" decimals="-3" id="ixv-29122" unitRef="usd">-259000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-29123" unitRef="usd">-14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-29124" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c296"
      decimals="-3"
      id="ixv-29125"
      unitRef="usd">2879000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c4" decimals="-3" id="ixv-29126" unitRef="usd">2879000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c296"
      decimals="-3"
      id="ixv-29127"
      unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c4" decimals="-3" id="ixv-29128" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c295"
      decimals="-3"
      id="ixv-29129"
      unitRef="usd">5359000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c296"
      decimals="-3"
      id="ixv-29130"
      unitRef="usd">1456000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-29131" unitRef="usd">6815000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c4" decimals="-3" id="ixv-29132" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c4" decimals="-3" id="ixv-29133" unitRef="usd">-1164000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="-3" id="ixv-29134" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-29135" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherIntangibleAssets contextRef="c2" decimals="0" id="ixv-29136" unitRef="usd">1288</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c292" decimals="0" id="ixv-29137" unitRef="usd">1344</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c3" decimals="0" id="ixv-29138" unitRef="usd">1042</ifrs-full:OtherIntangibleAssets>
    <sprcy:ExternalRevenues
      contextRef="c298"
      decimals="-3"
      id="ixv-29139"
      unitRef="usd">1347000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c5" decimals="-3" id="ixv-29140" unitRef="usd">1347000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c298"
      decimals="-3"
      id="ixv-29141"
      unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c5" decimals="-3" id="ixv-29142" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c297"
      decimals="-3"
      id="ixv-29143"
      unitRef="usd">8405000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c298"
      decimals="-3"
      id="ixv-29144"
      unitRef="usd">-118000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-29145" unitRef="usd">8287000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c5" decimals="-3" id="ixv-29146" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c5" decimals="-3" id="ixv-29147" unitRef="usd">-5818000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="-3" id="ixv-29148" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-29149" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c299"
      decimals="-3"
      id="ixv-29150"
      unitRef="usd">8407000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c300"
      decimals="-3"
      id="ixv-29151"
      unitRef="usd">1764000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c2" decimals="-3" id="ixv-29152" unitRef="usd">10171000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c299"
      decimals="-3"
      id="ixv-29153"
      unitRef="usd">1194000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c300"
      decimals="-3"
      id="ixv-29154"
      unitRef="usd">226000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c2" decimals="-3" id="ixv-29155" unitRef="usd">1420000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c301"
      decimals="-3"
      id="ixv-29156"
      unitRef="usd">7069000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c302"
      decimals="-3"
      id="ixv-29157"
      unitRef="usd">4113000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c3" decimals="-3" id="ixv-29158" unitRef="usd">11182000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c301"
      decimals="-3"
      id="ixv-29159"
      unitRef="usd">1441000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c302"
      decimals="-3"
      id="ixv-29160"
      unitRef="usd">154000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c3" decimals="-3" id="ixv-29161" unitRef="usd">1595000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0" id="ixv-27623">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;24:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRANSACTIONS AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;765&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#x2019;s wholly owned subsidiary, SciSparc US which owns Wellution, for $2,500 in cash, and additional deferred cash payments of approximately $489 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjustment&#x201d;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#x2019; Brands, the Company holds approximately 51% of the share capital of SciSparc US.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the agreement, at the closing
of the transaction, Jeffs&#x2019; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#x2019; Brands provides
management services to SciSparc US for the Wellution brand for a monthly fee of $20 and Jeffs&#x2019; Brands received a one-time signing
bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30
days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2024, the Company has
recorded management services expenses in the amount of $120 (for the year ended December 31, 2023 - $220).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;In addition, in connection with the closing of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in the amount of $288 of ordinary shares from each of the Company and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands acquired 13,858 ordinary shares of the Company having an aggregate value of $288 which was adjusted from $300 according to the 4.99% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#x2019;s Brands on Nasdaq was $ 2.57, and the Company has recorded a loss in its statements of comprehensive loss of $17 on its investment (for the year ended December 31, 2023 -$180).&lt;br/&gt;
&lt;br/&gt;
Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands.&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#x2019;s Chief Technologies Officer, Mr. Weiss, the Company&#x2019;s President, and Mr. Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#x201c;Cooperation Agreement&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $63 and $40, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, the Company invested $1.5 million in Clearmind
in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing
9.33% of the outstanding share capital of Clearmind (see also Note 8).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Amitai Weiss, the Company&#x2019;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;On August 13, 2024, the Company entered into the license agreement
(the &#x201c;License Agreement&#x201d;) of the out-licensing of its SCI-160 program (the &#x201c;Assets&#x201d;), with Polyrizon Ltd. (the
&#x201c;Licensee&#x201d; or &#x201c;Polyrizon&#x201d;). According to the License Agreement, the Company granted the Licensee a royalty-bearing,
exclusive, sub-licensable right and license to the Assets (the &#x201c;License&#x201d;). In consideration for the License, the Company received
and will receive certain shares of the Licensee, reflecting an issue price of $805, and royalties from sales related to and income generated
from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones
relating to the Assets. &lt;br/&gt;
&lt;br/&gt;
Pursuant to the terms of the License Agreement, the Company is entitled to up to $3,320 based on the achievement of certain milestones, including (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction. Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of 5%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. &lt;br/&gt;
&lt;br/&gt;
On October 31, 2024, following an initial public offering of the Licensee, the Company received 684,931 units, of which (i) 320,000 units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (960,000 warrants in total); and (ii) 364,931 units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (1,094,793 warrants in total). Altogether, the Company received 320,000 ordinary shares, 364,931 pre-funded warrants to purchase one ordinary share of the Licensee, and 2,054,793 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. &#160; &lt;br/&gt;
&lt;br/&gt;
On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of 1,541,096 Licensee common warrants to third parties, for aggregate consideration of $771. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; &lt;br/&gt;
&lt;br/&gt;
As of December 31, 2024, the Company holds 513,698 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. The warrants expire on October 31, 2029. The value of the warrants on December 31, 2024, is $517.&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer, is a director
of the Licensee.&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"&gt;&lt;i&gt;General Overview of Valuation Approaches used in the Valuation:&lt;/i&gt;
&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"&gt;The warrants&#x2019; fair value
was calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated,
in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Underlying Share Price of Polyrizon Ltd. ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#x201c;Merger Agreement&#x201d;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#x2019;s shareholders and AutoMax&#x2019;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 14, 2024, SciSparc and AutoMax
entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated
by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second
addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred
to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right
to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the effective time of the Merger (the &#x201c;Effective Time&#x201d;,
as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#x2019;s share capital will be converted into the
right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;).
Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the
Company) are expected to hold together approximately 49.99% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate
number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of
the Company, together with the holders of the Company&#x2019;s convertible securities, immediately before the Merger are expected to hold
together approximately 50.01% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject
to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#x201c;Closing&#x201d;),
and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised
of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall
be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <sprcy:RelatedPartyBalancetextBlock contextRef="c0" id="ixv-27639">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:RelatedPartyBalancetextBlock>
    <sprcy:CurrentAsset
      contextRef="c327"
      decimals="-3"
      id="ixv-29162"
      unitRef="usd">15000</sprcy:CurrentAsset>
    <sprcy:CurrentAsset
      contextRef="c329"
      decimals="-3"
      id="ixv-29163"
      unitRef="usd">121000</sprcy:CurrentAsset>
    <ifrs-full:CurrentAssets
      contextRef="c327"
      decimals="-3"
      id="ixv-29164"
      unitRef="usd">4224000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c329"
      decimals="-3"
      id="ixv-29165"
      unitRef="usd">108000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentLiabilities
      contextRef="c326"
      decimals="-3"
      id="ixv-29166"
      unitRef="usd">55000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c327"
      decimals="-3"
      id="ixv-29167"
      unitRef="usd">245000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c328"
      decimals="-3"
      id="ixv-29168"
      unitRef="usd">95000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-27762">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c0" decimals="-3" id="ixv-29169" unitRef="usd">63000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c4" decimals="-3" id="ixv-29170" unitRef="usd">40000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c5" decimals="-3" id="ixv-29171" unitRef="usd">208000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <sprcy:SaleOfMinorityInterestInSubsidiary contextRef="c4" decimals="-3" id="ixv-29172" unitRef="usd">2985000</sprcy:SaleOfMinorityInterestInSubsidiary>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-27820">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;765&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="-3" id="ixv-29173" unitRef="usd">765000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c4" decimals="-3" id="ixv-29174" unitRef="usd">1204000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c5" decimals="-3" id="ixv-29175" unitRef="usd">1940000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c0" decimals="-3" id="ixv-29176" unitRef="usd">120000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c4" decimals="-3" id="ixv-29177" unitRef="usd">220000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="-3" id="ixv-29178" unitRef="usd">157000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c4" decimals="-3" id="ixv-29179" unitRef="usd">84000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c5" decimals="-3" id="ixv-29180" unitRef="usd">779000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:InterestPercentage
      contextRef="c303"
      decimals="2"
      id="ixv-29181"
      unitRef="pure">0.49</sprcy:InterestPercentage>
    <ifrs-full:Cash
      contextRef="c304"
      decimals="-3"
      id="ixv-29182"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:DeferredCashPayment
      contextRef="c304"
      decimals="-3"
      id="ixv-29183"
      unitRef="usd">489000</sprcy:DeferredCashPayment>
    <sprcy:ShareCapitalPercentage
      contextRef="c305"
      decimals="2"
      id="ixv-29184"
      unitRef="pure">0.51</sprcy:ShareCapitalPercentage>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="c305"
      decimals="-3"
      id="ixv-29185"
      unitRef="usd">20000</ifrs-full:OtherFeeAndCommissionExpense>
    <sprcy:BonusAmountReceived
      contextRef="c305"
      decimals="-3"
      id="ixv-29186"
      unitRef="usd">51000</sprcy:BonusAmountReceived>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="c306"
      decimals="-3"
      id="ixv-29187"
      unitRef="usd">10000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:ServicesExpense
      contextRef="c307"
      decimals="-3"
      id="ixv-29188"
      unitRef="usd">120000</ifrs-full:ServicesExpense>
    <ifrs-full:ServicesExpense
      contextRef="c308"
      decimals="-3"
      id="ixv-29189"
      unitRef="usd">220000</ifrs-full:ServicesExpense>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="c309"
      decimals="-3"
      id="ixv-29190"
      unitRef="usd">288000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <sprcy:AcquiredOrdinaryShares
      contextRef="c0"
      decimals="0"
      id="ixv-29191"
      unitRef="shares">35345</sprcy:AcquiredOrdinaryShares>
    <sprcy:AcquiredOrdinaryShares
      contextRef="c307"
      decimals="0"
      id="ixv-29192"
      unitRef="shares">13858</sprcy:AcquiredOrdinaryShares>
    <sprcy:AggregateValues contextRef="c0" decimals="-3" id="ixv-29193" unitRef="usd">288000</sprcy:AggregateValues>
    <sprcy:AggregateValueAdjusted contextRef="c0" decimals="-3" id="ixv-29194" unitRef="usd">300000</sprcy:AggregateValueAdjusted>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c0" decimals="4" id="ixv-29195" unitRef="pure">0.0499</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sprcy:ListedSharePrice
      contextRef="c2"
      decimals="2"
      id="ixv-29196"
      unitRef="usdPershares">2.57</sprcy:ListedSharePrice>
    <sprcy:ComprehensiveLossOnInvestment
      contextRef="c309"
      decimals="-3"
      id="ixv-29197"
      unitRef="usd">17000</sprcy:ComprehensiveLossOnInvestment>
    <sprcy:ComprehensiveLossOnInvestment
      contextRef="c310"
      decimals="-3"
      id="ixv-29198"
      unitRef="usd">180000</sprcy:ComprehensiveLossOnInvestment>
    <sprcy:CooperationAgreementAmount contextRef="c0" decimals="-3" id="ixv-29199" unitRef="usd">63000</sprcy:CooperationAgreementAmount>
    <sprcy:CooperationAgreementAmount contextRef="c4" decimals="-3" id="ixv-29200" unitRef="usd">40000</sprcy:CooperationAgreementAmount>
    <ifrs-full:CurrentInvestments
      contextRef="c311"
      decimals="-5"
      id="ixv-29201"
      unitRef="usd">1500000</ifrs-full:CurrentInvestments>
    <sprcy:ExchangeOfCommonShares
      contextRef="c101"
      decimals="0"
      id="ixv-29202"
      unitRef="shares">7692</sprcy:ExchangeOfCommonShares>
    <sprcy:OutstandingShareCapital
      contextRef="c101"
      decimals="4"
      id="ixv-29203"
      unitRef="pure">0.0933</sprcy:OutstandingShareCapital>
    <sprcy:LicenseeIssuePrice
      contextRef="c312"
      decimals="-3"
      id="ixv-29204"
      unitRef="usd">805000</sprcy:LicenseeIssuePrice>
    <sprcy:MilestonesAmount
      contextRef="c312"
      decimals="-3"
      id="ixv-29205"
      unitRef="usd">3320000</sprcy:MilestonesAmount>
    <sprcy:LicenseAgreementDescription contextRef="c312" id="ixv-29206">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.</sprcy:LicenseAgreementDescription>
    <sprcy:PercentageOfAggregateNetSales
      contextRef="c312"
      decimals="2"
      id="ixv-29207"
      unitRef="pure">0.05</sprcy:PercentageOfAggregateNetSales>
    <sprcy:NumberOfUnitsReceived
      contextRef="c313"
      decimals="0"
      id="ixv-29208"
      unitRef="shares">684931</sprcy:NumberOfUnitsReceived>
    <sprcy:NumberOfUnitsReceived
      contextRef="c314"
      decimals="0"
      id="ixv-29209"
      unitRef="shares">320000</sprcy:NumberOfUnitsReceived>
    <sprcy:PurchasePricePerShare
      contextRef="c315"
      decimals="2"
      id="ixv-29210"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c316"
      decimals="0"
      id="ixv-29211"
      unitRef="shares">960000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:NumberOfUnitsReceived
      contextRef="c317"
      decimals="0"
      id="ixv-29212"
      unitRef="shares">364931</sprcy:NumberOfUnitsReceived>
    <sprcy:PurchasePricePerShare
      contextRef="c318"
      decimals="2"
      id="ixv-29213"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c318"
      decimals="0"
      id="ixv-29214"
      unitRef="shares">1094793</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c315"
      decimals="0"
      id="ixv-29215"
      unitRef="shares">320000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c319"
      decimals="0"
      id="ixv-29216"
      unitRef="shares">364931</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c320"
      decimals="0"
      id="ixv-29217"
      unitRef="shares">2054793</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c320"
      decimals="2"
      id="ixv-29218"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c321"
      decimals="0"
      id="ixv-29219"
      unitRef="shares">1541096</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c322"
      decimals="-3"
      id="ixv-29220"
      unitRef="usd">771000</ifrs-full:ConsiderationPaidReceived>
    <sprcy:NumberOfWarrantsHolds
      contextRef="c323"
      decimals="0"
      id="ixv-29221"
      unitRef="shares">513698</sprcy:NumberOfWarrantsHolds>
    <sprcy:PurchasePricePerShare
      contextRef="c323"
      decimals="2"
      id="ixv-29222"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <sprcy:WarrantsExpireDate contextRef="c323" id="ixv-29223">2029-10-31</sprcy:WarrantsExpireDate>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c324"
      decimals="-3"
      id="ixv-29224"
      unitRef="usd">517000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0" id="ixv-28052">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.25in"&gt;The warrants&#x2019; fair value
was calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated,
in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Underlying Share Price of Polyrizon Ltd. ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c323"
      decimals="2"
      id="ixv-29225"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c320"
      decimals="2"
      id="ixv-29226"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c323"
      decimals="2"
      id="ixv-29227"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c320"
      decimals="2"
      id="ixv-29228"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c323"
      decimals="4"
      id="ixv-29229"
      unitRef="pure">0.0217</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c320"
      decimals="4"
      id="ixv-29230"
      unitRef="pure">0.0415</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c323"
      decimals="2"
      id="ixv-29231"
      unitRef="usdPershares">0.36</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c320"
      decimals="2"
      id="ixv-29232"
      unitRef="usdPershares">4.38</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c323"
      decimals="2"
      id="ixv-29233"
      unitRef="usdPershares">4.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c320"
      decimals="2"
      id="ixv-29234"
      unitRef="usdPershares">4.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c324"
      decimals="-3"
      id="ixv-29235"
      unitRef="usd">517000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c330"
      decimals="-3"
      id="ixv-29236"
      unitRef="usd">1399000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage
      contextRef="c325"
      decimals="4"
      id="ixv-29237"
      unitRef="pure">0.4999</sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage>
    <sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage contextRef="c0" decimals="4" id="ixv-29238" unitRef="pure">0.5001</sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage>
    <sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock contextRef="c0" id="ixv-28164">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 25:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT EVENTS DURING THE REPORTING PERIOD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#x201c;Miza&#x201d;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#x201c;Target Assets&#x201d;)&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The agreement is based on the approximate total $3,300 (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of the Company&#x2019;s assets.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 28, 2025, the Company entered into a second amendment (the &#x201c;Miza Amendment&#x201d;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock>
    <sprcy:EnterpriseValue contextRef="c0" decimals="-3" id="ixv-29239" unitRef="usd">3300000</sprcy:EnterpriseValue>
    <sprcy:EnterpriseValue contextRef="c0" decimals="-5" id="ixv-29240" unitRef="cad">4500000</sprcy:EnterpriseValue>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-29241" unitRef="usd">1000000</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherAssets
      contextRef="c331"
      decimals="-3"
      id="ixv-29242"
      unitRef="usd">11600000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c331"
      decimals="-5"
      id="ixv-29243"
      unitRef="cad">15800000</ifrs-full:OtherAssets>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c332"
      decimals="-3"
      id="ixv-29244"
      unitRef="usd">63300000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c333"
      decimals="-3"
      id="ixv-29245"
      unitRef="usd">48000000000</ifrs-full:ConsiderationPaidReceived>
    <sprcy:ShareCapitalPercentage
      contextRef="c333"
      decimals="2"
      id="ixv-29246"
      unitRef="pure">0.75</sprcy:ShareCapitalPercentage>
    <sprcy:ShareCapitalPercentage
      contextRef="c332"
      decimals="4"
      id="ixv-29247"
      unitRef="pure">0.8453</sprcy:ShareCapitalPercentage>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-28213">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;26:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EVENTS AFTER THE REPORTING DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2025, the Company announced that it has reached a settlement
agreement (the &#x201c;Settlement&#x201d;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa
District Court against six of the Company&#x2019;s former directors (the &#x201c;Defendants&#x201d;) case number 34426-02-22 (the &#x201c;Suit&#x201d;).
The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior
acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $411 cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#x201c;License Agreement&#x201d;). As part of the Settlement, Dekel clarified, to SciSparc&#x2019;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#x2019;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#x2019;s pipeline and development program.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $2,000 loan (the &#x201c;New Loan&#x201d;). The funding will support AutoMax&#x2019;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4,250 (the &#x201c;Previous Loans&#x201d;). The Previous Loans were provided in lieu of SciSparc&#x2019;s obligation to provide a $4,250 closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The loan, bearing an 8% annual interest rate, will be repaid in equal monthly installments of $50 and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#x2019;s shares.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 25, 2025, the Company entered into securities purchase agreements (the &#x201c;Securities Purchase Agreements&#x201d;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#x201c;Debentures&#x201d;) in the aggregate principal amount of $4,200 (the &#x201c;Subscription Amount&#x201d;), which are convertible into the Company&#x2019;s ordinary shares, no par value per share (the &#x201c;Ordinary Shares&#x201d; and, as converted, the &#x201c;Conversion Shares&#x201d;), at a purchase price equal to 95% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) 110% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) 95% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (20) consecutive trading days immediately preceding the conversion date or other date of determination (the &#x201c;Market Price&#x201d;); provided that the Market Price may not be lower than the floor price, which will be equal to 20% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the closing of the transaction, the Company issued to the investors
3,615,656 warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors
divided by a price equal to 130% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or
$0.5532 per warrant. The warrants are exercisable for a term of five years from the issuance date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;d.&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span&gt;On April 1, 2025, we entered
into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested
$100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and Series A warrants to purchase
ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing
ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;The Company entered into a global guaranty
agreement (the &#x201c;Global Guaranty Agreement&#x201d;) with one of the investors (the &#x201c;Investor&#x201d;) through certain of the
Company&#x2019;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#x2019;s obligations under the Debenture with
the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.&lt;br/&gt;
&lt;br/&gt;
The Company
entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Investor, pursuant to which the
Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act
of 1933, as amended (the &#x201c;Act&#x201d;) and the rules and regulations promulgated thereunder, and applicable state securities laws.&lt;br/&gt;
&lt;br/&gt;
In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#x201c;Deed&#x201d;) with
AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $2,000
to AutoMax in lieu of making the payment under the Loan Agreement (the &#x201c;Loan Agreement&#x201d;) to which the Company entered into
with AutoMax on February 24, 2025.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 25, 2025, the Company announced it has signed a definitive
agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO)
(&#x201c;N2OFF&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell 4,961 shares of MitoCareX to N2OFF for $700 and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to 40% of the company&#x2019;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#x2019;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#x2019;s control.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to 25% of N2OFF&#x2019;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive 30% of N2OFF&#x2019;s financing proceeds over five years, up to a maximum of $1,600. N2OFF has also committed to investing $1,000 in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of 5% of N2OFF&#x2019;s capital stock, vesting over three years. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;- - - - - - - - - - - - - - - - - - - - - - -
- -&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:Cash
      contextRef="c334"
      decimals="-3"
      id="ixv-29248"
      unitRef="usd">411000</ifrs-full:Cash>
    <ifrs-full:LoansReceived
      contextRef="c335"
      decimals="-3"
      id="ixv-29249"
      unitRef="usd">2000000</ifrs-full:LoansReceived>
    <sprcy:AggregateLoanAmount
      contextRef="c336"
      decimals="-3"
      id="ixv-29250"
      unitRef="usd">4250000</sprcy:AggregateLoanAmount>
    <sprcy:AggregateLoanAmount
      contextRef="c337"
      decimals="-3"
      id="ixv-29251"
      unitRef="usd">4250000</sprcy:AggregateLoanAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c338"
      decimals="2"
      id="ixv-29252"
      unitRef="pure">0.08</ifrs-full:BorrowingsInterestRate>
    <sprcy:RepaidOfMonthlyInstallments
      contextRef="c339"
      decimals="-3"
      id="ixv-29253"
      unitRef="usd">50000</sprcy:RepaidOfMonthlyInstallments>
    <ifrs-full:NotionalAmount
      contextRef="c340"
      decimals="-3"
      id="ixv-29254"
      unitRef="usd">4200000</ifrs-full:NotionalAmount>
    <sprcy:PurchasePricePercentage
      contextRef="c341"
      decimals="2"
      id="ixv-29255"
      unitRef="pure">0.95</sprcy:PurchasePricePercentage>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c342"
      decimals="2"
      id="ixv-29256"
      unitRef="pure">0.08</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c343"
      decimals="2"
      id="ixv-29257"
      unitRef="pure">0.18</ifrs-full:BorrowingsInterestRate>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay
      contextRef="c341"
      decimals="2"
      id="ixv-29258"
      unitRef="pure">1.10</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays
      contextRef="c341"
      decimals="2"
      id="ixv-29259"
      unitRef="pure">0.95</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays>
    <sprcy:ConsecutiveTradingDays contextRef="c341" id="ixv-29260">P20D</sprcy:ConsecutiveTradingDays>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing
      contextRef="c341"
      decimals="2"
      id="ixv-29261"
      unitRef="pure">0.20</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing>
    <sprcy:NumberOfWarrantsIssued
      contextRef="c344"
      decimals="0"
      id="ixv-29262"
      unitRef="shares">3615656</sprcy:NumberOfWarrantsIssued>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing
      contextRef="c345"
      decimals="2"
      id="ixv-29263"
      unitRef="pure">1.30</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing>
    <sprcy:VolumeWeightedAveragePricePerWarrant
      contextRef="c344"
      decimals="4"
      id="ixv-29264"
      unitRef="usdPershares">0.5532</sprcy:VolumeWeightedAveragePricePerWarrant>
    <sprcy:WarrantExercisableTerm contextRef="c341" id="ixv-29265">P5Y</sprcy:WarrantExercisableTerm>
    <ifrs-full:InvestmentIncome
      contextRef="c346"
      decimals="-3"
      id="ixv-29266"
      unitRef="usd">100000000</ifrs-full:InvestmentIncome>
    <sprcy:AggregateInvestment
      contextRef="c346"
      decimals="-6"
      id="ixv-29267"
      unitRef="usd">17000000</sprcy:AggregateInvestment>
    <ifrs-full:LoansReceived
      contextRef="c347"
      decimals="-3"
      id="ixv-29268"
      unitRef="usd">2000000</ifrs-full:LoansReceived>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c348"
      decimals="0"
      id="ixv-29269"
      unitRef="shares">4961</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c349"
      decimals="-3"
      id="ixv-29270"
      unitRef="shares">700000</ifrs-full:NumberOfSharesIssued>
    <sprcy:PercentageOfFullyDilutedCapitalStock
      contextRef="c341"
      decimals="2"
      id="ixv-29271"
      unitRef="pure">0.40</sprcy:PercentageOfFullyDilutedCapitalStock>
    <sprcy:PercentageOfFullyDilutedCapitalStock
      contextRef="c350"
      decimals="2"
      id="ixv-29272"
      unitRef="pure">0.25</sprcy:PercentageOfFullyDilutedCapitalStock>
    <sprcy:PercentageOfFinancingProceeds
      contextRef="c341"
      decimals="2"
      id="ixv-29273"
      unitRef="pure">0.30</sprcy:PercentageOfFinancingProceeds>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="c341"
      decimals="-3"
      id="ixv-29274"
      unitRef="usd">1600000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:InvestmentIncome
      contextRef="c351"
      decimals="-3"
      id="ixv-29275"
      unitRef="usd">1000000</ifrs-full:InvestmentIncome>
    <sprcy:RestrictedStockGrantPercentage
      contextRef="c340"
      decimals="2"
      id="ixv-29276"
      unitRef="pure">0.05</sprcy:RestrictedStockGrantPercentage>
    <sprcy:VestingPeriod contextRef="c341" id="ixv-29277">P3Y</sprcy:VestingPeriod>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentWarrantLiability
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c13"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c15"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c16"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c22"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c16"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c17"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c18"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c19"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c20"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c22"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c17"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c18"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c19"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c22"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c30"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c33"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c34"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c36"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c32"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c33"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c34"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c36"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c37"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c33"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c34"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c35"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c36"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c37"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c39"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c33"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c34"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c35"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c36"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c37"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c39"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c34"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c35"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c36"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c37"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c39"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c48"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c49"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c50"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c51"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c52"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c49"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c50"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c51"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c52"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c53"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c55"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c50"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c51"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c53"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c55"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c5"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c5"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForIncreaseInRelatedParties
      contextRef="c4"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForIncreaseInRelatedParties
      contextRef="c5"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c5"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SalepurchaseOfPropertyAndEquipment
      contextRef="c4"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="c5"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c0"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c4"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c5"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c5"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:LeaseholdImprovementsMainlyRate
      contextRef="c74"
      id="hidden-fact-90"
      unitRef="pure"
      xsi:nil="true"/>
    <sprcy:ReceivablesInRespectOfDownpaymentOnMerger
      contextRef="c3"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="c14"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:OptionToExtendLeaseTerm contextRef="c108" id="hidden-fact-94">P3Y</sprcy:OptionToExtendLeaseTerm>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c114"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c140"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c141"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c2"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c2"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c2"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c158"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c159"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c158"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c159"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c160"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c160"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c161"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c2"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c171"
      id="hidden-fact-110"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c172"
      id="hidden-fact-111"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-112"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c3"
      id="hidden-fact-114"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-115"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-116"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c198"
      decimals="0"
      id="hidden-fact-117"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c206"
      decimals="0"
      id="hidden-fact-118"
      unitRef="pure">530000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c269"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c271"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c4"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c276"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c277"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c279"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c280"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c278"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c290"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c0"
      id="hidden-fact-128"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c0"
      id="hidden-fact-129"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c4"
      id="hidden-fact-130"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c4"
      id="hidden-fact-131"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c5"
      id="hidden-fact-132"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c5"
      id="hidden-fact-133"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c293"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c293"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c295"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c295"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c297"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c297"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CurrentAsset
      contextRef="c326"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CurrentAsset
      contextRef="c328"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c326"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c328"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c329"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c326"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c327"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c328"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c329"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SaleOfMinorityInterestInSubsidiary
      contextRef="c0"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SaleOfMinorityInterestInSubsidiary
      contextRef="c5"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c5"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-29432">0001611746</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-29433">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-29434">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-109"
          xlink:label="hidden-fact-109"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than $1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-109"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
